data_2lt1_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lt1 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.2 tt . . . . . 0 CA--C 1.543 0.692 0 CA-C-O 120.91 0.386 . . . . 0.0 111.234 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -129.73 178.85 6.2 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 125.615 1.566 . . . . 0.0 112.045 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.87 133.0 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 O-C-N 121.003 -1.061 . . . . 0.0 110.574 174.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.03 -0.15 87.48 Favored Glycine 0 CA--C 1.532 1.144 0 C-N-CA 124.711 1.148 . . . . 0.0 114.868 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -66.08 171.41 4.62 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 124.39 1.076 . . . . 0.0 112.397 175.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -107.07 144.2 34.08 Favored 'General case' 0 N--CA 1.463 0.203 0 C-N-CA 125.392 1.477 . . . . 0.0 111.347 -176.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 4.9 m -138.84 144.64 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 123.482 0.713 . . . . 0.0 109.76 -176.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.0 p -137.09 140.64 42.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 124.527 1.131 . . . . 0.0 109.4 175.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -92.37 161.55 32.35 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 124.488 1.115 . . . . 0.0 111.169 176.425 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -67.9 -14.01 40.08 Favored 'Trans proline' 0 CA--C 1.546 1.106 0 C-N-CA 122.816 2.344 . . . . 0.0 113.632 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.4 m-80 -148.76 -41.19 0.15 Allowed 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 126.064 1.746 . . . . 0.0 114.36 177.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 3.2 tm0? -52.34 -44.41 65.15 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 126.672 1.989 . . . . 0.0 114.107 -172.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 132.26 -150.28 19.6 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 125.937 1.732 . . . . 0.0 111.738 -178.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.9 m -112.27 146.57 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 C-N-CA 125.505 1.522 . . . . 0.0 110.917 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 78.1 m -137.06 179.71 6.22 Favored 'General case' 0 CA--C 1.551 1.016 0 C-N-CA 125.922 1.689 . . . . 0.0 110.589 175.042 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -136.1 129.49 31.92 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 125.185 1.394 . . . . 0.0 110.901 -179.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 26.5 t -68.73 139.21 20.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.362 0.665 . . . . 0.0 110.565 -175.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 46.7 t -117.89 -45.44 2.67 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 124.462 1.105 . . . . 0.0 112.647 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -151.93 160.7 43.43 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 124.483 1.113 . . . . 0.0 111.046 175.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -141.93 135.72 29.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 C-N-CA 124.663 1.185 . . . . 0.0 108.653 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -148.4 169.72 19.57 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.453 0.701 . . . . 0.0 111.646 175.298 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.9 m -109.58 140.42 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 O-C-N 120.782 -1.199 . . . . 0.0 110.203 176.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -152.6 169.42 22.71 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.589 0.755 . . . . 0.0 111.974 176.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.73 116.22 32.24 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.205 1.402 . . . . 0.0 109.742 174.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.4 p -124.61 139.39 51.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 C-N-CA 124.227 1.011 . . . . 0.0 109.574 175.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.52 29.1 1.95 Allowed 'General case' 0 CA--C 1.558 1.253 0 N-CA-C 114.702 1.371 . . . . 0.0 114.702 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.08 25.19 52.97 Favored Glycine 0 CA--C 1.54 1.594 0 C-N-CA 125.044 1.307 . . . . 0.0 115.414 -175.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.59 115.06 10.49 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 125.85 1.66 . . . . 0.0 111.387 -172.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 10.5 tttt -95.01 118.28 31.56 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.639 1.176 . . . . 0.0 111.79 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -155.51 171.6 19.65 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.344 0.658 . . . . 0.0 111.662 177.797 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 6.8 m -74.55 116.48 15.28 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.179 0.992 . . . . 0.0 111.296 175.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -109.83 113.35 26.03 Favored 'General case' 0 C--O 1.234 0.252 0 C-N-CA 124.627 1.171 . . . . 0.0 110.16 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 24.1 m -80.59 145.75 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.041 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 16.5 m -126.31 110.12 13.03 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 122.217 1.008 . . . . 0.0 110.972 179.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 2.2 mpp? -109.64 151.0 27.42 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 125.278 1.431 . . . . 0.0 110.095 -178.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 37.5 mtm180 -136.17 110.29 8.32 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.69 1.196 . . . . 0.0 109.677 -176.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -76.44 109.01 9.81 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 177.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -69.73 -13.78 62.46 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.498 1.119 . . . . 0.0 113.818 176.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -60.44 -39.49 87.7 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 125.559 1.543 . . . . 0.0 112.75 178.108 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -128.59 -18.82 3.86 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 125.793 1.637 . . . . 0.0 113.915 178.404 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.2 15.42 48.0 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 125.438 1.494 . . . . 0.0 114.766 -177.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -78.41 163.98 25.17 Favored 'General case' 0 CA--C 1.54 0.574 0 CA-C-N 118.416 1.108 . . . . 0.0 112.376 175.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 25.9 m -128.98 142.0 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.146 1.379 . . . . 0.0 110.665 175.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 21.9 m -131.87 133.71 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 125.114 1.366 . . . . 0.0 108.719 177.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -129.72 127.11 39.79 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 124.257 1.023 . . . . 0.0 109.051 177.085 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 27.5 m -133.73 156.66 79.25 Favored Pre-proline 0 N--CA 1.471 0.596 0 C-N-CA 124.3 1.04 . . . . 0.0 111.635 178.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -76.1 116.71 4.45 Favored 'Trans proline' 0 CA--C 1.535 0.565 0 C-N-CA 123.567 2.845 . . . . 0.0 114.571 176.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -63.65 -34.89 78.84 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 120.537 -1.352 . . . . 0.0 114.024 177.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.1 6.86 78.91 Favored Glycine 0 N--CA 1.473 1.139 0 C-N-CA 124.201 0.905 . . . . 0.0 114.693 176.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -136.74 3.98 2.77 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.225 1.41 . . . . 0.0 113.698 -178.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.2 m -49.86 -28.54 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.556 1.543 . . . . 0.0 113.421 175.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 12.0 mt -56.54 -29.77 62.3 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 125.805 1.642 . . . . 0.0 112.3 176.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.51 -49.89 15.35 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.811 1.644 . . . . 0.0 112.493 176.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.6 mp -65.7 -32.9 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 124.488 1.115 . . . . 0.0 111.741 177.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 85.21 4.41 86.48 Favored Glycine 0 CA--C 1.536 1.379 0 C-N-CA 125.397 1.475 . . . . 0.0 114.093 -175.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 13.9 p -80.83 132.9 30.53 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 124.905 1.282 . . . . 0.0 110.988 175.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.6 mmt180 -109.87 109.32 19.92 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 174.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.465 0.277 0 C-N-CA 123.879 0.872 . . . . 0.0 109.337 177.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.7 mm? . . . . . 0 N--CA 1.467 0.391 0 CA-C-O 120.957 0.408 . . . . 0.0 110.841 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.22 174.51 10.47 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.503 1.521 . . . . 0.0 111.39 176.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.5 t -60.89 126.2 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 123.718 0.807 . . . . 0.0 110.772 177.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.55 -8.74 74.45 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 125.131 1.348 . . . . 0.0 115.186 -176.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.1 t0 -71.51 167.6 19.33 Favored 'General case' 0 CA--C 1.548 0.9 0 CA-C-N 119.195 1.497 . . . . 0.0 111.4 174.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 12.4 tpp180 -92.98 151.39 19.94 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.036 0.934 . . . . 0.0 111.877 -179.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.0 p -151.99 130.01 2.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 C-N-CA 124.895 1.278 . . . . 0.0 110.622 178.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.6 p -137.09 155.82 33.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 C-N-CA 125.837 1.655 . . . . 0.0 108.484 174.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -101.46 158.69 31.3 Favored Pre-proline 0 CA--C 1.537 0.467 0 C-N-CA 125.047 1.339 . . . . 0.0 111.373 175.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_endo -68.21 -21.48 41.89 Favored 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 123.103 2.536 . . . . 0.0 112.458 -176.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -159.8 51.31 0.33 Allowed 'General case' 0 CA--C 1.557 1.221 0 C-N-CA 124.875 1.27 . . . . 0.0 112.896 176.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -140.36 -61.6 0.51 Allowed 'General case' 0 N--CA 1.483 1.216 0 O-C-N 120.835 -1.166 . . . . 0.0 113.116 -177.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 162.42 174.98 32.97 Favored Glycine 0 CA--C 1.534 1.245 0 C-N-CA 124.927 1.251 . . . . 0.0 113.65 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.9 t -91.19 140.42 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 125.461 1.504 . . . . 0.0 110.233 176.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 38.1 m -130.34 -177.85 4.5 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 126.258 1.823 . . . . 0.0 110.198 178.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 -141.96 124.21 15.56 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.074 0.95 . . . . 0.0 110.661 176.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.7 t -58.24 121.32 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 123.849 0.859 . . . . 0.0 110.815 -178.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.5 t -116.28 -35.2 4.4 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.458 1.503 . . . . 0.0 112.179 -175.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -148.14 157.95 43.8 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 125.179 1.392 . . . . 0.0 110.914 175.049 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 65.6 mt -143.15 132.59 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 O-C-N 120.816 -1.177 . . . . 0.0 108.242 175.238 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -138.51 172.25 13.16 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 125.247 1.419 . . . . 0.0 111.422 175.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.9 t -129.88 136.9 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.619 1.168 . . . . 0.0 109.3 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.0 ptmt -144.46 161.98 37.69 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.694 1.198 . . . . 0.0 111.817 177.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -90.14 116.05 27.85 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 124.458 1.103 . . . . 0.0 109.631 175.111 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 p -112.72 128.14 69.58 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 125.348 1.459 . . . . 0.0 109.346 174.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.94 29.07 3.17 Favored 'General case' 0 CA--C 1.557 1.214 0 N-CA-C 114.815 1.413 . . . . 0.0 114.815 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.86 23.57 55.31 Favored Glycine 0 CA--C 1.541 1.715 0 C-N-CA 124.647 1.117 . . . . 0.0 115.323 -175.287 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -138.25 118.7 13.8 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 126.277 1.831 . . . . 0.0 111.194 178.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.8 tttt -85.68 135.85 33.6 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 123.904 0.882 . . . . 0.0 111.439 175.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -154.93 159.16 40.23 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 122.823 0.449 . . . . 0.0 111.832 177.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 6.6 m -68.99 116.69 9.74 Favored 'General case' 0 N--CA 1.478 0.956 0 C-N-CA 124.056 0.942 . . . . 0.0 111.835 178.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -104.72 113.15 26.55 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 119.667 1.121 . . . . 0.0 110.776 174.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.7 m -84.73 136.86 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 123.796 0.838 . . . . 0.0 110.71 178.01 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 13.6 m -126.49 132.24 51.45 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 122.924 1.345 . . . . 0.0 111.876 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -130.13 161.93 29.98 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 125.151 1.381 . . . . 0.0 110.661 -174.217 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 14.3 mtp85 -131.09 103.12 6.33 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.911 1.284 . . . . 0.0 110.425 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.75 109.06 13.81 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.612 0.765 . . . . 0.0 110.766 177.345 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -63.56 -20.41 65.61 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.901 1.28 . . . . 0.0 112.72 178.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -58.63 -38.45 78.09 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.207 1.803 . . . . 0.0 113.344 -178.28 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -128.56 4.18 5.58 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 125.797 1.639 . . . . 0.0 112.702 174.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 62.91 29.86 75.49 Favored Glycine 0 CA--C 1.533 1.196 0 C-N-CA 125.526 1.536 . . . . 0.0 113.711 -174.336 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.62 172.26 7.6 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 118.343 1.072 . . . . 0.0 111.399 -174.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 30.3 m -114.55 144.25 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 C-N-CA 123.566 0.746 . . . . 0.0 111.098 174.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.9 t -124.33 112.11 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.253 1.421 . . . . 0.0 107.987 176.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.2 ttt -120.73 118.82 31.06 Favored 'General case' 0 C--O 1.235 0.317 0 C-N-CA 124.516 1.126 . . . . 0.0 109.734 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 17.1 m -137.03 158.32 72.98 Favored Pre-proline 0 N--CA 1.471 0.607 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -178.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -78.69 111.87 3.05 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.192 2.595 . . . . 0.0 114.56 176.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -60.95 -35.28 76.32 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 120.398 -1.439 . . . . 0.0 113.567 178.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.12 5.74 78.58 Favored Glycine 0 N--CA 1.474 1.222 0 C-N-CA 124.543 1.068 . . . . 0.0 114.961 176.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -135.51 1.47 2.86 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 125.207 1.403 . . . . 0.0 113.353 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.0 m -49.86 -28.1 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.917 1.687 . . . . 0.0 114.149 176.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.1 mt -56.22 -34.53 66.4 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.064 1.746 . . . . 0.0 112.071 175.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.78 -48.61 45.45 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.779 1.632 . . . . 0.0 112.586 177.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.5 mp -68.28 -27.92 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 123.972 0.909 . . . . 0.0 111.49 176.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.78 19.49 63.38 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.433 1.492 . . . . 0.0 113.853 -178.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 15.6 m -95.27 123.16 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 126.254 1.821 . . . . 0.0 111.059 -175.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 11.0 mmt180 -107.7 109.24 20.79 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 121.272 -0.892 . . . . 0.0 109.076 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.473 0.689 0 O-C-N 121.525 -0.734 . . . . 0.0 110.558 -179.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.537 0.461 0 CA-C-O 120.737 0.303 . . . . 0.0 110.602 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -128.37 169.65 14.01 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.9 1.68 . . . . 0.0 112.052 178.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.4 t -63.75 130.47 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 O-C-N 121.226 -0.921 . . . . 0.0 110.693 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.73 -8.81 76.45 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.216 1.389 . . . . 0.0 114.663 -177.3 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -67.65 154.91 40.42 Favored 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 118.958 1.379 . . . . 0.0 110.818 174.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -74.96 157.41 35.01 Favored 'General case' 0 N--CA 1.472 0.664 0 O-C-N 121.312 -0.867 . . . . 0.0 110.046 174.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 14.9 m -149.25 138.2 15.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 C-N-CA 124.676 1.19 . . . . 0.0 110.449 179.279 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.6 p -137.09 157.79 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 125.355 1.462 . . . . 0.0 109.56 177.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -102.9 160.36 26.45 Favored Pre-proline 0 CA--C 1.542 0.667 0 C-N-CA 124.919 1.288 . . . . 0.0 111.732 175.034 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_endo -68.95 -28.02 29.71 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 123.806 3.004 . . . . 0.0 112.102 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.8 t30 -158.51 55.5 0.44 Allowed 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 124.472 1.109 . . . . 0.0 112.848 177.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.82 -60.79 0.29 Allowed 'General case' 0 N--CA 1.482 1.139 0 O-C-N 121.009 -1.057 . . . . 0.0 113.351 -174.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 162.43 -173.34 38.7 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 124.818 1.199 . . . . 0.0 113.59 -177.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.7 p -100.49 144.95 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 126.362 1.865 . . . . 0.0 110.945 176.211 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 38.7 m -131.75 -175.85 3.85 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 125.49 1.516 . . . . 0.0 110.306 175.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -137.53 124.8 21.78 Favored 'General case' 0 N--CA 1.48 1.028 0 O-C-N 121.091 -1.006 . . . . 0.0 111.634 177.021 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 60.4 t -64.61 136.04 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 C-N-CA 124.425 1.09 . . . . 0.0 110.657 -179.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.5 p -115.44 -44.95 2.94 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 124.635 1.174 . . . . 0.0 113.026 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.3 163.56 37.25 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 126.319 1.847 . . . . 0.0 110.796 176.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 75.0 mt -141.83 132.82 26.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 124.543 1.137 . . . . 0.0 108.979 178.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -147.37 167.23 24.86 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.615 0.766 . . . . 0.0 112.581 175.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 20.9 m -103.3 141.93 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 O-C-N 121.117 -0.989 . . . . 0.0 110.699 175.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 3.9 ptmt -154.83 170.18 22.24 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 124.25 1.02 . . . . 0.0 112.234 175.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -102.46 116.34 32.42 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 125.999 1.72 . . . . 0.0 109.579 175.013 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.6 p -126.5 137.87 56.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.901 0.88 . . . . 0.0 110.025 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.5 28.97 1.89 Allowed 'General case' 0 CA--C 1.558 1.251 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 -177.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.28 22.69 53.81 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 125.172 1.367 . . . . 0.0 115.516 -176.565 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 35.8 tt0 -136.51 113.7 10.65 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 119.062 1.431 . . . . 0.0 111.666 -173.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 13.0 tttt -94.47 116.04 28.32 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.054 1.342 . . . . 0.0 111.747 -178.135 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -157.16 173.26 17.25 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.394 0.678 . . . . 0.0 111.887 177.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.2 m -73.96 116.41 14.55 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 124.934 1.293 . . . . 0.0 111.351 175.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -109.44 113.22 25.85 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.614 1.166 . . . . 0.0 109.939 177.195 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 27.3 m -73.61 150.71 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 O-C-N 121.817 -0.552 . . . . 0.0 110.894 177.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.2 m -126.5 121.18 31.62 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.801 0.84 . . . . 0.0 110.407 176.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -124.43 158.98 31.49 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 125.759 1.624 . . . . 0.0 110.51 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 13.4 ptm180 -136.18 111.5 9.11 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 126.061 1.744 . . . . 0.0 110.306 -178.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.9 109.07 19.08 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 123.258 0.623 . . . . 0.0 109.95 176.596 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 22.5 pt-20 -65.16 -18.43 65.3 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 113.337 0.866 . . . . 0.0 113.337 177.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -59.78 -36.72 77.26 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.027 1.731 . . . . 0.0 113.379 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -128.62 3.24 5.53 Favored 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.98 1.312 . . . . 0.0 112.665 174.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 64.61 24.18 69.37 Favored Glycine 0 CA--C 1.535 1.341 0 C-N-CA 125.447 1.498 . . . . 0.0 114.089 -172.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -90.74 173.53 7.97 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 118.671 1.236 . . . . 0.0 111.429 -176.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 27.0 m -117.9 143.77 27.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 124.168 0.987 . . . . 0.0 110.483 174.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 45.0 t -125.86 112.31 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 C-N-CA 125.375 1.47 . . . . 0.0 107.499 177.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.1 tmm? -125.34 119.34 28.1 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.145 0.978 . . . . 0.0 109.972 176.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.8 m -132.14 156.76 79.71 Favored Pre-proline 0 N--CA 1.469 0.519 0 C-N-CA 124.746 1.219 . . . . 0.0 111.834 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -78.01 113.61 3.46 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 124.053 3.169 . . . . 0.0 115.38 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -60.78 -34.42 74.46 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 120.134 -1.604 . . . . 0.0 114.315 178.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.17 5.57 78.37 Favored Glycine 0 N--CA 1.474 1.218 0 C-N-CA 124.202 0.905 . . . . 0.0 114.847 176.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 17.4 tttt -137.56 3.05 2.51 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 125.413 1.485 . . . . 0.0 113.212 -176.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.0 m -50.21 -29.13 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 C-N-CA 125.581 1.552 . . . . 0.0 113.513 175.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.8 mt -58.41 -28.77 65.52 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 126.098 1.759 . . . . 0.0 112.201 177.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.9 -51.64 13.32 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.035 1.734 . . . . 0.0 112.479 175.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 2.3 mp -68.61 -31.11 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 124.192 0.997 . . . . 0.0 111.367 178.07 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.83 10.48 72.4 Favored Glycine 0 CA--C 1.538 1.504 0 C-N-CA 126.047 1.784 . . . . 0.0 114.468 -177.555 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 31.2 m -97.35 123.47 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 C-N-CA 125.705 1.602 . . . . 0.0 110.75 -173.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 21.3 mmt85 -107.2 109.32 21.1 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.47 0.543 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -177.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.546 0.807 0 CA-C-O 120.831 0.348 . . . . 0.0 110.876 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -146.81 176.42 9.89 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.469 1.908 . . . . 0.0 112.137 177.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.3 t -59.14 129.2 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 O-C-N 120.965 -1.084 . . . . 0.0 111.786 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.53 -4.93 85.0 Favored Glycine 0 CA--C 1.534 1.243 0 C-N-CA 125.197 1.38 . . . . 0.0 114.1 -178.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -67.32 161.44 25.04 Favored 'General case' 0 CA--C 1.547 0.858 0 CA-C-N 118.454 1.127 . . . . 0.0 112.561 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -96.55 124.14 40.44 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.951 1.701 . . . . 0.0 111.968 -173.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 19.4 m -139.75 139.72 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 C-N-CA 123.34 0.656 . . . . 0.0 110.968 -175.102 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.9 p -137.03 145.1 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 124.002 0.921 . . . . 0.0 110.384 177.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -74.71 160.51 80.77 Favored Pre-proline 0 CA--C 1.547 0.83 0 O-C-N 121.83 -0.544 . . . . 0.0 110.59 174.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -67.97 -25.73 38.17 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.04 2.493 . . . . 0.0 112.253 -179.048 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.3 t30 -159.07 48.87 0.33 Allowed 'General case' 0 CA--C 1.554 1.12 0 C-N-CA 124.494 1.117 . . . . 0.0 113.633 178.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -139.41 -64.12 0.5 Allowed 'General case' 0 N--CA 1.482 1.157 0 O-C-N 120.85 -1.156 . . . . 0.0 113.132 -174.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 166.39 172.49 33.76 Favored Glycine 0 CA--C 1.533 1.162 0 C-N-CA 125.015 1.293 . . . . 0.0 113.192 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.29 142.58 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 124.893 1.277 . . . . 0.0 110.804 -178.249 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 6.2 m -131.48 173.0 11.54 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.917 1.687 . . . . 0.0 111.148 176.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.8 tmt_? -133.76 118.96 18.67 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 125.863 1.665 . . . . 0.0 110.325 -178.022 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.3 t -60.84 131.1 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 O-C-N 121.762 -0.586 . . . . 0.0 111.01 -175.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 83.0 p -112.06 -42.64 3.71 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -178.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.8 162.68 34.83 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.527 1.531 . . . . 0.0 110.817 178.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 71.1 mt -143.69 136.04 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.5 1.12 . . . . 0.0 108.965 -178.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -149.04 163.49 37.37 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 124.352 1.061 . . . . 0.0 111.913 175.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.8 p -106.85 141.91 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 124.593 1.157 . . . . 0.0 109.775 175.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.28 168.04 26.68 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 125.259 1.423 . . . . 0.0 110.854 176.233 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -101.38 118.71 37.51 Favored 'General case' 0 N--CA 1.467 0.395 0 C-N-CA 125.307 1.443 . . . . 0.0 109.488 175.41 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.0 p -121.08 132.54 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 124.272 1.029 . . . . 0.0 109.774 174.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.05 29.08 2.29 Favored 'General case' 0 CA--C 1.557 1.218 0 N-CA-C 114.775 1.398 . . . . 0.0 114.775 -178.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.29 26.23 48.58 Favored Glycine 0 CA--C 1.542 1.781 0 C-N-CA 124.692 1.139 . . . . 0.0 115.296 -175.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 5.9 mt-30 -135.42 113.53 11.27 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 126.401 1.881 . . . . 0.0 111.081 -178.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 8.9 tttt -94.01 121.43 35.48 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.968 1.307 . . . . 0.0 111.423 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -157.1 161.47 39.43 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 122.848 0.459 . . . . 0.0 111.41 178.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.4 m -67.77 116.39 8.4 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 121.313 -0.867 . . . . 0.0 110.516 177.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -104.65 113.56 27.22 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 120.869 -1.144 . . . . 0.0 110.041 175.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.9 m -83.22 141.16 15.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 C-N-CA 123.525 0.73 . . . . 0.0 110.184 177.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 24.8 m -122.32 112.7 18.44 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.668 1.187 . . . . 0.0 109.896 -178.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -112.15 154.9 24.79 Favored 'General case' 0 C--O 1.233 0.224 0 C-N-CA 124.011 0.924 . . . . 0.0 109.405 -178.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 41.7 mtm180 -133.72 154.73 50.74 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 124.495 1.118 . . . . 0.0 109.791 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -120.94 109.08 14.66 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -67.57 -19.87 65.32 Favored 'General case' 0 CA--C 1.544 0.714 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 177.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -51.1 -46.81 61.97 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 127.046 2.139 . . . . 0.0 112.75 175.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -123.61 -19.19 5.89 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.517 1.527 . . . . 0.0 113.424 -179.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.25 37.61 8.93 Favored Glycine 0 CA--C 1.538 1.488 0 C-N-CA 125.429 1.49 . . . . 0.0 114.372 -177.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -110.06 166.64 10.79 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.4 1.48 . . . . 0.0 112.085 177.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.4 m -129.7 146.91 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 125.047 1.339 . . . . 0.0 111.52 178.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.0 m -136.94 112.2 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 C-N-CA 126.409 1.883 . . . . 0.0 109.151 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 9.4 ptt? -107.9 124.45 50.14 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 124.424 1.09 . . . . 0.0 110.364 176.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.1 m -131.97 157.21 78.83 Favored Pre-proline 0 N--CA 1.469 0.488 0 C-N-CA 123.949 0.9 . . . . 0.0 111.119 -178.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -77.73 114.94 3.75 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.382 2.721 . . . . 0.0 114.596 176.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -62.54 -35.77 80.51 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 120.37 -1.456 . . . . 0.0 113.909 178.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.99 6.35 79.1 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.245 0.926 . . . . 0.0 114.794 176.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 3.0 tttm -136.0 4.5 3.0 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.685 1.594 . . . . 0.0 112.861 -178.705 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -50.05 -30.0 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 126.12 1.768 . . . . 0.0 113.072 175.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.7 mt -55.05 -29.91 58.46 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.315 1.846 . . . . 0.0 112.585 176.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.78 -50.47 13.45 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.647 1.579 . . . . 0.0 112.529 177.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.6 mp -66.42 -32.98 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 C-N-CA 124.664 1.186 . . . . 0.0 111.237 177.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.4 4.61 76.8 Favored Glycine 0 CA--C 1.534 1.278 0 C-N-CA 125.647 1.594 . . . . 0.0 114.137 -176.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 30.2 m -82.31 137.55 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 124.404 1.082 . . . . 0.0 111.105 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -117.79 109.62 16.8 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.012 0.925 . . . . 0.0 110.535 175.771 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.468 0.435 0 C-N-CA 126.51 1.924 . . . . 0.0 109.345 178.403 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.542 0.656 0 CA-C-O 120.852 0.358 . . . . 0.0 111.109 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -121.45 169.08 10.99 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 125.926 1.69 . . . . 0.0 111.972 175.005 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.4 t -61.37 129.84 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 O-C-N 121.413 -0.805 . . . . 0.0 110.634 176.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.12 -6.54 78.78 Favored Glycine 0 CA--C 1.534 1.23 0 C-N-CA 124.876 1.227 . . . . 0.0 114.651 -177.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -69.61 176.41 3.54 Favored 'General case' 0 CA--C 1.546 0.814 0 CA-C-N 119.079 1.439 . . . . 0.0 110.593 174.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.42 169.91 10.67 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.998 1.38 . . . . 0.0 112.998 -179.673 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.5 p -161.02 149.78 5.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 C-N-CA 125.539 1.536 . . . . 0.0 110.643 175.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.8 p -127.42 160.43 36.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 126.991 2.116 . . . . 0.0 107.685 174.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -125.84 154.55 73.46 Favored Pre-proline 0 CA--C 1.539 0.547 0 C-N-CA 125.063 1.345 . . . . 0.0 110.974 176.696 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.83 -9.83 26.5 Favored 'Trans proline' 0 CA--C 1.545 1.06 0 C-N-CA 123.17 2.58 . . . . 0.0 113.761 178.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 26.7 m-20 -133.46 -60.17 0.85 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.352 1.861 . . . . 0.0 112.922 176.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 65.5 mm-40 -52.48 -54.35 33.56 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 125.133 1.373 . . . . 0.0 112.952 -175.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 114.53 -147.36 18.82 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 125.479 1.514 . . . . 0.0 111.68 -174.059 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.2 m -70.17 144.66 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 124.004 0.922 . . . . 0.0 112.984 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 30.9 m -141.81 177.53 8.11 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 126.383 1.873 . . . . 0.0 110.653 178.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -132.38 129.47 39.43 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 124.759 1.224 . . . . 0.0 111.881 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.6 t -72.56 142.48 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 O-C-N 121.758 -0.588 . . . . 0.0 110.946 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.9 t -116.94 -44.78 2.79 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.419 1.488 . . . . 0.0 112.593 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.95 159.27 37.92 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 124.437 1.095 . . . . 0.0 110.553 177.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -142.59 133.59 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 120.911 -1.118 . . . . 0.0 108.823 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -149.47 169.4 20.97 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.298 0.639 . . . . 0.0 111.953 175.566 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.6 m -103.57 142.59 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 O-C-N 120.942 -1.099 . . . . 0.0 110.576 175.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.9 pttt -154.65 172.58 17.65 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.664 0.786 . . . . 0.0 112.011 176.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -104.64 116.6 32.33 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 125.727 1.611 . . . . 0.0 110.177 175.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.9 p -125.98 137.73 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 C-N-CA 124.262 1.025 . . . . 0.0 109.965 174.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.81 28.86 2.05 Favored 'General case' 0 CA--C 1.556 1.193 0 C-N-CA 125.182 1.393 . . . . 0.0 114.69 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.94 27.94 48.01 Favored Glycine 0 CA--C 1.541 1.701 0 C-N-CA 124.936 1.255 . . . . 0.0 115.144 -174.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.96 115.53 11.28 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 125.577 1.551 . . . . 0.0 111.856 -176.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -98.45 111.02 23.51 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 126.104 1.762 . . . . 0.0 111.356 -176.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -155.36 172.82 17.56 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.401 0.68 . . . . 0.0 111.655 -179.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 6.0 m -73.64 116.29 14.06 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.248 1.019 . . . . 0.0 111.116 175.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -108.94 113.21 25.91 Favored 'General case' 0 N--CA 1.467 0.394 0 O-C-N 121.221 -0.924 . . . . 0.0 109.612 176.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 19.3 m -73.2 146.56 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 123.3 0.64 . . . . 0.0 110.452 176.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 3.7 m -126.58 109.93 12.67 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 122.623 1.201 . . . . 0.0 110.243 176.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 1.6 mpp? -112.91 165.43 12.34 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.274 1.43 . . . . 0.0 110.483 179.174 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 26.8 ptt180 -142.75 117.29 9.72 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 124.835 1.254 . . . . 0.0 110.079 179.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 8.7 ttp180 -74.46 109.07 7.64 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.333 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -70.23 -14.32 62.56 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 178.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -57.58 -39.91 77.84 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 126.204 1.802 . . . . 0.0 112.791 176.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.63 -20.94 3.51 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 126.346 1.858 . . . . 0.0 114.75 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.12 14.49 51.46 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 125.104 1.335 . . . . 0.0 115.199 -174.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -76.85 163.34 26.86 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-N 118.85 1.325 . . . . 0.0 112.597 175.327 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 33.6 m -108.57 147.66 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.586 1.154 . . . . 0.0 110.344 174.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.2 t -138.53 112.72 8.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 C-N-CA 125.403 1.481 . . . . 0.0 107.699 -178.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.24 132.02 53.03 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 123.689 0.795 . . . . 0.0 111.89 178.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 33.4 m -139.9 157.38 69.66 Favored Pre-proline 0 N--CA 1.473 0.681 0 C-N-CA 124.164 0.985 . . . . 0.0 112.088 -178.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -77.95 116.28 3.94 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 123.705 2.937 . . . . 0.0 114.576 175.379 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -64.35 -33.74 76.55 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 120.327 -1.483 . . . . 0.0 114.284 178.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.64 6.7 80.08 Favored Glycine 0 N--CA 1.475 1.275 0 O-C-N 121.264 -0.897 . . . . 0.0 114.64 176.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 30.5 tttt -137.57 3.11 2.51 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 125.34 1.456 . . . . 0.0 113.194 -177.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 1.2 m -49.55 -29.22 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.631 1.572 . . . . 0.0 113.282 176.122 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 12.4 mt -56.08 -29.55 60.71 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.172 1.789 . . . . 0.0 112.574 176.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.6 -50.88 12.73 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.891 1.676 . . . . 0.0 112.98 175.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.8 mp -65.41 -33.2 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 C-N-CA 124.117 0.967 . . . . 0.0 111.537 178.147 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 87.4 0.2 84.84 Favored Glycine 0 CA--C 1.536 1.364 0 C-N-CA 125.623 1.582 . . . . 0.0 113.97 -175.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 7.7 p -73.53 123.15 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 124.588 1.155 . . . . 0.0 110.338 174.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -106.07 109.29 21.18 Favored 'General case' 0 N--CA 1.473 0.709 0 O-C-N 121.071 -1.018 . . . . 0.0 108.789 175.174 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.469 0.478 0 C-N-CA 123.642 0.777 . . . . 0.0 110.177 178.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 9.7 mt . . . . . 0 CA--C 1.537 0.446 0 CA-C-O 121.588 0.708 . . . . 0.0 112.53 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -125.62 166.5 16.61 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.981 1.712 . . . . 0.0 111.122 176.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 75.2 t -67.93 131.87 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 123.628 0.771 . . . . 0.0 110.135 175.147 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.03 -3.45 70.18 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 125.84 1.686 . . . . 0.0 114.737 -178.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -76.63 152.15 35.94 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 119.085 1.443 . . . . 0.0 112.719 -179.29 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -86.89 135.0 33.47 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 125.453 1.501 . . . . 0.0 111.68 -177.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.3 m -143.54 135.71 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.796 1.239 . . . . 0.0 111.167 -177.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.7 p -102.92 165.63 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 O-C-N 121.152 -0.967 . . . . 0.0 111.33 175.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -125.99 158.44 65.94 Favored Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 125.277 1.431 . . . . 0.0 111.886 175.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -71.36 -40.78 2.85 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 123.328 2.685 . . . . 0.0 112.615 -178.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -148.75 32.37 0.78 Allowed 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.707 1.203 . . . . 0.0 112.87 -177.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -130.03 -23.11 2.79 Favored 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 125.817 1.647 . . . . 0.0 114.245 -173.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 104.17 168.15 24.94 Favored Glycine 0 CA--C 1.539 1.592 0 C-N-CA 126.406 1.955 . . . . 0.0 114.436 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 42.9 t -66.52 133.47 31.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 O-C-N 121.1 -1.235 . . . . 0.0 110.338 176.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 63.4 m -122.53 -179.85 4.35 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 126.302 1.841 . . . . 0.0 111.226 178.245 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.0 ttt180 -144.43 120.64 10.84 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 125.066 1.347 . . . . 0.0 110.562 176.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.7 t -57.96 126.76 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 C-N-CA 123.643 0.777 . . . . 0.0 111.089 -177.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.3 m -112.99 -36.46 5.1 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 124.748 1.219 . . . . 0.0 113.463 -176.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.88 159.54 41.82 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.96 1.704 . . . . 0.0 110.582 175.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 41.0 mt -143.81 118.19 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 124.851 1.26 . . . . 0.0 108.631 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -144.72 171.71 14.02 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 123.653 0.781 . . . . 0.0 112.003 177.33 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.5 m -111.8 142.18 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 O-C-N 121.331 -0.855 . . . . 0.0 111.455 175.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.46 170.82 21.06 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 124.314 1.045 . . . . 0.0 112.122 175.407 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -102.52 118.29 36.55 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.935 1.694 . . . . 0.0 109.536 174.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.8 p -129.68 137.65 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.695 0.798 . . . . 0.0 109.691 174.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.41 29.2 1.91 Allowed 'General case' 0 CA--C 1.556 1.184 0 C-N-CA 125.17 1.388 . . . . 0.0 114.696 -176.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.2 22.2 55.16 Favored Glycine 0 CA--C 1.538 1.528 0 C-N-CA 125.131 1.348 . . . . 0.0 115.454 -177.23 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -135.97 113.5 10.85 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 119.149 1.475 . . . . 0.0 111.062 -173.38 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -96.0 114.06 25.74 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 125.541 1.536 . . . . 0.0 111.843 -176.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -158.21 173.69 16.32 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 123.437 0.695 . . . . 0.0 111.924 179.283 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.3 m -73.36 116.28 13.73 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.456 1.103 . . . . 0.0 111.165 174.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -108.75 113.13 25.84 Favored 'General case' 0 C--O 1.235 0.311 0 O-C-N 120.969 -1.082 . . . . 0.0 109.43 175.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.2 m -70.49 150.95 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 CA-C-N 116.242 -0.436 . . . . 0.0 109.993 175.28 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 25.4 m -126.47 128.58 47.16 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 125.252 1.421 . . . . 0.0 109.533 175.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.94 166.98 23.73 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 125.674 1.589 . . . . 0.0 110.599 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.23 141.31 27.27 Favored 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 124.347 1.059 . . . . 0.0 111.165 175.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 59.9 mtm180 -78.71 124.62 28.38 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.106 1.362 . . . . 0.0 111.059 178.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -63.18 -40.64 98.1 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.441 1.096 . . . . 0.0 113.237 177.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -87.09 -46.65 9.6 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.977 0.911 . . . . 0.0 112.666 178.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -71.78 -21.61 61.7 Favored 'General case' 0 N--CA 1.475 0.809 0 O-C-N 121.517 -0.739 . . . . 0.0 112.815 -177.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 66.26 12.47 58.23 Favored Glycine 0 CA--C 1.536 1.38 0 C-N-CA 126.062 1.791 . . . . 0.0 114.81 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -109.32 145.59 35.74 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.672 1.589 . . . . 0.0 112.56 -168.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 16.3 m -70.21 150.87 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.871 1.268 . . . . 0.0 111.837 177.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.2 t -145.21 123.67 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 125.602 1.561 . . . . 0.0 108.91 178.127 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 43.8 mtt -141.26 121.74 14.12 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 123.813 0.845 . . . . 0.0 109.845 178.009 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 26.8 m -132.67 157.48 78.21 Favored Pre-proline 0 N--CA 1.475 0.796 0 C-N-CA 124.0 0.92 . . . . 0.0 112.335 177.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -77.91 114.33 3.6 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 123.546 2.831 . . . . 0.0 114.915 178.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -60.69 -36.51 78.95 Favored 'General case' 0 N--CA 1.476 0.828 0 O-C-N 120.346 -1.471 . . . . 0.0 114.297 178.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.11 5.77 78.61 Favored Glycine 0 N--CA 1.475 1.246 0 C-N-CA 124.338 0.97 . . . . 0.0 114.863 176.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 15.0 tttp -135.88 3.2 2.93 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.286 1.435 . . . . 0.0 113.106 -177.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.8 m -49.75 -29.87 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 125.635 1.574 . . . . 0.0 113.11 175.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.0 mt -57.56 -28.65 63.75 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 126.164 1.786 . . . . 0.0 112.595 176.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.03 -50.04 15.89 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 125.863 1.665 . . . . 0.0 112.605 176.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.0 mp -69.56 -33.68 58.05 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 124.15 0.98 . . . . 0.0 111.465 178.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.97 3.25 73.67 Favored Glycine 0 CA--C 1.537 1.466 0 C-N-CA 125.799 1.666 . . . . 0.0 114.208 -174.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 31.3 m -71.5 125.96 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 124.774 1.229 . . . . 0.0 110.834 177.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.3 mmm180 -109.72 109.34 20.01 Favored 'General case' 0 N--CA 1.474 0.769 0 O-C-N 121.076 -1.015 . . . . 0.0 108.931 175.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.465 0.3 0 C-N-CA 125.901 1.681 . . . . 0.0 109.117 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 CA--C 1.544 0.746 0 CA-C-O 120.521 0.201 . . . . 0.0 111.492 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -140.57 172.74 12.29 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.86 1.664 . . . . 0.0 112.382 175.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 85.2 t -59.72 131.93 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 O-C-N 120.977 -1.077 . . . . 0.0 111.095 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.52 -6.24 83.73 Favored Glycine 0 CA--C 1.535 1.332 0 C-N-CA 125.045 1.307 . . . . 0.0 114.958 -177.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -69.65 176.85 3.28 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-N 118.805 1.303 . . . . 0.0 112.815 175.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 15.8 mmt85 -119.91 134.15 55.34 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.449 1.5 . . . . 0.0 111.884 -174.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 17.2 m -139.35 136.92 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 125.091 1.356 . . . . 0.0 109.506 -173.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.6 p -137.03 139.05 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 C-N-CA 123.989 0.916 . . . . 0.0 110.118 176.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -69.61 160.4 79.74 Favored Pre-proline 0 CA--C 1.542 0.646 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 174.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -68.8 -27.29 31.52 Favored 'Trans proline' 0 CA--C 1.54 0.802 0 C-N-CA 122.781 2.32 . . . . 0.0 112.326 -177.351 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 56.9 t30 -157.77 47.66 0.38 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 124.401 1.081 . . . . 0.0 113.553 177.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -137.86 -64.19 0.55 Allowed 'General case' 0 N--CA 1.481 1.099 0 O-C-N 121.155 -0.965 . . . . 0.0 112.994 -174.117 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.55 168.44 30.63 Favored Glycine 0 CA--C 1.534 1.246 0 C-N-CA 125.081 1.324 . . . . 0.0 113.398 178.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.3 p -77.73 146.83 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 124.891 1.277 . . . . 0.0 111.411 175.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 3.7 m -130.36 173.83 10.43 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.568 1.547 . . . . 0.0 111.271 175.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.11 117.78 17.92 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.552 1.541 . . . . 0.0 110.909 -176.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.4 t -65.95 116.09 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.078 1.351 . . . . 0.0 111.124 -177.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.3 m -107.62 -47.85 3.54 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.852 1.261 . . . . 0.0 112.34 -176.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -148.8 169.71 19.87 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.334 1.854 . . . . 0.0 110.403 178.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 48.8 mt -147.28 140.36 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.054 1.342 . . . . 0.0 108.266 175.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.34 173.65 11.3 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.106 0.962 . . . . 0.0 112.313 175.706 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.9 m -123.26 140.77 45.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 124.711 1.204 . . . . 0.0 110.728 177.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -155.53 167.42 30.44 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 123.935 0.894 . . . . 0.0 112.385 177.209 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -100.56 119.79 39.06 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.349 1.459 . . . . 0.0 108.745 174.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.0 p -127.33 136.8 59.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.851 1.261 . . . . 0.0 109.058 175.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.85 28.95 1.48 Allowed 'General case' 0 CA--C 1.557 1.233 0 N-CA-C 114.882 1.438 . . . . 0.0 114.882 -178.003 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.06 26.51 48.54 Favored Glycine 0 CA--C 1.542 1.72 0 C-N-CA 124.822 1.201 . . . . 0.0 115.363 -176.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -137.57 116.98 12.79 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 126.229 1.811 . . . . 0.0 110.835 -175.459 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -96.3 118.94 33.87 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 125.338 1.455 . . . . 0.0 111.105 179.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -155.16 172.63 17.84 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 123.432 0.693 . . . . 0.0 111.892 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 48.2 m -82.25 116.41 21.77 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.078 1.351 . . . . 0.0 111.943 176.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -102.2 113.17 26.22 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.483 1.113 . . . . 0.0 109.529 174.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.0 m -63.04 148.1 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 O-C-N 121.895 -0.503 . . . . 0.0 110.812 174.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 1.5 m -126.61 109.85 12.56 Favored 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 122.09 0.948 . . . . 0.0 110.605 176.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 2.4 mpp? -123.58 160.17 27.64 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 124.055 0.942 . . . . 0.0 110.239 -178.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -130.91 125.06 32.51 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 123.843 0.857 . . . . 0.0 110.831 174.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 79.4 mtm180 -83.38 109.02 16.96 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 125.355 1.462 . . . . 0.0 108.462 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -65.62 -18.09 65.07 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.865 0.866 . . . . 0.0 112.494 177.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 31.0 tt0 -57.54 -39.22 76.16 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.622 1.969 . . . . 0.0 113.225 177.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -128.62 1.73 5.52 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 125.011 1.324 . . . . 0.0 113.645 177.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.79 11.77 60.98 Favored Glycine 0 CA--C 1.538 1.476 0 C-N-CA 125.427 1.489 . . . . 0.0 114.306 -171.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -81.04 159.01 24.91 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.489 1.516 . . . . 0.0 112.566 -176.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 20.4 m -97.95 162.05 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 123.481 0.712 . . . . 0.0 110.601 175.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 3.9 p -151.95 122.05 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 125.347 1.459 . . . . 0.0 109.111 174.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 19.3 ptm -125.93 135.26 51.68 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 125.076 1.35 . . . . 0.0 110.608 175.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.2 m -137.58 154.24 74.88 Favored Pre-proline 0 N--CA 1.468 0.454 0 C-N-CA 123.819 0.847 . . . . 0.0 111.253 175.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -75.51 117.24 4.73 Favored 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 123.271 2.648 . . . . 0.0 114.439 178.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -59.65 -40.53 87.97 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.61 7.31 79.86 Favored Glycine 0 N--CA 1.474 1.173 0 C-N-CA 124.418 1.009 . . . . 0.0 114.588 178.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.2 tttm -133.7 3.4 3.53 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.203 1.401 . . . . 0.0 113.509 -178.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.5 m -48.75 -28.87 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.933 1.293 . . . . 0.0 113.598 175.007 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.3 mt -57.31 -29.09 63.63 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.989 1.715 . . . . 0.0 112.61 177.276 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.05 -50.61 15.9 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 125.64 1.576 . . . . 0.0 112.673 175.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.9 mp -68.75 -33.55 60.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 124.244 1.018 . . . . 0.0 111.435 178.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.7 2.19 79.23 Favored Glycine 0 CA--C 1.537 1.415 0 C-N-CA 125.844 1.688 . . . . 0.0 114.349 -175.198 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.6 t -80.69 123.16 37.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 CA-C-N 118.96 1.38 . . . . 0.0 110.472 178.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 3.3 mmt180 -99.58 109.24 21.76 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 174.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.472 0.651 0 C-N-CA 125.527 1.531 . . . . 0.0 109.352 176.521 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.541 0.63 0 CA-C-O 121.074 0.464 . . . . 0.0 111.836 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -140.06 172.91 12.08 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.017 1.327 . . . . 0.0 112.559 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.3 t -60.22 126.37 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.123 0.969 . . . . 0.0 110.475 177.203 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.23 -8.36 72.48 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.051 1.31 . . . . 0.0 114.856 -177.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -72.2 169.53 15.94 Favored 'General case' 0 CA--C 1.55 0.973 0 CA-C-N 119.215 1.507 . . . . 0.0 111.056 174.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -88.3 159.26 18.16 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.614 1.566 . . . . 0.0 112.018 175.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 1.5 p -150.86 130.14 3.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 C-N-CA 124.739 1.216 . . . . 0.0 110.134 175.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.2 p -137.19 142.59 36.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 C-N-CA 125.995 1.718 . . . . 0.0 107.903 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -88.46 161.97 40.94 Favored Pre-proline 0 CA--C 1.545 0.765 0 C-N-CA 124.685 1.194 . . . . 0.0 110.965 175.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.67 -26.66 27.77 Favored 'Trans proline' 0 CA--C 1.536 0.59 0 C-N-CA 123.439 2.759 . . . . 0.0 112.37 -175.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -158.15 62.77 0.45 Allowed 'General case' 0 CA--C 1.551 1.013 0 C-N-CA 125.863 1.665 . . . . 0.0 111.57 176.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -146.43 -61.88 0.31 Allowed 'General case' 0 N--CA 1.481 1.084 0 O-C-N 121.085 -1.009 . . . . 0.0 112.463 179.147 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 158.67 -179.42 34.35 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 124.661 1.124 . . . . 0.0 113.422 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.3 m -81.87 147.8 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.542 1.537 . . . . 0.0 112.037 175.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 97.7 m -138.18 179.62 6.34 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.856 2.062 . . . . 0.0 109.851 179.027 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.01 135.6 39.61 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 125.102 1.361 . . . . 0.0 110.462 175.245 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -66.54 129.99 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 C-N-CA 123.95 0.9 . . . . 0.0 110.401 175.074 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -115.06 -51.69 2.71 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.622 1.169 . . . . 0.0 111.759 -178.21 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.73 164.54 37.57 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.849 1.66 . . . . 0.0 110.875 175.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 64.2 mt -144.9 134.45 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 O-C-N 120.752 -1.217 . . . . 0.0 108.756 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -143.53 174.09 11.07 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.355 1.062 . . . . 0.0 112.162 176.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.4 p -124.75 137.89 55.94 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 125.168 1.387 . . . . 0.0 110.842 177.378 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 13.2 ptmt -150.74 153.4 35.44 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 124.961 1.304 . . . . 0.0 112.088 178.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -81.05 115.18 20.38 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 123.787 0.835 . . . . 0.0 108.924 174.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.6 p -118.6 133.36 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 124.311 1.044 . . . . 0.0 109.653 174.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.54 29.01 2.74 Favored 'General case' 0 CA--C 1.557 1.227 0 N-CA-C 114.772 1.397 . . . . 0.0 114.772 -178.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.43 20.42 56.74 Favored Glycine 0 CA--C 1.538 1.529 0 C-N-CA 124.854 1.216 . . . . 0.0 115.422 -175.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -142.87 114.11 7.81 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.491 1.516 . . . . 0.0 111.814 -176.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 5.1 ptmt -91.77 133.96 35.16 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.721 1.208 . . . . 0.0 111.656 175.007 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.3 pp -160.05 163.58 33.84 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.266 1.026 . . . . 0.0 110.483 176.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.0 m -66.39 116.49 7.46 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 121.279 -0.888 . . . . 0.0 110.986 178.012 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -104.91 113.3 26.82 Favored 'General case' 0 N--CA 1.467 0.407 0 O-C-N 120.748 -1.22 . . . . 0.0 109.409 175.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.2 m -75.73 143.68 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-O 119.035 -0.507 . . . . 0.0 110.19 177.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -125.82 112.86 16.51 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 122.41 1.1 . . . . 0.0 110.918 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -122.73 165.74 16.07 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.897 1.279 . . . . 0.0 109.647 -176.033 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.5 mtt180 -134.98 160.79 37.2 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 124.425 1.09 . . . . 0.0 110.589 175.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -122.28 109.1 14.03 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 125.733 1.613 . . . . 0.0 109.463 174.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -64.86 -17.66 64.48 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 113.331 0.863 . . . . 0.0 113.331 176.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -54.63 -44.37 73.1 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 127.199 2.2 . . . . 0.0 112.451 178.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -126.19 -1.29 7.05 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.47 1.908 . . . . 0.0 112.494 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.62 34.31 88.61 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 125.157 1.361 . . . . 0.0 113.552 -174.066 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.59 165.61 10.95 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 124.252 1.021 . . . . 0.0 112.145 -176.233 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.5 m -110.28 155.78 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.013 1.325 . . . . 0.0 111.265 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 3.7 p -151.05 125.83 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 124.713 1.205 . . . . 0.0 109.405 175.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 22.8 ptt? -130.21 137.81 50.26 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 123.9 0.88 . . . . 0.0 110.803 175.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.466 ' CG2' ' HE2' ' A' ' 70' ' ' LYS . 14.0 m -140.24 157.34 69.01 Favored Pre-proline 0 N--CA 1.474 0.731 0 C-N-CA 123.584 0.754 . . . . 0.0 111.414 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -75.59 116.03 4.37 Favored 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 123.726 2.95 . . . . 0.0 114.861 176.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -63.97 -33.42 75.69 Favored 'General case' 0 N--CA 1.482 1.132 0 O-C-N 120.394 -1.441 . . . . 0.0 113.573 178.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.92 4.57 78.57 Favored Glycine 0 N--CA 1.476 1.328 0 C-N-CA 124.769 1.176 . . . . 0.0 114.686 175.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.0 tttm -136.74 3.84 2.76 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.437 1.495 . . . . 0.0 112.992 -177.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.2 m -50.26 -28.31 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 C-N-CA 125.731 1.613 . . . . 0.0 113.012 175.188 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.0 mt -56.02 -30.16 61.45 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 125.945 1.698 . . . . 0.0 112.385 176.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.53 -50.34 15.95 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 125.86 1.664 . . . . 0.0 112.828 175.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.0 mp -68.16 -33.38 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 124.054 0.941 . . . . 0.0 111.465 178.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.49 3.56 77.91 Favored Glycine 0 CA--C 1.537 1.445 0 C-N-CA 126.166 1.841 . . . . 0.0 114.605 -177.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 31.4 m -82.21 125.56 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 C-N-CA 126.451 1.9 . . . . 0.0 111.216 -178.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.69 109.25 17.92 Favored 'General case' 0 N--CA 1.475 0.782 0 O-C-N 121.252 -0.905 . . . . 0.0 110.105 177.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.466 ' HE2' ' CG2' ' A' ' 58' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.47 0.536 0 C-N-CA 123.226 0.61 . . . . 0.0 110.477 178.127 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.541 0.605 0 CA-C-O 120.438 0.161 . . . . 0.0 110.803 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -124.79 169.85 11.61 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.141 1.377 . . . . 0.0 112.316 177.193 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.42 129.11 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 O-C-N 121.414 -0.803 . . . . 0.0 110.567 176.305 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.26 -6.15 75.29 Favored Glycine 0 CA--C 1.534 1.231 0 C-N-CA 125.075 1.322 . . . . 0.0 114.901 -179.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -68.77 176.74 2.86 Favored 'General case' 0 CA--C 1.549 0.917 0 CA-C-N 119.068 1.434 . . . . 0.0 111.883 174.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.9 mmt180 -113.08 139.57 48.59 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.564 1.545 . . . . 0.0 111.35 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 15.1 m -139.71 137.09 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 C-N-CA 124.204 1.002 . . . . 0.0 109.477 -178.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.5 p -137.04 137.99 46.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 124.151 0.981 . . . . 0.0 110.085 177.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -71.67 161.95 75.77 Favored Pre-proline 0 CA--C 1.546 0.826 0 N-CA-C 112.113 0.412 . . . . 0.0 112.113 175.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -70.11 -28.54 23.46 Favored 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.43 2.753 . . . . 0.0 112.265 -178.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 32.3 m-20 -157.95 64.4 0.46 Allowed 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 127.026 2.13 . . . . 0.0 111.357 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 5.4 mm-40 -151.9 -71.07 0.16 Allowed 'General case' 0 N--CA 1.479 1.021 0 O-C-N 120.794 -1.191 . . . . 0.0 111.776 174.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 173.55 174.09 40.28 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.403 1.478 . . . . 0.0 112.406 -174.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.5 p -84.39 149.3 4.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 124.949 1.299 . . . . 0.0 110.704 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.7 m -128.82 174.59 9.34 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.774 1.63 . . . . 0.0 110.52 175.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -131.82 118.82 20.4 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 124.004 0.922 . . . . 0.0 110.9 -178.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.2 t -57.82 126.88 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 C-N-CA 124.111 0.964 . . . . 0.0 110.593 -179.399 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.9 t -111.01 -51.88 2.83 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 125.135 1.374 . . . . 0.0 110.984 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.81 169.87 21.72 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 124.861 1.265 . . . . 0.0 111.064 177.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 62.0 mt -145.2 138.68 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 124.722 1.209 . . . . 0.0 108.457 175.042 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -150.26 167.0 28.24 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 124.853 1.261 . . . . 0.0 112.158 175.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 13.8 m -106.77 143.09 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.109 0.964 . . . . 0.0 110.908 176.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -155.25 170.82 20.97 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 124.623 1.169 . . . . 0.0 111.795 175.423 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -106.28 116.22 31.57 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.949 1.699 . . . . 0.0 109.697 175.001 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.8 p -125.62 138.03 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 C-N-CA 124.462 1.105 . . . . 0.0 110.725 174.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.53 29.09 1.95 Allowed 'General case' 0 CA--C 1.556 1.208 0 C-N-CA 124.856 1.262 . . . . 0.0 114.26 -179.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.35 27.04 53.36 Favored Glycine 0 CA--C 1.54 1.604 0 C-N-CA 125.2 1.381 . . . . 0.0 115.613 -174.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.8 tp60 -135.14 113.54 11.48 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.761 1.624 . . . . 0.0 110.436 -175.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 18.6 tttt -96.28 114.86 26.58 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 124.899 1.28 . . . . 0.0 111.25 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -157.59 173.07 17.42 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 123.155 0.582 . . . . 0.0 111.765 179.532 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 17.2 m -79.73 116.58 19.99 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.367 1.067 . . . . 0.0 111.595 175.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -102.38 114.5 28.73 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.03 0.932 . . . . 0.0 109.763 175.028 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 5.7 m -66.87 145.27 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 O-C-N 121.863 -0.523 . . . . 0.0 110.783 174.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -126.65 109.8 12.49 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.532 1.133 . . . . 0.0 111.109 -179.445 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 1.8 mpp? -123.22 160.72 25.99 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 124.229 1.011 . . . . 0.0 110.546 -177.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.64 134.03 40.74 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.875 0.87 . . . . 0.0 110.905 174.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 60.9 mtm180 -94.27 108.76 20.62 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 124.824 1.25 . . . . 0.0 108.209 176.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -69.53 -17.78 63.61 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.343 1.057 . . . . 0.0 113.562 175.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -55.49 -42.12 73.98 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 126.032 1.733 . . . . 0.0 112.538 178.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -121.97 -20.25 6.39 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 125.474 1.509 . . . . 0.0 113.387 177.828 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.47 49.15 4.5 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 125.305 1.431 . . . . 0.0 113.122 -177.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -125.37 159.98 30.47 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.097 1.359 . . . . 0.0 112.163 178.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 27.1 m -98.41 158.62 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.431 1.092 . . . . 0.0 111.117 176.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 3.4 p -150.17 122.86 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 125.271 1.428 . . . . 0.0 109.324 175.098 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.0 ptm -126.9 139.44 53.07 Favored 'General case' 0 C--O 1.233 0.211 0 C-N-CA 124.098 0.959 . . . . 0.0 111.018 175.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 27.0 m -142.82 154.73 62.75 Favored Pre-proline 0 N--CA 1.468 0.473 0 C-N-CA 123.986 0.914 . . . . 0.0 111.469 177.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -74.8 119.92 5.9 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.156 2.571 . . . . 0.0 114.381 177.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 14.1 mt-10 -62.09 -39.93 94.11 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 178.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.27 7.71 78.01 Favored Glycine 0 N--CA 1.475 1.273 0 C-N-CA 124.677 1.132 . . . . 0.0 114.762 178.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 7.9 tttt -135.53 5.56 3.19 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.775 1.63 . . . . 0.0 112.451 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -49.65 -29.36 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 C-N-CA 125.329 1.452 . . . . 0.0 113.476 174.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 11.4 mt -58.01 -28.68 64.67 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.003 1.721 . . . . 0.0 112.286 177.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.42 -51.01 14.07 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.834 1.653 . . . . 0.0 112.218 177.202 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.5 mp -67.53 -29.47 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 124.375 1.07 . . . . 0.0 111.216 176.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 84.61 8.39 83.06 Favored Glycine 0 CA--C 1.536 1.358 0 C-N-CA 125.815 1.674 . . . . 0.0 114.069 -176.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 17.0 m -90.84 123.32 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 125.373 1.469 . . . . 0.0 111.345 -175.302 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.35 109.6 21.51 Favored 'General case' 0 N--CA 1.469 0.507 0 O-C-N 120.881 -1.137 . . . . 0.0 109.434 178.224 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.468 0.427 0 C-N-CA 123.989 0.916 . . . . 0.0 109.06 177.271 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.54 0.566 0 CA-C-O 120.567 0.222 . . . . 0.0 111.1 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.0 177.28 8.16 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.711 1.604 . . . . 0.0 112.184 176.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.8 t -59.69 129.3 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.175 0.99 . . . . 0.0 110.777 175.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.66 -4.68 85.76 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 124.835 1.207 . . . . 0.0 115.151 -177.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -70.83 165.75 22.5 Favored 'General case' 0 CA--C 1.549 0.916 0 CA-C-N 119.211 1.506 . . . . 0.0 111.613 174.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -89.56 148.73 23.21 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.902 0.881 . . . . 0.0 111.883 177.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.8 m -147.48 138.88 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 125.976 1.71 . . . . 0.0 109.184 176.266 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.0 p -137.11 146.33 28.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 C-N-CA 124.741 1.216 . . . . 0.0 110.483 176.273 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -84.19 158.77 60.69 Favored Pre-proline 0 CA--C 1.548 0.867 0 C-N-CA 123.409 0.684 . . . . 0.0 111.959 175.168 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -68.69 -25.91 33.59 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 123.809 3.006 . . . . 0.0 112.993 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -160.2 62.62 0.34 Allowed 'General case' 0 CA--C 1.554 1.118 0 C-N-CA 124.764 1.226 . . . . 0.0 112.316 177.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.86 -68.53 0.17 Allowed 'General case' 0 N--CA 1.48 1.053 0 O-C-N 120.988 -1.07 . . . . 0.0 112.222 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.42 179.82 43.5 Favored Glycine 0 CA--C 1.534 1.221 0 C-N-CA 125.04 1.305 . . . . 0.0 113.215 -174.36 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.7 m -94.94 149.96 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.466 1.506 . . . . 0.0 111.38 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.4 m -133.85 -177.85 4.75 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 124.622 1.169 . . . . 0.0 111.544 174.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -137.85 124.59 21.08 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.365 1.466 . . . . 0.0 111.749 177.236 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 61.1 t -63.47 126.74 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.036 0 C-N-CA 124.735 1.214 . . . . 0.0 111.173 -177.307 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 21.6 t -109.37 -53.92 2.6 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.049 1.34 . . . . 0.0 111.869 -177.092 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -151.68 162.02 41.7 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.142 1.377 . . . . 0.0 111.042 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -141.44 136.53 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 124.649 1.18 . . . . 0.0 108.55 -179.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -144.42 172.1 13.42 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 123.942 0.897 . . . . 0.0 111.773 177.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.3 p -120.54 138.29 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 O-C-N 120.691 -1.256 . . . . 0.0 110.758 175.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.89 164.29 36.66 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.175 1.39 . . . . 0.0 111.543 178.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -97.48 118.88 34.96 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 125.204 1.401 . . . . 0.0 109.77 174.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.3 p -123.54 135.47 63.22 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 124.303 1.041 . . . . 0.0 109.783 174.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.09 29.13 2.35 Favored 'General case' 0 CA--C 1.557 1.245 0 N-CA-C 114.625 1.343 . . . . 0.0 114.625 -177.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.01 25.28 52.9 Favored Glycine 0 CA--C 1.54 1.646 0 C-N-CA 124.787 1.184 . . . . 0.0 115.188 -176.184 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -139.44 116.78 11.24 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.35 1.46 . . . . 0.0 111.175 -174.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 3.5 tttt -95.21 124.81 39.45 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 124.83 1.252 . . . . 0.0 111.656 -178.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -158.17 162.97 37.97 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 123.033 0.533 . . . . 0.0 111.697 179.428 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.3 m -69.37 116.43 9.79 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 124.192 0.997 . . . . 0.0 111.147 177.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -105.2 113.14 26.56 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 124.875 1.27 . . . . 0.0 110.068 175.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 30.1 m -81.42 144.06 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.838 177.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 26.2 m -126.55 117.12 22.17 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.277 1.031 . . . . 0.0 110.735 178.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 1.5 mpp? -119.15 156.17 30.28 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 124.818 1.247 . . . . 0.0 110.116 -176.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -132.09 136.35 47.11 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.184 1.394 . . . . 0.0 110.259 -178.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 13.0 mtm180 -98.36 109.12 21.93 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 177.076 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -70.28 -15.46 62.9 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 123.239 0.616 . . . . 0.0 112.557 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -57.57 -42.18 82.56 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 126.779 2.031 . . . . 0.0 112.961 176.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -128.66 -15.41 4.45 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 124.874 1.27 . . . . 0.0 114.111 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.23 4.99 64.11 Favored Glycine 0 CA--C 1.538 1.5 0 C-N-CA 126.105 1.812 . . . . 0.0 114.952 -177.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -74.07 163.47 27.84 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 118.644 1.222 . . . . 0.0 112.819 177.449 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 15.9 m -126.32 156.12 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 125.592 1.557 . . . . 0.0 110.727 174.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 23.3 m -140.13 150.94 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 125.951 1.701 . . . . 0.0 109.898 176.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 62.9 ttp -145.03 122.08 11.4 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.791 0.836 . . . . 0.0 110.139 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.6 m -130.4 155.14 81.45 Favored Pre-proline 0 N--CA 1.476 0.84 0 C-N-CA 124.034 0.934 . . . . 0.0 112.17 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -76.05 115.82 4.24 Favored 'Trans proline' 0 CA--C 1.538 0.698 0 C-N-CA 123.486 2.791 . . . . 0.0 114.438 176.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -64.63 -34.02 77.29 Favored 'General case' 0 N--CA 1.479 0.992 0 O-C-N 120.335 -1.478 . . . . 0.0 114.013 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.23 5.06 78.03 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 124.403 1.001 . . . . 0.0 114.876 176.32 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.6 tttm -135.57 3.34 3.03 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.493 1.517 . . . . 0.0 112.922 -177.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 1.6 m -49.7 -29.53 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 C-N-CA 125.685 1.594 . . . . 0.0 113.308 175.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.6 mt -57.62 -28.9 64.08 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.093 1.757 . . . . 0.0 112.302 177.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.81 -49.92 16.65 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.974 1.709 . . . . 0.0 112.854 175.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.8 mp -67.85 -33.21 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 124.013 0.925 . . . . 0.0 111.37 177.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 91.68 3.68 68.43 Favored Glycine 0 CA--C 1.537 1.434 0 C-N-CA 125.776 1.655 . . . . 0.0 114.239 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 29.1 m -87.47 123.18 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.045 1.338 . . . . 0.0 110.616 -176.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -104.46 109.28 21.1 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 120.625 -1.297 . . . . 0.0 108.652 176.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.468 0.475 0 C-N-CA 123.1 0.56 . . . . 0.0 109.532 177.397 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.436 HD11 ' HE2' ' A' ' 70' ' ' LYS . 1.4 tt . . . . . 0 CA--C 1.548 0.891 0 CA-C-O 120.827 0.346 . . . . 0.0 111.671 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -143.77 177.36 8.57 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 125.544 1.538 . . . . 0.0 112.214 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 97.5 t -60.02 130.96 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 O-C-N 121.082 -1.012 . . . . 0.0 110.796 178.049 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.32 -2.57 88.06 Favored Glycine 0 CA--C 1.537 1.455 0 C-N-CA 124.809 1.195 . . . . 0.0 115.02 -179.228 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -71.09 -179.84 2.5 Favored 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.22 1.408 . . . . 0.0 112.539 176.095 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 26.7 mmt180 -112.44 154.08 26.37 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 124.953 1.301 . . . . 0.0 112.966 -178.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.4 p -152.63 126.83 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 125.77 1.628 . . . . 0.0 110.493 -179.073 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.0 p -135.6 120.08 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 C-N-CA 126.79 2.036 . . . . 0.0 110.486 174.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 -58.65 156.61 22.9 Favored Pre-proline 0 CA--C 1.544 0.74 0 O-C-N 121.055 -1.028 . . . . 0.0 112.281 175.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -67.16 -24.59 44.25 Favored 'Trans proline' 0 CA--C 1.539 0.77 0 C-N-CA 122.716 2.277 . . . . 0.0 112.52 -176.312 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -157.78 62.48 0.47 Allowed 'General case' 0 CA--C 1.555 1.149 0 C-N-CA 124.809 1.244 . . . . 0.0 112.444 175.528 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.9 mm-40 -150.24 -66.37 0.2 Allowed 'General case' 0 N--CA 1.483 1.189 0 O-C-N 120.841 -1.162 . . . . 0.0 112.451 179.362 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 166.01 175.17 36.19 Favored Glycine 0 CA--C 1.533 1.198 0 C-N-CA 124.929 1.252 . . . . 0.0 113.451 -178.074 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 38.4 t -93.42 145.64 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 125.929 1.692 . . . . 0.0 110.818 -177.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.3 m -130.34 178.41 6.61 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 126.503 1.921 . . . . 0.0 111.116 174.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.3 130.48 44.55 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.128 1.771 . . . . 0.0 110.658 -179.304 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 35.7 t -68.05 125.47 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 124.61 1.164 . . . . 0.0 110.903 178.355 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.9 p -109.3 -41.16 4.72 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.728 0.811 . . . . 0.0 112.776 178.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -160.5 173.3 15.77 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 126.746 2.018 . . . . 0.0 110.659 175.754 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 64.2 mt -146.88 139.87 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.311 1.444 . . . . 0.0 108.728 174.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -146.62 172.72 13.17 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.803 1.241 . . . . 0.0 112.116 174.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 20.6 m -115.81 142.63 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.344 1.058 . . . . 0.0 110.523 176.44 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -157.89 171.95 19.35 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.895 0.878 . . . . 0.0 112.18 176.663 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.61 115.17 29.93 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.906 1.682 . . . . 0.0 110.464 174.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 m -121.97 138.72 51.28 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 124.811 1.244 . . . . 0.0 109.092 174.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 46.06 28.99 0.7 Allowed 'General case' 0 CA--C 1.559 1.317 0 N-CA-C 115.391 1.626 . . . . 0.0 115.391 179.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.11 24.22 52.77 Favored Glycine 0 CA--C 1.544 1.895 0 C-N-CA 124.892 1.234 . . . . 0.0 115.88 -175.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 7.4 tp60 -135.39 113.52 11.29 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.593 1.957 . . . . 0.0 110.268 -174.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -95.37 113.38 25.04 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 125.121 1.369 . . . . 0.0 111.218 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -156.19 173.65 16.53 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.375 0.67 . . . . 0.0 112.049 179.537 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.0 m -76.88 116.37 17.49 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 124.338 1.055 . . . . 0.0 111.895 175.309 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -106.54 115.33 30.01 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.971 1.308 . . . . 0.0 109.222 175.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.445 HG11 ' HE3' ' A' ' 70' ' ' LYS . 13.6 m -63.94 153.5 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 O-C-N 121.877 -0.514 . . . . 0.0 111.609 176.001 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 10.9 m -126.48 109.82 12.61 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 122.137 0.97 . . . . 0.0 111.043 175.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -128.89 155.77 44.74 Favored 'General case' 0 C--O 1.236 0.38 0 C-N-CA 124.703 1.201 . . . . 0.0 109.865 -178.704 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -131.08 125.54 33.44 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.893 1.277 . . . . 0.0 110.183 176.349 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.0 ttm-85 -85.08 109.06 17.96 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.524 1.13 . . . . 0.0 109.123 175.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.68 -15.38 63.16 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 176.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -62.23 -35.46 78.97 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.18 1.792 . . . . 0.0 112.779 -177.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 29.8 p30 -128.63 -16.68 4.23 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 126.637 1.975 . . . . 0.0 114.129 175.053 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.65 4.66 63.64 Favored Glycine 0 CA--C 1.538 1.49 0 C-N-CA 126.137 1.827 . . . . 0.0 115.086 -177.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -77.1 168.9 19.29 Favored 'General case' 0 CA--C 1.546 0.798 0 CA-C-N 119.387 1.594 . . . . 0.0 113.149 178.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 m -111.48 157.59 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 125.092 1.357 . . . . 0.0 111.138 175.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.4 p -147.48 118.86 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 124.517 1.127 . . . . 0.0 110.017 179.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -132.93 97.01 3.91 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 124.822 1.249 . . . . 0.0 110.076 -178.02 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 36.0 m -99.86 157.24 34.25 Favored Pre-proline 0 N--CA 1.472 0.638 0 C-N-CA 123.369 0.668 . . . . 0.0 111.684 176.708 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -77.22 118.75 4.77 Favored 'Trans proline' 0 CA--C 1.536 0.608 0 C-N-CA 123.488 2.792 . . . . 0.0 114.558 175.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -61.6 -38.98 89.59 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 120.479 -1.388 . . . . 0.0 114.22 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.14 5.97 78.57 Favored Glycine 0 N--CA 1.476 1.338 0 C-N-CA 124.723 1.154 . . . . 0.0 115.027 178.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 17.9 tttp -133.21 3.37 3.66 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 125.751 1.62 . . . . 0.0 112.597 -178.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.3 m -48.33 -29.63 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 125.428 1.491 . . . . 0.0 113.726 175.077 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 17.2 mt -54.71 -30.64 56.51 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.024 1.73 . . . . 0.0 112.492 176.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.07 -48.69 22.66 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.734 1.613 . . . . 0.0 112.872 176.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.0 mp -66.74 -32.52 58.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.431 1.093 . . . . 0.0 111.285 176.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 87.05 3.99 82.22 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 125.545 1.545 . . . . 0.0 114.014 -176.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 93.2 t -81.51 147.95 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.598 1.159 . . . . 0.0 109.888 175.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.73 124.54 49.89 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 104.745 -2.317 . . . . 0.0 104.745 175.008 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.445 ' HE3' HG11 ' A' ' 45' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.467 0.389 0 C-N-CA 124.497 1.119 . . . . 0.0 108.269 177.301 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.1 mm? . . . . . 0 CA--C 1.533 0.323 0 CA-C-O 121.24 0.543 . . . . 0.0 110.578 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.74 175.5 9.66 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 125.871 1.668 . . . . 0.0 111.254 179.006 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 59.7 t -58.05 129.8 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 123.811 0.844 . . . . 0.0 110.772 176.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.52 -5.25 85.07 Favored Glycine 0 CA--C 1.536 1.359 0 C-N-CA 125.136 1.351 . . . . 0.0 115.2 -175.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -69.72 163.28 26.03 Favored 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 119.836 1.818 . . . . 0.0 112.099 175.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -101.04 130.87 47.11 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.71 1.204 . . . . 0.0 111.06 -175.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.6 m -142.34 143.3 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.797 0.839 . . . . 0.0 110.326 -178.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.4 p -137.08 148.22 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 C-N-CA 124.526 1.13 . . . . 0.0 110.685 178.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -79.15 161.13 69.23 Favored Pre-proline 0 CA--C 1.549 0.919 0 O-C-N 121.853 -0.529 . . . . 0.0 111.655 175.091 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -71.57 -22.33 24.57 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 123.312 2.675 . . . . 0.0 112.837 -177.24 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 16.2 t-20 -162.68 68.29 0.23 Allowed 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 126.273 1.829 . . . . 0.0 111.296 175.007 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -156.28 -71.83 0.11 Allowed 'General case' 0 N--CA 1.482 1.141 0 O-C-N 121.15 -0.968 . . . . 0.0 112.319 177.224 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 176.43 172.93 41.6 Favored Glycine 0 CA--C 1.534 1.222 0 C-N-CA 124.548 1.07 . . . . 0.0 113.734 -176.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.1 m -85.86 148.47 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 125.187 1.395 . . . . 0.0 111.231 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 15.6 m -137.18 171.87 13.85 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.996 1.718 . . . . 0.0 110.921 179.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -137.71 120.01 15.78 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 124.414 1.086 . . . . 0.0 110.596 -175.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -63.73 124.78 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 123.615 0.766 . . . . 0.0 111.518 -174.106 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 86.1 p -107.43 -40.95 5.21 Favored 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 -177.769 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.43 162.78 35.75 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.489 1.516 . . . . 0.0 110.839 176.127 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 67.8 mt -141.83 134.87 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.781 0 O-C-N 121.029 -1.044 . . . . 0.0 109.076 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -142.72 177.64 8.18 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 124.269 1.028 . . . . 0.0 111.854 178.017 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 p -127.31 137.09 58.8 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 C-N-CA 124.963 1.305 . . . . 0.0 110.425 176.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.43 165.81 32.01 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 124.698 1.199 . . . . 0.0 111.963 178.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -97.89 118.93 35.56 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 125.088 1.355 . . . . 0.0 109.763 174.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.9 p -124.43 134.9 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 C-N-CA 124.251 1.02 . . . . 0.0 109.562 175.112 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.75 29.0 2.05 Favored 'General case' 0 CA--C 1.556 1.2 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 -177.208 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.99 25.66 51.67 Favored Glycine 0 CA--C 1.541 1.708 0 C-N-CA 124.616 1.103 . . . . 0.0 115.174 -176.266 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -137.43 119.73 15.74 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 126.02 1.728 . . . . 0.0 111.053 -178.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 13.7 ttpt -96.12 124.34 40.08 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.636 1.175 . . . . 0.0 111.582 178.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -157.69 163.53 38.09 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.008 0.523 . . . . 0.0 111.805 178.771 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.8 m -68.64 116.58 9.33 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.997 0.919 . . . . 0.0 110.971 177.365 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -105.51 113.26 26.72 Favored 'General case' 0 N--CA 1.467 0.377 0 O-C-N 121.076 -1.015 . . . . 0.0 109.591 174.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.0 m -78.16 141.9 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 C-N-CA 123.486 0.714 . . . . 0.0 110.502 176.338 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 8.1 m -120.31 120.32 35.7 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.602 1.161 . . . . 0.0 109.281 176.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 2.1 mpp? -123.18 157.49 32.88 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 124.703 1.201 . . . . 0.0 109.736 179.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 31.2 mtt85 -136.58 132.56 35.3 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 124.39 1.076 . . . . 0.0 109.875 -179.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -93.89 109.16 20.88 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 177.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -70.32 -14.37 62.55 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 175.151 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -60.21 -36.97 78.88 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.459 1.504 . . . . 0.0 113.066 177.652 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -127.99 -23.31 3.36 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.459 1.503 . . . . 0.0 113.356 178.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 96.3 25.98 11.73 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 125.565 1.555 . . . . 0.0 114.42 -177.05 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.62 169.53 10.26 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.957 1.303 . . . . 0.0 112.752 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.7 m -124.4 154.38 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 125.255 1.422 . . . . 0.0 111.65 177.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.8 p -151.1 123.47 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 C-N-CA 125.581 1.553 . . . . 0.0 109.689 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.9 ttt -125.83 121.21 32.61 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.625 1.17 . . . . 0.0 109.914 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 28.6 m -129.21 156.33 78.48 Favored Pre-proline 0 N--CA 1.478 0.932 0 C-N-CA 124.087 0.955 . . . . 0.0 112.112 -179.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -77.84 114.58 3.66 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 123.628 2.885 . . . . 0.0 114.586 176.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -63.83 -33.72 76.32 Favored 'General case' 0 N--CA 1.481 1.096 0 O-C-N 120.271 -1.518 . . . . 0.0 113.957 179.422 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.19 4.43 77.53 Favored Glycine 0 N--CA 1.475 1.272 0 C-N-CA 124.459 1.028 . . . . 0.0 115.074 175.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.1 tttm -135.58 3.42 3.03 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 125.489 1.515 . . . . 0.0 112.978 -177.569 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 1.6 m -49.98 -30.77 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 125.598 1.559 . . . . 0.0 113.079 175.402 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.1 mt -56.51 -28.9 61.1 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.123 1.769 . . . . 0.0 112.494 177.227 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.95 -48.66 17.48 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.736 1.614 . . . . 0.0 112.66 177.223 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 2.9 mp -68.59 -30.55 47.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 124.085 0.954 . . . . 0.0 111.357 176.264 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.58 3.23 78.08 Favored Glycine 0 CA--C 1.537 1.416 0 C-N-CA 126.092 1.806 . . . . 0.0 114.309 -176.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 18.7 m -80.17 123.2 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.8 0 C-N-CA 125.596 1.558 . . . . 0.0 110.858 -178.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.66 109.39 20.97 Favored 'General case' 0 N--CA 1.472 0.653 0 O-C-N 120.847 -1.158 . . . . 0.0 108.881 175.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.471 0.576 0 O-C-N 121.749 -0.595 . . . . 0.0 109.76 176.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.425 ' HG ' ' HZ1' ' A' ' 70' ' ' LYS . 0.8 OUTLIER . . . . . 0 CA--C 1.543 0.676 0 CA-C-O 120.644 0.259 . . . . 0.0 111.188 . . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -133.82 166.34 22.89 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 125.516 1.526 . . . . 0.0 112.297 179.538 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.8 t -56.65 135.76 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.399 1.08 . . . . 0.0 111.035 175.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.15 -13.01 60.72 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 125.635 1.588 . . . . 0.0 115.216 -176.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -72.88 170.0 15.66 Favored 'General case' 0 CA--C 1.549 0.921 0 CA-C-N 119.06 1.43 . . . . 0.0 111.376 175.075 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.9 mmt180 -108.56 142.81 38.45 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 126.194 1.797 . . . . 0.0 111.141 -171.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 32.9 m -143.92 128.04 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 124.278 1.031 . . . . 0.0 111.769 -171.099 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 8.2 p -95.2 164.45 2.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 125.416 1.487 . . . . 0.0 111.052 176.092 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -137.01 156.6 75.66 Favored Pre-proline 0 CA--C 1.535 0.381 0 C-N-CA 124.571 1.148 . . . . 0.0 112.991 178.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.7 -28.84 30.36 Favored 'Trans proline' 0 CA--C 1.538 0.721 0 C-N-CA 123.038 2.492 . . . . 0.0 112.762 -178.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -151.88 54.28 0.83 Allowed 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 125.337 1.455 . . . . 0.0 111.919 178.435 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -145.01 -60.58 0.36 Allowed 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 124.332 1.053 . . . . 0.0 110.653 175.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 124.2 -169.4 16.28 Favored Glycine 0 CA--C 1.535 1.284 0 C-N-CA 126.413 1.958 . . . . 0.0 112.25 -173.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -72.42 136.51 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.642 1.177 . . . . 0.0 110.932 177.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.4 ' HG ' HG12 ' A' ' 56' ' ' VAL . 25.6 m -128.7 175.13 8.83 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 126.105 1.762 . . . . 0.0 111.777 175.229 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -130.57 119.02 21.89 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 126.242 1.817 . . . . 0.0 110.833 -179.258 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.5 t -64.61 127.87 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 123.691 0.796 . . . . 0.0 111.025 -178.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.7 p -112.5 -40.55 4.07 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.219 1.008 . . . . 0.0 112.699 -176.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -155.1 167.11 31.46 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.716 2.006 . . . . 0.0 110.656 175.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 60.7 mt -146.06 137.16 19.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.895 1.278 . . . . 0.0 108.504 176.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -146.02 171.92 14.15 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.01 0.924 . . . . 0.0 112.059 176.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.2 m -113.9 144.57 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.147 -0.971 . . . . 0.0 111.543 175.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 9.7 ptmt -156.25 171.99 19.23 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 124.854 1.262 . . . . 0.0 111.874 177.197 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -108.03 117.73 34.91 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.168 1.787 . . . . 0.0 109.79 174.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.3 p -127.67 138.21 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 124.843 1.257 . . . . 0.0 109.322 174.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.74 29.35 1.52 Allowed 'General case' 0 CA--C 1.557 1.23 0 N-CA-C 114.707 1.373 . . . . 0.0 114.707 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.0 24.39 57.84 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.281 1.42 . . . . 0.0 115.543 -176.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -132.55 113.54 13.19 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 126.106 1.762 . . . . 0.0 110.817 -175.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 67.3 tttt -95.96 114.35 26.05 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.085 1.354 . . . . 0.0 111.321 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -157.89 173.61 16.53 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 123.066 0.547 . . . . 0.0 111.791 -179.376 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 20.1 m -79.01 116.43 19.31 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.362 1.065 . . . . 0.0 112.122 175.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -105.04 115.83 30.94 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.512 1.125 . . . . 0.0 109.77 175.094 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.24 147.53 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.382 0.673 . . . . 0.0 111.245 176.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 19.7 m -123.27 110.06 14.72 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.723 0.809 . . . . 0.0 109.634 177.123 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.92 162.44 25.94 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 121.724 0.773 . . . . 0.0 110.929 178.409 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 3.0 ptt180 -144.88 116.81 8.28 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 124.801 1.24 . . . . 0.0 109.987 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 6.4 mtp85 -62.69 115.01 3.93 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 124.818 1.247 . . . . 0.0 110.602 179.327 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.2 pp20? -60.54 -36.03 77.44 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.658 0.783 . . . . 0.0 112.877 179.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -91.45 -46.73 7.83 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 123.889 0.875 . . . . 0.0 113.033 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -73.1 -19.41 61.16 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 113.543 0.942 . . . . 0.0 113.543 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.44 8.77 56.64 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 126.27 1.89 . . . . 0.0 115.151 -178.53 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.0 138.32 40.71 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.6 1.56 . . . . 0.0 112.246 -173.257 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 26.7 m -80.02 152.26 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 123.319 0.648 . . . . 0.0 110.023 174.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.4 HG12 ' HG ' ' A' ' 27' ' ' CYS . 13.6 p -145.23 138.7 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 124.514 1.125 . . . . 0.0 109.887 177.139 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 11.4 ttp -145.03 115.9 7.79 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 124.579 1.152 . . . . 0.0 110.004 -179.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.6 m -121.66 156.93 58.14 Favored Pre-proline 0 N--CA 1.472 0.673 0 C-N-CA 124.83 1.252 . . . . 0.0 111.27 177.021 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -79.8 114.45 3.19 Favored 'Trans proline' 0 CA--C 1.537 0.637 0 C-N-CA 123.488 2.792 . . . . 0.0 114.954 178.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -58.39 -39.23 79.11 Favored 'General case' 0 N--CA 1.48 1.041 0 O-C-N 120.424 -1.422 . . . . 0.0 114.286 -178.496 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.06 7.32 78.78 Favored Glycine 0 N--CA 1.474 1.19 0 C-N-CA 124.751 1.167 . . . . 0.0 114.753 179.008 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.0 tttt -134.62 1.72 3.12 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.596 1.559 . . . . 0.0 112.888 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.0 m -48.34 -30.74 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.593 1.557 . . . . 0.0 113.546 175.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.6 mt -57.66 -29.86 64.96 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 126.47 1.908 . . . . 0.0 112.735 176.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.99 -49.97 16.18 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.781 1.632 . . . . 0.0 112.635 176.025 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.3 mp -67.93 -32.22 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 123.66 0.784 . . . . 0.0 111.31 177.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.52 9.41 66.76 Favored Glycine 0 CA--C 1.534 1.256 0 C-N-CA 125.532 1.539 . . . . 0.0 113.889 -174.446 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 12.2 m -75.8 155.89 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 118.317 1.058 . . . . 0.0 110.804 177.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -139.91 109.69 6.36 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.881 1.272 . . . . 0.0 110.221 175.264 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.432 ' HE3' ' O ' ' A' ' 70' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.47 0.567 0 C-N-CA 125.454 1.502 . . . . 0.0 110.65 177.528 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 14.3 tp . . . . . 0 CA--C 1.542 0.65 0 CA-C-O 120.62 0.248 . . . . 0.0 110.887 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -148.19 177.63 9.23 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.508 1.523 . . . . 0.0 111.427 175.02 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.9 t -59.33 133.7 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 O-C-N 121.395 -0.815 . . . . 0.0 111.296 176.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.31 -4.48 85.54 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 124.817 1.198 . . . . 0.0 115.211 -178.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -71.56 178.35 3.56 Favored 'General case' 0 CA--C 1.553 1.066 0 CA-C-N 118.835 1.318 . . . . 0.0 110.906 174.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 19.2 mmt180 -98.49 151.44 20.61 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.499 1.52 . . . . 0.0 111.378 178.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.8 p -140.02 125.67 21.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 C-N-CA 124.225 1.01 . . . . 0.0 110.94 176.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.7 p -132.14 145.68 34.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 C-N-CA 125.59 1.556 . . . . 0.0 108.532 175.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -91.72 161.06 34.98 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 125.005 1.322 . . . . 0.0 111.948 175.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.34 -28.84 26.8 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.848 2.365 . . . . 0.0 111.954 -175.208 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -159.08 54.16 0.41 Allowed 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 124.311 1.044 . . . . 0.0 113.032 176.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -142.86 -62.25 0.42 Allowed 'General case' 0 N--CA 1.478 0.974 0 O-C-N 121.14 -0.975 . . . . 0.0 113.567 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.1 -172.52 44.44 Favored Glycine 0 CA--C 1.533 1.168 0 C-N-CA 124.291 0.948 . . . . 0.0 113.514 -176.193 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.6 p -115.68 144.5 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 126.728 2.011 . . . . 0.0 110.567 179.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 77.2 m -132.84 -175.02 3.64 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 126.614 1.966 . . . . 0.0 110.572 175.565 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -129.46 123.94 32.82 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 125.037 1.335 . . . . 0.0 111.198 -177.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.6 t -63.42 128.38 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 O-C-N 121.778 -0.576 . . . . 0.0 111.189 -177.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.4 t -109.92 -53.52 2.66 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.981 1.712 . . . . 0.0 111.515 -176.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.64 165.95 34.8 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 125.204 1.402 . . . . 0.0 111.032 174.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.4 mt -142.05 130.92 22.49 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 124.62 1.168 . . . . 0.0 108.76 178.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -147.73 173.93 12.29 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 123.543 0.737 . . . . 0.0 112.338 175.292 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 25.5 m -106.72 142.21 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.984 0 O-C-N 121.022 -1.049 . . . . 0.0 110.852 176.106 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -156.14 171.63 19.82 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.986 0.914 . . . . 0.0 112.336 176.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -104.55 115.77 30.92 Favored 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 125.94 1.696 . . . . 0.0 109.704 175.201 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.1 p -127.89 138.12 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.792 0.837 . . . . 0.0 109.626 175.122 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.77 28.98 1.43 Allowed 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 114.905 1.446 . . . . 0.0 114.905 -177.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.49 23.98 55.02 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.235 1.398 . . . . 0.0 115.441 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -131.97 113.48 13.46 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 126.193 1.797 . . . . 0.0 109.771 -174.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 16.5 tttt -96.43 112.43 24.17 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.48 1.112 . . . . 0.0 111.635 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -157.43 173.78 16.4 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 123.407 0.683 . . . . 0.0 112.217 179.262 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.2 m -73.34 116.49 13.95 Favored 'General case' 0 N--CA 1.475 0.82 0 C-N-CA 124.724 1.209 . . . . 0.0 111.101 175.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -111.38 113.78 26.48 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 124.671 1.189 . . . . 0.0 110.036 177.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 27.4 m -75.2 145.45 10.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 123.326 0.65 . . . . 0.0 110.537 177.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 21.7 m -126.52 116.05 20.48 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 124.367 1.067 . . . . 0.0 110.948 -179.603 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 2.1 mpp? -126.32 141.94 51.72 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.097 0.959 . . . . 0.0 109.619 -175.236 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.7 mtt85 -127.58 109.65 11.92 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 125.233 1.413 . . . . 0.0 109.2 -172.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -77.32 109.11 10.94 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 56.5 mt-10 -67.05 -23.0 65.84 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.886 0.875 . . . . 0.0 112.56 178.292 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -55.81 -39.56 71.51 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.462 1.905 . . . . 0.0 113.14 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -128.55 2.94 5.56 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.598 1.559 . . . . 0.0 113.377 -179.692 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.56 17.3 64.35 Favored Glycine 0 CA--C 1.538 1.472 0 C-N-CA 126.1 1.81 . . . . 0.0 114.669 -171.415 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -75.84 165.55 24.85 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 124.903 1.281 . . . . 0.0 112.484 -178.489 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.5 m -131.61 150.83 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 124.918 1.287 . . . . 0.0 111.02 177.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.8 p -146.73 144.18 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 C-N-CA 125.22 1.408 . . . . 0.0 109.49 176.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 8.8 ttm -138.28 127.25 24.01 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.62 1.168 . . . . 0.0 108.997 174.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.8 m -129.44 156.26 78.82 Favored Pre-proline 0 N--CA 1.473 0.718 0 C-N-CA 123.576 0.751 . . . . 0.0 111.615 175.066 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -79.45 115.7 3.46 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.511 2.807 . . . . 0.0 114.9 177.191 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -62.31 -35.28 78.55 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 119.988 -1.695 . . . . 0.0 114.689 176.307 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.4 6.34 80.68 Favored Glycine 0 N--CA 1.473 1.131 0 O-C-N 121.547 -0.721 . . . . 0.0 114.639 176.691 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.5 tttt -137.06 0.59 2.38 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.902 1.281 . . . . 0.0 113.687 -177.182 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.5 m -49.93 -29.02 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 C-N-CA 125.166 1.386 . . . . 0.0 113.795 175.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.2 mt -58.32 -27.44 64.12 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.594 1.557 . . . . 0.0 112.127 177.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.13 -50.96 11.84 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.945 1.698 . . . . 0.0 112.386 175.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.5 mp -69.51 -33.55 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 123.863 0.865 . . . . 0.0 111.824 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 90.35 12.72 61.02 Favored Glycine 0 CA--C 1.538 1.521 0 C-N-CA 126.03 1.776 . . . . 0.0 114.914 -178.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 97.6 t -89.56 135.38 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 C-N-CA 125.375 1.47 . . . . 0.0 110.657 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.37 109.2 11.54 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 123.721 0.808 . . . . 0.0 110.315 175.039 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.471 0.596 0 CA-C-O 121.631 0.729 . . . . 0.0 110.192 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 11.8 mt . . . . . 0 CA--C 1.543 0.692 0 CA-C-O 121.459 0.647 . . . . 0.0 110.281 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -146.78 157.1 43.59 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 125.196 1.398 . . . . 0.0 110.849 175.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.4 t -57.31 125.72 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.834 0.854 . . . . 0.0 111.056 178.016 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.44 -5.06 84.61 Favored Glycine 0 CA--C 1.533 1.165 0 C-N-CA 124.973 1.273 . . . . 0.0 115.005 -176.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -68.69 152.8 44.86 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 118.97 1.385 . . . . 0.0 109.79 174.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 9.4 mpt_? -85.0 167.74 15.57 Favored 'General case' 0 N--CA 1.471 0.616 0 O-C-N 121.246 -0.909 . . . . 0.0 110.74 176.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 26.1 m -151.16 158.54 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 127.054 2.141 . . . . 0.0 111.068 175.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.4 p -136.55 160.11 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 125.8 1.64 . . . . 0.0 109.515 174.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -114.16 160.43 32.57 Favored Pre-proline 0 CA--C 1.542 0.664 0 C-N-CA 125.354 1.461 . . . . 0.0 111.539 175.016 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -67.48 -27.66 39.39 Favored 'Trans proline' 0 CA--C 1.539 0.734 0 C-N-CA 123.002 2.468 . . . . 0.0 112.822 178.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -158.77 53.81 0.42 Allowed 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 124.081 0.952 . . . . 0.0 113.278 178.502 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.11 -57.73 0.38 Allowed 'General case' 0 N--CA 1.479 0.997 0 O-C-N 121.107 -0.996 . . . . 0.0 113.58 -176.83 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 156.09 -160.26 29.96 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.526 1.06 . . . . 0.0 112.513 -174.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.4 m -118.98 147.97 22.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 125.844 1.658 . . . . 0.0 111.524 177.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 6.3 m -139.02 178.87 6.85 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.303 1.441 . . . . 0.0 110.886 177.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 49.4 ttt-85 -133.74 131.87 39.9 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.16 1.384 . . . . 0.0 111.673 179.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.0 t -59.09 132.64 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.674 1.189 . . . . 0.0 111.293 -179.034 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.9 t -112.07 -53.05 2.74 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 126.505 1.922 . . . . 0.0 111.15 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -145.98 159.14 43.67 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.562 1.145 . . . . 0.0 111.023 -178.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.4 mt -143.74 127.26 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.514 1.125 . . . . 0.0 109.108 178.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -149.8 157.14 42.91 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.218 1.007 . . . . 0.0 112.351 175.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 m -97.02 141.56 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 O-C-N 121.279 -0.888 . . . . 0.0 110.342 175.474 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -154.51 171.44 19.41 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.878 0.871 . . . . 0.0 111.728 175.171 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -103.61 116.62 32.69 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.543 1.537 . . . . 0.0 109.372 175.373 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 p -124.33 137.86 55.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.025 0 C-N-CA 124.419 1.088 . . . . 0.0 108.941 175.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.22 29.74 1.97 Allowed 'General case' 0 CA--C 1.557 1.233 0 N-CA-C 114.809 1.411 . . . . 0.0 114.809 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.39 23.36 56.79 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 125.046 1.308 . . . . 0.0 115.49 -176.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -136.91 113.48 10.17 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 125.365 1.466 . . . . 0.0 111.822 -173.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -94.81 114.41 26.28 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.862 1.665 . . . . 0.0 111.132 -177.207 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -155.07 171.59 19.51 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.2 0.6 . . . . 0.0 111.669 178.698 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.7 m -73.8 116.56 14.54 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 124.035 0.934 . . . . 0.0 110.945 175.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -107.08 113.13 26.39 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 122.239 1.018 . . . . 0.0 109.68 176.03 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.0 m -83.11 146.16 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 C-N-CA 123.438 0.695 . . . . 0.0 110.148 176.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 3.9 m -124.39 113.46 18.21 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 125.142 1.377 . . . . 0.0 109.865 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 2.8 mtm -107.28 165.21 11.55 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 124.685 1.194 . . . . 0.0 110.221 175.025 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 35.2 ptt180 -140.48 162.03 36.31 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 125.873 1.669 . . . . 0.0 111.219 175.12 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.0 mpt_? -109.25 131.26 55.23 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.745 0.818 . . . . 0.0 110.035 175.015 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 70.2 mt-10 -68.3 -35.64 78.14 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.988 0.915 . . . . 0.0 111.827 176.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -91.96 -46.58 7.75 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 124.523 1.129 . . . . 0.0 112.831 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.05 -24.04 62.26 Favored 'General case' 0 N--CA 1.476 0.864 0 O-C-N 121.559 -0.713 . . . . 0.0 111.937 -178.133 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.81 9.77 47.46 Favored Glycine 0 CA--C 1.536 1.371 0 C-N-CA 125.719 1.628 . . . . 0.0 114.651 -179.176 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -101.1 159.88 14.86 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.289 1.836 . . . . 0.0 111.235 -177.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 31.3 m -111.63 151.57 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 124.881 1.272 . . . . 0.0 110.479 175.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.4 p -135.04 124.91 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.66 1.584 . . . . 0.0 108.42 176.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.41 125.3 54.06 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 124.734 1.214 . . . . 0.0 109.033 176.092 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 15.4 m -137.74 156.24 74.63 Favored Pre-proline 0 N--CA 1.472 0.652 0 C-N-CA 123.108 0.563 . . . . 0.0 111.524 176.164 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -77.14 115.66 4.03 Favored 'Trans proline' 0 CA--C 1.536 0.59 0 C-N-CA 123.516 2.811 . . . . 0.0 114.232 177.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -59.08 -45.62 90.35 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 120.557 -1.339 . . . . 0.0 112.497 175.639 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -83.33 6.37 72.65 Favored Glycine 0 N--CA 1.475 1.25 0 O-C-N 120.999 -1.063 . . . . 0.0 115.282 178.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 15.6 tttt -137.5 4.6 2.63 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 125.434 1.493 . . . . 0.0 113.027 -178.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.8 m -51.88 -29.15 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 125.297 1.439 . . . . 0.0 113.35 176.097 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.1 mt -58.06 -29.14 65.17 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 125.926 1.691 . . . . 0.0 112.426 176.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.09 -49.48 23.78 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 125.672 1.589 . . . . 0.0 112.61 175.22 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 2.5 mp -67.0 -32.68 59.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 C-N-CA 123.476 0.71 . . . . 0.0 111.339 177.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.79 20.38 43.89 Favored Glycine 0 CA--C 1.534 1.243 0 C-N-CA 124.834 1.207 . . . . 0.0 113.811 -177.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 40.9 t -102.58 123.75 56.11 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 124.328 1.051 . . . . 0.0 110.096 -178.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -98.67 110.14 22.79 Favored 'General case' 0 N--CA 1.475 0.821 0 O-C-N 121.178 -0.951 . . . . 0.0 110.523 175.041 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.7 ptpm? . . . . . 0 N--CA 1.47 0.55 0 C-N-CA 127.423 2.289 . . . . 0.0 109.699 179.138 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.542 0.666 0 CA-C-O 120.71 0.29 . . . . 0.0 110.514 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -147.45 177.34 9.32 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.198 1.399 . . . . 0.0 112.013 177.021 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -58.71 129.84 21.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 123.756 0.822 . . . . 0.0 111.276 175.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 88.5 -4.3 85.19 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 125.191 1.377 . . . . 0.0 115.126 -178.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -72.0 176.37 5.11 Favored 'General case' 0 CA--C 1.551 0.986 0 CA-C-N 118.946 1.373 . . . . 0.0 112.075 175.027 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 2.4 tpt180 -119.49 142.01 48.67 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 125.278 1.431 . . . . 0.0 111.578 -177.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 15.6 m -136.76 142.39 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 123.996 0.918 . . . . 0.0 110.541 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 p -136.99 141.0 41.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 124.08 0.952 . . . . 0.0 110.724 177.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -80.51 158.66 71.03 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 124.271 1.028 . . . . 0.0 112.126 176.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -68.55 -23.41 37.07 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 123.699 2.933 . . . . 0.0 112.98 -177.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -159.91 51.73 0.33 Allowed 'General case' 0 CA--C 1.555 1.164 0 C-N-CA 124.752 1.221 . . . . 0.0 112.656 177.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.41 -58.11 0.37 Allowed 'General case' 0 N--CA 1.483 1.184 0 O-C-N 120.743 -1.223 . . . . 0.0 112.982 -176.407 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 155.97 179.25 30.89 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.099 1.333 . . . . 0.0 113.314 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.2 p -85.27 152.28 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.959 1.304 . . . . 0.0 111.268 175.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.0 m -132.77 170.18 15.64 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.195 1.798 . . . . 0.0 110.725 174.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -128.68 121.05 27.69 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.369 1.068 . . . . 0.0 111.36 -174.313 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 50.0 t -63.61 121.5 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 124.436 1.094 . . . . 0.0 110.617 -178.139 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.8 m -112.42 -41.51 3.86 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.573 1.149 . . . . 0.0 112.1 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.98 165.21 36.81 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.287 1.835 . . . . 0.0 110.612 174.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 41.7 mt -147.65 138.15 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.971 1.308 . . . . 0.0 108.76 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -147.48 170.58 17.1 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.449 1.1 . . . . 0.0 112.785 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.6 m -108.51 139.25 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 124.909 1.284 . . . . 0.0 110.599 175.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 7.5 ptmt -155.92 168.13 28.21 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.291 1.036 . . . . 0.0 112.543 175.311 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.12 116.05 31.24 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 125.648 1.579 . . . . 0.0 109.516 175.006 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.7 p -126.09 137.25 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.15 0.98 . . . . 0.0 109.648 174.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.94 28.98 2.17 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 114.829 1.418 . . . . 0.0 114.829 -179.02 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.45 25.18 48.28 Favored Glycine 0 CA--C 1.54 1.597 0 C-N-CA 124.839 1.209 . . . . 0.0 115.322 -176.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -139.08 113.52 8.95 Favored 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 125.413 1.485 . . . . 0.0 111.462 -174.133 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -95.85 116.7 29.3 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.144 1.377 . . . . 0.0 111.917 -179.29 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -159.75 175.08 13.57 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 123.813 0.845 . . . . 0.0 112.02 179.224 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 15.3 m -77.35 116.33 17.86 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.314 1.046 . . . . 0.0 111.934 175.001 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -106.01 113.45 27.01 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 124.849 1.26 . . . . 0.0 109.351 175.194 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.2 m -63.73 150.7 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 O-C-N 122.052 -0.405 . . . . 0.0 111.331 175.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -126.55 109.89 12.64 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 122.037 0.922 . . . . 0.0 110.638 174.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -128.43 162.57 26.86 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 125.095 1.358 . . . . 0.0 110.181 179.597 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.3 mtt180 -138.67 113.85 9.44 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 125.491 1.516 . . . . 0.0 109.298 177.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 44.5 mtp85 -69.91 109.09 4.29 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 174.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -70.17 -13.86 62.38 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.188 0.995 . . . . 0.0 113.286 176.072 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -59.36 -42.82 92.49 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 125.96 1.704 . . . . 0.0 112.66 177.253 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -128.52 -15.45 4.51 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.843 1.424 . . . . 0.0 114.843 177.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 84.07 59.03 2.12 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 125.578 1.561 . . . . 0.0 113.446 -179.242 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -135.66 128.72 31.59 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.657 1.183 . . . . 0.0 112.532 179.021 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.0 p -67.05 141.87 17.36 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 C-N-CA 124.286 1.034 . . . . 0.0 110.127 175.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 5.6 p -137.31 114.41 12.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 C-N-CA 126.244 1.818 . . . . 0.0 108.969 178.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.3 ptt? -126.79 125.63 42.04 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 125.794 1.638 . . . . 0.0 109.832 179.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 33.8 m -131.89 152.98 81.23 Favored Pre-proline 0 N--CA 1.468 0.457 0 C-N-CA 123.7 0.8 . . . . 0.0 111.359 178.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -77.01 116.5 4.22 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.912 2.408 . . . . 0.0 114.557 178.01 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -60.65 -38.22 84.13 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 114.572 1.323 . . . . 0.0 114.572 -179.623 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.91 5.81 79.21 Favored Glycine 0 N--CA 1.476 1.34 0 C-N-CA 124.545 1.069 . . . . 0.0 114.697 178.408 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.9 tttt -133.85 3.03 3.46 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.474 1.51 . . . . 0.0 112.889 -177.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.54 -29.72 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 125.533 1.533 . . . . 0.0 113.745 175.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.5 mt -56.3 -29.4 61.17 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 126.093 1.757 . . . . 0.0 112.542 177.164 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.42 -50.4 15.94 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 125.849 1.66 . . . . 0.0 112.873 175.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.9 mp -67.33 -33.31 61.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 124.134 0.973 . . . . 0.0 111.355 178.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.53 8.29 68.16 Favored Glycine 0 CA--C 1.535 1.335 0 C-N-CA 125.617 1.58 . . . . 0.0 114.356 -176.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 24.9 m -93.26 123.27 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 125.407 1.483 . . . . 0.0 110.763 -176.689 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.62 109.31 21.37 Favored 'General case' 0 N--CA 1.471 0.607 0 O-C-N 120.827 -1.17 . . . . 0.0 109.58 178.089 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.47 0.566 0 C-N-CA 123.764 0.826 . . . . 0.0 109.91 176.255 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.544 0.725 0 CA-C-O 120.505 0.193 . . . . 0.0 110.981 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -135.25 175.16 9.83 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.572 1.549 . . . . 0.0 112.336 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.6 t -59.61 132.8 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 O-C-N 121.184 -0.948 . . . . 0.0 111.127 177.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.62 -5.52 83.33 Favored Glycine 0 CA--C 1.537 1.427 0 C-N-CA 124.854 1.216 . . . . 0.0 115.005 -179.272 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -68.51 173.32 5.12 Favored 'General case' 0 CA--C 1.553 1.058 0 CA-C-N 118.761 1.281 . . . . 0.0 110.246 175.041 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -84.33 158.31 21.2 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 125.102 1.361 . . . . 0.0 112.007 174.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.4 p -160.32 124.37 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 124.688 1.195 . . . . 0.0 109.997 175.019 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 2.9 m -131.56 159.74 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.618 0.723 . . . . 0.0 109.35 174.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -95.27 162.02 26.08 Favored Pre-proline 0 CA--C 1.544 0.72 0 C-N-CA 123.515 0.726 . . . . 0.0 110.796 177.043 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -69.35 -24.84 31.1 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 123.191 2.594 . . . . 0.0 112.429 -179.2 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -159.48 55.65 0.39 Allowed 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 124.725 1.21 . . . . 0.0 112.572 178.608 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 9.8 tm0? -142.7 -58.81 0.44 Allowed 'General case' 0 N--CA 1.482 1.165 0 O-C-N 120.832 -1.167 . . . . 0.0 113.024 -178.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 158.58 -168.66 34.87 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 124.849 1.214 . . . . 0.0 112.995 -174.266 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.5 m -109.52 146.8 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 125.176 1.39 . . . . 0.0 112.656 -176.547 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 61.3 m -137.25 179.55 6.33 Favored 'General case' 0 CA--C 1.551 1.01 0 C-N-CA 126.168 1.787 . . . . 0.0 110.944 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.89 132.35 43.54 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 126.892 2.077 . . . . 0.0 111.362 175.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -67.6 129.94 32.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.149 0.98 . . . . 0.0 111.233 179.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.76 -48.57 3.12 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.9 1.28 . . . . 0.0 112.781 -175.56 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.99 163.06 36.79 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.372 1.469 . . . . 0.0 110.961 174.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -140.94 133.42 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 124.263 1.025 . . . . 0.0 109.252 178.166 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -148.46 168.04 23.73 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.713 1.205 . . . . 0.0 112.19 176.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.8 m -106.69 141.3 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 O-C-N 121.257 -0.902 . . . . 0.0 110.373 175.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.1 ptmt -153.45 168.59 25.59 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 123.809 0.843 . . . . 0.0 112.211 176.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -100.67 117.62 35.15 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 125.485 1.514 . . . . 0.0 109.991 175.014 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.0 p -127.26 138.14 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 124.106 0.962 . . . . 0.0 109.656 175.021 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.98 29.06 1.59 Allowed 'General case' 0 CA--C 1.557 1.223 0 N-CA-C 114.776 1.398 . . . . 0.0 114.776 -177.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.08 27.52 49.19 Favored Glycine 0 CA--C 1.542 1.748 0 C-N-CA 124.88 1.229 . . . . 0.0 115.361 -176.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 10.5 tp60 -137.41 114.95 11.16 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.223 1.809 . . . . 0.0 110.656 -175.7 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.02 115.07 26.96 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.69 1.196 . . . . 0.0 111.492 178.621 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -153.11 172.56 16.71 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 123.448 0.699 . . . . 0.0 111.649 177.388 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.3 m -74.16 116.35 14.7 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 125.011 1.324 . . . . 0.0 111.105 175.793 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -109.83 113.07 25.52 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 124.451 1.1 . . . . 0.0 110.105 177.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 22.0 m -77.45 145.0 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 123.156 0.582 . . . . 0.0 110.903 178.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.1 m -126.31 112.36 15.61 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 122.116 0.96 . . . . 0.0 110.689 -179.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 2.0 mpp? -122.42 162.7 21.16 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 124.816 1.246 . . . . 0.0 109.638 -176.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.3 mtt180 -134.84 151.87 51.28 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 125.38 1.472 . . . . 0.0 110.314 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.5 ptt180 -118.58 109.12 15.79 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.379 1.072 . . . . 0.0 109.793 175.028 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -64.96 -17.37 64.34 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.745 1.218 . . . . 0.0 112.408 174.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -55.4 -42.92 74.73 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 126.249 1.82 . . . . 0.0 112.693 175.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -128.68 3.4 5.5 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 125.126 1.37 . . . . 0.0 113.845 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 64.56 33.89 88.45 Favored Glycine 0 CA--C 1.535 1.292 0 C-N-CA 125.659 1.6 . . . . 0.0 113.979 -174.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -103.82 167.43 9.78 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.15 0.98 . . . . 0.0 111.988 -176.493 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 17.3 m -116.85 151.0 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.092 1.357 . . . . 0.0 110.258 178.441 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.3 p -143.82 126.36 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 C-N-CA 124.821 1.249 . . . . 0.0 109.202 176.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.6 tmm? -127.86 128.17 44.73 Favored 'General case' 0 C--O 1.234 0.267 0 C-N-CA 124.408 1.083 . . . . 0.0 109.839 177.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.7 m -132.95 155.45 81.14 Favored Pre-proline 0 N--CA 1.469 0.485 0 C-N-CA 124.396 1.078 . . . . 0.0 111.599 178.448 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -76.14 116.14 4.3 Favored 'Trans proline' 0 CA--C 1.537 0.634 0 C-N-CA 123.749 2.966 . . . . 0.0 114.466 176.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -63.43 -34.64 78.2 Favored 'General case' 0 N--CA 1.479 1.005 0 O-C-N 120.341 -1.474 . . . . 0.0 114.172 177.484 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.17 5.9 78.47 Favored Glycine 0 N--CA 1.472 1.055 0 C-N-CA 124.175 0.893 . . . . 0.0 114.653 176.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.4 ttmm -136.76 4.11 2.78 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.269 1.428 . . . . 0.0 113.364 -178.588 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 1.4 m -49.38 -30.13 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.468 1.507 . . . . 0.0 113.042 175.303 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.3 mt -56.58 -29.14 61.73 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 126.288 1.835 . . . . 0.0 112.684 176.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.31 -50.2 13.34 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 126.05 1.74 . . . . 0.0 112.645 177.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.7 mp -66.8 -32.38 57.74 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 124.211 1.004 . . . . 0.0 111.291 176.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.39 2.71 79.39 Favored Glycine 0 CA--C 1.535 1.303 0 C-N-CA 125.789 1.662 . . . . 0.0 113.866 -174.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 18.6 m -83.57 123.23 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 118.338 1.069 . . . . 0.0 111.031 -178.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.1 mmt-85 -100.4 127.21 46.78 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 174.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.464 0.225 0 C-N-CA 123.331 0.652 . . . . 0.0 110.481 176.794 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.54 0.573 0 CA-C-O 120.773 0.32 . . . . 0.0 110.893 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -144.91 169.28 18.36 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.378 1.071 . . . . 0.0 111.772 177.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.3 t -61.21 130.34 25.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 123.586 0.754 . . . . 0.0 110.572 176.23 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.27 -8.81 79.0 Favored Glycine 0 CA--C 1.537 1.414 0 C-N-CA 124.997 1.284 . . . . 0.0 114.886 -176.036 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -72.67 165.16 25.3 Favored 'General case' 0 CA--C 1.551 0.998 0 CA-C-N 119.302 1.551 . . . . 0.0 111.496 175.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -85.82 154.93 21.22 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.669 0.747 . . . . 0.0 112.288 178.234 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 24.2 m -144.09 147.69 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 C-N-CA 125.204 1.402 . . . . 0.0 109.623 174.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.94 155.75 41.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 C-N-CA 126.461 1.905 . . . . 0.0 108.984 176.054 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -126.35 161.99 49.03 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 125.4 1.48 . . . . 0.0 111.433 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -74.02 -17.66 22.05 Favored 'Trans proline' 0 CA--C 1.541 0.841 0 C-N-CA 123.132 2.555 . . . . 0.0 113.023 -177.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -151.97 -40.08 0.11 Allowed 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 125.611 1.564 . . . . 0.0 112.543 176.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -53.91 -26.49 25.42 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.71 1.604 . . . . 0.0 114.777 179.428 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.46 -176.18 32.38 Favored Glycine 0 CA--C 1.535 1.336 0 C-N-CA 125.014 1.292 . . . . 0.0 114.383 179.306 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.0 m -74.74 144.14 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 O-C-N 121.234 -1.157 . . . . 0.0 111.788 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 33.5 m -136.26 -177.11 4.56 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 125.154 1.381 . . . . 0.0 110.809 177.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -138.16 115.91 11.45 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.913 1.285 . . . . 0.0 111.563 -173.187 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.4 t -63.45 128.18 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 C-N-CA 123.907 0.883 . . . . 0.0 111.541 -172.411 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 44.0 t -111.02 -49.39 3.03 Favored 'General case' 0 N--CA 1.469 0.505 0 C-N-CA 125.653 1.581 . . . . 0.0 112.039 -174.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -154.73 161.85 41.36 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.919 1.288 . . . . 0.0 111.208 175.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -142.81 127.93 16.21 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 124.713 1.205 . . . . 0.0 108.785 177.373 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -148.92 169.54 20.33 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 123.647 0.779 . . . . 0.0 112.361 175.447 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 19.9 m -104.93 142.43 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 O-C-N 121.229 -0.919 . . . . 0.0 110.946 174.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.9 ptmt -155.51 171.0 20.67 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.745 0.818 . . . . 0.0 112.683 175.206 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -103.59 117.47 34.5 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.136 1.374 . . . . 0.0 109.821 176.403 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.7 p -129.69 135.96 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 178.243 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.38 28.73 1.75 Allowed 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 125.582 1.553 . . . . 0.0 114.656 -177.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.14 23.77 50.59 Favored Glycine 0 CA--C 1.538 1.519 0 C-N-CA 125.45 1.5 . . . . 0.0 115.286 -176.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -134.26 113.76 12.32 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 126.16 1.784 . . . . 0.0 111.128 -174.591 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 54.6 tttt -96.33 112.48 24.2 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 124.942 1.297 . . . . 0.0 111.585 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -156.09 172.41 18.47 Favored 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 123.405 0.682 . . . . 0.0 112.161 179.035 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.8 m -72.95 119.17 16.82 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.644 1.178 . . . . 0.0 110.591 175.431 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -110.19 116.65 31.88 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 174.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.7 m -81.3 143.57 12.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 123.935 0.894 . . . . 0.0 109.027 175.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.9 m -126.38 117.34 22.77 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.527 1.531 . . . . 0.0 110.054 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -120.71 160.23 23.74 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 125.257 1.423 . . . . 0.0 110.202 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 55.0 mtm180 -140.51 121.29 14.41 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 124.926 1.29 . . . . 0.0 110.338 -179.131 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.68 108.85 17.61 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 124.647 1.179 . . . . 0.0 111.045 176.238 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -69.96 -15.39 63.04 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 124.026 0.93 . . . . 0.0 112.264 175.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -59.67 -37.65 79.33 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 124.949 1.3 . . . . 0.0 113.439 177.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -128.39 -12.83 5.0 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 124.892 1.277 . . . . 0.0 113.677 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.57 50.94 5.42 Favored Glycine 0 CA--C 1.531 1.077 0 C-N-CA 125.56 1.552 . . . . 0.0 113.177 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -124.53 162.6 23.67 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.741 1.216 . . . . 0.0 112.264 178.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.1 m -109.13 152.84 11.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 125.07 1.348 . . . . 0.0 110.736 178.07 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 3.9 p -151.57 122.25 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 125.21 1.404 . . . . 0.0 109.252 178.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 22.6 ptt? -127.01 139.38 53.06 Favored 'General case' 0 C--O 1.236 0.374 0 C-N-CA 123.644 0.778 . . . . 0.0 110.884 177.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.1 m -141.19 158.2 64.85 Favored Pre-proline 0 N--CA 1.473 0.707 0 C-N-CA 123.858 0.863 . . . . 0.0 112.069 178.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -76.67 115.02 3.97 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 123.497 2.798 . . . . 0.0 114.509 176.175 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.5 -34.43 77.76 Favored 'General case' 0 N--CA 1.477 0.912 0 O-C-N 120.315 -1.49 . . . . 0.0 114.173 178.604 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.0 5.98 78.96 Favored Glycine 0 N--CA 1.473 1.158 0 C-N-CA 124.017 0.818 . . . . 0.0 114.509 176.483 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 19.5 tttp -136.24 2.23 2.75 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.293 1.437 . . . . 0.0 113.359 -178.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.93 -30.12 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 125.612 1.565 . . . . 0.0 113.116 175.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.9 mt -57.34 -28.82 63.46 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 126.435 1.894 . . . . 0.0 112.556 177.133 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.74 -50.47 15.22 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.986 1.714 . . . . 0.0 112.668 175.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.6 mp -68.53 -31.1 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 124.145 0.978 . . . . 0.0 111.227 178.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.35 8.85 70.62 Favored Glycine 0 CA--C 1.535 1.285 0 C-N-CA 125.82 1.676 . . . . 0.0 114.187 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 15.2 m -87.66 137.43 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.669 1.588 . . . . 0.0 110.356 -177.473 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.9 108.88 13.47 Favored 'General case' 0 N--CA 1.469 0.511 0 O-C-N 120.881 -1.137 . . . . 0.0 110.737 176.04 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.464 0.274 0 C-N-CA 124.25 1.02 . . . . 0.0 109.3 175.594 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.542 0.646 0 N-CA-C 110.224 -0.287 . . . . 0.0 110.224 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.56 163.7 19.5 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.363 1.465 . . . . 0.0 112.433 177.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 98.1 t -60.35 129.57 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 123.975 0.91 . . . . 0.0 110.225 178.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.11 -11.86 65.59 Favored Glycine 0 CA--C 1.534 1.267 0 C-N-CA 125.012 1.291 . . . . 0.0 114.761 -176.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -74.99 168.52 19.8 Favored 'General case' 0 CA--C 1.544 0.729 0 CA-C-N 119.445 1.622 . . . . 0.0 110.971 175.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.84 163.86 20.91 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 123.964 0.906 . . . . 0.0 111.426 175.133 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 17.9 m -149.84 150.49 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 125.488 1.515 . . . . 0.0 109.691 175.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 6.6 p -137.03 156.3 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 C-N-CA 126.239 1.815 . . . . 0.0 110.035 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -130.43 157.62 76.88 Favored Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 125.471 1.508 . . . . 0.0 111.638 -177.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.11 -40.47 6.3 Favored 'Trans proline' 0 CA--C 1.536 0.582 0 C-N-CA 123.913 3.075 . . . . 0.0 112.313 -177.15 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -148.96 43.82 0.98 Allowed 'General case' 0 CA--C 1.552 1.034 0 C-N-CA 126.057 1.743 . . . . 0.0 112.153 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -128.35 -51.3 1.29 Allowed 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 124.38 1.072 . . . . 0.0 111.945 177.252 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 128.88 -179.02 16.91 Favored Glycine 0 CA--C 1.535 1.305 0 C-N-CA 126.41 1.957 . . . . 0.0 113.035 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.1 m -77.49 143.76 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 O-C-N 121.766 -0.843 . . . . 0.0 111.281 174.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 85.3 m -136.04 -176.96 4.49 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 125.116 1.366 . . . . 0.0 110.786 176.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.5 ttt180 -140.7 124.54 17.18 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 125.01 1.324 . . . . 0.0 110.921 -178.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.8 t -62.06 119.22 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 123.464 0.706 . . . . 0.0 111.827 -175.575 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.9 p -100.58 -46.21 5.27 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.031 0.932 . . . . 0.0 111.902 -178.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.76 172.06 17.92 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 126.366 1.866 . . . . 0.0 111.133 176.166 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 79.8 mt -146.02 137.15 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 C-N-CA 124.759 1.224 . . . . 0.0 108.358 174.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -141.97 168.97 18.49 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 124.146 0.978 . . . . 0.0 111.781 176.227 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.9 m -116.19 145.25 22.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 O-C-N 120.986 -1.072 . . . . 0.0 110.924 175.388 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.6 174.74 14.07 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.199 0.999 . . . . 0.0 111.952 174.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -107.75 121.68 45.21 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 125.906 1.682 . . . . 0.0 108.9 175.008 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.6 p -125.2 129.15 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 125.058 1.343 . . . . 0.0 109.159 174.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.97 28.99 2.19 Favored 'General case' 0 CA--C 1.556 1.203 0 N-CA-C 114.735 1.383 . . . . 0.0 114.735 -178.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.78 21.08 54.57 Favored Glycine 0 CA--C 1.539 1.571 0 C-N-CA 124.814 1.197 . . . . 0.0 115.301 -176.504 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -126.16 113.5 17.12 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 125.924 1.69 . . . . 0.0 110.275 -176.275 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 11.2 tttt -96.77 117.75 31.73 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 124.734 1.213 . . . . 0.0 111.068 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.1 pp -158.56 172.46 18.26 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 122.984 0.514 . . . . 0.0 111.75 178.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 22.6 m -80.04 116.47 20.18 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 124.946 1.298 . . . . 0.0 112.521 176.219 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -102.89 113.24 26.52 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 124.487 1.115 . . . . 0.0 109.104 174.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.1 m -63.79 149.05 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 O-C-N 121.843 -0.536 . . . . 0.0 111.223 175.133 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 24.6 m -126.49 109.95 12.74 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.447 1.099 . . . . 0.0 110.942 178.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -128.8 165.43 20.97 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 121.512 -0.742 . . . . 0.0 111.002 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -140.0 120.07 13.68 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.417 1.087 . . . . 0.0 111.403 178.016 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 15.0 ptm180 -74.08 110.06 8.07 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 125.089 1.356 . . . . 0.0 110.865 175.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -64.51 -17.25 63.72 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 177.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -59.43 -37.71 78.78 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.453 1.501 . . . . 0.0 113.895 177.821 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.63 -0.39 5.5 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 124.834 1.253 . . . . 0.0 112.908 178.079 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.65 20.9 68.57 Favored Glycine 0 CA--C 1.537 1.419 0 C-N-CA 125.254 1.407 . . . . 0.0 113.851 -170.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -87.87 163.55 16.34 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 118.516 1.158 . . . . 0.0 111.541 -176.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 27.5 m -108.8 143.74 18.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.064 1.346 . . . . 0.0 110.874 -179.67 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.7 m -135.33 130.44 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 124.813 1.245 . . . . 0.0 109.483 178.068 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 38.8 mtm -141.84 123.82 15.37 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.336 1.054 . . . . 0.0 110.261 -178.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.5 m -135.05 157.21 77.45 Favored Pre-proline 0 N--CA 1.474 0.744 0 C-N-CA 123.952 0.901 . . . . 0.0 112.116 179.173 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -76.79 117.49 4.52 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 123.374 2.716 . . . . 0.0 114.949 179.721 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -60.54 -38.92 86.04 Favored 'General case' 0 N--CA 1.478 0.928 0 O-C-N 120.463 -1.398 . . . . 0.0 114.253 179.617 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.18 5.71 78.37 Favored Glycine 0 N--CA 1.475 1.244 0 C-N-CA 124.549 1.071 . . . . 0.0 114.9 179.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 5.2 tttm -133.92 2.8 3.42 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.658 1.583 . . . . 0.0 112.639 -178.415 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.64 -30.19 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 C-N-CA 125.405 1.482 . . . . 0.0 113.233 175.028 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.5 mt -57.04 -28.74 62.8 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 125.938 1.695 . . . . 0.0 112.641 177.558 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.61 -50.91 14.11 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.593 1.557 . . . . 0.0 112.713 175.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.0 mp -69.04 -33.6 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 124.001 0.92 . . . . 0.0 111.264 179.201 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.66 4.36 76.23 Favored Glycine 0 CA--C 1.536 1.406 0 C-N-CA 125.881 1.705 . . . . 0.0 114.352 -177.033 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.3 m -83.57 133.29 29.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.952 1.701 . . . . 0.0 109.837 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.9 mtp180 -122.55 109.17 13.99 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 119.957 1.253 . . . . 0.0 110.194 175.385 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.467 0.402 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.114 178.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.423 ' HG ' ' HE2' ' A' ' 70' ' ' LYS . 0.5 OUTLIER . . . . . 0 CA--C 1.544 0.732 0 CA-C-O 120.567 0.222 . . . . 0.0 111.394 . . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -143.2 179.01 7.32 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.937 1.695 . . . . 0.0 112.199 176.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.4 t -59.51 129.34 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 O-C-N 121.054 -1.029 . . . . 0.0 110.821 175.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.28 -2.63 86.73 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 125.109 1.338 . . . . 0.0 115.372 -178.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -70.98 170.17 13.34 Favored 'General case' 0 CA--C 1.55 0.972 0 CA-C-N 119.319 1.56 . . . . 0.0 112.284 174.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.71 142.86 28.99 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.796 1.238 . . . . 0.0 111.602 178.263 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.9 m -139.02 146.48 25.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 124.061 0.944 . . . . 0.0 110.286 175.078 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 13.7 p -137.09 149.5 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 C-N-CA 124.554 1.142 . . . . 0.0 110.584 174.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.1 m-85 -86.33 162.67 45.1 Favored Pre-proline 0 CA--C 1.545 0.764 0 C-N-CA 124.034 0.934 . . . . 0.0 111.704 175.027 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -71.15 -24.97 22.88 Favored 'Trans proline' 0 CA--C 1.539 0.772 0 C-N-CA 122.883 2.389 . . . . 0.0 112.434 -176.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -165.91 55.02 0.1 Allowed 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 126.755 2.022 . . . . 0.0 111.844 -176.435 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 7.3 tp-100 -148.06 -63.52 0.26 Allowed 'General case' 0 N--CA 1.478 0.942 0 O-C-N 120.964 -1.085 . . . . 0.0 112.935 179.076 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.06 178.3 41.49 Favored Glycine 0 CA--C 1.534 1.245 0 C-N-CA 124.574 1.083 . . . . 0.0 113.754 -179.165 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.5 m -88.28 153.12 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 125.167 1.387 . . . . 0.0 110.783 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.2 m -140.02 172.45 12.74 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 125.256 1.423 . . . . 0.0 110.635 176.2 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 47.8 ttt-85 -133.81 123.95 25.69 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.108 0.963 . . . . 0.0 112.746 -179.283 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.3 t -69.39 122.76 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 125.751 1.62 . . . . 0.0 111.086 -179.28 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.6 t -108.87 -34.63 6.6 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 124.55 1.14 . . . . 0.0 112.485 178.352 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.14 167.28 29.54 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 126.224 1.81 . . . . 0.0 110.483 175.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 50.1 mt -144.89 140.61 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 125.19 1.396 . . . . 0.0 108.993 175.407 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -148.04 169.01 20.86 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.732 0.813 . . . . 0.0 112.568 175.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 10.9 m -104.69 143.21 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 124.819 1.248 . . . . 0.0 111.796 175.561 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.66 172.77 18.01 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 124.457 1.103 . . . . 0.0 112.311 174.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.64 121.83 45.47 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 126.137 1.775 . . . . 0.0 109.291 175.171 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.7 p -132.77 136.83 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 124.443 1.097 . . . . 0.0 109.259 174.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.91 29.05 1.54 Allowed 'General case' 0 CA--C 1.556 1.206 0 N-CA-C 114.939 1.459 . . . . 0.0 114.939 -177.063 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.9 26.21 50.21 Favored Glycine 0 CA--C 1.541 1.666 0 C-N-CA 124.76 1.172 . . . . 0.0 115.349 -177.2 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -134.44 113.46 11.88 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.054 1.742 . . . . 0.0 109.7 -175.54 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 20.9 tttt -96.85 116.4 29.1 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 124.696 1.199 . . . . 0.0 111.677 -179.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -159.73 174.55 14.36 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 123.634 0.774 . . . . 0.0 112.203 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 17.6 m -79.06 116.39 19.32 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.588 1.555 . . . . 0.0 112.107 176.03 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -104.77 113.28 26.78 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 124.416 1.086 . . . . 0.0 109.88 175.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 25.4 m -63.68 151.92 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 O-C-N 121.707 -0.621 . . . . 0.0 111.5 175.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -126.51 109.82 12.58 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-O 121.723 0.773 . . . . 0.0 110.499 176.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 5.2 mpp? -113.42 157.52 21.82 Favored 'General case' 0 C--O 1.232 0.144 0 C-N-CA 124.804 1.242 . . . . 0.0 111.616 176.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 43.1 mtp85 -133.88 105.58 6.84 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 126.191 1.797 . . . . 0.0 109.926 179.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 46.8 mtp85 -74.91 109.05 8.06 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.664 0.786 . . . . 0.0 109.435 175.034 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -69.73 -14.55 62.84 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 176.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -57.96 -43.2 86.3 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 126.072 1.749 . . . . 0.0 112.97 175.115 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -128.57 -12.93 4.88 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 125.024 1.33 . . . . 0.0 114.123 -177.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.92 4.88 78.19 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 125.935 1.731 . . . . 0.0 114.802 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -75.04 161.44 29.45 Favored 'General case' 0 CA--C 1.543 0.692 0 CA-C-N 118.532 1.166 . . . . 0.0 113.166 179.469 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.3 m -105.85 139.24 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 125.397 1.479 . . . . 0.0 109.865 174.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.3 t -123.31 114.96 44.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.82 1.248 . . . . 0.0 108.427 177.146 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.1 tmm? -127.97 123.91 35.97 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 124.94 1.296 . . . . 0.0 109.547 178.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.4 m -131.56 155.02 82.0 Favored Pre-proline 0 N--CA 1.469 0.52 0 C-N-CA 124.592 1.157 . . . . 0.0 111.388 176.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -76.68 118.52 4.86 Favored 'Trans proline' 0 CA--C 1.536 0.577 0 C-N-CA 123.488 2.792 . . . . 0.0 114.763 177.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -59.87 -41.03 90.65 Favored 'General case' 0 N--CA 1.475 0.775 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.89 6.31 79.35 Favored Glycine 0 N--CA 1.475 1.299 0 C-N-CA 124.344 0.974 . . . . 0.0 114.69 178.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.9 tttp -132.98 3.63 3.74 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.667 1.587 . . . . 0.0 112.773 -178.533 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.61 -30.07 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 C-N-CA 125.128 1.371 . . . . 0.0 113.453 175.149 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.8 mt -55.93 -29.33 59.94 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 126.208 1.803 . . . . 0.0 112.652 177.591 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.83 -49.16 21.59 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 125.702 1.601 . . . . 0.0 112.837 175.76 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.0 mp -69.12 -33.61 59.35 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 124.202 1.001 . . . . 0.0 111.387 178.327 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.38 3.06 78.93 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 125.717 1.627 . . . . 0.0 114.365 -175.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.6 t -75.79 148.58 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 CA-C-N 118.47 1.135 . . . . 0.0 110.281 175.002 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.38 109.3 10.97 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-O 122.033 0.921 . . . . 0.0 108.679 175.018 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.423 ' HE2' ' HG ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER . . . . . 0 N--CA 1.466 0.37 0 C-N-CA 125.5 1.52 . . . . 0.0 108.896 179.42 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.184 0 CA-C-O 120.67 0.271 . . . . 0.0 111.344 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 75.15 154.89 4.55 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 125.384 1.469 . . . . 0.0 112.996 -173.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 19.1 m80 -78.97 144.18 35.02 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 121.771 -0.841 . . . . 0.0 110.466 174.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 5.8 mtm -74.12 163.05 71.1 Favored Pre-proline 0 CA--C 1.544 0.744 0 C-N-CA 123.355 0.662 . . . . 0.0 112.542 175.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -70.61 79.49 1.2 Allowed 'Trans proline' 0 CA--C 1.543 0.94 0 C-N-CA 124.722 3.615 . . . . 0.0 112.287 175.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -71.56 174.81 6.19 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 124.097 0.959 . . . . 0.0 112.058 174.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -130.92 124.1 4.06 Favored Glycine 0 C--N 1.342 0.895 0 C-N-CA 124.378 0.989 . . . . 0.0 114.841 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -152.76 18.76 0.6 Allowed 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 125.355 1.462 . . . . 0.0 113.779 -178.611 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -122.85 -170.04 2.03 Favored 'General case' 0 CA--C 1.549 0.923 0 C-N-CA 126.227 1.811 . . . . 0.0 112.267 -176.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -61.84 177.03 0.47 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 126.318 1.847 . . . . 0.0 112.856 175.042 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 10.5 mp -66.49 -73.63 0.13 Allowed 'General case' 0 N--CA 1.473 0.687 0 O-C-N 121.166 -0.959 . . . . 0.0 111.764 178.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 -55.24 140.53 38.66 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 123.937 0.895 . . . . 0.0 112.133 177.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.2 tt -63.14 148.42 48.0 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 123.699 0.799 . . . . 0.0 111.234 175.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -129.73 178.85 6.2 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 125.615 1.566 . . . . 0.0 112.045 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.87 133.0 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 O-C-N 121.003 -1.061 . . . . 0.0 110.574 174.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.03 -0.15 87.48 Favored Glycine 0 CA--C 1.532 1.144 0 C-N-CA 124.711 1.148 . . . . 0.0 114.868 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -66.08 171.41 4.62 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 124.39 1.076 . . . . 0.0 112.397 175.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -107.07 144.2 34.08 Favored 'General case' 0 N--CA 1.463 0.203 0 C-N-CA 125.392 1.477 . . . . 0.0 111.347 -176.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 4.9 m -138.84 144.64 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 123.482 0.713 . . . . 0.0 109.76 -176.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.0 p -137.09 140.64 42.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 124.527 1.131 . . . . 0.0 109.4 175.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -92.37 161.55 32.35 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 124.488 1.115 . . . . 0.0 111.169 176.425 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -67.9 -14.01 40.08 Favored 'Trans proline' 0 CA--C 1.546 1.106 0 C-N-CA 122.816 2.344 . . . . 0.0 113.632 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.4 m-80 -148.76 -41.19 0.15 Allowed 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 126.064 1.746 . . . . 0.0 114.36 177.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 3.2 tm0? -52.34 -44.41 65.15 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 126.672 1.989 . . . . 0.0 114.107 -172.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 132.26 -150.28 19.6 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 125.937 1.732 . . . . 0.0 111.738 -178.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.9 m -112.27 146.57 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 C-N-CA 125.505 1.522 . . . . 0.0 110.917 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 78.1 m -137.06 179.71 6.22 Favored 'General case' 0 CA--C 1.551 1.016 0 C-N-CA 125.922 1.689 . . . . 0.0 110.589 175.042 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -136.1 129.49 31.92 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 125.185 1.394 . . . . 0.0 110.901 -179.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 26.5 t -68.73 139.21 20.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.362 0.665 . . . . 0.0 110.565 -175.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 46.7 t -117.89 -45.44 2.67 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 124.462 1.105 . . . . 0.0 112.647 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -151.93 160.7 43.43 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 124.483 1.113 . . . . 0.0 111.046 175.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -141.93 135.72 29.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 C-N-CA 124.663 1.185 . . . . 0.0 108.653 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -148.4 169.72 19.57 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.453 0.701 . . . . 0.0 111.646 175.298 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.9 m -109.58 140.42 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 O-C-N 120.782 -1.199 . . . . 0.0 110.203 176.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -152.6 169.42 22.71 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.589 0.755 . . . . 0.0 111.974 176.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.73 116.22 32.24 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.205 1.402 . . . . 0.0 109.742 174.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.4 p -124.61 139.39 51.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 C-N-CA 124.227 1.011 . . . . 0.0 109.574 175.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.52 29.1 1.95 Allowed 'General case' 0 CA--C 1.558 1.253 0 N-CA-C 114.702 1.371 . . . . 0.0 114.702 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.08 25.19 52.97 Favored Glycine 0 CA--C 1.54 1.594 0 C-N-CA 125.044 1.307 . . . . 0.0 115.414 -175.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.59 115.06 10.49 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 125.85 1.66 . . . . 0.0 111.387 -172.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 10.5 tttt -95.01 118.28 31.56 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.639 1.176 . . . . 0.0 111.79 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -155.51 171.6 19.65 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.344 0.658 . . . . 0.0 111.662 177.797 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 6.8 m -74.55 116.48 15.28 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.179 0.992 . . . . 0.0 111.296 175.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -109.83 113.35 26.03 Favored 'General case' 0 C--O 1.234 0.252 0 C-N-CA 124.627 1.171 . . . . 0.0 110.16 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 24.1 m -80.59 145.75 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.041 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 16.5 m -126.31 110.12 13.03 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 122.217 1.008 . . . . 0.0 110.972 179.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 2.2 mpp? -109.64 151.0 27.42 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 125.278 1.431 . . . . 0.0 110.095 -178.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 37.5 mtm180 -136.17 110.29 8.32 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.69 1.196 . . . . 0.0 109.677 -176.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -76.44 109.01 9.81 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 177.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -69.73 -13.78 62.46 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.498 1.119 . . . . 0.0 113.818 176.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -60.44 -39.49 87.7 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 125.559 1.543 . . . . 0.0 112.75 178.108 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -128.59 -18.82 3.86 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 125.793 1.637 . . . . 0.0 113.915 178.404 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.2 15.42 48.0 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 125.438 1.494 . . . . 0.0 114.766 -177.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -78.41 163.98 25.17 Favored 'General case' 0 CA--C 1.54 0.574 0 CA-C-N 118.416 1.108 . . . . 0.0 112.376 175.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 25.9 m -128.98 142.0 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.146 1.379 . . . . 0.0 110.665 175.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 21.9 m -131.87 133.71 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 125.114 1.366 . . . . 0.0 108.719 177.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -129.72 127.11 39.79 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 124.257 1.023 . . . . 0.0 109.051 177.085 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 27.5 m -133.73 156.66 79.25 Favored Pre-proline 0 N--CA 1.471 0.596 0 C-N-CA 124.3 1.04 . . . . 0.0 111.635 178.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -76.1 116.71 4.45 Favored 'Trans proline' 0 CA--C 1.535 0.565 0 C-N-CA 123.567 2.845 . . . . 0.0 114.571 176.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -63.65 -34.89 78.84 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 120.537 -1.352 . . . . 0.0 114.024 177.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.1 6.86 78.91 Favored Glycine 0 N--CA 1.473 1.139 0 C-N-CA 124.201 0.905 . . . . 0.0 114.693 176.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -136.74 3.98 2.77 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.225 1.41 . . . . 0.0 113.698 -178.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.2 m -49.86 -28.54 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.556 1.543 . . . . 0.0 113.421 175.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 12.0 mt -56.54 -29.77 62.3 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 125.805 1.642 . . . . 0.0 112.3 176.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.51 -49.89 15.35 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.811 1.644 . . . . 0.0 112.493 176.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.6 mp -65.7 -32.9 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 124.488 1.115 . . . . 0.0 111.741 177.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 85.21 4.41 86.48 Favored Glycine 0 CA--C 1.536 1.379 0 C-N-CA 125.397 1.475 . . . . 0.0 114.093 -175.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 13.9 p -80.83 132.9 30.53 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 124.905 1.282 . . . . 0.0 110.988 175.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.6 mmt180 -109.87 109.32 19.92 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 174.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.32 106.54 11.18 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 123.879 0.872 . . . . 0.0 109.337 177.071 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.4 t -155.45 165.42 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 124.791 1.236 . . . . 0.0 109.276 -178.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -51.89 -28.07 14.99 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 113.661 0.986 . . . . 0.0 113.661 174.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.6 t -120.97 -41.59 2.54 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.43 1.092 . . . . 0.0 113.285 176.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.66 131.66 47.54 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.011 0.924 . . . . 0.0 113.315 -179.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 . . . . . 0 C--O 1.254 1.325 0 C-N-CA 128.531 2.732 . . . . 0.0 111.581 175.026 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.24 0 CA-C-O 119.395 -0.336 . . . . 0.0 111.373 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.61 113.49 0.57 Allowed Glycine 0 N--CA 1.472 1.063 0 C-N-CA 124.381 0.991 . . . . 0.0 112.669 -179.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.0 m80 -92.77 105.97 18.02 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.056 0.943 . . . . 0.0 110.805 174.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -86.69 162.02 46.06 Favored Pre-proline 0 CA--C 1.543 0.697 0 C-N-CA 124.669 1.188 . . . . 0.0 110.619 174.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -68.94 136.05 34.12 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 122.716 2.277 . . . . 0.0 109.811 175.006 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -142.22 169.15 18.12 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 126.688 1.995 . . . . 0.0 110.647 176.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.41 -147.51 8.58 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 125.169 1.366 . . . . 0.0 111.303 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.5 t -131.15 -74.33 0.53 Allowed 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 123.835 0.854 . . . . 0.0 111.845 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -165.97 118.66 1.1 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.238 1.815 . . . . 0.0 110.307 177.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.67 158.17 43.85 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.589 1.155 . . . . 0.0 111.229 178.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 50.8 mt -115.66 -71.67 0.73 Allowed 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 124.627 1.171 . . . . 0.0 111.11 -179.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.65 148.4 35.05 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 124.886 1.274 . . . . 0.0 111.671 175.775 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -82.34 128.97 34.74 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.62 1.168 . . . . 0.0 110.841 175.012 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.22 174.51 10.47 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.503 1.521 . . . . 0.0 111.39 176.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.5 t -60.89 126.2 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 123.718 0.807 . . . . 0.0 110.772 177.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.55 -8.74 74.45 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 125.131 1.348 . . . . 0.0 115.186 -176.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.1 t0 -71.51 167.6 19.33 Favored 'General case' 0 CA--C 1.548 0.9 0 CA-C-N 119.195 1.497 . . . . 0.0 111.4 174.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 12.4 tpp180 -92.98 151.39 19.94 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.036 0.934 . . . . 0.0 111.877 -179.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.0 p -151.99 130.01 2.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 C-N-CA 124.895 1.278 . . . . 0.0 110.622 178.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.6 p -137.09 155.82 33.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 C-N-CA 125.837 1.655 . . . . 0.0 108.484 174.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -101.46 158.69 31.3 Favored Pre-proline 0 CA--C 1.537 0.467 0 C-N-CA 125.047 1.339 . . . . 0.0 111.373 175.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_endo -68.21 -21.48 41.89 Favored 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 123.103 2.536 . . . . 0.0 112.458 -176.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -159.8 51.31 0.33 Allowed 'General case' 0 CA--C 1.557 1.221 0 C-N-CA 124.875 1.27 . . . . 0.0 112.896 176.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -140.36 -61.6 0.51 Allowed 'General case' 0 N--CA 1.483 1.216 0 O-C-N 120.835 -1.166 . . . . 0.0 113.116 -177.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 162.42 174.98 32.97 Favored Glycine 0 CA--C 1.534 1.245 0 C-N-CA 124.927 1.251 . . . . 0.0 113.65 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.9 t -91.19 140.42 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 125.461 1.504 . . . . 0.0 110.233 176.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 38.1 m -130.34 -177.85 4.5 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 126.258 1.823 . . . . 0.0 110.198 178.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 -141.96 124.21 15.56 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.074 0.95 . . . . 0.0 110.661 176.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.7 t -58.24 121.32 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 123.849 0.859 . . . . 0.0 110.815 -178.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.5 t -116.28 -35.2 4.4 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.458 1.503 . . . . 0.0 112.179 -175.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -148.14 157.95 43.8 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 125.179 1.392 . . . . 0.0 110.914 175.049 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 65.6 mt -143.15 132.59 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 O-C-N 120.816 -1.177 . . . . 0.0 108.242 175.238 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -138.51 172.25 13.16 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 125.247 1.419 . . . . 0.0 111.422 175.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.9 t -129.88 136.9 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.619 1.168 . . . . 0.0 109.3 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.0 ptmt -144.46 161.98 37.69 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.694 1.198 . . . . 0.0 111.817 177.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -90.14 116.05 27.85 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 124.458 1.103 . . . . 0.0 109.631 175.111 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 p -112.72 128.14 69.58 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 125.348 1.459 . . . . 0.0 109.346 174.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.94 29.07 3.17 Favored 'General case' 0 CA--C 1.557 1.214 0 N-CA-C 114.815 1.413 . . . . 0.0 114.815 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.86 23.57 55.31 Favored Glycine 0 CA--C 1.541 1.715 0 C-N-CA 124.647 1.117 . . . . 0.0 115.323 -175.287 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -138.25 118.7 13.8 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 126.277 1.831 . . . . 0.0 111.194 178.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.8 tttt -85.68 135.85 33.6 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 123.904 0.882 . . . . 0.0 111.439 175.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -154.93 159.16 40.23 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 122.823 0.449 . . . . 0.0 111.832 177.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 6.6 m -68.99 116.69 9.74 Favored 'General case' 0 N--CA 1.478 0.956 0 C-N-CA 124.056 0.942 . . . . 0.0 111.835 178.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -104.72 113.15 26.55 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 119.667 1.121 . . . . 0.0 110.776 174.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.7 m -84.73 136.86 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 123.796 0.838 . . . . 0.0 110.71 178.01 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 13.6 m -126.49 132.24 51.45 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 122.924 1.345 . . . . 0.0 111.876 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -130.13 161.93 29.98 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 125.151 1.381 . . . . 0.0 110.661 -174.217 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 14.3 mtp85 -131.09 103.12 6.33 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.911 1.284 . . . . 0.0 110.425 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.75 109.06 13.81 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.612 0.765 . . . . 0.0 110.766 177.345 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -63.56 -20.41 65.61 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.901 1.28 . . . . 0.0 112.72 178.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -58.63 -38.45 78.09 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.207 1.803 . . . . 0.0 113.344 -178.28 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -128.56 4.18 5.58 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 125.797 1.639 . . . . 0.0 112.702 174.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 62.91 29.86 75.49 Favored Glycine 0 CA--C 1.533 1.196 0 C-N-CA 125.526 1.536 . . . . 0.0 113.711 -174.336 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.62 172.26 7.6 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 118.343 1.072 . . . . 0.0 111.399 -174.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 30.3 m -114.55 144.25 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 C-N-CA 123.566 0.746 . . . . 0.0 111.098 174.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.9 t -124.33 112.11 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.253 1.421 . . . . 0.0 107.987 176.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.2 ttt -120.73 118.82 31.06 Favored 'General case' 0 C--O 1.235 0.317 0 C-N-CA 124.516 1.126 . . . . 0.0 109.734 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 17.1 m -137.03 158.32 72.98 Favored Pre-proline 0 N--CA 1.471 0.607 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -178.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -78.69 111.87 3.05 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.192 2.595 . . . . 0.0 114.56 176.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -60.95 -35.28 76.32 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 120.398 -1.439 . . . . 0.0 113.567 178.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.12 5.74 78.58 Favored Glycine 0 N--CA 1.474 1.222 0 C-N-CA 124.543 1.068 . . . . 0.0 114.961 176.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -135.51 1.47 2.86 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 125.207 1.403 . . . . 0.0 113.353 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.0 m -49.86 -28.1 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.917 1.687 . . . . 0.0 114.149 176.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.1 mt -56.22 -34.53 66.4 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.064 1.746 . . . . 0.0 112.071 175.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.78 -48.61 45.45 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.779 1.632 . . . . 0.0 112.586 177.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.5 mp -68.28 -27.92 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 123.972 0.909 . . . . 0.0 111.49 176.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.78 19.49 63.38 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.433 1.492 . . . . 0.0 113.853 -178.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 15.6 m -95.27 123.16 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 126.254 1.821 . . . . 0.0 111.059 -175.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 11.0 mmt180 -107.7 109.24 20.79 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 121.272 -0.892 . . . . 0.0 109.076 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.97 106.59 17.92 Favored 'General case' 0 N--CA 1.473 0.689 0 O-C-N 121.525 -0.734 . . . . 0.0 110.558 -179.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 1.6 t -153.98 176.68 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 123.412 0.685 . . . . 0.0 110.168 -175.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -61.98 -19.44 62.81 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 125.018 1.327 . . . . 0.0 114.269 175.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 3.5 m -138.31 -51.3 0.58 Allowed 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 125.472 1.509 . . . . 0.0 113.311 178.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -56.11 147.21 20.81 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 124.121 0.969 . . . . 0.0 112.497 176.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 24.8 pt-20 . . . . . 0 C--O 1.255 1.372 0 C-N-CA 128.062 2.545 . . . . 0.0 113.11 -178.081 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.275 0 N-CA-C 110.568 -0.16 . . . . 0.0 110.568 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 157.26 -168.93 34.21 Favored Glycine 0 CA--C 1.535 1.317 0 C-N-CA 125.011 1.291 . . . . 0.0 112.858 -178.442 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 -56.98 133.91 55.28 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 123.943 0.897 . . . . 0.0 111.979 174.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -88.36 163.63 35.8 Favored Pre-proline 0 CA--C 1.544 0.747 0 C-N-CA 125.388 1.475 . . . . 0.0 112.425 175.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -72.35 124.69 10.12 Favored 'Trans proline' 0 CA--C 1.539 0.749 0 C-N-CA 124.048 3.165 . . . . 0.0 110.931 174.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -134.87 116.64 14.99 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.98 1.312 . . . . 0.0 110.455 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.72 -172.38 30.11 Favored Glycine 0 CA--C 1.534 1.256 0 C-N-CA 125.331 1.443 . . . . 0.0 112.919 -178.33 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.2 m -59.11 95.51 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 126.544 1.937 . . . . 0.0 112.912 -177.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -61.84 126.38 27.14 Favored 'General case' 0 CA--C 1.545 0.762 0 O-C-N 121.26 -0.9 . . . . 0.0 112.413 -176.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.9 t -154.51 169.92 22.66 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.852 1.261 . . . . 0.0 112.333 178.279 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 6.0 mp -79.6 -61.62 1.94 Allowed 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.837 1.255 . . . . 0.0 111.151 176.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -77.81 177.36 8.25 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.505 1.522 . . . . 0.0 111.66 177.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -118.2 124.51 48.09 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.712 1.205 . . . . 0.0 110.602 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -128.37 169.65 14.01 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.9 1.68 . . . . 0.0 112.052 178.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.4 t -63.75 130.47 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 O-C-N 121.226 -0.921 . . . . 0.0 110.693 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.73 -8.81 76.45 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.216 1.389 . . . . 0.0 114.663 -177.3 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -67.65 154.91 40.42 Favored 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 118.958 1.379 . . . . 0.0 110.818 174.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -74.96 157.41 35.01 Favored 'General case' 0 N--CA 1.472 0.664 0 O-C-N 121.312 -0.867 . . . . 0.0 110.046 174.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 14.9 m -149.25 138.2 15.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 C-N-CA 124.676 1.19 . . . . 0.0 110.449 179.279 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.6 p -137.09 157.79 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 125.355 1.462 . . . . 0.0 109.56 177.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -102.9 160.36 26.45 Favored Pre-proline 0 CA--C 1.542 0.667 0 C-N-CA 124.919 1.288 . . . . 0.0 111.732 175.034 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_endo -68.95 -28.02 29.71 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 123.806 3.004 . . . . 0.0 112.102 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.8 t30 -158.51 55.5 0.44 Allowed 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 124.472 1.109 . . . . 0.0 112.848 177.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.82 -60.79 0.29 Allowed 'General case' 0 N--CA 1.482 1.139 0 O-C-N 121.009 -1.057 . . . . 0.0 113.351 -174.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 162.43 -173.34 38.7 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 124.818 1.199 . . . . 0.0 113.59 -177.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.7 p -100.49 144.95 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 126.362 1.865 . . . . 0.0 110.945 176.211 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 38.7 m -131.75 -175.85 3.85 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 125.49 1.516 . . . . 0.0 110.306 175.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -137.53 124.8 21.78 Favored 'General case' 0 N--CA 1.48 1.028 0 O-C-N 121.091 -1.006 . . . . 0.0 111.634 177.021 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 60.4 t -64.61 136.04 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 C-N-CA 124.425 1.09 . . . . 0.0 110.657 -179.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.5 p -115.44 -44.95 2.94 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 124.635 1.174 . . . . 0.0 113.026 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.3 163.56 37.25 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 126.319 1.847 . . . . 0.0 110.796 176.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 75.0 mt -141.83 132.82 26.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 124.543 1.137 . . . . 0.0 108.979 178.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -147.37 167.23 24.86 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.615 0.766 . . . . 0.0 112.581 175.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 20.9 m -103.3 141.93 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 O-C-N 121.117 -0.989 . . . . 0.0 110.699 175.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 3.9 ptmt -154.83 170.18 22.24 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 124.25 1.02 . . . . 0.0 112.234 175.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -102.46 116.34 32.42 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 125.999 1.72 . . . . 0.0 109.579 175.013 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.6 p -126.5 137.87 56.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.901 0.88 . . . . 0.0 110.025 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.5 28.97 1.89 Allowed 'General case' 0 CA--C 1.558 1.251 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 -177.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.28 22.69 53.81 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 125.172 1.367 . . . . 0.0 115.516 -176.565 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 35.8 tt0 -136.51 113.7 10.65 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 119.062 1.431 . . . . 0.0 111.666 -173.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 13.0 tttt -94.47 116.04 28.32 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.054 1.342 . . . . 0.0 111.747 -178.135 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -157.16 173.26 17.25 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.394 0.678 . . . . 0.0 111.887 177.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.2 m -73.96 116.41 14.55 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 124.934 1.293 . . . . 0.0 111.351 175.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -109.44 113.22 25.85 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.614 1.166 . . . . 0.0 109.939 177.195 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 27.3 m -73.61 150.71 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 O-C-N 121.817 -0.552 . . . . 0.0 110.894 177.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.2 m -126.5 121.18 31.62 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.801 0.84 . . . . 0.0 110.407 176.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -124.43 158.98 31.49 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 125.759 1.624 . . . . 0.0 110.51 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 13.4 ptm180 -136.18 111.5 9.11 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 126.061 1.744 . . . . 0.0 110.306 -178.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.9 109.07 19.08 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 123.258 0.623 . . . . 0.0 109.95 176.596 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 22.5 pt-20 -65.16 -18.43 65.3 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 113.337 0.866 . . . . 0.0 113.337 177.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -59.78 -36.72 77.26 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.027 1.731 . . . . 0.0 113.379 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -128.62 3.24 5.53 Favored 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.98 1.312 . . . . 0.0 112.665 174.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 64.61 24.18 69.37 Favored Glycine 0 CA--C 1.535 1.341 0 C-N-CA 125.447 1.498 . . . . 0.0 114.089 -172.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -90.74 173.53 7.97 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 118.671 1.236 . . . . 0.0 111.429 -176.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 27.0 m -117.9 143.77 27.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 124.168 0.987 . . . . 0.0 110.483 174.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 45.0 t -125.86 112.31 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 C-N-CA 125.375 1.47 . . . . 0.0 107.499 177.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.1 tmm? -125.34 119.34 28.1 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.145 0.978 . . . . 0.0 109.972 176.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.8 m -132.14 156.76 79.71 Favored Pre-proline 0 N--CA 1.469 0.519 0 C-N-CA 124.746 1.219 . . . . 0.0 111.834 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -78.01 113.61 3.46 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 124.053 3.169 . . . . 0.0 115.38 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -60.78 -34.42 74.46 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 120.134 -1.604 . . . . 0.0 114.315 178.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.17 5.57 78.37 Favored Glycine 0 N--CA 1.474 1.218 0 C-N-CA 124.202 0.905 . . . . 0.0 114.847 176.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 17.4 tttt -137.56 3.05 2.51 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 125.413 1.485 . . . . 0.0 113.212 -176.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 3.0 m -50.21 -29.13 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 C-N-CA 125.581 1.552 . . . . 0.0 113.513 175.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.8 mt -58.41 -28.77 65.52 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 126.098 1.759 . . . . 0.0 112.201 177.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.9 -51.64 13.32 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.035 1.734 . . . . 0.0 112.479 175.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 2.3 mp -68.61 -31.11 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 124.192 0.997 . . . . 0.0 111.367 178.07 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.83 10.48 72.4 Favored Glycine 0 CA--C 1.538 1.504 0 C-N-CA 126.047 1.784 . . . . 0.0 114.468 -177.555 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 31.2 m -97.35 123.47 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 C-N-CA 125.705 1.602 . . . . 0.0 110.75 -173.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 21.3 mmt85 -107.2 109.32 21.1 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.71 106.53 18.85 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -177.472 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -158.73 171.78 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 C-N-CA 126.257 1.823 . . . . 0.0 110.784 -175.08 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -61.0 -16.46 43.48 Favored 'General case' 0 CA--C 1.547 0.838 0 N-CA-C 115.415 1.635 . . . . 0.0 115.415 178.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.6 t -146.88 -55.71 0.25 Allowed 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 126.758 2.023 . . . . 0.0 111.727 -173.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -55.27 144.5 24.57 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 124.093 0.957 . . . . 0.0 112.515 175.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.115 0 C-N-CA 128.333 2.653 . . . . 0.0 113.757 -173.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.137 0 CA-C-O 121.22 0.533 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -143.06 77.73 0.28 Allowed Glycine 0 N--CA 1.469 0.842 0 C-N-CA 125.424 1.488 . . . . 0.0 111.666 -177.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 28.1 m-70 -63.59 152.94 37.4 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 123.773 0.829 . . . . 0.0 111.507 175.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.12 157.67 38.15 Favored Pre-proline 0 CA--C 1.54 0.592 0 C-N-CA 125.449 1.5 . . . . 0.0 111.894 -179.311 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -70.03 120.45 7.19 Favored 'Trans proline' 0 CA--C 1.535 0.556 0 C-N-CA 122.97 2.447 . . . . 0.0 110.199 176.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -138.63 164.96 28.16 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.638 1.175 . . . . 0.0 111.554 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -75.78 170.9 54.57 Favored Glycine 0 CA--C 1.536 1.388 0 C-N-CA 123.344 0.497 . . . . 0.0 113.437 177.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 44.7 m -132.78 -78.96 0.49 Allowed 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 124.687 1.195 . . . . 0.0 111.252 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -158.31 48.01 0.36 Allowed 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 125.447 1.499 . . . . 0.0 112.331 -178.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 24.0 m -130.1 163.96 25.45 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 125.619 1.568 . . . . 0.0 112.474 -179.156 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.1 mp -117.0 -34.81 4.28 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.298 1.439 . . . . 0.0 113.014 -177.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 33.5 mt-30 -131.14 166.86 20.17 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 126.35 1.86 . . . . 0.0 110.754 179.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -64.8 123.06 18.38 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 123.956 0.903 . . . . 0.0 110.876 176.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -146.81 176.42 9.89 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.469 1.908 . . . . 0.0 112.137 177.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.3 t -59.14 129.2 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 O-C-N 120.965 -1.084 . . . . 0.0 111.786 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.53 -4.93 85.0 Favored Glycine 0 CA--C 1.534 1.243 0 C-N-CA 125.197 1.38 . . . . 0.0 114.1 -178.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -67.32 161.44 25.04 Favored 'General case' 0 CA--C 1.547 0.858 0 CA-C-N 118.454 1.127 . . . . 0.0 112.561 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -96.55 124.14 40.44 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.951 1.701 . . . . 0.0 111.968 -173.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 19.4 m -139.75 139.72 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 C-N-CA 123.34 0.656 . . . . 0.0 110.968 -175.102 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.9 p -137.03 145.1 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 124.002 0.921 . . . . 0.0 110.384 177.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -74.71 160.51 80.77 Favored Pre-proline 0 CA--C 1.547 0.83 0 O-C-N 121.83 -0.544 . . . . 0.0 110.59 174.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -67.97 -25.73 38.17 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.04 2.493 . . . . 0.0 112.253 -179.048 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.3 t30 -159.07 48.87 0.33 Allowed 'General case' 0 CA--C 1.554 1.12 0 C-N-CA 124.494 1.117 . . . . 0.0 113.633 178.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -139.41 -64.12 0.5 Allowed 'General case' 0 N--CA 1.482 1.157 0 O-C-N 120.85 -1.156 . . . . 0.0 113.132 -174.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 166.39 172.49 33.76 Favored Glycine 0 CA--C 1.533 1.162 0 C-N-CA 125.015 1.293 . . . . 0.0 113.192 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.29 142.58 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 124.893 1.277 . . . . 0.0 110.804 -178.249 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 6.2 m -131.48 173.0 11.54 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.917 1.687 . . . . 0.0 111.148 176.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.8 tmt_? -133.76 118.96 18.67 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 125.863 1.665 . . . . 0.0 110.325 -178.022 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.3 t -60.84 131.1 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 O-C-N 121.762 -0.586 . . . . 0.0 111.01 -175.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 83.0 p -112.06 -42.64 3.71 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -178.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.8 162.68 34.83 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.527 1.531 . . . . 0.0 110.817 178.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 71.1 mt -143.69 136.04 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.5 1.12 . . . . 0.0 108.965 -178.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -149.04 163.49 37.37 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 124.352 1.061 . . . . 0.0 111.913 175.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.8 p -106.85 141.91 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 124.593 1.157 . . . . 0.0 109.775 175.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.28 168.04 26.68 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 125.259 1.423 . . . . 0.0 110.854 176.233 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -101.38 118.71 37.51 Favored 'General case' 0 N--CA 1.467 0.395 0 C-N-CA 125.307 1.443 . . . . 0.0 109.488 175.41 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.0 p -121.08 132.54 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 124.272 1.029 . . . . 0.0 109.774 174.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.05 29.08 2.29 Favored 'General case' 0 CA--C 1.557 1.218 0 N-CA-C 114.775 1.398 . . . . 0.0 114.775 -178.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.29 26.23 48.58 Favored Glycine 0 CA--C 1.542 1.781 0 C-N-CA 124.692 1.139 . . . . 0.0 115.296 -175.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 5.9 mt-30 -135.42 113.53 11.27 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 126.401 1.881 . . . . 0.0 111.081 -178.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 8.9 tttt -94.01 121.43 35.48 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.968 1.307 . . . . 0.0 111.423 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -157.1 161.47 39.43 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 122.848 0.459 . . . . 0.0 111.41 178.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.4 m -67.77 116.39 8.4 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 121.313 -0.867 . . . . 0.0 110.516 177.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -104.65 113.56 27.22 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 120.869 -1.144 . . . . 0.0 110.041 175.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.9 m -83.22 141.16 15.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 C-N-CA 123.525 0.73 . . . . 0.0 110.184 177.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 24.8 m -122.32 112.7 18.44 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.668 1.187 . . . . 0.0 109.896 -178.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -112.15 154.9 24.79 Favored 'General case' 0 C--O 1.233 0.224 0 C-N-CA 124.011 0.924 . . . . 0.0 109.405 -178.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 41.7 mtm180 -133.72 154.73 50.74 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 124.495 1.118 . . . . 0.0 109.791 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -120.94 109.08 14.66 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -67.57 -19.87 65.32 Favored 'General case' 0 CA--C 1.544 0.714 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 177.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -51.1 -46.81 61.97 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 127.046 2.139 . . . . 0.0 112.75 175.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -123.61 -19.19 5.89 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.517 1.527 . . . . 0.0 113.424 -179.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.25 37.61 8.93 Favored Glycine 0 CA--C 1.538 1.488 0 C-N-CA 125.429 1.49 . . . . 0.0 114.372 -177.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -110.06 166.64 10.79 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.4 1.48 . . . . 0.0 112.085 177.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.4 m -129.7 146.91 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 125.047 1.339 . . . . 0.0 111.52 178.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.0 m -136.94 112.2 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 C-N-CA 126.409 1.883 . . . . 0.0 109.151 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 9.4 ptt? -107.9 124.45 50.14 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 124.424 1.09 . . . . 0.0 110.364 176.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.1 m -131.97 157.21 78.83 Favored Pre-proline 0 N--CA 1.469 0.488 0 C-N-CA 123.949 0.9 . . . . 0.0 111.119 -178.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -77.73 114.94 3.75 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.382 2.721 . . . . 0.0 114.596 176.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -62.54 -35.77 80.51 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 120.37 -1.456 . . . . 0.0 113.909 178.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.99 6.35 79.1 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.245 0.926 . . . . 0.0 114.794 176.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 3.0 tttm -136.0 4.5 3.0 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.685 1.594 . . . . 0.0 112.861 -178.705 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -50.05 -30.0 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 126.12 1.768 . . . . 0.0 113.072 175.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.7 mt -55.05 -29.91 58.46 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.315 1.846 . . . . 0.0 112.585 176.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.78 -50.47 13.45 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.647 1.579 . . . . 0.0 112.529 177.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.6 mp -66.42 -32.98 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 C-N-CA 124.664 1.186 . . . . 0.0 111.237 177.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.4 4.61 76.8 Favored Glycine 0 CA--C 1.534 1.278 0 C-N-CA 125.647 1.594 . . . . 0.0 114.137 -176.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 30.2 m -82.31 137.55 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 124.404 1.082 . . . . 0.0 111.105 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -117.79 109.62 16.8 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.012 0.925 . . . . 0.0 110.535 175.771 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.05 106.6 10.5 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 126.51 1.924 . . . . 0.0 109.345 178.403 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 2.7 t -154.05 167.47 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 C-N-CA 124.599 1.159 . . . . 0.0 109.184 177.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -52.68 -19.33 2.31 Favored 'General case' 0 CA--C 1.546 0.804 0 N-CA-C 115.536 1.68 . . . . 0.0 115.536 175.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -124.52 -25.33 4.05 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.597 1.559 . . . . 0.0 113.404 175.695 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -73.98 98.63 3.09 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.585 1.154 . . . . 0.0 111.18 179.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 . . . . . 0 C--O 1.253 1.269 0 C-N-CA 126.235 1.814 . . . . 0.0 110.946 -179.743 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.182 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -91.91 -104.63 1.46 Allowed Glycine 0 N--CA 1.476 1.33 0 C-N-CA 124.641 1.115 . . . . 0.0 111.609 177.471 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 32.5 m80 -91.83 144.66 25.26 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.551 1.14 . . . . 0.0 109.94 175.174 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -55.43 155.19 10.37 Favored Pre-proline 0 CA--C 1.546 0.798 0 C-N-CA 125.631 1.572 . . . . 0.0 112.789 175.04 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -69.71 118.68 5.83 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 123.231 2.621 . . . . 0.0 110.614 -177.047 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -55.75 121.84 10.1 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.613 1.165 . . . . 0.0 112.371 179.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 163.96 155.58 8.35 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.176 0.893 . . . . 0.0 112.522 176.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.6 t -147.23 -33.49 0.28 Allowed 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.43 1.092 . . . . 0.0 113.292 -176.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -69.37 165.17 21.32 Favored 'General case' 0 CA--C 1.552 1.028 0 C-N-CA 124.52 1.128 . . . . 0.0 112.052 175.018 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 m -130.36 89.4 2.78 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.786 1.634 . . . . 0.0 111.338 -178.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.4 mp -138.21 179.2 6.59 Favored 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 125.848 1.659 . . . . 0.0 111.553 177.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -58.39 152.96 16.6 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 124.784 1.234 . . . . 0.0 111.836 175.148 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -77.88 123.01 26.23 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.728 0.811 . . . . 0.0 111.109 179.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -121.45 169.08 10.99 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 125.926 1.69 . . . . 0.0 111.972 175.005 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.4 t -61.37 129.84 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 O-C-N 121.413 -0.805 . . . . 0.0 110.634 176.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.12 -6.54 78.78 Favored Glycine 0 CA--C 1.534 1.23 0 C-N-CA 124.876 1.227 . . . . 0.0 114.651 -177.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -69.61 176.41 3.54 Favored 'General case' 0 CA--C 1.546 0.814 0 CA-C-N 119.079 1.439 . . . . 0.0 110.593 174.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.42 169.91 10.67 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.998 1.38 . . . . 0.0 112.998 -179.673 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.5 p -161.02 149.78 5.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 C-N-CA 125.539 1.536 . . . . 0.0 110.643 175.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.8 p -127.42 160.43 36.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 126.991 2.116 . . . . 0.0 107.685 174.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -125.84 154.55 73.46 Favored Pre-proline 0 CA--C 1.539 0.547 0 C-N-CA 125.063 1.345 . . . . 0.0 110.974 176.696 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.83 -9.83 26.5 Favored 'Trans proline' 0 CA--C 1.545 1.06 0 C-N-CA 123.17 2.58 . . . . 0.0 113.761 178.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 26.7 m-20 -133.46 -60.17 0.85 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.352 1.861 . . . . 0.0 112.922 176.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 65.5 mm-40 -52.48 -54.35 33.56 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 125.133 1.373 . . . . 0.0 112.952 -175.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 114.53 -147.36 18.82 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 125.479 1.514 . . . . 0.0 111.68 -174.059 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.2 m -70.17 144.66 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 124.004 0.922 . . . . 0.0 112.984 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 30.9 m -141.81 177.53 8.11 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 126.383 1.873 . . . . 0.0 110.653 178.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -132.38 129.47 39.43 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 124.759 1.224 . . . . 0.0 111.881 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.6 t -72.56 142.48 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 O-C-N 121.758 -0.588 . . . . 0.0 110.946 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.9 t -116.94 -44.78 2.79 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.419 1.488 . . . . 0.0 112.593 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.95 159.27 37.92 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 124.437 1.095 . . . . 0.0 110.553 177.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -142.59 133.59 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 120.911 -1.118 . . . . 0.0 108.823 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -149.47 169.4 20.97 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.298 0.639 . . . . 0.0 111.953 175.566 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.6 m -103.57 142.59 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 O-C-N 120.942 -1.099 . . . . 0.0 110.576 175.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.9 pttt -154.65 172.58 17.65 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.664 0.786 . . . . 0.0 112.011 176.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -104.64 116.6 32.33 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 125.727 1.611 . . . . 0.0 110.177 175.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.9 p -125.98 137.73 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 C-N-CA 124.262 1.025 . . . . 0.0 109.965 174.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.81 28.86 2.05 Favored 'General case' 0 CA--C 1.556 1.193 0 C-N-CA 125.182 1.393 . . . . 0.0 114.69 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.94 27.94 48.01 Favored Glycine 0 CA--C 1.541 1.701 0 C-N-CA 124.936 1.255 . . . . 0.0 115.144 -174.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.96 115.53 11.28 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 125.577 1.551 . . . . 0.0 111.856 -176.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -98.45 111.02 23.51 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 126.104 1.762 . . . . 0.0 111.356 -176.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -155.36 172.82 17.56 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.401 0.68 . . . . 0.0 111.655 -179.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 6.0 m -73.64 116.29 14.06 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.248 1.019 . . . . 0.0 111.116 175.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -108.94 113.21 25.91 Favored 'General case' 0 N--CA 1.467 0.394 0 O-C-N 121.221 -0.924 . . . . 0.0 109.612 176.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 19.3 m -73.2 146.56 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 123.3 0.64 . . . . 0.0 110.452 176.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 3.7 m -126.58 109.93 12.67 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 122.623 1.201 . . . . 0.0 110.243 176.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 1.6 mpp? -112.91 165.43 12.34 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.274 1.43 . . . . 0.0 110.483 179.174 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 26.8 ptt180 -142.75 117.29 9.72 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 124.835 1.254 . . . . 0.0 110.079 179.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 8.7 ttp180 -74.46 109.07 7.64 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.333 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -70.23 -14.32 62.56 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 178.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -57.58 -39.91 77.84 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 126.204 1.802 . . . . 0.0 112.791 176.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.63 -20.94 3.51 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 126.346 1.858 . . . . 0.0 114.75 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.12 14.49 51.46 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 125.104 1.335 . . . . 0.0 115.199 -174.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -76.85 163.34 26.86 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-N 118.85 1.325 . . . . 0.0 112.597 175.327 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 33.6 m -108.57 147.66 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.586 1.154 . . . . 0.0 110.344 174.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.2 t -138.53 112.72 8.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 C-N-CA 125.403 1.481 . . . . 0.0 107.699 -178.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.24 132.02 53.03 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 123.689 0.795 . . . . 0.0 111.89 178.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 33.4 m -139.9 157.38 69.66 Favored Pre-proline 0 N--CA 1.473 0.681 0 C-N-CA 124.164 0.985 . . . . 0.0 112.088 -178.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -77.95 116.28 3.94 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 123.705 2.937 . . . . 0.0 114.576 175.379 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -64.35 -33.74 76.55 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 120.327 -1.483 . . . . 0.0 114.284 178.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.64 6.7 80.08 Favored Glycine 0 N--CA 1.475 1.275 0 O-C-N 121.264 -0.897 . . . . 0.0 114.64 176.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 30.5 tttt -137.57 3.11 2.51 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 125.34 1.456 . . . . 0.0 113.194 -177.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 1.2 m -49.55 -29.22 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.631 1.572 . . . . 0.0 113.282 176.122 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 12.4 mt -56.08 -29.55 60.71 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.172 1.789 . . . . 0.0 112.574 176.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.6 -50.88 12.73 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.891 1.676 . . . . 0.0 112.98 175.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.8 mp -65.41 -33.2 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 C-N-CA 124.117 0.967 . . . . 0.0 111.537 178.147 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 87.4 0.2 84.84 Favored Glycine 0 CA--C 1.536 1.364 0 C-N-CA 125.623 1.582 . . . . 0.0 113.97 -175.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 7.7 p -73.53 123.15 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 124.588 1.155 . . . . 0.0 110.338 174.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -106.07 109.29 21.18 Favored 'General case' 0 N--CA 1.473 0.709 0 O-C-N 121.071 -1.018 . . . . 0.0 108.789 175.174 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.15 106.63 13.55 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 123.642 0.777 . . . . 0.0 110.177 178.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.2 t -154.07 166.39 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 C-N-CA 123.921 0.888 . . . . 0.0 109.478 177.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -55.96 -31.05 62.63 Favored 'General case' 0 CA--C 1.555 1.16 0 C-N-CA 124.414 1.086 . . . . 0.0 112.521 175.009 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 46.5 m -104.29 -41.33 5.81 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 124.764 1.226 . . . . 0.0 112.97 174.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.21 106.83 0.79 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.905 1.282 . . . . 0.0 111.461 -177.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 . . . . . 0 C--O 1.251 1.18 0 C-N-CA 126.503 1.921 . . . . 0.0 113.684 -170.768 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.277 0 N-CA-C 111.435 0.161 . . . . 0.0 111.435 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.68 58.89 0.22 Allowed Glycine 0 CA--C 1.529 0.949 0 C-N-CA 124.378 0.99 . . . . 0.0 112.689 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -57.97 114.75 2.48 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 124.281 1.033 . . . . 0.0 110.848 175.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -57.42 156.37 16.23 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 123.828 0.851 . . . . 0.0 112.621 178.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -64.03 127.25 18.94 Favored 'Trans proline' 0 CA--C 1.542 0.879 0 C-N-CA 123.341 2.694 . . . . 0.0 111.457 177.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -142.98 157.29 44.7 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 125.909 1.683 . . . . 0.0 111.923 177.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 178.56 -178.83 48.76 Favored Glycine 0 CA--C 1.538 1.514 0 C-N-CA 125.929 1.728 . . . . 0.0 113.226 177.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 49.7 m -71.9 -171.77 0.75 Allowed 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 125.908 1.683 . . . . 0.0 112.366 175.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -124.85 115.37 20.54 Favored 'General case' 0 CA--C 1.546 0.803 0 O-C-N 120.38 -1.45 . . . . 0.0 111.852 177.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.0 m -143.76 170.46 15.83 Favored 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 126.17 1.788 . . . . 0.0 111.615 -179.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -69.52 -75.41 0.11 Allowed 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.886 1.275 . . . . 0.0 111.233 176.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -78.94 162.08 26.24 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.718 1.207 . . . . 0.0 111.513 175.38 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 9.7 mt -97.33 168.23 10.53 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.549 1.14 . . . . 0.0 112.53 175.015 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -125.62 166.5 16.61 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.981 1.712 . . . . 0.0 111.122 176.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 75.2 t -67.93 131.87 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 123.628 0.771 . . . . 0.0 110.135 175.147 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.03 -3.45 70.18 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 125.84 1.686 . . . . 0.0 114.737 -178.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -76.63 152.15 35.94 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 119.085 1.443 . . . . 0.0 112.719 -179.29 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -86.89 135.0 33.47 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 125.453 1.501 . . . . 0.0 111.68 -177.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.3 m -143.54 135.71 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.796 1.239 . . . . 0.0 111.167 -177.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.7 p -102.92 165.63 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 O-C-N 121.152 -0.967 . . . . 0.0 111.33 175.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -125.99 158.44 65.94 Favored Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 125.277 1.431 . . . . 0.0 111.886 175.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -71.36 -40.78 2.85 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 123.328 2.685 . . . . 0.0 112.615 -178.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -148.75 32.37 0.78 Allowed 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.707 1.203 . . . . 0.0 112.87 -177.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -130.03 -23.11 2.79 Favored 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 125.817 1.647 . . . . 0.0 114.245 -173.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 104.17 168.15 24.94 Favored Glycine 0 CA--C 1.539 1.592 0 C-N-CA 126.406 1.955 . . . . 0.0 114.436 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 42.9 t -66.52 133.47 31.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 O-C-N 121.1 -1.235 . . . . 0.0 110.338 176.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 63.4 m -122.53 -179.85 4.35 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 126.302 1.841 . . . . 0.0 111.226 178.245 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.0 ttt180 -144.43 120.64 10.84 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 125.066 1.347 . . . . 0.0 110.562 176.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.7 t -57.96 126.76 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 C-N-CA 123.643 0.777 . . . . 0.0 111.089 -177.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.3 m -112.99 -36.46 5.1 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 124.748 1.219 . . . . 0.0 113.463 -176.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.88 159.54 41.82 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.96 1.704 . . . . 0.0 110.582 175.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 41.0 mt -143.81 118.19 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 124.851 1.26 . . . . 0.0 108.631 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -144.72 171.71 14.02 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 123.653 0.781 . . . . 0.0 112.003 177.33 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.5 m -111.8 142.18 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 O-C-N 121.331 -0.855 . . . . 0.0 111.455 175.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.46 170.82 21.06 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 124.314 1.045 . . . . 0.0 112.122 175.407 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -102.52 118.29 36.55 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.935 1.694 . . . . 0.0 109.536 174.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.8 p -129.68 137.65 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.695 0.798 . . . . 0.0 109.691 174.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.41 29.2 1.91 Allowed 'General case' 0 CA--C 1.556 1.184 0 C-N-CA 125.17 1.388 . . . . 0.0 114.696 -176.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.2 22.2 55.16 Favored Glycine 0 CA--C 1.538 1.528 0 C-N-CA 125.131 1.348 . . . . 0.0 115.454 -177.23 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -135.97 113.5 10.85 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 119.149 1.475 . . . . 0.0 111.062 -173.38 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -96.0 114.06 25.74 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 125.541 1.536 . . . . 0.0 111.843 -176.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -158.21 173.69 16.32 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 123.437 0.695 . . . . 0.0 111.924 179.283 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.3 m -73.36 116.28 13.73 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.456 1.103 . . . . 0.0 111.165 174.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -108.75 113.13 25.84 Favored 'General case' 0 C--O 1.235 0.311 0 O-C-N 120.969 -1.082 . . . . 0.0 109.43 175.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.2 m -70.49 150.95 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 CA-C-N 116.242 -0.436 . . . . 0.0 109.993 175.28 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 25.4 m -126.47 128.58 47.16 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 125.252 1.421 . . . . 0.0 109.533 175.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.94 166.98 23.73 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 125.674 1.589 . . . . 0.0 110.599 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.23 141.31 27.27 Favored 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 124.347 1.059 . . . . 0.0 111.165 175.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 59.9 mtm180 -78.71 124.62 28.38 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.106 1.362 . . . . 0.0 111.059 178.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -63.18 -40.64 98.1 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.441 1.096 . . . . 0.0 113.237 177.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -87.09 -46.65 9.6 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.977 0.911 . . . . 0.0 112.666 178.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -71.78 -21.61 61.7 Favored 'General case' 0 N--CA 1.475 0.809 0 O-C-N 121.517 -0.739 . . . . 0.0 112.815 -177.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 66.26 12.47 58.23 Favored Glycine 0 CA--C 1.536 1.38 0 C-N-CA 126.062 1.791 . . . . 0.0 114.81 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -109.32 145.59 35.74 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.672 1.589 . . . . 0.0 112.56 -168.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 16.3 m -70.21 150.87 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.871 1.268 . . . . 0.0 111.837 177.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.2 t -145.21 123.67 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 125.602 1.561 . . . . 0.0 108.91 178.127 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 43.8 mtt -141.26 121.74 14.12 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 123.813 0.845 . . . . 0.0 109.845 178.009 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 26.8 m -132.67 157.48 78.21 Favored Pre-proline 0 N--CA 1.475 0.796 0 C-N-CA 124.0 0.92 . . . . 0.0 112.335 177.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -77.91 114.33 3.6 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 123.546 2.831 . . . . 0.0 114.915 178.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -60.69 -36.51 78.95 Favored 'General case' 0 N--CA 1.476 0.828 0 O-C-N 120.346 -1.471 . . . . 0.0 114.297 178.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.11 5.77 78.61 Favored Glycine 0 N--CA 1.475 1.246 0 C-N-CA 124.338 0.97 . . . . 0.0 114.863 176.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 15.0 tttp -135.88 3.2 2.93 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.286 1.435 . . . . 0.0 113.106 -177.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.8 m -49.75 -29.87 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 125.635 1.574 . . . . 0.0 113.11 175.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.0 mt -57.56 -28.65 63.75 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 126.164 1.786 . . . . 0.0 112.595 176.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.03 -50.04 15.89 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 125.863 1.665 . . . . 0.0 112.605 176.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.0 mp -69.56 -33.68 58.05 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 124.15 0.98 . . . . 0.0 111.465 178.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.97 3.25 73.67 Favored Glycine 0 CA--C 1.537 1.466 0 C-N-CA 125.799 1.666 . . . . 0.0 114.208 -174.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 31.3 m -71.5 125.96 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 124.774 1.229 . . . . 0.0 110.834 177.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.3 mmm180 -109.72 109.34 20.01 Favored 'General case' 0 N--CA 1.474 0.769 0 O-C-N 121.076 -1.015 . . . . 0.0 108.931 175.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -131.78 106.62 8.23 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 125.901 1.681 . . . . 0.0 109.117 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 3.4 t -153.76 168.28 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 C-N-CA 124.76 1.224 . . . . 0.0 107.708 -179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -53.06 -33.66 52.99 Favored 'General case' 0 CA--C 1.549 0.938 0 CA-C-N 119.097 0.862 . . . . 0.0 112.726 177.275 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 2.0 t -104.52 -16.7 14.98 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.991 1.716 . . . . 0.0 114.46 176.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -87.39 89.28 7.94 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.545 1.138 . . . . 0.0 110.394 -179.287 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 . . . . . 0 C--O 1.255 1.361 0 C-N-CA 127.677 2.391 . . . . 0.0 113.556 -169.577 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.299 0 N-CA-C 110.932 -0.025 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 92.05 42.11 4.76 Favored Glycine 0 CA--C 1.534 1.224 0 C-N-CA 124.296 0.95 . . . . 0.0 114.021 -178.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 49.5 m80 -62.35 105.91 0.68 Allowed 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 124.898 1.279 . . . . 0.0 111.155 175.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -76.45 164.16 61.49 Favored Pre-proline 0 CA--C 1.549 0.905 0 C-N-CA 124.166 0.986 . . . . 0.0 113.295 178.513 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -70.6 98.25 0.76 Allowed 'Trans proline' 0 CA--C 1.54 0.806 0 C-N-CA 124.232 3.288 . . . . 0.0 112.383 175.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -142.83 161.51 37.91 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 126.116 1.766 . . . . 0.0 111.541 178.44 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 164.85 82.87 0.05 OUTLIER Glycine 0 CA--C 1.534 1.268 0 N-CA-C 114.953 0.741 . . . . 0.0 114.953 -175.077 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 14.8 p -79.73 98.97 7.21 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 125.661 1.584 . . . . 0.0 113.615 177.288 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -152.99 -82.15 0.09 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 124.858 1.263 . . . . 0.0 111.757 174.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 31.9 p -79.15 173.16 12.86 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 126.588 1.955 . . . . 0.0 112.941 177.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 45.4 mt -95.64 -66.92 0.88 Allowed 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.693 1.197 . . . . 0.0 111.113 178.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.11 171.14 13.47 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 125.319 1.447 . . . . 0.0 112.114 176.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -73.91 133.38 43.09 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 123.893 0.877 . . . . 0.0 111.492 176.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -140.57 172.74 12.29 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.86 1.664 . . . . 0.0 112.382 175.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 85.2 t -59.72 131.93 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 O-C-N 120.977 -1.077 . . . . 0.0 111.095 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.52 -6.24 83.73 Favored Glycine 0 CA--C 1.535 1.332 0 C-N-CA 125.045 1.307 . . . . 0.0 114.958 -177.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -69.65 176.85 3.28 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-N 118.805 1.303 . . . . 0.0 112.815 175.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 15.8 mmt85 -119.91 134.15 55.34 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.449 1.5 . . . . 0.0 111.884 -174.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 17.2 m -139.35 136.92 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 125.091 1.356 . . . . 0.0 109.506 -173.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.6 p -137.03 139.05 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 C-N-CA 123.989 0.916 . . . . 0.0 110.118 176.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -69.61 160.4 79.74 Favored Pre-proline 0 CA--C 1.542 0.646 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 174.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -68.8 -27.29 31.52 Favored 'Trans proline' 0 CA--C 1.54 0.802 0 C-N-CA 122.781 2.32 . . . . 0.0 112.326 -177.351 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 56.9 t30 -157.77 47.66 0.38 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 124.401 1.081 . . . . 0.0 113.553 177.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -137.86 -64.19 0.55 Allowed 'General case' 0 N--CA 1.481 1.099 0 O-C-N 121.155 -0.965 . . . . 0.0 112.994 -174.117 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.55 168.44 30.63 Favored Glycine 0 CA--C 1.534 1.246 0 C-N-CA 125.081 1.324 . . . . 0.0 113.398 178.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.3 p -77.73 146.83 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 124.891 1.277 . . . . 0.0 111.411 175.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 3.7 m -130.36 173.83 10.43 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.568 1.547 . . . . 0.0 111.271 175.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.11 117.78 17.92 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.552 1.541 . . . . 0.0 110.909 -176.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.4 t -65.95 116.09 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.078 1.351 . . . . 0.0 111.124 -177.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.3 m -107.62 -47.85 3.54 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.852 1.261 . . . . 0.0 112.34 -176.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -148.8 169.71 19.87 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.334 1.854 . . . . 0.0 110.403 178.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 48.8 mt -147.28 140.36 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.054 1.342 . . . . 0.0 108.266 175.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.34 173.65 11.3 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.106 0.962 . . . . 0.0 112.313 175.706 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.9 m -123.26 140.77 45.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 124.711 1.204 . . . . 0.0 110.728 177.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -155.53 167.42 30.44 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 123.935 0.894 . . . . 0.0 112.385 177.209 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -100.56 119.79 39.06 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.349 1.459 . . . . 0.0 108.745 174.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.0 p -127.33 136.8 59.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.851 1.261 . . . . 0.0 109.058 175.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.85 28.95 1.48 Allowed 'General case' 0 CA--C 1.557 1.233 0 N-CA-C 114.882 1.438 . . . . 0.0 114.882 -178.003 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.06 26.51 48.54 Favored Glycine 0 CA--C 1.542 1.72 0 C-N-CA 124.822 1.201 . . . . 0.0 115.363 -176.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -137.57 116.98 12.79 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 126.229 1.811 . . . . 0.0 110.835 -175.459 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -96.3 118.94 33.87 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 125.338 1.455 . . . . 0.0 111.105 179.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -155.16 172.63 17.84 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 123.432 0.693 . . . . 0.0 111.892 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 48.2 m -82.25 116.41 21.77 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.078 1.351 . . . . 0.0 111.943 176.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -102.2 113.17 26.22 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.483 1.113 . . . . 0.0 109.529 174.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.0 m -63.04 148.1 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 O-C-N 121.895 -0.503 . . . . 0.0 110.812 174.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 1.5 m -126.61 109.85 12.56 Favored 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 122.09 0.948 . . . . 0.0 110.605 176.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 2.4 mpp? -123.58 160.17 27.64 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 124.055 0.942 . . . . 0.0 110.239 -178.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -130.91 125.06 32.51 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 123.843 0.857 . . . . 0.0 110.831 174.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 79.4 mtm180 -83.38 109.02 16.96 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 125.355 1.462 . . . . 0.0 108.462 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -65.62 -18.09 65.07 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.865 0.866 . . . . 0.0 112.494 177.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 31.0 tt0 -57.54 -39.22 76.16 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.622 1.969 . . . . 0.0 113.225 177.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -128.62 1.73 5.52 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 125.011 1.324 . . . . 0.0 113.645 177.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.79 11.77 60.98 Favored Glycine 0 CA--C 1.538 1.476 0 C-N-CA 125.427 1.489 . . . . 0.0 114.306 -171.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -81.04 159.01 24.91 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.489 1.516 . . . . 0.0 112.566 -176.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 20.4 m -97.95 162.05 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 123.481 0.712 . . . . 0.0 110.601 175.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 3.9 p -151.95 122.05 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 125.347 1.459 . . . . 0.0 109.111 174.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 19.3 ptm -125.93 135.26 51.68 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 125.076 1.35 . . . . 0.0 110.608 175.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.2 m -137.58 154.24 74.88 Favored Pre-proline 0 N--CA 1.468 0.454 0 C-N-CA 123.819 0.847 . . . . 0.0 111.253 175.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -75.51 117.24 4.73 Favored 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 123.271 2.648 . . . . 0.0 114.439 178.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -59.65 -40.53 87.97 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.61 7.31 79.86 Favored Glycine 0 N--CA 1.474 1.173 0 C-N-CA 124.418 1.009 . . . . 0.0 114.588 178.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.2 tttm -133.7 3.4 3.53 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.203 1.401 . . . . 0.0 113.509 -178.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.5 m -48.75 -28.87 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.933 1.293 . . . . 0.0 113.598 175.007 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.3 mt -57.31 -29.09 63.63 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.989 1.715 . . . . 0.0 112.61 177.276 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.05 -50.61 15.9 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 125.64 1.576 . . . . 0.0 112.673 175.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.9 mp -68.75 -33.55 60.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 124.244 1.018 . . . . 0.0 111.435 178.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.7 2.19 79.23 Favored Glycine 0 CA--C 1.537 1.415 0 C-N-CA 125.844 1.688 . . . . 0.0 114.349 -175.198 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.6 t -80.69 123.16 37.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 CA-C-N 118.96 1.38 . . . . 0.0 110.472 178.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 3.3 mmt180 -99.58 109.24 21.76 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 174.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.7 106.48 13.93 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.527 1.531 . . . . 0.0 109.352 176.521 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 3.2 t -161.37 157.52 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.275 0 C-N-CA 126.281 1.833 . . . . 0.0 109.172 -178.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -54.02 -25.29 20.49 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.893 1.677 . . . . 0.0 115.156 176.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 3.5 t -126.7 11.86 7.31 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 126.104 1.762 . . . . 0.0 113.326 -178.308 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -80.95 -66.83 0.84 Allowed 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.483 1.113 . . . . 0.0 112.406 177.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 7.1 tm-20 . . . . . 0 C--O 1.253 1.238 0 C-N-CA 126.062 1.745 . . . . 0.0 112.674 -165.785 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.32 0 CA-C-O 120.636 0.255 . . . . 0.0 111.462 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 168.88 54.47 0.03 OUTLIER Glycine 0 CA--C 1.535 1.301 0 C-N-CA 124.257 0.932 . . . . 0.0 114.073 178.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 19.0 m80 -70.95 135.8 48.11 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.508 1.123 . . . . 0.0 111.98 -179.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 5.2 mtt -79.58 163.94 56.25 Favored Pre-proline 0 CA--C 1.545 0.781 0 N-CA-C 113.467 0.914 . . . . 0.0 113.467 176.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -72.59 103.93 1.63 Allowed 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 123.694 2.929 . . . . 0.0 109.316 175.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -138.0 161.7 36.03 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.458 1.503 . . . . 0.0 111.69 178.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -170.2 -178.38 41.06 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 124.968 1.271 . . . . 0.0 113.149 -177.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 24.2 m -85.46 -46.96 10.4 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.21 1.004 . . . . 0.0 113.27 -175.045 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -148.79 167.24 26.14 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.866 1.667 . . . . 0.0 112.473 -179.176 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 39.3 t -86.97 100.59 12.72 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 125.902 1.681 . . . . 0.0 111.294 177.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -110.88 168.34 9.55 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 125.881 1.673 . . . . 0.0 111.817 176.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.76 143.04 57.77 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 124.88 1.272 . . . . 0.0 111.741 179.063 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -68.47 120.64 14.87 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 124.288 1.035 . . . . 0.0 111.836 -174.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -140.06 172.91 12.08 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.017 1.327 . . . . 0.0 112.559 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.3 t -60.22 126.37 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.123 0.969 . . . . 0.0 110.475 177.203 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.23 -8.36 72.48 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.051 1.31 . . . . 0.0 114.856 -177.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -72.2 169.53 15.94 Favored 'General case' 0 CA--C 1.55 0.973 0 CA-C-N 119.215 1.507 . . . . 0.0 111.056 174.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -88.3 159.26 18.16 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.614 1.566 . . . . 0.0 112.018 175.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 1.5 p -150.86 130.14 3.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 C-N-CA 124.739 1.216 . . . . 0.0 110.134 175.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.2 p -137.19 142.59 36.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 C-N-CA 125.995 1.718 . . . . 0.0 107.903 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -88.46 161.97 40.94 Favored Pre-proline 0 CA--C 1.545 0.765 0 C-N-CA 124.685 1.194 . . . . 0.0 110.965 175.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.67 -26.66 27.77 Favored 'Trans proline' 0 CA--C 1.536 0.59 0 C-N-CA 123.439 2.759 . . . . 0.0 112.37 -175.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -158.15 62.77 0.45 Allowed 'General case' 0 CA--C 1.551 1.013 0 C-N-CA 125.863 1.665 . . . . 0.0 111.57 176.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -146.43 -61.88 0.31 Allowed 'General case' 0 N--CA 1.481 1.084 0 O-C-N 121.085 -1.009 . . . . 0.0 112.463 179.147 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 158.67 -179.42 34.35 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 124.661 1.124 . . . . 0.0 113.422 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.3 m -81.87 147.8 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.542 1.537 . . . . 0.0 112.037 175.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 97.7 m -138.18 179.62 6.34 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.856 2.062 . . . . 0.0 109.851 179.027 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.01 135.6 39.61 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 125.102 1.361 . . . . 0.0 110.462 175.245 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -66.54 129.99 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 C-N-CA 123.95 0.9 . . . . 0.0 110.401 175.074 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -115.06 -51.69 2.71 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.622 1.169 . . . . 0.0 111.759 -178.21 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.73 164.54 37.57 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.849 1.66 . . . . 0.0 110.875 175.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 64.2 mt -144.9 134.45 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 O-C-N 120.752 -1.217 . . . . 0.0 108.756 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -143.53 174.09 11.07 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.355 1.062 . . . . 0.0 112.162 176.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.4 p -124.75 137.89 55.94 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 125.168 1.387 . . . . 0.0 110.842 177.378 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 13.2 ptmt -150.74 153.4 35.44 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 124.961 1.304 . . . . 0.0 112.088 178.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -81.05 115.18 20.38 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 123.787 0.835 . . . . 0.0 108.924 174.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.6 p -118.6 133.36 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 124.311 1.044 . . . . 0.0 109.653 174.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.54 29.01 2.74 Favored 'General case' 0 CA--C 1.557 1.227 0 N-CA-C 114.772 1.397 . . . . 0.0 114.772 -178.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.43 20.42 56.74 Favored Glycine 0 CA--C 1.538 1.529 0 C-N-CA 124.854 1.216 . . . . 0.0 115.422 -175.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -142.87 114.11 7.81 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.491 1.516 . . . . 0.0 111.814 -176.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 5.1 ptmt -91.77 133.96 35.16 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.721 1.208 . . . . 0.0 111.656 175.007 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.3 pp -160.05 163.58 33.84 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.266 1.026 . . . . 0.0 110.483 176.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.0 m -66.39 116.49 7.46 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 121.279 -0.888 . . . . 0.0 110.986 178.012 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -104.91 113.3 26.82 Favored 'General case' 0 N--CA 1.467 0.407 0 O-C-N 120.748 -1.22 . . . . 0.0 109.409 175.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.2 m -75.73 143.68 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-O 119.035 -0.507 . . . . 0.0 110.19 177.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -125.82 112.86 16.51 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 122.41 1.1 . . . . 0.0 110.918 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -122.73 165.74 16.07 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.897 1.279 . . . . 0.0 109.647 -176.033 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.5 mtt180 -134.98 160.79 37.2 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 124.425 1.09 . . . . 0.0 110.589 175.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -122.28 109.1 14.03 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 125.733 1.613 . . . . 0.0 109.463 174.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -64.86 -17.66 64.48 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 113.331 0.863 . . . . 0.0 113.331 176.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -54.63 -44.37 73.1 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 127.199 2.2 . . . . 0.0 112.451 178.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -126.19 -1.29 7.05 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.47 1.908 . . . . 0.0 112.494 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.62 34.31 88.61 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 125.157 1.361 . . . . 0.0 113.552 -174.066 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.59 165.61 10.95 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 124.252 1.021 . . . . 0.0 112.145 -176.233 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.5 m -110.28 155.78 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.013 1.325 . . . . 0.0 111.265 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 3.7 p -151.05 125.83 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 124.713 1.205 . . . . 0.0 109.405 175.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 22.8 ptt? -130.21 137.81 50.26 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 123.9 0.88 . . . . 0.0 110.803 175.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.466 ' CG2' ' HE2' ' A' ' 70' ' ' LYS . 14.0 m -140.24 157.34 69.01 Favored Pre-proline 0 N--CA 1.474 0.731 0 C-N-CA 123.584 0.754 . . . . 0.0 111.414 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -75.59 116.03 4.37 Favored 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 123.726 2.95 . . . . 0.0 114.861 176.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -63.97 -33.42 75.69 Favored 'General case' 0 N--CA 1.482 1.132 0 O-C-N 120.394 -1.441 . . . . 0.0 113.573 178.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.92 4.57 78.57 Favored Glycine 0 N--CA 1.476 1.328 0 C-N-CA 124.769 1.176 . . . . 0.0 114.686 175.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.0 tttm -136.74 3.84 2.76 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.437 1.495 . . . . 0.0 112.992 -177.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.2 m -50.26 -28.31 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 C-N-CA 125.731 1.613 . . . . 0.0 113.012 175.188 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.0 mt -56.02 -30.16 61.45 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 125.945 1.698 . . . . 0.0 112.385 176.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.53 -50.34 15.95 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 125.86 1.664 . . . . 0.0 112.828 175.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.0 mp -68.16 -33.38 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 124.054 0.941 . . . . 0.0 111.465 178.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.49 3.56 77.91 Favored Glycine 0 CA--C 1.537 1.445 0 C-N-CA 126.166 1.841 . . . . 0.0 114.605 -177.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 31.4 m -82.21 125.56 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 C-N-CA 126.451 1.9 . . . . 0.0 111.216 -178.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.69 109.25 17.92 Favored 'General case' 0 N--CA 1.475 0.782 0 O-C-N 121.252 -0.905 . . . . 0.0 110.105 177.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.466 ' HE2' ' CG2' ' A' ' 58' ' ' VAL . 0.0 OUTLIER -98.37 106.59 18.89 Favored 'General case' 0 N--CA 1.47 0.536 0 C-N-CA 123.226 0.61 . . . . 0.0 110.477 178.127 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.6 t -153.35 170.37 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 125.231 1.412 . . . . 0.0 108.567 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -61.5 -20.89 63.7 Favored 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 124.547 1.139 . . . . 0.0 113.632 175.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 9.0 m -129.27 -40.43 1.46 Allowed 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 125.519 1.528 . . . . 0.0 114.621 178.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.91 159.27 20.15 Favored 'General case' 0 CA--C 1.545 0.768 0 CA-C-N 119.002 0.819 . . . . 0.0 112.484 176.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.254 1.328 0 C-N-CA 126.447 1.899 . . . . 0.0 111.945 175.566 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.161 0 CA-C-O 120.605 0.24 . . . . 0.0 110.414 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.59 -165.66 36.28 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 123.806 0.717 . . . . 0.0 113.402 -175.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 82.5 m-70 -98.89 146.26 26.16 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 124.463 1.105 . . . . 0.0 111.135 174.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 7.7 ptp -111.93 157.22 40.25 Favored Pre-proline 0 CA--C 1.547 0.831 0 C-N-CA 125.772 1.629 . . . . 0.0 111.523 178.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -71.52 132.67 20.94 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 123.99 3.127 . . . . 0.0 111.095 175.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -168.17 174.37 7.24 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 126.201 1.8 . . . . 0.0 111.077 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 145.94 179.63 22.3 Favored Glycine 0 CA--C 1.534 1.235 0 C-N-CA 125.627 1.584 . . . . 0.0 112.85 178.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 15.9 p -151.95 116.33 5.03 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.376 1.47 . . . . 0.0 111.369 -178.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -164.99 -172.99 2.76 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 125.624 1.57 . . . . 0.0 111.564 179.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 22.2 m -64.15 172.07 2.63 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 125.509 1.524 . . . . 0.0 112.116 174.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 39.6 mt -84.06 55.64 3.39 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 124.589 1.156 . . . . 0.0 112.402 -177.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.32 117.27 7.73 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 124.049 0.94 . . . . 0.0 111.72 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.94 126.56 30.24 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.096 0.958 . . . . 0.0 110.803 176.26 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -124.79 169.85 11.61 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.141 1.377 . . . . 0.0 112.316 177.193 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.42 129.11 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 O-C-N 121.414 -0.803 . . . . 0.0 110.567 176.305 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.26 -6.15 75.29 Favored Glycine 0 CA--C 1.534 1.231 0 C-N-CA 125.075 1.322 . . . . 0.0 114.901 -179.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -68.77 176.74 2.86 Favored 'General case' 0 CA--C 1.549 0.917 0 CA-C-N 119.068 1.434 . . . . 0.0 111.883 174.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.9 mmt180 -113.08 139.57 48.59 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.564 1.545 . . . . 0.0 111.35 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 15.1 m -139.71 137.09 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 C-N-CA 124.204 1.002 . . . . 0.0 109.477 -178.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.5 p -137.04 137.99 46.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 124.151 0.981 . . . . 0.0 110.085 177.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -71.67 161.95 75.77 Favored Pre-proline 0 CA--C 1.546 0.826 0 N-CA-C 112.113 0.412 . . . . 0.0 112.113 175.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -70.11 -28.54 23.46 Favored 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.43 2.753 . . . . 0.0 112.265 -178.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 32.3 m-20 -157.95 64.4 0.46 Allowed 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 127.026 2.13 . . . . 0.0 111.357 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 5.4 mm-40 -151.9 -71.07 0.16 Allowed 'General case' 0 N--CA 1.479 1.021 0 O-C-N 120.794 -1.191 . . . . 0.0 111.776 174.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 173.55 174.09 40.28 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.403 1.478 . . . . 0.0 112.406 -174.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.5 p -84.39 149.3 4.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 124.949 1.299 . . . . 0.0 110.704 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.7 m -128.82 174.59 9.34 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.774 1.63 . . . . 0.0 110.52 175.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -131.82 118.82 20.4 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 124.004 0.922 . . . . 0.0 110.9 -178.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.2 t -57.82 126.88 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 C-N-CA 124.111 0.964 . . . . 0.0 110.593 -179.399 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.9 t -111.01 -51.88 2.83 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 125.135 1.374 . . . . 0.0 110.984 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.81 169.87 21.72 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 124.861 1.265 . . . . 0.0 111.064 177.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 62.0 mt -145.2 138.68 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 124.722 1.209 . . . . 0.0 108.457 175.042 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -150.26 167.0 28.24 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 124.853 1.261 . . . . 0.0 112.158 175.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 13.8 m -106.77 143.09 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.109 0.964 . . . . 0.0 110.908 176.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -155.25 170.82 20.97 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 124.623 1.169 . . . . 0.0 111.795 175.423 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -106.28 116.22 31.57 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.949 1.699 . . . . 0.0 109.697 175.001 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.8 p -125.62 138.03 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 C-N-CA 124.462 1.105 . . . . 0.0 110.725 174.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.53 29.09 1.95 Allowed 'General case' 0 CA--C 1.556 1.208 0 C-N-CA 124.856 1.262 . . . . 0.0 114.26 -179.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.35 27.04 53.36 Favored Glycine 0 CA--C 1.54 1.604 0 C-N-CA 125.2 1.381 . . . . 0.0 115.613 -174.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.8 tp60 -135.14 113.54 11.48 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.761 1.624 . . . . 0.0 110.436 -175.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 18.6 tttt -96.28 114.86 26.58 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 124.899 1.28 . . . . 0.0 111.25 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -157.59 173.07 17.42 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 123.155 0.582 . . . . 0.0 111.765 179.532 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 17.2 m -79.73 116.58 19.99 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.367 1.067 . . . . 0.0 111.595 175.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -102.38 114.5 28.73 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.03 0.932 . . . . 0.0 109.763 175.028 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 5.7 m -66.87 145.27 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 O-C-N 121.863 -0.523 . . . . 0.0 110.783 174.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -126.65 109.8 12.49 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.532 1.133 . . . . 0.0 111.109 -179.445 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 1.8 mpp? -123.22 160.72 25.99 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 124.229 1.011 . . . . 0.0 110.546 -177.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.64 134.03 40.74 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.875 0.87 . . . . 0.0 110.905 174.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 60.9 mtm180 -94.27 108.76 20.62 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 124.824 1.25 . . . . 0.0 108.209 176.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -69.53 -17.78 63.61 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.343 1.057 . . . . 0.0 113.562 175.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -55.49 -42.12 73.98 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 126.032 1.733 . . . . 0.0 112.538 178.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -121.97 -20.25 6.39 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 125.474 1.509 . . . . 0.0 113.387 177.828 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.47 49.15 4.5 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 125.305 1.431 . . . . 0.0 113.122 -177.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -125.37 159.98 30.47 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.097 1.359 . . . . 0.0 112.163 178.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 27.1 m -98.41 158.62 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.431 1.092 . . . . 0.0 111.117 176.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 3.4 p -150.17 122.86 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 125.271 1.428 . . . . 0.0 109.324 175.098 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.0 ptm -126.9 139.44 53.07 Favored 'General case' 0 C--O 1.233 0.211 0 C-N-CA 124.098 0.959 . . . . 0.0 111.018 175.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 27.0 m -142.82 154.73 62.75 Favored Pre-proline 0 N--CA 1.468 0.473 0 C-N-CA 123.986 0.914 . . . . 0.0 111.469 177.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -74.8 119.92 5.9 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.156 2.571 . . . . 0.0 114.381 177.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 14.1 mt-10 -62.09 -39.93 94.11 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 178.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.27 7.71 78.01 Favored Glycine 0 N--CA 1.475 1.273 0 C-N-CA 124.677 1.132 . . . . 0.0 114.762 178.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 7.9 tttt -135.53 5.56 3.19 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.775 1.63 . . . . 0.0 112.451 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -49.65 -29.36 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 C-N-CA 125.329 1.452 . . . . 0.0 113.476 174.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 11.4 mt -58.01 -28.68 64.67 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.003 1.721 . . . . 0.0 112.286 177.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.42 -51.01 14.07 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.834 1.653 . . . . 0.0 112.218 177.202 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.5 mp -67.53 -29.47 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 124.375 1.07 . . . . 0.0 111.216 176.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 84.61 8.39 83.06 Favored Glycine 0 CA--C 1.536 1.358 0 C-N-CA 125.815 1.674 . . . . 0.0 114.069 -176.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 17.0 m -90.84 123.32 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 125.373 1.469 . . . . 0.0 111.345 -175.302 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.35 109.6 21.51 Favored 'General case' 0 N--CA 1.469 0.507 0 O-C-N 120.881 -1.137 . . . . 0.0 109.434 178.224 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.61 106.63 17.72 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.989 0.916 . . . . 0.0 109.06 177.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 85.8 t -150.41 -75.81 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 124.68 1.192 . . . . 0.0 111.246 179.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -177.57 -45.44 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 127.666 2.386 . . . . 0.0 111.186 -179.094 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -127.33 -1.69 6.3 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 126.49 1.916 . . . . 0.0 113.957 -178.393 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -73.71 -53.6 10.0 Favored 'General case' 0 CA--C 1.548 0.889 0 C-N-CA 125.332 1.453 . . . . 0.0 113.069 -176.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . 0.315 13.3 pt-20 . . . . . 0 N--CA 1.486 1.349 0 C-N-CA 131.571 3.948 . . . . 0.0 118.524 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.183 0 CA-C-O 120.666 0.269 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.86 39.82 0.39 Allowed Glycine 0 N--CA 1.475 1.285 0 C-N-CA 124.043 0.83 . . . . 0.0 114.441 -175.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 37.6 m170 -80.81 105.94 12.43 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 124.406 1.082 . . . . 0.0 111.781 177.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.3 mtm -67.64 161.09 68.94 Favored Pre-proline 0 CA--C 1.551 1.002 0 C-N-CA 124.63 1.172 . . . . 0.0 112.157 174.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -72.42 89.55 0.82 Allowed 'Trans proline' 0 CA--C 1.547 1.131 0 C-N-CA 124.491 3.461 . . . . 0.0 112.942 -179.337 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 10.2 mt-10 -75.39 -63.87 1.19 Allowed 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 124.35 1.06 . . . . 0.0 113.585 174.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 82.83 -110.79 3.29 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 124.706 1.146 . . . . 0.0 113.335 -178.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.7 t -144.01 173.28 11.86 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 125.078 1.351 . . . . 0.0 112.436 -178.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -82.41 63.39 6.56 Favored 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 125.979 1.712 . . . . 0.0 112.263 -179.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.5 m -142.06 169.25 17.94 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 125.701 1.601 . . . . 0.0 111.73 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -109.03 -45.37 3.79 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 124.988 1.315 . . . . 0.0 111.429 174.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 40.3 mt-30 -68.12 170.08 9.1 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 124.681 1.192 . . . . 0.0 111.834 176.233 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -107.24 126.84 52.94 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 125.013 1.325 . . . . 0.0 111.1 -179.48 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.0 177.28 8.16 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.711 1.604 . . . . 0.0 112.184 176.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.8 t -59.69 129.3 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.175 0.99 . . . . 0.0 110.777 175.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.66 -4.68 85.76 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 124.835 1.207 . . . . 0.0 115.151 -177.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -70.83 165.75 22.5 Favored 'General case' 0 CA--C 1.549 0.916 0 CA-C-N 119.211 1.506 . . . . 0.0 111.613 174.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -89.56 148.73 23.21 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.902 0.881 . . . . 0.0 111.883 177.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.8 m -147.48 138.88 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 125.976 1.71 . . . . 0.0 109.184 176.266 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.0 p -137.11 146.33 28.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 C-N-CA 124.741 1.216 . . . . 0.0 110.483 176.273 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -84.19 158.77 60.69 Favored Pre-proline 0 CA--C 1.548 0.867 0 C-N-CA 123.409 0.684 . . . . 0.0 111.959 175.168 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -68.69 -25.91 33.59 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 123.809 3.006 . . . . 0.0 112.993 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -160.2 62.62 0.34 Allowed 'General case' 0 CA--C 1.554 1.118 0 C-N-CA 124.764 1.226 . . . . 0.0 112.316 177.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.86 -68.53 0.17 Allowed 'General case' 0 N--CA 1.48 1.053 0 O-C-N 120.988 -1.07 . . . . 0.0 112.222 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.42 179.82 43.5 Favored Glycine 0 CA--C 1.534 1.221 0 C-N-CA 125.04 1.305 . . . . 0.0 113.215 -174.36 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.7 m -94.94 149.96 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.466 1.506 . . . . 0.0 111.38 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.4 m -133.85 -177.85 4.75 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 124.622 1.169 . . . . 0.0 111.544 174.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -137.85 124.59 21.08 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.365 1.466 . . . . 0.0 111.749 177.236 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 61.1 t -63.47 126.74 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.036 0 C-N-CA 124.735 1.214 . . . . 0.0 111.173 -177.307 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 21.6 t -109.37 -53.92 2.6 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.049 1.34 . . . . 0.0 111.869 -177.092 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -151.68 162.02 41.7 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.142 1.377 . . . . 0.0 111.042 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -141.44 136.53 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 124.649 1.18 . . . . 0.0 108.55 -179.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -144.42 172.1 13.42 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 123.942 0.897 . . . . 0.0 111.773 177.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.3 p -120.54 138.29 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 O-C-N 120.691 -1.256 . . . . 0.0 110.758 175.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.89 164.29 36.66 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.175 1.39 . . . . 0.0 111.543 178.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -97.48 118.88 34.96 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 125.204 1.401 . . . . 0.0 109.77 174.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.3 p -123.54 135.47 63.22 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 124.303 1.041 . . . . 0.0 109.783 174.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.09 29.13 2.35 Favored 'General case' 0 CA--C 1.557 1.245 0 N-CA-C 114.625 1.343 . . . . 0.0 114.625 -177.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.01 25.28 52.9 Favored Glycine 0 CA--C 1.54 1.646 0 C-N-CA 124.787 1.184 . . . . 0.0 115.188 -176.184 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -139.44 116.78 11.24 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.35 1.46 . . . . 0.0 111.175 -174.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 3.5 tttt -95.21 124.81 39.45 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 124.83 1.252 . . . . 0.0 111.656 -178.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -158.17 162.97 37.97 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 123.033 0.533 . . . . 0.0 111.697 179.428 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.3 m -69.37 116.43 9.79 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 124.192 0.997 . . . . 0.0 111.147 177.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -105.2 113.14 26.56 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 124.875 1.27 . . . . 0.0 110.068 175.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 30.1 m -81.42 144.06 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.838 177.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 26.2 m -126.55 117.12 22.17 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.277 1.031 . . . . 0.0 110.735 178.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 1.5 mpp? -119.15 156.17 30.28 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 124.818 1.247 . . . . 0.0 110.116 -176.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -132.09 136.35 47.11 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.184 1.394 . . . . 0.0 110.259 -178.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 13.0 mtm180 -98.36 109.12 21.93 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 177.076 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -70.28 -15.46 62.9 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 123.239 0.616 . . . . 0.0 112.557 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -57.57 -42.18 82.56 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 126.779 2.031 . . . . 0.0 112.961 176.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -128.66 -15.41 4.45 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 124.874 1.27 . . . . 0.0 114.111 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.23 4.99 64.11 Favored Glycine 0 CA--C 1.538 1.5 0 C-N-CA 126.105 1.812 . . . . 0.0 114.952 -177.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -74.07 163.47 27.84 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 118.644 1.222 . . . . 0.0 112.819 177.449 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 15.9 m -126.32 156.12 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 125.592 1.557 . . . . 0.0 110.727 174.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 23.3 m -140.13 150.94 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 125.951 1.701 . . . . 0.0 109.898 176.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 62.9 ttp -145.03 122.08 11.4 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.791 0.836 . . . . 0.0 110.139 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.6 m -130.4 155.14 81.45 Favored Pre-proline 0 N--CA 1.476 0.84 0 C-N-CA 124.034 0.934 . . . . 0.0 112.17 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -76.05 115.82 4.24 Favored 'Trans proline' 0 CA--C 1.538 0.698 0 C-N-CA 123.486 2.791 . . . . 0.0 114.438 176.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -64.63 -34.02 77.29 Favored 'General case' 0 N--CA 1.479 0.992 0 O-C-N 120.335 -1.478 . . . . 0.0 114.013 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.23 5.06 78.03 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 124.403 1.001 . . . . 0.0 114.876 176.32 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.6 tttm -135.57 3.34 3.03 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.493 1.517 . . . . 0.0 112.922 -177.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 1.6 m -49.7 -29.53 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 C-N-CA 125.685 1.594 . . . . 0.0 113.308 175.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.6 mt -57.62 -28.9 64.08 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.093 1.757 . . . . 0.0 112.302 177.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.81 -49.92 16.65 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.974 1.709 . . . . 0.0 112.854 175.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.8 mp -67.85 -33.21 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 124.013 0.925 . . . . 0.0 111.37 177.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 91.68 3.68 68.43 Favored Glycine 0 CA--C 1.537 1.434 0 C-N-CA 125.776 1.655 . . . . 0.0 114.239 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 29.1 m -87.47 123.18 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.045 1.338 . . . . 0.0 110.616 -176.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -104.46 109.28 21.1 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 120.625 -1.297 . . . . 0.0 108.652 176.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.85 106.52 17.09 Favored 'General case' 0 N--CA 1.468 0.475 0 C-N-CA 123.1 0.56 . . . . 0.0 109.532 177.397 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -157.74 169.07 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 C-N-CA 124.987 1.315 . . . . 0.0 110.212 -175.019 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -56.29 -19.62 15.08 Favored 'General case' 0 CA--C 1.551 0.992 0 N-CA-C 115.152 1.538 . . . . 0.0 115.152 177.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 47.2 m -137.5 -48.66 0.58 Allowed 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 125.483 1.513 . . . . 0.0 113.516 174.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -58.77 147.25 33.98 Favored 'General case' 0 CA--C 1.552 1.024 0 C-N-CA 124.479 1.112 . . . . 0.0 113.453 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 . . . . . 0 C--O 1.256 1.428 0 C-N-CA 129.13 2.972 . . . . 0.0 112.397 -172.468 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.242 0 CA-C-O 120.858 0.361 . . . . 0.0 110.89 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 139.25 61.95 0.04 OUTLIER Glycine 0 N--CA 1.476 1.315 0 C-N-CA 124.441 1.019 . . . . 0.0 113.705 -179.213 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 23.5 t60 -75.05 157.85 34.15 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 117.653 0.726 . . . . 0.0 111.65 175.372 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.8 mtt -71.83 161.01 81.01 Favored Pre-proline 0 CA--C 1.545 0.768 0 O-C-N 121.863 -0.523 . . . . 0.0 111.587 175.038 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -65.1 152.59 81.78 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 122.611 2.207 . . . . 0.0 109.404 175.007 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -138.07 -54.59 0.65 Allowed 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 123.875 0.87 . . . . 0.0 113.243 177.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 79.93 164.63 29.92 Favored Glycine 0 CA--C 1.539 1.566 0 C-N-CA 124.119 0.866 . . . . 0.0 114.527 -177.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 78.9 p -156.48 97.57 1.75 Allowed 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.18 1.392 . . . . 0.0 112.31 178.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -156.43 173.53 16.76 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 126.035 1.734 . . . . 0.0 110.988 174.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 55.6 m -66.54 -74.24 0.12 Allowed 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 124.642 1.177 . . . . 0.0 111.952 176.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 53.0 mt -123.6 -80.02 0.62 Allowed 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 125.915 1.686 . . . . 0.0 110.183 -178.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 21.4 mt-30 -64.24 163.59 12.54 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 126.432 1.893 . . . . 0.0 113.182 174.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.436 HD11 ' HE2' ' A' ' 70' ' ' LYS . 1.4 tt -65.44 150.45 48.32 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 124.148 0.979 . . . . 0.0 111.671 175.487 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -143.77 177.36 8.57 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 125.544 1.538 . . . . 0.0 112.214 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 97.5 t -60.02 130.96 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 O-C-N 121.082 -1.012 . . . . 0.0 110.796 178.049 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.32 -2.57 88.06 Favored Glycine 0 CA--C 1.537 1.455 0 C-N-CA 124.809 1.195 . . . . 0.0 115.02 -179.228 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -71.09 -179.84 2.5 Favored 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.22 1.408 . . . . 0.0 112.539 176.095 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 26.7 mmt180 -112.44 154.08 26.37 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 124.953 1.301 . . . . 0.0 112.966 -178.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.4 p -152.63 126.83 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 125.77 1.628 . . . . 0.0 110.493 -179.073 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.0 p -135.6 120.08 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 C-N-CA 126.79 2.036 . . . . 0.0 110.486 174.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 -58.65 156.61 22.9 Favored Pre-proline 0 CA--C 1.544 0.74 0 O-C-N 121.055 -1.028 . . . . 0.0 112.281 175.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -67.16 -24.59 44.25 Favored 'Trans proline' 0 CA--C 1.539 0.77 0 C-N-CA 122.716 2.277 . . . . 0.0 112.52 -176.312 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -157.78 62.48 0.47 Allowed 'General case' 0 CA--C 1.555 1.149 0 C-N-CA 124.809 1.244 . . . . 0.0 112.444 175.528 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.9 mm-40 -150.24 -66.37 0.2 Allowed 'General case' 0 N--CA 1.483 1.189 0 O-C-N 120.841 -1.162 . . . . 0.0 112.451 179.362 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 166.01 175.17 36.19 Favored Glycine 0 CA--C 1.533 1.198 0 C-N-CA 124.929 1.252 . . . . 0.0 113.451 -178.074 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 38.4 t -93.42 145.64 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 125.929 1.692 . . . . 0.0 110.818 -177.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.3 m -130.34 178.41 6.61 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 126.503 1.921 . . . . 0.0 111.116 174.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.3 130.48 44.55 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.128 1.771 . . . . 0.0 110.658 -179.304 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 35.7 t -68.05 125.47 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 124.61 1.164 . . . . 0.0 110.903 178.355 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.9 p -109.3 -41.16 4.72 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.728 0.811 . . . . 0.0 112.776 178.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -160.5 173.3 15.77 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 126.746 2.018 . . . . 0.0 110.659 175.754 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 64.2 mt -146.88 139.87 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.311 1.444 . . . . 0.0 108.728 174.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -146.62 172.72 13.17 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.803 1.241 . . . . 0.0 112.116 174.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 20.6 m -115.81 142.63 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.344 1.058 . . . . 0.0 110.523 176.44 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -157.89 171.95 19.35 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.895 0.878 . . . . 0.0 112.18 176.663 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.61 115.17 29.93 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.906 1.682 . . . . 0.0 110.464 174.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 m -121.97 138.72 51.28 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 124.811 1.244 . . . . 0.0 109.092 174.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 46.06 28.99 0.7 Allowed 'General case' 0 CA--C 1.559 1.317 0 N-CA-C 115.391 1.626 . . . . 0.0 115.391 179.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.11 24.22 52.77 Favored Glycine 0 CA--C 1.544 1.895 0 C-N-CA 124.892 1.234 . . . . 0.0 115.88 -175.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 7.4 tp60 -135.39 113.52 11.29 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.593 1.957 . . . . 0.0 110.268 -174.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -95.37 113.38 25.04 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 125.121 1.369 . . . . 0.0 111.218 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -156.19 173.65 16.53 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.375 0.67 . . . . 0.0 112.049 179.537 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 10.0 m -76.88 116.37 17.49 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 124.338 1.055 . . . . 0.0 111.895 175.309 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -106.54 115.33 30.01 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.971 1.308 . . . . 0.0 109.222 175.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.445 HG11 ' HE3' ' A' ' 70' ' ' LYS . 13.6 m -63.94 153.5 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 O-C-N 121.877 -0.514 . . . . 0.0 111.609 176.001 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 10.9 m -126.48 109.82 12.61 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 122.137 0.97 . . . . 0.0 111.043 175.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -128.89 155.77 44.74 Favored 'General case' 0 C--O 1.236 0.38 0 C-N-CA 124.703 1.201 . . . . 0.0 109.865 -178.704 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -131.08 125.54 33.44 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.893 1.277 . . . . 0.0 110.183 176.349 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.0 ttm-85 -85.08 109.06 17.96 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.524 1.13 . . . . 0.0 109.123 175.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.68 -15.38 63.16 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 176.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -62.23 -35.46 78.97 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.18 1.792 . . . . 0.0 112.779 -177.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 29.8 p30 -128.63 -16.68 4.23 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 126.637 1.975 . . . . 0.0 114.129 175.053 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.65 4.66 63.64 Favored Glycine 0 CA--C 1.538 1.49 0 C-N-CA 126.137 1.827 . . . . 0.0 115.086 -177.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -77.1 168.9 19.29 Favored 'General case' 0 CA--C 1.546 0.798 0 CA-C-N 119.387 1.594 . . . . 0.0 113.149 178.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 m -111.48 157.59 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 125.092 1.357 . . . . 0.0 111.138 175.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.4 p -147.48 118.86 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 124.517 1.127 . . . . 0.0 110.017 179.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -132.93 97.01 3.91 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 124.822 1.249 . . . . 0.0 110.076 -178.02 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 36.0 m -99.86 157.24 34.25 Favored Pre-proline 0 N--CA 1.472 0.638 0 C-N-CA 123.369 0.668 . . . . 0.0 111.684 176.708 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -77.22 118.75 4.77 Favored 'Trans proline' 0 CA--C 1.536 0.608 0 C-N-CA 123.488 2.792 . . . . 0.0 114.558 175.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -61.6 -38.98 89.59 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 120.479 -1.388 . . . . 0.0 114.22 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.14 5.97 78.57 Favored Glycine 0 N--CA 1.476 1.338 0 C-N-CA 124.723 1.154 . . . . 0.0 115.027 178.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 17.9 tttp -133.21 3.37 3.66 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 125.751 1.62 . . . . 0.0 112.597 -178.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.3 m -48.33 -29.63 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 125.428 1.491 . . . . 0.0 113.726 175.077 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 17.2 mt -54.71 -30.64 56.51 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.024 1.73 . . . . 0.0 112.492 176.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.07 -48.69 22.66 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.734 1.613 . . . . 0.0 112.872 176.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.0 mp -66.74 -32.52 58.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.431 1.093 . . . . 0.0 111.285 176.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 87.05 3.99 82.22 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 125.545 1.545 . . . . 0.0 114.014 -176.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 93.2 t -81.51 147.95 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.598 1.159 . . . . 0.0 109.888 175.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.73 124.54 49.89 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 104.745 -2.317 . . . . 0.0 104.745 175.008 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.445 ' HE3' HG11 ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.3 106.56 5.25 Favored 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 124.497 1.119 . . . . 0.0 108.269 177.301 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 1.1 t -159.49 173.43 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 C-N-CA 124.901 1.28 . . . . 0.0 110.347 -174.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -59.94 -15.32 20.91 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.348 1.859 . . . . 0.0 115.551 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -137.19 -47.02 0.57 Allowed 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 126.271 1.828 . . . . 0.0 110.904 175.688 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -78.2 62.5 2.92 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 125.379 1.472 . . . . 0.0 110.018 174.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.259 1.566 0 C-N-CA 125.339 1.456 . . . . 0.0 114.857 176.267 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.276 0 CA-C-O 120.339 0.114 . . . . 0.0 111.147 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.65 88.52 0.08 OUTLIER Glycine 0 N--CA 1.474 1.171 0 C-N-CA 123.922 0.772 . . . . 0.0 113.185 179.347 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 34.1 m80 -82.68 161.81 22.03 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 124.119 0.968 . . . . 0.0 111.677 174.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 15.4 ptm -60.33 156.87 38.03 Favored Pre-proline 0 CA--C 1.55 0.968 0 C-N-CA 124.708 1.203 . . . . 0.0 112.904 175.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -72.4 88.25 0.88 Allowed 'Trans proline' 0 CA--C 1.542 0.896 0 C-N-CA 124.228 3.285 . . . . 0.0 111.843 179.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -121.57 146.75 46.65 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 126.354 1.862 . . . . 0.0 110.97 178.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 178.35 87.6 0.07 OUTLIER Glycine 0 CA--C 1.533 1.203 0 C-N-CA 123.905 0.764 . . . . 0.0 113.635 -178.478 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 36.7 p -81.83 83.91 7.04 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.024 1.329 . . . . 0.0 112.512 178.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -140.98 -48.49 0.41 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.164 1.386 . . . . 0.0 113.347 179.634 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.0 m -148.43 156.35 42.37 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 125.812 1.645 . . . . 0.0 111.8 175.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -94.71 -33.15 13.04 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.842 1.257 . . . . 0.0 112.428 176.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -66.68 156.3 35.64 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 124.45 1.1 . . . . 0.0 112.604 175.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -95.01 113.98 25.74 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 125.392 1.477 . . . . 0.0 110.578 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.74 175.5 9.66 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 125.871 1.668 . . . . 0.0 111.254 179.006 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 59.7 t -58.05 129.8 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 123.811 0.844 . . . . 0.0 110.772 176.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.52 -5.25 85.07 Favored Glycine 0 CA--C 1.536 1.359 0 C-N-CA 125.136 1.351 . . . . 0.0 115.2 -175.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -69.72 163.28 26.03 Favored 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 119.836 1.818 . . . . 0.0 112.099 175.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -101.04 130.87 47.11 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.71 1.204 . . . . 0.0 111.06 -175.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.6 m -142.34 143.3 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.797 0.839 . . . . 0.0 110.326 -178.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.4 p -137.08 148.22 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 C-N-CA 124.526 1.13 . . . . 0.0 110.685 178.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -79.15 161.13 69.23 Favored Pre-proline 0 CA--C 1.549 0.919 0 O-C-N 121.853 -0.529 . . . . 0.0 111.655 175.091 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -71.57 -22.33 24.57 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 123.312 2.675 . . . . 0.0 112.837 -177.24 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 16.2 t-20 -162.68 68.29 0.23 Allowed 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 126.273 1.829 . . . . 0.0 111.296 175.007 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -156.28 -71.83 0.11 Allowed 'General case' 0 N--CA 1.482 1.141 0 O-C-N 121.15 -0.968 . . . . 0.0 112.319 177.224 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 176.43 172.93 41.6 Favored Glycine 0 CA--C 1.534 1.222 0 C-N-CA 124.548 1.07 . . . . 0.0 113.734 -176.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.1 m -85.86 148.47 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 125.187 1.395 . . . . 0.0 111.231 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 15.6 m -137.18 171.87 13.85 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.996 1.718 . . . . 0.0 110.921 179.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -137.71 120.01 15.78 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 124.414 1.086 . . . . 0.0 110.596 -175.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -63.73 124.78 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 123.615 0.766 . . . . 0.0 111.518 -174.106 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 86.1 p -107.43 -40.95 5.21 Favored 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 -177.769 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.43 162.78 35.75 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.489 1.516 . . . . 0.0 110.839 176.127 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 67.8 mt -141.83 134.87 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.781 0 O-C-N 121.029 -1.044 . . . . 0.0 109.076 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -142.72 177.64 8.18 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 124.269 1.028 . . . . 0.0 111.854 178.017 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 p -127.31 137.09 58.8 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 C-N-CA 124.963 1.305 . . . . 0.0 110.425 176.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.43 165.81 32.01 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 124.698 1.199 . . . . 0.0 111.963 178.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -97.89 118.93 35.56 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 125.088 1.355 . . . . 0.0 109.763 174.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.9 p -124.43 134.9 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 C-N-CA 124.251 1.02 . . . . 0.0 109.562 175.112 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.75 29.0 2.05 Favored 'General case' 0 CA--C 1.556 1.2 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 -177.208 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.99 25.66 51.67 Favored Glycine 0 CA--C 1.541 1.708 0 C-N-CA 124.616 1.103 . . . . 0.0 115.174 -176.266 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -137.43 119.73 15.74 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 126.02 1.728 . . . . 0.0 111.053 -178.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 13.7 ttpt -96.12 124.34 40.08 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.636 1.175 . . . . 0.0 111.582 178.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -157.69 163.53 38.09 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.008 0.523 . . . . 0.0 111.805 178.771 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.8 m -68.64 116.58 9.33 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.997 0.919 . . . . 0.0 110.971 177.365 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -105.51 113.26 26.72 Favored 'General case' 0 N--CA 1.467 0.377 0 O-C-N 121.076 -1.015 . . . . 0.0 109.591 174.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.0 m -78.16 141.9 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 C-N-CA 123.486 0.714 . . . . 0.0 110.502 176.338 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 8.1 m -120.31 120.32 35.7 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.602 1.161 . . . . 0.0 109.281 176.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 2.1 mpp? -123.18 157.49 32.88 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 124.703 1.201 . . . . 0.0 109.736 179.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 31.2 mtt85 -136.58 132.56 35.3 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 124.39 1.076 . . . . 0.0 109.875 -179.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -93.89 109.16 20.88 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 177.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -70.32 -14.37 62.55 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 175.151 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -60.21 -36.97 78.88 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.459 1.504 . . . . 0.0 113.066 177.652 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -127.99 -23.31 3.36 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.459 1.503 . . . . 0.0 113.356 178.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 96.3 25.98 11.73 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 125.565 1.555 . . . . 0.0 114.42 -177.05 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.62 169.53 10.26 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.957 1.303 . . . . 0.0 112.752 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.7 m -124.4 154.38 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 125.255 1.422 . . . . 0.0 111.65 177.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.8 p -151.1 123.47 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 C-N-CA 125.581 1.553 . . . . 0.0 109.689 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.9 ttt -125.83 121.21 32.61 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.625 1.17 . . . . 0.0 109.914 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 28.6 m -129.21 156.33 78.48 Favored Pre-proline 0 N--CA 1.478 0.932 0 C-N-CA 124.087 0.955 . . . . 0.0 112.112 -179.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -77.84 114.58 3.66 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 123.628 2.885 . . . . 0.0 114.586 176.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -63.83 -33.72 76.32 Favored 'General case' 0 N--CA 1.481 1.096 0 O-C-N 120.271 -1.518 . . . . 0.0 113.957 179.422 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.19 4.43 77.53 Favored Glycine 0 N--CA 1.475 1.272 0 C-N-CA 124.459 1.028 . . . . 0.0 115.074 175.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.1 tttm -135.58 3.42 3.03 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 125.489 1.515 . . . . 0.0 112.978 -177.569 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 1.6 m -49.98 -30.77 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 125.598 1.559 . . . . 0.0 113.079 175.402 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.1 mt -56.51 -28.9 61.1 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.123 1.769 . . . . 0.0 112.494 177.227 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.95 -48.66 17.48 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.736 1.614 . . . . 0.0 112.66 177.223 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 2.9 mp -68.59 -30.55 47.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 124.085 0.954 . . . . 0.0 111.357 176.264 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.58 3.23 78.08 Favored Glycine 0 CA--C 1.537 1.416 0 C-N-CA 126.092 1.806 . . . . 0.0 114.309 -176.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 18.7 m -80.17 123.2 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.8 0 C-N-CA 125.596 1.558 . . . . 0.0 110.858 -178.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.66 109.39 20.97 Favored 'General case' 0 N--CA 1.472 0.653 0 O-C-N 120.847 -1.158 . . . . 0.0 108.881 175.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.13 106.6 17.15 Favored 'General case' 0 N--CA 1.471 0.576 0 O-C-N 121.749 -0.595 . . . . 0.0 109.76 176.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -157.48 166.58 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 125.668 1.587 . . . . 0.0 110.706 -176.383 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -52.64 -16.25 0.9 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 126.875 2.07 . . . . 0.0 115.8 175.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 36.1 p -142.42 -52.52 0.4 Allowed 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 125.651 1.58 . . . . 0.0 113.34 175.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -54.45 145.61 17.97 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 125.585 1.554 . . . . 0.0 113.512 178.625 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 . . . . . 0 C--O 1.251 1.172 0 C-N-CA 127.81 2.444 . . . . 0.0 113.273 -177.937 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.185 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -164.36 46.22 0.3 Allowed Glycine 0 N--CA 1.473 1.153 0 C-N-CA 123.585 0.612 . . . . 0.0 113.836 -176.218 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -75.23 157.81 33.92 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.531 0.732 . . . . 0.0 111.859 175.469 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.78 162.23 22.72 Favored Pre-proline 0 CA--C 1.541 0.627 0 C-N-CA 125.45 1.5 . . . . 0.0 111.061 175.254 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -70.11 148.52 62.95 Favored 'Trans proline' 0 CA--C 1.54 0.819 0 C-N-CA 123.278 2.652 . . . . 0.0 110.857 175.079 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 179.18 -55.7 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 125.892 1.677 . . . . 0.0 112.182 176.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 91.88 -126.0 8.3 Favored Glycine 0 CA--C 1.535 1.322 0 C-N-CA 124.731 1.158 . . . . 0.0 112.298 -172.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.7 t -154.74 -45.9 0.09 Allowed 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 124.559 1.143 . . . . 0.0 112.995 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -121.41 163.52 18.58 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 125.891 1.676 . . . . 0.0 112.499 -178.329 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 27.8 t -95.99 90.08 5.44 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 125.241 1.416 . . . . 0.0 111.636 -178.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 5.6 mp -140.93 179.53 6.66 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 126.391 1.877 . . . . 0.0 111.322 179.681 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.9 mm-40 -62.6 161.04 12.79 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.516 1.126 . . . . 0.0 111.18 174.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.425 ' HG ' ' HZ1' ' A' ' 70' ' ' LYS . 0.8 OUTLIER -66.53 129.75 40.88 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 123.864 0.866 . . . . 0.0 111.188 179.19 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -133.82 166.34 22.89 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 125.516 1.526 . . . . 0.0 112.297 179.538 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.8 t -56.65 135.76 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.399 1.08 . . . . 0.0 111.035 175.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.15 -13.01 60.72 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 125.635 1.588 . . . . 0.0 115.216 -176.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -72.88 170.0 15.66 Favored 'General case' 0 CA--C 1.549 0.921 0 CA-C-N 119.06 1.43 . . . . 0.0 111.376 175.075 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.9 mmt180 -108.56 142.81 38.45 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 126.194 1.797 . . . . 0.0 111.141 -171.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 32.9 m -143.92 128.04 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 124.278 1.031 . . . . 0.0 111.769 -171.099 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 8.2 p -95.2 164.45 2.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 125.416 1.487 . . . . 0.0 111.052 176.092 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -137.01 156.6 75.66 Favored Pre-proline 0 CA--C 1.535 0.381 0 C-N-CA 124.571 1.148 . . . . 0.0 112.991 178.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.7 -28.84 30.36 Favored 'Trans proline' 0 CA--C 1.538 0.721 0 C-N-CA 123.038 2.492 . . . . 0.0 112.762 -178.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -151.88 54.28 0.83 Allowed 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 125.337 1.455 . . . . 0.0 111.919 178.435 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -145.01 -60.58 0.36 Allowed 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 124.332 1.053 . . . . 0.0 110.653 175.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 124.2 -169.4 16.28 Favored Glycine 0 CA--C 1.535 1.284 0 C-N-CA 126.413 1.958 . . . . 0.0 112.25 -173.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -72.42 136.51 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.642 1.177 . . . . 0.0 110.932 177.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.4 ' HG ' HG12 ' A' ' 56' ' ' VAL . 25.6 m -128.7 175.13 8.83 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 126.105 1.762 . . . . 0.0 111.777 175.229 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -130.57 119.02 21.89 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 126.242 1.817 . . . . 0.0 110.833 -179.258 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.5 t -64.61 127.87 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 123.691 0.796 . . . . 0.0 111.025 -178.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.7 p -112.5 -40.55 4.07 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.219 1.008 . . . . 0.0 112.699 -176.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -155.1 167.11 31.46 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.716 2.006 . . . . 0.0 110.656 175.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 60.7 mt -146.06 137.16 19.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.895 1.278 . . . . 0.0 108.504 176.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -146.02 171.92 14.15 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.01 0.924 . . . . 0.0 112.059 176.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.2 m -113.9 144.57 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.147 -0.971 . . . . 0.0 111.543 175.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 9.7 ptmt -156.25 171.99 19.23 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 124.854 1.262 . . . . 0.0 111.874 177.197 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -108.03 117.73 34.91 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.168 1.787 . . . . 0.0 109.79 174.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.3 p -127.67 138.21 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 124.843 1.257 . . . . 0.0 109.322 174.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.74 29.35 1.52 Allowed 'General case' 0 CA--C 1.557 1.23 0 N-CA-C 114.707 1.373 . . . . 0.0 114.707 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.0 24.39 57.84 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.281 1.42 . . . . 0.0 115.543 -176.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -132.55 113.54 13.19 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 126.106 1.762 . . . . 0.0 110.817 -175.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 67.3 tttt -95.96 114.35 26.05 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.085 1.354 . . . . 0.0 111.321 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -157.89 173.61 16.53 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 123.066 0.547 . . . . 0.0 111.791 -179.376 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 20.1 m -79.01 116.43 19.31 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.362 1.065 . . . . 0.0 112.122 175.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -105.04 115.83 30.94 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.512 1.125 . . . . 0.0 109.77 175.094 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 15.8 m -66.24 147.53 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.382 0.673 . . . . 0.0 111.245 176.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 19.7 m -123.27 110.06 14.72 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.723 0.809 . . . . 0.0 109.634 177.123 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.92 162.44 25.94 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 121.724 0.773 . . . . 0.0 110.929 178.409 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 3.0 ptt180 -144.88 116.81 8.28 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 124.801 1.24 . . . . 0.0 109.987 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 6.4 mtp85 -62.69 115.01 3.93 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 124.818 1.247 . . . . 0.0 110.602 179.327 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.2 pp20? -60.54 -36.03 77.44 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.658 0.783 . . . . 0.0 112.877 179.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -91.45 -46.73 7.83 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 123.889 0.875 . . . . 0.0 113.033 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -73.1 -19.41 61.16 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 113.543 0.942 . . . . 0.0 113.543 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.44 8.77 56.64 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 126.27 1.89 . . . . 0.0 115.151 -178.53 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.0 138.32 40.71 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.6 1.56 . . . . 0.0 112.246 -173.257 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 26.7 m -80.02 152.26 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 123.319 0.648 . . . . 0.0 110.023 174.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.4 HG12 ' HG ' ' A' ' 27' ' ' CYS . 13.6 p -145.23 138.7 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 124.514 1.125 . . . . 0.0 109.887 177.139 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 11.4 ttp -145.03 115.9 7.79 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 124.579 1.152 . . . . 0.0 110.004 -179.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.6 m -121.66 156.93 58.14 Favored Pre-proline 0 N--CA 1.472 0.673 0 C-N-CA 124.83 1.252 . . . . 0.0 111.27 177.021 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -79.8 114.45 3.19 Favored 'Trans proline' 0 CA--C 1.537 0.637 0 C-N-CA 123.488 2.792 . . . . 0.0 114.954 178.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -58.39 -39.23 79.11 Favored 'General case' 0 N--CA 1.48 1.041 0 O-C-N 120.424 -1.422 . . . . 0.0 114.286 -178.496 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.06 7.32 78.78 Favored Glycine 0 N--CA 1.474 1.19 0 C-N-CA 124.751 1.167 . . . . 0.0 114.753 179.008 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.0 tttt -134.62 1.72 3.12 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.596 1.559 . . . . 0.0 112.888 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.0 m -48.34 -30.74 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.593 1.557 . . . . 0.0 113.546 175.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.6 mt -57.66 -29.86 64.96 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 126.47 1.908 . . . . 0.0 112.735 176.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.99 -49.97 16.18 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.781 1.632 . . . . 0.0 112.635 176.025 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.3 mp -67.93 -32.22 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 123.66 0.784 . . . . 0.0 111.31 177.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.52 9.41 66.76 Favored Glycine 0 CA--C 1.534 1.256 0 C-N-CA 125.532 1.539 . . . . 0.0 113.889 -174.446 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 12.2 m -75.8 155.89 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 118.317 1.058 . . . . 0.0 110.804 177.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -139.91 109.69 6.36 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.881 1.272 . . . . 0.0 110.221 175.264 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.432 ' HE3' ' O ' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -126.28 106.56 9.61 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 125.454 1.502 . . . . 0.0 110.65 177.528 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 3.5 t -160.09 157.91 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 127.173 2.189 . . . . 0.0 107.755 -177.131 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -55.26 -31.62 61.7 Favored 'General case' 0 CA--C 1.55 0.972 0 N-CA-C 113.415 0.895 . . . . 0.0 113.415 177.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -93.93 -26.91 16.66 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 124.83 1.252 . . . . 0.0 114.295 175.64 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.98 -18.58 65.45 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 124.059 0.943 . . . . 0.0 111.491 175.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 . . . . . 0 C--O 1.249 1.049 0 C-N-CA 127.465 2.306 . . . . 0.0 113.466 -169.674 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.263 0 CA-C-O 119.517 -0.278 . . . . 0.0 111.648 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -169.32 96.93 0.12 Allowed Glycine 0 CA--C 1.533 1.163 0 C-N-CA 124.277 0.942 . . . . 0.0 112.773 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -97.02 115.83 28.15 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 125.053 1.341 . . . . 0.0 111.713 177.521 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.28 161.86 44.84 Favored Pre-proline 0 CA--C 1.545 0.78 0 C-N-CA 124.109 0.964 . . . . 0.0 111.239 174.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -68.33 115.52 3.9 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 123.916 3.078 . . . . 0.0 109.359 174.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -143.3 157.43 44.48 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.797 1.239 . . . . 0.0 111.708 177.632 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 135.8 175.16 13.68 Favored Glycine 0 CA--C 1.535 1.32 0 C-N-CA 125.4 1.476 . . . . 0.0 113.399 -178.092 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -153.55 18.28 0.54 Allowed 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 114.09 1.144 . . . . 0.0 114.09 179.291 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -53.96 -57.11 12.22 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 126.13 1.772 . . . . 0.0 114.155 -172.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.9 m -135.09 166.77 22.29 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 125.932 1.693 . . . . 0.0 111.416 178.609 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 11.0 mp -96.1 -61.18 1.48 Allowed 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 124.791 1.237 . . . . 0.0 111.458 -177.18 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -63.67 152.75 38.19 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 124.515 1.126 . . . . 0.0 112.214 176.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 14.3 tp -81.52 137.57 35.56 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.428 1.091 . . . . 0.0 110.887 174.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -148.19 177.63 9.23 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.508 1.523 . . . . 0.0 111.427 175.02 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.9 t -59.33 133.7 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 O-C-N 121.395 -0.815 . . . . 0.0 111.296 176.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.31 -4.48 85.54 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 124.817 1.198 . . . . 0.0 115.211 -178.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -71.56 178.35 3.56 Favored 'General case' 0 CA--C 1.553 1.066 0 CA-C-N 118.835 1.318 . . . . 0.0 110.906 174.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 19.2 mmt180 -98.49 151.44 20.61 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.499 1.52 . . . . 0.0 111.378 178.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.8 p -140.02 125.67 21.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 C-N-CA 124.225 1.01 . . . . 0.0 110.94 176.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.7 p -132.14 145.68 34.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 C-N-CA 125.59 1.556 . . . . 0.0 108.532 175.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -91.72 161.06 34.98 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 125.005 1.322 . . . . 0.0 111.948 175.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.34 -28.84 26.8 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.848 2.365 . . . . 0.0 111.954 -175.208 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -159.08 54.16 0.41 Allowed 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 124.311 1.044 . . . . 0.0 113.032 176.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -142.86 -62.25 0.42 Allowed 'General case' 0 N--CA 1.478 0.974 0 O-C-N 121.14 -0.975 . . . . 0.0 113.567 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.1 -172.52 44.44 Favored Glycine 0 CA--C 1.533 1.168 0 C-N-CA 124.291 0.948 . . . . 0.0 113.514 -176.193 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.6 p -115.68 144.5 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 126.728 2.011 . . . . 0.0 110.567 179.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 77.2 m -132.84 -175.02 3.64 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 126.614 1.966 . . . . 0.0 110.572 175.565 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -129.46 123.94 32.82 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 125.037 1.335 . . . . 0.0 111.198 -177.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.6 t -63.42 128.38 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 O-C-N 121.778 -0.576 . . . . 0.0 111.189 -177.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.4 t -109.92 -53.52 2.66 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.981 1.712 . . . . 0.0 111.515 -176.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.64 165.95 34.8 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 125.204 1.402 . . . . 0.0 111.032 174.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.4 mt -142.05 130.92 22.49 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 124.62 1.168 . . . . 0.0 108.76 178.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -147.73 173.93 12.29 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 123.543 0.737 . . . . 0.0 112.338 175.292 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 25.5 m -106.72 142.21 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.984 0 O-C-N 121.022 -1.049 . . . . 0.0 110.852 176.106 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -156.14 171.63 19.82 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.986 0.914 . . . . 0.0 112.336 176.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -104.55 115.77 30.92 Favored 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 125.94 1.696 . . . . 0.0 109.704 175.201 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.1 p -127.89 138.12 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.792 0.837 . . . . 0.0 109.626 175.122 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.77 28.98 1.43 Allowed 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 114.905 1.446 . . . . 0.0 114.905 -177.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.49 23.98 55.02 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.235 1.398 . . . . 0.0 115.441 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -131.97 113.48 13.46 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 126.193 1.797 . . . . 0.0 109.771 -174.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 16.5 tttt -96.43 112.43 24.17 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.48 1.112 . . . . 0.0 111.635 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -157.43 173.78 16.4 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 123.407 0.683 . . . . 0.0 112.217 179.262 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.2 m -73.34 116.49 13.95 Favored 'General case' 0 N--CA 1.475 0.82 0 C-N-CA 124.724 1.209 . . . . 0.0 111.101 175.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -111.38 113.78 26.48 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 124.671 1.189 . . . . 0.0 110.036 177.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 27.4 m -75.2 145.45 10.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 123.326 0.65 . . . . 0.0 110.537 177.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 21.7 m -126.52 116.05 20.48 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 124.367 1.067 . . . . 0.0 110.948 -179.603 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 2.1 mpp? -126.32 141.94 51.72 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.097 0.959 . . . . 0.0 109.619 -175.236 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.7 mtt85 -127.58 109.65 11.92 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 125.233 1.413 . . . . 0.0 109.2 -172.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -77.32 109.11 10.94 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 56.5 mt-10 -67.05 -23.0 65.84 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.886 0.875 . . . . 0.0 112.56 178.292 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -55.81 -39.56 71.51 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.462 1.905 . . . . 0.0 113.14 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -128.55 2.94 5.56 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.598 1.559 . . . . 0.0 113.377 -179.692 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.56 17.3 64.35 Favored Glycine 0 CA--C 1.538 1.472 0 C-N-CA 126.1 1.81 . . . . 0.0 114.669 -171.415 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -75.84 165.55 24.85 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 124.903 1.281 . . . . 0.0 112.484 -178.489 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.5 m -131.61 150.83 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 124.918 1.287 . . . . 0.0 111.02 177.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.8 p -146.73 144.18 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 C-N-CA 125.22 1.408 . . . . 0.0 109.49 176.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 8.8 ttm -138.28 127.25 24.01 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.62 1.168 . . . . 0.0 108.997 174.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.8 m -129.44 156.26 78.82 Favored Pre-proline 0 N--CA 1.473 0.718 0 C-N-CA 123.576 0.751 . . . . 0.0 111.615 175.066 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -79.45 115.7 3.46 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.511 2.807 . . . . 0.0 114.9 177.191 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -62.31 -35.28 78.55 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 119.988 -1.695 . . . . 0.0 114.689 176.307 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.4 6.34 80.68 Favored Glycine 0 N--CA 1.473 1.131 0 O-C-N 121.547 -0.721 . . . . 0.0 114.639 176.691 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.5 tttt -137.06 0.59 2.38 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.902 1.281 . . . . 0.0 113.687 -177.182 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.5 m -49.93 -29.02 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 C-N-CA 125.166 1.386 . . . . 0.0 113.795 175.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.2 mt -58.32 -27.44 64.12 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.594 1.557 . . . . 0.0 112.127 177.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.13 -50.96 11.84 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.945 1.698 . . . . 0.0 112.386 175.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.5 mp -69.51 -33.55 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 123.863 0.865 . . . . 0.0 111.824 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 90.35 12.72 61.02 Favored Glycine 0 CA--C 1.538 1.521 0 C-N-CA 126.03 1.776 . . . . 0.0 114.914 -178.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 97.6 t -89.56 135.38 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 C-N-CA 125.375 1.47 . . . . 0.0 110.657 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.37 109.2 11.54 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 123.721 0.808 . . . . 0.0 110.315 175.039 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.11 106.62 18.98 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 121.631 0.729 . . . . 0.0 110.192 179.42 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 6.8 t -154.01 169.27 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 125.454 1.502 . . . . 0.0 108.28 -177.257 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -62.6 -20.51 64.81 Favored 'General case' 0 CA--C 1.55 0.975 0 N-CA-C 113.8 1.037 . . . . 0.0 113.8 175.057 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 69.5 m -127.26 -40.6 1.81 Allowed 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 114.606 1.336 . . . . 0.0 114.606 176.235 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.55 161.43 20.25 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.693 0.797 . . . . 0.0 112.571 177.051 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 . . . . . 0 C--O 1.254 1.334 0 C-N-CA 127.283 2.233 . . . . 0.0 112.075 178.864 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.196 0 CA-C-O 120.567 0.222 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 134.56 -97.26 0.29 Allowed Glycine 0 N--CA 1.473 1.104 0 C-N-CA 125.071 1.319 . . . . 0.0 112.656 178.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -70.69 131.13 43.43 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 124.061 0.944 . . . . 0.0 111.689 176.368 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.38 161.17 80.33 Favored Pre-proline 0 CA--C 1.548 0.878 0 C-N-CA 123.735 0.814 . . . . 0.0 113.037 175.215 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -68.5 110.31 2.26 Favored 'Trans proline' 0 CA--C 1.541 0.868 0 C-N-CA 124.345 3.363 . . . . 0.0 112.33 174.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -162.03 -175.66 4.75 Favored 'General case' 0 CA--C 1.55 0.961 0 C-N-CA 125.575 1.55 . . . . 0.0 111.967 177.353 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 168.22 -175.96 42.82 Favored Glycine 0 CA--C 1.538 1.5 0 C-N-CA 126.607 2.051 . . . . 0.0 112.478 -175.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.4 t -142.19 16.13 2.07 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 124.625 1.17 . . . . 0.0 114.02 -179.101 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -70.55 -174.72 0.92 Allowed 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 124.893 1.277 . . . . 0.0 113.084 176.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.2 m -66.14 -179.66 0.8 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 125.332 1.453 . . . . 0.0 113.184 176.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 38.1 mt -74.29 46.13 0.25 Allowed 'General case' 0 CA--C 1.551 0.986 0 C-N-CA 126.194 1.797 . . . . 0.0 113.976 -178.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -160.12 163.44 33.79 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 125.43 1.492 . . . . 0.0 111.609 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 11.8 mt -71.13 159.55 34.48 Favored 'General case' 0 CA--C 1.543 0.692 0 CA-C-O 121.459 0.647 . . . . 0.0 110.281 174.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -146.78 157.1 43.59 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 125.196 1.398 . . . . 0.0 110.849 175.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.4 t -57.31 125.72 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.834 0.854 . . . . 0.0 111.056 178.016 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.44 -5.06 84.61 Favored Glycine 0 CA--C 1.533 1.165 0 C-N-CA 124.973 1.273 . . . . 0.0 115.005 -176.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -68.69 152.8 44.86 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 118.97 1.385 . . . . 0.0 109.79 174.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 9.4 mpt_? -85.0 167.74 15.57 Favored 'General case' 0 N--CA 1.471 0.616 0 O-C-N 121.246 -0.909 . . . . 0.0 110.74 176.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 26.1 m -151.16 158.54 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 127.054 2.141 . . . . 0.0 111.068 175.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.4 p -136.55 160.11 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 125.8 1.64 . . . . 0.0 109.515 174.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -114.16 160.43 32.57 Favored Pre-proline 0 CA--C 1.542 0.664 0 C-N-CA 125.354 1.461 . . . . 0.0 111.539 175.016 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -67.48 -27.66 39.39 Favored 'Trans proline' 0 CA--C 1.539 0.734 0 C-N-CA 123.002 2.468 . . . . 0.0 112.822 178.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -158.77 53.81 0.42 Allowed 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 124.081 0.952 . . . . 0.0 113.278 178.502 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.11 -57.73 0.38 Allowed 'General case' 0 N--CA 1.479 0.997 0 O-C-N 121.107 -0.996 . . . . 0.0 113.58 -176.83 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 156.09 -160.26 29.96 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.526 1.06 . . . . 0.0 112.513 -174.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.4 m -118.98 147.97 22.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 125.844 1.658 . . . . 0.0 111.524 177.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 6.3 m -139.02 178.87 6.85 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.303 1.441 . . . . 0.0 110.886 177.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 49.4 ttt-85 -133.74 131.87 39.9 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.16 1.384 . . . . 0.0 111.673 179.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.0 t -59.09 132.64 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.674 1.189 . . . . 0.0 111.293 -179.034 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.9 t -112.07 -53.05 2.74 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 126.505 1.922 . . . . 0.0 111.15 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -145.98 159.14 43.67 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.562 1.145 . . . . 0.0 111.023 -178.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.4 mt -143.74 127.26 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.514 1.125 . . . . 0.0 109.108 178.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -149.8 157.14 42.91 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.218 1.007 . . . . 0.0 112.351 175.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 m -97.02 141.56 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 O-C-N 121.279 -0.888 . . . . 0.0 110.342 175.474 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -154.51 171.44 19.41 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.878 0.871 . . . . 0.0 111.728 175.171 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -103.61 116.62 32.69 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.543 1.537 . . . . 0.0 109.372 175.373 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 p -124.33 137.86 55.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.025 0 C-N-CA 124.419 1.088 . . . . 0.0 108.941 175.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.22 29.74 1.97 Allowed 'General case' 0 CA--C 1.557 1.233 0 N-CA-C 114.809 1.411 . . . . 0.0 114.809 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.39 23.36 56.79 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 125.046 1.308 . . . . 0.0 115.49 -176.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -136.91 113.48 10.17 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 125.365 1.466 . . . . 0.0 111.822 -173.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -94.81 114.41 26.28 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.862 1.665 . . . . 0.0 111.132 -177.207 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -155.07 171.59 19.51 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.2 0.6 . . . . 0.0 111.669 178.698 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.7 m -73.8 116.56 14.54 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 124.035 0.934 . . . . 0.0 110.945 175.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -107.08 113.13 26.39 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 122.239 1.018 . . . . 0.0 109.68 176.03 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.0 m -83.11 146.16 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 C-N-CA 123.438 0.695 . . . . 0.0 110.148 176.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 3.9 m -124.39 113.46 18.21 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 125.142 1.377 . . . . 0.0 109.865 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 2.8 mtm -107.28 165.21 11.55 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 124.685 1.194 . . . . 0.0 110.221 175.025 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 35.2 ptt180 -140.48 162.03 36.31 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 125.873 1.669 . . . . 0.0 111.219 175.12 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.0 mpt_? -109.25 131.26 55.23 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.745 0.818 . . . . 0.0 110.035 175.015 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 70.2 mt-10 -68.3 -35.64 78.14 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.988 0.915 . . . . 0.0 111.827 176.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -91.96 -46.58 7.75 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 124.523 1.129 . . . . 0.0 112.831 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.05 -24.04 62.26 Favored 'General case' 0 N--CA 1.476 0.864 0 O-C-N 121.559 -0.713 . . . . 0.0 111.937 -178.133 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.81 9.77 47.46 Favored Glycine 0 CA--C 1.536 1.371 0 C-N-CA 125.719 1.628 . . . . 0.0 114.651 -179.176 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -101.1 159.88 14.86 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.289 1.836 . . . . 0.0 111.235 -177.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 31.3 m -111.63 151.57 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 124.881 1.272 . . . . 0.0 110.479 175.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.4 p -135.04 124.91 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.66 1.584 . . . . 0.0 108.42 176.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.41 125.3 54.06 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 124.734 1.214 . . . . 0.0 109.033 176.092 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 15.4 m -137.74 156.24 74.63 Favored Pre-proline 0 N--CA 1.472 0.652 0 C-N-CA 123.108 0.563 . . . . 0.0 111.524 176.164 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -77.14 115.66 4.03 Favored 'Trans proline' 0 CA--C 1.536 0.59 0 C-N-CA 123.516 2.811 . . . . 0.0 114.232 177.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -59.08 -45.62 90.35 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 120.557 -1.339 . . . . 0.0 112.497 175.639 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -83.33 6.37 72.65 Favored Glycine 0 N--CA 1.475 1.25 0 O-C-N 120.999 -1.063 . . . . 0.0 115.282 178.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 15.6 tttt -137.5 4.6 2.63 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 125.434 1.493 . . . . 0.0 113.027 -178.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.8 m -51.88 -29.15 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 125.297 1.439 . . . . 0.0 113.35 176.097 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.1 mt -58.06 -29.14 65.17 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 125.926 1.691 . . . . 0.0 112.426 176.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.09 -49.48 23.78 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 125.672 1.589 . . . . 0.0 112.61 175.22 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 2.5 mp -67.0 -32.68 59.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 C-N-CA 123.476 0.71 . . . . 0.0 111.339 177.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.79 20.38 43.89 Favored Glycine 0 CA--C 1.534 1.243 0 C-N-CA 124.834 1.207 . . . . 0.0 113.811 -177.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 40.9 t -102.58 123.75 56.11 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 124.328 1.051 . . . . 0.0 110.096 -178.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -98.67 110.14 22.79 Favored 'General case' 0 N--CA 1.475 0.821 0 O-C-N 121.178 -0.951 . . . . 0.0 110.523 175.041 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.7 ptpm? -127.83 106.55 9.19 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 127.423 2.289 . . . . 0.0 109.699 179.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 3.8 t -161.19 159.68 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 125.648 1.579 . . . . 0.0 107.607 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -48.11 -41.08 25.48 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.492 1.117 . . . . 0.0 113.322 176.227 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 36.6 p -87.3 -41.88 13.33 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 125.238 1.415 . . . . 0.0 114.51 175.172 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -54.47 -62.76 1.44 Allowed 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.334 1.454 . . . . 0.0 111.442 -176.156 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.251 1.158 0 C-N-CA 131.438 3.895 . . . . 0.0 107.742 -179.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.164 0 N-CA-C 110.524 -0.176 . . . . 0.0 110.524 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 132.06 -70.45 0.52 Allowed Glycine 0 N--CA 1.475 1.256 0 C-N-CA 125.204 1.383 . . . . 0.0 112.63 178.714 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -81.69 114.51 20.41 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.175 1.39 . . . . 0.0 111.288 177.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 37.8 mtm -108.5 159.77 29.59 Favored Pre-proline 0 CA--C 1.545 0.765 0 C-N-CA 124.805 1.242 . . . . 0.0 112.782 177.088 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -68.46 120.71 7.64 Favored 'Trans proline' 0 CA--C 1.538 0.706 0 C-N-CA 124.075 3.184 . . . . 0.0 111.486 177.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -154.47 156.49 36.83 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 125.645 1.578 . . . . 0.0 111.477 175.023 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 142.4 147.82 4.87 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 125.288 1.423 . . . . 0.0 113.552 175.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 50.5 m -145.02 97.96 3.1 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 125.574 1.55 . . . . 0.0 110.761 -176.22 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -135.86 -71.27 0.47 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.496 1.118 . . . . 0.0 112.498 -178.313 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 95.5 p -119.48 175.9 5.61 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 125.936 1.694 . . . . 0.0 112.022 178.229 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 42.1 mt -101.77 14.87 30.69 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 125.325 1.45 . . . . 0.0 113.026 -178.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.9 mt-30 -119.8 171.52 8.35 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 126.512 1.925 . . . . 0.0 112.208 177.384 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -118.34 153.9 33.25 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.81 1.644 . . . . 0.0 110.514 174.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -147.45 177.34 9.32 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.198 1.399 . . . . 0.0 112.013 177.021 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -58.71 129.84 21.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 123.756 0.822 . . . . 0.0 111.276 175.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 88.5 -4.3 85.19 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 125.191 1.377 . . . . 0.0 115.126 -178.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -72.0 176.37 5.11 Favored 'General case' 0 CA--C 1.551 0.986 0 CA-C-N 118.946 1.373 . . . . 0.0 112.075 175.027 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 2.4 tpt180 -119.49 142.01 48.67 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 125.278 1.431 . . . . 0.0 111.578 -177.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 15.6 m -136.76 142.39 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 123.996 0.918 . . . . 0.0 110.541 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 p -136.99 141.0 41.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 124.08 0.952 . . . . 0.0 110.724 177.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -80.51 158.66 71.03 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 124.271 1.028 . . . . 0.0 112.126 176.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -68.55 -23.41 37.07 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 123.699 2.933 . . . . 0.0 112.98 -177.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -159.91 51.73 0.33 Allowed 'General case' 0 CA--C 1.555 1.164 0 C-N-CA 124.752 1.221 . . . . 0.0 112.656 177.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.41 -58.11 0.37 Allowed 'General case' 0 N--CA 1.483 1.184 0 O-C-N 120.743 -1.223 . . . . 0.0 112.982 -176.407 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 155.97 179.25 30.89 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.099 1.333 . . . . 0.0 113.314 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.2 p -85.27 152.28 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.959 1.304 . . . . 0.0 111.268 175.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.0 m -132.77 170.18 15.64 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.195 1.798 . . . . 0.0 110.725 174.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -128.68 121.05 27.69 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.369 1.068 . . . . 0.0 111.36 -174.313 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 50.0 t -63.61 121.5 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 124.436 1.094 . . . . 0.0 110.617 -178.139 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.8 m -112.42 -41.51 3.86 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.573 1.149 . . . . 0.0 112.1 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.98 165.21 36.81 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.287 1.835 . . . . 0.0 110.612 174.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 41.7 mt -147.65 138.15 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.971 1.308 . . . . 0.0 108.76 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -147.48 170.58 17.1 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.449 1.1 . . . . 0.0 112.785 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.6 m -108.51 139.25 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 124.909 1.284 . . . . 0.0 110.599 175.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 7.5 ptmt -155.92 168.13 28.21 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.291 1.036 . . . . 0.0 112.543 175.311 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.12 116.05 31.24 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 125.648 1.579 . . . . 0.0 109.516 175.006 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.7 p -126.09 137.25 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.15 0.98 . . . . 0.0 109.648 174.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.94 28.98 2.17 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 114.829 1.418 . . . . 0.0 114.829 -179.02 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.45 25.18 48.28 Favored Glycine 0 CA--C 1.54 1.597 0 C-N-CA 124.839 1.209 . . . . 0.0 115.322 -176.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -139.08 113.52 8.95 Favored 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 125.413 1.485 . . . . 0.0 111.462 -174.133 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -95.85 116.7 29.3 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.144 1.377 . . . . 0.0 111.917 -179.29 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -159.75 175.08 13.57 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 123.813 0.845 . . . . 0.0 112.02 179.224 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 15.3 m -77.35 116.33 17.86 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.314 1.046 . . . . 0.0 111.934 175.001 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -106.01 113.45 27.01 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 124.849 1.26 . . . . 0.0 109.351 175.194 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.2 m -63.73 150.7 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 O-C-N 122.052 -0.405 . . . . 0.0 111.331 175.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -126.55 109.89 12.64 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 122.037 0.922 . . . . 0.0 110.638 174.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -128.43 162.57 26.86 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 125.095 1.358 . . . . 0.0 110.181 179.597 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.3 mtt180 -138.67 113.85 9.44 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 125.491 1.516 . . . . 0.0 109.298 177.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 44.5 mtp85 -69.91 109.09 4.29 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 174.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -70.17 -13.86 62.38 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.188 0.995 . . . . 0.0 113.286 176.072 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -59.36 -42.82 92.49 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 125.96 1.704 . . . . 0.0 112.66 177.253 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -128.52 -15.45 4.51 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.843 1.424 . . . . 0.0 114.843 177.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 84.07 59.03 2.12 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 125.578 1.561 . . . . 0.0 113.446 -179.242 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -135.66 128.72 31.59 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.657 1.183 . . . . 0.0 112.532 179.021 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.0 p -67.05 141.87 17.36 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 C-N-CA 124.286 1.034 . . . . 0.0 110.127 175.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 5.6 p -137.31 114.41 12.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 C-N-CA 126.244 1.818 . . . . 0.0 108.969 178.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.3 ptt? -126.79 125.63 42.04 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 125.794 1.638 . . . . 0.0 109.832 179.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 33.8 m -131.89 152.98 81.23 Favored Pre-proline 0 N--CA 1.468 0.457 0 C-N-CA 123.7 0.8 . . . . 0.0 111.359 178.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -77.01 116.5 4.22 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.912 2.408 . . . . 0.0 114.557 178.01 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -60.65 -38.22 84.13 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 114.572 1.323 . . . . 0.0 114.572 -179.623 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.91 5.81 79.21 Favored Glycine 0 N--CA 1.476 1.34 0 C-N-CA 124.545 1.069 . . . . 0.0 114.697 178.408 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.9 tttt -133.85 3.03 3.46 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.474 1.51 . . . . 0.0 112.889 -177.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.54 -29.72 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 125.533 1.533 . . . . 0.0 113.745 175.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.5 mt -56.3 -29.4 61.17 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 126.093 1.757 . . . . 0.0 112.542 177.164 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.42 -50.4 15.94 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 125.849 1.66 . . . . 0.0 112.873 175.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.9 mp -67.33 -33.31 61.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 124.134 0.973 . . . . 0.0 111.355 178.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.53 8.29 68.16 Favored Glycine 0 CA--C 1.535 1.335 0 C-N-CA 125.617 1.58 . . . . 0.0 114.356 -176.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 24.9 m -93.26 123.27 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 125.407 1.483 . . . . 0.0 110.763 -176.689 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.62 109.31 21.37 Favored 'General case' 0 N--CA 1.471 0.607 0 O-C-N 120.827 -1.17 . . . . 0.0 109.58 178.089 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.5 106.58 17.7 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 123.764 0.826 . . . . 0.0 109.91 176.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 97.3 t -147.49 -71.19 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 C-N-CA 124.654 1.182 . . . . 0.0 111.798 176.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . 175.32 -46.18 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 128.052 2.541 . . . . 0.0 110.924 -175.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 71.3 p -123.52 -4.61 8.25 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 126.007 1.723 . . . . 0.0 114.652 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -73.23 -59.01 2.91 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.283 1.433 . . . . 0.0 113.341 -173.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 68.4 tt0 . . . . . 0 C--O 1.254 1.301 0 C-N-CA 129.704 3.201 . . . . 0.0 117.116 175.207 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.207 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 142.14 106.33 0.59 Allowed Glycine 0 N--CA 1.474 1.199 0 C-N-CA 124.269 0.937 . . . . 0.0 113.221 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.2 m170 -69.11 155.18 40.81 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 123.871 0.868 . . . . 0.0 111.662 174.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 3.9 mpp? -83.32 164.97 43.19 Favored Pre-proline 0 CA--C 1.545 0.785 0 C-N-CA 124.444 1.098 . . . . 0.0 112.686 175.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -71.09 113.38 3.57 Favored 'Trans proline' 0 CA--C 1.54 0.796 0 C-N-CA 123.743 2.962 . . . . 0.0 112.039 175.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -126.69 94.39 4.04 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 125.478 1.511 . . . . 0.0 110.364 178.511 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -167.25 65.9 0.19 Allowed Glycine 0 CA--C 1.531 1.06 0 N-CA-C 115.026 0.77 . . . . 0.0 115.026 -178.263 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 57.8 m -67.46 110.03 3.45 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 124.867 1.267 . . . . 0.0 113.525 177.014 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -61.87 -71.11 0.16 Allowed 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 124.104 0.962 . . . . 0.0 112.507 174.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.2 p -158.88 -79.24 0.06 Allowed 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 125.277 1.431 . . . . 0.0 111.813 -177.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -117.6 -61.8 1.65 Allowed 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 126.541 1.937 . . . . 0.0 111.308 -177.034 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 -110.41 175.45 5.42 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.899 1.68 . . . . 0.0 110.703 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -66.02 128.91 37.92 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.285 1.034 . . . . 0.0 110.981 175.127 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -135.25 175.16 9.83 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.572 1.549 . . . . 0.0 112.336 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.6 t -59.61 132.8 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 O-C-N 121.184 -0.948 . . . . 0.0 111.127 177.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.62 -5.52 83.33 Favored Glycine 0 CA--C 1.537 1.427 0 C-N-CA 124.854 1.216 . . . . 0.0 115.005 -179.272 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -68.51 173.32 5.12 Favored 'General case' 0 CA--C 1.553 1.058 0 CA-C-N 118.761 1.281 . . . . 0.0 110.246 175.041 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -84.33 158.31 21.2 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 125.102 1.361 . . . . 0.0 112.007 174.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.4 p -160.32 124.37 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 124.688 1.195 . . . . 0.0 109.997 175.019 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 2.9 m -131.56 159.74 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.618 0.723 . . . . 0.0 109.35 174.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -95.27 162.02 26.08 Favored Pre-proline 0 CA--C 1.544 0.72 0 C-N-CA 123.515 0.726 . . . . 0.0 110.796 177.043 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -69.35 -24.84 31.1 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 123.191 2.594 . . . . 0.0 112.429 -179.2 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -159.48 55.65 0.39 Allowed 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 124.725 1.21 . . . . 0.0 112.572 178.608 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 9.8 tm0? -142.7 -58.81 0.44 Allowed 'General case' 0 N--CA 1.482 1.165 0 O-C-N 120.832 -1.167 . . . . 0.0 113.024 -178.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 158.58 -168.66 34.87 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 124.849 1.214 . . . . 0.0 112.995 -174.266 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.5 m -109.52 146.8 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 125.176 1.39 . . . . 0.0 112.656 -176.547 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 61.3 m -137.25 179.55 6.33 Favored 'General case' 0 CA--C 1.551 1.01 0 C-N-CA 126.168 1.787 . . . . 0.0 110.944 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.89 132.35 43.54 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 126.892 2.077 . . . . 0.0 111.362 175.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -67.6 129.94 32.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.149 0.98 . . . . 0.0 111.233 179.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.76 -48.57 3.12 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.9 1.28 . . . . 0.0 112.781 -175.56 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.99 163.06 36.79 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.372 1.469 . . . . 0.0 110.961 174.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -140.94 133.42 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 124.263 1.025 . . . . 0.0 109.252 178.166 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -148.46 168.04 23.73 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.713 1.205 . . . . 0.0 112.19 176.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.8 m -106.69 141.3 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 O-C-N 121.257 -0.902 . . . . 0.0 110.373 175.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.1 ptmt -153.45 168.59 25.59 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 123.809 0.843 . . . . 0.0 112.211 176.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -100.67 117.62 35.15 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 125.485 1.514 . . . . 0.0 109.991 175.014 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.0 p -127.26 138.14 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 124.106 0.962 . . . . 0.0 109.656 175.021 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.98 29.06 1.59 Allowed 'General case' 0 CA--C 1.557 1.223 0 N-CA-C 114.776 1.398 . . . . 0.0 114.776 -177.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.08 27.52 49.19 Favored Glycine 0 CA--C 1.542 1.748 0 C-N-CA 124.88 1.229 . . . . 0.0 115.361 -176.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 10.5 tp60 -137.41 114.95 11.16 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.223 1.809 . . . . 0.0 110.656 -175.7 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.02 115.07 26.96 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.69 1.196 . . . . 0.0 111.492 178.621 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -153.11 172.56 16.71 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 123.448 0.699 . . . . 0.0 111.649 177.388 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.3 m -74.16 116.35 14.7 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 125.011 1.324 . . . . 0.0 111.105 175.793 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -109.83 113.07 25.52 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 124.451 1.1 . . . . 0.0 110.105 177.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 22.0 m -77.45 145.0 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 123.156 0.582 . . . . 0.0 110.903 178.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.1 m -126.31 112.36 15.61 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 122.116 0.96 . . . . 0.0 110.689 -179.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 2.0 mpp? -122.42 162.7 21.16 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 124.816 1.246 . . . . 0.0 109.638 -176.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.3 mtt180 -134.84 151.87 51.28 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 125.38 1.472 . . . . 0.0 110.314 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.5 ptt180 -118.58 109.12 15.79 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.379 1.072 . . . . 0.0 109.793 175.028 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -64.96 -17.37 64.34 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.745 1.218 . . . . 0.0 112.408 174.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -55.4 -42.92 74.73 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 126.249 1.82 . . . . 0.0 112.693 175.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -128.68 3.4 5.5 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 125.126 1.37 . . . . 0.0 113.845 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 64.56 33.89 88.45 Favored Glycine 0 CA--C 1.535 1.292 0 C-N-CA 125.659 1.6 . . . . 0.0 113.979 -174.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -103.82 167.43 9.78 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.15 0.98 . . . . 0.0 111.988 -176.493 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 17.3 m -116.85 151.0 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.092 1.357 . . . . 0.0 110.258 178.441 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.3 p -143.82 126.36 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 C-N-CA 124.821 1.249 . . . . 0.0 109.202 176.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.6 tmm? -127.86 128.17 44.73 Favored 'General case' 0 C--O 1.234 0.267 0 C-N-CA 124.408 1.083 . . . . 0.0 109.839 177.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.7 m -132.95 155.45 81.14 Favored Pre-proline 0 N--CA 1.469 0.485 0 C-N-CA 124.396 1.078 . . . . 0.0 111.599 178.448 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -76.14 116.14 4.3 Favored 'Trans proline' 0 CA--C 1.537 0.634 0 C-N-CA 123.749 2.966 . . . . 0.0 114.466 176.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -63.43 -34.64 78.2 Favored 'General case' 0 N--CA 1.479 1.005 0 O-C-N 120.341 -1.474 . . . . 0.0 114.172 177.484 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.17 5.9 78.47 Favored Glycine 0 N--CA 1.472 1.055 0 C-N-CA 124.175 0.893 . . . . 0.0 114.653 176.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.4 ttmm -136.76 4.11 2.78 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.269 1.428 . . . . 0.0 113.364 -178.588 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 1.4 m -49.38 -30.13 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.468 1.507 . . . . 0.0 113.042 175.303 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.3 mt -56.58 -29.14 61.73 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 126.288 1.835 . . . . 0.0 112.684 176.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.31 -50.2 13.34 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 126.05 1.74 . . . . 0.0 112.645 177.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.7 mp -66.8 -32.38 57.74 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 124.211 1.004 . . . . 0.0 111.291 176.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.39 2.71 79.39 Favored Glycine 0 CA--C 1.535 1.303 0 C-N-CA 125.789 1.662 . . . . 0.0 113.866 -174.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 18.6 m -83.57 123.23 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 118.338 1.069 . . . . 0.0 111.031 -178.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.1 mmt-85 -100.4 127.21 46.78 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 174.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -138.29 106.55 5.78 Favored 'General case' 0 N--CA 1.464 0.225 0 C-N-CA 123.331 0.652 . . . . 0.0 110.481 176.794 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 3.2 t -159.52 163.02 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 125.511 1.524 . . . . 0.0 108.628 -173.561 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -48.83 -32.9 9.53 Favored 'General case' 0 CA--C 1.551 0.999 0 C-N-CA 125.717 1.607 . . . . 0.0 114.681 175.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.1 m -115.35 -50.95 2.72 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.859 1.663 . . . . 0.0 113.064 175.262 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -72.53 83.9 1.12 Allowed 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 124.239 1.016 . . . . 0.0 111.48 174.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . 0.266 54.7 mt-10 . . . . . 0 C--O 1.251 1.166 0 C-N-CA 128.576 2.75 . . . . 0.0 115.698 177.57 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.279 0 CA-C-O 119.492 -0.29 . . . . 0.0 110.946 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -125.56 -179.07 15.57 Favored Glycine 0 CA--C 1.534 1.236 0 C-N-CA 125.533 1.54 . . . . 0.0 112.901 175.06 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -129.64 149.26 51.47 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 125.662 1.585 . . . . 0.0 110.432 175.024 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.9 ptt? -114.89 158.53 40.4 Favored Pre-proline 0 CA--C 1.544 0.743 0 C-N-CA 125.575 1.55 . . . . 0.0 111.504 177.212 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -72.37 86.55 0.98 Allowed 'Trans proline' 0 CA--C 1.539 0.748 0 C-N-CA 123.795 2.996 . . . . 0.0 111.744 177.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -99.61 177.74 5.06 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.753 1.621 . . . . 0.0 112.425 177.188 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.47 -124.54 1.09 Allowed Glycine 0 CA--C 1.53 0.995 0 C-N-CA 124.445 1.021 . . . . 0.0 111.638 177.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 19.6 p -162.46 -75.69 0.05 OUTLIER 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 125.075 1.35 . . . . 0.0 110.944 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -157.95 105.22 1.96 Allowed 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 126.167 1.787 . . . . 0.0 111.099 178.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 74.1 m -140.98 154.4 46.03 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 125.295 1.438 . . . . 0.0 111.615 176.114 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -111.75 -75.54 0.61 Allowed 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 125.785 1.634 . . . . 0.0 110.384 178.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -65.48 152.35 44.18 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 123.875 0.87 . . . . 0.0 110.973 175.028 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.69 162.8 14.09 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.946 1.298 . . . . 0.0 110.893 179.59 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -144.91 169.28 18.36 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.378 1.071 . . . . 0.0 111.772 177.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.3 t -61.21 130.34 25.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 123.586 0.754 . . . . 0.0 110.572 176.23 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.27 -8.81 79.0 Favored Glycine 0 CA--C 1.537 1.414 0 C-N-CA 124.997 1.284 . . . . 0.0 114.886 -176.036 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -72.67 165.16 25.3 Favored 'General case' 0 CA--C 1.551 0.998 0 CA-C-N 119.302 1.551 . . . . 0.0 111.496 175.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -85.82 154.93 21.22 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.669 0.747 . . . . 0.0 112.288 178.234 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 24.2 m -144.09 147.69 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 C-N-CA 125.204 1.402 . . . . 0.0 109.623 174.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.94 155.75 41.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 C-N-CA 126.461 1.905 . . . . 0.0 108.984 176.054 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -126.35 161.99 49.03 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 125.4 1.48 . . . . 0.0 111.433 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -74.02 -17.66 22.05 Favored 'Trans proline' 0 CA--C 1.541 0.841 0 C-N-CA 123.132 2.555 . . . . 0.0 113.023 -177.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -151.97 -40.08 0.11 Allowed 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 125.611 1.564 . . . . 0.0 112.543 176.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -53.91 -26.49 25.42 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.71 1.604 . . . . 0.0 114.777 179.428 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.46 -176.18 32.38 Favored Glycine 0 CA--C 1.535 1.336 0 C-N-CA 125.014 1.292 . . . . 0.0 114.383 179.306 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.0 m -74.74 144.14 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 O-C-N 121.234 -1.157 . . . . 0.0 111.788 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 33.5 m -136.26 -177.11 4.56 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 125.154 1.381 . . . . 0.0 110.809 177.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -138.16 115.91 11.45 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.913 1.285 . . . . 0.0 111.563 -173.187 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.4 t -63.45 128.18 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 C-N-CA 123.907 0.883 . . . . 0.0 111.541 -172.411 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 44.0 t -111.02 -49.39 3.03 Favored 'General case' 0 N--CA 1.469 0.505 0 C-N-CA 125.653 1.581 . . . . 0.0 112.039 -174.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -154.73 161.85 41.36 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.919 1.288 . . . . 0.0 111.208 175.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -142.81 127.93 16.21 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 124.713 1.205 . . . . 0.0 108.785 177.373 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -148.92 169.54 20.33 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 123.647 0.779 . . . . 0.0 112.361 175.447 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 19.9 m -104.93 142.43 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 O-C-N 121.229 -0.919 . . . . 0.0 110.946 174.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.9 ptmt -155.51 171.0 20.67 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.745 0.818 . . . . 0.0 112.683 175.206 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -103.59 117.47 34.5 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.136 1.374 . . . . 0.0 109.821 176.403 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.7 p -129.69 135.96 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 178.243 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.38 28.73 1.75 Allowed 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 125.582 1.553 . . . . 0.0 114.656 -177.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.14 23.77 50.59 Favored Glycine 0 CA--C 1.538 1.519 0 C-N-CA 125.45 1.5 . . . . 0.0 115.286 -176.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -134.26 113.76 12.32 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 126.16 1.784 . . . . 0.0 111.128 -174.591 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 54.6 tttt -96.33 112.48 24.2 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 124.942 1.297 . . . . 0.0 111.585 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -156.09 172.41 18.47 Favored 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 123.405 0.682 . . . . 0.0 112.161 179.035 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.8 m -72.95 119.17 16.82 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.644 1.178 . . . . 0.0 110.591 175.431 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -110.19 116.65 31.88 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 174.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.7 m -81.3 143.57 12.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 123.935 0.894 . . . . 0.0 109.027 175.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.9 m -126.38 117.34 22.77 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.527 1.531 . . . . 0.0 110.054 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -120.71 160.23 23.74 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 125.257 1.423 . . . . 0.0 110.202 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 55.0 mtm180 -140.51 121.29 14.41 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 124.926 1.29 . . . . 0.0 110.338 -179.131 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.68 108.85 17.61 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 124.647 1.179 . . . . 0.0 111.045 176.238 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -69.96 -15.39 63.04 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 124.026 0.93 . . . . 0.0 112.264 175.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -59.67 -37.65 79.33 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 124.949 1.3 . . . . 0.0 113.439 177.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -128.39 -12.83 5.0 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 124.892 1.277 . . . . 0.0 113.677 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.57 50.94 5.42 Favored Glycine 0 CA--C 1.531 1.077 0 C-N-CA 125.56 1.552 . . . . 0.0 113.177 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -124.53 162.6 23.67 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.741 1.216 . . . . 0.0 112.264 178.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.1 m -109.13 152.84 11.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 125.07 1.348 . . . . 0.0 110.736 178.07 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 3.9 p -151.57 122.25 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 125.21 1.404 . . . . 0.0 109.252 178.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 22.6 ptt? -127.01 139.38 53.06 Favored 'General case' 0 C--O 1.236 0.374 0 C-N-CA 123.644 0.778 . . . . 0.0 110.884 177.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.1 m -141.19 158.2 64.85 Favored Pre-proline 0 N--CA 1.473 0.707 0 C-N-CA 123.858 0.863 . . . . 0.0 112.069 178.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -76.67 115.02 3.97 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 123.497 2.798 . . . . 0.0 114.509 176.175 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.5 -34.43 77.76 Favored 'General case' 0 N--CA 1.477 0.912 0 O-C-N 120.315 -1.49 . . . . 0.0 114.173 178.604 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.0 5.98 78.96 Favored Glycine 0 N--CA 1.473 1.158 0 C-N-CA 124.017 0.818 . . . . 0.0 114.509 176.483 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 19.5 tttp -136.24 2.23 2.75 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.293 1.437 . . . . 0.0 113.359 -178.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.93 -30.12 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 125.612 1.565 . . . . 0.0 113.116 175.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.9 mt -57.34 -28.82 63.46 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 126.435 1.894 . . . . 0.0 112.556 177.133 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.74 -50.47 15.22 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.986 1.714 . . . . 0.0 112.668 175.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.6 mp -68.53 -31.1 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 124.145 0.978 . . . . 0.0 111.227 178.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.35 8.85 70.62 Favored Glycine 0 CA--C 1.535 1.285 0 C-N-CA 125.82 1.676 . . . . 0.0 114.187 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 15.2 m -87.66 137.43 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.669 1.588 . . . . 0.0 110.356 -177.473 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.9 108.88 13.47 Favored 'General case' 0 N--CA 1.469 0.511 0 O-C-N 120.881 -1.137 . . . . 0.0 110.737 176.04 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.21 106.72 18.68 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 124.25 1.02 . . . . 0.0 109.3 175.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 57.6 t -151.45 -69.97 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 C-N-CA 124.939 1.296 . . . . 0.0 111.398 176.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . 175.32 -56.51 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 128.565 2.746 . . . . 0.0 110.002 -176.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 3.3 m -121.76 1.02 9.92 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 125.556 1.542 . . . . 0.0 114.439 -179.111 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -71.28 -50.6 31.0 Favored 'General case' 0 CA--C 1.548 0.88 0 C-N-CA 124.694 1.198 . . . . 0.0 113.348 -179.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . 0.302 10.0 pt-20 . . . . . 0 N--CA 1.485 1.302 1 C-N-CA 131.868 4.067 . . . . 0.0 119.615 -177.997 . . . . . . . . 2 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.202 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -91.45 5.91 80.53 Favored Glycine 0 CA--C 1.538 1.475 0 C-N-CA 124.627 1.108 . . . . 0.0 115.079 178.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 30.2 m170 -60.83 127.94 34.05 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.25 1.42 . . . . 0.0 112.153 -179.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 22.8 mtt -65.16 160.22 59.15 Favored Pre-proline 0 CA--C 1.547 0.832 0 C-N-CA 123.938 0.895 . . . . 0.0 112.42 175.06 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -69.6 131.67 21.96 Favored 'Trans proline' 0 CA--C 1.537 0.637 0 C-N-CA 123.5 2.8 . . . . 0.0 110.354 175.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -162.06 175.92 11.27 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 125.19 1.396 . . . . 0.0 111.409 177.527 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 97.62 66.41 0.9 Allowed Glycine 0 CA--C 1.531 1.083 0 C-N-CA 124.882 1.229 . . . . 0.0 113.298 175.381 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.2 t -111.71 161.75 15.94 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 124.867 1.267 . . . . 0.0 112.447 177.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -161.96 -62.75 0.05 OUTLIER 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 125.372 1.469 . . . . 0.0 111.628 176.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 43.5 m -66.86 155.9 37.12 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.234 1.014 . . . . 0.0 112.586 177.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.5 mp -86.51 21.13 2.22 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 125.775 1.63 . . . . 0.0 113.378 179.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -147.89 145.32 28.61 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 125.122 1.369 . . . . 0.0 111.173 178.211 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.37 132.41 35.0 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.152 0.981 . . . . 0.0 110.224 175.138 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.56 163.7 19.5 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.363 1.465 . . . . 0.0 112.433 177.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 98.1 t -60.35 129.57 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 123.975 0.91 . . . . 0.0 110.225 178.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.11 -11.86 65.59 Favored Glycine 0 CA--C 1.534 1.267 0 C-N-CA 125.012 1.291 . . . . 0.0 114.761 -176.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -74.99 168.52 19.8 Favored 'General case' 0 CA--C 1.544 0.729 0 CA-C-N 119.445 1.622 . . . . 0.0 110.971 175.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.84 163.86 20.91 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 123.964 0.906 . . . . 0.0 111.426 175.133 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 17.9 m -149.84 150.49 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 125.488 1.515 . . . . 0.0 109.691 175.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 6.6 p -137.03 156.3 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 C-N-CA 126.239 1.815 . . . . 0.0 110.035 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -130.43 157.62 76.88 Favored Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 125.471 1.508 . . . . 0.0 111.638 -177.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.11 -40.47 6.3 Favored 'Trans proline' 0 CA--C 1.536 0.582 0 C-N-CA 123.913 3.075 . . . . 0.0 112.313 -177.15 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -148.96 43.82 0.98 Allowed 'General case' 0 CA--C 1.552 1.034 0 C-N-CA 126.057 1.743 . . . . 0.0 112.153 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -128.35 -51.3 1.29 Allowed 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 124.38 1.072 . . . . 0.0 111.945 177.252 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 128.88 -179.02 16.91 Favored Glycine 0 CA--C 1.535 1.305 0 C-N-CA 126.41 1.957 . . . . 0.0 113.035 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.1 m -77.49 143.76 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 O-C-N 121.766 -0.843 . . . . 0.0 111.281 174.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 85.3 m -136.04 -176.96 4.49 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 125.116 1.366 . . . . 0.0 110.786 176.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.5 ttt180 -140.7 124.54 17.18 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 125.01 1.324 . . . . 0.0 110.921 -178.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.8 t -62.06 119.22 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 123.464 0.706 . . . . 0.0 111.827 -175.575 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.9 p -100.58 -46.21 5.27 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.031 0.932 . . . . 0.0 111.902 -178.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.76 172.06 17.92 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 126.366 1.866 . . . . 0.0 111.133 176.166 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 79.8 mt -146.02 137.15 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 C-N-CA 124.759 1.224 . . . . 0.0 108.358 174.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -141.97 168.97 18.49 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 124.146 0.978 . . . . 0.0 111.781 176.227 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.9 m -116.19 145.25 22.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 O-C-N 120.986 -1.072 . . . . 0.0 110.924 175.388 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.6 174.74 14.07 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.199 0.999 . . . . 0.0 111.952 174.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -107.75 121.68 45.21 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 125.906 1.682 . . . . 0.0 108.9 175.008 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.6 p -125.2 129.15 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 125.058 1.343 . . . . 0.0 109.159 174.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.97 28.99 2.19 Favored 'General case' 0 CA--C 1.556 1.203 0 N-CA-C 114.735 1.383 . . . . 0.0 114.735 -178.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.78 21.08 54.57 Favored Glycine 0 CA--C 1.539 1.571 0 C-N-CA 124.814 1.197 . . . . 0.0 115.301 -176.504 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -126.16 113.5 17.12 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 125.924 1.69 . . . . 0.0 110.275 -176.275 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 11.2 tttt -96.77 117.75 31.73 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 124.734 1.213 . . . . 0.0 111.068 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.1 pp -158.56 172.46 18.26 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 122.984 0.514 . . . . 0.0 111.75 178.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 22.6 m -80.04 116.47 20.18 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 124.946 1.298 . . . . 0.0 112.521 176.219 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -102.89 113.24 26.52 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 124.487 1.115 . . . . 0.0 109.104 174.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.1 m -63.79 149.05 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 O-C-N 121.843 -0.536 . . . . 0.0 111.223 175.133 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 24.6 m -126.49 109.95 12.74 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.447 1.099 . . . . 0.0 110.942 178.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -128.8 165.43 20.97 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 121.512 -0.742 . . . . 0.0 111.002 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -140.0 120.07 13.68 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.417 1.087 . . . . 0.0 111.403 178.016 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 15.0 ptm180 -74.08 110.06 8.07 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 125.089 1.356 . . . . 0.0 110.865 175.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -64.51 -17.25 63.72 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 177.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -59.43 -37.71 78.78 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.453 1.501 . . . . 0.0 113.895 177.821 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.63 -0.39 5.5 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 124.834 1.253 . . . . 0.0 112.908 178.079 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.65 20.9 68.57 Favored Glycine 0 CA--C 1.537 1.419 0 C-N-CA 125.254 1.407 . . . . 0.0 113.851 -170.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -87.87 163.55 16.34 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 118.516 1.158 . . . . 0.0 111.541 -176.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 27.5 m -108.8 143.74 18.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.064 1.346 . . . . 0.0 110.874 -179.67 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.7 m -135.33 130.44 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 124.813 1.245 . . . . 0.0 109.483 178.068 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 38.8 mtm -141.84 123.82 15.37 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.336 1.054 . . . . 0.0 110.261 -178.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.5 m -135.05 157.21 77.45 Favored Pre-proline 0 N--CA 1.474 0.744 0 C-N-CA 123.952 0.901 . . . . 0.0 112.116 179.173 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -76.79 117.49 4.52 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 123.374 2.716 . . . . 0.0 114.949 179.721 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -60.54 -38.92 86.04 Favored 'General case' 0 N--CA 1.478 0.928 0 O-C-N 120.463 -1.398 . . . . 0.0 114.253 179.617 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.18 5.71 78.37 Favored Glycine 0 N--CA 1.475 1.244 0 C-N-CA 124.549 1.071 . . . . 0.0 114.9 179.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 5.2 tttm -133.92 2.8 3.42 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.658 1.583 . . . . 0.0 112.639 -178.415 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.64 -30.19 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 C-N-CA 125.405 1.482 . . . . 0.0 113.233 175.028 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.5 mt -57.04 -28.74 62.8 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 125.938 1.695 . . . . 0.0 112.641 177.558 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.61 -50.91 14.11 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.593 1.557 . . . . 0.0 112.713 175.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.0 mp -69.04 -33.6 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 124.001 0.92 . . . . 0.0 111.264 179.201 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.66 4.36 76.23 Favored Glycine 0 CA--C 1.536 1.406 0 C-N-CA 125.881 1.705 . . . . 0.0 114.352 -177.033 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.3 m -83.57 133.29 29.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.952 1.701 . . . . 0.0 109.837 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.9 mtp180 -122.55 109.17 13.99 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 119.957 1.253 . . . . 0.0 110.194 175.385 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.77 106.63 18.57 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.114 178.181 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 69.4 t -149.25 -65.94 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.2 0 C-N-CA 124.0 0.92 . . . . 0.0 112.587 178.012 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . 169.99 -59.25 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 128.7 2.8 . . . . 0.0 109.247 -173.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 m -117.33 -2.76 11.52 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 125.651 1.581 . . . . 0.0 114.561 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.97 -59.91 3.09 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.311 1.044 . . . . 0.0 112.746 -179.45 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.484 1.227 0 C-N-CA 129.19 2.996 . . . . 0.0 116.579 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.301 0 CA-C-O 121.007 0.432 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 159.46 95.1 0.1 Allowed Glycine 0 N--CA 1.472 1.09 0 O-C-N 121.013 -1.054 . . . . 0.0 112.558 -175.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 18.5 t60 -87.22 105.84 17.49 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.814 0.807 . . . . 0.0 110.953 179.116 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.1 mpt? -78.29 161.43 70.28 Favored Pre-proline 0 CA--C 1.548 0.873 0 C-N-CA 124.799 1.24 . . . . 0.0 112.098 178.511 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -68.27 -21.35 41.74 Favored 'Trans proline' 0 CA--C 1.539 0.758 0 C-N-CA 123.664 2.909 . . . . 0.0 113.828 177.04 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -51.65 -34.58 38.55 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.449 1.9 . . . . 0.0 114.879 -177.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 40.51 -132.74 2.75 Favored Glycine 0 CA--C 1.538 1.483 0 C-N-CA 126.274 1.892 . . . . 0.0 113.825 -176.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.0 p -165.22 74.39 0.22 Allowed 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 125.695 1.598 . . . . 0.0 111.484 175.024 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -156.86 177.73 11.16 Favored 'General case' 0 CA--C 1.55 0.969 0 C-N-CA 125.471 1.508 . . . . 0.0 112.926 176.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.6 p -147.55 75.04 1.34 Allowed 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 125.659 1.584 . . . . 0.0 112.336 175.28 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -121.09 165.4 15.38 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 126.16 1.784 . . . . 0.0 111.936 -179.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.1 152.07 42.61 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.166 0.986 . . . . 0.0 112.046 174.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.423 ' HG ' ' HE2' ' A' ' 70' ' ' LYS . 0.5 OUTLIER -67.91 129.54 40.23 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 124.373 1.069 . . . . 0.0 111.394 176.105 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -143.2 179.01 7.32 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.937 1.695 . . . . 0.0 112.199 176.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.4 t -59.51 129.34 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 O-C-N 121.054 -1.029 . . . . 0.0 110.821 175.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.28 -2.63 86.73 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 125.109 1.338 . . . . 0.0 115.372 -178.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -70.98 170.17 13.34 Favored 'General case' 0 CA--C 1.55 0.972 0 CA-C-N 119.319 1.56 . . . . 0.0 112.284 174.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.71 142.86 28.99 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.796 1.238 . . . . 0.0 111.602 178.263 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.9 m -139.02 146.48 25.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 124.061 0.944 . . . . 0.0 110.286 175.078 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 13.7 p -137.09 149.5 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 C-N-CA 124.554 1.142 . . . . 0.0 110.584 174.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.1 m-85 -86.33 162.67 45.1 Favored Pre-proline 0 CA--C 1.545 0.764 0 C-N-CA 124.034 0.934 . . . . 0.0 111.704 175.027 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -71.15 -24.97 22.88 Favored 'Trans proline' 0 CA--C 1.539 0.772 0 C-N-CA 122.883 2.389 . . . . 0.0 112.434 -176.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -165.91 55.02 0.1 Allowed 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 126.755 2.022 . . . . 0.0 111.844 -176.435 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 7.3 tp-100 -148.06 -63.52 0.26 Allowed 'General case' 0 N--CA 1.478 0.942 0 O-C-N 120.964 -1.085 . . . . 0.0 112.935 179.076 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.06 178.3 41.49 Favored Glycine 0 CA--C 1.534 1.245 0 C-N-CA 124.574 1.083 . . . . 0.0 113.754 -179.165 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.5 m -88.28 153.12 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 125.167 1.387 . . . . 0.0 110.783 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.2 m -140.02 172.45 12.74 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 125.256 1.423 . . . . 0.0 110.635 176.2 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 47.8 ttt-85 -133.81 123.95 25.69 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.108 0.963 . . . . 0.0 112.746 -179.283 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.3 t -69.39 122.76 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 125.751 1.62 . . . . 0.0 111.086 -179.28 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.6 t -108.87 -34.63 6.6 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 124.55 1.14 . . . . 0.0 112.485 178.352 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.14 167.28 29.54 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 126.224 1.81 . . . . 0.0 110.483 175.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 50.1 mt -144.89 140.61 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 125.19 1.396 . . . . 0.0 108.993 175.407 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -148.04 169.01 20.86 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.732 0.813 . . . . 0.0 112.568 175.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 10.9 m -104.69 143.21 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 124.819 1.248 . . . . 0.0 111.796 175.561 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.66 172.77 18.01 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 124.457 1.103 . . . . 0.0 112.311 174.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.64 121.83 45.47 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 126.137 1.775 . . . . 0.0 109.291 175.171 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.7 p -132.77 136.83 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 124.443 1.097 . . . . 0.0 109.259 174.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.91 29.05 1.54 Allowed 'General case' 0 CA--C 1.556 1.206 0 N-CA-C 114.939 1.459 . . . . 0.0 114.939 -177.063 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.9 26.21 50.21 Favored Glycine 0 CA--C 1.541 1.666 0 C-N-CA 124.76 1.172 . . . . 0.0 115.349 -177.2 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -134.44 113.46 11.88 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.054 1.742 . . . . 0.0 109.7 -175.54 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 20.9 tttt -96.85 116.4 29.1 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 124.696 1.199 . . . . 0.0 111.677 -179.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -159.73 174.55 14.36 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 123.634 0.774 . . . . 0.0 112.203 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 17.6 m -79.06 116.39 19.32 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.588 1.555 . . . . 0.0 112.107 176.03 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -104.77 113.28 26.78 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 124.416 1.086 . . . . 0.0 109.88 175.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 25.4 m -63.68 151.92 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 O-C-N 121.707 -0.621 . . . . 0.0 111.5 175.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -126.51 109.82 12.58 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-O 121.723 0.773 . . . . 0.0 110.499 176.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 5.2 mpp? -113.42 157.52 21.82 Favored 'General case' 0 C--O 1.232 0.144 0 C-N-CA 124.804 1.242 . . . . 0.0 111.616 176.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 43.1 mtp85 -133.88 105.58 6.84 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 126.191 1.797 . . . . 0.0 109.926 179.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 46.8 mtp85 -74.91 109.05 8.06 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.664 0.786 . . . . 0.0 109.435 175.034 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -69.73 -14.55 62.84 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 176.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -57.96 -43.2 86.3 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 126.072 1.749 . . . . 0.0 112.97 175.115 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -128.57 -12.93 4.88 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 125.024 1.33 . . . . 0.0 114.123 -177.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.92 4.88 78.19 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 125.935 1.731 . . . . 0.0 114.802 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -75.04 161.44 29.45 Favored 'General case' 0 CA--C 1.543 0.692 0 CA-C-N 118.532 1.166 . . . . 0.0 113.166 179.469 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.3 m -105.85 139.24 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 125.397 1.479 . . . . 0.0 109.865 174.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.3 t -123.31 114.96 44.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.82 1.248 . . . . 0.0 108.427 177.146 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.1 tmm? -127.97 123.91 35.97 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 124.94 1.296 . . . . 0.0 109.547 178.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.4 m -131.56 155.02 82.0 Favored Pre-proline 0 N--CA 1.469 0.52 0 C-N-CA 124.592 1.157 . . . . 0.0 111.388 176.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -76.68 118.52 4.86 Favored 'Trans proline' 0 CA--C 1.536 0.577 0 C-N-CA 123.488 2.792 . . . . 0.0 114.763 177.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -59.87 -41.03 90.65 Favored 'General case' 0 N--CA 1.475 0.775 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.89 6.31 79.35 Favored Glycine 0 N--CA 1.475 1.299 0 C-N-CA 124.344 0.974 . . . . 0.0 114.69 178.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.9 tttp -132.98 3.63 3.74 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.667 1.587 . . . . 0.0 112.773 -178.533 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.61 -30.07 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 C-N-CA 125.128 1.371 . . . . 0.0 113.453 175.149 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.8 mt -55.93 -29.33 59.94 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 126.208 1.803 . . . . 0.0 112.652 177.591 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.83 -49.16 21.59 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 125.702 1.601 . . . . 0.0 112.837 175.76 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.0 mp -69.12 -33.61 59.35 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 124.202 1.001 . . . . 0.0 111.387 178.327 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.38 3.06 78.93 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 125.717 1.627 . . . . 0.0 114.365 -175.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.6 t -75.79 148.58 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 CA-C-N 118.47 1.135 . . . . 0.0 110.281 175.002 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.38 109.3 10.97 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-O 122.033 0.921 . . . . 0.0 108.679 175.018 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.423 ' HE2' ' HG ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER -112.5 106.59 15.09 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 125.5 1.52 . . . . 0.0 108.896 179.42 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 87.0 t -148.87 -72.29 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 C-N-CA 125.091 1.356 . . . . 0.0 111.07 177.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . 179.1 -57.61 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 128.777 2.831 . . . . 0.0 109.215 -176.513 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 86.2 p -114.08 3.71 15.37 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 126.769 2.028 . . . . 0.0 114.392 -176.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -77.04 -65.38 0.96 Allowed 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.196 1.398 . . . . 0.0 111.968 -179.511 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.483 1.202 0 C-N-CA 130.162 3.385 . . . . 0.0 116.583 178.595 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.607 HD21 HG21 ' A' ' 29' ' ' VAL . 1.2 tt . . . . . 0 CA--C 1.543 0.692 0 CA-C-O 120.91 0.386 . . . . 0.0 111.234 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -129.73 178.85 6.2 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 125.615 1.566 . . . . 0.0 112.045 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.87 133.0 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 O-C-N 121.003 -1.061 . . . . 0.0 110.574 174.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.03 -0.15 87.48 Favored Glycine 0 CA--C 1.532 1.144 0 C-N-CA 124.711 1.148 . . . . 0.0 114.868 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -66.08 171.41 4.62 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 124.39 1.076 . . . . 0.0 112.397 175.001 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -107.07 144.2 34.08 Favored 'General case' 0 N--CA 1.463 0.203 0 C-N-CA 125.392 1.477 . . . . 0.0 111.347 -176.539 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.448 HG21 ' HE2' ' A' ' 47' ' ' MET . 4.9 m -138.84 144.64 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 123.482 0.713 . . . . 0.0 109.76 -176.542 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.0 p -137.09 140.64 42.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 124.527 1.131 . . . . 0.0 109.4 175.709 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -92.37 161.55 32.35 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 124.488 1.115 . . . . 0.0 111.169 176.425 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -67.9 -14.01 40.08 Favored 'Trans proline' 0 CA--C 1.546 1.106 0 C-N-CA 122.816 2.344 . . . . 0.0 113.632 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.4 m-80 -148.76 -41.19 0.15 Allowed 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 126.064 1.746 . . . . 0.0 114.36 177.35 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 3.2 tm0? -52.34 -44.41 65.15 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 126.672 1.989 . . . . 0.0 114.107 -172.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 132.26 -150.28 19.6 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 125.937 1.732 . . . . 0.0 111.738 -178.08 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.9 m -112.27 146.57 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 C-N-CA 125.505 1.522 . . . . 0.0 110.917 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 78.1 m -137.06 179.71 6.22 Favored 'General case' 0 CA--C 1.551 1.016 0 C-N-CA 125.922 1.689 . . . . 0.0 110.589 175.042 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -136.1 129.49 31.92 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 125.185 1.394 . . . . 0.0 110.901 -179.209 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.607 HG21 HD21 ' A' ' 13' ' ' LEU . 26.5 t -68.73 139.21 20.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.362 0.665 . . . . 0.0 110.565 -175.833 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 46.7 t -117.89 -45.44 2.67 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 124.462 1.105 . . . . 0.0 112.647 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -151.93 160.7 43.43 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 124.483 1.113 . . . . 0.0 111.046 175.568 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -141.93 135.72 29.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 C-N-CA 124.663 1.185 . . . . 0.0 108.653 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -148.4 169.72 19.57 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.453 0.701 . . . . 0.0 111.646 175.298 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.603 HG12 ' HA ' ' A' ' 43' ' ' THR . 21.9 m -109.58 140.42 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 O-C-N 120.782 -1.199 . . . . 0.0 110.203 176.726 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -152.6 169.42 22.71 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.589 0.755 . . . . 0.0 111.974 176.712 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.73 116.22 32.24 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.205 1.402 . . . . 0.0 109.742 174.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.4 p -124.61 139.39 51.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 C-N-CA 124.227 1.011 . . . . 0.0 109.574 175.014 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.52 29.1 1.95 Allowed 'General case' 0 CA--C 1.558 1.253 0 N-CA-C 114.702 1.371 . . . . 0.0 114.702 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.08 25.19 52.97 Favored Glycine 0 CA--C 1.54 1.594 0 C-N-CA 125.044 1.307 . . . . 0.0 115.414 -175.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLN . . . . . 0.404 ' HG2' ' HE3' ' A' ' 62' ' ' LYS . 5.9 tp60 -138.59 115.06 10.49 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 125.85 1.66 . . . . 0.0 111.387 -172.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 10.5 tttt -95.01 118.28 31.56 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.639 1.176 . . . . 0.0 111.79 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.606 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -155.51 171.6 19.65 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.344 0.658 . . . . 0.0 111.662 177.797 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.603 ' HA ' HG12 ' A' ' 34' ' ' VAL . 6.8 m -74.55 116.48 15.28 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.179 0.992 . . . . 0.0 111.296 175.633 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -109.83 113.35 26.03 Favored 'General case' 0 C--O 1.234 0.252 0 C-N-CA 124.627 1.171 . . . . 0.0 110.16 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.662 HG21 ' CE ' ' A' ' 70' ' ' LYS . 24.1 m -80.59 145.75 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.041 179.791 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 16.5 m -126.31 110.12 13.03 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 122.217 1.008 . . . . 0.0 110.972 179.104 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' MET . . . . . 0.448 ' HE2' HG21 ' A' ' 19' ' ' VAL . 2.2 mpp? -109.64 151.0 27.42 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 125.278 1.431 . . . . 0.0 110.095 -178.51 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 37.5 mtm180 -136.17 110.29 8.32 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.69 1.196 . . . . 0.0 109.677 -176.359 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -76.44 109.01 9.81 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 177.863 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -69.73 -13.78 62.46 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.498 1.119 . . . . 0.0 113.818 176.04 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -60.44 -39.49 87.7 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 125.559 1.543 . . . . 0.0 112.75 178.108 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -128.59 -18.82 3.86 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 125.793 1.637 . . . . 0.0 113.915 178.404 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.2 15.42 48.0 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 125.438 1.494 . . . . 0.0 114.766 -177.801 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -78.41 163.98 25.17 Favored 'General case' 0 CA--C 1.54 0.574 0 CA-C-N 118.416 1.108 . . . . 0.0 112.376 175.336 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 25.9 m -128.98 142.0 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.146 1.379 . . . . 0.0 110.665 175.451 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 21.9 m -131.87 133.71 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 125.114 1.366 . . . . 0.0 108.719 177.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -129.72 127.11 39.79 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 124.257 1.023 . . . . 0.0 109.051 177.085 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.415 ' O ' HG22 ' A' ' 45' ' ' VAL . 27.5 m -133.73 156.66 79.25 Favored Pre-proline 0 N--CA 1.471 0.596 0 C-N-CA 124.3 1.04 . . . . 0.0 111.635 178.119 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.606 ' CB ' HD11 ' A' ' 42' ' ' LEU . 45.5 Cg_endo -76.1 116.71 4.45 Favored 'Trans proline' 0 CA--C 1.535 0.565 0 C-N-CA 123.567 2.845 . . . . 0.0 114.571 176.391 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -63.65 -34.89 78.84 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 120.537 -1.352 . . . . 0.0 114.024 177.772 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.1 6.86 78.91 Favored Glycine 0 N--CA 1.473 1.139 0 C-N-CA 124.201 0.905 . . . . 0.0 114.693 176.474 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.404 ' HE3' ' HG2' ' A' ' 40' ' ' GLN . 0.9 OUTLIER -136.74 3.98 2.77 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.225 1.41 . . . . 0.0 113.698 -178.779 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.486 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.2 m -49.86 -28.54 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.556 1.543 . . . . 0.0 113.421 175.442 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 12.0 mt -56.54 -29.77 62.3 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 125.805 1.642 . . . . 0.0 112.3 176.454 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.51 -49.89 15.35 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.811 1.644 . . . . 0.0 112.493 176.22 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.6 mp -65.7 -32.9 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 124.488 1.115 . . . . 0.0 111.741 177.594 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 85.21 4.41 86.48 Favored Glycine 0 CA--C 1.536 1.379 0 C-N-CA 125.397 1.475 . . . . 0.0 114.093 -175.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 13.9 p -80.83 132.9 30.53 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 124.905 1.282 . . . . 0.0 110.988 175.405 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.6 mmt180 -109.87 109.32 19.92 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 174.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.662 ' CE ' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.465 0.277 0 C-N-CA 123.879 0.872 . . . . 0.0 109.337 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.7 mm? . . . . . 0 N--CA 1.467 0.391 0 CA-C-O 120.957 0.408 . . . . 0.0 110.841 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.22 174.51 10.47 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.503 1.521 . . . . 0.0 111.39 176.775 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.5 t -60.89 126.2 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 123.718 0.807 . . . . 0.0 110.772 177.647 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.55 -8.74 74.45 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 125.131 1.348 . . . . 0.0 115.186 -176.442 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.1 t0 -71.51 167.6 19.33 Favored 'General case' 0 CA--C 1.548 0.9 0 CA-C-N 119.195 1.497 . . . . 0.0 111.4 174.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 12.4 tpp180 -92.98 151.39 19.94 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.036 0.934 . . . . 0.0 111.877 -179.239 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.669 HG11 ' HG2' ' A' ' 47' ' ' MET . 2.0 p -151.99 130.01 2.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 C-N-CA 124.895 1.278 . . . . 0.0 110.622 178.667 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.6 p -137.09 155.82 33.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 C-N-CA 125.837 1.655 . . . . 0.0 108.484 174.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.466 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.5 OUTLIER -101.46 158.69 31.3 Favored Pre-proline 0 CA--C 1.537 0.467 0 C-N-CA 125.047 1.339 . . . . 0.0 111.373 175.091 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.446 ' CD ' HG12 ' A' ' 68' ' ' VAL . 66.7 Cg_endo -68.21 -21.48 41.89 Favored 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 123.103 2.536 . . . . 0.0 112.458 -176.452 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -159.8 51.31 0.33 Allowed 'General case' 0 CA--C 1.557 1.221 0 C-N-CA 124.875 1.27 . . . . 0.0 112.896 176.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -140.36 -61.6 0.51 Allowed 'General case' 0 N--CA 1.483 1.216 0 O-C-N 120.835 -1.166 . . . . 0.0 113.116 -177.659 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 162.42 174.98 32.97 Favored Glycine 0 CA--C 1.534 1.245 0 C-N-CA 124.927 1.251 . . . . 0.0 113.65 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.9 t -91.19 140.42 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 125.461 1.504 . . . . 0.0 110.233 176.329 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 38.1 m -130.34 -177.85 4.5 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 126.258 1.823 . . . . 0.0 110.198 178.481 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 -141.96 124.21 15.56 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.074 0.95 . . . . 0.0 110.661 176.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.7 t -58.24 121.32 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 123.849 0.859 . . . . 0.0 110.815 -178.198 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.5 t -116.28 -35.2 4.4 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.458 1.503 . . . . 0.0 112.179 -175.498 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -148.14 157.95 43.8 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 125.179 1.392 . . . . 0.0 110.914 175.049 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 65.6 mt -143.15 132.59 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 O-C-N 120.816 -1.177 . . . . 0.0 108.242 175.238 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -138.51 172.25 13.16 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 125.247 1.419 . . . . 0.0 111.422 175.107 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.474 HG22 ' HA ' ' A' ' 43' ' ' THR . 21.9 t -129.88 136.9 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.619 1.168 . . . . 0.0 109.3 179.682 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.0 ptmt -144.46 161.98 37.69 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.694 1.198 . . . . 0.0 111.817 177.535 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -90.14 116.05 27.85 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 124.458 1.103 . . . . 0.0 109.631 175.111 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 p -112.72 128.14 69.58 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 125.348 1.459 . . . . 0.0 109.346 174.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.94 29.07 3.17 Favored 'General case' 0 CA--C 1.557 1.214 0 N-CA-C 114.815 1.413 . . . . 0.0 114.815 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.86 23.57 55.31 Favored Glycine 0 CA--C 1.541 1.715 0 C-N-CA 124.647 1.117 . . . . 0.0 115.323 -175.287 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -138.25 118.7 13.8 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 126.277 1.831 . . . . 0.0 111.194 178.513 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.461 ' HG2' HG12 ' A' ' 34' ' ' VAL . 1.8 tttt -85.68 135.85 33.6 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 123.904 0.882 . . . . 0.0 111.439 175.876 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.594 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.5 OUTLIER -154.93 159.16 40.23 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 122.823 0.449 . . . . 0.0 111.832 177.633 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.474 ' HA ' HG22 ' A' ' 34' ' ' VAL . 6.6 m -68.99 116.69 9.74 Favored 'General case' 0 N--CA 1.478 0.956 0 C-N-CA 124.056 0.942 . . . . 0.0 111.835 178.047 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -104.72 113.15 26.55 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 119.667 1.121 . . . . 0.0 110.776 174.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.7 m -84.73 136.86 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 123.796 0.838 . . . . 0.0 110.71 178.01 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 13.6 m -126.49 132.24 51.45 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 122.924 1.345 . . . . 0.0 111.876 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' MET . . . . . 0.669 ' HG2' HG11 ' A' ' 19' ' ' VAL . 0.7 OUTLIER -130.13 161.93 29.98 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 125.151 1.381 . . . . 0.0 110.661 -174.217 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 14.3 mtp85 -131.09 103.12 6.33 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.911 1.284 . . . . 0.0 110.425 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.75 109.06 13.81 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.612 0.765 . . . . 0.0 110.766 177.345 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -63.56 -20.41 65.61 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.901 1.28 . . . . 0.0 112.72 178.617 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -58.63 -38.45 78.09 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.207 1.803 . . . . 0.0 113.344 -178.28 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -128.56 4.18 5.58 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 125.797 1.639 . . . . 0.0 112.702 174.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 62.91 29.86 75.49 Favored Glycine 0 CA--C 1.533 1.196 0 C-N-CA 125.526 1.536 . . . . 0.0 113.711 -174.336 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.62 172.26 7.6 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 118.343 1.072 . . . . 0.0 111.399 -174.712 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 30.3 m -114.55 144.25 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 C-N-CA 123.566 0.746 . . . . 0.0 111.098 174.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.9 t -124.33 112.11 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.253 1.421 . . . . 0.0 107.987 176.519 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.2 ttt -120.73 118.82 31.06 Favored 'General case' 0 C--O 1.235 0.317 0 C-N-CA 124.516 1.126 . . . . 0.0 109.734 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.433 HG21 ' NZ ' ' A' ' 70' ' ' LYS . 17.1 m -137.03 158.32 72.98 Favored Pre-proline 0 N--CA 1.471 0.607 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -178.842 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.594 ' CB ' HD11 ' A' ' 42' ' ' LEU . 64.7 Cg_endo -78.69 111.87 3.05 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.192 2.595 . . . . 0.0 114.56 176.858 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -60.95 -35.28 76.32 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 120.398 -1.439 . . . . 0.0 113.567 178.264 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.12 5.74 78.58 Favored Glycine 0 N--CA 1.474 1.222 0 C-N-CA 124.543 1.068 . . . . 0.0 114.961 176.73 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -135.51 1.47 2.86 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 125.207 1.403 . . . . 0.0 113.353 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.559 HG13 ' O ' ' A' ' 59' ' ' PRO . 3.0 m -49.86 -28.1 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.917 1.687 . . . . 0.0 114.149 176.524 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.1 mt -56.22 -34.53 66.4 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.064 1.746 . . . . 0.0 112.071 175.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.78 -48.61 45.45 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.779 1.632 . . . . 0.0 112.586 177.005 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.404 HG22 HG13 ' A' ' 68' ' ' VAL . 3.5 mp -68.28 -27.92 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 123.972 0.909 . . . . 0.0 111.49 176.432 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.78 19.49 63.38 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.433 1.492 . . . . 0.0 113.853 -178.688 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.466 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 15.6 m -95.27 123.16 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 126.254 1.821 . . . . 0.0 111.059 -175.583 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 11.0 mmt180 -107.7 109.24 20.79 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 121.272 -0.892 . . . . 0.0 109.076 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.509 ' HB3' HG23 ' A' ' 19' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.473 0.689 0 O-C-N 121.525 -0.734 . . . . 0.0 110.558 -179.338 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.444 HD11 HG21 ' A' ' 29' ' ' VAL . 0.4 OUTLIER . . . . . 0 CA--C 1.537 0.461 0 CA-C-O 120.737 0.303 . . . . 0.0 110.602 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -128.37 169.65 14.01 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.9 1.68 . . . . 0.0 112.052 178.594 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.4 t -63.75 130.47 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 O-C-N 121.226 -0.921 . . . . 0.0 110.693 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.73 -8.81 76.45 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.216 1.389 . . . . 0.0 114.663 -177.3 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -67.65 154.91 40.42 Favored 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 118.958 1.379 . . . . 0.0 110.818 174.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -74.96 157.41 35.01 Favored 'General case' 0 N--CA 1.472 0.664 0 O-C-N 121.312 -0.867 . . . . 0.0 110.046 174.941 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 14.9 m -149.25 138.2 15.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 C-N-CA 124.676 1.19 . . . . 0.0 110.449 179.279 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.6 p -137.09 157.79 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 125.355 1.462 . . . . 0.0 109.56 177.549 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -102.9 160.36 26.45 Favored Pre-proline 0 CA--C 1.542 0.667 0 C-N-CA 124.919 1.288 . . . . 0.0 111.732 175.034 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_endo -68.95 -28.02 29.71 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 123.806 3.004 . . . . 0.0 112.102 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.8 t30 -158.51 55.5 0.44 Allowed 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 124.472 1.109 . . . . 0.0 112.848 177.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.82 -60.79 0.29 Allowed 'General case' 0 N--CA 1.482 1.139 0 O-C-N 121.009 -1.057 . . . . 0.0 113.351 -174.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 162.43 -173.34 38.7 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 124.818 1.199 . . . . 0.0 113.59 -177.467 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.7 p -100.49 144.95 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 126.362 1.865 . . . . 0.0 110.945 176.211 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.417 ' SG ' HG21 ' A' ' 56' ' ' VAL . 38.7 m -131.75 -175.85 3.85 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 125.49 1.516 . . . . 0.0 110.306 175.434 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -137.53 124.8 21.78 Favored 'General case' 0 N--CA 1.48 1.028 0 O-C-N 121.091 -1.006 . . . . 0.0 111.634 177.021 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.444 HG21 HD11 ' A' ' 13' ' ' LEU . 60.4 t -64.61 136.04 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 C-N-CA 124.425 1.09 . . . . 0.0 110.657 -179.493 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.5 p -115.44 -44.95 2.94 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 124.635 1.174 . . . . 0.0 113.026 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.3 163.56 37.25 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 126.319 1.847 . . . . 0.0 110.796 176.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 75.0 mt -141.83 132.82 26.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 124.543 1.137 . . . . 0.0 108.979 178.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -147.37 167.23 24.86 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.615 0.766 . . . . 0.0 112.581 175.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.485 HG12 ' HA ' ' A' ' 43' ' ' THR . 20.9 m -103.3 141.93 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 O-C-N 121.117 -0.989 . . . . 0.0 110.699 175.703 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 3.9 ptmt -154.83 170.18 22.24 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 124.25 1.02 . . . . 0.0 112.234 175.47 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -102.46 116.34 32.42 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 125.999 1.72 . . . . 0.0 109.579 175.013 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.6 p -126.5 137.87 56.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.901 0.88 . . . . 0.0 110.025 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.5 28.97 1.89 Allowed 'General case' 0 CA--C 1.558 1.251 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 -177.742 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.28 22.69 53.81 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 125.172 1.367 . . . . 0.0 115.516 -176.565 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 35.8 tt0 -136.51 113.7 10.65 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 119.062 1.431 . . . . 0.0 111.666 -173.604 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 13.0 tttt -94.47 116.04 28.32 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.054 1.342 . . . . 0.0 111.747 -178.135 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.614 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -157.16 173.26 17.25 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.394 0.678 . . . . 0.0 111.887 177.777 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.485 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.2 m -73.96 116.41 14.55 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 124.934 1.293 . . . . 0.0 111.351 175.016 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -109.44 113.22 25.85 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.614 1.166 . . . . 0.0 109.939 177.195 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.613 HG21 ' HE2' ' A' ' 70' ' ' LYS . 27.3 m -73.61 150.71 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 O-C-N 121.817 -0.552 . . . . 0.0 110.894 177.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.2 m -126.5 121.18 31.62 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.801 0.84 . . . . 0.0 110.407 176.946 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -124.43 158.98 31.49 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 125.759 1.624 . . . . 0.0 110.51 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 13.4 ptm180 -136.18 111.5 9.11 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 126.061 1.744 . . . . 0.0 110.306 -178.153 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.9 109.07 19.08 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 123.258 0.623 . . . . 0.0 109.95 176.596 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 22.5 pt-20 -65.16 -18.43 65.3 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 113.337 0.866 . . . . 0.0 113.337 177.821 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -59.78 -36.72 77.26 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.027 1.731 . . . . 0.0 113.379 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -128.62 3.24 5.53 Favored 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.98 1.312 . . . . 0.0 112.665 174.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 64.61 24.18 69.37 Favored Glycine 0 CA--C 1.535 1.341 0 C-N-CA 125.447 1.498 . . . . 0.0 114.089 -172.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -90.74 173.53 7.97 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 118.671 1.236 . . . . 0.0 111.429 -176.361 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 27.0 m -117.9 143.77 27.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 124.168 0.987 . . . . 0.0 110.483 174.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.417 HG21 ' SG ' ' A' ' 27' ' ' CYS . 45.0 t -125.86 112.31 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 C-N-CA 125.375 1.47 . . . . 0.0 107.499 177.428 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.1 tmm? -125.34 119.34 28.1 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.145 0.978 . . . . 0.0 109.972 176.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.8 m -132.14 156.76 79.71 Favored Pre-proline 0 N--CA 1.469 0.519 0 C-N-CA 124.746 1.219 . . . . 0.0 111.834 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.614 ' CB ' HD11 ' A' ' 42' ' ' LEU . 58.3 Cg_endo -78.01 113.61 3.46 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 124.053 3.169 . . . . 0.0 115.38 179.576 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -60.78 -34.42 74.46 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 120.134 -1.604 . . . . 0.0 114.315 178.009 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.17 5.57 78.37 Favored Glycine 0 N--CA 1.474 1.218 0 C-N-CA 124.202 0.905 . . . . 0.0 114.847 176.809 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 17.4 tttt -137.56 3.05 2.51 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 125.413 1.485 . . . . 0.0 113.212 -176.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 59' ' ' PRO . 3.0 m -50.21 -29.13 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 C-N-CA 125.581 1.552 . . . . 0.0 113.513 175.393 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.8 mt -58.41 -28.77 65.52 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 126.098 1.759 . . . . 0.0 112.201 177.558 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.9 -51.64 13.32 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.035 1.734 . . . . 0.0 112.479 175.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.538 HG22 HG13 ' A' ' 68' ' ' VAL . 2.3 mp -68.61 -31.11 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 124.192 0.997 . . . . 0.0 111.367 178.07 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.83 10.48 72.4 Favored Glycine 0 CA--C 1.538 1.504 0 C-N-CA 126.047 1.784 . . . . 0.0 114.468 -177.555 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.538 HG13 HG22 ' A' ' 66' ' ' ILE . 31.2 m -97.35 123.47 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 C-N-CA 125.705 1.602 . . . . 0.0 110.75 -173.263 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 21.3 mmt85 -107.2 109.32 21.1 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.613 ' HE2' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.47 0.543 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -177.472 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.521 HD21 ' CG1' ' A' ' 19' ' ' VAL . 0.7 OUTLIER . . . . . 0 CA--C 1.546 0.807 0 CA-C-O 120.831 0.348 . . . . 0.0 110.876 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.428 ' N ' HD13 ' A' ' 13' ' ' LEU . . . -146.81 176.42 9.89 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.469 1.908 . . . . 0.0 112.137 177.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.3 t -59.14 129.2 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 O-C-N 120.965 -1.084 . . . . 0.0 111.786 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.53 -4.93 85.0 Favored Glycine 0 CA--C 1.534 1.243 0 C-N-CA 125.197 1.38 . . . . 0.0 114.1 -178.219 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -67.32 161.44 25.04 Favored 'General case' 0 CA--C 1.547 0.858 0 CA-C-N 118.454 1.127 . . . . 0.0 112.561 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -96.55 124.14 40.44 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.951 1.701 . . . . 0.0 111.968 -173.446 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.521 ' CG1' HD21 ' A' ' 13' ' ' LEU . 19.4 m -139.75 139.72 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 C-N-CA 123.34 0.656 . . . . 0.0 110.968 -175.102 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.9 p -137.03 145.1 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 124.002 0.921 . . . . 0.0 110.384 177.212 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.528 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.9 OUTLIER -74.71 160.51 80.77 Favored Pre-proline 0 CA--C 1.547 0.83 0 O-C-N 121.83 -0.544 . . . . 0.0 110.59 174.997 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.599 ' CD ' HG12 ' A' ' 68' ' ' VAL . 60.8 Cg_endo -67.97 -25.73 38.17 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.04 2.493 . . . . 0.0 112.253 -179.048 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.3 t30 -159.07 48.87 0.33 Allowed 'General case' 0 CA--C 1.554 1.12 0 C-N-CA 124.494 1.117 . . . . 0.0 113.633 178.747 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -139.41 -64.12 0.5 Allowed 'General case' 0 N--CA 1.482 1.157 0 O-C-N 120.85 -1.156 . . . . 0.0 113.132 -174.808 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 166.39 172.49 33.76 Favored Glycine 0 CA--C 1.533 1.162 0 C-N-CA 125.015 1.293 . . . . 0.0 113.192 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.29 142.58 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 124.893 1.277 . . . . 0.0 110.804 -178.249 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 6.2 m -131.48 173.0 11.54 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.917 1.687 . . . . 0.0 111.148 176.08 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.8 tmt_? -133.76 118.96 18.67 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 125.863 1.665 . . . . 0.0 110.325 -178.022 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.634 HG22 ' SD ' ' A' ' 47' ' ' MET . 39.3 t -60.84 131.1 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 O-C-N 121.762 -0.586 . . . . 0.0 111.01 -175.562 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 83.0 p -112.06 -42.64 3.71 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -178.672 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.8 162.68 34.83 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.527 1.531 . . . . 0.0 110.817 178.438 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 71.1 mt -143.69 136.04 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.5 1.12 . . . . 0.0 108.965 -178.243 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -149.04 163.49 37.37 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 124.352 1.061 . . . . 0.0 111.913 175.533 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.8 p -106.85 141.91 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 124.593 1.157 . . . . 0.0 109.775 175.346 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.28 168.04 26.68 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 125.259 1.423 . . . . 0.0 110.854 176.233 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -101.38 118.71 37.51 Favored 'General case' 0 N--CA 1.467 0.395 0 C-N-CA 125.307 1.443 . . . . 0.0 109.488 175.41 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.0 p -121.08 132.54 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 124.272 1.029 . . . . 0.0 109.774 174.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.05 29.08 2.29 Favored 'General case' 0 CA--C 1.557 1.218 0 N-CA-C 114.775 1.398 . . . . 0.0 114.775 -178.206 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.29 26.23 48.58 Favored Glycine 0 CA--C 1.542 1.781 0 C-N-CA 124.692 1.139 . . . . 0.0 115.296 -175.111 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 5.9 mt-30 -135.42 113.53 11.27 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 126.401 1.881 . . . . 0.0 111.081 -178.043 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 8.9 tttt -94.01 121.43 35.48 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.968 1.307 . . . . 0.0 111.423 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.613 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -157.1 161.47 39.43 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 122.848 0.459 . . . . 0.0 111.41 178.859 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.4 m -67.77 116.39 8.4 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 121.313 -0.867 . . . . 0.0 110.516 177.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -104.65 113.56 27.22 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 120.869 -1.144 . . . . 0.0 110.041 175.433 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.9 m -83.22 141.16 15.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 C-N-CA 123.525 0.73 . . . . 0.0 110.184 177.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 24.8 m -122.32 112.7 18.44 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.668 1.187 . . . . 0.0 109.896 -178.776 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' MET . . . . . 0.634 ' SD ' HG22 ' A' ' 29' ' ' VAL . 1.0 OUTLIER -112.15 154.9 24.79 Favored 'General case' 0 C--O 1.233 0.224 0 C-N-CA 124.011 0.924 . . . . 0.0 109.405 -178.9 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 41.7 mtm180 -133.72 154.73 50.74 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 124.495 1.118 . . . . 0.0 109.791 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ARG . . . . . 0.593 ' HE ' ' HB3' ' A' ' 54' ' ' ALA . 0.2 OUTLIER -120.94 109.08 14.66 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.85 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -67.57 -19.87 65.32 Favored 'General case' 0 CA--C 1.544 0.714 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 177.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -51.1 -46.81 61.97 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 127.046 2.139 . . . . 0.0 112.75 175.423 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -123.61 -19.19 5.89 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.517 1.527 . . . . 0.0 113.424 -179.164 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.25 37.61 8.93 Favored Glycine 0 CA--C 1.538 1.488 0 C-N-CA 125.429 1.49 . . . . 0.0 114.372 -177.456 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.593 ' HB3' ' HE ' ' A' ' 49' ' ' ARG . . . -110.06 166.64 10.79 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.4 1.48 . . . . 0.0 112.085 177.784 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.4 m -129.7 146.91 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 125.047 1.339 . . . . 0.0 111.52 178.467 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.0 m -136.94 112.2 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 C-N-CA 126.409 1.883 . . . . 0.0 109.151 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 9.4 ptt? -107.9 124.45 50.14 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 124.424 1.09 . . . . 0.0 110.364 176.037 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.615 HG21 ' HE2' ' A' ' 70' ' ' LYS . 30.1 m -131.97 157.21 78.83 Favored Pre-proline 0 N--CA 1.469 0.488 0 C-N-CA 123.949 0.9 . . . . 0.0 111.119 -178.442 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.613 ' CB ' HD11 ' A' ' 42' ' ' LEU . 56.1 Cg_endo -77.73 114.94 3.75 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.382 2.721 . . . . 0.0 114.596 176.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -62.54 -35.77 80.51 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 120.37 -1.456 . . . . 0.0 113.909 178.53 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.99 6.35 79.1 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.245 0.926 . . . . 0.0 114.794 176.919 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 3.0 tttm -136.0 4.5 3.0 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.685 1.594 . . . . 0.0 112.861 -178.705 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -50.05 -30.0 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 126.12 1.768 . . . . 0.0 113.072 175.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.7 mt -55.05 -29.91 58.46 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.315 1.846 . . . . 0.0 112.585 176.578 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.78 -50.47 13.45 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.647 1.579 . . . . 0.0 112.529 177.747 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.509 HG22 HG13 ' A' ' 68' ' ' VAL . 3.6 mp -66.42 -32.98 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 C-N-CA 124.664 1.186 . . . . 0.0 111.237 177.574 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.4 4.61 76.8 Favored Glycine 0 CA--C 1.534 1.278 0 C-N-CA 125.647 1.594 . . . . 0.0 114.137 -176.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.599 HG12 ' CD ' ' A' ' 22' ' ' PRO . 30.2 m -82.31 137.55 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 124.404 1.082 . . . . 0.0 111.105 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -117.79 109.62 16.8 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.012 0.925 . . . . 0.0 110.535 175.771 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.615 ' HE2' HG21 ' A' ' 58' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.468 0.435 0 C-N-CA 126.51 1.924 . . . . 0.0 109.345 178.403 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.542 0.656 0 CA-C-O 120.852 0.358 . . . . 0.0 111.109 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -121.45 169.08 10.99 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 125.926 1.69 . . . . 0.0 111.972 175.005 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.4 t -61.37 129.84 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 O-C-N 121.413 -0.805 . . . . 0.0 110.634 176.846 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.12 -6.54 78.78 Favored Glycine 0 CA--C 1.534 1.23 0 C-N-CA 124.876 1.227 . . . . 0.0 114.651 -177.677 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -69.61 176.41 3.54 Favored 'General case' 0 CA--C 1.546 0.814 0 CA-C-N 119.079 1.439 . . . . 0.0 110.593 174.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.42 169.91 10.67 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.998 1.38 . . . . 0.0 112.998 -179.673 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.54 HG13 ' HB2' ' A' ' 27' ' ' CYS . 2.5 p -161.02 149.78 5.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 C-N-CA 125.539 1.536 . . . . 0.0 110.643 175.366 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.8 p -127.42 160.43 36.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 126.991 2.116 . . . . 0.0 107.685 174.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -125.84 154.55 73.46 Favored Pre-proline 0 CA--C 1.539 0.547 0 C-N-CA 125.063 1.345 . . . . 0.0 110.974 176.696 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.83 -9.83 26.5 Favored 'Trans proline' 0 CA--C 1.545 1.06 0 C-N-CA 123.17 2.58 . . . . 0.0 113.761 178.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 26.7 m-20 -133.46 -60.17 0.85 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.352 1.861 . . . . 0.0 112.922 176.863 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 65.5 mm-40 -52.48 -54.35 33.56 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 125.133 1.373 . . . . 0.0 112.952 -175.685 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 114.53 -147.36 18.82 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 125.479 1.514 . . . . 0.0 111.68 -174.059 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.2 m -70.17 144.66 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 124.004 0.922 . . . . 0.0 112.984 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.54 ' HB2' HG13 ' A' ' 19' ' ' VAL . 30.9 m -141.81 177.53 8.11 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 126.383 1.873 . . . . 0.0 110.653 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -132.38 129.47 39.43 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 124.759 1.224 . . . . 0.0 111.881 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.6 t -72.56 142.48 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 O-C-N 121.758 -0.588 . . . . 0.0 110.946 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.9 t -116.94 -44.78 2.79 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.419 1.488 . . . . 0.0 112.593 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.95 159.27 37.92 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 124.437 1.095 . . . . 0.0 110.553 177.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -142.59 133.59 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 120.911 -1.118 . . . . 0.0 108.823 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -149.47 169.4 20.97 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.298 0.639 . . . . 0.0 111.953 175.566 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.504 HG12 ' HA ' ' A' ' 43' ' ' THR . 18.6 m -103.57 142.59 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 O-C-N 120.942 -1.099 . . . . 0.0 110.576 175.584 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.9 pttt -154.65 172.58 17.65 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.664 0.786 . . . . 0.0 112.011 176.269 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -104.64 116.6 32.33 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 125.727 1.611 . . . . 0.0 110.177 175.032 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.9 p -125.98 137.73 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 C-N-CA 124.262 1.025 . . . . 0.0 109.965 174.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.81 28.86 2.05 Favored 'General case' 0 CA--C 1.556 1.193 0 C-N-CA 125.182 1.393 . . . . 0.0 114.69 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.94 27.94 48.01 Favored Glycine 0 CA--C 1.541 1.701 0 C-N-CA 124.936 1.255 . . . . 0.0 115.144 -174.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.96 115.53 11.28 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 125.577 1.551 . . . . 0.0 111.856 -176.636 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -98.45 111.02 23.51 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 126.104 1.762 . . . . 0.0 111.356 -176.477 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.601 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -155.36 172.82 17.56 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.401 0.68 . . . . 0.0 111.655 -179.425 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.504 ' HA ' HG12 ' A' ' 34' ' ' VAL . 6.0 m -73.64 116.29 14.06 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.248 1.019 . . . . 0.0 111.116 175.441 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -108.94 113.21 25.91 Favored 'General case' 0 N--CA 1.467 0.394 0 O-C-N 121.221 -0.924 . . . . 0.0 109.612 176.612 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.57 HG21 ' HE3' ' A' ' 70' ' ' LYS . 19.3 m -73.2 146.56 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 123.3 0.64 . . . . 0.0 110.452 176.654 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 3.7 m -126.58 109.93 12.67 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 122.623 1.201 . . . . 0.0 110.243 176.12 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' MET . . . . . 0.461 ' HG2' HG11 ' A' ' 19' ' ' VAL . 1.6 mpp? -112.91 165.43 12.34 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.274 1.43 . . . . 0.0 110.483 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 26.8 ptt180 -142.75 117.29 9.72 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 124.835 1.254 . . . . 0.0 110.079 179.295 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 8.7 ttp180 -74.46 109.07 7.64 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.333 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -70.23 -14.32 62.56 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 178.624 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -57.58 -39.91 77.84 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 126.204 1.802 . . . . 0.0 112.791 176.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.63 -20.94 3.51 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 126.346 1.858 . . . . 0.0 114.75 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.12 14.49 51.46 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 125.104 1.335 . . . . 0.0 115.199 -174.71 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -76.85 163.34 26.86 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-N 118.85 1.325 . . . . 0.0 112.597 175.327 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 33.6 m -108.57 147.66 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.586 1.154 . . . . 0.0 110.344 174.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.2 t -138.53 112.72 8.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 C-N-CA 125.403 1.481 . . . . 0.0 107.699 -178.55 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.24 132.02 53.03 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 123.689 0.795 . . . . 0.0 111.89 178.445 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.449 ' O ' HG22 ' A' ' 45' ' ' VAL . 33.4 m -139.9 157.38 69.66 Favored Pre-proline 0 N--CA 1.473 0.681 0 C-N-CA 124.164 0.985 . . . . 0.0 112.088 -178.528 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.601 ' CB ' HD11 ' A' ' 42' ' ' LEU . 55.5 Cg_endo -77.95 116.28 3.94 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 123.705 2.937 . . . . 0.0 114.576 175.379 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -64.35 -33.74 76.55 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 120.327 -1.483 . . . . 0.0 114.284 178.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.64 6.7 80.08 Favored Glycine 0 N--CA 1.475 1.275 0 O-C-N 121.264 -0.897 . . . . 0.0 114.64 176.06 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 30.5 tttt -137.57 3.11 2.51 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 125.34 1.456 . . . . 0.0 113.194 -177.853 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.411 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.2 m -49.55 -29.22 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.631 1.572 . . . . 0.0 113.282 176.122 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 12.4 mt -56.08 -29.55 60.71 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.172 1.789 . . . . 0.0 112.574 176.619 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.6 -50.88 12.73 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.891 1.676 . . . . 0.0 112.98 175.35 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.8 mp -65.41 -33.2 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 C-N-CA 124.117 0.967 . . . . 0.0 111.537 178.147 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 87.4 0.2 84.84 Favored Glycine 0 CA--C 1.536 1.364 0 C-N-CA 125.623 1.582 . . . . 0.0 113.97 -175.053 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.402 HG13 HG12 ' A' ' 63' ' ' VAL . 7.7 p -73.53 123.15 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 124.588 1.155 . . . . 0.0 110.338 174.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -106.07 109.29 21.18 Favored 'General case' 0 N--CA 1.473 0.709 0 O-C-N 121.071 -1.018 . . . . 0.0 108.789 175.174 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.57 ' HE3' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.469 0.478 0 C-N-CA 123.642 0.777 . . . . 0.0 110.177 178.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.469 HD22 ' HB3' ' A' ' 17' ' ' ASP . 9.7 mt . . . . . 0 CA--C 1.537 0.446 0 CA-C-O 121.588 0.708 . . . . 0.0 112.53 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -125.62 166.5 16.61 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.981 1.712 . . . . 0.0 111.122 176.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 75.2 t -67.93 131.87 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 123.628 0.771 . . . . 0.0 110.135 175.147 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.03 -3.45 70.18 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 125.84 1.686 . . . . 0.0 114.737 -178.74 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.469 ' HB3' HD22 ' A' ' 13' ' ' LEU . 0.5 OUTLIER -76.63 152.15 35.94 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 119.085 1.443 . . . . 0.0 112.719 -179.29 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -86.89 135.0 33.47 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 125.453 1.501 . . . . 0.0 111.68 -177.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.477 HG23 ' HB2' ' A' ' 27' ' ' CYS . 28.3 m -143.54 135.71 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.796 1.239 . . . . 0.0 111.167 -177.579 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.7 p -102.92 165.63 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 O-C-N 121.152 -0.967 . . . . 0.0 111.33 175.025 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -125.99 158.44 65.94 Favored Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 125.277 1.431 . . . . 0.0 111.886 175.656 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.429 ' CD ' HG12 ' A' ' 68' ' ' VAL . 58.6 Cg_endo -71.36 -40.78 2.85 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 123.328 2.685 . . . . 0.0 112.615 -178.506 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -148.75 32.37 0.78 Allowed 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.707 1.203 . . . . 0.0 112.87 -177.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -130.03 -23.11 2.79 Favored 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 125.817 1.647 . . . . 0.0 114.245 -173.883 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 104.17 168.15 24.94 Favored Glycine 0 CA--C 1.539 1.592 0 C-N-CA 126.406 1.955 . . . . 0.0 114.436 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 42.9 t -66.52 133.47 31.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 O-C-N 121.1 -1.235 . . . . 0.0 110.338 176.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.477 ' HB2' HG23 ' A' ' 19' ' ' VAL . 63.4 m -122.53 -179.85 4.35 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 126.302 1.841 . . . . 0.0 111.226 178.245 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.0 ttt180 -144.43 120.64 10.84 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 125.066 1.347 . . . . 0.0 110.562 176.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.402 HG21 HD13 ' A' ' 13' ' ' LEU . 39.7 t -57.96 126.76 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 C-N-CA 123.643 0.777 . . . . 0.0 111.089 -177.192 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.3 m -112.99 -36.46 5.1 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 124.748 1.219 . . . . 0.0 113.463 -176.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.88 159.54 41.82 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.96 1.704 . . . . 0.0 110.582 175.212 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 41.0 mt -143.81 118.19 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 124.851 1.26 . . . . 0.0 108.631 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -144.72 171.71 14.02 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 123.653 0.781 . . . . 0.0 112.003 177.33 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.41 HG12 ' HA ' ' A' ' 43' ' ' THR . 14.5 m -111.8 142.18 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 O-C-N 121.331 -0.855 . . . . 0.0 111.455 175.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.46 170.82 21.06 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 124.314 1.045 . . . . 0.0 112.122 175.407 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -102.52 118.29 36.55 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.935 1.694 . . . . 0.0 109.536 174.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.8 p -129.68 137.65 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.695 0.798 . . . . 0.0 109.691 174.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.41 29.2 1.91 Allowed 'General case' 0 CA--C 1.556 1.184 0 C-N-CA 125.17 1.388 . . . . 0.0 114.696 -176.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.2 22.2 55.16 Favored Glycine 0 CA--C 1.538 1.528 0 C-N-CA 125.131 1.348 . . . . 0.0 115.454 -177.23 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -135.97 113.5 10.85 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 119.149 1.475 . . . . 0.0 111.062 -173.38 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -96.0 114.06 25.74 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 125.541 1.536 . . . . 0.0 111.843 -176.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.597 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -158.21 173.69 16.32 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 123.437 0.695 . . . . 0.0 111.924 179.283 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.41 ' HA ' HG12 ' A' ' 34' ' ' VAL . 5.3 m -73.36 116.28 13.73 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.456 1.103 . . . . 0.0 111.165 174.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -108.75 113.13 25.84 Favored 'General case' 0 C--O 1.235 0.311 0 O-C-N 120.969 -1.082 . . . . 0.0 109.43 175.273 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.604 HG21 ' HE3' ' A' ' 70' ' ' LYS . 16.2 m -70.49 150.95 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 CA-C-N 116.242 -0.436 . . . . 0.0 109.993 175.28 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 25.4 m -126.47 128.58 47.16 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 125.252 1.421 . . . . 0.0 109.533 175.444 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.94 166.98 23.73 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 125.674 1.589 . . . . 0.0 110.599 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.23 141.31 27.27 Favored 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 124.347 1.059 . . . . 0.0 111.165 175.004 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 59.9 mtm180 -78.71 124.62 28.38 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.106 1.362 . . . . 0.0 111.059 178.54 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -63.18 -40.64 98.1 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.441 1.096 . . . . 0.0 113.237 177.825 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -87.09 -46.65 9.6 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.977 0.911 . . . . 0.0 112.666 178.176 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -71.78 -21.61 61.7 Favored 'General case' 0 N--CA 1.475 0.809 0 O-C-N 121.517 -0.739 . . . . 0.0 112.815 -177.399 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 66.26 12.47 58.23 Favored Glycine 0 CA--C 1.536 1.38 0 C-N-CA 126.062 1.791 . . . . 0.0 114.81 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -109.32 145.59 35.74 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.672 1.589 . . . . 0.0 112.56 -168.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 16.3 m -70.21 150.87 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.871 1.268 . . . . 0.0 111.837 177.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.2 t -145.21 123.67 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 125.602 1.561 . . . . 0.0 108.91 178.127 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 43.8 mtt -141.26 121.74 14.12 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 123.813 0.845 . . . . 0.0 109.845 178.009 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 26.8 m -132.67 157.48 78.21 Favored Pre-proline 0 N--CA 1.475 0.796 0 C-N-CA 124.0 0.92 . . . . 0.0 112.335 177.259 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.597 ' CB ' HD11 ' A' ' 42' ' ' LEU . 57.6 Cg_endo -77.91 114.33 3.6 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 123.546 2.831 . . . . 0.0 114.915 178.082 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -60.69 -36.51 78.95 Favored 'General case' 0 N--CA 1.476 0.828 0 O-C-N 120.346 -1.471 . . . . 0.0 114.297 178.791 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.11 5.77 78.61 Favored Glycine 0 N--CA 1.475 1.246 0 C-N-CA 124.338 0.97 . . . . 0.0 114.863 176.537 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 15.0 tttp -135.88 3.2 2.93 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.286 1.435 . . . . 0.0 113.106 -177.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.441 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.8 m -49.75 -29.87 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 125.635 1.574 . . . . 0.0 113.11 175.68 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.0 mt -57.56 -28.65 63.75 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 126.164 1.786 . . . . 0.0 112.595 176.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.03 -50.04 15.89 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 125.863 1.665 . . . . 0.0 112.605 176.078 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.437 HG22 HG13 ' A' ' 68' ' ' VAL . 4.0 mp -69.56 -33.68 58.05 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 124.15 0.98 . . . . 0.0 111.465 178.624 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.97 3.25 73.67 Favored Glycine 0 CA--C 1.537 1.466 0 C-N-CA 125.799 1.666 . . . . 0.0 114.208 -174.683 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.437 HG13 HG22 ' A' ' 66' ' ' ILE . 31.3 m -71.5 125.96 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 124.774 1.229 . . . . 0.0 110.834 177.685 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.3 mmm180 -109.72 109.34 20.01 Favored 'General case' 0 N--CA 1.474 0.769 0 O-C-N 121.076 -1.015 . . . . 0.0 108.931 175.208 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.604 ' HE3' HG21 ' A' ' 45' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.465 0.3 0 C-N-CA 125.901 1.681 . . . . 0.0 109.117 179.803 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.605 HD11 HG21 ' A' ' 29' ' ' VAL . 0.6 OUTLIER . . . . . 0 CA--C 1.544 0.746 0 CA-C-O 120.521 0.201 . . . . 0.0 111.492 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.449 ' N ' HD13 ' A' ' 13' ' ' LEU . . . -140.57 172.74 12.29 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.86 1.664 . . . . 0.0 112.382 175.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 85.2 t -59.72 131.93 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 O-C-N 120.977 -1.077 . . . . 0.0 111.095 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.52 -6.24 83.73 Favored Glycine 0 CA--C 1.535 1.332 0 C-N-CA 125.045 1.307 . . . . 0.0 114.958 -177.717 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -69.65 176.85 3.28 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-N 118.805 1.303 . . . . 0.0 112.815 175.419 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 15.8 mmt85 -119.91 134.15 55.34 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.449 1.5 . . . . 0.0 111.884 -174.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.508 ' CG1' HD21 ' A' ' 13' ' ' LEU . 17.2 m -139.35 136.92 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 125.091 1.356 . . . . 0.0 109.506 -173.721 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.6 p -137.03 139.05 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 C-N-CA 123.989 0.916 . . . . 0.0 110.118 176.503 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -69.61 160.4 79.74 Favored Pre-proline 0 CA--C 1.542 0.646 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 174.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.546 ' CD ' HG22 ' A' ' 68' ' ' VAL . 58.3 Cg_endo -68.8 -27.29 31.52 Favored 'Trans proline' 0 CA--C 1.54 0.802 0 C-N-CA 122.781 2.32 . . . . 0.0 112.326 -177.351 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 56.9 t30 -157.77 47.66 0.38 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 124.401 1.081 . . . . 0.0 113.553 177.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -137.86 -64.19 0.55 Allowed 'General case' 0 N--CA 1.481 1.099 0 O-C-N 121.155 -0.965 . . . . 0.0 112.994 -174.117 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.55 168.44 30.63 Favored Glycine 0 CA--C 1.534 1.246 0 C-N-CA 125.081 1.324 . . . . 0.0 113.398 178.25 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.3 p -77.73 146.83 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 124.891 1.277 . . . . 0.0 111.411 175.062 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.484 ' SG ' HG11 ' A' ' 56' ' ' VAL . 3.7 m -130.36 173.83 10.43 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.568 1.547 . . . . 0.0 111.271 175.761 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.11 117.78 17.92 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.552 1.541 . . . . 0.0 110.909 -176.135 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.605 HG21 HD11 ' A' ' 13' ' ' LEU . 25.4 t -65.95 116.09 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.078 1.351 . . . . 0.0 111.124 -177.665 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.3 m -107.62 -47.85 3.54 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.852 1.261 . . . . 0.0 112.34 -176.318 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -148.8 169.71 19.87 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.334 1.854 . . . . 0.0 110.403 178.185 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 48.8 mt -147.28 140.36 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.054 1.342 . . . . 0.0 108.266 175.908 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.34 173.65 11.3 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.106 0.962 . . . . 0.0 112.313 175.706 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.468 HG12 ' HA ' ' A' ' 43' ' ' THR . 28.9 m -123.26 140.77 45.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 124.711 1.204 . . . . 0.0 110.728 177.635 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -155.53 167.42 30.44 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 123.935 0.894 . . . . 0.0 112.385 177.209 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -100.56 119.79 39.06 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.349 1.459 . . . . 0.0 108.745 174.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.0 p -127.33 136.8 59.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.851 1.261 . . . . 0.0 109.058 175.062 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.85 28.95 1.48 Allowed 'General case' 0 CA--C 1.557 1.233 0 N-CA-C 114.882 1.438 . . . . 0.0 114.882 -178.003 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.06 26.51 48.54 Favored Glycine 0 CA--C 1.542 1.72 0 C-N-CA 124.822 1.201 . . . . 0.0 115.363 -176.393 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -137.57 116.98 12.79 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 126.229 1.811 . . . . 0.0 110.835 -175.459 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -96.3 118.94 33.87 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 125.338 1.455 . . . . 0.0 111.105 179.85 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.503 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.9 OUTLIER -155.16 172.63 17.84 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 123.432 0.693 . . . . 0.0 111.892 -179.623 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.468 ' HA ' HG12 ' A' ' 34' ' ' VAL . 48.2 m -82.25 116.41 21.77 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.078 1.351 . . . . 0.0 111.943 176.61 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -102.2 113.17 26.22 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.483 1.113 . . . . 0.0 109.529 174.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.0 m -63.04 148.1 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 O-C-N 121.895 -0.503 . . . . 0.0 110.812 174.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 1.5 m -126.61 109.85 12.56 Favored 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 122.09 0.948 . . . . 0.0 110.605 176.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' MET . . . . . 0.455 ' HB2' HG13 ' A' ' 56' ' ' VAL . 2.4 mpp? -123.58 160.17 27.64 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 124.055 0.942 . . . . 0.0 110.239 -178.139 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.469 ' HG3' HG12 ' A' ' 55' ' ' VAL . 1.1 mpt_? -130.91 125.06 32.51 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 123.843 0.857 . . . . 0.0 110.831 174.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 79.4 mtm180 -83.38 109.02 16.96 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 125.355 1.462 . . . . 0.0 108.462 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -65.62 -18.09 65.07 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.865 0.866 . . . . 0.0 112.494 177.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 31.0 tt0 -57.54 -39.22 76.16 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.622 1.969 . . . . 0.0 113.225 177.619 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -128.62 1.73 5.52 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 125.011 1.324 . . . . 0.0 113.645 177.109 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.79 11.77 60.98 Favored Glycine 0 CA--C 1.538 1.476 0 C-N-CA 125.427 1.489 . . . . 0.0 114.306 -171.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -81.04 159.01 24.91 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.489 1.516 . . . . 0.0 112.566 -176.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.469 HG12 ' HG3' ' A' ' 48' ' ' ARG . 20.4 m -97.95 162.05 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 123.481 0.712 . . . . 0.0 110.601 175.033 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.484 HG11 ' SG ' ' A' ' 27' ' ' CYS . 3.9 p -151.95 122.05 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 125.347 1.459 . . . . 0.0 109.111 174.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 19.3 ptm -125.93 135.26 51.68 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 125.076 1.35 . . . . 0.0 110.608 175.113 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.2 m -137.58 154.24 74.88 Favored Pre-proline 0 N--CA 1.468 0.454 0 C-N-CA 123.819 0.847 . . . . 0.0 111.253 175.18 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.503 ' CB ' HD11 ' A' ' 42' ' ' LEU . 44.2 Cg_endo -75.51 117.24 4.73 Favored 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 123.271 2.648 . . . . 0.0 114.439 178.084 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -59.65 -40.53 87.97 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.61 7.31 79.86 Favored Glycine 0 N--CA 1.474 1.173 0 C-N-CA 124.418 1.009 . . . . 0.0 114.588 178.019 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.2 tttm -133.7 3.4 3.53 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.203 1.401 . . . . 0.0 113.509 -178.55 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.5 m -48.75 -28.87 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.933 1.293 . . . . 0.0 113.598 175.007 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.3 mt -57.31 -29.09 63.63 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.989 1.715 . . . . 0.0 112.61 177.276 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.05 -50.61 15.9 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 125.64 1.576 . . . . 0.0 112.673 175.631 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.463 HG22 HG23 ' A' ' 68' ' ' VAL . 3.9 mp -68.75 -33.55 60.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 124.244 1.018 . . . . 0.0 111.435 178.767 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.7 2.19 79.23 Favored Glycine 0 CA--C 1.537 1.415 0 C-N-CA 125.844 1.688 . . . . 0.0 114.349 -175.198 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.546 HG22 ' CD ' ' A' ' 22' ' ' PRO . 71.6 t -80.69 123.16 37.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 CA-C-N 118.96 1.38 . . . . 0.0 110.472 178.273 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 3.3 mmt180 -99.58 109.24 21.76 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 174.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.472 0.651 0 C-N-CA 125.527 1.531 . . . . 0.0 109.352 176.521 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.541 0.63 0 CA-C-O 121.074 0.464 . . . . 0.0 111.836 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -140.06 172.91 12.08 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.017 1.327 . . . . 0.0 112.559 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.3 t -60.22 126.37 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.123 0.969 . . . . 0.0 110.475 177.203 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.23 -8.36 72.48 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.051 1.31 . . . . 0.0 114.856 -177.468 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -72.2 169.53 15.94 Favored 'General case' 0 CA--C 1.55 0.973 0 CA-C-N 119.215 1.507 . . . . 0.0 111.056 174.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -88.3 159.26 18.16 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.614 1.566 . . . . 0.0 112.018 175.501 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.44 HG13 ' HB2' ' A' ' 27' ' ' CYS . 1.5 p -150.86 130.14 3.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 C-N-CA 124.739 1.216 . . . . 0.0 110.134 175.216 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.2 p -137.19 142.59 36.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 C-N-CA 125.995 1.718 . . . . 0.0 107.903 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.419 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.4 OUTLIER -88.46 161.97 40.94 Favored Pre-proline 0 CA--C 1.545 0.765 0 C-N-CA 124.685 1.194 . . . . 0.0 110.965 175.784 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.67 -26.66 27.77 Favored 'Trans proline' 0 CA--C 1.536 0.59 0 C-N-CA 123.439 2.759 . . . . 0.0 112.37 -175.18 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -158.15 62.77 0.45 Allowed 'General case' 0 CA--C 1.551 1.013 0 C-N-CA 125.863 1.665 . . . . 0.0 111.57 176.011 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -146.43 -61.88 0.31 Allowed 'General case' 0 N--CA 1.481 1.084 0 O-C-N 121.085 -1.009 . . . . 0.0 112.463 179.147 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 158.67 -179.42 34.35 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 124.661 1.124 . . . . 0.0 113.422 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.3 m -81.87 147.8 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.542 1.537 . . . . 0.0 112.037 175.518 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.44 ' HB2' HG13 ' A' ' 19' ' ' VAL . 97.7 m -138.18 179.62 6.34 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.856 2.062 . . . . 0.0 109.851 179.027 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.01 135.6 39.61 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 125.102 1.361 . . . . 0.0 110.462 175.245 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -66.54 129.99 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 C-N-CA 123.95 0.9 . . . . 0.0 110.401 175.074 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -115.06 -51.69 2.71 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.622 1.169 . . . . 0.0 111.759 -178.21 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.73 164.54 37.57 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.849 1.66 . . . . 0.0 110.875 175.571 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 64.2 mt -144.9 134.45 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 O-C-N 120.752 -1.217 . . . . 0.0 108.756 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -143.53 174.09 11.07 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.355 1.062 . . . . 0.0 112.162 176.856 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.4 p -124.75 137.89 55.94 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 125.168 1.387 . . . . 0.0 110.842 177.378 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 13.2 ptmt -150.74 153.4 35.44 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 124.961 1.304 . . . . 0.0 112.088 178.452 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -81.05 115.18 20.38 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 123.787 0.835 . . . . 0.0 108.924 174.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.6 p -118.6 133.36 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 124.311 1.044 . . . . 0.0 109.653 174.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.54 29.01 2.74 Favored 'General case' 0 CA--C 1.557 1.227 0 N-CA-C 114.772 1.397 . . . . 0.0 114.772 -178.141 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.43 20.42 56.74 Favored Glycine 0 CA--C 1.538 1.529 0 C-N-CA 124.854 1.216 . . . . 0.0 115.422 -175.664 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -142.87 114.11 7.81 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.491 1.516 . . . . 0.0 111.814 -176.098 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 5.1 ptmt -91.77 133.96 35.16 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.721 1.208 . . . . 0.0 111.656 175.007 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.645 HD11 ' CB ' ' A' ' 59' ' ' PRO . 1.3 pp -160.05 163.58 33.84 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.266 1.026 . . . . 0.0 110.483 176.075 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.0 m -66.39 116.49 7.46 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 121.279 -0.888 . . . . 0.0 110.986 178.012 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -104.91 113.3 26.82 Favored 'General case' 0 N--CA 1.467 0.407 0 O-C-N 120.748 -1.22 . . . . 0.0 109.409 175.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.2 m -75.73 143.68 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-O 119.035 -0.507 . . . . 0.0 110.19 177.042 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -125.82 112.86 16.51 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 122.41 1.1 . . . . 0.0 110.918 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -122.73 165.74 16.07 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.897 1.279 . . . . 0.0 109.647 -176.033 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.5 mtt180 -134.98 160.79 37.2 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 124.425 1.09 . . . . 0.0 110.589 175.141 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -122.28 109.1 14.03 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 125.733 1.613 . . . . 0.0 109.463 174.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -64.86 -17.66 64.48 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 113.331 0.863 . . . . 0.0 113.331 176.206 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -54.63 -44.37 73.1 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 127.199 2.2 . . . . 0.0 112.451 178.358 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -126.19 -1.29 7.05 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.47 1.908 . . . . 0.0 112.494 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.62 34.31 88.61 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 125.157 1.361 . . . . 0.0 113.552 -174.066 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.59 165.61 10.95 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 124.252 1.021 . . . . 0.0 112.145 -176.233 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.5 m -110.28 155.78 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.013 1.325 . . . . 0.0 111.265 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 3.7 p -151.05 125.83 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 124.713 1.205 . . . . 0.0 109.405 175.695 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 22.8 ptt? -130.21 137.81 50.26 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 123.9 0.88 . . . . 0.0 110.803 175.024 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.461 ' CG2' ' HE2' ' A' ' 70' ' ' LYS . 14.0 m -140.24 157.34 69.01 Favored Pre-proline 0 N--CA 1.474 0.731 0 C-N-CA 123.584 0.754 . . . . 0.0 111.414 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.645 ' CB ' HD11 ' A' ' 42' ' ' LEU . 53.7 Cg_endo -75.59 116.03 4.37 Favored 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 123.726 2.95 . . . . 0.0 114.861 176.482 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -63.97 -33.42 75.69 Favored 'General case' 0 N--CA 1.482 1.132 0 O-C-N 120.394 -1.441 . . . . 0.0 113.573 178.72 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.92 4.57 78.57 Favored Glycine 0 N--CA 1.476 1.328 0 C-N-CA 124.769 1.176 . . . . 0.0 114.686 175.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.0 tttm -136.74 3.84 2.76 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.437 1.495 . . . . 0.0 112.992 -177.207 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.2 m -50.26 -28.31 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 C-N-CA 125.731 1.613 . . . . 0.0 113.012 175.188 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.0 mt -56.02 -30.16 61.45 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 125.945 1.698 . . . . 0.0 112.385 176.479 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.53 -50.34 15.95 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 125.86 1.664 . . . . 0.0 112.828 175.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.486 HG22 HG13 ' A' ' 68' ' ' VAL . 4.0 mp -68.16 -33.38 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 124.054 0.941 . . . . 0.0 111.465 178.565 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.49 3.56 77.91 Favored Glycine 0 CA--C 1.537 1.445 0 C-N-CA 126.166 1.841 . . . . 0.0 114.605 -177.741 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.486 HG13 HG22 ' A' ' 66' ' ' ILE . 31.4 m -82.21 125.56 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 C-N-CA 126.451 1.9 . . . . 0.0 111.216 -178.5 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.69 109.25 17.92 Favored 'General case' 0 N--CA 1.475 0.782 0 O-C-N 121.252 -0.905 . . . . 0.0 110.105 177.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.461 ' HE2' ' CG2' ' A' ' 58' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.47 0.536 0 C-N-CA 123.226 0.61 . . . . 0.0 110.477 178.127 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.541 0.605 0 CA-C-O 120.438 0.161 . . . . 0.0 110.803 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -124.79 169.85 11.61 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.141 1.377 . . . . 0.0 112.316 177.193 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.42 129.11 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 O-C-N 121.414 -0.803 . . . . 0.0 110.567 176.305 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.26 -6.15 75.29 Favored Glycine 0 CA--C 1.534 1.231 0 C-N-CA 125.075 1.322 . . . . 0.0 114.901 -179.347 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -68.77 176.74 2.86 Favored 'General case' 0 CA--C 1.549 0.917 0 CA-C-N 119.068 1.434 . . . . 0.0 111.883 174.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.9 mmt180 -113.08 139.57 48.59 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.564 1.545 . . . . 0.0 111.35 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.419 HG21 ' CE ' ' A' ' 47' ' ' MET . 15.1 m -139.71 137.09 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 C-N-CA 124.204 1.002 . . . . 0.0 109.477 -178.508 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.5 p -137.04 137.99 46.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 124.151 0.981 . . . . 0.0 110.085 177.826 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.465 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 1.3 m-85 -71.67 161.95 75.77 Favored Pre-proline 0 CA--C 1.546 0.826 0 N-CA-C 112.113 0.412 . . . . 0.0 112.113 175.39 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.498 ' CD ' HG12 ' A' ' 68' ' ' VAL . 59.9 Cg_endo -70.11 -28.54 23.46 Favored 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.43 2.753 . . . . 0.0 112.265 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 32.3 m-20 -157.95 64.4 0.46 Allowed 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 127.026 2.13 . . . . 0.0 111.357 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 5.4 mm-40 -151.9 -71.07 0.16 Allowed 'General case' 0 N--CA 1.479 1.021 0 O-C-N 120.794 -1.191 . . . . 0.0 111.776 174.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 173.55 174.09 40.28 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.403 1.478 . . . . 0.0 112.406 -174.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.5 p -84.39 149.3 4.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 124.949 1.299 . . . . 0.0 110.704 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.553 ' SG ' HG11 ' A' ' 56' ' ' VAL . 4.7 m -128.82 174.59 9.34 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.774 1.63 . . . . 0.0 110.52 175.069 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -131.82 118.82 20.4 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 124.004 0.922 . . . . 0.0 110.9 -178.262 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.2 t -57.82 126.88 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 C-N-CA 124.111 0.964 . . . . 0.0 110.593 -179.399 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.9 t -111.01 -51.88 2.83 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 125.135 1.374 . . . . 0.0 110.984 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.81 169.87 21.72 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 124.861 1.265 . . . . 0.0 111.064 177.522 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 62.0 mt -145.2 138.68 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 124.722 1.209 . . . . 0.0 108.457 175.042 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -150.26 167.0 28.24 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 124.853 1.261 . . . . 0.0 112.158 175.482 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 13.8 m -106.77 143.09 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.109 0.964 . . . . 0.0 110.908 176.002 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -155.25 170.82 20.97 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 124.623 1.169 . . . . 0.0 111.795 175.423 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -106.28 116.22 31.57 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.949 1.699 . . . . 0.0 109.697 175.001 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.8 p -125.62 138.03 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 C-N-CA 124.462 1.105 . . . . 0.0 110.725 174.857 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.53 29.09 1.95 Allowed 'General case' 0 CA--C 1.556 1.208 0 C-N-CA 124.856 1.262 . . . . 0.0 114.26 -179.019 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.35 27.04 53.36 Favored Glycine 0 CA--C 1.54 1.604 0 C-N-CA 125.2 1.381 . . . . 0.0 115.613 -174.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.8 tp60 -135.14 113.54 11.48 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.761 1.624 . . . . 0.0 110.436 -175.604 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 18.6 tttt -96.28 114.86 26.58 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 124.899 1.28 . . . . 0.0 111.25 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.5 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -157.59 173.07 17.42 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 123.155 0.582 . . . . 0.0 111.765 179.532 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 17.2 m -79.73 116.58 19.99 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.367 1.067 . . . . 0.0 111.595 175.04 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -102.38 114.5 28.73 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.03 0.932 . . . . 0.0 109.763 175.028 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.513 HG13 ' CG ' ' A' ' 60' ' ' GLU . 5.7 m -66.87 145.27 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 O-C-N 121.863 -0.523 . . . . 0.0 110.783 174.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -126.65 109.8 12.49 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.532 1.133 . . . . 0.0 111.109 -179.445 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' MET . . . . . 0.439 ' HB2' HG13 ' A' ' 56' ' ' VAL . 1.8 mpp? -123.22 160.72 25.99 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 124.229 1.011 . . . . 0.0 110.546 -177.144 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.605 ' HG3' HG12 ' A' ' 55' ' ' VAL . 0.1 OUTLIER -134.64 134.03 40.74 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.875 0.87 . . . . 0.0 110.905 174.859 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 60.9 mtm180 -94.27 108.76 20.62 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 124.824 1.25 . . . . 0.0 108.209 176.303 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -69.53 -17.78 63.61 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.343 1.057 . . . . 0.0 113.562 175.307 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -55.49 -42.12 73.98 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 126.032 1.733 . . . . 0.0 112.538 178.338 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -121.97 -20.25 6.39 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 125.474 1.509 . . . . 0.0 113.387 177.828 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.47 49.15 4.5 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 125.305 1.431 . . . . 0.0 113.122 -177.671 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -125.37 159.98 30.47 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.097 1.359 . . . . 0.0 112.163 178.789 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.605 HG12 ' HG3' ' A' ' 48' ' ' ARG . 27.1 m -98.41 158.62 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.431 1.092 . . . . 0.0 111.117 176.288 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.553 HG11 ' SG ' ' A' ' 27' ' ' CYS . 3.4 p -150.17 122.86 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 125.271 1.428 . . . . 0.0 109.324 175.098 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.0 ptm -126.9 139.44 53.07 Favored 'General case' 0 C--O 1.233 0.211 0 C-N-CA 124.098 0.959 . . . . 0.0 111.018 175.706 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 27.0 m -142.82 154.73 62.75 Favored Pre-proline 0 N--CA 1.468 0.473 0 C-N-CA 123.986 0.914 . . . . 0.0 111.469 177.385 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.5 ' CB ' HD11 ' A' ' 42' ' ' LEU . 43.6 Cg_endo -74.8 119.92 5.9 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.156 2.571 . . . . 0.0 114.381 177.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.513 ' CG ' HG13 ' A' ' 45' ' ' VAL . 14.1 mt-10 -62.09 -39.93 94.11 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 178.818 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.27 7.71 78.01 Favored Glycine 0 N--CA 1.475 1.273 0 C-N-CA 124.677 1.132 . . . . 0.0 114.762 178.624 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 7.9 tttt -135.53 5.56 3.19 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.775 1.63 . . . . 0.0 112.451 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.462 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -49.65 -29.36 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 C-N-CA 125.329 1.452 . . . . 0.0 113.476 174.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 11.4 mt -58.01 -28.68 64.67 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.003 1.721 . . . . 0.0 112.286 177.178 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.42 -51.01 14.07 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.834 1.653 . . . . 0.0 112.218 177.202 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.485 HG22 HG13 ' A' ' 68' ' ' VAL . 4.5 mp -67.53 -29.47 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 124.375 1.07 . . . . 0.0 111.216 176.479 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 84.61 8.39 83.06 Favored Glycine 0 CA--C 1.536 1.358 0 C-N-CA 125.815 1.674 . . . . 0.0 114.069 -176.304 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.498 HG12 ' CD ' ' A' ' 22' ' ' PRO . 17.0 m -90.84 123.32 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 125.373 1.469 . . . . 0.0 111.345 -175.302 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.35 109.6 21.51 Favored 'General case' 0 N--CA 1.469 0.507 0 O-C-N 120.881 -1.137 . . . . 0.0 109.434 178.224 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.468 0.427 0 C-N-CA 123.989 0.916 . . . . 0.0 109.06 177.271 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.557 HD11 HG21 ' A' ' 29' ' ' VAL . 0.3 OUTLIER . . . . . 0 CA--C 1.54 0.566 0 CA-C-O 120.567 0.222 . . . . 0.0 111.1 . . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.0 177.28 8.16 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.711 1.604 . . . . 0.0 112.184 176.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.8 t -59.69 129.3 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.175 0.99 . . . . 0.0 110.777 175.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.66 -4.68 85.76 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 124.835 1.207 . . . . 0.0 115.151 -177.633 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -70.83 165.75 22.5 Favored 'General case' 0 CA--C 1.549 0.916 0 CA-C-N 119.211 1.506 . . . . 0.0 111.613 174.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -89.56 148.73 23.21 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.902 0.881 . . . . 0.0 111.883 177.232 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.8 m -147.48 138.88 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 125.976 1.71 . . . . 0.0 109.184 176.266 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.0 p -137.11 146.33 28.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 C-N-CA 124.741 1.216 . . . . 0.0 110.483 176.273 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.5 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.8 OUTLIER -84.19 158.77 60.69 Favored Pre-proline 0 CA--C 1.548 0.867 0 C-N-CA 123.409 0.684 . . . . 0.0 111.959 175.168 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.433 ' CD ' HG12 ' A' ' 68' ' ' VAL . 71.6 Cg_endo -68.69 -25.91 33.59 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 123.809 3.006 . . . . 0.0 112.993 -178.535 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -160.2 62.62 0.34 Allowed 'General case' 0 CA--C 1.554 1.118 0 C-N-CA 124.764 1.226 . . . . 0.0 112.316 177.219 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.86 -68.53 0.17 Allowed 'General case' 0 N--CA 1.48 1.053 0 O-C-N 120.988 -1.07 . . . . 0.0 112.222 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.42 179.82 43.5 Favored Glycine 0 CA--C 1.534 1.221 0 C-N-CA 125.04 1.305 . . . . 0.0 113.215 -174.36 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.7 m -94.94 149.96 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.466 1.506 . . . . 0.0 111.38 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.4 m -133.85 -177.85 4.75 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 124.622 1.169 . . . . 0.0 111.544 174.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -137.85 124.59 21.08 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.365 1.466 . . . . 0.0 111.749 177.236 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.557 HG21 HD11 ' A' ' 13' ' ' LEU . 61.1 t -63.47 126.74 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.036 0 C-N-CA 124.735 1.214 . . . . 0.0 111.173 -177.307 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 21.6 t -109.37 -53.92 2.6 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.049 1.34 . . . . 0.0 111.869 -177.092 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -151.68 162.02 41.7 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.142 1.377 . . . . 0.0 111.042 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -141.44 136.53 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 124.649 1.18 . . . . 0.0 108.55 -179.408 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -144.42 172.1 13.42 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 123.942 0.897 . . . . 0.0 111.773 177.226 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.3 p -120.54 138.29 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 O-C-N 120.691 -1.256 . . . . 0.0 110.758 175.564 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.89 164.29 36.66 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.175 1.39 . . . . 0.0 111.543 178.602 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -97.48 118.88 34.96 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 125.204 1.401 . . . . 0.0 109.77 174.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.3 p -123.54 135.47 63.22 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 124.303 1.041 . . . . 0.0 109.783 174.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.09 29.13 2.35 Favored 'General case' 0 CA--C 1.557 1.245 0 N-CA-C 114.625 1.343 . . . . 0.0 114.625 -177.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.01 25.28 52.9 Favored Glycine 0 CA--C 1.54 1.646 0 C-N-CA 124.787 1.184 . . . . 0.0 115.188 -176.184 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -139.44 116.78 11.24 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.35 1.46 . . . . 0.0 111.175 -174.778 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 3.5 tttt -95.21 124.81 39.45 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 124.83 1.252 . . . . 0.0 111.656 -178.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.613 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -158.17 162.97 37.97 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 123.033 0.533 . . . . 0.0 111.697 179.428 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.3 m -69.37 116.43 9.79 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 124.192 0.997 . . . . 0.0 111.147 177.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -105.2 113.14 26.56 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 124.875 1.27 . . . . 0.0 110.068 175.42 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.532 HG21 ' CD ' ' A' ' 70' ' ' LYS . 30.1 m -81.42 144.06 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.838 177.823 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 26.2 m -126.55 117.12 22.17 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.277 1.031 . . . . 0.0 110.735 178.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 1.5 mpp? -119.15 156.17 30.28 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 124.818 1.247 . . . . 0.0 110.116 -176.591 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -132.09 136.35 47.11 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.184 1.394 . . . . 0.0 110.259 -178.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 13.0 mtm180 -98.36 109.12 21.93 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 177.076 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -70.28 -15.46 62.9 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 123.239 0.616 . . . . 0.0 112.557 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -57.57 -42.18 82.56 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 126.779 2.031 . . . . 0.0 112.961 176.549 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -128.66 -15.41 4.45 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 124.874 1.27 . . . . 0.0 114.111 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.23 4.99 64.11 Favored Glycine 0 CA--C 1.538 1.5 0 C-N-CA 126.105 1.812 . . . . 0.0 114.952 -177.773 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -74.07 163.47 27.84 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 118.644 1.222 . . . . 0.0 112.819 177.449 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 15.9 m -126.32 156.12 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 125.592 1.557 . . . . 0.0 110.727 174.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 23.3 m -140.13 150.94 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 125.951 1.701 . . . . 0.0 109.898 176.073 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 62.9 ttp -145.03 122.08 11.4 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.791 0.836 . . . . 0.0 110.139 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.6 m -130.4 155.14 81.45 Favored Pre-proline 0 N--CA 1.476 0.84 0 C-N-CA 124.034 0.934 . . . . 0.0 112.17 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.613 ' CB ' HD11 ' A' ' 42' ' ' LEU . 52.3 Cg_endo -76.05 115.82 4.24 Favored 'Trans proline' 0 CA--C 1.538 0.698 0 C-N-CA 123.486 2.791 . . . . 0.0 114.438 176.742 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -64.63 -34.02 77.29 Favored 'General case' 0 N--CA 1.479 0.992 0 O-C-N 120.335 -1.478 . . . . 0.0 114.013 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.23 5.06 78.03 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 124.403 1.001 . . . . 0.0 114.876 176.32 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.6 tttm -135.57 3.34 3.03 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.493 1.517 . . . . 0.0 112.922 -177.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.43 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.6 m -49.7 -29.53 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 C-N-CA 125.685 1.594 . . . . 0.0 113.308 175.612 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.6 mt -57.62 -28.9 64.08 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.093 1.757 . . . . 0.0 112.302 177.433 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.81 -49.92 16.65 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.974 1.709 . . . . 0.0 112.854 175.78 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.432 HG22 HG13 ' A' ' 68' ' ' VAL . 3.8 mp -67.85 -33.21 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 124.013 0.925 . . . . 0.0 111.37 177.723 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 91.68 3.68 68.43 Favored Glycine 0 CA--C 1.537 1.434 0 C-N-CA 125.776 1.655 . . . . 0.0 114.239 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.5 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 29.1 m -87.47 123.18 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.045 1.338 . . . . 0.0 110.616 -176.461 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -104.46 109.28 21.1 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 120.625 -1.297 . . . . 0.0 108.652 176.592 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.532 ' CD ' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.468 0.475 0 C-N-CA 123.1 0.56 . . . . 0.0 109.532 177.397 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.641 HD13 ' HE2' ' A' ' 70' ' ' LYS . 1.4 tt . . . . . 0 CA--C 1.548 0.891 0 CA-C-O 120.827 0.346 . . . . 0.0 111.671 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -143.77 177.36 8.57 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 125.544 1.538 . . . . 0.0 112.214 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 97.5 t -60.02 130.96 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 O-C-N 121.082 -1.012 . . . . 0.0 110.796 178.049 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.32 -2.57 88.06 Favored Glycine 0 CA--C 1.537 1.455 0 C-N-CA 124.809 1.195 . . . . 0.0 115.02 -179.228 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -71.09 -179.84 2.5 Favored 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.22 1.408 . . . . 0.0 112.539 176.095 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 26.7 mmt180 -112.44 154.08 26.37 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 124.953 1.301 . . . . 0.0 112.966 -178.333 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.4 p -152.63 126.83 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 125.77 1.628 . . . . 0.0 110.493 -179.073 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.0 p -135.6 120.08 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 C-N-CA 126.79 2.036 . . . . 0.0 110.486 174.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 -58.65 156.61 22.9 Favored Pre-proline 0 CA--C 1.544 0.74 0 O-C-N 121.055 -1.028 . . . . 0.0 112.281 175.487 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.423 ' CD ' HG22 ' A' ' 68' ' ' VAL . 60.0 Cg_endo -67.16 -24.59 44.25 Favored 'Trans proline' 0 CA--C 1.539 0.77 0 C-N-CA 122.716 2.277 . . . . 0.0 112.52 -176.312 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -157.78 62.48 0.47 Allowed 'General case' 0 CA--C 1.555 1.149 0 C-N-CA 124.809 1.244 . . . . 0.0 112.444 175.528 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.9 mm-40 -150.24 -66.37 0.2 Allowed 'General case' 0 N--CA 1.483 1.189 0 O-C-N 120.841 -1.162 . . . . 0.0 112.451 179.362 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 166.01 175.17 36.19 Favored Glycine 0 CA--C 1.533 1.198 0 C-N-CA 124.929 1.252 . . . . 0.0 113.451 -178.074 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 38.4 t -93.42 145.64 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 125.929 1.692 . . . . 0.0 110.818 -177.633 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.3 m -130.34 178.41 6.61 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 126.503 1.921 . . . . 0.0 111.116 174.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.3 130.48 44.55 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.128 1.771 . . . . 0.0 110.658 -179.304 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.402 HG21 HD21 ' A' ' 13' ' ' LEU . 35.7 t -68.05 125.47 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 124.61 1.164 . . . . 0.0 110.903 178.355 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.9 p -109.3 -41.16 4.72 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.728 0.811 . . . . 0.0 112.776 178.405 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -160.5 173.3 15.77 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 126.746 2.018 . . . . 0.0 110.659 175.754 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.432 HD11 HD23 ' A' ' 13' ' ' LEU . 64.2 mt -146.88 139.87 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.311 1.444 . . . . 0.0 108.728 174.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -146.62 172.72 13.17 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.803 1.241 . . . . 0.0 112.116 174.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.43 HG12 ' HA ' ' A' ' 43' ' ' THR . 20.6 m -115.81 142.63 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.344 1.058 . . . . 0.0 110.523 176.44 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -157.89 171.95 19.35 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.895 0.878 . . . . 0.0 112.18 176.663 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.61 115.17 29.93 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.906 1.682 . . . . 0.0 110.464 174.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 m -121.97 138.72 51.28 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 124.811 1.244 . . . . 0.0 109.092 174.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 46.06 28.99 0.7 Allowed 'General case' 0 CA--C 1.559 1.317 0 N-CA-C 115.391 1.626 . . . . 0.0 115.391 179.558 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.11 24.22 52.77 Favored Glycine 0 CA--C 1.544 1.895 0 C-N-CA 124.892 1.234 . . . . 0.0 115.88 -175.805 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 7.4 tp60 -135.39 113.52 11.29 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.593 1.957 . . . . 0.0 110.268 -174.305 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -95.37 113.38 25.04 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 125.121 1.369 . . . . 0.0 111.218 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.557 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -156.19 173.65 16.53 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.375 0.67 . . . . 0.0 112.049 179.537 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.43 ' HA ' HG12 ' A' ' 34' ' ' VAL . 10.0 m -76.88 116.37 17.49 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 124.338 1.055 . . . . 0.0 111.895 175.309 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -106.54 115.33 30.01 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.971 1.308 . . . . 0.0 109.222 175.248 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.694 HG11 ' HE3' ' A' ' 70' ' ' LYS . 13.6 m -63.94 153.5 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 O-C-N 121.877 -0.514 . . . . 0.0 111.609 176.001 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 10.9 m -126.48 109.82 12.61 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 122.137 0.97 . . . . 0.0 111.043 175.817 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' MET . . . . . 0.534 ' HB2' HG13 ' A' ' 56' ' ' VAL . 0.2 OUTLIER -128.89 155.77 44.74 Favored 'General case' 0 C--O 1.236 0.38 0 C-N-CA 124.703 1.201 . . . . 0.0 109.865 -178.704 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -131.08 125.54 33.44 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.893 1.277 . . . . 0.0 110.183 176.349 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.0 ttm-85 -85.08 109.06 17.96 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.524 1.13 . . . . 0.0 109.123 175.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.68 -15.38 63.16 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 176.849 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -62.23 -35.46 78.97 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.18 1.792 . . . . 0.0 112.779 -177.558 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 29.8 p30 -128.63 -16.68 4.23 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 126.637 1.975 . . . . 0.0 114.129 175.053 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.65 4.66 63.64 Favored Glycine 0 CA--C 1.538 1.49 0 C-N-CA 126.137 1.827 . . . . 0.0 115.086 -177.71 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -77.1 168.9 19.29 Favored 'General case' 0 CA--C 1.546 0.798 0 CA-C-N 119.387 1.594 . . . . 0.0 113.149 178.897 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 m -111.48 157.59 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 125.092 1.357 . . . . 0.0 111.138 175.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.534 HG13 ' HB2' ' A' ' 47' ' ' MET . 4.4 p -147.48 118.86 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 124.517 1.127 . . . . 0.0 110.017 179.725 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -132.93 97.01 3.91 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 124.822 1.249 . . . . 0.0 110.076 -178.02 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 36.0 m -99.86 157.24 34.25 Favored Pre-proline 0 N--CA 1.472 0.638 0 C-N-CA 123.369 0.668 . . . . 0.0 111.684 176.708 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.557 ' CB ' HD11 ' A' ' 42' ' ' LEU . 45.9 Cg_endo -77.22 118.75 4.77 Favored 'Trans proline' 0 CA--C 1.536 0.608 0 C-N-CA 123.488 2.792 . . . . 0.0 114.558 175.637 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.406 ' CG ' HG13 ' A' ' 45' ' ' VAL . 14.9 mt-10 -61.6 -38.98 89.59 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 120.479 -1.388 . . . . 0.0 114.22 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.14 5.97 78.57 Favored Glycine 0 N--CA 1.476 1.338 0 C-N-CA 124.723 1.154 . . . . 0.0 115.027 178.618 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 17.9 tttp -133.21 3.37 3.66 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 125.751 1.62 . . . . 0.0 112.597 -178.868 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.3 m -48.33 -29.63 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 125.428 1.491 . . . . 0.0 113.726 175.077 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 17.2 mt -54.71 -30.64 56.51 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.024 1.73 . . . . 0.0 112.492 176.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.07 -48.69 22.66 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.734 1.613 . . . . 0.0 112.872 176.582 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.445 HG22 HG23 ' A' ' 68' ' ' VAL . 4.0 mp -66.74 -32.52 58.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.431 1.093 . . . . 0.0 111.285 176.949 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 87.05 3.99 82.22 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 125.545 1.545 . . . . 0.0 114.014 -176.838 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.445 HG23 HG22 ' A' ' 66' ' ' ILE . 93.2 t -81.51 147.95 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.598 1.159 . . . . 0.0 109.888 175.727 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.73 124.54 49.89 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 104.745 -2.317 . . . . 0.0 104.745 175.008 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.694 ' HE3' HG11 ' A' ' 45' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.467 0.389 0 C-N-CA 124.497 1.119 . . . . 0.0 108.269 177.301 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.1 mm? . . . . . 0 CA--C 1.533 0.323 0 CA-C-O 121.24 0.543 . . . . 0.0 110.578 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.74 175.5 9.66 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 125.871 1.668 . . . . 0.0 111.254 179.006 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 59.7 t -58.05 129.8 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 123.811 0.844 . . . . 0.0 110.772 176.778 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.52 -5.25 85.07 Favored Glycine 0 CA--C 1.536 1.359 0 C-N-CA 125.136 1.351 . . . . 0.0 115.2 -175.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -69.72 163.28 26.03 Favored 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 119.836 1.818 . . . . 0.0 112.099 175.985 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -101.04 130.87 47.11 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.71 1.204 . . . . 0.0 111.06 -175.494 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.6 m -142.34 143.3 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.797 0.839 . . . . 0.0 110.326 -178.693 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.4 p -137.08 148.22 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 C-N-CA 124.526 1.13 . . . . 0.0 110.685 178.481 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.436 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 1.0 OUTLIER -79.15 161.13 69.23 Favored Pre-proline 0 CA--C 1.549 0.919 0 O-C-N 121.853 -0.529 . . . . 0.0 111.655 175.091 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -71.57 -22.33 24.57 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 123.312 2.675 . . . . 0.0 112.837 -177.24 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 16.2 t-20 -162.68 68.29 0.23 Allowed 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 126.273 1.829 . . . . 0.0 111.296 175.007 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -156.28 -71.83 0.11 Allowed 'General case' 0 N--CA 1.482 1.141 0 O-C-N 121.15 -0.968 . . . . 0.0 112.319 177.224 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 176.43 172.93 41.6 Favored Glycine 0 CA--C 1.534 1.222 0 C-N-CA 124.548 1.07 . . . . 0.0 113.734 -176.443 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.1 m -85.86 148.47 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 125.187 1.395 . . . . 0.0 111.231 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.404 ' SG ' HG11 ' A' ' 56' ' ' VAL . 15.6 m -137.18 171.87 13.85 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.996 1.718 . . . . 0.0 110.921 179.535 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -137.71 120.01 15.78 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 124.414 1.086 . . . . 0.0 110.596 -175.779 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -63.73 124.78 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 123.615 0.766 . . . . 0.0 111.518 -174.106 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 86.1 p -107.43 -40.95 5.21 Favored 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 -177.769 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.43 162.78 35.75 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.489 1.516 . . . . 0.0 110.839 176.127 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 67.8 mt -141.83 134.87 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.781 0 O-C-N 121.029 -1.044 . . . . 0.0 109.076 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -142.72 177.64 8.18 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 124.269 1.028 . . . . 0.0 111.854 178.017 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 p -127.31 137.09 58.8 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 C-N-CA 124.963 1.305 . . . . 0.0 110.425 176.498 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.43 165.81 32.01 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 124.698 1.199 . . . . 0.0 111.963 178.851 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -97.89 118.93 35.56 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 125.088 1.355 . . . . 0.0 109.763 174.978 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.9 p -124.43 134.9 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 C-N-CA 124.251 1.02 . . . . 0.0 109.562 175.112 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.75 29.0 2.05 Favored 'General case' 0 CA--C 1.556 1.2 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 -177.208 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.99 25.66 51.67 Favored Glycine 0 CA--C 1.541 1.708 0 C-N-CA 124.616 1.103 . . . . 0.0 115.174 -176.266 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -137.43 119.73 15.74 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 126.02 1.728 . . . . 0.0 111.053 -178.804 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 13.7 ttpt -96.12 124.34 40.08 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.636 1.175 . . . . 0.0 111.582 178.171 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.603 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -157.69 163.53 38.09 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.008 0.523 . . . . 0.0 111.805 178.771 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.8 m -68.64 116.58 9.33 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.997 0.919 . . . . 0.0 110.971 177.365 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -105.51 113.26 26.72 Favored 'General case' 0 N--CA 1.467 0.377 0 O-C-N 121.076 -1.015 . . . . 0.0 109.591 174.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.0 m -78.16 141.9 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 C-N-CA 123.486 0.714 . . . . 0.0 110.502 176.338 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 8.1 m -120.31 120.32 35.7 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.602 1.161 . . . . 0.0 109.281 176.393 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' MET . . . . . 0.446 ' HB2' HG13 ' A' ' 56' ' ' VAL . 2.1 mpp? -123.18 157.49 32.88 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 124.703 1.201 . . . . 0.0 109.736 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 31.2 mtt85 -136.58 132.56 35.3 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 124.39 1.076 . . . . 0.0 109.875 -179.41 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -93.89 109.16 20.88 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 177.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -70.32 -14.37 62.55 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 175.151 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -60.21 -36.97 78.88 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.459 1.504 . . . . 0.0 113.066 177.652 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -127.99 -23.31 3.36 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.459 1.503 . . . . 0.0 113.356 178.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 96.3 25.98 11.73 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 125.565 1.555 . . . . 0.0 114.42 -177.05 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.62 169.53 10.26 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.957 1.303 . . . . 0.0 112.752 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.7 m -124.4 154.38 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 125.255 1.422 . . . . 0.0 111.65 177.726 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.446 HG13 ' HB2' ' A' ' 47' ' ' MET . 2.8 p -151.1 123.47 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 C-N-CA 125.581 1.553 . . . . 0.0 109.689 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.9 ttt -125.83 121.21 32.61 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.625 1.17 . . . . 0.0 109.914 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 28.6 m -129.21 156.33 78.48 Favored Pre-proline 0 N--CA 1.478 0.932 0 C-N-CA 124.087 0.955 . . . . 0.0 112.112 -179.36 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.603 ' CB ' HD11 ' A' ' 42' ' ' LEU . 55.2 Cg_endo -77.84 114.58 3.66 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 123.628 2.885 . . . . 0.0 114.586 176.631 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -63.83 -33.72 76.32 Favored 'General case' 0 N--CA 1.481 1.096 0 O-C-N 120.271 -1.518 . . . . 0.0 113.957 179.422 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.19 4.43 77.53 Favored Glycine 0 N--CA 1.475 1.272 0 C-N-CA 124.459 1.028 . . . . 0.0 115.074 175.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.1 tttm -135.58 3.42 3.03 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 125.489 1.515 . . . . 0.0 112.978 -177.569 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.428 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.6 m -49.98 -30.77 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 125.598 1.559 . . . . 0.0 113.079 175.402 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.1 mt -56.51 -28.9 61.1 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.123 1.769 . . . . 0.0 112.494 177.227 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.95 -48.66 17.48 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.736 1.614 . . . . 0.0 112.66 177.223 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.442 HG22 HG13 ' A' ' 68' ' ' VAL . 2.9 mp -68.59 -30.55 47.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 124.085 0.954 . . . . 0.0 111.357 176.264 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.58 3.23 78.08 Favored Glycine 0 CA--C 1.537 1.416 0 C-N-CA 126.092 1.806 . . . . 0.0 114.309 -176.85 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.442 HG13 HG22 ' A' ' 66' ' ' ILE . 18.7 m -80.17 123.2 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.8 0 C-N-CA 125.596 1.558 . . . . 0.0 110.858 -178.541 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.66 109.39 20.97 Favored 'General case' 0 N--CA 1.472 0.653 0 O-C-N 120.847 -1.158 . . . . 0.0 108.881 175.103 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.471 0.576 0 O-C-N 121.749 -0.595 . . . . 0.0 109.76 176.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.585 HD11 HG21 ' A' ' 29' ' ' VAL . 0.8 OUTLIER . . . . . 0 CA--C 1.543 0.676 0 CA-C-O 120.644 0.259 . . . . 0.0 111.188 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -133.82 166.34 22.89 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 125.516 1.526 . . . . 0.0 112.297 179.538 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.8 t -56.65 135.76 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.399 1.08 . . . . 0.0 111.035 175.347 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.15 -13.01 60.72 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 125.635 1.588 . . . . 0.0 115.216 -176.515 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -72.88 170.0 15.66 Favored 'General case' 0 CA--C 1.549 0.921 0 CA-C-N 119.06 1.43 . . . . 0.0 111.376 175.075 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.9 mmt180 -108.56 142.81 38.45 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 126.194 1.797 . . . . 0.0 111.141 -171.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.468 HG21 ' CE ' ' A' ' 47' ' ' MET . 32.9 m -143.92 128.04 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 124.278 1.031 . . . . 0.0 111.769 -171.099 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 8.2 p -95.2 164.45 2.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 125.416 1.487 . . . . 0.0 111.052 176.092 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -137.01 156.6 75.66 Favored Pre-proline 0 CA--C 1.535 0.381 0 C-N-CA 124.571 1.148 . . . . 0.0 112.991 178.648 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.7 -28.84 30.36 Favored 'Trans proline' 0 CA--C 1.538 0.721 0 C-N-CA 123.038 2.492 . . . . 0.0 112.762 -178.427 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -151.88 54.28 0.83 Allowed 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 125.337 1.455 . . . . 0.0 111.919 178.435 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -145.01 -60.58 0.36 Allowed 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 124.332 1.053 . . . . 0.0 110.653 175.0 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 124.2 -169.4 16.28 Favored Glycine 0 CA--C 1.535 1.284 0 C-N-CA 126.413 1.958 . . . . 0.0 112.25 -173.158 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -72.42 136.51 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.642 1.177 . . . . 0.0 110.932 177.711 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 25.6 m -128.7 175.13 8.83 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 126.105 1.762 . . . . 0.0 111.777 175.229 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -130.57 119.02 21.89 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 126.242 1.817 . . . . 0.0 110.833 -179.258 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.585 HG21 HD11 ' A' ' 13' ' ' LEU . 47.5 t -64.61 127.87 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 123.691 0.796 . . . . 0.0 111.025 -178.608 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.7 p -112.5 -40.55 4.07 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.219 1.008 . . . . 0.0 112.699 -176.767 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -155.1 167.11 31.46 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.716 2.006 . . . . 0.0 110.656 175.002 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 60.7 mt -146.06 137.16 19.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.895 1.278 . . . . 0.0 108.504 176.664 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -146.02 171.92 14.15 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.01 0.924 . . . . 0.0 112.059 176.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.2 m -113.9 144.57 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.147 -0.971 . . . . 0.0 111.543 175.848 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 9.7 ptmt -156.25 171.99 19.23 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 124.854 1.262 . . . . 0.0 111.874 177.197 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -108.03 117.73 34.91 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.168 1.787 . . . . 0.0 109.79 174.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.3 p -127.67 138.21 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 124.843 1.257 . . . . 0.0 109.322 174.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.74 29.35 1.52 Allowed 'General case' 0 CA--C 1.557 1.23 0 N-CA-C 114.707 1.373 . . . . 0.0 114.707 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.0 24.39 57.84 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.281 1.42 . . . . 0.0 115.543 -176.846 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -132.55 113.54 13.19 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 126.106 1.762 . . . . 0.0 110.817 -175.501 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 67.3 tttt -95.96 114.35 26.05 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.085 1.354 . . . . 0.0 111.321 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.565 HD11 ' CB ' ' A' ' 59' ' ' PRO . 1.0 OUTLIER -157.89 173.61 16.53 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 123.066 0.547 . . . . 0.0 111.791 -179.376 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 20.1 m -79.01 116.43 19.31 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.362 1.065 . . . . 0.0 112.122 175.543 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -105.04 115.83 30.94 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.512 1.125 . . . . 0.0 109.77 175.094 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.446 HG13 ' CG ' ' A' ' 60' ' ' GLU . 15.8 m -66.24 147.53 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.382 0.673 . . . . 0.0 111.245 176.834 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 19.7 m -123.27 110.06 14.72 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.723 0.809 . . . . 0.0 109.634 177.123 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' MET . . . . . 0.468 ' CE ' HG21 ' A' ' 19' ' ' VAL . 0.0 OUTLIER -126.92 162.44 25.94 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 121.724 0.773 . . . . 0.0 110.929 178.409 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 3.0 ptt180 -144.88 116.81 8.28 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 124.801 1.24 . . . . 0.0 109.987 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 6.4 mtp85 -62.69 115.01 3.93 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 124.818 1.247 . . . . 0.0 110.602 179.327 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.2 pp20? -60.54 -36.03 77.44 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.658 0.783 . . . . 0.0 112.877 179.14 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -91.45 -46.73 7.83 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 123.889 0.875 . . . . 0.0 113.033 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -73.1 -19.41 61.16 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 113.543 0.942 . . . . 0.0 113.543 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.44 8.77 56.64 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 126.27 1.89 . . . . 0.0 115.151 -178.53 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.0 138.32 40.71 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.6 1.56 . . . . 0.0 112.246 -173.257 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 26.7 m -80.02 152.26 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 123.319 0.648 . . . . 0.0 110.023 174.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 13.6 p -145.23 138.7 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 124.514 1.125 . . . . 0.0 109.887 177.139 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 11.4 ttp -145.03 115.9 7.79 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 124.579 1.152 . . . . 0.0 110.004 -179.268 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.6 m -121.66 156.93 58.14 Favored Pre-proline 0 N--CA 1.472 0.673 0 C-N-CA 124.83 1.252 . . . . 0.0 111.27 177.021 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.565 ' CB ' HD11 ' A' ' 42' ' ' LEU . 55.8 Cg_endo -79.8 114.45 3.19 Favored 'Trans proline' 0 CA--C 1.537 0.637 0 C-N-CA 123.488 2.792 . . . . 0.0 114.954 178.616 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.446 ' CG ' HG13 ' A' ' 45' ' ' VAL . 18.9 mt-10 -58.39 -39.23 79.11 Favored 'General case' 0 N--CA 1.48 1.041 0 O-C-N 120.424 -1.422 . . . . 0.0 114.286 -178.496 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.06 7.32 78.78 Favored Glycine 0 N--CA 1.474 1.19 0 C-N-CA 124.751 1.167 . . . . 0.0 114.753 179.008 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.0 tttt -134.62 1.72 3.12 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.596 1.559 . . . . 0.0 112.888 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 59' ' ' PRO . 7.0 m -48.34 -30.74 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.593 1.557 . . . . 0.0 113.546 175.762 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.6 mt -57.66 -29.86 64.96 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 126.47 1.908 . . . . 0.0 112.735 176.887 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.99 -49.97 16.18 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.781 1.632 . . . . 0.0 112.635 176.025 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.3 mp -67.93 -32.22 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 123.66 0.784 . . . . 0.0 111.31 177.757 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.52 9.41 66.76 Favored Glycine 0 CA--C 1.534 1.256 0 C-N-CA 125.532 1.539 . . . . 0.0 113.889 -174.446 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 12.2 m -75.8 155.89 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 118.317 1.058 . . . . 0.0 110.804 177.79 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -139.91 109.69 6.36 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.881 1.272 . . . . 0.0 110.221 175.264 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.445 ' O ' ' HE3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.47 0.567 0 C-N-CA 125.454 1.502 . . . . 0.0 110.65 177.528 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 14.3 tp . . . . . 0 CA--C 1.542 0.65 0 CA-C-O 120.62 0.248 . . . . 0.0 110.887 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -148.19 177.63 9.23 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.508 1.523 . . . . 0.0 111.427 175.02 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.9 t -59.33 133.7 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 O-C-N 121.395 -0.815 . . . . 0.0 111.296 176.694 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.31 -4.48 85.54 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 124.817 1.198 . . . . 0.0 115.211 -178.584 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -71.56 178.35 3.56 Favored 'General case' 0 CA--C 1.553 1.066 0 CA-C-N 118.835 1.318 . . . . 0.0 110.906 174.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 19.2 mmt180 -98.49 151.44 20.61 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.499 1.52 . . . . 0.0 111.378 178.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.6 HG23 ' HB3' ' A' ' 70' ' ' LYS . 2.8 p -140.02 125.67 21.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 C-N-CA 124.225 1.01 . . . . 0.0 110.94 176.47 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.7 p -132.14 145.68 34.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 C-N-CA 125.59 1.556 . . . . 0.0 108.532 175.186 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -91.72 161.06 34.98 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 125.005 1.322 . . . . 0.0 111.948 175.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.34 -28.84 26.8 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.848 2.365 . . . . 0.0 111.954 -175.208 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -159.08 54.16 0.41 Allowed 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 124.311 1.044 . . . . 0.0 113.032 176.348 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -142.86 -62.25 0.42 Allowed 'General case' 0 N--CA 1.478 0.974 0 O-C-N 121.14 -0.975 . . . . 0.0 113.567 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.1 -172.52 44.44 Favored Glycine 0 CA--C 1.533 1.168 0 C-N-CA 124.291 0.948 . . . . 0.0 113.514 -176.193 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.6 p -115.68 144.5 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 126.728 2.011 . . . . 0.0 110.567 179.327 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 77.2 m -132.84 -175.02 3.64 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 126.614 1.966 . . . . 0.0 110.572 175.565 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -129.46 123.94 32.82 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 125.037 1.335 . . . . 0.0 111.198 -177.831 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.6 t -63.42 128.38 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 O-C-N 121.778 -0.576 . . . . 0.0 111.189 -177.53 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.4 t -109.92 -53.52 2.66 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.981 1.712 . . . . 0.0 111.515 -176.158 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.64 165.95 34.8 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 125.204 1.402 . . . . 0.0 111.032 174.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.4 mt -142.05 130.92 22.49 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 124.62 1.168 . . . . 0.0 108.76 178.794 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -147.73 173.93 12.29 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 123.543 0.737 . . . . 0.0 112.338 175.292 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.486 HG12 ' HA ' ' A' ' 43' ' ' THR . 25.5 m -106.72 142.21 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.984 0 O-C-N 121.022 -1.049 . . . . 0.0 110.852 176.106 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -156.14 171.63 19.82 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.986 0.914 . . . . 0.0 112.336 176.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -104.55 115.77 30.92 Favored 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 125.94 1.696 . . . . 0.0 109.704 175.201 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.1 p -127.89 138.12 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.792 0.837 . . . . 0.0 109.626 175.122 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.77 28.98 1.43 Allowed 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 114.905 1.446 . . . . 0.0 114.905 -177.22 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.49 23.98 55.02 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.235 1.398 . . . . 0.0 115.441 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -131.97 113.48 13.46 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 126.193 1.797 . . . . 0.0 109.771 -174.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 16.5 tttt -96.43 112.43 24.17 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.48 1.112 . . . . 0.0 111.635 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.609 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -157.43 173.78 16.4 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 123.407 0.683 . . . . 0.0 112.217 179.262 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.486 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.2 m -73.34 116.49 13.95 Favored 'General case' 0 N--CA 1.475 0.82 0 C-N-CA 124.724 1.209 . . . . 0.0 111.101 175.113 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -111.38 113.78 26.48 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 124.671 1.189 . . . . 0.0 110.036 177.723 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 27.4 m -75.2 145.45 10.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 123.326 0.65 . . . . 0.0 110.537 177.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 21.7 m -126.52 116.05 20.48 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 124.367 1.067 . . . . 0.0 110.948 -179.603 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' MET . . . . . 0.428 ' CE ' HG21 ' A' ' 19' ' ' VAL . 2.1 mpp? -126.32 141.94 51.72 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.097 0.959 . . . . 0.0 109.619 -175.236 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.7 mtt85 -127.58 109.65 11.92 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 125.233 1.413 . . . . 0.0 109.2 -172.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -77.32 109.11 10.94 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 56.5 mt-10 -67.05 -23.0 65.84 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.886 0.875 . . . . 0.0 112.56 178.292 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -55.81 -39.56 71.51 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.462 1.905 . . . . 0.0 113.14 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -128.55 2.94 5.56 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.598 1.559 . . . . 0.0 113.377 -179.692 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.56 17.3 64.35 Favored Glycine 0 CA--C 1.538 1.472 0 C-N-CA 126.1 1.81 . . . . 0.0 114.669 -171.415 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -75.84 165.55 24.85 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 124.903 1.281 . . . . 0.0 112.484 -178.489 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.5 m -131.61 150.83 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 124.918 1.287 . . . . 0.0 111.02 177.677 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.8 p -146.73 144.18 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 C-N-CA 125.22 1.408 . . . . 0.0 109.49 176.839 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 8.8 ttm -138.28 127.25 24.01 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.62 1.168 . . . . 0.0 108.997 174.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.8 m -129.44 156.26 78.82 Favored Pre-proline 0 N--CA 1.473 0.718 0 C-N-CA 123.576 0.751 . . . . 0.0 111.615 175.066 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.609 ' CB ' HD11 ' A' ' 42' ' ' LEU . 57.5 Cg_endo -79.45 115.7 3.46 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.511 2.807 . . . . 0.0 114.9 177.191 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -62.31 -35.28 78.55 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 119.988 -1.695 . . . . 0.0 114.689 176.307 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.4 6.34 80.68 Favored Glycine 0 N--CA 1.473 1.131 0 O-C-N 121.547 -0.721 . . . . 0.0 114.639 176.691 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.5 tttt -137.06 0.59 2.38 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.902 1.281 . . . . 0.0 113.687 -177.182 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.468 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.5 m -49.93 -29.02 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 C-N-CA 125.166 1.386 . . . . 0.0 113.795 175.805 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.2 mt -58.32 -27.44 64.12 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.594 1.557 . . . . 0.0 112.127 177.571 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.13 -50.96 11.84 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.945 1.698 . . . . 0.0 112.386 175.007 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.5 mp -69.51 -33.55 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 123.863 0.865 . . . . 0.0 111.824 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 90.35 12.72 61.02 Favored Glycine 0 CA--C 1.538 1.521 0 C-N-CA 126.03 1.776 . . . . 0.0 114.914 -178.831 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 97.6 t -89.56 135.38 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 C-N-CA 125.375 1.47 . . . . 0.0 110.657 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.37 109.2 11.54 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 123.721 0.808 . . . . 0.0 110.315 175.039 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.6 ' HB3' HG23 ' A' ' 19' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.471 0.596 0 CA-C-O 121.631 0.729 . . . . 0.0 110.192 179.42 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.544 HD22 HG21 ' A' ' 29' ' ' VAL . 11.8 mt . . . . . 0 CA--C 1.543 0.692 0 CA-C-O 121.459 0.647 . . . . 0.0 110.281 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -146.78 157.1 43.59 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 125.196 1.398 . . . . 0.0 110.849 175.622 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.4 t -57.31 125.72 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.834 0.854 . . . . 0.0 111.056 178.016 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.44 -5.06 84.61 Favored Glycine 0 CA--C 1.533 1.165 0 C-N-CA 124.973 1.273 . . . . 0.0 115.005 -176.647 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -68.69 152.8 44.86 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 118.97 1.385 . . . . 0.0 109.79 174.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 9.4 mpt_? -85.0 167.74 15.57 Favored 'General case' 0 N--CA 1.471 0.616 0 O-C-N 121.246 -0.909 . . . . 0.0 110.74 176.363 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 70' ' ' LYS . 26.1 m -151.16 158.54 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 127.054 2.141 . . . . 0.0 111.068 175.067 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.4 p -136.55 160.11 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 125.8 1.64 . . . . 0.0 109.515 174.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -114.16 160.43 32.57 Favored Pre-proline 0 CA--C 1.542 0.664 0 C-N-CA 125.354 1.461 . . . . 0.0 111.539 175.016 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.57 ' HD3' HG22 ' A' ' 68' ' ' VAL . 59.0 Cg_endo -67.48 -27.66 39.39 Favored 'Trans proline' 0 CA--C 1.539 0.734 0 C-N-CA 123.002 2.468 . . . . 0.0 112.822 178.357 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -158.77 53.81 0.42 Allowed 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 124.081 0.952 . . . . 0.0 113.278 178.502 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.11 -57.73 0.38 Allowed 'General case' 0 N--CA 1.479 0.997 0 O-C-N 121.107 -0.996 . . . . 0.0 113.58 -176.83 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 156.09 -160.26 29.96 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.526 1.06 . . . . 0.0 112.513 -174.554 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.4 m -118.98 147.97 22.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 125.844 1.658 . . . . 0.0 111.524 177.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 6.3 m -139.02 178.87 6.85 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.303 1.441 . . . . 0.0 110.886 177.759 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 49.4 ttt-85 -133.74 131.87 39.9 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.16 1.384 . . . . 0.0 111.673 179.051 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.544 HG21 HD22 ' A' ' 13' ' ' LEU . 40.0 t -59.09 132.64 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.674 1.189 . . . . 0.0 111.293 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.9 t -112.07 -53.05 2.74 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 126.505 1.922 . . . . 0.0 111.15 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -145.98 159.14 43.67 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.562 1.145 . . . . 0.0 111.023 -178.17 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.4 mt -143.74 127.26 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.514 1.125 . . . . 0.0 109.108 178.835 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -149.8 157.14 42.91 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.218 1.007 . . . . 0.0 112.351 175.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.54 HG12 ' HA ' ' A' ' 43' ' ' THR . 21.5 m -97.02 141.56 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 O-C-N 121.279 -0.888 . . . . 0.0 110.342 175.474 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -154.51 171.44 19.41 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.878 0.871 . . . . 0.0 111.728 175.171 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -103.61 116.62 32.69 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.543 1.537 . . . . 0.0 109.372 175.373 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 p -124.33 137.86 55.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.025 0 C-N-CA 124.419 1.088 . . . . 0.0 108.941 175.132 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.22 29.74 1.97 Allowed 'General case' 0 CA--C 1.557 1.233 0 N-CA-C 114.809 1.411 . . . . 0.0 114.809 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.39 23.36 56.79 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 125.046 1.308 . . . . 0.0 115.49 -176.458 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -136.91 113.48 10.17 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 125.365 1.466 . . . . 0.0 111.822 -173.854 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -94.81 114.41 26.28 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.862 1.665 . . . . 0.0 111.132 -177.207 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.611 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -155.07 171.59 19.51 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.2 0.6 . . . . 0.0 111.669 178.698 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.54 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.7 m -73.8 116.56 14.54 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 124.035 0.934 . . . . 0.0 110.945 175.287 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -107.08 113.13 26.39 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 122.239 1.018 . . . . 0.0 109.68 176.03 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.556 HG23 ' HE1' ' A' ' 47' ' ' MET . 18.0 m -83.11 146.16 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 C-N-CA 123.438 0.695 . . . . 0.0 110.148 176.708 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 3.9 m -124.39 113.46 18.21 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 125.142 1.377 . . . . 0.0 109.865 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' MET . . . . . 0.556 ' HE1' HG23 ' A' ' 45' ' ' VAL . 2.8 mtm -107.28 165.21 11.55 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 124.685 1.194 . . . . 0.0 110.221 175.025 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 35.2 ptt180 -140.48 162.03 36.31 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 125.873 1.669 . . . . 0.0 111.219 175.12 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.0 mpt_? -109.25 131.26 55.23 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.745 0.818 . . . . 0.0 110.035 175.015 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 70.2 mt-10 -68.3 -35.64 78.14 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.988 0.915 . . . . 0.0 111.827 176.825 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -91.96 -46.58 7.75 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 124.523 1.129 . . . . 0.0 112.831 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.05 -24.04 62.26 Favored 'General case' 0 N--CA 1.476 0.864 0 O-C-N 121.559 -0.713 . . . . 0.0 111.937 -178.133 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.81 9.77 47.46 Favored Glycine 0 CA--C 1.536 1.371 0 C-N-CA 125.719 1.628 . . . . 0.0 114.651 -179.176 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -101.1 159.88 14.86 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.289 1.836 . . . . 0.0 111.235 -177.716 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 31.3 m -111.63 151.57 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 124.881 1.272 . . . . 0.0 110.479 175.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.4 p -135.04 124.91 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.66 1.584 . . . . 0.0 108.42 176.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.41 125.3 54.06 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 124.734 1.214 . . . . 0.0 109.033 176.092 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.763 HG21 ' HE3' ' A' ' 70' ' ' LYS . 15.4 m -137.74 156.24 74.63 Favored Pre-proline 0 N--CA 1.472 0.652 0 C-N-CA 123.108 0.563 . . . . 0.0 111.524 176.164 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.611 ' CB ' HD11 ' A' ' 42' ' ' LEU . 57.2 Cg_endo -77.14 115.66 4.03 Favored 'Trans proline' 0 CA--C 1.536 0.59 0 C-N-CA 123.516 2.811 . . . . 0.0 114.232 177.916 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -59.08 -45.62 90.35 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 120.557 -1.339 . . . . 0.0 112.497 175.639 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -83.33 6.37 72.65 Favored Glycine 0 N--CA 1.475 1.25 0 O-C-N 120.999 -1.063 . . . . 0.0 115.282 178.798 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 15.6 tttt -137.5 4.6 2.63 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 125.434 1.493 . . . . 0.0 113.027 -178.679 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.519 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.8 m -51.88 -29.15 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 125.297 1.439 . . . . 0.0 113.35 176.097 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.1 mt -58.06 -29.14 65.17 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 125.926 1.691 . . . . 0.0 112.426 176.348 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.09 -49.48 23.78 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 125.672 1.589 . . . . 0.0 112.61 175.22 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.441 HG22 HG23 ' A' ' 68' ' ' VAL . 2.5 mp -67.0 -32.68 59.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 C-N-CA 123.476 0.71 . . . . 0.0 111.339 177.764 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.79 20.38 43.89 Favored Glycine 0 CA--C 1.534 1.243 0 C-N-CA 124.834 1.207 . . . . 0.0 113.811 -177.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.57 HG22 ' HD3' ' A' ' 22' ' ' PRO . 40.9 t -102.58 123.75 56.11 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 124.328 1.051 . . . . 0.0 110.096 -178.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -98.67 110.14 22.79 Favored 'General case' 0 N--CA 1.475 0.821 0 O-C-N 121.178 -0.951 . . . . 0.0 110.523 175.041 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.763 ' HE3' HG21 ' A' ' 58' ' ' VAL . 1.7 ptpm? . . . . . 0 N--CA 1.47 0.55 0 C-N-CA 127.423 2.289 . . . . 0.0 109.699 179.138 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.542 0.666 0 CA-C-O 120.71 0.29 . . . . 0.0 110.514 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -147.45 177.34 9.32 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.198 1.399 . . . . 0.0 112.013 177.021 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -58.71 129.84 21.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 123.756 0.822 . . . . 0.0 111.276 175.095 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 88.5 -4.3 85.19 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 125.191 1.377 . . . . 0.0 115.126 -178.831 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -72.0 176.37 5.11 Favored 'General case' 0 CA--C 1.551 0.986 0 CA-C-N 118.946 1.373 . . . . 0.0 112.075 175.027 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 2.4 tpt180 -119.49 142.01 48.67 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 125.278 1.431 . . . . 0.0 111.578 -177.186 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 15.6 m -136.76 142.39 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 123.996 0.918 . . . . 0.0 110.541 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 p -136.99 141.0 41.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 124.08 0.952 . . . . 0.0 110.724 177.258 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.479 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 1.3 m-85 -80.51 158.66 71.03 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 124.271 1.028 . . . . 0.0 112.126 176.0 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.441 ' CD ' HG12 ' A' ' 68' ' ' VAL . 70.8 Cg_endo -68.55 -23.41 37.07 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 123.699 2.933 . . . . 0.0 112.98 -177.825 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -159.91 51.73 0.33 Allowed 'General case' 0 CA--C 1.555 1.164 0 C-N-CA 124.752 1.221 . . . . 0.0 112.656 177.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.41 -58.11 0.37 Allowed 'General case' 0 N--CA 1.483 1.184 0 O-C-N 120.743 -1.223 . . . . 0.0 112.982 -176.407 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 155.97 179.25 30.89 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.099 1.333 . . . . 0.0 113.314 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.2 p -85.27 152.28 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.959 1.304 . . . . 0.0 111.268 175.646 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.52 ' SG ' HG11 ' A' ' 56' ' ' VAL . 4.0 m -132.77 170.18 15.64 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.195 1.798 . . . . 0.0 110.725 174.926 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -128.68 121.05 27.69 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.369 1.068 . . . . 0.0 111.36 -174.313 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.403 HG22 ' CE ' ' A' ' 47' ' ' MET . 50.0 t -63.61 121.5 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 124.436 1.094 . . . . 0.0 110.617 -178.139 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.8 m -112.42 -41.51 3.86 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.573 1.149 . . . . 0.0 112.1 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.98 165.21 36.81 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.287 1.835 . . . . 0.0 110.612 174.92 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 41.7 mt -147.65 138.15 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.971 1.308 . . . . 0.0 108.76 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -147.48 170.58 17.1 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.449 1.1 . . . . 0.0 112.785 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.6 m -108.51 139.25 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 124.909 1.284 . . . . 0.0 110.599 175.852 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 7.5 ptmt -155.92 168.13 28.21 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.291 1.036 . . . . 0.0 112.543 175.311 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.12 116.05 31.24 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 125.648 1.579 . . . . 0.0 109.516 175.006 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.7 p -126.09 137.25 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.15 0.98 . . . . 0.0 109.648 174.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.94 28.98 2.17 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 114.829 1.418 . . . . 0.0 114.829 -179.02 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.45 25.18 48.28 Favored Glycine 0 CA--C 1.54 1.597 0 C-N-CA 124.839 1.209 . . . . 0.0 115.322 -176.62 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -139.08 113.52 8.95 Favored 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 125.413 1.485 . . . . 0.0 111.462 -174.133 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -95.85 116.7 29.3 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.144 1.377 . . . . 0.0 111.917 -179.29 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.55 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -159.75 175.08 13.57 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 123.813 0.845 . . . . 0.0 112.02 179.224 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 15.3 m -77.35 116.33 17.86 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.314 1.046 . . . . 0.0 111.934 175.001 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -106.01 113.45 27.01 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 124.849 1.26 . . . . 0.0 109.351 175.194 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.2 m -63.73 150.7 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 O-C-N 122.052 -0.405 . . . . 0.0 111.331 175.822 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -126.55 109.89 12.64 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 122.037 0.922 . . . . 0.0 110.638 174.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' MET . . . . . 0.471 ' HB2' HG13 ' A' ' 56' ' ' VAL . 0.7 OUTLIER -128.43 162.57 26.86 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 125.095 1.358 . . . . 0.0 110.181 179.597 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.3 mtt180 -138.67 113.85 9.44 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 125.491 1.516 . . . . 0.0 109.298 177.664 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 44.5 mtp85 -69.91 109.09 4.29 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 174.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -70.17 -13.86 62.38 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.188 0.995 . . . . 0.0 113.286 176.072 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -59.36 -42.82 92.49 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 125.96 1.704 . . . . 0.0 112.66 177.253 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -128.52 -15.45 4.51 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.843 1.424 . . . . 0.0 114.843 177.768 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 84.07 59.03 2.12 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 125.578 1.561 . . . . 0.0 113.446 -179.242 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -135.66 128.72 31.59 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.657 1.183 . . . . 0.0 112.532 179.021 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.0 p -67.05 141.87 17.36 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 C-N-CA 124.286 1.034 . . . . 0.0 110.127 175.367 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.52 HG11 ' SG ' ' A' ' 27' ' ' CYS . 5.6 p -137.31 114.41 12.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 C-N-CA 126.244 1.818 . . . . 0.0 108.969 178.344 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.3 ptt? -126.79 125.63 42.04 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 125.794 1.638 . . . . 0.0 109.832 179.717 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 33.8 m -131.89 152.98 81.23 Favored Pre-proline 0 N--CA 1.468 0.457 0 C-N-CA 123.7 0.8 . . . . 0.0 111.359 178.433 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.55 ' CB ' HD11 ' A' ' 42' ' ' LEU . 51.5 Cg_endo -77.01 116.5 4.22 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.912 2.408 . . . . 0.0 114.557 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -60.65 -38.22 84.13 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 114.572 1.323 . . . . 0.0 114.572 -179.623 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.91 5.81 79.21 Favored Glycine 0 N--CA 1.476 1.34 0 C-N-CA 124.545 1.069 . . . . 0.0 114.697 178.408 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.9 tttt -133.85 3.03 3.46 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.474 1.51 . . . . 0.0 112.889 -177.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.54 -29.72 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 125.533 1.533 . . . . 0.0 113.745 175.306 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.5 mt -56.3 -29.4 61.17 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 126.093 1.757 . . . . 0.0 112.542 177.164 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.42 -50.4 15.94 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 125.849 1.66 . . . . 0.0 112.873 175.52 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.429 HG22 HG13 ' A' ' 68' ' ' VAL . 3.9 mp -67.33 -33.31 61.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 124.134 0.973 . . . . 0.0 111.355 178.034 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.53 8.29 68.16 Favored Glycine 0 CA--C 1.535 1.335 0 C-N-CA 125.617 1.58 . . . . 0.0 114.356 -176.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.479 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 24.9 m -93.26 123.27 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 125.407 1.483 . . . . 0.0 110.763 -176.689 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.62 109.31 21.37 Favored 'General case' 0 N--CA 1.471 0.607 0 O-C-N 120.827 -1.17 . . . . 0.0 109.58 178.089 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.47 0.566 0 C-N-CA 123.764 0.826 . . . . 0.0 109.91 176.255 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.641 HD11 HG21 ' A' ' 29' ' ' VAL . 0.7 OUTLIER . . . . . 0 CA--C 1.544 0.725 0 CA-C-O 120.505 0.193 . . . . 0.0 110.981 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -135.25 175.16 9.83 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.572 1.549 . . . . 0.0 112.336 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.6 t -59.61 132.8 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 O-C-N 121.184 -0.948 . . . . 0.0 111.127 177.598 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.62 -5.52 83.33 Favored Glycine 0 CA--C 1.537 1.427 0 C-N-CA 124.854 1.216 . . . . 0.0 115.005 -179.272 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -68.51 173.32 5.12 Favored 'General case' 0 CA--C 1.553 1.058 0 CA-C-N 118.761 1.281 . . . . 0.0 110.246 175.041 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -84.33 158.31 21.2 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 125.102 1.361 . . . . 0.0 112.007 174.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.745 HG11 ' HG2' ' A' ' 47' ' ' MET . 2.4 p -160.32 124.37 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 124.688 1.195 . . . . 0.0 109.997 175.019 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 2.9 m -131.56 159.74 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.618 0.723 . . . . 0.0 109.35 174.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.494 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.8 OUTLIER -95.27 162.02 26.08 Favored Pre-proline 0 CA--C 1.544 0.72 0 C-N-CA 123.515 0.726 . . . . 0.0 110.796 177.043 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.437 ' CD ' HG12 ' A' ' 68' ' ' VAL . 68.0 Cg_endo -69.35 -24.84 31.1 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 123.191 2.594 . . . . 0.0 112.429 -179.2 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -159.48 55.65 0.39 Allowed 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 124.725 1.21 . . . . 0.0 112.572 178.608 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 9.8 tm0? -142.7 -58.81 0.44 Allowed 'General case' 0 N--CA 1.482 1.165 0 O-C-N 120.832 -1.167 . . . . 0.0 113.024 -178.506 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 158.58 -168.66 34.87 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 124.849 1.214 . . . . 0.0 112.995 -174.266 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.5 m -109.52 146.8 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 125.176 1.39 . . . . 0.0 112.656 -176.547 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.551 ' HB2' HG13 ' A' ' 19' ' ' VAL . 61.3 m -137.25 179.55 6.33 Favored 'General case' 0 CA--C 1.551 1.01 0 C-N-CA 126.168 1.787 . . . . 0.0 110.944 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.89 132.35 43.54 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 126.892 2.077 . . . . 0.0 111.362 175.113 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.641 HG21 HD11 ' A' ' 13' ' ' LEU . 21.9 t -67.6 129.94 32.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.149 0.98 . . . . 0.0 111.233 179.523 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.76 -48.57 3.12 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.9 1.28 . . . . 0.0 112.781 -175.56 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.99 163.06 36.79 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.372 1.469 . . . . 0.0 110.961 174.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -140.94 133.42 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 124.263 1.025 . . . . 0.0 109.252 178.166 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -148.46 168.04 23.73 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.713 1.205 . . . . 0.0 112.19 176.566 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.539 HG12 ' HA ' ' A' ' 43' ' ' THR . 18.8 m -106.69 141.3 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 O-C-N 121.257 -0.902 . . . . 0.0 110.373 175.864 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.1 ptmt -153.45 168.59 25.59 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 123.809 0.843 . . . . 0.0 112.211 176.666 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -100.67 117.62 35.15 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 125.485 1.514 . . . . 0.0 109.991 175.014 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.0 p -127.26 138.14 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 124.106 0.962 . . . . 0.0 109.656 175.021 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.98 29.06 1.59 Allowed 'General case' 0 CA--C 1.557 1.223 0 N-CA-C 114.776 1.398 . . . . 0.0 114.776 -177.823 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.08 27.52 49.19 Favored Glycine 0 CA--C 1.542 1.748 0 C-N-CA 124.88 1.229 . . . . 0.0 115.361 -176.473 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 10.5 tp60 -137.41 114.95 11.16 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.223 1.809 . . . . 0.0 110.656 -175.7 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.02 115.07 26.96 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.69 1.196 . . . . 0.0 111.492 178.621 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.602 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -153.11 172.56 16.71 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 123.448 0.699 . . . . 0.0 111.649 177.388 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.539 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.3 m -74.16 116.35 14.7 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 125.011 1.324 . . . . 0.0 111.105 175.793 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -109.83 113.07 25.52 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 124.451 1.1 . . . . 0.0 110.105 177.071 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.535 HG21 ' HE3' ' A' ' 70' ' ' LYS . 22.0 m -77.45 145.0 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 123.156 0.582 . . . . 0.0 110.903 178.323 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.1 m -126.31 112.36 15.61 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 122.116 0.96 . . . . 0.0 110.689 -179.053 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' MET . . . . . 0.745 ' HG2' HG11 ' A' ' 19' ' ' VAL . 2.0 mpp? -122.42 162.7 21.16 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 124.816 1.246 . . . . 0.0 109.638 -176.423 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.438 ' CG ' HG12 ' A' ' 55' ' ' VAL . 1.3 mtt180 -134.84 151.87 51.28 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 125.38 1.472 . . . . 0.0 110.314 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.5 ptt180 -118.58 109.12 15.79 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.379 1.072 . . . . 0.0 109.793 175.028 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -64.96 -17.37 64.34 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.745 1.218 . . . . 0.0 112.408 174.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -55.4 -42.92 74.73 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 126.249 1.82 . . . . 0.0 112.693 175.708 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -128.68 3.4 5.5 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 125.126 1.37 . . . . 0.0 113.845 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 64.56 33.89 88.45 Favored Glycine 0 CA--C 1.535 1.292 0 C-N-CA 125.659 1.6 . . . . 0.0 113.979 -174.789 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -103.82 167.43 9.78 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.15 0.98 . . . . 0.0 111.988 -176.493 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.438 HG12 ' CG ' ' A' ' 48' ' ' ARG . 17.3 m -116.85 151.0 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.092 1.357 . . . . 0.0 110.258 178.441 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.3 p -143.82 126.36 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 C-N-CA 124.821 1.249 . . . . 0.0 109.202 176.498 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.6 tmm? -127.86 128.17 44.73 Favored 'General case' 0 C--O 1.234 0.267 0 C-N-CA 124.408 1.083 . . . . 0.0 109.839 177.759 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.7 m -132.95 155.45 81.14 Favored Pre-proline 0 N--CA 1.469 0.485 0 C-N-CA 124.396 1.078 . . . . 0.0 111.599 178.448 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.602 ' CB ' HD11 ' A' ' 42' ' ' LEU . 52.6 Cg_endo -76.14 116.14 4.3 Favored 'Trans proline' 0 CA--C 1.537 0.634 0 C-N-CA 123.749 2.966 . . . . 0.0 114.466 176.361 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -63.43 -34.64 78.2 Favored 'General case' 0 N--CA 1.479 1.005 0 O-C-N 120.341 -1.474 . . . . 0.0 114.172 177.484 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.17 5.9 78.47 Favored Glycine 0 N--CA 1.472 1.055 0 C-N-CA 124.175 0.893 . . . . 0.0 114.653 176.28 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.4 ttmm -136.76 4.11 2.78 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.269 1.428 . . . . 0.0 113.364 -178.588 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.429 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.4 m -49.38 -30.13 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.468 1.507 . . . . 0.0 113.042 175.303 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.3 mt -56.58 -29.14 61.73 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 126.288 1.835 . . . . 0.0 112.684 176.634 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.31 -50.2 13.34 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 126.05 1.74 . . . . 0.0 112.645 177.069 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.455 HG22 HG13 ' A' ' 68' ' ' VAL . 3.7 mp -66.8 -32.38 57.74 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 124.211 1.004 . . . . 0.0 111.291 176.886 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.39 2.71 79.39 Favored Glycine 0 CA--C 1.535 1.303 0 C-N-CA 125.789 1.662 . . . . 0.0 113.866 -174.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.494 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 18.6 m -83.57 123.23 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 118.338 1.069 . . . . 0.0 111.031 -178.822 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.1 mmt-85 -100.4 127.21 46.78 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 174.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.535 ' HE3' HG21 ' A' ' 45' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.464 0.225 0 C-N-CA 123.331 0.652 . . . . 0.0 110.481 176.794 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.597 HD23 HG21 ' A' ' 29' ' ' VAL . 0.3 OUTLIER . . . . . 0 CA--C 1.54 0.573 0 CA-C-O 120.773 0.32 . . . . 0.0 110.893 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -144.91 169.28 18.36 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.378 1.071 . . . . 0.0 111.772 177.554 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.3 t -61.21 130.34 25.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 123.586 0.754 . . . . 0.0 110.572 176.23 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.27 -8.81 79.0 Favored Glycine 0 CA--C 1.537 1.414 0 C-N-CA 124.997 1.284 . . . . 0.0 114.886 -176.036 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -72.67 165.16 25.3 Favored 'General case' 0 CA--C 1.551 0.998 0 CA-C-N 119.302 1.551 . . . . 0.0 111.496 175.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -85.82 154.93 21.22 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.669 0.747 . . . . 0.0 112.288 178.234 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 24.2 m -144.09 147.69 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 C-N-CA 125.204 1.402 . . . . 0.0 109.623 174.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.94 155.75 41.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 C-N-CA 126.461 1.905 . . . . 0.0 108.984 176.054 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -126.35 161.99 49.03 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 125.4 1.48 . . . . 0.0 111.433 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -74.02 -17.66 22.05 Favored 'Trans proline' 0 CA--C 1.541 0.841 0 C-N-CA 123.132 2.555 . . . . 0.0 113.023 -177.839 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -151.97 -40.08 0.11 Allowed 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 125.611 1.564 . . . . 0.0 112.543 176.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -53.91 -26.49 25.42 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.71 1.604 . . . . 0.0 114.777 179.428 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.46 -176.18 32.38 Favored Glycine 0 CA--C 1.535 1.336 0 C-N-CA 125.014 1.292 . . . . 0.0 114.383 179.306 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.0 m -74.74 144.14 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 O-C-N 121.234 -1.157 . . . . 0.0 111.788 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.495 ' SG ' HG11 ' A' ' 56' ' ' VAL . 33.5 m -136.26 -177.11 4.56 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 125.154 1.381 . . . . 0.0 110.809 177.793 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -138.16 115.91 11.45 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.913 1.285 . . . . 0.0 111.563 -173.187 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.597 HG21 HD23 ' A' ' 13' ' ' LEU . 42.4 t -63.45 128.18 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 C-N-CA 123.907 0.883 . . . . 0.0 111.541 -172.411 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 44.0 t -111.02 -49.39 3.03 Favored 'General case' 0 N--CA 1.469 0.505 0 C-N-CA 125.653 1.581 . . . . 0.0 112.039 -174.758 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -154.73 161.85 41.36 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.919 1.288 . . . . 0.0 111.208 175.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -142.81 127.93 16.21 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 124.713 1.205 . . . . 0.0 108.785 177.373 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -148.92 169.54 20.33 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 123.647 0.779 . . . . 0.0 112.361 175.447 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.466 HG12 ' HA ' ' A' ' 43' ' ' THR . 19.9 m -104.93 142.43 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 O-C-N 121.229 -0.919 . . . . 0.0 110.946 174.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.9 ptmt -155.51 171.0 20.67 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.745 0.818 . . . . 0.0 112.683 175.206 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -103.59 117.47 34.5 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.136 1.374 . . . . 0.0 109.821 176.403 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.7 p -129.69 135.96 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 178.243 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.38 28.73 1.75 Allowed 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 125.582 1.553 . . . . 0.0 114.656 -177.786 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.14 23.77 50.59 Favored Glycine 0 CA--C 1.538 1.519 0 C-N-CA 125.45 1.5 . . . . 0.0 115.286 -176.743 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -134.26 113.76 12.32 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 126.16 1.784 . . . . 0.0 111.128 -174.591 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 54.6 tttt -96.33 112.48 24.2 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 124.942 1.297 . . . . 0.0 111.585 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.63 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.8 OUTLIER -156.09 172.41 18.47 Favored 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 123.405 0.682 . . . . 0.0 112.161 179.035 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.466 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.8 m -72.95 119.17 16.82 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.644 1.178 . . . . 0.0 110.591 175.431 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -110.19 116.65 31.88 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 174.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.7 m -81.3 143.57 12.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 123.935 0.894 . . . . 0.0 109.027 175.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.9 m -126.38 117.34 22.77 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.527 1.531 . . . . 0.0 110.054 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -120.71 160.23 23.74 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 125.257 1.423 . . . . 0.0 110.202 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 55.0 mtm180 -140.51 121.29 14.41 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 124.926 1.29 . . . . 0.0 110.338 -179.131 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.68 108.85 17.61 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 124.647 1.179 . . . . 0.0 111.045 176.238 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -69.96 -15.39 63.04 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 124.026 0.93 . . . . 0.0 112.264 175.452 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -59.67 -37.65 79.33 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 124.949 1.3 . . . . 0.0 113.439 177.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -128.39 -12.83 5.0 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 124.892 1.277 . . . . 0.0 113.677 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.57 50.94 5.42 Favored Glycine 0 CA--C 1.531 1.077 0 C-N-CA 125.56 1.552 . . . . 0.0 113.177 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -124.53 162.6 23.67 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.741 1.216 . . . . 0.0 112.264 178.529 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.1 m -109.13 152.84 11.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 125.07 1.348 . . . . 0.0 110.736 178.07 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.495 HG11 ' SG ' ' A' ' 27' ' ' CYS . 3.9 p -151.57 122.25 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 125.21 1.404 . . . . 0.0 109.252 178.756 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 22.6 ptt? -127.01 139.38 53.06 Favored 'General case' 0 C--O 1.236 0.374 0 C-N-CA 123.644 0.778 . . . . 0.0 110.884 177.825 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.1 m -141.19 158.2 64.85 Favored Pre-proline 0 N--CA 1.473 0.707 0 C-N-CA 123.858 0.863 . . . . 0.0 112.069 178.487 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.63 ' CB ' HD11 ' A' ' 42' ' ' LEU . 56.6 Cg_endo -76.67 115.02 3.97 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 123.497 2.798 . . . . 0.0 114.509 176.175 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.5 -34.43 77.76 Favored 'General case' 0 N--CA 1.477 0.912 0 O-C-N 120.315 -1.49 . . . . 0.0 114.173 178.604 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.0 5.98 78.96 Favored Glycine 0 N--CA 1.473 1.158 0 C-N-CA 124.017 0.818 . . . . 0.0 114.509 176.483 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 19.5 tttp -136.24 2.23 2.75 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.293 1.437 . . . . 0.0 113.359 -178.478 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -48.93 -30.12 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 125.612 1.565 . . . . 0.0 113.116 175.98 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.9 mt -57.34 -28.82 63.46 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 126.435 1.894 . . . . 0.0 112.556 177.133 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.74 -50.47 15.22 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.986 1.714 . . . . 0.0 112.668 175.557 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.436 ' H ' HD12 ' A' ' 66' ' ' ILE . 3.6 mp -68.53 -31.1 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 124.145 0.978 . . . . 0.0 111.227 178.309 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.35 8.85 70.62 Favored Glycine 0 CA--C 1.535 1.285 0 C-N-CA 125.82 1.676 . . . . 0.0 114.187 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 15.2 m -87.66 137.43 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.669 1.588 . . . . 0.0 110.356 -177.473 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.9 108.88 13.47 Favored 'General case' 0 N--CA 1.469 0.511 0 O-C-N 120.881 -1.137 . . . . 0.0 110.737 176.04 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.452 ' HE2' HD22 ' A' ' 13' ' ' LEU . 0.1 OUTLIER . . . . . 0 N--CA 1.464 0.274 0 C-N-CA 124.25 1.02 . . . . 0.0 109.3 175.594 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.542 0.646 0 N-CA-C 110.224 -0.287 . . . . 0.0 110.224 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.56 163.7 19.5 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.363 1.465 . . . . 0.0 112.433 177.018 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 98.1 t -60.35 129.57 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 123.975 0.91 . . . . 0.0 110.225 178.668 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.11 -11.86 65.59 Favored Glycine 0 CA--C 1.534 1.267 0 C-N-CA 125.012 1.291 . . . . 0.0 114.761 -176.88 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -74.99 168.52 19.8 Favored 'General case' 0 CA--C 1.544 0.729 0 CA-C-N 119.445 1.622 . . . . 0.0 110.971 175.018 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.84 163.86 20.91 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 123.964 0.906 . . . . 0.0 111.426 175.133 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 17.9 m -149.84 150.49 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 125.488 1.515 . . . . 0.0 109.691 175.0 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 6.6 p -137.03 156.3 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 C-N-CA 126.239 1.815 . . . . 0.0 110.035 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -130.43 157.62 76.88 Favored Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 125.471 1.508 . . . . 0.0 111.638 -177.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.11 -40.47 6.3 Favored 'Trans proline' 0 CA--C 1.536 0.582 0 C-N-CA 123.913 3.075 . . . . 0.0 112.313 -177.15 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -148.96 43.82 0.98 Allowed 'General case' 0 CA--C 1.552 1.034 0 C-N-CA 126.057 1.743 . . . . 0.0 112.153 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -128.35 -51.3 1.29 Allowed 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 124.38 1.072 . . . . 0.0 111.945 177.252 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 128.88 -179.02 16.91 Favored Glycine 0 CA--C 1.535 1.305 0 C-N-CA 126.41 1.957 . . . . 0.0 113.035 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.1 m -77.49 143.76 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 O-C-N 121.766 -0.843 . . . . 0.0 111.281 174.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 85.3 m -136.04 -176.96 4.49 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 125.116 1.366 . . . . 0.0 110.786 176.154 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.5 ttt180 -140.7 124.54 17.18 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 125.01 1.324 . . . . 0.0 110.921 -178.597 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.8 t -62.06 119.22 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 123.464 0.706 . . . . 0.0 111.827 -175.575 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.9 p -100.58 -46.21 5.27 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.031 0.932 . . . . 0.0 111.902 -178.735 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.76 172.06 17.92 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 126.366 1.866 . . . . 0.0 111.133 176.166 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 79.8 mt -146.02 137.15 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 C-N-CA 124.759 1.224 . . . . 0.0 108.358 174.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -141.97 168.97 18.49 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 124.146 0.978 . . . . 0.0 111.781 176.227 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.463 HG12 ' HA ' ' A' ' 43' ' ' THR . 15.9 m -116.19 145.25 22.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 O-C-N 120.986 -1.072 . . . . 0.0 110.924 175.388 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.6 174.74 14.07 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.199 0.999 . . . . 0.0 111.952 174.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -107.75 121.68 45.21 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 125.906 1.682 . . . . 0.0 108.9 175.008 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.6 p -125.2 129.15 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 125.058 1.343 . . . . 0.0 109.159 174.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.97 28.99 2.19 Favored 'General case' 0 CA--C 1.556 1.203 0 N-CA-C 114.735 1.383 . . . . 0.0 114.735 -178.509 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.78 21.08 54.57 Favored Glycine 0 CA--C 1.539 1.571 0 C-N-CA 124.814 1.197 . . . . 0.0 115.301 -176.504 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -126.16 113.5 17.12 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 125.924 1.69 . . . . 0.0 110.275 -176.275 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 11.2 tttt -96.77 117.75 31.73 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 124.734 1.213 . . . . 0.0 111.068 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.566 HD11 ' CB ' ' A' ' 59' ' ' PRO . 1.1 pp -158.56 172.46 18.26 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 122.984 0.514 . . . . 0.0 111.75 178.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.463 ' HA ' HG12 ' A' ' 34' ' ' VAL . 22.6 m -80.04 116.47 20.18 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 124.946 1.298 . . . . 0.0 112.521 176.219 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -102.89 113.24 26.52 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 124.487 1.115 . . . . 0.0 109.104 174.912 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.1 m -63.79 149.05 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 O-C-N 121.843 -0.536 . . . . 0.0 111.223 175.133 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 24.6 m -126.49 109.95 12.74 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.447 1.099 . . . . 0.0 110.942 178.393 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -128.8 165.43 20.97 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 121.512 -0.742 . . . . 0.0 111.002 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -140.0 120.07 13.68 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.417 1.087 . . . . 0.0 111.403 178.016 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 15.0 ptm180 -74.08 110.06 8.07 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 125.089 1.356 . . . . 0.0 110.865 175.252 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -64.51 -17.25 63.72 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 177.442 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -59.43 -37.71 78.78 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.453 1.501 . . . . 0.0 113.895 177.821 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.63 -0.39 5.5 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 124.834 1.253 . . . . 0.0 112.908 178.079 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.65 20.9 68.57 Favored Glycine 0 CA--C 1.537 1.419 0 C-N-CA 125.254 1.407 . . . . 0.0 113.851 -170.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -87.87 163.55 16.34 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 118.516 1.158 . . . . 0.0 111.541 -176.139 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 27.5 m -108.8 143.74 18.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.064 1.346 . . . . 0.0 110.874 -179.67 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.7 m -135.33 130.44 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 124.813 1.245 . . . . 0.0 109.483 178.068 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 38.8 mtm -141.84 123.82 15.37 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.336 1.054 . . . . 0.0 110.261 -178.308 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.5 m -135.05 157.21 77.45 Favored Pre-proline 0 N--CA 1.474 0.744 0 C-N-CA 123.952 0.901 . . . . 0.0 112.116 179.173 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.566 ' CB ' HD11 ' A' ' 42' ' ' LEU . 42.9 Cg_endo -76.79 117.49 4.52 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 123.374 2.716 . . . . 0.0 114.949 179.721 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -60.54 -38.92 86.04 Favored 'General case' 0 N--CA 1.478 0.928 0 O-C-N 120.463 -1.398 . . . . 0.0 114.253 179.617 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.18 5.71 78.37 Favored Glycine 0 N--CA 1.475 1.244 0 C-N-CA 124.549 1.071 . . . . 0.0 114.9 179.031 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 5.2 tttm -133.92 2.8 3.42 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.658 1.583 . . . . 0.0 112.639 -178.415 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.406 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -48.64 -30.19 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 C-N-CA 125.405 1.482 . . . . 0.0 113.233 175.028 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.5 mt -57.04 -28.74 62.8 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 125.938 1.695 . . . . 0.0 112.641 177.558 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.61 -50.91 14.11 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.593 1.557 . . . . 0.0 112.713 175.68 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.556 HG22 HG13 ' A' ' 68' ' ' VAL . 4.0 mp -69.04 -33.6 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 124.001 0.92 . . . . 0.0 111.264 179.201 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.66 4.36 76.23 Favored Glycine 0 CA--C 1.536 1.406 0 C-N-CA 125.881 1.705 . . . . 0.0 114.352 -177.033 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.556 HG13 HG22 ' A' ' 66' ' ' ILE . 27.3 m -83.57 133.29 29.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.952 1.701 . . . . 0.0 109.837 179.812 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.9 mtp180 -122.55 109.17 13.99 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 119.957 1.253 . . . . 0.0 110.194 175.385 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.467 0.402 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.114 178.181 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.435 ' HG ' ' HE2' ' A' ' 70' ' ' LYS . 0.5 OUTLIER . . . . . 0 CA--C 1.544 0.732 0 CA-C-O 120.567 0.222 . . . . 0.0 111.394 . . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -143.2 179.01 7.32 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.937 1.695 . . . . 0.0 112.199 176.869 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.4 t -59.51 129.34 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 O-C-N 121.054 -1.029 . . . . 0.0 110.821 175.623 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.28 -2.63 86.73 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 125.109 1.338 . . . . 0.0 115.372 -178.429 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -70.98 170.17 13.34 Favored 'General case' 0 CA--C 1.55 0.972 0 CA-C-N 119.319 1.56 . . . . 0.0 112.284 174.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.71 142.86 28.99 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.796 1.238 . . . . 0.0 111.602 178.263 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.9 m -139.02 146.48 25.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 124.061 0.944 . . . . 0.0 110.286 175.078 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 13.7 p -137.09 149.5 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 C-N-CA 124.554 1.142 . . . . 0.0 110.584 174.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.1 m-85 -86.33 162.67 45.1 Favored Pre-proline 0 CA--C 1.545 0.764 0 C-N-CA 124.034 0.934 . . . . 0.0 111.704 175.027 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.475 ' CD ' HG22 ' A' ' 68' ' ' VAL . 62.1 Cg_endo -71.15 -24.97 22.88 Favored 'Trans proline' 0 CA--C 1.539 0.772 0 C-N-CA 122.883 2.389 . . . . 0.0 112.434 -176.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -165.91 55.02 0.1 Allowed 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 126.755 2.022 . . . . 0.0 111.844 -176.435 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 7.3 tp-100 -148.06 -63.52 0.26 Allowed 'General case' 0 N--CA 1.478 0.942 0 O-C-N 120.964 -1.085 . . . . 0.0 112.935 179.076 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.06 178.3 41.49 Favored Glycine 0 CA--C 1.534 1.245 0 C-N-CA 124.574 1.083 . . . . 0.0 113.754 -179.165 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.5 m -88.28 153.12 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 125.167 1.387 . . . . 0.0 110.783 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.2 m -140.02 172.45 12.74 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 125.256 1.423 . . . . 0.0 110.635 176.2 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 47.8 ttt-85 -133.81 123.95 25.69 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.108 0.963 . . . . 0.0 112.746 -179.283 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.3 t -69.39 122.76 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 125.751 1.62 . . . . 0.0 111.086 -179.28 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.6 t -108.87 -34.63 6.6 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 124.55 1.14 . . . . 0.0 112.485 178.352 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.14 167.28 29.54 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 126.224 1.81 . . . . 0.0 110.483 175.052 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 50.1 mt -144.89 140.61 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 125.19 1.396 . . . . 0.0 108.993 175.407 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -148.04 169.01 20.86 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.732 0.813 . . . . 0.0 112.568 175.551 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 10.9 m -104.69 143.21 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 124.819 1.248 . . . . 0.0 111.796 175.561 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.66 172.77 18.01 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 124.457 1.103 . . . . 0.0 112.311 174.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.64 121.83 45.47 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 126.137 1.775 . . . . 0.0 109.291 175.171 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.7 p -132.77 136.83 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 124.443 1.097 . . . . 0.0 109.259 174.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.91 29.05 1.54 Allowed 'General case' 0 CA--C 1.556 1.206 0 N-CA-C 114.939 1.459 . . . . 0.0 114.939 -177.063 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.9 26.21 50.21 Favored Glycine 0 CA--C 1.541 1.666 0 C-N-CA 124.76 1.172 . . . . 0.0 115.349 -177.2 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -134.44 113.46 11.88 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.054 1.742 . . . . 0.0 109.7 -175.54 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 20.9 tttt -96.85 116.4 29.1 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 124.696 1.199 . . . . 0.0 111.677 -179.682 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.525 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.9 OUTLIER -159.73 174.55 14.36 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 123.634 0.774 . . . . 0.0 112.203 -179.682 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 17.6 m -79.06 116.39 19.32 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.588 1.555 . . . . 0.0 112.107 176.03 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -104.77 113.28 26.78 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 124.416 1.086 . . . . 0.0 109.88 175.908 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 25.4 m -63.68 151.92 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 O-C-N 121.707 -0.621 . . . . 0.0 111.5 175.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -126.51 109.82 12.58 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-O 121.723 0.773 . . . . 0.0 110.499 176.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 5.2 mpp? -113.42 157.52 21.82 Favored 'General case' 0 C--O 1.232 0.144 0 C-N-CA 124.804 1.242 . . . . 0.0 111.616 176.78 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 43.1 mtp85 -133.88 105.58 6.84 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 126.191 1.797 . . . . 0.0 109.926 179.623 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 46.8 mtp85 -74.91 109.05 8.06 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.664 0.786 . . . . 0.0 109.435 175.034 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -69.73 -14.55 62.84 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 176.558 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -57.96 -43.2 86.3 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 126.072 1.749 . . . . 0.0 112.97 175.115 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -128.57 -12.93 4.88 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 125.024 1.33 . . . . 0.0 114.123 -177.886 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.92 4.88 78.19 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 125.935 1.731 . . . . 0.0 114.802 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -75.04 161.44 29.45 Favored 'General case' 0 CA--C 1.543 0.692 0 CA-C-N 118.532 1.166 . . . . 0.0 113.166 179.469 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.3 m -105.85 139.24 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 125.397 1.479 . . . . 0.0 109.865 174.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.3 t -123.31 114.96 44.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.82 1.248 . . . . 0.0 108.427 177.146 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.1 tmm? -127.97 123.91 35.97 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 124.94 1.296 . . . . 0.0 109.547 178.812 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.4 m -131.56 155.02 82.0 Favored Pre-proline 0 N--CA 1.469 0.52 0 C-N-CA 124.592 1.157 . . . . 0.0 111.388 176.868 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.525 ' CB ' HD11 ' A' ' 42' ' ' LEU . 46.4 Cg_endo -76.68 118.52 4.86 Favored 'Trans proline' 0 CA--C 1.536 0.577 0 C-N-CA 123.488 2.792 . . . . 0.0 114.763 177.597 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -59.87 -41.03 90.65 Favored 'General case' 0 N--CA 1.475 0.775 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.89 6.31 79.35 Favored Glycine 0 N--CA 1.475 1.299 0 C-N-CA 124.344 0.974 . . . . 0.0 114.69 178.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.9 tttp -132.98 3.63 3.74 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.667 1.587 . . . . 0.0 112.773 -178.533 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.61 -30.07 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 C-N-CA 125.128 1.371 . . . . 0.0 113.453 175.149 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.8 mt -55.93 -29.33 59.94 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 126.208 1.803 . . . . 0.0 112.652 177.591 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.83 -49.16 21.59 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 125.702 1.601 . . . . 0.0 112.837 175.76 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.405 HG22 HG23 ' A' ' 68' ' ' VAL . 4.0 mp -69.12 -33.61 59.35 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 124.202 1.001 . . . . 0.0 111.387 178.327 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.38 3.06 78.93 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 125.717 1.627 . . . . 0.0 114.365 -175.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.475 HG22 ' CD ' ' A' ' 22' ' ' PRO . 71.6 t -75.79 148.58 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 CA-C-N 118.47 1.135 . . . . 0.0 110.281 175.002 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.38 109.3 10.97 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-O 122.033 0.921 . . . . 0.0 108.679 175.018 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.435 ' HE2' ' HG ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER . . . . . 0 N--CA 1.466 0.37 0 C-N-CA 125.5 1.52 . . . . 0.0 108.896 179.42 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.184 0 CA-C-O 120.67 0.271 . . . . 0.0 111.344 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 75.15 154.89 4.55 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 125.384 1.469 . . . . 0.0 112.996 -173.218 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 19.1 m80 -78.97 144.18 35.02 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 121.771 -0.841 . . . . 0.0 110.466 174.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 5.8 mtm -74.12 163.05 71.1 Favored Pre-proline 0 CA--C 1.544 0.744 0 C-N-CA 123.355 0.662 . . . . 0.0 112.542 175.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -70.61 79.49 1.2 Allowed 'Trans proline' 0 CA--C 1.543 0.94 0 C-N-CA 124.722 3.615 . . . . 0.0 112.287 175.081 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -71.56 174.81 6.19 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 124.097 0.959 . . . . 0.0 112.058 174.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -130.92 124.1 4.06 Favored Glycine 0 C--N 1.342 0.895 0 C-N-CA 124.378 0.989 . . . . 0.0 114.841 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -152.76 18.76 0.6 Allowed 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 125.355 1.462 . . . . 0.0 113.779 -178.611 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -122.85 -170.04 2.03 Favored 'General case' 0 CA--C 1.549 0.923 0 C-N-CA 126.227 1.811 . . . . 0.0 112.267 -176.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -61.84 177.03 0.47 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 126.318 1.847 . . . . 0.0 112.856 175.042 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 10.5 mp -66.49 -73.63 0.13 Allowed 'General case' 0 N--CA 1.473 0.687 0 O-C-N 121.166 -0.959 . . . . 0.0 111.764 178.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 -55.24 140.53 38.66 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 123.937 0.895 . . . . 0.0 112.133 177.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.607 HD21 HG21 ' A' ' 29' ' ' VAL . 1.2 tt -63.14 148.42 48.0 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 123.699 0.799 . . . . 0.0 111.234 175.533 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -129.73 178.85 6.2 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 125.615 1.566 . . . . 0.0 112.045 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.87 133.0 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 O-C-N 121.003 -1.061 . . . . 0.0 110.574 174.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.03 -0.15 87.48 Favored Glycine 0 CA--C 1.532 1.144 0 C-N-CA 124.711 1.148 . . . . 0.0 114.868 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -66.08 171.41 4.62 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 124.39 1.076 . . . . 0.0 112.397 175.001 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -107.07 144.2 34.08 Favored 'General case' 0 N--CA 1.463 0.203 0 C-N-CA 125.392 1.477 . . . . 0.0 111.347 -176.539 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.448 HG21 ' HE2' ' A' ' 47' ' ' MET . 4.9 m -138.84 144.64 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 123.482 0.713 . . . . 0.0 109.76 -176.542 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.0 p -137.09 140.64 42.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 124.527 1.131 . . . . 0.0 109.4 175.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -92.37 161.55 32.35 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 124.488 1.115 . . . . 0.0 111.169 176.425 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -67.9 -14.01 40.08 Favored 'Trans proline' 0 CA--C 1.546 1.106 0 C-N-CA 122.816 2.344 . . . . 0.0 113.632 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.4 m-80 -148.76 -41.19 0.15 Allowed 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 126.064 1.746 . . . . 0.0 114.36 177.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 3.2 tm0? -52.34 -44.41 65.15 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 126.672 1.989 . . . . 0.0 114.107 -172.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 132.26 -150.28 19.6 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 125.937 1.732 . . . . 0.0 111.738 -178.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.9 m -112.27 146.57 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 C-N-CA 125.505 1.522 . . . . 0.0 110.917 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 78.1 m -137.06 179.71 6.22 Favored 'General case' 0 CA--C 1.551 1.016 0 C-N-CA 125.922 1.689 . . . . 0.0 110.589 175.042 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -136.1 129.49 31.92 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 125.185 1.394 . . . . 0.0 110.901 -179.209 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.607 HG21 HD21 ' A' ' 13' ' ' LEU . 26.5 t -68.73 139.21 20.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.362 0.665 . . . . 0.0 110.565 -175.833 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 46.7 t -117.89 -45.44 2.67 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 124.462 1.105 . . . . 0.0 112.647 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -151.93 160.7 43.43 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 124.483 1.113 . . . . 0.0 111.046 175.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -141.93 135.72 29.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 C-N-CA 124.663 1.185 . . . . 0.0 108.653 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -148.4 169.72 19.57 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.453 0.701 . . . . 0.0 111.646 175.298 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.603 HG12 ' HA ' ' A' ' 43' ' ' THR . 21.9 m -109.58 140.42 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 O-C-N 120.782 -1.199 . . . . 0.0 110.203 176.726 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -152.6 169.42 22.71 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.589 0.755 . . . . 0.0 111.974 176.712 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.73 116.22 32.24 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.205 1.402 . . . . 0.0 109.742 174.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.4 p -124.61 139.39 51.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 C-N-CA 124.227 1.011 . . . . 0.0 109.574 175.014 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.52 29.1 1.95 Allowed 'General case' 0 CA--C 1.558 1.253 0 N-CA-C 114.702 1.371 . . . . 0.0 114.702 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.08 25.19 52.97 Favored Glycine 0 CA--C 1.54 1.594 0 C-N-CA 125.044 1.307 . . . . 0.0 115.414 -175.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLN . . . . . 0.404 ' HG2' ' HE3' ' A' ' 62' ' ' LYS . 5.9 tp60 -138.59 115.06 10.49 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 125.85 1.66 . . . . 0.0 111.387 -172.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 10.5 tttt -95.01 118.28 31.56 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.639 1.176 . . . . 0.0 111.79 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.606 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -155.51 171.6 19.65 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.344 0.658 . . . . 0.0 111.662 177.797 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.603 ' HA ' HG12 ' A' ' 34' ' ' VAL . 6.8 m -74.55 116.48 15.28 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.179 0.992 . . . . 0.0 111.296 175.633 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -109.83 113.35 26.03 Favored 'General case' 0 C--O 1.234 0.252 0 C-N-CA 124.627 1.171 . . . . 0.0 110.16 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.662 HG21 ' CE ' ' A' ' 70' ' ' LYS . 24.1 m -80.59 145.75 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.041 179.791 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 16.5 m -126.31 110.12 13.03 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 122.217 1.008 . . . . 0.0 110.972 179.104 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' MET . . . . . 0.448 ' HE2' HG21 ' A' ' 19' ' ' VAL . 2.2 mpp? -109.64 151.0 27.42 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 125.278 1.431 . . . . 0.0 110.095 -178.51 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 37.5 mtm180 -136.17 110.29 8.32 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.69 1.196 . . . . 0.0 109.677 -176.359 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -76.44 109.01 9.81 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 177.863 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -69.73 -13.78 62.46 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.498 1.119 . . . . 0.0 113.818 176.04 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -60.44 -39.49 87.7 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 125.559 1.543 . . . . 0.0 112.75 178.108 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -128.59 -18.82 3.86 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 125.793 1.637 . . . . 0.0 113.915 178.404 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.2 15.42 48.0 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 125.438 1.494 . . . . 0.0 114.766 -177.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -78.41 163.98 25.17 Favored 'General case' 0 CA--C 1.54 0.574 0 CA-C-N 118.416 1.108 . . . . 0.0 112.376 175.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 25.9 m -128.98 142.0 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.146 1.379 . . . . 0.0 110.665 175.451 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 21.9 m -131.87 133.71 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 125.114 1.366 . . . . 0.0 108.719 177.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -129.72 127.11 39.79 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 124.257 1.023 . . . . 0.0 109.051 177.085 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.415 ' O ' HG22 ' A' ' 45' ' ' VAL . 27.5 m -133.73 156.66 79.25 Favored Pre-proline 0 N--CA 1.471 0.596 0 C-N-CA 124.3 1.04 . . . . 0.0 111.635 178.119 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.606 ' CB ' HD11 ' A' ' 42' ' ' LEU . 45.5 Cg_endo -76.1 116.71 4.45 Favored 'Trans proline' 0 CA--C 1.535 0.565 0 C-N-CA 123.567 2.845 . . . . 0.0 114.571 176.391 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -63.65 -34.89 78.84 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 120.537 -1.352 . . . . 0.0 114.024 177.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.1 6.86 78.91 Favored Glycine 0 N--CA 1.473 1.139 0 C-N-CA 124.201 0.905 . . . . 0.0 114.693 176.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.404 ' HE3' ' HG2' ' A' ' 40' ' ' GLN . 0.9 OUTLIER -136.74 3.98 2.77 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.225 1.41 . . . . 0.0 113.698 -178.779 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.486 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.2 m -49.86 -28.54 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.556 1.543 . . . . 0.0 113.421 175.442 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 12.0 mt -56.54 -29.77 62.3 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 125.805 1.642 . . . . 0.0 112.3 176.454 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.51 -49.89 15.35 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.811 1.644 . . . . 0.0 112.493 176.22 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.6 mp -65.7 -32.9 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 124.488 1.115 . . . . 0.0 111.741 177.594 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 85.21 4.41 86.48 Favored Glycine 0 CA--C 1.536 1.379 0 C-N-CA 125.397 1.475 . . . . 0.0 114.093 -175.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 13.9 p -80.83 132.9 30.53 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 124.905 1.282 . . . . 0.0 110.988 175.405 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.6 mmt180 -109.87 109.32 19.92 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 174.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.662 ' CE ' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER -122.32 106.54 11.18 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 123.879 0.872 . . . . 0.0 109.337 177.071 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.401 ' HB ' ' HB3' ' A' ' 74' ' ' ALA . 4.4 t -155.45 165.42 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 124.791 1.236 . . . . 0.0 109.276 -178.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -51.89 -28.07 14.99 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 113.661 0.986 . . . . 0.0 113.661 174.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.6 t -120.97 -41.59 2.54 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.43 1.092 . . . . 0.0 113.285 176.217 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.401 ' HB3' ' HB ' ' A' ' 71' ' ' VAL . . . -64.66 131.66 47.54 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.011 0.924 . . . . 0.0 113.315 -179.509 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 . . . . . 0 C--O 1.254 1.325 0 C-N-CA 128.531 2.732 . . . . 0.0 111.581 175.026 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.24 0 CA-C-O 119.395 -0.336 . . . . 0.0 111.373 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.61 113.49 0.57 Allowed Glycine 0 N--CA 1.472 1.063 0 C-N-CA 124.381 0.991 . . . . 0.0 112.669 -179.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.0 m80 -92.77 105.97 18.02 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.056 0.943 . . . . 0.0 110.805 174.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -86.69 162.02 46.06 Favored Pre-proline 0 CA--C 1.543 0.697 0 C-N-CA 124.669 1.188 . . . . 0.0 110.619 174.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.574 ' HG3' HG11 ' A' ' 20' ' ' VAL . 71.7 Cg_endo -68.94 136.05 34.12 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 122.716 2.277 . . . . 0.0 109.811 175.006 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -142.22 169.15 18.12 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 126.688 1.995 . . . . 0.0 110.647 176.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.41 -147.51 8.58 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 125.169 1.366 . . . . 0.0 111.303 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.5 t -131.15 -74.33 0.53 Allowed 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 123.835 0.854 . . . . 0.0 111.845 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -165.97 118.66 1.1 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.238 1.815 . . . . 0.0 110.307 177.406 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.67 158.17 43.85 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.589 1.155 . . . . 0.0 111.229 178.778 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 50.8 mt -115.66 -71.67 0.73 Allowed 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 124.627 1.171 . . . . 0.0 111.11 -179.433 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.65 148.4 35.05 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 124.886 1.274 . . . . 0.0 111.671 175.775 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -82.34 128.97 34.74 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.62 1.168 . . . . 0.0 110.841 175.012 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.22 174.51 10.47 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.503 1.521 . . . . 0.0 111.39 176.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.5 t -60.89 126.2 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 123.718 0.807 . . . . 0.0 110.772 177.647 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.55 -8.74 74.45 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 125.131 1.348 . . . . 0.0 115.186 -176.442 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.1 t0 -71.51 167.6 19.33 Favored 'General case' 0 CA--C 1.548 0.9 0 CA-C-N 119.195 1.497 . . . . 0.0 111.4 174.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 12.4 tpp180 -92.98 151.39 19.94 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.036 0.934 . . . . 0.0 111.877 -179.239 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.669 HG11 ' HG2' ' A' ' 47' ' ' MET . 2.0 p -151.99 130.01 2.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 C-N-CA 124.895 1.278 . . . . 0.0 110.622 178.667 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.574 HG11 ' HG3' ' A' ' 5' ' ' PRO . 3.6 p -137.09 155.82 33.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 C-N-CA 125.837 1.655 . . . . 0.0 108.484 174.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.466 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.5 OUTLIER -101.46 158.69 31.3 Favored Pre-proline 0 CA--C 1.537 0.467 0 C-N-CA 125.047 1.339 . . . . 0.0 111.373 175.091 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.446 ' CD ' HG12 ' A' ' 68' ' ' VAL . 66.7 Cg_endo -68.21 -21.48 41.89 Favored 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 123.103 2.536 . . . . 0.0 112.458 -176.452 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -159.8 51.31 0.33 Allowed 'General case' 0 CA--C 1.557 1.221 0 C-N-CA 124.875 1.27 . . . . 0.0 112.896 176.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -140.36 -61.6 0.51 Allowed 'General case' 0 N--CA 1.483 1.216 0 O-C-N 120.835 -1.166 . . . . 0.0 113.116 -177.659 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 162.42 174.98 32.97 Favored Glycine 0 CA--C 1.534 1.245 0 C-N-CA 124.927 1.251 . . . . 0.0 113.65 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.9 t -91.19 140.42 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 125.461 1.504 . . . . 0.0 110.233 176.329 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 38.1 m -130.34 -177.85 4.5 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 126.258 1.823 . . . . 0.0 110.198 178.481 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 -141.96 124.21 15.56 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.074 0.95 . . . . 0.0 110.661 176.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.7 t -58.24 121.32 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 123.849 0.859 . . . . 0.0 110.815 -178.198 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.5 t -116.28 -35.2 4.4 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.458 1.503 . . . . 0.0 112.179 -175.498 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -148.14 157.95 43.8 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 125.179 1.392 . . . . 0.0 110.914 175.049 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 65.6 mt -143.15 132.59 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 O-C-N 120.816 -1.177 . . . . 0.0 108.242 175.238 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -138.51 172.25 13.16 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 125.247 1.419 . . . . 0.0 111.422 175.107 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.474 HG22 ' HA ' ' A' ' 43' ' ' THR . 21.9 t -129.88 136.9 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.619 1.168 . . . . 0.0 109.3 179.682 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.0 ptmt -144.46 161.98 37.69 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.694 1.198 . . . . 0.0 111.817 177.535 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -90.14 116.05 27.85 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 124.458 1.103 . . . . 0.0 109.631 175.111 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 p -112.72 128.14 69.58 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 125.348 1.459 . . . . 0.0 109.346 174.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.94 29.07 3.17 Favored 'General case' 0 CA--C 1.557 1.214 0 N-CA-C 114.815 1.413 . . . . 0.0 114.815 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.86 23.57 55.31 Favored Glycine 0 CA--C 1.541 1.715 0 C-N-CA 124.647 1.117 . . . . 0.0 115.323 -175.287 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -138.25 118.7 13.8 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 126.277 1.831 . . . . 0.0 111.194 178.513 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.461 ' HG2' HG12 ' A' ' 34' ' ' VAL . 1.8 tttt -85.68 135.85 33.6 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 123.904 0.882 . . . . 0.0 111.439 175.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.594 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.5 OUTLIER -154.93 159.16 40.23 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 122.823 0.449 . . . . 0.0 111.832 177.633 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.474 ' HA ' HG22 ' A' ' 34' ' ' VAL . 6.6 m -68.99 116.69 9.74 Favored 'General case' 0 N--CA 1.478 0.956 0 C-N-CA 124.056 0.942 . . . . 0.0 111.835 178.047 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -104.72 113.15 26.55 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 119.667 1.121 . . . . 0.0 110.776 174.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.7 m -84.73 136.86 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 123.796 0.838 . . . . 0.0 110.71 178.01 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 13.6 m -126.49 132.24 51.45 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 122.924 1.345 . . . . 0.0 111.876 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' MET . . . . . 0.669 ' HG2' HG11 ' A' ' 19' ' ' VAL . 0.7 OUTLIER -130.13 161.93 29.98 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 125.151 1.381 . . . . 0.0 110.661 -174.217 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 14.3 mtp85 -131.09 103.12 6.33 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.911 1.284 . . . . 0.0 110.425 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.75 109.06 13.81 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.612 0.765 . . . . 0.0 110.766 177.345 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -63.56 -20.41 65.61 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.901 1.28 . . . . 0.0 112.72 178.617 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -58.63 -38.45 78.09 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.207 1.803 . . . . 0.0 113.344 -178.28 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -128.56 4.18 5.58 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 125.797 1.639 . . . . 0.0 112.702 174.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 62.91 29.86 75.49 Favored Glycine 0 CA--C 1.533 1.196 0 C-N-CA 125.526 1.536 . . . . 0.0 113.711 -174.336 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.62 172.26 7.6 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 118.343 1.072 . . . . 0.0 111.399 -174.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 30.3 m -114.55 144.25 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 C-N-CA 123.566 0.746 . . . . 0.0 111.098 174.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.9 t -124.33 112.11 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.253 1.421 . . . . 0.0 107.987 176.519 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.2 ttt -120.73 118.82 31.06 Favored 'General case' 0 C--O 1.235 0.317 0 C-N-CA 124.516 1.126 . . . . 0.0 109.734 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.433 HG21 ' NZ ' ' A' ' 70' ' ' LYS . 17.1 m -137.03 158.32 72.98 Favored Pre-proline 0 N--CA 1.471 0.607 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -178.842 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.594 ' CB ' HD11 ' A' ' 42' ' ' LEU . 64.7 Cg_endo -78.69 111.87 3.05 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.192 2.595 . . . . 0.0 114.56 176.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -60.95 -35.28 76.32 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 120.398 -1.439 . . . . 0.0 113.567 178.264 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.12 5.74 78.58 Favored Glycine 0 N--CA 1.474 1.222 0 C-N-CA 124.543 1.068 . . . . 0.0 114.961 176.73 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -135.51 1.47 2.86 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 125.207 1.403 . . . . 0.0 113.353 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.559 HG13 ' O ' ' A' ' 59' ' ' PRO . 3.0 m -49.86 -28.1 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.917 1.687 . . . . 0.0 114.149 176.524 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.1 mt -56.22 -34.53 66.4 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.064 1.746 . . . . 0.0 112.071 175.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.78 -48.61 45.45 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.779 1.632 . . . . 0.0 112.586 177.005 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.404 HG22 HG13 ' A' ' 68' ' ' VAL . 3.5 mp -68.28 -27.92 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 123.972 0.909 . . . . 0.0 111.49 176.432 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.78 19.49 63.38 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.433 1.492 . . . . 0.0 113.853 -178.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.466 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 15.6 m -95.27 123.16 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 126.254 1.821 . . . . 0.0 111.059 -175.583 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 11.0 mmt180 -107.7 109.24 20.79 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 121.272 -0.892 . . . . 0.0 109.076 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.509 ' HB3' HG23 ' A' ' 19' ' ' VAL . 0.0 OUTLIER -100.97 106.59 17.92 Favored 'General case' 0 N--CA 1.473 0.689 0 O-C-N 121.525 -0.734 . . . . 0.0 110.558 -179.338 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.548 HG12 ' H ' ' A' ' 72' ' ' ALA . 1.6 t -153.98 176.68 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 123.412 0.685 . . . . 0.0 110.168 -175.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ALA . . . . . 0.548 ' H ' HG12 ' A' ' 71' ' ' VAL . . . -61.98 -19.44 62.81 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 125.018 1.327 . . . . 0.0 114.269 175.013 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 3.5 m -138.31 -51.3 0.58 Allowed 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 125.472 1.509 . . . . 0.0 113.311 178.35 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.439 ' HB3' ' CG2' ' A' ' 71' ' ' VAL . . . -56.11 147.21 20.81 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 124.121 0.969 . . . . 0.0 112.497 176.883 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 24.8 pt-20 . . . . . 0 C--O 1.255 1.372 0 C-N-CA 128.062 2.545 . . . . 0.0 113.11 -178.081 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.275 0 N-CA-C 110.568 -0.16 . . . . 0.0 110.568 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 157.26 -168.93 34.21 Favored Glycine 0 CA--C 1.535 1.317 0 C-N-CA 125.011 1.291 . . . . 0.0 112.858 -178.442 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 -56.98 133.91 55.28 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 123.943 0.897 . . . . 0.0 111.979 174.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -88.36 163.63 35.8 Favored Pre-proline 0 CA--C 1.544 0.747 0 C-N-CA 125.388 1.475 . . . . 0.0 112.425 175.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.46 ' HG3' HG11 ' A' ' 20' ' ' VAL . 75.1 Cg_endo -72.35 124.69 10.12 Favored 'Trans proline' 0 CA--C 1.539 0.749 0 C-N-CA 124.048 3.165 . . . . 0.0 110.931 174.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -134.87 116.64 14.99 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.98 1.312 . . . . 0.0 110.455 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.72 -172.38 30.11 Favored Glycine 0 CA--C 1.534 1.256 0 C-N-CA 125.331 1.443 . . . . 0.0 112.919 -178.33 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.2 m -59.11 95.51 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 126.544 1.937 . . . . 0.0 112.912 -177.704 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -61.84 126.38 27.14 Favored 'General case' 0 CA--C 1.545 0.762 0 O-C-N 121.26 -0.9 . . . . 0.0 112.413 -176.335 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.9 t -154.51 169.92 22.66 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.852 1.261 . . . . 0.0 112.333 178.279 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 6.0 mp -79.6 -61.62 1.94 Allowed 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.837 1.255 . . . . 0.0 111.151 176.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -77.81 177.36 8.25 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.505 1.522 . . . . 0.0 111.66 177.838 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.444 HD11 HG21 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -118.2 124.51 48.09 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.712 1.205 . . . . 0.0 110.602 -179.981 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -128.37 169.65 14.01 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.9 1.68 . . . . 0.0 112.052 178.594 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.4 t -63.75 130.47 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 O-C-N 121.226 -0.921 . . . . 0.0 110.693 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.73 -8.81 76.45 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.216 1.389 . . . . 0.0 114.663 -177.3 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -67.65 154.91 40.42 Favored 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 118.958 1.379 . . . . 0.0 110.818 174.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -74.96 157.41 35.01 Favored 'General case' 0 N--CA 1.472 0.664 0 O-C-N 121.312 -0.867 . . . . 0.0 110.046 174.941 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 14.9 m -149.25 138.2 15.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 C-N-CA 124.676 1.19 . . . . 0.0 110.449 179.279 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.46 HG11 ' HG3' ' A' ' 5' ' ' PRO . 7.6 p -137.09 157.79 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 125.355 1.462 . . . . 0.0 109.56 177.549 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -102.9 160.36 26.45 Favored Pre-proline 0 CA--C 1.542 0.667 0 C-N-CA 124.919 1.288 . . . . 0.0 111.732 175.034 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_endo -68.95 -28.02 29.71 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 123.806 3.004 . . . . 0.0 112.102 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.8 t30 -158.51 55.5 0.44 Allowed 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 124.472 1.109 . . . . 0.0 112.848 177.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.82 -60.79 0.29 Allowed 'General case' 0 N--CA 1.482 1.139 0 O-C-N 121.009 -1.057 . . . . 0.0 113.351 -174.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 162.43 -173.34 38.7 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 124.818 1.199 . . . . 0.0 113.59 -177.467 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.7 p -100.49 144.95 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 126.362 1.865 . . . . 0.0 110.945 176.211 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.417 ' SG ' HG21 ' A' ' 56' ' ' VAL . 38.7 m -131.75 -175.85 3.85 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 125.49 1.516 . . . . 0.0 110.306 175.434 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -137.53 124.8 21.78 Favored 'General case' 0 N--CA 1.48 1.028 0 O-C-N 121.091 -1.006 . . . . 0.0 111.634 177.021 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.444 HG21 HD11 ' A' ' 13' ' ' LEU . 60.4 t -64.61 136.04 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 C-N-CA 124.425 1.09 . . . . 0.0 110.657 -179.493 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.5 p -115.44 -44.95 2.94 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 124.635 1.174 . . . . 0.0 113.026 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.3 163.56 37.25 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 126.319 1.847 . . . . 0.0 110.796 176.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 75.0 mt -141.83 132.82 26.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 124.543 1.137 . . . . 0.0 108.979 178.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -147.37 167.23 24.86 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.615 0.766 . . . . 0.0 112.581 175.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.485 HG12 ' HA ' ' A' ' 43' ' ' THR . 20.9 m -103.3 141.93 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 O-C-N 121.117 -0.989 . . . . 0.0 110.699 175.703 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 3.9 ptmt -154.83 170.18 22.24 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 124.25 1.02 . . . . 0.0 112.234 175.47 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -102.46 116.34 32.42 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 125.999 1.72 . . . . 0.0 109.579 175.013 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.6 p -126.5 137.87 56.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.901 0.88 . . . . 0.0 110.025 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.5 28.97 1.89 Allowed 'General case' 0 CA--C 1.558 1.251 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 -177.742 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.28 22.69 53.81 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 125.172 1.367 . . . . 0.0 115.516 -176.565 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 35.8 tt0 -136.51 113.7 10.65 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 119.062 1.431 . . . . 0.0 111.666 -173.604 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 13.0 tttt -94.47 116.04 28.32 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.054 1.342 . . . . 0.0 111.747 -178.135 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.614 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -157.16 173.26 17.25 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.394 0.678 . . . . 0.0 111.887 177.777 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.485 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.2 m -73.96 116.41 14.55 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 124.934 1.293 . . . . 0.0 111.351 175.016 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -109.44 113.22 25.85 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.614 1.166 . . . . 0.0 109.939 177.195 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.613 HG21 ' HE2' ' A' ' 70' ' ' LYS . 27.3 m -73.61 150.71 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 O-C-N 121.817 -0.552 . . . . 0.0 110.894 177.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.2 m -126.5 121.18 31.62 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.801 0.84 . . . . 0.0 110.407 176.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -124.43 158.98 31.49 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 125.759 1.624 . . . . 0.0 110.51 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 13.4 ptm180 -136.18 111.5 9.11 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 126.061 1.744 . . . . 0.0 110.306 -178.153 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.9 109.07 19.08 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 123.258 0.623 . . . . 0.0 109.95 176.596 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 22.5 pt-20 -65.16 -18.43 65.3 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 113.337 0.866 . . . . 0.0 113.337 177.821 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -59.78 -36.72 77.26 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.027 1.731 . . . . 0.0 113.379 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -128.62 3.24 5.53 Favored 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.98 1.312 . . . . 0.0 112.665 174.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 64.61 24.18 69.37 Favored Glycine 0 CA--C 1.535 1.341 0 C-N-CA 125.447 1.498 . . . . 0.0 114.089 -172.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -90.74 173.53 7.97 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 118.671 1.236 . . . . 0.0 111.429 -176.361 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 27.0 m -117.9 143.77 27.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 124.168 0.987 . . . . 0.0 110.483 174.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.417 HG21 ' SG ' ' A' ' 27' ' ' CYS . 45.0 t -125.86 112.31 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 C-N-CA 125.375 1.47 . . . . 0.0 107.499 177.428 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.1 tmm? -125.34 119.34 28.1 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.145 0.978 . . . . 0.0 109.972 176.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.8 m -132.14 156.76 79.71 Favored Pre-proline 0 N--CA 1.469 0.519 0 C-N-CA 124.746 1.219 . . . . 0.0 111.834 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.614 ' CB ' HD11 ' A' ' 42' ' ' LEU . 58.3 Cg_endo -78.01 113.61 3.46 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 124.053 3.169 . . . . 0.0 115.38 179.576 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -60.78 -34.42 74.46 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 120.134 -1.604 . . . . 0.0 114.315 178.009 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.17 5.57 78.37 Favored Glycine 0 N--CA 1.474 1.218 0 C-N-CA 124.202 0.905 . . . . 0.0 114.847 176.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 17.4 tttt -137.56 3.05 2.51 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 125.413 1.485 . . . . 0.0 113.212 -176.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 59' ' ' PRO . 3.0 m -50.21 -29.13 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 C-N-CA 125.581 1.552 . . . . 0.0 113.513 175.393 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.8 mt -58.41 -28.77 65.52 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 126.098 1.759 . . . . 0.0 112.201 177.558 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.9 -51.64 13.32 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.035 1.734 . . . . 0.0 112.479 175.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.538 HG22 HG13 ' A' ' 68' ' ' VAL . 2.3 mp -68.61 -31.11 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 124.192 0.997 . . . . 0.0 111.367 178.07 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.83 10.48 72.4 Favored Glycine 0 CA--C 1.538 1.504 0 C-N-CA 126.047 1.784 . . . . 0.0 114.468 -177.555 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.538 HG13 HG22 ' A' ' 66' ' ' ILE . 31.2 m -97.35 123.47 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 C-N-CA 125.705 1.602 . . . . 0.0 110.75 -173.263 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 21.3 mmt85 -107.2 109.32 21.1 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.613 ' HE2' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER -97.71 106.53 18.85 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -177.472 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.489 ' CG2' ' HB3' ' A' ' 74' ' ' ALA . 0.2 OUTLIER -158.73 171.78 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 C-N-CA 126.257 1.823 . . . . 0.0 110.784 -175.08 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -61.0 -16.46 43.48 Favored 'General case' 0 CA--C 1.547 0.838 0 N-CA-C 115.415 1.635 . . . . 0.0 115.415 178.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.6 t -146.88 -55.71 0.25 Allowed 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 126.758 2.023 . . . . 0.0 111.727 -173.47 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.489 ' HB3' ' CG2' ' A' ' 71' ' ' VAL . . . -55.27 144.5 24.57 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 124.093 0.957 . . . . 0.0 112.515 175.458 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.115 0 C-N-CA 128.333 2.653 . . . . 0.0 113.757 -173.71 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.137 0 CA-C-O 121.22 0.533 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -143.06 77.73 0.28 Allowed Glycine 0 N--CA 1.469 0.842 0 C-N-CA 125.424 1.488 . . . . 0.0 111.666 -177.287 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 28.1 m-70 -63.59 152.94 37.4 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 123.773 0.829 . . . . 0.0 111.507 175.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.12 157.67 38.15 Favored Pre-proline 0 CA--C 1.54 0.592 0 C-N-CA 125.449 1.5 . . . . 0.0 111.894 -179.311 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -70.03 120.45 7.19 Favored 'Trans proline' 0 CA--C 1.535 0.556 0 C-N-CA 122.97 2.447 . . . . 0.0 110.199 176.653 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -138.63 164.96 28.16 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.638 1.175 . . . . 0.0 111.554 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -75.78 170.9 54.57 Favored Glycine 0 CA--C 1.536 1.388 0 C-N-CA 123.344 0.497 . . . . 0.0 113.437 177.091 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 44.7 m -132.78 -78.96 0.49 Allowed 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 124.687 1.195 . . . . 0.0 111.252 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -158.31 48.01 0.36 Allowed 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 125.447 1.499 . . . . 0.0 112.331 -178.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 24.0 m -130.1 163.96 25.45 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 125.619 1.568 . . . . 0.0 112.474 -179.156 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.1 mp -117.0 -34.81 4.28 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.298 1.439 . . . . 0.0 113.014 -177.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 33.5 mt-30 -131.14 166.86 20.17 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 126.35 1.86 . . . . 0.0 110.754 179.703 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.521 HD21 ' CG1' ' A' ' 19' ' ' VAL . 0.7 OUTLIER -64.8 123.06 18.38 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 123.956 0.903 . . . . 0.0 110.876 176.469 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.428 ' N ' HD13 ' A' ' 13' ' ' LEU . . . -146.81 176.42 9.89 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.469 1.908 . . . . 0.0 112.137 177.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.3 t -59.14 129.2 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 O-C-N 120.965 -1.084 . . . . 0.0 111.786 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.53 -4.93 85.0 Favored Glycine 0 CA--C 1.534 1.243 0 C-N-CA 125.197 1.38 . . . . 0.0 114.1 -178.219 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -67.32 161.44 25.04 Favored 'General case' 0 CA--C 1.547 0.858 0 CA-C-N 118.454 1.127 . . . . 0.0 112.561 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -96.55 124.14 40.44 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.951 1.701 . . . . 0.0 111.968 -173.446 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.521 ' CG1' HD21 ' A' ' 13' ' ' LEU . 19.4 m -139.75 139.72 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 C-N-CA 123.34 0.656 . . . . 0.0 110.968 -175.102 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.444 HG12 ' HA ' ' A' ' 75' ' ' GLU . 11.9 p -137.03 145.1 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 124.002 0.921 . . . . 0.0 110.384 177.212 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.528 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.9 OUTLIER -74.71 160.51 80.77 Favored Pre-proline 0 CA--C 1.547 0.83 0 O-C-N 121.83 -0.544 . . . . 0.0 110.59 174.997 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.599 ' CD ' HG12 ' A' ' 68' ' ' VAL . 60.8 Cg_endo -67.97 -25.73 38.17 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.04 2.493 . . . . 0.0 112.253 -179.048 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.3 t30 -159.07 48.87 0.33 Allowed 'General case' 0 CA--C 1.554 1.12 0 C-N-CA 124.494 1.117 . . . . 0.0 113.633 178.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -139.41 -64.12 0.5 Allowed 'General case' 0 N--CA 1.482 1.157 0 O-C-N 120.85 -1.156 . . . . 0.0 113.132 -174.808 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 166.39 172.49 33.76 Favored Glycine 0 CA--C 1.533 1.162 0 C-N-CA 125.015 1.293 . . . . 0.0 113.192 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.29 142.58 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 124.893 1.277 . . . . 0.0 110.804 -178.249 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 6.2 m -131.48 173.0 11.54 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.917 1.687 . . . . 0.0 111.148 176.08 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.8 tmt_? -133.76 118.96 18.67 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 125.863 1.665 . . . . 0.0 110.325 -178.022 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.634 HG22 ' SD ' ' A' ' 47' ' ' MET . 39.3 t -60.84 131.1 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 O-C-N 121.762 -0.586 . . . . 0.0 111.01 -175.562 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 83.0 p -112.06 -42.64 3.71 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -178.672 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.8 162.68 34.83 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.527 1.531 . . . . 0.0 110.817 178.438 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 71.1 mt -143.69 136.04 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.5 1.12 . . . . 0.0 108.965 -178.243 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -149.04 163.49 37.37 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 124.352 1.061 . . . . 0.0 111.913 175.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.8 p -106.85 141.91 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 124.593 1.157 . . . . 0.0 109.775 175.346 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.28 168.04 26.68 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 125.259 1.423 . . . . 0.0 110.854 176.233 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -101.38 118.71 37.51 Favored 'General case' 0 N--CA 1.467 0.395 0 C-N-CA 125.307 1.443 . . . . 0.0 109.488 175.41 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.0 p -121.08 132.54 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 124.272 1.029 . . . . 0.0 109.774 174.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.05 29.08 2.29 Favored 'General case' 0 CA--C 1.557 1.218 0 N-CA-C 114.775 1.398 . . . . 0.0 114.775 -178.206 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.29 26.23 48.58 Favored Glycine 0 CA--C 1.542 1.781 0 C-N-CA 124.692 1.139 . . . . 0.0 115.296 -175.111 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 5.9 mt-30 -135.42 113.53 11.27 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 126.401 1.881 . . . . 0.0 111.081 -178.043 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 8.9 tttt -94.01 121.43 35.48 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.968 1.307 . . . . 0.0 111.423 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.613 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -157.1 161.47 39.43 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 122.848 0.459 . . . . 0.0 111.41 178.859 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.4 m -67.77 116.39 8.4 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 121.313 -0.867 . . . . 0.0 110.516 177.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -104.65 113.56 27.22 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 120.869 -1.144 . . . . 0.0 110.041 175.433 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.9 m -83.22 141.16 15.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 C-N-CA 123.525 0.73 . . . . 0.0 110.184 177.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 24.8 m -122.32 112.7 18.44 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.668 1.187 . . . . 0.0 109.896 -178.776 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' MET . . . . . 0.634 ' SD ' HG22 ' A' ' 29' ' ' VAL . 1.0 OUTLIER -112.15 154.9 24.79 Favored 'General case' 0 C--O 1.233 0.224 0 C-N-CA 124.011 0.924 . . . . 0.0 109.405 -178.9 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 41.7 mtm180 -133.72 154.73 50.74 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 124.495 1.118 . . . . 0.0 109.791 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.593 ' HE ' ' HB3' ' A' ' 54' ' ' ALA . 0.2 OUTLIER -120.94 109.08 14.66 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.85 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -67.57 -19.87 65.32 Favored 'General case' 0 CA--C 1.544 0.714 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 177.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -51.1 -46.81 61.97 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 127.046 2.139 . . . . 0.0 112.75 175.423 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -123.61 -19.19 5.89 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.517 1.527 . . . . 0.0 113.424 -179.164 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.25 37.61 8.93 Favored Glycine 0 CA--C 1.538 1.488 0 C-N-CA 125.429 1.49 . . . . 0.0 114.372 -177.456 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.593 ' HB3' ' HE ' ' A' ' 49' ' ' ARG . . . -110.06 166.64 10.79 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.4 1.48 . . . . 0.0 112.085 177.784 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.4 m -129.7 146.91 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 125.047 1.339 . . . . 0.0 111.52 178.467 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.0 m -136.94 112.2 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 C-N-CA 126.409 1.883 . . . . 0.0 109.151 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 9.4 ptt? -107.9 124.45 50.14 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 124.424 1.09 . . . . 0.0 110.364 176.037 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.615 HG21 ' HE2' ' A' ' 70' ' ' LYS . 30.1 m -131.97 157.21 78.83 Favored Pre-proline 0 N--CA 1.469 0.488 0 C-N-CA 123.949 0.9 . . . . 0.0 111.119 -178.442 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.613 ' CB ' HD11 ' A' ' 42' ' ' LEU . 56.1 Cg_endo -77.73 114.94 3.75 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.382 2.721 . . . . 0.0 114.596 176.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -62.54 -35.77 80.51 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 120.37 -1.456 . . . . 0.0 113.909 178.53 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.99 6.35 79.1 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.245 0.926 . . . . 0.0 114.794 176.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 3.0 tttm -136.0 4.5 3.0 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.685 1.594 . . . . 0.0 112.861 -178.705 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -50.05 -30.0 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 126.12 1.768 . . . . 0.0 113.072 175.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.7 mt -55.05 -29.91 58.46 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.315 1.846 . . . . 0.0 112.585 176.578 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.78 -50.47 13.45 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.647 1.579 . . . . 0.0 112.529 177.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.509 HG22 HG13 ' A' ' 68' ' ' VAL . 3.6 mp -66.42 -32.98 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 C-N-CA 124.664 1.186 . . . . 0.0 111.237 177.574 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.4 4.61 76.8 Favored Glycine 0 CA--C 1.534 1.278 0 C-N-CA 125.647 1.594 . . . . 0.0 114.137 -176.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.599 HG12 ' CD ' ' A' ' 22' ' ' PRO . 30.2 m -82.31 137.55 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 124.404 1.082 . . . . 0.0 111.105 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.421 ' HB3' ' HB1' ' A' ' 74' ' ' ALA . 0.6 OUTLIER -117.79 109.62 16.8 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.012 0.925 . . . . 0.0 110.535 175.771 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.615 ' HE2' HG21 ' A' ' 58' ' ' VAL . 0.0 OUTLIER -124.05 106.6 10.5 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 126.51 1.924 . . . . 0.0 109.345 178.403 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 2.7 t -154.05 167.47 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 C-N-CA 124.599 1.159 . . . . 0.0 109.184 177.675 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -52.68 -19.33 2.31 Favored 'General case' 0 CA--C 1.546 0.804 0 N-CA-C 115.536 1.68 . . . . 0.0 115.536 175.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -124.52 -25.33 4.05 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.597 1.559 . . . . 0.0 113.404 175.695 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.421 ' HB1' ' HB3' ' A' ' 69' ' ' ARG . . . -73.98 98.63 3.09 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.585 1.154 . . . . 0.0 111.18 179.4 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.444 ' HA ' HG12 ' A' ' 20' ' ' VAL . 3.3 mt-10 . . . . . 0 C--O 1.253 1.269 0 C-N-CA 126.235 1.814 . . . . 0.0 110.946 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.182 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -91.91 -104.63 1.46 Allowed Glycine 0 N--CA 1.476 1.33 0 C-N-CA 124.641 1.115 . . . . 0.0 111.609 177.471 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.409 ' O ' HG11 ' A' ' 26' ' ' VAL . 32.5 m80 -91.83 144.66 25.26 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.551 1.14 . . . . 0.0 109.94 175.174 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -55.43 155.19 10.37 Favored Pre-proline 0 CA--C 1.546 0.798 0 C-N-CA 125.631 1.572 . . . . 0.0 112.789 175.04 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.419 ' HD3' HG12 ' A' ' 26' ' ' VAL . 82.5 Cg_endo -69.71 118.68 5.83 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 123.231 2.621 . . . . 0.0 110.614 -177.047 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -55.75 121.84 10.1 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.613 1.165 . . . . 0.0 112.371 179.456 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 163.96 155.58 8.35 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.176 0.893 . . . . 0.0 112.522 176.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.6 t -147.23 -33.49 0.28 Allowed 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.43 1.092 . . . . 0.0 113.292 -176.561 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -69.37 165.17 21.32 Favored 'General case' 0 CA--C 1.552 1.028 0 C-N-CA 124.52 1.128 . . . . 0.0 112.052 175.018 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 m -130.36 89.4 2.78 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.786 1.634 . . . . 0.0 111.338 -178.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.4 mp -138.21 179.2 6.59 Favored 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 125.848 1.659 . . . . 0.0 111.553 177.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -58.39 152.96 16.6 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 124.784 1.234 . . . . 0.0 111.836 175.148 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -77.88 123.01 26.23 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.728 0.811 . . . . 0.0 111.109 179.109 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -121.45 169.08 10.99 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 125.926 1.69 . . . . 0.0 111.972 175.005 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.4 t -61.37 129.84 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 O-C-N 121.413 -0.805 . . . . 0.0 110.634 176.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.12 -6.54 78.78 Favored Glycine 0 CA--C 1.534 1.23 0 C-N-CA 124.876 1.227 . . . . 0.0 114.651 -177.677 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -69.61 176.41 3.54 Favored 'General case' 0 CA--C 1.546 0.814 0 CA-C-N 119.079 1.439 . . . . 0.0 110.593 174.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.42 169.91 10.67 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.998 1.38 . . . . 0.0 112.998 -179.673 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.54 HG13 ' HB2' ' A' ' 27' ' ' CYS . 2.5 p -161.02 149.78 5.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 C-N-CA 125.539 1.536 . . . . 0.0 110.643 175.366 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.8 p -127.42 160.43 36.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 126.991 2.116 . . . . 0.0 107.685 174.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -125.84 154.55 73.46 Favored Pre-proline 0 CA--C 1.539 0.547 0 C-N-CA 125.063 1.345 . . . . 0.0 110.974 176.696 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.83 -9.83 26.5 Favored 'Trans proline' 0 CA--C 1.545 1.06 0 C-N-CA 123.17 2.58 . . . . 0.0 113.761 178.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 26.7 m-20 -133.46 -60.17 0.85 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.352 1.861 . . . . 0.0 112.922 176.863 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 65.5 mm-40 -52.48 -54.35 33.56 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 125.133 1.373 . . . . 0.0 112.952 -175.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 114.53 -147.36 18.82 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 125.479 1.514 . . . . 0.0 111.68 -174.059 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.419 HG12 ' HD3' ' A' ' 5' ' ' PRO . 10.2 m -70.17 144.66 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 124.004 0.922 . . . . 0.0 112.984 -177.594 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.54 ' HB2' HG13 ' A' ' 19' ' ' VAL . 30.9 m -141.81 177.53 8.11 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 126.383 1.873 . . . . 0.0 110.653 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -132.38 129.47 39.43 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 124.759 1.224 . . . . 0.0 111.881 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.6 t -72.56 142.48 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 O-C-N 121.758 -0.588 . . . . 0.0 110.946 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.9 t -116.94 -44.78 2.79 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.419 1.488 . . . . 0.0 112.593 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.95 159.27 37.92 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 124.437 1.095 . . . . 0.0 110.553 177.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -142.59 133.59 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 120.911 -1.118 . . . . 0.0 108.823 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -149.47 169.4 20.97 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.298 0.639 . . . . 0.0 111.953 175.566 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.504 HG12 ' HA ' ' A' ' 43' ' ' THR . 18.6 m -103.57 142.59 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 O-C-N 120.942 -1.099 . . . . 0.0 110.576 175.584 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.9 pttt -154.65 172.58 17.65 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.664 0.786 . . . . 0.0 112.011 176.269 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -104.64 116.6 32.33 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 125.727 1.611 . . . . 0.0 110.177 175.032 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.9 p -125.98 137.73 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 C-N-CA 124.262 1.025 . . . . 0.0 109.965 174.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.81 28.86 2.05 Favored 'General case' 0 CA--C 1.556 1.193 0 C-N-CA 125.182 1.393 . . . . 0.0 114.69 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.94 27.94 48.01 Favored Glycine 0 CA--C 1.541 1.701 0 C-N-CA 124.936 1.255 . . . . 0.0 115.144 -174.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.96 115.53 11.28 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 125.577 1.551 . . . . 0.0 111.856 -176.636 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -98.45 111.02 23.51 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 126.104 1.762 . . . . 0.0 111.356 -176.477 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.601 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -155.36 172.82 17.56 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.401 0.68 . . . . 0.0 111.655 -179.425 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.504 ' HA ' HG12 ' A' ' 34' ' ' VAL . 6.0 m -73.64 116.29 14.06 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.248 1.019 . . . . 0.0 111.116 175.441 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -108.94 113.21 25.91 Favored 'General case' 0 N--CA 1.467 0.394 0 O-C-N 121.221 -0.924 . . . . 0.0 109.612 176.612 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.57 HG21 ' HE3' ' A' ' 70' ' ' LYS . 19.3 m -73.2 146.56 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 123.3 0.64 . . . . 0.0 110.452 176.654 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 3.7 m -126.58 109.93 12.67 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 122.623 1.201 . . . . 0.0 110.243 176.12 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' MET . . . . . 0.461 ' HG2' HG11 ' A' ' 19' ' ' VAL . 1.6 mpp? -112.91 165.43 12.34 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.274 1.43 . . . . 0.0 110.483 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 26.8 ptt180 -142.75 117.29 9.72 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 124.835 1.254 . . . . 0.0 110.079 179.295 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 8.7 ttp180 -74.46 109.07 7.64 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.333 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -70.23 -14.32 62.56 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 178.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -57.58 -39.91 77.84 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 126.204 1.802 . . . . 0.0 112.791 176.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.63 -20.94 3.51 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 126.346 1.858 . . . . 0.0 114.75 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.12 14.49 51.46 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 125.104 1.335 . . . . 0.0 115.199 -174.71 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -76.85 163.34 26.86 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-N 118.85 1.325 . . . . 0.0 112.597 175.327 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 33.6 m -108.57 147.66 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.586 1.154 . . . . 0.0 110.344 174.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.2 t -138.53 112.72 8.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 C-N-CA 125.403 1.481 . . . . 0.0 107.699 -178.55 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.24 132.02 53.03 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 123.689 0.795 . . . . 0.0 111.89 178.445 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.449 ' O ' HG22 ' A' ' 45' ' ' VAL . 33.4 m -139.9 157.38 69.66 Favored Pre-proline 0 N--CA 1.473 0.681 0 C-N-CA 124.164 0.985 . . . . 0.0 112.088 -178.528 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.601 ' CB ' HD11 ' A' ' 42' ' ' LEU . 55.5 Cg_endo -77.95 116.28 3.94 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 123.705 2.937 . . . . 0.0 114.576 175.379 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -64.35 -33.74 76.55 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 120.327 -1.483 . . . . 0.0 114.284 178.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.64 6.7 80.08 Favored Glycine 0 N--CA 1.475 1.275 0 O-C-N 121.264 -0.897 . . . . 0.0 114.64 176.06 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 30.5 tttt -137.57 3.11 2.51 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 125.34 1.456 . . . . 0.0 113.194 -177.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.411 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.2 m -49.55 -29.22 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.631 1.572 . . . . 0.0 113.282 176.122 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 12.4 mt -56.08 -29.55 60.71 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.172 1.789 . . . . 0.0 112.574 176.619 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.6 -50.88 12.73 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.891 1.676 . . . . 0.0 112.98 175.35 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.8 mp -65.41 -33.2 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 C-N-CA 124.117 0.967 . . . . 0.0 111.537 178.147 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 87.4 0.2 84.84 Favored Glycine 0 CA--C 1.536 1.364 0 C-N-CA 125.623 1.582 . . . . 0.0 113.97 -175.053 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.402 HG13 HG12 ' A' ' 63' ' ' VAL . 7.7 p -73.53 123.15 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 124.588 1.155 . . . . 0.0 110.338 174.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.418 ' HB3' ' HB1' ' A' ' 74' ' ' ALA . 0.5 OUTLIER -106.07 109.29 21.18 Favored 'General case' 0 N--CA 1.473 0.709 0 O-C-N 121.071 -1.018 . . . . 0.0 108.789 175.174 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.57 ' HE3' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER -117.15 106.63 13.55 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 123.642 0.777 . . . . 0.0 110.177 178.993 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.2 t -154.07 166.39 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 C-N-CA 123.921 0.888 . . . . 0.0 109.478 177.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -55.96 -31.05 62.63 Favored 'General case' 0 CA--C 1.555 1.16 0 C-N-CA 124.414 1.086 . . . . 0.0 112.521 175.009 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 46.5 m -104.29 -41.33 5.81 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 124.764 1.226 . . . . 0.0 112.97 174.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.418 ' HB1' ' HB3' ' A' ' 69' ' ' ARG . . . -62.21 106.83 0.79 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.905 1.282 . . . . 0.0 111.461 -177.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 . . . . . 0 C--O 1.251 1.18 0 C-N-CA 126.503 1.921 . . . . 0.0 113.684 -170.768 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.277 0 N-CA-C 111.435 0.161 . . . . 0.0 111.435 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.68 58.89 0.22 Allowed Glycine 0 CA--C 1.529 0.949 0 C-N-CA 124.378 0.99 . . . . 0.0 112.689 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -57.97 114.75 2.48 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 124.281 1.033 . . . . 0.0 110.848 175.434 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -57.42 156.37 16.23 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 123.828 0.851 . . . . 0.0 112.621 178.609 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -64.03 127.25 18.94 Favored 'Trans proline' 0 CA--C 1.542 0.879 0 C-N-CA 123.341 2.694 . . . . 0.0 111.457 177.274 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -142.98 157.29 44.7 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 125.909 1.683 . . . . 0.0 111.923 177.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 178.56 -178.83 48.76 Favored Glycine 0 CA--C 1.538 1.514 0 C-N-CA 125.929 1.728 . . . . 0.0 113.226 177.682 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 49.7 m -71.9 -171.77 0.75 Allowed 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 125.908 1.683 . . . . 0.0 112.366 175.078 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -124.85 115.37 20.54 Favored 'General case' 0 CA--C 1.546 0.803 0 O-C-N 120.38 -1.45 . . . . 0.0 111.852 177.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.0 m -143.76 170.46 15.83 Favored 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 126.17 1.788 . . . . 0.0 111.615 -179.731 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -69.52 -75.41 0.11 Allowed 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.886 1.275 . . . . 0.0 111.233 176.458 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -78.94 162.08 26.24 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.718 1.207 . . . . 0.0 111.513 175.38 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.469 HD22 ' HB3' ' A' ' 17' ' ' ASP . 9.7 mt -97.33 168.23 10.53 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.549 1.14 . . . . 0.0 112.53 175.015 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -125.62 166.5 16.61 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.981 1.712 . . . . 0.0 111.122 176.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 75.2 t -67.93 131.87 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 123.628 0.771 . . . . 0.0 110.135 175.147 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.03 -3.45 70.18 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 125.84 1.686 . . . . 0.0 114.737 -178.74 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.469 ' HB3' HD22 ' A' ' 13' ' ' LEU . 0.5 OUTLIER -76.63 152.15 35.94 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 119.085 1.443 . . . . 0.0 112.719 -179.29 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -86.89 135.0 33.47 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 125.453 1.501 . . . . 0.0 111.68 -177.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.477 HG23 ' HB2' ' A' ' 27' ' ' CYS . 28.3 m -143.54 135.71 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.796 1.239 . . . . 0.0 111.167 -177.579 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.7 p -102.92 165.63 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 O-C-N 121.152 -0.967 . . . . 0.0 111.33 175.025 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -125.99 158.44 65.94 Favored Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 125.277 1.431 . . . . 0.0 111.886 175.656 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.429 ' CD ' HG12 ' A' ' 68' ' ' VAL . 58.6 Cg_endo -71.36 -40.78 2.85 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 123.328 2.685 . . . . 0.0 112.615 -178.506 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -148.75 32.37 0.78 Allowed 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.707 1.203 . . . . 0.0 112.87 -177.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -130.03 -23.11 2.79 Favored 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 125.817 1.647 . . . . 0.0 114.245 -173.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 104.17 168.15 24.94 Favored Glycine 0 CA--C 1.539 1.592 0 C-N-CA 126.406 1.955 . . . . 0.0 114.436 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 42.9 t -66.52 133.47 31.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 O-C-N 121.1 -1.235 . . . . 0.0 110.338 176.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.477 ' HB2' HG23 ' A' ' 19' ' ' VAL . 63.4 m -122.53 -179.85 4.35 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 126.302 1.841 . . . . 0.0 111.226 178.245 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.0 ttt180 -144.43 120.64 10.84 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 125.066 1.347 . . . . 0.0 110.562 176.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.402 HG21 HD13 ' A' ' 13' ' ' LEU . 39.7 t -57.96 126.76 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 C-N-CA 123.643 0.777 . . . . 0.0 111.089 -177.192 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.3 m -112.99 -36.46 5.1 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 124.748 1.219 . . . . 0.0 113.463 -176.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.88 159.54 41.82 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.96 1.704 . . . . 0.0 110.582 175.212 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 41.0 mt -143.81 118.19 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 124.851 1.26 . . . . 0.0 108.631 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -144.72 171.71 14.02 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 123.653 0.781 . . . . 0.0 112.003 177.33 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.41 HG12 ' HA ' ' A' ' 43' ' ' THR . 14.5 m -111.8 142.18 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 O-C-N 121.331 -0.855 . . . . 0.0 111.455 175.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.46 170.82 21.06 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 124.314 1.045 . . . . 0.0 112.122 175.407 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -102.52 118.29 36.55 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.935 1.694 . . . . 0.0 109.536 174.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.8 p -129.68 137.65 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.695 0.798 . . . . 0.0 109.691 174.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.41 29.2 1.91 Allowed 'General case' 0 CA--C 1.556 1.184 0 C-N-CA 125.17 1.388 . . . . 0.0 114.696 -176.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.2 22.2 55.16 Favored Glycine 0 CA--C 1.538 1.528 0 C-N-CA 125.131 1.348 . . . . 0.0 115.454 -177.23 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -135.97 113.5 10.85 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 119.149 1.475 . . . . 0.0 111.062 -173.38 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -96.0 114.06 25.74 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 125.541 1.536 . . . . 0.0 111.843 -176.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.597 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -158.21 173.69 16.32 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 123.437 0.695 . . . . 0.0 111.924 179.283 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.41 ' HA ' HG12 ' A' ' 34' ' ' VAL . 5.3 m -73.36 116.28 13.73 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.456 1.103 . . . . 0.0 111.165 174.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -108.75 113.13 25.84 Favored 'General case' 0 C--O 1.235 0.311 0 O-C-N 120.969 -1.082 . . . . 0.0 109.43 175.273 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.604 HG21 ' HE3' ' A' ' 70' ' ' LYS . 16.2 m -70.49 150.95 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 CA-C-N 116.242 -0.436 . . . . 0.0 109.993 175.28 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 25.4 m -126.47 128.58 47.16 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 125.252 1.421 . . . . 0.0 109.533 175.444 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.94 166.98 23.73 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 125.674 1.589 . . . . 0.0 110.599 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.23 141.31 27.27 Favored 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 124.347 1.059 . . . . 0.0 111.165 175.004 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 59.9 mtm180 -78.71 124.62 28.38 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.106 1.362 . . . . 0.0 111.059 178.54 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -63.18 -40.64 98.1 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.441 1.096 . . . . 0.0 113.237 177.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -87.09 -46.65 9.6 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.977 0.911 . . . . 0.0 112.666 178.176 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -71.78 -21.61 61.7 Favored 'General case' 0 N--CA 1.475 0.809 0 O-C-N 121.517 -0.739 . . . . 0.0 112.815 -177.399 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 66.26 12.47 58.23 Favored Glycine 0 CA--C 1.536 1.38 0 C-N-CA 126.062 1.791 . . . . 0.0 114.81 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -109.32 145.59 35.74 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.672 1.589 . . . . 0.0 112.56 -168.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 16.3 m -70.21 150.87 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.871 1.268 . . . . 0.0 111.837 177.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.2 t -145.21 123.67 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 125.602 1.561 . . . . 0.0 108.91 178.127 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 43.8 mtt -141.26 121.74 14.12 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 123.813 0.845 . . . . 0.0 109.845 178.009 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 26.8 m -132.67 157.48 78.21 Favored Pre-proline 0 N--CA 1.475 0.796 0 C-N-CA 124.0 0.92 . . . . 0.0 112.335 177.259 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.597 ' CB ' HD11 ' A' ' 42' ' ' LEU . 57.6 Cg_endo -77.91 114.33 3.6 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 123.546 2.831 . . . . 0.0 114.915 178.082 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -60.69 -36.51 78.95 Favored 'General case' 0 N--CA 1.476 0.828 0 O-C-N 120.346 -1.471 . . . . 0.0 114.297 178.791 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.11 5.77 78.61 Favored Glycine 0 N--CA 1.475 1.246 0 C-N-CA 124.338 0.97 . . . . 0.0 114.863 176.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 15.0 tttp -135.88 3.2 2.93 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.286 1.435 . . . . 0.0 113.106 -177.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.441 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.8 m -49.75 -29.87 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 125.635 1.574 . . . . 0.0 113.11 175.68 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.0 mt -57.56 -28.65 63.75 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 126.164 1.786 . . . . 0.0 112.595 176.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.03 -50.04 15.89 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 125.863 1.665 . . . . 0.0 112.605 176.078 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.437 HG22 HG13 ' A' ' 68' ' ' VAL . 4.0 mp -69.56 -33.68 58.05 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 124.15 0.98 . . . . 0.0 111.465 178.624 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.97 3.25 73.67 Favored Glycine 0 CA--C 1.537 1.466 0 C-N-CA 125.799 1.666 . . . . 0.0 114.208 -174.683 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.437 HG13 HG22 ' A' ' 66' ' ' ILE . 31.3 m -71.5 125.96 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 124.774 1.229 . . . . 0.0 110.834 177.685 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.3 mmm180 -109.72 109.34 20.01 Favored 'General case' 0 N--CA 1.474 0.769 0 O-C-N 121.076 -1.015 . . . . 0.0 108.931 175.208 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.604 ' HE3' HG21 ' A' ' 45' ' ' VAL . 0.5 OUTLIER -131.78 106.62 8.23 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 125.901 1.681 . . . . 0.0 109.117 179.803 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.403 HG12 ' H ' ' A' ' 72' ' ' ALA . 3.4 t -153.76 168.28 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 C-N-CA 124.76 1.224 . . . . 0.0 107.708 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ALA . . . . . 0.403 ' H ' HG12 ' A' ' 71' ' ' VAL . . . -53.06 -33.66 52.99 Favored 'General case' 0 CA--C 1.549 0.938 0 CA-C-N 119.097 0.862 . . . . 0.0 112.726 177.275 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 2.0 t -104.52 -16.7 14.98 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.991 1.716 . . . . 0.0 114.46 176.504 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -87.39 89.28 7.94 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.545 1.138 . . . . 0.0 110.394 -179.287 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 . . . . . 0 C--O 1.255 1.361 0 C-N-CA 127.677 2.391 . . . . 0.0 113.556 -169.577 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.299 0 N-CA-C 110.932 -0.025 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 92.05 42.11 4.76 Favored Glycine 0 CA--C 1.534 1.224 0 C-N-CA 124.296 0.95 . . . . 0.0 114.021 -178.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 49.5 m80 -62.35 105.91 0.68 Allowed 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 124.898 1.279 . . . . 0.0 111.155 175.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -76.45 164.16 61.49 Favored Pre-proline 0 CA--C 1.549 0.905 0 C-N-CA 124.166 0.986 . . . . 0.0 113.295 178.513 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -70.6 98.25 0.76 Allowed 'Trans proline' 0 CA--C 1.54 0.806 0 C-N-CA 124.232 3.288 . . . . 0.0 112.383 175.055 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -142.83 161.51 37.91 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 126.116 1.766 . . . . 0.0 111.541 178.44 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 164.85 82.87 0.05 OUTLIER Glycine 0 CA--C 1.534 1.268 0 N-CA-C 114.953 0.741 . . . . 0.0 114.953 -175.077 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 14.8 p -79.73 98.97 7.21 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 125.661 1.584 . . . . 0.0 113.615 177.288 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -152.99 -82.15 0.09 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 124.858 1.263 . . . . 0.0 111.757 174.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 31.9 p -79.15 173.16 12.86 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 126.588 1.955 . . . . 0.0 112.941 177.033 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 45.4 mt -95.64 -66.92 0.88 Allowed 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.693 1.197 . . . . 0.0 111.113 178.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.11 171.14 13.47 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 125.319 1.447 . . . . 0.0 112.114 176.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.605 HD11 HG21 ' A' ' 29' ' ' VAL . 0.6 OUTLIER -73.91 133.38 43.09 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 123.893 0.877 . . . . 0.0 111.492 176.74 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.449 ' N ' HD13 ' A' ' 13' ' ' LEU . . . -140.57 172.74 12.29 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.86 1.664 . . . . 0.0 112.382 175.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 85.2 t -59.72 131.93 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 O-C-N 120.977 -1.077 . . . . 0.0 111.095 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.52 -6.24 83.73 Favored Glycine 0 CA--C 1.535 1.332 0 C-N-CA 125.045 1.307 . . . . 0.0 114.958 -177.717 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -69.65 176.85 3.28 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-N 118.805 1.303 . . . . 0.0 112.815 175.419 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 15.8 mmt85 -119.91 134.15 55.34 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.449 1.5 . . . . 0.0 111.884 -174.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.508 ' CG1' HD21 ' A' ' 13' ' ' LEU . 17.2 m -139.35 136.92 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 125.091 1.356 . . . . 0.0 109.506 -173.721 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.6 p -137.03 139.05 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 C-N-CA 123.989 0.916 . . . . 0.0 110.118 176.503 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -69.61 160.4 79.74 Favored Pre-proline 0 CA--C 1.542 0.646 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 174.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.546 ' CD ' HG22 ' A' ' 68' ' ' VAL . 58.3 Cg_endo -68.8 -27.29 31.52 Favored 'Trans proline' 0 CA--C 1.54 0.802 0 C-N-CA 122.781 2.32 . . . . 0.0 112.326 -177.351 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 56.9 t30 -157.77 47.66 0.38 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 124.401 1.081 . . . . 0.0 113.553 177.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -137.86 -64.19 0.55 Allowed 'General case' 0 N--CA 1.481 1.099 0 O-C-N 121.155 -0.965 . . . . 0.0 112.994 -174.117 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.55 168.44 30.63 Favored Glycine 0 CA--C 1.534 1.246 0 C-N-CA 125.081 1.324 . . . . 0.0 113.398 178.25 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.3 p -77.73 146.83 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 124.891 1.277 . . . . 0.0 111.411 175.062 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.484 ' SG ' HG11 ' A' ' 56' ' ' VAL . 3.7 m -130.36 173.83 10.43 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.568 1.547 . . . . 0.0 111.271 175.761 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.11 117.78 17.92 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.552 1.541 . . . . 0.0 110.909 -176.135 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.605 HG21 HD11 ' A' ' 13' ' ' LEU . 25.4 t -65.95 116.09 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.078 1.351 . . . . 0.0 111.124 -177.665 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.3 m -107.62 -47.85 3.54 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.852 1.261 . . . . 0.0 112.34 -176.318 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -148.8 169.71 19.87 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.334 1.854 . . . . 0.0 110.403 178.185 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 48.8 mt -147.28 140.36 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.054 1.342 . . . . 0.0 108.266 175.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.34 173.65 11.3 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.106 0.962 . . . . 0.0 112.313 175.706 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.468 HG12 ' HA ' ' A' ' 43' ' ' THR . 28.9 m -123.26 140.77 45.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 124.711 1.204 . . . . 0.0 110.728 177.635 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -155.53 167.42 30.44 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 123.935 0.894 . . . . 0.0 112.385 177.209 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -100.56 119.79 39.06 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.349 1.459 . . . . 0.0 108.745 174.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.0 p -127.33 136.8 59.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.851 1.261 . . . . 0.0 109.058 175.062 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.85 28.95 1.48 Allowed 'General case' 0 CA--C 1.557 1.233 0 N-CA-C 114.882 1.438 . . . . 0.0 114.882 -178.003 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.06 26.51 48.54 Favored Glycine 0 CA--C 1.542 1.72 0 C-N-CA 124.822 1.201 . . . . 0.0 115.363 -176.393 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -137.57 116.98 12.79 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 126.229 1.811 . . . . 0.0 110.835 -175.459 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -96.3 118.94 33.87 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 125.338 1.455 . . . . 0.0 111.105 179.85 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.503 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.9 OUTLIER -155.16 172.63 17.84 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 123.432 0.693 . . . . 0.0 111.892 -179.623 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.468 ' HA ' HG12 ' A' ' 34' ' ' VAL . 48.2 m -82.25 116.41 21.77 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.078 1.351 . . . . 0.0 111.943 176.61 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -102.2 113.17 26.22 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.483 1.113 . . . . 0.0 109.529 174.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.0 m -63.04 148.1 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 O-C-N 121.895 -0.503 . . . . 0.0 110.812 174.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 1.5 m -126.61 109.85 12.56 Favored 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 122.09 0.948 . . . . 0.0 110.605 176.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' MET . . . . . 0.455 ' HB2' HG13 ' A' ' 56' ' ' VAL . 2.4 mpp? -123.58 160.17 27.64 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 124.055 0.942 . . . . 0.0 110.239 -178.139 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.469 ' HG3' HG12 ' A' ' 55' ' ' VAL . 1.1 mpt_? -130.91 125.06 32.51 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 123.843 0.857 . . . . 0.0 110.831 174.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 79.4 mtm180 -83.38 109.02 16.96 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 125.355 1.462 . . . . 0.0 108.462 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -65.62 -18.09 65.07 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.865 0.866 . . . . 0.0 112.494 177.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 31.0 tt0 -57.54 -39.22 76.16 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.622 1.969 . . . . 0.0 113.225 177.619 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -128.62 1.73 5.52 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 125.011 1.324 . . . . 0.0 113.645 177.109 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.79 11.77 60.98 Favored Glycine 0 CA--C 1.538 1.476 0 C-N-CA 125.427 1.489 . . . . 0.0 114.306 -171.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -81.04 159.01 24.91 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.489 1.516 . . . . 0.0 112.566 -176.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.469 HG12 ' HG3' ' A' ' 48' ' ' ARG . 20.4 m -97.95 162.05 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 123.481 0.712 . . . . 0.0 110.601 175.033 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.484 HG11 ' SG ' ' A' ' 27' ' ' CYS . 3.9 p -151.95 122.05 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 125.347 1.459 . . . . 0.0 109.111 174.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 19.3 ptm -125.93 135.26 51.68 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 125.076 1.35 . . . . 0.0 110.608 175.113 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.2 m -137.58 154.24 74.88 Favored Pre-proline 0 N--CA 1.468 0.454 0 C-N-CA 123.819 0.847 . . . . 0.0 111.253 175.18 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.503 ' CB ' HD11 ' A' ' 42' ' ' LEU . 44.2 Cg_endo -75.51 117.24 4.73 Favored 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 123.271 2.648 . . . . 0.0 114.439 178.084 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -59.65 -40.53 87.97 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.61 7.31 79.86 Favored Glycine 0 N--CA 1.474 1.173 0 C-N-CA 124.418 1.009 . . . . 0.0 114.588 178.019 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.2 tttm -133.7 3.4 3.53 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.203 1.401 . . . . 0.0 113.509 -178.55 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.5 m -48.75 -28.87 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.933 1.293 . . . . 0.0 113.598 175.007 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.3 mt -57.31 -29.09 63.63 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.989 1.715 . . . . 0.0 112.61 177.276 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.05 -50.61 15.9 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 125.64 1.576 . . . . 0.0 112.673 175.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.463 HG22 HG23 ' A' ' 68' ' ' VAL . 3.9 mp -68.75 -33.55 60.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 124.244 1.018 . . . . 0.0 111.435 178.767 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.7 2.19 79.23 Favored Glycine 0 CA--C 1.537 1.415 0 C-N-CA 125.844 1.688 . . . . 0.0 114.349 -175.198 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.546 HG22 ' CD ' ' A' ' 22' ' ' PRO . 71.6 t -80.69 123.16 37.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 CA-C-N 118.96 1.38 . . . . 0.0 110.472 178.273 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 3.3 mmt180 -99.58 109.24 21.76 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 174.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.7 106.48 13.93 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.527 1.531 . . . . 0.0 109.352 176.521 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 3.2 t -161.37 157.52 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.275 0 C-N-CA 126.281 1.833 . . . . 0.0 109.172 -178.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -54.02 -25.29 20.49 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.893 1.677 . . . . 0.0 115.156 176.389 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 3.5 t -126.7 11.86 7.31 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 126.104 1.762 . . . . 0.0 113.326 -178.308 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -80.95 -66.83 0.84 Allowed 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.483 1.113 . . . . 0.0 112.406 177.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 7.1 tm-20 . . . . . 0 C--O 1.253 1.238 0 C-N-CA 126.062 1.745 . . . . 0.0 112.674 -165.785 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.32 0 CA-C-O 120.636 0.255 . . . . 0.0 111.462 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 168.88 54.47 0.03 OUTLIER Glycine 0 CA--C 1.535 1.301 0 C-N-CA 124.257 0.932 . . . . 0.0 114.073 178.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 19.0 m80 -70.95 135.8 48.11 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.508 1.123 . . . . 0.0 111.98 -179.593 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 5.2 mtt -79.58 163.94 56.25 Favored Pre-proline 0 CA--C 1.545 0.781 0 N-CA-C 113.467 0.914 . . . . 0.0 113.467 176.645 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -72.59 103.93 1.63 Allowed 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 123.694 2.929 . . . . 0.0 109.316 175.01 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -138.0 161.7 36.03 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.458 1.503 . . . . 0.0 111.69 178.376 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.49 ' HA3' ' HB1' ' A' ' 72' ' ' ALA . . . -170.2 -178.38 41.06 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 124.968 1.271 . . . . 0.0 113.149 -177.765 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 24.2 m -85.46 -46.96 10.4 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.21 1.004 . . . . 0.0 113.27 -175.045 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -148.79 167.24 26.14 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.866 1.667 . . . . 0.0 112.473 -179.176 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 39.3 t -86.97 100.59 12.72 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 125.902 1.681 . . . . 0.0 111.294 177.482 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -110.88 168.34 9.55 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 125.881 1.673 . . . . 0.0 111.817 176.604 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.76 143.04 57.77 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 124.88 1.272 . . . . 0.0 111.741 179.063 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -68.47 120.64 14.87 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 124.288 1.035 . . . . 0.0 111.836 -174.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -140.06 172.91 12.08 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.017 1.327 . . . . 0.0 112.559 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.3 t -60.22 126.37 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.123 0.969 . . . . 0.0 110.475 177.203 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.23 -8.36 72.48 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.051 1.31 . . . . 0.0 114.856 -177.468 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -72.2 169.53 15.94 Favored 'General case' 0 CA--C 1.55 0.973 0 CA-C-N 119.215 1.507 . . . . 0.0 111.056 174.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -88.3 159.26 18.16 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.614 1.566 . . . . 0.0 112.018 175.501 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.44 HG13 ' HB2' ' A' ' 27' ' ' CYS . 1.5 p -150.86 130.14 3.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 C-N-CA 124.739 1.216 . . . . 0.0 110.134 175.216 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.2 p -137.19 142.59 36.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 C-N-CA 125.995 1.718 . . . . 0.0 107.903 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.419 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.4 OUTLIER -88.46 161.97 40.94 Favored Pre-proline 0 CA--C 1.545 0.765 0 C-N-CA 124.685 1.194 . . . . 0.0 110.965 175.784 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.67 -26.66 27.77 Favored 'Trans proline' 0 CA--C 1.536 0.59 0 C-N-CA 123.439 2.759 . . . . 0.0 112.37 -175.18 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -158.15 62.77 0.45 Allowed 'General case' 0 CA--C 1.551 1.013 0 C-N-CA 125.863 1.665 . . . . 0.0 111.57 176.011 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -146.43 -61.88 0.31 Allowed 'General case' 0 N--CA 1.481 1.084 0 O-C-N 121.085 -1.009 . . . . 0.0 112.463 179.147 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 158.67 -179.42 34.35 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 124.661 1.124 . . . . 0.0 113.422 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.3 m -81.87 147.8 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.542 1.537 . . . . 0.0 112.037 175.518 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.44 ' HB2' HG13 ' A' ' 19' ' ' VAL . 97.7 m -138.18 179.62 6.34 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.856 2.062 . . . . 0.0 109.851 179.027 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.01 135.6 39.61 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 125.102 1.361 . . . . 0.0 110.462 175.245 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -66.54 129.99 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 C-N-CA 123.95 0.9 . . . . 0.0 110.401 175.074 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -115.06 -51.69 2.71 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.622 1.169 . . . . 0.0 111.759 -178.21 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.73 164.54 37.57 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.849 1.66 . . . . 0.0 110.875 175.571 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 64.2 mt -144.9 134.45 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 O-C-N 120.752 -1.217 . . . . 0.0 108.756 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -143.53 174.09 11.07 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.355 1.062 . . . . 0.0 112.162 176.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.4 p -124.75 137.89 55.94 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 125.168 1.387 . . . . 0.0 110.842 177.378 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 13.2 ptmt -150.74 153.4 35.44 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 124.961 1.304 . . . . 0.0 112.088 178.452 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -81.05 115.18 20.38 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 123.787 0.835 . . . . 0.0 108.924 174.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.6 p -118.6 133.36 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 124.311 1.044 . . . . 0.0 109.653 174.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.54 29.01 2.74 Favored 'General case' 0 CA--C 1.557 1.227 0 N-CA-C 114.772 1.397 . . . . 0.0 114.772 -178.141 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.43 20.42 56.74 Favored Glycine 0 CA--C 1.538 1.529 0 C-N-CA 124.854 1.216 . . . . 0.0 115.422 -175.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -142.87 114.11 7.81 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.491 1.516 . . . . 0.0 111.814 -176.098 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 5.1 ptmt -91.77 133.96 35.16 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.721 1.208 . . . . 0.0 111.656 175.007 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.645 HD11 ' CB ' ' A' ' 59' ' ' PRO . 1.3 pp -160.05 163.58 33.84 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.266 1.026 . . . . 0.0 110.483 176.075 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.0 m -66.39 116.49 7.46 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 121.279 -0.888 . . . . 0.0 110.986 178.012 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -104.91 113.3 26.82 Favored 'General case' 0 N--CA 1.467 0.407 0 O-C-N 120.748 -1.22 . . . . 0.0 109.409 175.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.2 m -75.73 143.68 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-O 119.035 -0.507 . . . . 0.0 110.19 177.042 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -125.82 112.86 16.51 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 122.41 1.1 . . . . 0.0 110.918 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -122.73 165.74 16.07 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.897 1.279 . . . . 0.0 109.647 -176.033 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.5 mtt180 -134.98 160.79 37.2 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 124.425 1.09 . . . . 0.0 110.589 175.141 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -122.28 109.1 14.03 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 125.733 1.613 . . . . 0.0 109.463 174.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -64.86 -17.66 64.48 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 113.331 0.863 . . . . 0.0 113.331 176.206 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -54.63 -44.37 73.1 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 127.199 2.2 . . . . 0.0 112.451 178.358 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -126.19 -1.29 7.05 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.47 1.908 . . . . 0.0 112.494 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.62 34.31 88.61 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 125.157 1.361 . . . . 0.0 113.552 -174.066 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.59 165.61 10.95 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 124.252 1.021 . . . . 0.0 112.145 -176.233 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.5 m -110.28 155.78 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.013 1.325 . . . . 0.0 111.265 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 3.7 p -151.05 125.83 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 124.713 1.205 . . . . 0.0 109.405 175.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 22.8 ptt? -130.21 137.81 50.26 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 123.9 0.88 . . . . 0.0 110.803 175.024 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.461 ' CG2' ' HE2' ' A' ' 70' ' ' LYS . 14.0 m -140.24 157.34 69.01 Favored Pre-proline 0 N--CA 1.474 0.731 0 C-N-CA 123.584 0.754 . . . . 0.0 111.414 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.645 ' CB ' HD11 ' A' ' 42' ' ' LEU . 53.7 Cg_endo -75.59 116.03 4.37 Favored 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 123.726 2.95 . . . . 0.0 114.861 176.482 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -63.97 -33.42 75.69 Favored 'General case' 0 N--CA 1.482 1.132 0 O-C-N 120.394 -1.441 . . . . 0.0 113.573 178.72 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.92 4.57 78.57 Favored Glycine 0 N--CA 1.476 1.328 0 C-N-CA 124.769 1.176 . . . . 0.0 114.686 175.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.0 tttm -136.74 3.84 2.76 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.437 1.495 . . . . 0.0 112.992 -177.207 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.2 m -50.26 -28.31 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 C-N-CA 125.731 1.613 . . . . 0.0 113.012 175.188 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.0 mt -56.02 -30.16 61.45 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 125.945 1.698 . . . . 0.0 112.385 176.479 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.53 -50.34 15.95 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 125.86 1.664 . . . . 0.0 112.828 175.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.486 HG22 HG13 ' A' ' 68' ' ' VAL . 4.0 mp -68.16 -33.38 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 124.054 0.941 . . . . 0.0 111.465 178.565 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.49 3.56 77.91 Favored Glycine 0 CA--C 1.537 1.445 0 C-N-CA 126.166 1.841 . . . . 0.0 114.605 -177.741 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.486 HG13 HG22 ' A' ' 66' ' ' ILE . 31.4 m -82.21 125.56 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 C-N-CA 126.451 1.9 . . . . 0.0 111.216 -178.5 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.69 109.25 17.92 Favored 'General case' 0 N--CA 1.475 0.782 0 O-C-N 121.252 -0.905 . . . . 0.0 110.105 177.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.461 ' HE2' ' CG2' ' A' ' 58' ' ' VAL . 0.0 OUTLIER -98.37 106.59 18.89 Favored 'General case' 0 N--CA 1.47 0.536 0 C-N-CA 123.226 0.61 . . . . 0.0 110.477 178.127 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.6 t -153.35 170.37 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 125.231 1.412 . . . . 0.0 108.567 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ALA . . . . . 0.49 ' HB1' ' HA3' ' A' ' 7' ' ' GLY . . . -61.5 -20.89 63.7 Favored 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 124.547 1.139 . . . . 0.0 113.632 175.053 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 9.0 m -129.27 -40.43 1.46 Allowed 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 125.519 1.528 . . . . 0.0 114.621 178.408 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.91 159.27 20.15 Favored 'General case' 0 CA--C 1.545 0.768 0 CA-C-N 119.002 0.819 . . . . 0.0 112.484 176.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.254 1.328 0 C-N-CA 126.447 1.899 . . . . 0.0 111.945 175.566 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.161 0 CA-C-O 120.605 0.24 . . . . 0.0 110.414 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.59 -165.66 36.28 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 123.806 0.717 . . . . 0.0 113.402 -175.233 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 82.5 m-70 -98.89 146.26 26.16 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 124.463 1.105 . . . . 0.0 111.135 174.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 7.7 ptp -111.93 157.22 40.25 Favored Pre-proline 0 CA--C 1.547 0.831 0 C-N-CA 125.772 1.629 . . . . 0.0 111.523 178.081 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -71.52 132.67 20.94 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 123.99 3.127 . . . . 0.0 111.095 175.668 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -168.17 174.37 7.24 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 126.201 1.8 . . . . 0.0 111.077 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 145.94 179.63 22.3 Favored Glycine 0 CA--C 1.534 1.235 0 C-N-CA 125.627 1.584 . . . . 0.0 112.85 178.58 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 15.9 p -151.95 116.33 5.03 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.376 1.47 . . . . 0.0 111.369 -178.764 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -164.99 -172.99 2.76 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 125.624 1.57 . . . . 0.0 111.564 179.464 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 22.2 m -64.15 172.07 2.63 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 125.509 1.524 . . . . 0.0 112.116 174.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 39.6 mt -84.06 55.64 3.39 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 124.589 1.156 . . . . 0.0 112.402 -177.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.32 117.27 7.73 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 124.049 0.94 . . . . 0.0 111.72 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.94 126.56 30.24 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.096 0.958 . . . . 0.0 110.803 176.26 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -124.79 169.85 11.61 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.141 1.377 . . . . 0.0 112.316 177.193 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.42 129.11 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 O-C-N 121.414 -0.803 . . . . 0.0 110.567 176.305 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.26 -6.15 75.29 Favored Glycine 0 CA--C 1.534 1.231 0 C-N-CA 125.075 1.322 . . . . 0.0 114.901 -179.347 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -68.77 176.74 2.86 Favored 'General case' 0 CA--C 1.549 0.917 0 CA-C-N 119.068 1.434 . . . . 0.0 111.883 174.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.9 mmt180 -113.08 139.57 48.59 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.564 1.545 . . . . 0.0 111.35 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.419 HG21 ' CE ' ' A' ' 47' ' ' MET . 15.1 m -139.71 137.09 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 C-N-CA 124.204 1.002 . . . . 0.0 109.477 -178.508 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.5 p -137.04 137.99 46.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 124.151 0.981 . . . . 0.0 110.085 177.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.465 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 1.3 m-85 -71.67 161.95 75.77 Favored Pre-proline 0 CA--C 1.546 0.826 0 N-CA-C 112.113 0.412 . . . . 0.0 112.113 175.39 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.498 ' CD ' HG12 ' A' ' 68' ' ' VAL . 59.9 Cg_endo -70.11 -28.54 23.46 Favored 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.43 2.753 . . . . 0.0 112.265 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 32.3 m-20 -157.95 64.4 0.46 Allowed 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 127.026 2.13 . . . . 0.0 111.357 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 5.4 mm-40 -151.9 -71.07 0.16 Allowed 'General case' 0 N--CA 1.479 1.021 0 O-C-N 120.794 -1.191 . . . . 0.0 111.776 174.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 173.55 174.09 40.28 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.403 1.478 . . . . 0.0 112.406 -174.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.5 p -84.39 149.3 4.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 124.949 1.299 . . . . 0.0 110.704 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.553 ' SG ' HG11 ' A' ' 56' ' ' VAL . 4.7 m -128.82 174.59 9.34 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.774 1.63 . . . . 0.0 110.52 175.069 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -131.82 118.82 20.4 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 124.004 0.922 . . . . 0.0 110.9 -178.262 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.2 t -57.82 126.88 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 C-N-CA 124.111 0.964 . . . . 0.0 110.593 -179.399 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.9 t -111.01 -51.88 2.83 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 125.135 1.374 . . . . 0.0 110.984 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.81 169.87 21.72 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 124.861 1.265 . . . . 0.0 111.064 177.522 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 62.0 mt -145.2 138.68 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 124.722 1.209 . . . . 0.0 108.457 175.042 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -150.26 167.0 28.24 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 124.853 1.261 . . . . 0.0 112.158 175.482 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 13.8 m -106.77 143.09 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.109 0.964 . . . . 0.0 110.908 176.002 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -155.25 170.82 20.97 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 124.623 1.169 . . . . 0.0 111.795 175.423 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -106.28 116.22 31.57 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.949 1.699 . . . . 0.0 109.697 175.001 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.8 p -125.62 138.03 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 C-N-CA 124.462 1.105 . . . . 0.0 110.725 174.857 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.53 29.09 1.95 Allowed 'General case' 0 CA--C 1.556 1.208 0 C-N-CA 124.856 1.262 . . . . 0.0 114.26 -179.019 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.35 27.04 53.36 Favored Glycine 0 CA--C 1.54 1.604 0 C-N-CA 125.2 1.381 . . . . 0.0 115.613 -174.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.8 tp60 -135.14 113.54 11.48 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.761 1.624 . . . . 0.0 110.436 -175.604 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 18.6 tttt -96.28 114.86 26.58 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 124.899 1.28 . . . . 0.0 111.25 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.5 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -157.59 173.07 17.42 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 123.155 0.582 . . . . 0.0 111.765 179.532 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 17.2 m -79.73 116.58 19.99 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.367 1.067 . . . . 0.0 111.595 175.04 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -102.38 114.5 28.73 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.03 0.932 . . . . 0.0 109.763 175.028 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.513 HG13 ' CG ' ' A' ' 60' ' ' GLU . 5.7 m -66.87 145.27 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 O-C-N 121.863 -0.523 . . . . 0.0 110.783 174.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -126.65 109.8 12.49 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.532 1.133 . . . . 0.0 111.109 -179.445 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' MET . . . . . 0.439 ' HB2' HG13 ' A' ' 56' ' ' VAL . 1.8 mpp? -123.22 160.72 25.99 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 124.229 1.011 . . . . 0.0 110.546 -177.144 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.605 ' HG3' HG12 ' A' ' 55' ' ' VAL . 0.1 OUTLIER -134.64 134.03 40.74 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.875 0.87 . . . . 0.0 110.905 174.859 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 60.9 mtm180 -94.27 108.76 20.62 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 124.824 1.25 . . . . 0.0 108.209 176.303 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -69.53 -17.78 63.61 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.343 1.057 . . . . 0.0 113.562 175.307 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -55.49 -42.12 73.98 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 126.032 1.733 . . . . 0.0 112.538 178.338 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -121.97 -20.25 6.39 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 125.474 1.509 . . . . 0.0 113.387 177.828 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.47 49.15 4.5 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 125.305 1.431 . . . . 0.0 113.122 -177.671 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -125.37 159.98 30.47 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.097 1.359 . . . . 0.0 112.163 178.789 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.605 HG12 ' HG3' ' A' ' 48' ' ' ARG . 27.1 m -98.41 158.62 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.431 1.092 . . . . 0.0 111.117 176.288 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.553 HG11 ' SG ' ' A' ' 27' ' ' CYS . 3.4 p -150.17 122.86 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 125.271 1.428 . . . . 0.0 109.324 175.098 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.0 ptm -126.9 139.44 53.07 Favored 'General case' 0 C--O 1.233 0.211 0 C-N-CA 124.098 0.959 . . . . 0.0 111.018 175.706 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 27.0 m -142.82 154.73 62.75 Favored Pre-proline 0 N--CA 1.468 0.473 0 C-N-CA 123.986 0.914 . . . . 0.0 111.469 177.385 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.5 ' CB ' HD11 ' A' ' 42' ' ' LEU . 43.6 Cg_endo -74.8 119.92 5.9 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.156 2.571 . . . . 0.0 114.381 177.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.513 ' CG ' HG13 ' A' ' 45' ' ' VAL . 14.1 mt-10 -62.09 -39.93 94.11 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 178.818 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.27 7.71 78.01 Favored Glycine 0 N--CA 1.475 1.273 0 C-N-CA 124.677 1.132 . . . . 0.0 114.762 178.624 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 7.9 tttt -135.53 5.56 3.19 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.775 1.63 . . . . 0.0 112.451 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.462 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -49.65 -29.36 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 C-N-CA 125.329 1.452 . . . . 0.0 113.476 174.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 11.4 mt -58.01 -28.68 64.67 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.003 1.721 . . . . 0.0 112.286 177.178 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.42 -51.01 14.07 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.834 1.653 . . . . 0.0 112.218 177.202 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.485 HG22 HG13 ' A' ' 68' ' ' VAL . 4.5 mp -67.53 -29.47 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 124.375 1.07 . . . . 0.0 111.216 176.479 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 84.61 8.39 83.06 Favored Glycine 0 CA--C 1.536 1.358 0 C-N-CA 125.815 1.674 . . . . 0.0 114.069 -176.304 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.498 HG12 ' CD ' ' A' ' 22' ' ' PRO . 17.0 m -90.84 123.32 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 125.373 1.469 . . . . 0.0 111.345 -175.302 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.35 109.6 21.51 Favored 'General case' 0 N--CA 1.469 0.507 0 O-C-N 120.881 -1.137 . . . . 0.0 109.434 178.224 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.61 106.63 17.72 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.989 0.916 . . . . 0.0 109.06 177.271 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 85.8 t -150.41 -75.81 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 124.68 1.192 . . . . 0.0 111.246 179.437 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -177.57 -45.44 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 127.666 2.386 . . . . 0.0 111.186 -179.094 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -127.33 -1.69 6.3 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 126.49 1.916 . . . . 0.0 113.957 -178.393 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -73.71 -53.6 10.0 Favored 'General case' 0 CA--C 1.548 0.889 0 C-N-CA 125.332 1.453 . . . . 0.0 113.069 -176.532 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . 0.315 13.3 pt-20 . . . . . 0 N--CA 1.486 1.349 0 C-N-CA 131.571 3.948 . . . . 0.0 118.524 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.183 0 CA-C-O 120.666 0.269 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.86 39.82 0.39 Allowed Glycine 0 N--CA 1.475 1.285 0 C-N-CA 124.043 0.83 . . . . 0.0 114.441 -175.339 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 37.6 m170 -80.81 105.94 12.43 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 124.406 1.082 . . . . 0.0 111.781 177.161 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.3 mtm -67.64 161.09 68.94 Favored Pre-proline 0 CA--C 1.551 1.002 0 C-N-CA 124.63 1.172 . . . . 0.0 112.157 174.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -72.42 89.55 0.82 Allowed 'Trans proline' 0 CA--C 1.547 1.131 0 C-N-CA 124.491 3.461 . . . . 0.0 112.942 -179.337 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 10.2 mt-10 -75.39 -63.87 1.19 Allowed 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 124.35 1.06 . . . . 0.0 113.585 174.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 82.83 -110.79 3.29 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 124.706 1.146 . . . . 0.0 113.335 -178.002 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.7 t -144.01 173.28 11.86 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 125.078 1.351 . . . . 0.0 112.436 -178.669 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -82.41 63.39 6.56 Favored 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 125.979 1.712 . . . . 0.0 112.263 -179.473 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.5 m -142.06 169.25 17.94 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 125.701 1.601 . . . . 0.0 111.73 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -109.03 -45.37 3.79 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 124.988 1.315 . . . . 0.0 111.429 174.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 40.3 mt-30 -68.12 170.08 9.1 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 124.681 1.192 . . . . 0.0 111.834 176.233 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.642 HD23 ' HA ' ' A' ' 71' ' ' VAL . 0.3 OUTLIER -107.24 126.84 52.94 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 125.013 1.325 . . . . 0.0 111.1 -179.48 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.0 177.28 8.16 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.711 1.604 . . . . 0.0 112.184 176.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.8 t -59.69 129.3 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.175 0.99 . . . . 0.0 110.777 175.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.66 -4.68 85.76 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 124.835 1.207 . . . . 0.0 115.151 -177.633 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -70.83 165.75 22.5 Favored 'General case' 0 CA--C 1.549 0.916 0 CA-C-N 119.211 1.506 . . . . 0.0 111.613 174.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -89.56 148.73 23.21 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.902 0.881 . . . . 0.0 111.883 177.232 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.8 m -147.48 138.88 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 125.976 1.71 . . . . 0.0 109.184 176.266 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.0 p -137.11 146.33 28.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 C-N-CA 124.741 1.216 . . . . 0.0 110.483 176.273 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.5 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.8 OUTLIER -84.19 158.77 60.69 Favored Pre-proline 0 CA--C 1.548 0.867 0 C-N-CA 123.409 0.684 . . . . 0.0 111.959 175.168 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.433 ' CD ' HG12 ' A' ' 68' ' ' VAL . 71.6 Cg_endo -68.69 -25.91 33.59 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 123.809 3.006 . . . . 0.0 112.993 -178.535 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -160.2 62.62 0.34 Allowed 'General case' 0 CA--C 1.554 1.118 0 C-N-CA 124.764 1.226 . . . . 0.0 112.316 177.219 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.86 -68.53 0.17 Allowed 'General case' 0 N--CA 1.48 1.053 0 O-C-N 120.988 -1.07 . . . . 0.0 112.222 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.42 179.82 43.5 Favored Glycine 0 CA--C 1.534 1.221 0 C-N-CA 125.04 1.305 . . . . 0.0 113.215 -174.36 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.7 m -94.94 149.96 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.466 1.506 . . . . 0.0 111.38 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.4 m -133.85 -177.85 4.75 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 124.622 1.169 . . . . 0.0 111.544 174.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -137.85 124.59 21.08 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.365 1.466 . . . . 0.0 111.749 177.236 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.557 HG21 HD11 ' A' ' 13' ' ' LEU . 61.1 t -63.47 126.74 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.036 0 C-N-CA 124.735 1.214 . . . . 0.0 111.173 -177.307 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 21.6 t -109.37 -53.92 2.6 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.049 1.34 . . . . 0.0 111.869 -177.092 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -151.68 162.02 41.7 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.142 1.377 . . . . 0.0 111.042 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -141.44 136.53 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 124.649 1.18 . . . . 0.0 108.55 -179.408 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -144.42 172.1 13.42 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 123.942 0.897 . . . . 0.0 111.773 177.226 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.3 p -120.54 138.29 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 O-C-N 120.691 -1.256 . . . . 0.0 110.758 175.564 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.89 164.29 36.66 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.175 1.39 . . . . 0.0 111.543 178.602 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -97.48 118.88 34.96 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 125.204 1.401 . . . . 0.0 109.77 174.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.3 p -123.54 135.47 63.22 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 124.303 1.041 . . . . 0.0 109.783 174.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.09 29.13 2.35 Favored 'General case' 0 CA--C 1.557 1.245 0 N-CA-C 114.625 1.343 . . . . 0.0 114.625 -177.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.01 25.28 52.9 Favored Glycine 0 CA--C 1.54 1.646 0 C-N-CA 124.787 1.184 . . . . 0.0 115.188 -176.184 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -139.44 116.78 11.24 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.35 1.46 . . . . 0.0 111.175 -174.778 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 3.5 tttt -95.21 124.81 39.45 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 124.83 1.252 . . . . 0.0 111.656 -178.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.613 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -158.17 162.97 37.97 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 123.033 0.533 . . . . 0.0 111.697 179.428 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.3 m -69.37 116.43 9.79 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 124.192 0.997 . . . . 0.0 111.147 177.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -105.2 113.14 26.56 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 124.875 1.27 . . . . 0.0 110.068 175.42 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.532 HG21 ' CD ' ' A' ' 70' ' ' LYS . 30.1 m -81.42 144.06 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.838 177.823 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 26.2 m -126.55 117.12 22.17 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.277 1.031 . . . . 0.0 110.735 178.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 1.5 mpp? -119.15 156.17 30.28 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 124.818 1.247 . . . . 0.0 110.116 -176.591 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -132.09 136.35 47.11 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.184 1.394 . . . . 0.0 110.259 -178.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 13.0 mtm180 -98.36 109.12 21.93 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 177.076 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -70.28 -15.46 62.9 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 123.239 0.616 . . . . 0.0 112.557 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -57.57 -42.18 82.56 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 126.779 2.031 . . . . 0.0 112.961 176.549 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -128.66 -15.41 4.45 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 124.874 1.27 . . . . 0.0 114.111 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.23 4.99 64.11 Favored Glycine 0 CA--C 1.538 1.5 0 C-N-CA 126.105 1.812 . . . . 0.0 114.952 -177.773 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -74.07 163.47 27.84 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 118.644 1.222 . . . . 0.0 112.819 177.449 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 15.9 m -126.32 156.12 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 125.592 1.557 . . . . 0.0 110.727 174.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 23.3 m -140.13 150.94 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 125.951 1.701 . . . . 0.0 109.898 176.073 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 62.9 ttp -145.03 122.08 11.4 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.791 0.836 . . . . 0.0 110.139 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.6 m -130.4 155.14 81.45 Favored Pre-proline 0 N--CA 1.476 0.84 0 C-N-CA 124.034 0.934 . . . . 0.0 112.17 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.613 ' CB ' HD11 ' A' ' 42' ' ' LEU . 52.3 Cg_endo -76.05 115.82 4.24 Favored 'Trans proline' 0 CA--C 1.538 0.698 0 C-N-CA 123.486 2.791 . . . . 0.0 114.438 176.742 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -64.63 -34.02 77.29 Favored 'General case' 0 N--CA 1.479 0.992 0 O-C-N 120.335 -1.478 . . . . 0.0 114.013 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.23 5.06 78.03 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 124.403 1.001 . . . . 0.0 114.876 176.32 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.6 tttm -135.57 3.34 3.03 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.493 1.517 . . . . 0.0 112.922 -177.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.43 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.6 m -49.7 -29.53 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 C-N-CA 125.685 1.594 . . . . 0.0 113.308 175.612 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.6 mt -57.62 -28.9 64.08 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.093 1.757 . . . . 0.0 112.302 177.433 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.81 -49.92 16.65 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.974 1.709 . . . . 0.0 112.854 175.78 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.432 HG22 HG13 ' A' ' 68' ' ' VAL . 3.8 mp -67.85 -33.21 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 124.013 0.925 . . . . 0.0 111.37 177.723 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 91.68 3.68 68.43 Favored Glycine 0 CA--C 1.537 1.434 0 C-N-CA 125.776 1.655 . . . . 0.0 114.239 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.5 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 29.1 m -87.47 123.18 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.045 1.338 . . . . 0.0 110.616 -176.461 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -104.46 109.28 21.1 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 120.625 -1.297 . . . . 0.0 108.652 176.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.532 ' CD ' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER -106.85 106.52 17.09 Favored 'General case' 0 N--CA 1.468 0.475 0 C-N-CA 123.1 0.56 . . . . 0.0 109.532 177.397 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.642 ' HA ' HD23 ' A' ' 13' ' ' LEU . 0.6 OUTLIER -157.74 169.07 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 C-N-CA 124.987 1.315 . . . . 0.0 110.212 -175.019 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -56.29 -19.62 15.08 Favored 'General case' 0 CA--C 1.551 0.992 0 N-CA-C 115.152 1.538 . . . . 0.0 115.152 177.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 47.2 m -137.5 -48.66 0.58 Allowed 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 125.483 1.513 . . . . 0.0 113.516 174.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.429 ' HB3' ' CG2' ' A' ' 71' ' ' VAL . . . -58.77 147.25 33.98 Favored 'General case' 0 CA--C 1.552 1.024 0 C-N-CA 124.479 1.112 . . . . 0.0 113.453 -179.522 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 . . . . . 0 C--O 1.256 1.428 0 C-N-CA 129.13 2.972 . . . . 0.0 112.397 -172.468 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.242 0 CA-C-O 120.858 0.361 . . . . 0.0 110.89 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 139.25 61.95 0.04 OUTLIER Glycine 0 N--CA 1.476 1.315 0 C-N-CA 124.441 1.019 . . . . 0.0 113.705 -179.213 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 23.5 t60 -75.05 157.85 34.15 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 117.653 0.726 . . . . 0.0 111.65 175.372 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.8 mtt -71.83 161.01 81.01 Favored Pre-proline 0 CA--C 1.545 0.768 0 O-C-N 121.863 -0.523 . . . . 0.0 111.587 175.038 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -65.1 152.59 81.78 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 122.611 2.207 . . . . 0.0 109.404 175.007 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -138.07 -54.59 0.65 Allowed 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 123.875 0.87 . . . . 0.0 113.243 177.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 79.93 164.63 29.92 Favored Glycine 0 CA--C 1.539 1.566 0 C-N-CA 124.119 0.866 . . . . 0.0 114.527 -177.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 78.9 p -156.48 97.57 1.75 Allowed 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.18 1.392 . . . . 0.0 112.31 178.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.706 ' HB3' ' HB2' ' A' ' 72' ' ' ALA . . . -156.43 173.53 16.76 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 126.035 1.734 . . . . 0.0 110.988 174.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 55.6 m -66.54 -74.24 0.12 Allowed 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 124.642 1.177 . . . . 0.0 111.952 176.277 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 53.0 mt -123.6 -80.02 0.62 Allowed 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 125.915 1.686 . . . . 0.0 110.183 -178.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 21.4 mt-30 -64.24 163.59 12.54 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 126.432 1.893 . . . . 0.0 113.182 174.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.641 HD13 ' HE2' ' A' ' 70' ' ' LYS . 1.4 tt -65.44 150.45 48.32 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 124.148 0.979 . . . . 0.0 111.671 175.487 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -143.77 177.36 8.57 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 125.544 1.538 . . . . 0.0 112.214 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 97.5 t -60.02 130.96 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 O-C-N 121.082 -1.012 . . . . 0.0 110.796 178.049 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.32 -2.57 88.06 Favored Glycine 0 CA--C 1.537 1.455 0 C-N-CA 124.809 1.195 . . . . 0.0 115.02 -179.228 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -71.09 -179.84 2.5 Favored 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.22 1.408 . . . . 0.0 112.539 176.095 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 26.7 mmt180 -112.44 154.08 26.37 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 124.953 1.301 . . . . 0.0 112.966 -178.333 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.4 p -152.63 126.83 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 125.77 1.628 . . . . 0.0 110.493 -179.073 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.0 p -135.6 120.08 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 C-N-CA 126.79 2.036 . . . . 0.0 110.486 174.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 -58.65 156.61 22.9 Favored Pre-proline 0 CA--C 1.544 0.74 0 O-C-N 121.055 -1.028 . . . . 0.0 112.281 175.487 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.423 ' CD ' HG22 ' A' ' 68' ' ' VAL . 60.0 Cg_endo -67.16 -24.59 44.25 Favored 'Trans proline' 0 CA--C 1.539 0.77 0 C-N-CA 122.716 2.277 . . . . 0.0 112.52 -176.312 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -157.78 62.48 0.47 Allowed 'General case' 0 CA--C 1.555 1.149 0 C-N-CA 124.809 1.244 . . . . 0.0 112.444 175.528 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.9 mm-40 -150.24 -66.37 0.2 Allowed 'General case' 0 N--CA 1.483 1.189 0 O-C-N 120.841 -1.162 . . . . 0.0 112.451 179.362 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 166.01 175.17 36.19 Favored Glycine 0 CA--C 1.533 1.198 0 C-N-CA 124.929 1.252 . . . . 0.0 113.451 -178.074 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 38.4 t -93.42 145.64 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 125.929 1.692 . . . . 0.0 110.818 -177.633 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.3 m -130.34 178.41 6.61 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 126.503 1.921 . . . . 0.0 111.116 174.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.3 130.48 44.55 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.128 1.771 . . . . 0.0 110.658 -179.304 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.402 HG21 HD21 ' A' ' 13' ' ' LEU . 35.7 t -68.05 125.47 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 124.61 1.164 . . . . 0.0 110.903 178.355 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.9 p -109.3 -41.16 4.72 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.728 0.811 . . . . 0.0 112.776 178.405 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -160.5 173.3 15.77 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 126.746 2.018 . . . . 0.0 110.659 175.754 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.432 HD11 HD23 ' A' ' 13' ' ' LEU . 64.2 mt -146.88 139.87 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.311 1.444 . . . . 0.0 108.728 174.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -146.62 172.72 13.17 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.803 1.241 . . . . 0.0 112.116 174.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.43 HG12 ' HA ' ' A' ' 43' ' ' THR . 20.6 m -115.81 142.63 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.344 1.058 . . . . 0.0 110.523 176.44 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -157.89 171.95 19.35 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.895 0.878 . . . . 0.0 112.18 176.663 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.61 115.17 29.93 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.906 1.682 . . . . 0.0 110.464 174.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 m -121.97 138.72 51.28 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 124.811 1.244 . . . . 0.0 109.092 174.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 46.06 28.99 0.7 Allowed 'General case' 0 CA--C 1.559 1.317 0 N-CA-C 115.391 1.626 . . . . 0.0 115.391 179.558 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.11 24.22 52.77 Favored Glycine 0 CA--C 1.544 1.895 0 C-N-CA 124.892 1.234 . . . . 0.0 115.88 -175.805 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 7.4 tp60 -135.39 113.52 11.29 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.593 1.957 . . . . 0.0 110.268 -174.305 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -95.37 113.38 25.04 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 125.121 1.369 . . . . 0.0 111.218 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.557 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -156.19 173.65 16.53 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.375 0.67 . . . . 0.0 112.049 179.537 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.43 ' HA ' HG12 ' A' ' 34' ' ' VAL . 10.0 m -76.88 116.37 17.49 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 124.338 1.055 . . . . 0.0 111.895 175.309 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -106.54 115.33 30.01 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.971 1.308 . . . . 0.0 109.222 175.248 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.694 HG11 ' HE3' ' A' ' 70' ' ' LYS . 13.6 m -63.94 153.5 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 O-C-N 121.877 -0.514 . . . . 0.0 111.609 176.001 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 10.9 m -126.48 109.82 12.61 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 122.137 0.97 . . . . 0.0 111.043 175.817 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' MET . . . . . 0.534 ' HB2' HG13 ' A' ' 56' ' ' VAL . 0.2 OUTLIER -128.89 155.77 44.74 Favored 'General case' 0 C--O 1.236 0.38 0 C-N-CA 124.703 1.201 . . . . 0.0 109.865 -178.704 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -131.08 125.54 33.44 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.893 1.277 . . . . 0.0 110.183 176.349 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.0 ttm-85 -85.08 109.06 17.96 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.524 1.13 . . . . 0.0 109.123 175.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.68 -15.38 63.16 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 176.849 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -62.23 -35.46 78.97 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.18 1.792 . . . . 0.0 112.779 -177.558 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 29.8 p30 -128.63 -16.68 4.23 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 126.637 1.975 . . . . 0.0 114.129 175.053 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.65 4.66 63.64 Favored Glycine 0 CA--C 1.538 1.49 0 C-N-CA 126.137 1.827 . . . . 0.0 115.086 -177.71 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -77.1 168.9 19.29 Favored 'General case' 0 CA--C 1.546 0.798 0 CA-C-N 119.387 1.594 . . . . 0.0 113.149 178.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 m -111.48 157.59 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 125.092 1.357 . . . . 0.0 111.138 175.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.534 HG13 ' HB2' ' A' ' 47' ' ' MET . 4.4 p -147.48 118.86 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 124.517 1.127 . . . . 0.0 110.017 179.725 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -132.93 97.01 3.91 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 124.822 1.249 . . . . 0.0 110.076 -178.02 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 36.0 m -99.86 157.24 34.25 Favored Pre-proline 0 N--CA 1.472 0.638 0 C-N-CA 123.369 0.668 . . . . 0.0 111.684 176.708 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.557 ' CB ' HD11 ' A' ' 42' ' ' LEU . 45.9 Cg_endo -77.22 118.75 4.77 Favored 'Trans proline' 0 CA--C 1.536 0.608 0 C-N-CA 123.488 2.792 . . . . 0.0 114.558 175.637 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.406 ' CG ' HG13 ' A' ' 45' ' ' VAL . 14.9 mt-10 -61.6 -38.98 89.59 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 120.479 -1.388 . . . . 0.0 114.22 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.14 5.97 78.57 Favored Glycine 0 N--CA 1.476 1.338 0 C-N-CA 124.723 1.154 . . . . 0.0 115.027 178.618 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 17.9 tttp -133.21 3.37 3.66 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 125.751 1.62 . . . . 0.0 112.597 -178.868 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.3 m -48.33 -29.63 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 125.428 1.491 . . . . 0.0 113.726 175.077 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 17.2 mt -54.71 -30.64 56.51 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.024 1.73 . . . . 0.0 112.492 176.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.07 -48.69 22.66 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.734 1.613 . . . . 0.0 112.872 176.582 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.445 HG22 HG23 ' A' ' 68' ' ' VAL . 4.0 mp -66.74 -32.52 58.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.431 1.093 . . . . 0.0 111.285 176.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 87.05 3.99 82.22 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 125.545 1.545 . . . . 0.0 114.014 -176.838 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.445 HG23 HG22 ' A' ' 66' ' ' ILE . 93.2 t -81.51 147.95 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.598 1.159 . . . . 0.0 109.888 175.727 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.73 124.54 49.89 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 104.745 -2.317 . . . . 0.0 104.745 175.008 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.694 ' HE3' HG11 ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.3 106.56 5.25 Favored 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 124.497 1.119 . . . . 0.0 108.269 177.301 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.522 HG12 ' H ' ' A' ' 72' ' ' ALA . 1.1 t -159.49 173.43 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 C-N-CA 124.901 1.28 . . . . 0.0 110.347 -174.521 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ALA . . . . . 0.706 ' HB2' ' HB3' ' A' ' 9' ' ' ALA . . . -59.94 -15.32 20.91 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.348 1.859 . . . . 0.0 115.551 -179.709 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -137.19 -47.02 0.57 Allowed 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 126.271 1.828 . . . . 0.0 110.904 175.688 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -78.2 62.5 2.92 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 125.379 1.472 . . . . 0.0 110.018 174.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.259 1.566 0 C-N-CA 125.339 1.456 . . . . 0.0 114.857 176.267 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.276 0 CA-C-O 120.339 0.114 . . . . 0.0 111.147 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.65 88.52 0.08 OUTLIER Glycine 0 N--CA 1.474 1.171 0 C-N-CA 123.922 0.772 . . . . 0.0 113.185 179.347 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 34.1 m80 -82.68 161.81 22.03 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 124.119 0.968 . . . . 0.0 111.677 174.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 15.4 ptm -60.33 156.87 38.03 Favored Pre-proline 0 CA--C 1.55 0.968 0 C-N-CA 124.708 1.203 . . . . 0.0 112.904 175.31 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -72.4 88.25 0.88 Allowed 'Trans proline' 0 CA--C 1.542 0.896 0 C-N-CA 124.228 3.285 . . . . 0.0 111.843 179.602 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -121.57 146.75 46.65 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 126.354 1.862 . . . . 0.0 110.97 178.397 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 178.35 87.6 0.07 OUTLIER Glycine 0 CA--C 1.533 1.203 0 C-N-CA 123.905 0.764 . . . . 0.0 113.635 -178.478 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 36.7 p -81.83 83.91 7.04 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.024 1.329 . . . . 0.0 112.512 178.323 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -140.98 -48.49 0.41 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.164 1.386 . . . . 0.0 113.347 179.634 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.0 m -148.43 156.35 42.37 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 125.812 1.645 . . . . 0.0 111.8 175.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -94.71 -33.15 13.04 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.842 1.257 . . . . 0.0 112.428 176.01 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -66.68 156.3 35.64 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 124.45 1.1 . . . . 0.0 112.604 175.225 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.459 HD21 ' HA ' ' A' ' 71' ' ' VAL . 4.1 mm? -95.01 113.98 25.74 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 125.392 1.477 . . . . 0.0 110.578 -179.581 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.74 175.5 9.66 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 125.871 1.668 . . . . 0.0 111.254 179.006 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 59.7 t -58.05 129.8 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 123.811 0.844 . . . . 0.0 110.772 176.778 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.52 -5.25 85.07 Favored Glycine 0 CA--C 1.536 1.359 0 C-N-CA 125.136 1.351 . . . . 0.0 115.2 -175.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -69.72 163.28 26.03 Favored 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 119.836 1.818 . . . . 0.0 112.099 175.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -101.04 130.87 47.11 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.71 1.204 . . . . 0.0 111.06 -175.494 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.6 m -142.34 143.3 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.797 0.839 . . . . 0.0 110.326 -178.693 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.4 p -137.08 148.22 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 C-N-CA 124.526 1.13 . . . . 0.0 110.685 178.481 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.436 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 1.0 OUTLIER -79.15 161.13 69.23 Favored Pre-proline 0 CA--C 1.549 0.919 0 O-C-N 121.853 -0.529 . . . . 0.0 111.655 175.091 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -71.57 -22.33 24.57 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 123.312 2.675 . . . . 0.0 112.837 -177.24 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 16.2 t-20 -162.68 68.29 0.23 Allowed 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 126.273 1.829 . . . . 0.0 111.296 175.007 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -156.28 -71.83 0.11 Allowed 'General case' 0 N--CA 1.482 1.141 0 O-C-N 121.15 -0.968 . . . . 0.0 112.319 177.224 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 176.43 172.93 41.6 Favored Glycine 0 CA--C 1.534 1.222 0 C-N-CA 124.548 1.07 . . . . 0.0 113.734 -176.443 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.1 m -85.86 148.47 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 125.187 1.395 . . . . 0.0 111.231 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.404 ' SG ' HG11 ' A' ' 56' ' ' VAL . 15.6 m -137.18 171.87 13.85 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.996 1.718 . . . . 0.0 110.921 179.535 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -137.71 120.01 15.78 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 124.414 1.086 . . . . 0.0 110.596 -175.779 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -63.73 124.78 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 123.615 0.766 . . . . 0.0 111.518 -174.106 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 86.1 p -107.43 -40.95 5.21 Favored 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 -177.769 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.43 162.78 35.75 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.489 1.516 . . . . 0.0 110.839 176.127 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 67.8 mt -141.83 134.87 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.781 0 O-C-N 121.029 -1.044 . . . . 0.0 109.076 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -142.72 177.64 8.18 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 124.269 1.028 . . . . 0.0 111.854 178.017 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 p -127.31 137.09 58.8 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 C-N-CA 124.963 1.305 . . . . 0.0 110.425 176.498 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.43 165.81 32.01 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 124.698 1.199 . . . . 0.0 111.963 178.851 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -97.89 118.93 35.56 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 125.088 1.355 . . . . 0.0 109.763 174.978 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.9 p -124.43 134.9 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 C-N-CA 124.251 1.02 . . . . 0.0 109.562 175.112 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.75 29.0 2.05 Favored 'General case' 0 CA--C 1.556 1.2 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 -177.208 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.99 25.66 51.67 Favored Glycine 0 CA--C 1.541 1.708 0 C-N-CA 124.616 1.103 . . . . 0.0 115.174 -176.266 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -137.43 119.73 15.74 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 126.02 1.728 . . . . 0.0 111.053 -178.804 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 13.7 ttpt -96.12 124.34 40.08 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.636 1.175 . . . . 0.0 111.582 178.171 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.603 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -157.69 163.53 38.09 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.008 0.523 . . . . 0.0 111.805 178.771 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.8 m -68.64 116.58 9.33 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.997 0.919 . . . . 0.0 110.971 177.365 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -105.51 113.26 26.72 Favored 'General case' 0 N--CA 1.467 0.377 0 O-C-N 121.076 -1.015 . . . . 0.0 109.591 174.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.0 m -78.16 141.9 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 C-N-CA 123.486 0.714 . . . . 0.0 110.502 176.338 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 8.1 m -120.31 120.32 35.7 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.602 1.161 . . . . 0.0 109.281 176.393 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' MET . . . . . 0.446 ' HB2' HG13 ' A' ' 56' ' ' VAL . 2.1 mpp? -123.18 157.49 32.88 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 124.703 1.201 . . . . 0.0 109.736 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 31.2 mtt85 -136.58 132.56 35.3 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 124.39 1.076 . . . . 0.0 109.875 -179.41 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -93.89 109.16 20.88 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 177.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -70.32 -14.37 62.55 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 175.151 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -60.21 -36.97 78.88 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.459 1.504 . . . . 0.0 113.066 177.652 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -127.99 -23.31 3.36 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.459 1.503 . . . . 0.0 113.356 178.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 96.3 25.98 11.73 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 125.565 1.555 . . . . 0.0 114.42 -177.05 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.62 169.53 10.26 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.957 1.303 . . . . 0.0 112.752 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.7 m -124.4 154.38 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 125.255 1.422 . . . . 0.0 111.65 177.726 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.446 HG13 ' HB2' ' A' ' 47' ' ' MET . 2.8 p -151.1 123.47 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 C-N-CA 125.581 1.553 . . . . 0.0 109.689 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.9 ttt -125.83 121.21 32.61 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.625 1.17 . . . . 0.0 109.914 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 28.6 m -129.21 156.33 78.48 Favored Pre-proline 0 N--CA 1.478 0.932 0 C-N-CA 124.087 0.955 . . . . 0.0 112.112 -179.36 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.603 ' CB ' HD11 ' A' ' 42' ' ' LEU . 55.2 Cg_endo -77.84 114.58 3.66 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 123.628 2.885 . . . . 0.0 114.586 176.631 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -63.83 -33.72 76.32 Favored 'General case' 0 N--CA 1.481 1.096 0 O-C-N 120.271 -1.518 . . . . 0.0 113.957 179.422 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.19 4.43 77.53 Favored Glycine 0 N--CA 1.475 1.272 0 C-N-CA 124.459 1.028 . . . . 0.0 115.074 175.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.1 tttm -135.58 3.42 3.03 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 125.489 1.515 . . . . 0.0 112.978 -177.569 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.428 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.6 m -49.98 -30.77 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 125.598 1.559 . . . . 0.0 113.079 175.402 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.1 mt -56.51 -28.9 61.1 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.123 1.769 . . . . 0.0 112.494 177.227 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.95 -48.66 17.48 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.736 1.614 . . . . 0.0 112.66 177.223 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.442 HG22 HG13 ' A' ' 68' ' ' VAL . 2.9 mp -68.59 -30.55 47.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 124.085 0.954 . . . . 0.0 111.357 176.264 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.58 3.23 78.08 Favored Glycine 0 CA--C 1.537 1.416 0 C-N-CA 126.092 1.806 . . . . 0.0 114.309 -176.85 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.442 HG13 HG22 ' A' ' 66' ' ' ILE . 18.7 m -80.17 123.2 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.8 0 C-N-CA 125.596 1.558 . . . . 0.0 110.858 -178.541 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.66 109.39 20.97 Favored 'General case' 0 N--CA 1.472 0.653 0 O-C-N 120.847 -1.158 . . . . 0.0 108.881 175.103 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.13 106.6 17.15 Favored 'General case' 0 N--CA 1.471 0.576 0 O-C-N 121.749 -0.595 . . . . 0.0 109.76 176.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.459 ' HA ' HD21 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -157.48 166.58 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 125.668 1.587 . . . . 0.0 110.706 -176.383 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -52.64 -16.25 0.9 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 126.875 2.07 . . . . 0.0 115.8 175.415 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 36.1 p -142.42 -52.52 0.4 Allowed 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 125.651 1.58 . . . . 0.0 113.34 175.291 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.422 ' HB3' ' CG2' ' A' ' 71' ' ' VAL . . . -54.45 145.61 17.97 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 125.585 1.554 . . . . 0.0 113.512 178.625 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 . . . . . 0 C--O 1.251 1.172 0 C-N-CA 127.81 2.444 . . . . 0.0 113.273 -177.937 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.185 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -164.36 46.22 0.3 Allowed Glycine 0 N--CA 1.473 1.153 0 C-N-CA 123.585 0.612 . . . . 0.0 113.836 -176.218 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -75.23 157.81 33.92 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.531 0.732 . . . . 0.0 111.859 175.469 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.78 162.23 22.72 Favored Pre-proline 0 CA--C 1.541 0.627 0 C-N-CA 125.45 1.5 . . . . 0.0 111.061 175.254 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -70.11 148.52 62.95 Favored 'Trans proline' 0 CA--C 1.54 0.819 0 C-N-CA 123.278 2.652 . . . . 0.0 110.857 175.079 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 179.18 -55.7 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 125.892 1.677 . . . . 0.0 112.182 176.539 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 91.88 -126.0 8.3 Favored Glycine 0 CA--C 1.535 1.322 0 C-N-CA 124.731 1.158 . . . . 0.0 112.298 -172.677 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.7 t -154.74 -45.9 0.09 Allowed 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 124.559 1.143 . . . . 0.0 112.995 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -121.41 163.52 18.58 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 125.891 1.676 . . . . 0.0 112.499 -178.329 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 27.8 t -95.99 90.08 5.44 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 125.241 1.416 . . . . 0.0 111.636 -178.834 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 5.6 mp -140.93 179.53 6.66 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 126.391 1.877 . . . . 0.0 111.322 179.681 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.9 mm-40 -62.6 161.04 12.79 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.516 1.126 . . . . 0.0 111.18 174.854 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.585 HD11 HG21 ' A' ' 29' ' ' VAL . 0.8 OUTLIER -66.53 129.75 40.88 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 123.864 0.866 . . . . 0.0 111.188 179.19 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -133.82 166.34 22.89 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 125.516 1.526 . . . . 0.0 112.297 179.538 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.8 t -56.65 135.76 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.399 1.08 . . . . 0.0 111.035 175.347 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.15 -13.01 60.72 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 125.635 1.588 . . . . 0.0 115.216 -176.515 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -72.88 170.0 15.66 Favored 'General case' 0 CA--C 1.549 0.921 0 CA-C-N 119.06 1.43 . . . . 0.0 111.376 175.075 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.9 mmt180 -108.56 142.81 38.45 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 126.194 1.797 . . . . 0.0 111.141 -171.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.468 HG21 ' CE ' ' A' ' 47' ' ' MET . 32.9 m -143.92 128.04 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 124.278 1.031 . . . . 0.0 111.769 -171.099 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 8.2 p -95.2 164.45 2.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 125.416 1.487 . . . . 0.0 111.052 176.092 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -137.01 156.6 75.66 Favored Pre-proline 0 CA--C 1.535 0.381 0 C-N-CA 124.571 1.148 . . . . 0.0 112.991 178.648 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.7 -28.84 30.36 Favored 'Trans proline' 0 CA--C 1.538 0.721 0 C-N-CA 123.038 2.492 . . . . 0.0 112.762 -178.427 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -151.88 54.28 0.83 Allowed 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 125.337 1.455 . . . . 0.0 111.919 178.435 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -145.01 -60.58 0.36 Allowed 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 124.332 1.053 . . . . 0.0 110.653 175.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 124.2 -169.4 16.28 Favored Glycine 0 CA--C 1.535 1.284 0 C-N-CA 126.413 1.958 . . . . 0.0 112.25 -173.158 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -72.42 136.51 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.642 1.177 . . . . 0.0 110.932 177.711 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 25.6 m -128.7 175.13 8.83 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 126.105 1.762 . . . . 0.0 111.777 175.229 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -130.57 119.02 21.89 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 126.242 1.817 . . . . 0.0 110.833 -179.258 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.585 HG21 HD11 ' A' ' 13' ' ' LEU . 47.5 t -64.61 127.87 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 123.691 0.796 . . . . 0.0 111.025 -178.608 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.7 p -112.5 -40.55 4.07 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.219 1.008 . . . . 0.0 112.699 -176.767 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -155.1 167.11 31.46 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.716 2.006 . . . . 0.0 110.656 175.002 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 60.7 mt -146.06 137.16 19.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.895 1.278 . . . . 0.0 108.504 176.664 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -146.02 171.92 14.15 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.01 0.924 . . . . 0.0 112.059 176.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.2 m -113.9 144.57 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.147 -0.971 . . . . 0.0 111.543 175.848 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 9.7 ptmt -156.25 171.99 19.23 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 124.854 1.262 . . . . 0.0 111.874 177.197 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -108.03 117.73 34.91 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.168 1.787 . . . . 0.0 109.79 174.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.3 p -127.67 138.21 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 124.843 1.257 . . . . 0.0 109.322 174.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.74 29.35 1.52 Allowed 'General case' 0 CA--C 1.557 1.23 0 N-CA-C 114.707 1.373 . . . . 0.0 114.707 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.0 24.39 57.84 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.281 1.42 . . . . 0.0 115.543 -176.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -132.55 113.54 13.19 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 126.106 1.762 . . . . 0.0 110.817 -175.501 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 67.3 tttt -95.96 114.35 26.05 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.085 1.354 . . . . 0.0 111.321 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.565 HD11 ' CB ' ' A' ' 59' ' ' PRO . 1.0 OUTLIER -157.89 173.61 16.53 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 123.066 0.547 . . . . 0.0 111.791 -179.376 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 20.1 m -79.01 116.43 19.31 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.362 1.065 . . . . 0.0 112.122 175.543 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -105.04 115.83 30.94 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.512 1.125 . . . . 0.0 109.77 175.094 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.446 HG13 ' CG ' ' A' ' 60' ' ' GLU . 15.8 m -66.24 147.53 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.382 0.673 . . . . 0.0 111.245 176.834 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 19.7 m -123.27 110.06 14.72 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.723 0.809 . . . . 0.0 109.634 177.123 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' MET . . . . . 0.468 ' CE ' HG21 ' A' ' 19' ' ' VAL . 0.0 OUTLIER -126.92 162.44 25.94 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 121.724 0.773 . . . . 0.0 110.929 178.409 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 3.0 ptt180 -144.88 116.81 8.28 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 124.801 1.24 . . . . 0.0 109.987 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 6.4 mtp85 -62.69 115.01 3.93 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 124.818 1.247 . . . . 0.0 110.602 179.327 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.2 pp20? -60.54 -36.03 77.44 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.658 0.783 . . . . 0.0 112.877 179.14 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -91.45 -46.73 7.83 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 123.889 0.875 . . . . 0.0 113.033 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -73.1 -19.41 61.16 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 113.543 0.942 . . . . 0.0 113.543 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.44 8.77 56.64 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 126.27 1.89 . . . . 0.0 115.151 -178.53 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.0 138.32 40.71 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.6 1.56 . . . . 0.0 112.246 -173.257 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 26.7 m -80.02 152.26 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 123.319 0.648 . . . . 0.0 110.023 174.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 13.6 p -145.23 138.7 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 124.514 1.125 . . . . 0.0 109.887 177.139 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 11.4 ttp -145.03 115.9 7.79 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 124.579 1.152 . . . . 0.0 110.004 -179.268 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.6 m -121.66 156.93 58.14 Favored Pre-proline 0 N--CA 1.472 0.673 0 C-N-CA 124.83 1.252 . . . . 0.0 111.27 177.021 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.565 ' CB ' HD11 ' A' ' 42' ' ' LEU . 55.8 Cg_endo -79.8 114.45 3.19 Favored 'Trans proline' 0 CA--C 1.537 0.637 0 C-N-CA 123.488 2.792 . . . . 0.0 114.954 178.616 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.446 ' CG ' HG13 ' A' ' 45' ' ' VAL . 18.9 mt-10 -58.39 -39.23 79.11 Favored 'General case' 0 N--CA 1.48 1.041 0 O-C-N 120.424 -1.422 . . . . 0.0 114.286 -178.496 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.06 7.32 78.78 Favored Glycine 0 N--CA 1.474 1.19 0 C-N-CA 124.751 1.167 . . . . 0.0 114.753 179.008 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.0 tttt -134.62 1.72 3.12 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.596 1.559 . . . . 0.0 112.888 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 59' ' ' PRO . 7.0 m -48.34 -30.74 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.593 1.557 . . . . 0.0 113.546 175.762 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.6 mt -57.66 -29.86 64.96 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 126.47 1.908 . . . . 0.0 112.735 176.887 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.99 -49.97 16.18 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.781 1.632 . . . . 0.0 112.635 176.025 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.3 mp -67.93 -32.22 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 123.66 0.784 . . . . 0.0 111.31 177.757 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.52 9.41 66.76 Favored Glycine 0 CA--C 1.534 1.256 0 C-N-CA 125.532 1.539 . . . . 0.0 113.889 -174.446 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 12.2 m -75.8 155.89 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 118.317 1.058 . . . . 0.0 110.804 177.79 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -139.91 109.69 6.36 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.881 1.272 . . . . 0.0 110.221 175.264 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.445 ' O ' ' HE3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -126.28 106.56 9.61 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 125.454 1.502 . . . . 0.0 110.65 177.528 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.493 ' HA ' HD23 ' A' ' 13' ' ' LEU . 3.5 t -160.09 157.91 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 127.173 2.189 . . . . 0.0 107.755 -177.131 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -55.26 -31.62 61.7 Favored 'General case' 0 CA--C 1.55 0.972 0 N-CA-C 113.415 0.895 . . . . 0.0 113.415 177.607 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -93.93 -26.91 16.66 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 124.83 1.252 . . . . 0.0 114.295 175.64 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.98 -18.58 65.45 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 124.059 0.943 . . . . 0.0 111.491 175.084 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 . . . . . 0 C--O 1.249 1.049 0 C-N-CA 127.465 2.306 . . . . 0.0 113.466 -169.674 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.263 0 CA-C-O 119.517 -0.278 . . . . 0.0 111.648 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -169.32 96.93 0.12 Allowed Glycine 0 CA--C 1.533 1.163 0 C-N-CA 124.277 0.942 . . . . 0.0 112.773 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -97.02 115.83 28.15 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 125.053 1.341 . . . . 0.0 111.713 177.521 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.28 161.86 44.84 Favored Pre-proline 0 CA--C 1.545 0.78 0 C-N-CA 124.109 0.964 . . . . 0.0 111.239 174.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.536 ' HG3' HG11 ' A' ' 20' ' ' VAL . 68.1 Cg_endo -68.33 115.52 3.9 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 123.916 3.078 . . . . 0.0 109.359 174.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -143.3 157.43 44.48 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.797 1.239 . . . . 0.0 111.708 177.632 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 135.8 175.16 13.68 Favored Glycine 0 CA--C 1.535 1.32 0 C-N-CA 125.4 1.476 . . . . 0.0 113.399 -178.092 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -153.55 18.28 0.54 Allowed 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 114.09 1.144 . . . . 0.0 114.09 179.291 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -53.96 -57.11 12.22 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 126.13 1.772 . . . . 0.0 114.155 -172.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.9 m -135.09 166.77 22.29 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 125.932 1.693 . . . . 0.0 111.416 178.609 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 11.0 mp -96.1 -61.18 1.48 Allowed 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 124.791 1.237 . . . . 0.0 111.458 -177.18 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -63.67 152.75 38.19 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 124.515 1.126 . . . . 0.0 112.214 176.135 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 14.3 tp -81.52 137.57 35.56 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.428 1.091 . . . . 0.0 110.887 174.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -148.19 177.63 9.23 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.508 1.523 . . . . 0.0 111.427 175.02 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.9 t -59.33 133.7 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 O-C-N 121.395 -0.815 . . . . 0.0 111.296 176.694 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.31 -4.48 85.54 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 124.817 1.198 . . . . 0.0 115.211 -178.584 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -71.56 178.35 3.56 Favored 'General case' 0 CA--C 1.553 1.066 0 CA-C-N 118.835 1.318 . . . . 0.0 110.906 174.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 19.2 mmt180 -98.49 151.44 20.61 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.499 1.52 . . . . 0.0 111.378 178.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.6 HG23 ' HB3' ' A' ' 70' ' ' LYS . 2.8 p -140.02 125.67 21.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 C-N-CA 124.225 1.01 . . . . 0.0 110.94 176.47 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.536 HG11 ' HG3' ' A' ' 5' ' ' PRO . 3.7 p -132.14 145.68 34.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 C-N-CA 125.59 1.556 . . . . 0.0 108.532 175.186 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -91.72 161.06 34.98 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 125.005 1.322 . . . . 0.0 111.948 175.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.34 -28.84 26.8 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.848 2.365 . . . . 0.0 111.954 -175.208 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -159.08 54.16 0.41 Allowed 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 124.311 1.044 . . . . 0.0 113.032 176.348 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -142.86 -62.25 0.42 Allowed 'General case' 0 N--CA 1.478 0.974 0 O-C-N 121.14 -0.975 . . . . 0.0 113.567 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.1 -172.52 44.44 Favored Glycine 0 CA--C 1.533 1.168 0 C-N-CA 124.291 0.948 . . . . 0.0 113.514 -176.193 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.6 p -115.68 144.5 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 126.728 2.011 . . . . 0.0 110.567 179.327 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 77.2 m -132.84 -175.02 3.64 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 126.614 1.966 . . . . 0.0 110.572 175.565 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -129.46 123.94 32.82 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 125.037 1.335 . . . . 0.0 111.198 -177.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.6 t -63.42 128.38 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 O-C-N 121.778 -0.576 . . . . 0.0 111.189 -177.53 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.4 t -109.92 -53.52 2.66 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.981 1.712 . . . . 0.0 111.515 -176.158 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.64 165.95 34.8 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 125.204 1.402 . . . . 0.0 111.032 174.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.4 mt -142.05 130.92 22.49 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 124.62 1.168 . . . . 0.0 108.76 178.794 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -147.73 173.93 12.29 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 123.543 0.737 . . . . 0.0 112.338 175.292 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.486 HG12 ' HA ' ' A' ' 43' ' ' THR . 25.5 m -106.72 142.21 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.984 0 O-C-N 121.022 -1.049 . . . . 0.0 110.852 176.106 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -156.14 171.63 19.82 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.986 0.914 . . . . 0.0 112.336 176.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -104.55 115.77 30.92 Favored 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 125.94 1.696 . . . . 0.0 109.704 175.201 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.1 p -127.89 138.12 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.792 0.837 . . . . 0.0 109.626 175.122 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.77 28.98 1.43 Allowed 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 114.905 1.446 . . . . 0.0 114.905 -177.22 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.49 23.98 55.02 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.235 1.398 . . . . 0.0 115.441 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -131.97 113.48 13.46 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 126.193 1.797 . . . . 0.0 109.771 -174.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 16.5 tttt -96.43 112.43 24.17 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.48 1.112 . . . . 0.0 111.635 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.609 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -157.43 173.78 16.4 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 123.407 0.683 . . . . 0.0 112.217 179.262 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.486 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.2 m -73.34 116.49 13.95 Favored 'General case' 0 N--CA 1.475 0.82 0 C-N-CA 124.724 1.209 . . . . 0.0 111.101 175.113 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -111.38 113.78 26.48 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 124.671 1.189 . . . . 0.0 110.036 177.723 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 27.4 m -75.2 145.45 10.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 123.326 0.65 . . . . 0.0 110.537 177.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 21.7 m -126.52 116.05 20.48 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 124.367 1.067 . . . . 0.0 110.948 -179.603 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' MET . . . . . 0.428 ' CE ' HG21 ' A' ' 19' ' ' VAL . 2.1 mpp? -126.32 141.94 51.72 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.097 0.959 . . . . 0.0 109.619 -175.236 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.7 mtt85 -127.58 109.65 11.92 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 125.233 1.413 . . . . 0.0 109.2 -172.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -77.32 109.11 10.94 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 56.5 mt-10 -67.05 -23.0 65.84 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.886 0.875 . . . . 0.0 112.56 178.292 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -55.81 -39.56 71.51 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.462 1.905 . . . . 0.0 113.14 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -128.55 2.94 5.56 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.598 1.559 . . . . 0.0 113.377 -179.692 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.56 17.3 64.35 Favored Glycine 0 CA--C 1.538 1.472 0 C-N-CA 126.1 1.81 . . . . 0.0 114.669 -171.415 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -75.84 165.55 24.85 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 124.903 1.281 . . . . 0.0 112.484 -178.489 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.5 m -131.61 150.83 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 124.918 1.287 . . . . 0.0 111.02 177.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.8 p -146.73 144.18 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 C-N-CA 125.22 1.408 . . . . 0.0 109.49 176.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 8.8 ttm -138.28 127.25 24.01 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.62 1.168 . . . . 0.0 108.997 174.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.8 m -129.44 156.26 78.82 Favored Pre-proline 0 N--CA 1.473 0.718 0 C-N-CA 123.576 0.751 . . . . 0.0 111.615 175.066 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.609 ' CB ' HD11 ' A' ' 42' ' ' LEU . 57.5 Cg_endo -79.45 115.7 3.46 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.511 2.807 . . . . 0.0 114.9 177.191 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -62.31 -35.28 78.55 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 119.988 -1.695 . . . . 0.0 114.689 176.307 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.4 6.34 80.68 Favored Glycine 0 N--CA 1.473 1.131 0 O-C-N 121.547 -0.721 . . . . 0.0 114.639 176.691 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.5 tttt -137.06 0.59 2.38 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.902 1.281 . . . . 0.0 113.687 -177.182 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.468 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.5 m -49.93 -29.02 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 C-N-CA 125.166 1.386 . . . . 0.0 113.795 175.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.2 mt -58.32 -27.44 64.12 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.594 1.557 . . . . 0.0 112.127 177.571 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.13 -50.96 11.84 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.945 1.698 . . . . 0.0 112.386 175.007 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.5 mp -69.51 -33.55 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 123.863 0.865 . . . . 0.0 111.824 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 90.35 12.72 61.02 Favored Glycine 0 CA--C 1.538 1.521 0 C-N-CA 126.03 1.776 . . . . 0.0 114.914 -178.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 97.6 t -89.56 135.38 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 C-N-CA 125.375 1.47 . . . . 0.0 110.657 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.37 109.2 11.54 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 123.721 0.808 . . . . 0.0 110.315 175.039 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.6 ' HB3' HG23 ' A' ' 19' ' ' VAL . 0.0 OUTLIER -97.11 106.62 18.98 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 121.631 0.729 . . . . 0.0 110.192 179.42 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 6.8 t -154.01 169.27 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 125.454 1.502 . . . . 0.0 108.28 -177.257 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -62.6 -20.51 64.81 Favored 'General case' 0 CA--C 1.55 0.975 0 N-CA-C 113.8 1.037 . . . . 0.0 113.8 175.057 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 69.5 m -127.26 -40.6 1.81 Allowed 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 114.606 1.336 . . . . 0.0 114.606 176.235 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.55 161.43 20.25 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.693 0.797 . . . . 0.0 112.571 177.051 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 . . . . . 0 C--O 1.254 1.334 0 C-N-CA 127.283 2.233 . . . . 0.0 112.075 178.864 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.196 0 CA-C-O 120.567 0.222 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 134.56 -97.26 0.29 Allowed Glycine 0 N--CA 1.473 1.104 0 C-N-CA 125.071 1.319 . . . . 0.0 112.656 178.197 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -70.69 131.13 43.43 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 124.061 0.944 . . . . 0.0 111.689 176.368 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.38 161.17 80.33 Favored Pre-proline 0 CA--C 1.548 0.878 0 C-N-CA 123.735 0.814 . . . . 0.0 113.037 175.215 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -68.5 110.31 2.26 Favored 'Trans proline' 0 CA--C 1.541 0.868 0 C-N-CA 124.345 3.363 . . . . 0.0 112.33 174.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -162.03 -175.66 4.75 Favored 'General case' 0 CA--C 1.55 0.961 0 C-N-CA 125.575 1.55 . . . . 0.0 111.967 177.353 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 168.22 -175.96 42.82 Favored Glycine 0 CA--C 1.538 1.5 0 C-N-CA 126.607 2.051 . . . . 0.0 112.478 -175.832 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.4 t -142.19 16.13 2.07 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 124.625 1.17 . . . . 0.0 114.02 -179.101 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.44 ' HB3' ' HB2' ' A' ' 72' ' ' ALA . . . -70.55 -174.72 0.92 Allowed 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 124.893 1.277 . . . . 0.0 113.084 176.744 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.2 m -66.14 -179.66 0.8 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 125.332 1.453 . . . . 0.0 113.184 176.423 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 38.1 mt -74.29 46.13 0.25 Allowed 'General case' 0 CA--C 1.551 0.986 0 C-N-CA 126.194 1.797 . . . . 0.0 113.976 -178.848 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -160.12 163.44 33.79 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 125.43 1.492 . . . . 0.0 111.609 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.544 HD22 HG21 ' A' ' 29' ' ' VAL . 11.8 mt -71.13 159.55 34.48 Favored 'General case' 0 CA--C 1.543 0.692 0 CA-C-O 121.459 0.647 . . . . 0.0 110.281 174.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -146.78 157.1 43.59 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 125.196 1.398 . . . . 0.0 110.849 175.622 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.4 t -57.31 125.72 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.834 0.854 . . . . 0.0 111.056 178.016 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.44 -5.06 84.61 Favored Glycine 0 CA--C 1.533 1.165 0 C-N-CA 124.973 1.273 . . . . 0.0 115.005 -176.647 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -68.69 152.8 44.86 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 118.97 1.385 . . . . 0.0 109.79 174.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 9.4 mpt_? -85.0 167.74 15.57 Favored 'General case' 0 N--CA 1.471 0.616 0 O-C-N 121.246 -0.909 . . . . 0.0 110.74 176.363 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 70' ' ' LYS . 26.1 m -151.16 158.54 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 127.054 2.141 . . . . 0.0 111.068 175.067 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.4 p -136.55 160.11 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 125.8 1.64 . . . . 0.0 109.515 174.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -114.16 160.43 32.57 Favored Pre-proline 0 CA--C 1.542 0.664 0 C-N-CA 125.354 1.461 . . . . 0.0 111.539 175.016 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.57 ' HD3' HG22 ' A' ' 68' ' ' VAL . 59.0 Cg_endo -67.48 -27.66 39.39 Favored 'Trans proline' 0 CA--C 1.539 0.734 0 C-N-CA 123.002 2.468 . . . . 0.0 112.822 178.357 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -158.77 53.81 0.42 Allowed 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 124.081 0.952 . . . . 0.0 113.278 178.502 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.11 -57.73 0.38 Allowed 'General case' 0 N--CA 1.479 0.997 0 O-C-N 121.107 -0.996 . . . . 0.0 113.58 -176.83 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 156.09 -160.26 29.96 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.526 1.06 . . . . 0.0 112.513 -174.554 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.4 m -118.98 147.97 22.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 125.844 1.658 . . . . 0.0 111.524 177.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 6.3 m -139.02 178.87 6.85 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.303 1.441 . . . . 0.0 110.886 177.759 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 49.4 ttt-85 -133.74 131.87 39.9 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.16 1.384 . . . . 0.0 111.673 179.051 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.544 HG21 HD22 ' A' ' 13' ' ' LEU . 40.0 t -59.09 132.64 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.674 1.189 . . . . 0.0 111.293 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.9 t -112.07 -53.05 2.74 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 126.505 1.922 . . . . 0.0 111.15 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -145.98 159.14 43.67 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.562 1.145 . . . . 0.0 111.023 -178.17 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.4 mt -143.74 127.26 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.514 1.125 . . . . 0.0 109.108 178.835 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -149.8 157.14 42.91 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.218 1.007 . . . . 0.0 112.351 175.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.54 HG12 ' HA ' ' A' ' 43' ' ' THR . 21.5 m -97.02 141.56 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 O-C-N 121.279 -0.888 . . . . 0.0 110.342 175.474 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -154.51 171.44 19.41 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.878 0.871 . . . . 0.0 111.728 175.171 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -103.61 116.62 32.69 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.543 1.537 . . . . 0.0 109.372 175.373 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 p -124.33 137.86 55.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.025 0 C-N-CA 124.419 1.088 . . . . 0.0 108.941 175.132 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.22 29.74 1.97 Allowed 'General case' 0 CA--C 1.557 1.233 0 N-CA-C 114.809 1.411 . . . . 0.0 114.809 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.39 23.36 56.79 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 125.046 1.308 . . . . 0.0 115.49 -176.458 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -136.91 113.48 10.17 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 125.365 1.466 . . . . 0.0 111.822 -173.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -94.81 114.41 26.28 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.862 1.665 . . . . 0.0 111.132 -177.207 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.611 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -155.07 171.59 19.51 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.2 0.6 . . . . 0.0 111.669 178.698 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.54 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.7 m -73.8 116.56 14.54 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 124.035 0.934 . . . . 0.0 110.945 175.287 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -107.08 113.13 26.39 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 122.239 1.018 . . . . 0.0 109.68 176.03 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.556 HG23 ' HE1' ' A' ' 47' ' ' MET . 18.0 m -83.11 146.16 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 C-N-CA 123.438 0.695 . . . . 0.0 110.148 176.708 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 3.9 m -124.39 113.46 18.21 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 125.142 1.377 . . . . 0.0 109.865 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' MET . . . . . 0.556 ' HE1' HG23 ' A' ' 45' ' ' VAL . 2.8 mtm -107.28 165.21 11.55 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 124.685 1.194 . . . . 0.0 110.221 175.025 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 35.2 ptt180 -140.48 162.03 36.31 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 125.873 1.669 . . . . 0.0 111.219 175.12 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.0 mpt_? -109.25 131.26 55.23 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.745 0.818 . . . . 0.0 110.035 175.015 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 70.2 mt-10 -68.3 -35.64 78.14 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.988 0.915 . . . . 0.0 111.827 176.825 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -91.96 -46.58 7.75 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 124.523 1.129 . . . . 0.0 112.831 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.05 -24.04 62.26 Favored 'General case' 0 N--CA 1.476 0.864 0 O-C-N 121.559 -0.713 . . . . 0.0 111.937 -178.133 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.81 9.77 47.46 Favored Glycine 0 CA--C 1.536 1.371 0 C-N-CA 125.719 1.628 . . . . 0.0 114.651 -179.176 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -101.1 159.88 14.86 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.289 1.836 . . . . 0.0 111.235 -177.716 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 31.3 m -111.63 151.57 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 124.881 1.272 . . . . 0.0 110.479 175.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.4 p -135.04 124.91 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.66 1.584 . . . . 0.0 108.42 176.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.41 125.3 54.06 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 124.734 1.214 . . . . 0.0 109.033 176.092 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.763 HG21 ' HE3' ' A' ' 70' ' ' LYS . 15.4 m -137.74 156.24 74.63 Favored Pre-proline 0 N--CA 1.472 0.652 0 C-N-CA 123.108 0.563 . . . . 0.0 111.524 176.164 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.611 ' CB ' HD11 ' A' ' 42' ' ' LEU . 57.2 Cg_endo -77.14 115.66 4.03 Favored 'Trans proline' 0 CA--C 1.536 0.59 0 C-N-CA 123.516 2.811 . . . . 0.0 114.232 177.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -59.08 -45.62 90.35 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 120.557 -1.339 . . . . 0.0 112.497 175.639 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -83.33 6.37 72.65 Favored Glycine 0 N--CA 1.475 1.25 0 O-C-N 120.999 -1.063 . . . . 0.0 115.282 178.798 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 15.6 tttt -137.5 4.6 2.63 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 125.434 1.493 . . . . 0.0 113.027 -178.679 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.519 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.8 m -51.88 -29.15 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 125.297 1.439 . . . . 0.0 113.35 176.097 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.1 mt -58.06 -29.14 65.17 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 125.926 1.691 . . . . 0.0 112.426 176.348 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.09 -49.48 23.78 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 125.672 1.589 . . . . 0.0 112.61 175.22 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.441 HG22 HG23 ' A' ' 68' ' ' VAL . 2.5 mp -67.0 -32.68 59.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 C-N-CA 123.476 0.71 . . . . 0.0 111.339 177.764 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.79 20.38 43.89 Favored Glycine 0 CA--C 1.534 1.243 0 C-N-CA 124.834 1.207 . . . . 0.0 113.811 -177.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.57 HG22 ' HD3' ' A' ' 22' ' ' PRO . 40.9 t -102.58 123.75 56.11 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 124.328 1.051 . . . . 0.0 110.096 -178.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -98.67 110.14 22.79 Favored 'General case' 0 N--CA 1.475 0.821 0 O-C-N 121.178 -0.951 . . . . 0.0 110.523 175.041 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.763 ' HE3' HG21 ' A' ' 58' ' ' VAL . 1.7 ptpm? -127.83 106.55 9.19 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 127.423 2.289 . . . . 0.0 109.699 179.138 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 3.8 t -161.19 159.68 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 125.648 1.579 . . . . 0.0 107.607 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ALA . . . . . 0.44 ' HB2' ' HB3' ' A' ' 9' ' ' ALA . . . -48.11 -41.08 25.48 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.492 1.117 . . . . 0.0 113.322 176.227 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 36.6 p -87.3 -41.88 13.33 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 125.238 1.415 . . . . 0.0 114.51 175.172 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -54.47 -62.76 1.44 Allowed 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.334 1.454 . . . . 0.0 111.442 -176.156 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.251 1.158 0 C-N-CA 131.438 3.895 . . . . 0.0 107.742 -179.578 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.164 0 N-CA-C 110.524 -0.176 . . . . 0.0 110.524 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 132.06 -70.45 0.52 Allowed Glycine 0 N--CA 1.475 1.256 0 C-N-CA 125.204 1.383 . . . . 0.0 112.63 178.714 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -81.69 114.51 20.41 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.175 1.39 . . . . 0.0 111.288 177.737 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 37.8 mtm -108.5 159.77 29.59 Favored Pre-proline 0 CA--C 1.545 0.765 0 C-N-CA 124.805 1.242 . . . . 0.0 112.782 177.088 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -68.46 120.71 7.64 Favored 'Trans proline' 0 CA--C 1.538 0.706 0 C-N-CA 124.075 3.184 . . . . 0.0 111.486 177.835 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -154.47 156.49 36.83 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 125.645 1.578 . . . . 0.0 111.477 175.023 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 142.4 147.82 4.87 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 125.288 1.423 . . . . 0.0 113.552 175.718 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 50.5 m -145.02 97.96 3.1 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 125.574 1.55 . . . . 0.0 110.761 -176.22 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -135.86 -71.27 0.47 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.496 1.118 . . . . 0.0 112.498 -178.313 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 95.5 p -119.48 175.9 5.61 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 125.936 1.694 . . . . 0.0 112.022 178.229 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 42.1 mt -101.77 14.87 30.69 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 125.325 1.45 . . . . 0.0 113.026 -178.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.9 mt-30 -119.8 171.52 8.35 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 126.512 1.925 . . . . 0.0 112.208 177.384 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -118.34 153.9 33.25 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.81 1.644 . . . . 0.0 110.514 174.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -147.45 177.34 9.32 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.198 1.399 . . . . 0.0 112.013 177.021 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -58.71 129.84 21.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 123.756 0.822 . . . . 0.0 111.276 175.095 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 88.5 -4.3 85.19 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 125.191 1.377 . . . . 0.0 115.126 -178.831 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -72.0 176.37 5.11 Favored 'General case' 0 CA--C 1.551 0.986 0 CA-C-N 118.946 1.373 . . . . 0.0 112.075 175.027 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 2.4 tpt180 -119.49 142.01 48.67 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 125.278 1.431 . . . . 0.0 111.578 -177.186 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 15.6 m -136.76 142.39 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 123.996 0.918 . . . . 0.0 110.541 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 p -136.99 141.0 41.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 124.08 0.952 . . . . 0.0 110.724 177.258 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.479 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 1.3 m-85 -80.51 158.66 71.03 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 124.271 1.028 . . . . 0.0 112.126 176.0 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.441 ' CD ' HG12 ' A' ' 68' ' ' VAL . 70.8 Cg_endo -68.55 -23.41 37.07 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 123.699 2.933 . . . . 0.0 112.98 -177.825 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -159.91 51.73 0.33 Allowed 'General case' 0 CA--C 1.555 1.164 0 C-N-CA 124.752 1.221 . . . . 0.0 112.656 177.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.41 -58.11 0.37 Allowed 'General case' 0 N--CA 1.483 1.184 0 O-C-N 120.743 -1.223 . . . . 0.0 112.982 -176.407 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 155.97 179.25 30.89 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.099 1.333 . . . . 0.0 113.314 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.2 p -85.27 152.28 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.959 1.304 . . . . 0.0 111.268 175.646 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.52 ' SG ' HG11 ' A' ' 56' ' ' VAL . 4.0 m -132.77 170.18 15.64 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.195 1.798 . . . . 0.0 110.725 174.926 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -128.68 121.05 27.69 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.369 1.068 . . . . 0.0 111.36 -174.313 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.403 HG22 ' CE ' ' A' ' 47' ' ' MET . 50.0 t -63.61 121.5 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 124.436 1.094 . . . . 0.0 110.617 -178.139 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.8 m -112.42 -41.51 3.86 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.573 1.149 . . . . 0.0 112.1 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.98 165.21 36.81 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.287 1.835 . . . . 0.0 110.612 174.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 41.7 mt -147.65 138.15 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.971 1.308 . . . . 0.0 108.76 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -147.48 170.58 17.1 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.449 1.1 . . . . 0.0 112.785 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.6 m -108.51 139.25 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 124.909 1.284 . . . . 0.0 110.599 175.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 7.5 ptmt -155.92 168.13 28.21 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.291 1.036 . . . . 0.0 112.543 175.311 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.12 116.05 31.24 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 125.648 1.579 . . . . 0.0 109.516 175.006 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.7 p -126.09 137.25 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.15 0.98 . . . . 0.0 109.648 174.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.94 28.98 2.17 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 114.829 1.418 . . . . 0.0 114.829 -179.02 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.45 25.18 48.28 Favored Glycine 0 CA--C 1.54 1.597 0 C-N-CA 124.839 1.209 . . . . 0.0 115.322 -176.62 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -139.08 113.52 8.95 Favored 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 125.413 1.485 . . . . 0.0 111.462 -174.133 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -95.85 116.7 29.3 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.144 1.377 . . . . 0.0 111.917 -179.29 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.55 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -159.75 175.08 13.57 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 123.813 0.845 . . . . 0.0 112.02 179.224 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 15.3 m -77.35 116.33 17.86 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.314 1.046 . . . . 0.0 111.934 175.001 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -106.01 113.45 27.01 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 124.849 1.26 . . . . 0.0 109.351 175.194 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.2 m -63.73 150.7 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 O-C-N 122.052 -0.405 . . . . 0.0 111.331 175.822 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -126.55 109.89 12.64 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 122.037 0.922 . . . . 0.0 110.638 174.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' MET . . . . . 0.471 ' HB2' HG13 ' A' ' 56' ' ' VAL . 0.7 OUTLIER -128.43 162.57 26.86 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 125.095 1.358 . . . . 0.0 110.181 179.597 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.3 mtt180 -138.67 113.85 9.44 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 125.491 1.516 . . . . 0.0 109.298 177.664 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 44.5 mtp85 -69.91 109.09 4.29 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 174.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -70.17 -13.86 62.38 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.188 0.995 . . . . 0.0 113.286 176.072 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -59.36 -42.82 92.49 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 125.96 1.704 . . . . 0.0 112.66 177.253 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -128.52 -15.45 4.51 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.843 1.424 . . . . 0.0 114.843 177.768 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 84.07 59.03 2.12 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 125.578 1.561 . . . . 0.0 113.446 -179.242 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -135.66 128.72 31.59 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.657 1.183 . . . . 0.0 112.532 179.021 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.0 p -67.05 141.87 17.36 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 C-N-CA 124.286 1.034 . . . . 0.0 110.127 175.367 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.52 HG11 ' SG ' ' A' ' 27' ' ' CYS . 5.6 p -137.31 114.41 12.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 C-N-CA 126.244 1.818 . . . . 0.0 108.969 178.344 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.3 ptt? -126.79 125.63 42.04 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 125.794 1.638 . . . . 0.0 109.832 179.717 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 33.8 m -131.89 152.98 81.23 Favored Pre-proline 0 N--CA 1.468 0.457 0 C-N-CA 123.7 0.8 . . . . 0.0 111.359 178.433 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.55 ' CB ' HD11 ' A' ' 42' ' ' LEU . 51.5 Cg_endo -77.01 116.5 4.22 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.912 2.408 . . . . 0.0 114.557 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -60.65 -38.22 84.13 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 114.572 1.323 . . . . 0.0 114.572 -179.623 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.91 5.81 79.21 Favored Glycine 0 N--CA 1.476 1.34 0 C-N-CA 124.545 1.069 . . . . 0.0 114.697 178.408 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.9 tttt -133.85 3.03 3.46 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.474 1.51 . . . . 0.0 112.889 -177.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.54 -29.72 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 125.533 1.533 . . . . 0.0 113.745 175.306 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.5 mt -56.3 -29.4 61.17 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 126.093 1.757 . . . . 0.0 112.542 177.164 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.42 -50.4 15.94 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 125.849 1.66 . . . . 0.0 112.873 175.52 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.429 HG22 HG13 ' A' ' 68' ' ' VAL . 3.9 mp -67.33 -33.31 61.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 124.134 0.973 . . . . 0.0 111.355 178.034 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.53 8.29 68.16 Favored Glycine 0 CA--C 1.535 1.335 0 C-N-CA 125.617 1.58 . . . . 0.0 114.356 -176.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.479 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 24.9 m -93.26 123.27 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 125.407 1.483 . . . . 0.0 110.763 -176.689 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.62 109.31 21.37 Favored 'General case' 0 N--CA 1.471 0.607 0 O-C-N 120.827 -1.17 . . . . 0.0 109.58 178.089 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.5 106.58 17.7 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 123.764 0.826 . . . . 0.0 109.91 176.255 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 97.3 t -147.49 -71.19 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 C-N-CA 124.654 1.182 . . . . 0.0 111.798 176.756 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . 175.32 -46.18 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 128.052 2.541 . . . . 0.0 110.924 -175.629 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 71.3 p -123.52 -4.61 8.25 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 126.007 1.723 . . . . 0.0 114.652 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -73.23 -59.01 2.91 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.283 1.433 . . . . 0.0 113.341 -173.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 68.4 tt0 . . . . . 0 C--O 1.254 1.301 0 C-N-CA 129.704 3.201 . . . . 0.0 117.116 175.207 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.207 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 142.14 106.33 0.59 Allowed Glycine 0 N--CA 1.474 1.199 0 C-N-CA 124.269 0.937 . . . . 0.0 113.221 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.2 m170 -69.11 155.18 40.81 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 123.871 0.868 . . . . 0.0 111.662 174.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 3.9 mpp? -83.32 164.97 43.19 Favored Pre-proline 0 CA--C 1.545 0.785 0 C-N-CA 124.444 1.098 . . . . 0.0 112.686 175.438 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -71.09 113.38 3.57 Favored 'Trans proline' 0 CA--C 1.54 0.796 0 C-N-CA 123.743 2.962 . . . . 0.0 112.039 175.054 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -126.69 94.39 4.04 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 125.478 1.511 . . . . 0.0 110.364 178.511 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -167.25 65.9 0.19 Allowed Glycine 0 CA--C 1.531 1.06 0 N-CA-C 115.026 0.77 . . . . 0.0 115.026 -178.263 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.441 ' HA ' ' HB1' ' A' ' 72' ' ' ALA . 57.8 m -67.46 110.03 3.45 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 124.867 1.267 . . . . 0.0 113.525 177.014 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -61.87 -71.11 0.16 Allowed 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 124.104 0.962 . . . . 0.0 112.507 174.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.2 p -158.88 -79.24 0.06 Allowed 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 125.277 1.431 . . . . 0.0 111.813 -177.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -117.6 -61.8 1.65 Allowed 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 126.541 1.937 . . . . 0.0 111.308 -177.034 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 -110.41 175.45 5.42 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.899 1.68 . . . . 0.0 110.703 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.699 HD23 ' HA ' ' A' ' 71' ' ' VAL . 0.7 OUTLIER -66.02 128.91 37.92 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.285 1.034 . . . . 0.0 110.981 175.127 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -135.25 175.16 9.83 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.572 1.549 . . . . 0.0 112.336 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.6 t -59.61 132.8 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 O-C-N 121.184 -0.948 . . . . 0.0 111.127 177.598 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.62 -5.52 83.33 Favored Glycine 0 CA--C 1.537 1.427 0 C-N-CA 124.854 1.216 . . . . 0.0 115.005 -179.272 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -68.51 173.32 5.12 Favored 'General case' 0 CA--C 1.553 1.058 0 CA-C-N 118.761 1.281 . . . . 0.0 110.246 175.041 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -84.33 158.31 21.2 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 125.102 1.361 . . . . 0.0 112.007 174.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.745 HG11 ' HG2' ' A' ' 47' ' ' MET . 2.4 p -160.32 124.37 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 124.688 1.195 . . . . 0.0 109.997 175.019 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 2.9 m -131.56 159.74 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.618 0.723 . . . . 0.0 109.35 174.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.494 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.8 OUTLIER -95.27 162.02 26.08 Favored Pre-proline 0 CA--C 1.544 0.72 0 C-N-CA 123.515 0.726 . . . . 0.0 110.796 177.043 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.437 ' CD ' HG12 ' A' ' 68' ' ' VAL . 68.0 Cg_endo -69.35 -24.84 31.1 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 123.191 2.594 . . . . 0.0 112.429 -179.2 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -159.48 55.65 0.39 Allowed 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 124.725 1.21 . . . . 0.0 112.572 178.608 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 9.8 tm0? -142.7 -58.81 0.44 Allowed 'General case' 0 N--CA 1.482 1.165 0 O-C-N 120.832 -1.167 . . . . 0.0 113.024 -178.506 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 158.58 -168.66 34.87 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 124.849 1.214 . . . . 0.0 112.995 -174.266 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.5 m -109.52 146.8 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 125.176 1.39 . . . . 0.0 112.656 -176.547 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.551 ' HB2' HG13 ' A' ' 19' ' ' VAL . 61.3 m -137.25 179.55 6.33 Favored 'General case' 0 CA--C 1.551 1.01 0 C-N-CA 126.168 1.787 . . . . 0.0 110.944 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.89 132.35 43.54 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 126.892 2.077 . . . . 0.0 111.362 175.113 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.641 HG21 HD11 ' A' ' 13' ' ' LEU . 21.9 t -67.6 129.94 32.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.149 0.98 . . . . 0.0 111.233 179.523 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.76 -48.57 3.12 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.9 1.28 . . . . 0.0 112.781 -175.56 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.99 163.06 36.79 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.372 1.469 . . . . 0.0 110.961 174.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -140.94 133.42 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 124.263 1.025 . . . . 0.0 109.252 178.166 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -148.46 168.04 23.73 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.713 1.205 . . . . 0.0 112.19 176.566 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.539 HG12 ' HA ' ' A' ' 43' ' ' THR . 18.8 m -106.69 141.3 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 O-C-N 121.257 -0.902 . . . . 0.0 110.373 175.864 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.1 ptmt -153.45 168.59 25.59 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 123.809 0.843 . . . . 0.0 112.211 176.666 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -100.67 117.62 35.15 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 125.485 1.514 . . . . 0.0 109.991 175.014 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.0 p -127.26 138.14 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 124.106 0.962 . . . . 0.0 109.656 175.021 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.98 29.06 1.59 Allowed 'General case' 0 CA--C 1.557 1.223 0 N-CA-C 114.776 1.398 . . . . 0.0 114.776 -177.823 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.08 27.52 49.19 Favored Glycine 0 CA--C 1.542 1.748 0 C-N-CA 124.88 1.229 . . . . 0.0 115.361 -176.473 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 10.5 tp60 -137.41 114.95 11.16 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.223 1.809 . . . . 0.0 110.656 -175.7 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.02 115.07 26.96 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.69 1.196 . . . . 0.0 111.492 178.621 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.602 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -153.11 172.56 16.71 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 123.448 0.699 . . . . 0.0 111.649 177.388 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.539 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.3 m -74.16 116.35 14.7 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 125.011 1.324 . . . . 0.0 111.105 175.793 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -109.83 113.07 25.52 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 124.451 1.1 . . . . 0.0 110.105 177.071 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.535 HG21 ' HE3' ' A' ' 70' ' ' LYS . 22.0 m -77.45 145.0 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 123.156 0.582 . . . . 0.0 110.903 178.323 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.1 m -126.31 112.36 15.61 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 122.116 0.96 . . . . 0.0 110.689 -179.053 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' MET . . . . . 0.745 ' HG2' HG11 ' A' ' 19' ' ' VAL . 2.0 mpp? -122.42 162.7 21.16 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 124.816 1.246 . . . . 0.0 109.638 -176.423 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.438 ' CG ' HG12 ' A' ' 55' ' ' VAL . 1.3 mtt180 -134.84 151.87 51.28 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 125.38 1.472 . . . . 0.0 110.314 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.5 ptt180 -118.58 109.12 15.79 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.379 1.072 . . . . 0.0 109.793 175.028 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -64.96 -17.37 64.34 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.745 1.218 . . . . 0.0 112.408 174.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -55.4 -42.92 74.73 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 126.249 1.82 . . . . 0.0 112.693 175.708 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -128.68 3.4 5.5 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 125.126 1.37 . . . . 0.0 113.845 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 64.56 33.89 88.45 Favored Glycine 0 CA--C 1.535 1.292 0 C-N-CA 125.659 1.6 . . . . 0.0 113.979 -174.789 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -103.82 167.43 9.78 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.15 0.98 . . . . 0.0 111.988 -176.493 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.438 HG12 ' CG ' ' A' ' 48' ' ' ARG . 17.3 m -116.85 151.0 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.092 1.357 . . . . 0.0 110.258 178.441 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.3 p -143.82 126.36 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 C-N-CA 124.821 1.249 . . . . 0.0 109.202 176.498 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.6 tmm? -127.86 128.17 44.73 Favored 'General case' 0 C--O 1.234 0.267 0 C-N-CA 124.408 1.083 . . . . 0.0 109.839 177.759 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.7 m -132.95 155.45 81.14 Favored Pre-proline 0 N--CA 1.469 0.485 0 C-N-CA 124.396 1.078 . . . . 0.0 111.599 178.448 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.602 ' CB ' HD11 ' A' ' 42' ' ' LEU . 52.6 Cg_endo -76.14 116.14 4.3 Favored 'Trans proline' 0 CA--C 1.537 0.634 0 C-N-CA 123.749 2.966 . . . . 0.0 114.466 176.361 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -63.43 -34.64 78.2 Favored 'General case' 0 N--CA 1.479 1.005 0 O-C-N 120.341 -1.474 . . . . 0.0 114.172 177.484 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.17 5.9 78.47 Favored Glycine 0 N--CA 1.472 1.055 0 C-N-CA 124.175 0.893 . . . . 0.0 114.653 176.28 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.4 ttmm -136.76 4.11 2.78 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.269 1.428 . . . . 0.0 113.364 -178.588 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.429 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.4 m -49.38 -30.13 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.468 1.507 . . . . 0.0 113.042 175.303 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.3 mt -56.58 -29.14 61.73 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 126.288 1.835 . . . . 0.0 112.684 176.634 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.31 -50.2 13.34 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 126.05 1.74 . . . . 0.0 112.645 177.069 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.455 HG22 HG13 ' A' ' 68' ' ' VAL . 3.7 mp -66.8 -32.38 57.74 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 124.211 1.004 . . . . 0.0 111.291 176.886 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.39 2.71 79.39 Favored Glycine 0 CA--C 1.535 1.303 0 C-N-CA 125.789 1.662 . . . . 0.0 113.866 -174.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.494 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 18.6 m -83.57 123.23 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 118.338 1.069 . . . . 0.0 111.031 -178.822 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.1 mmt-85 -100.4 127.21 46.78 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 174.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.535 ' HE3' HG21 ' A' ' 45' ' ' VAL . 0.5 OUTLIER -138.29 106.55 5.78 Favored 'General case' 0 N--CA 1.464 0.225 0 C-N-CA 123.331 0.652 . . . . 0.0 110.481 176.794 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.699 ' HA ' HD23 ' A' ' 13' ' ' LEU . 3.2 t -159.52 163.02 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 125.511 1.524 . . . . 0.0 108.628 -173.561 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ALA . . . . . 0.441 ' HB1' ' HA ' ' A' ' 8' ' ' SER . . . -48.83 -32.9 9.53 Favored 'General case' 0 CA--C 1.551 0.999 0 C-N-CA 125.717 1.607 . . . . 0.0 114.681 175.099 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.1 m -115.35 -50.95 2.72 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.859 1.663 . . . . 0.0 113.064 175.262 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -72.53 83.9 1.12 Allowed 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 124.239 1.016 . . . . 0.0 111.48 174.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . 0.266 54.7 mt-10 . . . . . 0 C--O 1.251 1.166 0 C-N-CA 128.576 2.75 . . . . 0.0 115.698 177.57 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.279 0 CA-C-O 119.492 -0.29 . . . . 0.0 110.946 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -125.56 -179.07 15.57 Favored Glycine 0 CA--C 1.534 1.236 0 C-N-CA 125.533 1.54 . . . . 0.0 112.901 175.06 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -129.64 149.26 51.47 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 125.662 1.585 . . . . 0.0 110.432 175.024 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.9 ptt? -114.89 158.53 40.4 Favored Pre-proline 0 CA--C 1.544 0.743 0 C-N-CA 125.575 1.55 . . . . 0.0 111.504 177.212 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -72.37 86.55 0.98 Allowed 'Trans proline' 0 CA--C 1.539 0.748 0 C-N-CA 123.795 2.996 . . . . 0.0 111.744 177.403 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -99.61 177.74 5.06 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.753 1.621 . . . . 0.0 112.425 177.188 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.47 -124.54 1.09 Allowed Glycine 0 CA--C 1.53 0.995 0 C-N-CA 124.445 1.021 . . . . 0.0 111.638 177.416 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 19.6 p -162.46 -75.69 0.05 OUTLIER 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 125.075 1.35 . . . . 0.0 110.944 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -157.95 105.22 1.96 Allowed 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 126.167 1.787 . . . . 0.0 111.099 178.644 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 74.1 m -140.98 154.4 46.03 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 125.295 1.438 . . . . 0.0 111.615 176.114 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -111.75 -75.54 0.61 Allowed 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 125.785 1.634 . . . . 0.0 110.384 178.771 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -65.48 152.35 44.18 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 123.875 0.87 . . . . 0.0 110.973 175.028 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.597 HD23 HG21 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -109.69 162.8 14.09 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.946 1.298 . . . . 0.0 110.893 179.59 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -144.91 169.28 18.36 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.378 1.071 . . . . 0.0 111.772 177.554 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.3 t -61.21 130.34 25.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 123.586 0.754 . . . . 0.0 110.572 176.23 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.27 -8.81 79.0 Favored Glycine 0 CA--C 1.537 1.414 0 C-N-CA 124.997 1.284 . . . . 0.0 114.886 -176.036 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -72.67 165.16 25.3 Favored 'General case' 0 CA--C 1.551 0.998 0 CA-C-N 119.302 1.551 . . . . 0.0 111.496 175.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -85.82 154.93 21.22 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.669 0.747 . . . . 0.0 112.288 178.234 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 24.2 m -144.09 147.69 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 C-N-CA 125.204 1.402 . . . . 0.0 109.623 174.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.94 155.75 41.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 C-N-CA 126.461 1.905 . . . . 0.0 108.984 176.054 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -126.35 161.99 49.03 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 125.4 1.48 . . . . 0.0 111.433 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -74.02 -17.66 22.05 Favored 'Trans proline' 0 CA--C 1.541 0.841 0 C-N-CA 123.132 2.555 . . . . 0.0 113.023 -177.839 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -151.97 -40.08 0.11 Allowed 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 125.611 1.564 . . . . 0.0 112.543 176.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -53.91 -26.49 25.42 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.71 1.604 . . . . 0.0 114.777 179.428 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.46 -176.18 32.38 Favored Glycine 0 CA--C 1.535 1.336 0 C-N-CA 125.014 1.292 . . . . 0.0 114.383 179.306 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.0 m -74.74 144.14 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 O-C-N 121.234 -1.157 . . . . 0.0 111.788 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.495 ' SG ' HG11 ' A' ' 56' ' ' VAL . 33.5 m -136.26 -177.11 4.56 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 125.154 1.381 . . . . 0.0 110.809 177.793 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -138.16 115.91 11.45 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.913 1.285 . . . . 0.0 111.563 -173.187 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.597 HG21 HD23 ' A' ' 13' ' ' LEU . 42.4 t -63.45 128.18 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 C-N-CA 123.907 0.883 . . . . 0.0 111.541 -172.411 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 44.0 t -111.02 -49.39 3.03 Favored 'General case' 0 N--CA 1.469 0.505 0 C-N-CA 125.653 1.581 . . . . 0.0 112.039 -174.758 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -154.73 161.85 41.36 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.919 1.288 . . . . 0.0 111.208 175.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -142.81 127.93 16.21 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 124.713 1.205 . . . . 0.0 108.785 177.373 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -148.92 169.54 20.33 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 123.647 0.779 . . . . 0.0 112.361 175.447 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.466 HG12 ' HA ' ' A' ' 43' ' ' THR . 19.9 m -104.93 142.43 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 O-C-N 121.229 -0.919 . . . . 0.0 110.946 174.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.9 ptmt -155.51 171.0 20.67 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.745 0.818 . . . . 0.0 112.683 175.206 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -103.59 117.47 34.5 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.136 1.374 . . . . 0.0 109.821 176.403 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.7 p -129.69 135.96 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 178.243 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.38 28.73 1.75 Allowed 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 125.582 1.553 . . . . 0.0 114.656 -177.786 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.14 23.77 50.59 Favored Glycine 0 CA--C 1.538 1.519 0 C-N-CA 125.45 1.5 . . . . 0.0 115.286 -176.743 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -134.26 113.76 12.32 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 126.16 1.784 . . . . 0.0 111.128 -174.591 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 54.6 tttt -96.33 112.48 24.2 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 124.942 1.297 . . . . 0.0 111.585 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.63 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.8 OUTLIER -156.09 172.41 18.47 Favored 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 123.405 0.682 . . . . 0.0 112.161 179.035 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.466 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.8 m -72.95 119.17 16.82 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.644 1.178 . . . . 0.0 110.591 175.431 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -110.19 116.65 31.88 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 174.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.7 m -81.3 143.57 12.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 123.935 0.894 . . . . 0.0 109.027 175.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.9 m -126.38 117.34 22.77 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.527 1.531 . . . . 0.0 110.054 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -120.71 160.23 23.74 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 125.257 1.423 . . . . 0.0 110.202 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 55.0 mtm180 -140.51 121.29 14.41 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 124.926 1.29 . . . . 0.0 110.338 -179.131 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.68 108.85 17.61 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 124.647 1.179 . . . . 0.0 111.045 176.238 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -69.96 -15.39 63.04 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 124.026 0.93 . . . . 0.0 112.264 175.452 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -59.67 -37.65 79.33 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 124.949 1.3 . . . . 0.0 113.439 177.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -128.39 -12.83 5.0 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 124.892 1.277 . . . . 0.0 113.677 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.57 50.94 5.42 Favored Glycine 0 CA--C 1.531 1.077 0 C-N-CA 125.56 1.552 . . . . 0.0 113.177 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -124.53 162.6 23.67 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.741 1.216 . . . . 0.0 112.264 178.529 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.1 m -109.13 152.84 11.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 125.07 1.348 . . . . 0.0 110.736 178.07 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.495 HG11 ' SG ' ' A' ' 27' ' ' CYS . 3.9 p -151.57 122.25 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 125.21 1.404 . . . . 0.0 109.252 178.756 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 22.6 ptt? -127.01 139.38 53.06 Favored 'General case' 0 C--O 1.236 0.374 0 C-N-CA 123.644 0.778 . . . . 0.0 110.884 177.825 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.1 m -141.19 158.2 64.85 Favored Pre-proline 0 N--CA 1.473 0.707 0 C-N-CA 123.858 0.863 . . . . 0.0 112.069 178.487 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.63 ' CB ' HD11 ' A' ' 42' ' ' LEU . 56.6 Cg_endo -76.67 115.02 3.97 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 123.497 2.798 . . . . 0.0 114.509 176.175 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.5 -34.43 77.76 Favored 'General case' 0 N--CA 1.477 0.912 0 O-C-N 120.315 -1.49 . . . . 0.0 114.173 178.604 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.0 5.98 78.96 Favored Glycine 0 N--CA 1.473 1.158 0 C-N-CA 124.017 0.818 . . . . 0.0 114.509 176.483 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 19.5 tttp -136.24 2.23 2.75 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.293 1.437 . . . . 0.0 113.359 -178.478 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -48.93 -30.12 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 125.612 1.565 . . . . 0.0 113.116 175.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.9 mt -57.34 -28.82 63.46 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 126.435 1.894 . . . . 0.0 112.556 177.133 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.74 -50.47 15.22 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.986 1.714 . . . . 0.0 112.668 175.557 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.436 ' H ' HD12 ' A' ' 66' ' ' ILE . 3.6 mp -68.53 -31.1 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 124.145 0.978 . . . . 0.0 111.227 178.309 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.35 8.85 70.62 Favored Glycine 0 CA--C 1.535 1.285 0 C-N-CA 125.82 1.676 . . . . 0.0 114.187 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 15.2 m -87.66 137.43 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.669 1.588 . . . . 0.0 110.356 -177.473 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.9 108.88 13.47 Favored 'General case' 0 N--CA 1.469 0.511 0 O-C-N 120.881 -1.137 . . . . 0.0 110.737 176.04 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.452 ' HE2' HD22 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -90.21 106.72 18.68 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 124.25 1.02 . . . . 0.0 109.3 175.594 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 57.6 t -151.45 -69.97 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 C-N-CA 124.939 1.296 . . . . 0.0 111.398 176.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . 175.32 -56.51 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 128.565 2.746 . . . . 0.0 110.002 -176.548 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 3.3 m -121.76 1.02 9.92 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 125.556 1.542 . . . . 0.0 114.439 -179.111 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -71.28 -50.6 31.0 Favored 'General case' 0 CA--C 1.548 0.88 0 C-N-CA 124.694 1.198 . . . . 0.0 113.348 -179.559 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . 0.302 10.0 pt-20 . . . . . 0 N--CA 1.485 1.302 1 C-N-CA 131.868 4.067 . . . . 0.0 119.615 -177.997 . . . . . . . . 2 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.202 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -91.45 5.91 80.53 Favored Glycine 0 CA--C 1.538 1.475 0 C-N-CA 124.627 1.108 . . . . 0.0 115.079 178.63 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 30.2 m170 -60.83 127.94 34.05 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.25 1.42 . . . . 0.0 112.153 -179.543 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 22.8 mtt -65.16 160.22 59.15 Favored Pre-proline 0 CA--C 1.547 0.832 0 C-N-CA 123.938 0.895 . . . . 0.0 112.42 175.06 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -69.6 131.67 21.96 Favored 'Trans proline' 0 CA--C 1.537 0.637 0 C-N-CA 123.5 2.8 . . . . 0.0 110.354 175.834 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -162.06 175.92 11.27 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 125.19 1.396 . . . . 0.0 111.409 177.527 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 97.62 66.41 0.9 Allowed Glycine 0 CA--C 1.531 1.083 0 C-N-CA 124.882 1.229 . . . . 0.0 113.298 175.381 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.2 t -111.71 161.75 15.94 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 124.867 1.267 . . . . 0.0 112.447 177.711 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -161.96 -62.75 0.05 OUTLIER 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 125.372 1.469 . . . . 0.0 111.628 176.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 43.5 m -66.86 155.9 37.12 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.234 1.014 . . . . 0.0 112.586 177.226 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.5 mp -86.51 21.13 2.22 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 125.775 1.63 . . . . 0.0 113.378 179.714 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -147.89 145.32 28.61 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 125.122 1.369 . . . . 0.0 111.173 178.211 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.486 HD23 ' HA ' ' A' ' 71' ' ' VAL . 0.3 OUTLIER -83.37 132.41 35.0 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.152 0.981 . . . . 0.0 110.224 175.138 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.56 163.7 19.5 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.363 1.465 . . . . 0.0 112.433 177.018 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 98.1 t -60.35 129.57 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 123.975 0.91 . . . . 0.0 110.225 178.668 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.11 -11.86 65.59 Favored Glycine 0 CA--C 1.534 1.267 0 C-N-CA 125.012 1.291 . . . . 0.0 114.761 -176.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -74.99 168.52 19.8 Favored 'General case' 0 CA--C 1.544 0.729 0 CA-C-N 119.445 1.622 . . . . 0.0 110.971 175.018 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.84 163.86 20.91 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 123.964 0.906 . . . . 0.0 111.426 175.133 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 17.9 m -149.84 150.49 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 125.488 1.515 . . . . 0.0 109.691 175.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 6.6 p -137.03 156.3 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 C-N-CA 126.239 1.815 . . . . 0.0 110.035 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -130.43 157.62 76.88 Favored Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 125.471 1.508 . . . . 0.0 111.638 -177.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.11 -40.47 6.3 Favored 'Trans proline' 0 CA--C 1.536 0.582 0 C-N-CA 123.913 3.075 . . . . 0.0 112.313 -177.15 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -148.96 43.82 0.98 Allowed 'General case' 0 CA--C 1.552 1.034 0 C-N-CA 126.057 1.743 . . . . 0.0 112.153 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -128.35 -51.3 1.29 Allowed 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 124.38 1.072 . . . . 0.0 111.945 177.252 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 128.88 -179.02 16.91 Favored Glycine 0 CA--C 1.535 1.305 0 C-N-CA 126.41 1.957 . . . . 0.0 113.035 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.1 m -77.49 143.76 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 O-C-N 121.766 -0.843 . . . . 0.0 111.281 174.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 85.3 m -136.04 -176.96 4.49 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 125.116 1.366 . . . . 0.0 110.786 176.154 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.5 ttt180 -140.7 124.54 17.18 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 125.01 1.324 . . . . 0.0 110.921 -178.597 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.8 t -62.06 119.22 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 123.464 0.706 . . . . 0.0 111.827 -175.575 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.9 p -100.58 -46.21 5.27 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.031 0.932 . . . . 0.0 111.902 -178.735 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.76 172.06 17.92 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 126.366 1.866 . . . . 0.0 111.133 176.166 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 79.8 mt -146.02 137.15 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 C-N-CA 124.759 1.224 . . . . 0.0 108.358 174.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -141.97 168.97 18.49 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 124.146 0.978 . . . . 0.0 111.781 176.227 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.463 HG12 ' HA ' ' A' ' 43' ' ' THR . 15.9 m -116.19 145.25 22.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 O-C-N 120.986 -1.072 . . . . 0.0 110.924 175.388 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.6 174.74 14.07 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.199 0.999 . . . . 0.0 111.952 174.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -107.75 121.68 45.21 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 125.906 1.682 . . . . 0.0 108.9 175.008 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.6 p -125.2 129.15 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 125.058 1.343 . . . . 0.0 109.159 174.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.97 28.99 2.19 Favored 'General case' 0 CA--C 1.556 1.203 0 N-CA-C 114.735 1.383 . . . . 0.0 114.735 -178.509 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.78 21.08 54.57 Favored Glycine 0 CA--C 1.539 1.571 0 C-N-CA 124.814 1.197 . . . . 0.0 115.301 -176.504 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -126.16 113.5 17.12 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 125.924 1.69 . . . . 0.0 110.275 -176.275 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 11.2 tttt -96.77 117.75 31.73 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 124.734 1.213 . . . . 0.0 111.068 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.566 HD11 ' CB ' ' A' ' 59' ' ' PRO . 1.1 pp -158.56 172.46 18.26 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 122.984 0.514 . . . . 0.0 111.75 178.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.463 ' HA ' HG12 ' A' ' 34' ' ' VAL . 22.6 m -80.04 116.47 20.18 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 124.946 1.298 . . . . 0.0 112.521 176.219 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -102.89 113.24 26.52 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 124.487 1.115 . . . . 0.0 109.104 174.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.1 m -63.79 149.05 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 O-C-N 121.843 -0.536 . . . . 0.0 111.223 175.133 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 24.6 m -126.49 109.95 12.74 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.447 1.099 . . . . 0.0 110.942 178.393 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -128.8 165.43 20.97 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 121.512 -0.742 . . . . 0.0 111.002 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -140.0 120.07 13.68 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.417 1.087 . . . . 0.0 111.403 178.016 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 15.0 ptm180 -74.08 110.06 8.07 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 125.089 1.356 . . . . 0.0 110.865 175.252 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -64.51 -17.25 63.72 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 177.442 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -59.43 -37.71 78.78 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.453 1.501 . . . . 0.0 113.895 177.821 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.63 -0.39 5.5 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 124.834 1.253 . . . . 0.0 112.908 178.079 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.65 20.9 68.57 Favored Glycine 0 CA--C 1.537 1.419 0 C-N-CA 125.254 1.407 . . . . 0.0 113.851 -170.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -87.87 163.55 16.34 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 118.516 1.158 . . . . 0.0 111.541 -176.139 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 27.5 m -108.8 143.74 18.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.064 1.346 . . . . 0.0 110.874 -179.67 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.7 m -135.33 130.44 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 124.813 1.245 . . . . 0.0 109.483 178.068 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 38.8 mtm -141.84 123.82 15.37 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.336 1.054 . . . . 0.0 110.261 -178.308 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.5 m -135.05 157.21 77.45 Favored Pre-proline 0 N--CA 1.474 0.744 0 C-N-CA 123.952 0.901 . . . . 0.0 112.116 179.173 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.566 ' CB ' HD11 ' A' ' 42' ' ' LEU . 42.9 Cg_endo -76.79 117.49 4.52 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 123.374 2.716 . . . . 0.0 114.949 179.721 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -60.54 -38.92 86.04 Favored 'General case' 0 N--CA 1.478 0.928 0 O-C-N 120.463 -1.398 . . . . 0.0 114.253 179.617 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.18 5.71 78.37 Favored Glycine 0 N--CA 1.475 1.244 0 C-N-CA 124.549 1.071 . . . . 0.0 114.9 179.031 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 5.2 tttm -133.92 2.8 3.42 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.658 1.583 . . . . 0.0 112.639 -178.415 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.406 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -48.64 -30.19 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 C-N-CA 125.405 1.482 . . . . 0.0 113.233 175.028 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.5 mt -57.04 -28.74 62.8 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 125.938 1.695 . . . . 0.0 112.641 177.558 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.61 -50.91 14.11 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.593 1.557 . . . . 0.0 112.713 175.68 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.556 HG22 HG13 ' A' ' 68' ' ' VAL . 4.0 mp -69.04 -33.6 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 124.001 0.92 . . . . 0.0 111.264 179.201 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.66 4.36 76.23 Favored Glycine 0 CA--C 1.536 1.406 0 C-N-CA 125.881 1.705 . . . . 0.0 114.352 -177.033 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.556 HG13 HG22 ' A' ' 66' ' ' ILE . 27.3 m -83.57 133.29 29.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.952 1.701 . . . . 0.0 109.837 179.812 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.9 mtp180 -122.55 109.17 13.99 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 119.957 1.253 . . . . 0.0 110.194 175.385 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.77 106.63 18.57 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.114 178.181 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.486 ' HA ' HD23 ' A' ' 13' ' ' LEU . 69.4 t -149.25 -65.94 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.2 0 C-N-CA 124.0 0.92 . . . . 0.0 112.587 178.012 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . 169.99 -59.25 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 128.7 2.8 . . . . 0.0 109.247 -173.622 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 m -117.33 -2.76 11.52 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 125.651 1.581 . . . . 0.0 114.561 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.97 -59.91 3.09 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.311 1.044 . . . . 0.0 112.746 -179.45 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.484 1.227 0 C-N-CA 129.19 2.996 . . . . 0.0 116.579 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.301 0 CA-C-O 121.007 0.432 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 159.46 95.1 0.1 Allowed Glycine 0 N--CA 1.472 1.09 0 O-C-N 121.013 -1.054 . . . . 0.0 112.558 -175.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 18.5 t60 -87.22 105.84 17.49 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.814 0.807 . . . . 0.0 110.953 179.116 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.1 mpt? -78.29 161.43 70.28 Favored Pre-proline 0 CA--C 1.548 0.873 0 C-N-CA 124.799 1.24 . . . . 0.0 112.098 178.511 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -68.27 -21.35 41.74 Favored 'Trans proline' 0 CA--C 1.539 0.758 0 C-N-CA 123.664 2.909 . . . . 0.0 113.828 177.04 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -51.65 -34.58 38.55 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.449 1.9 . . . . 0.0 114.879 -177.441 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 40.51 -132.74 2.75 Favored Glycine 0 CA--C 1.538 1.483 0 C-N-CA 126.274 1.892 . . . . 0.0 113.825 -176.825 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.0 p -165.22 74.39 0.22 Allowed 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 125.695 1.598 . . . . 0.0 111.484 175.024 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -156.86 177.73 11.16 Favored 'General case' 0 CA--C 1.55 0.969 0 C-N-CA 125.471 1.508 . . . . 0.0 112.926 176.424 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.6 p -147.55 75.04 1.34 Allowed 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 125.659 1.584 . . . . 0.0 112.336 175.28 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -121.09 165.4 15.38 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 126.16 1.784 . . . . 0.0 111.936 -179.68 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.1 152.07 42.61 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.166 0.986 . . . . 0.0 112.046 174.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.435 ' HG ' ' HE2' ' A' ' 70' ' ' LYS . 0.5 OUTLIER -67.91 129.54 40.23 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 124.373 1.069 . . . . 0.0 111.394 176.105 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -143.2 179.01 7.32 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.937 1.695 . . . . 0.0 112.199 176.869 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.4 t -59.51 129.34 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 O-C-N 121.054 -1.029 . . . . 0.0 110.821 175.623 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.28 -2.63 86.73 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 125.109 1.338 . . . . 0.0 115.372 -178.429 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -70.98 170.17 13.34 Favored 'General case' 0 CA--C 1.55 0.972 0 CA-C-N 119.319 1.56 . . . . 0.0 112.284 174.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.71 142.86 28.99 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.796 1.238 . . . . 0.0 111.602 178.263 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.9 m -139.02 146.48 25.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 124.061 0.944 . . . . 0.0 110.286 175.078 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 13.7 p -137.09 149.5 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 C-N-CA 124.554 1.142 . . . . 0.0 110.584 174.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.1 m-85 -86.33 162.67 45.1 Favored Pre-proline 0 CA--C 1.545 0.764 0 C-N-CA 124.034 0.934 . . . . 0.0 111.704 175.027 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.475 ' CD ' HG22 ' A' ' 68' ' ' VAL . 62.1 Cg_endo -71.15 -24.97 22.88 Favored 'Trans proline' 0 CA--C 1.539 0.772 0 C-N-CA 122.883 2.389 . . . . 0.0 112.434 -176.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -165.91 55.02 0.1 Allowed 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 126.755 2.022 . . . . 0.0 111.844 -176.435 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 7.3 tp-100 -148.06 -63.52 0.26 Allowed 'General case' 0 N--CA 1.478 0.942 0 O-C-N 120.964 -1.085 . . . . 0.0 112.935 179.076 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.06 178.3 41.49 Favored Glycine 0 CA--C 1.534 1.245 0 C-N-CA 124.574 1.083 . . . . 0.0 113.754 -179.165 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.5 m -88.28 153.12 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 125.167 1.387 . . . . 0.0 110.783 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.2 m -140.02 172.45 12.74 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 125.256 1.423 . . . . 0.0 110.635 176.2 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 47.8 ttt-85 -133.81 123.95 25.69 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.108 0.963 . . . . 0.0 112.746 -179.283 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.3 t -69.39 122.76 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 125.751 1.62 . . . . 0.0 111.086 -179.28 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.6 t -108.87 -34.63 6.6 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 124.55 1.14 . . . . 0.0 112.485 178.352 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.14 167.28 29.54 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 126.224 1.81 . . . . 0.0 110.483 175.052 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 50.1 mt -144.89 140.61 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 125.19 1.396 . . . . 0.0 108.993 175.407 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -148.04 169.01 20.86 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.732 0.813 . . . . 0.0 112.568 175.551 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 10.9 m -104.69 143.21 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 124.819 1.248 . . . . 0.0 111.796 175.561 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.66 172.77 18.01 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 124.457 1.103 . . . . 0.0 112.311 174.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.64 121.83 45.47 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 126.137 1.775 . . . . 0.0 109.291 175.171 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.7 p -132.77 136.83 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 124.443 1.097 . . . . 0.0 109.259 174.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.91 29.05 1.54 Allowed 'General case' 0 CA--C 1.556 1.206 0 N-CA-C 114.939 1.459 . . . . 0.0 114.939 -177.063 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.9 26.21 50.21 Favored Glycine 0 CA--C 1.541 1.666 0 C-N-CA 124.76 1.172 . . . . 0.0 115.349 -177.2 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -134.44 113.46 11.88 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.054 1.742 . . . . 0.0 109.7 -175.54 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 20.9 tttt -96.85 116.4 29.1 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 124.696 1.199 . . . . 0.0 111.677 -179.682 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.525 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.9 OUTLIER -159.73 174.55 14.36 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 123.634 0.774 . . . . 0.0 112.203 -179.682 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 17.6 m -79.06 116.39 19.32 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.588 1.555 . . . . 0.0 112.107 176.03 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -104.77 113.28 26.78 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 124.416 1.086 . . . . 0.0 109.88 175.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 25.4 m -63.68 151.92 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 O-C-N 121.707 -0.621 . . . . 0.0 111.5 175.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -126.51 109.82 12.58 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-O 121.723 0.773 . . . . 0.0 110.499 176.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 5.2 mpp? -113.42 157.52 21.82 Favored 'General case' 0 C--O 1.232 0.144 0 C-N-CA 124.804 1.242 . . . . 0.0 111.616 176.78 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 43.1 mtp85 -133.88 105.58 6.84 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 126.191 1.797 . . . . 0.0 109.926 179.623 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 46.8 mtp85 -74.91 109.05 8.06 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.664 0.786 . . . . 0.0 109.435 175.034 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -69.73 -14.55 62.84 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 176.558 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -57.96 -43.2 86.3 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 126.072 1.749 . . . . 0.0 112.97 175.115 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -128.57 -12.93 4.88 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 125.024 1.33 . . . . 0.0 114.123 -177.886 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.92 4.88 78.19 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 125.935 1.731 . . . . 0.0 114.802 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -75.04 161.44 29.45 Favored 'General case' 0 CA--C 1.543 0.692 0 CA-C-N 118.532 1.166 . . . . 0.0 113.166 179.469 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.3 m -105.85 139.24 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 125.397 1.479 . . . . 0.0 109.865 174.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.3 t -123.31 114.96 44.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.82 1.248 . . . . 0.0 108.427 177.146 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.1 tmm? -127.97 123.91 35.97 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 124.94 1.296 . . . . 0.0 109.547 178.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.4 m -131.56 155.02 82.0 Favored Pre-proline 0 N--CA 1.469 0.52 0 C-N-CA 124.592 1.157 . . . . 0.0 111.388 176.868 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.525 ' CB ' HD11 ' A' ' 42' ' ' LEU . 46.4 Cg_endo -76.68 118.52 4.86 Favored 'Trans proline' 0 CA--C 1.536 0.577 0 C-N-CA 123.488 2.792 . . . . 0.0 114.763 177.597 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -59.87 -41.03 90.65 Favored 'General case' 0 N--CA 1.475 0.775 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.89 6.31 79.35 Favored Glycine 0 N--CA 1.475 1.299 0 C-N-CA 124.344 0.974 . . . . 0.0 114.69 178.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.9 tttp -132.98 3.63 3.74 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.667 1.587 . . . . 0.0 112.773 -178.533 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.61 -30.07 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 C-N-CA 125.128 1.371 . . . . 0.0 113.453 175.149 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.8 mt -55.93 -29.33 59.94 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 126.208 1.803 . . . . 0.0 112.652 177.591 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.83 -49.16 21.59 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 125.702 1.601 . . . . 0.0 112.837 175.76 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.405 HG22 HG23 ' A' ' 68' ' ' VAL . 4.0 mp -69.12 -33.61 59.35 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 124.202 1.001 . . . . 0.0 111.387 178.327 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.38 3.06 78.93 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 125.717 1.627 . . . . 0.0 114.365 -175.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.475 HG22 ' CD ' ' A' ' 22' ' ' PRO . 71.6 t -75.79 148.58 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 CA-C-N 118.47 1.135 . . . . 0.0 110.281 175.002 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.38 109.3 10.97 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-O 122.033 0.921 . . . . 0.0 108.679 175.018 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.435 ' HE2' ' HG ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER -112.5 106.59 15.09 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 125.5 1.52 . . . . 0.0 108.896 179.42 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 87.0 t -148.87 -72.29 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 C-N-CA 125.091 1.356 . . . . 0.0 111.07 177.69 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . 179.1 -57.61 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 128.777 2.831 . . . . 0.0 109.215 -176.513 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 86.2 p -114.08 3.71 15.37 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 126.769 2.028 . . . . 0.0 114.392 -176.723 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -77.04 -65.38 0.96 Allowed 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.196 1.398 . . . . 0.0 111.968 -179.511 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.483 1.202 0 C-N-CA 130.162 3.385 . . . . 0.0 116.583 178.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.607 HD21 HG21 ' A' ' 29' ' ' VAL . 1.2 tt . . . . . 0 CA--C 1.543 0.692 0 CA-C-O 120.91 0.386 . . . . 0.0 111.234 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -129.73 178.85 6.2 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 125.615 1.566 . . . . 0.0 112.045 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.87 133.0 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 O-C-N 121.003 -1.061 . . . . 0.0 110.574 174.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.03 -0.15 87.48 Favored Glycine 0 CA--C 1.532 1.144 0 C-N-CA 124.711 1.148 . . . . 0.0 114.868 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -66.08 171.41 4.62 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 124.39 1.076 . . . . 0.0 112.397 175.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -107.07 144.2 34.08 Favored 'General case' 0 N--CA 1.463 0.203 0 C-N-CA 125.392 1.477 . . . . 0.0 111.347 -176.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.448 HG21 ' HE2' ' A' ' 47' ' ' MET . 4.9 m -138.84 144.64 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 123.482 0.713 . . . . 0.0 109.76 -176.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.0 p -137.09 140.64 42.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 124.527 1.131 . . . . 0.0 109.4 175.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -92.37 161.55 32.35 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 124.488 1.115 . . . . 0.0 111.169 176.425 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -67.9 -14.01 40.08 Favored 'Trans proline' 0 CA--C 1.546 1.106 0 C-N-CA 122.816 2.344 . . . . 0.0 113.632 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.4 m-80 -148.76 -41.19 0.15 Allowed 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 126.064 1.746 . . . . 0.0 114.36 177.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 3.2 tm0? -52.34 -44.41 65.15 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 126.672 1.989 . . . . 0.0 114.107 -172.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 132.26 -150.28 19.6 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 125.937 1.732 . . . . 0.0 111.738 -178.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.9 m -112.27 146.57 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 C-N-CA 125.505 1.522 . . . . 0.0 110.917 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 78.1 m -137.06 179.71 6.22 Favored 'General case' 0 CA--C 1.551 1.016 0 C-N-CA 125.922 1.689 . . . . 0.0 110.589 175.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -136.1 129.49 31.92 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 125.185 1.394 . . . . 0.0 110.901 -179.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.607 HG21 HD21 ' A' ' 13' ' ' LEU . 26.5 t -68.73 139.21 20.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.362 0.665 . . . . 0.0 110.565 -175.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 46.7 t -117.89 -45.44 2.67 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 124.462 1.105 . . . . 0.0 112.647 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -151.93 160.7 43.43 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 124.483 1.113 . . . . 0.0 111.046 175.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -141.93 135.72 29.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 C-N-CA 124.663 1.185 . . . . 0.0 108.653 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -148.4 169.72 19.57 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.453 0.701 . . . . 0.0 111.646 175.298 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.603 HG12 ' HA ' ' A' ' 43' ' ' THR . 21.9 m -109.58 140.42 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 O-C-N 120.782 -1.199 . . . . 0.0 110.203 176.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -152.6 169.42 22.71 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.589 0.755 . . . . 0.0 111.974 176.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.73 116.22 32.24 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.205 1.402 . . . . 0.0 109.742 174.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.4 p -124.61 139.39 51.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 C-N-CA 124.227 1.011 . . . . 0.0 109.574 175.014 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.52 29.1 1.95 Allowed 'General case' 0 CA--C 1.558 1.253 0 N-CA-C 114.702 1.371 . . . . 0.0 114.702 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.08 25.19 52.97 Favored Glycine 0 CA--C 1.54 1.594 0 C-N-CA 125.044 1.307 . . . . 0.0 115.414 -175.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . 0.404 ' HG2' ' HE3' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -138.59 115.06 10.49 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 125.85 1.66 . . . . 0.0 111.387 -172.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 10.5 tttt -95.01 118.28 31.56 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.639 1.176 . . . . 0.0 111.79 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.606 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -155.51 171.6 19.65 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.344 0.658 . . . . 0.0 111.662 177.797 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.603 ' HA ' HG12 ' A' ' 34' ' ' VAL . 6.8 m -74.55 116.48 15.28 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.179 0.992 . . . . 0.0 111.296 175.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -109.83 113.35 26.03 Favored 'General case' 0 C--O 1.234 0.252 0 C-N-CA 124.627 1.171 . . . . 0.0 110.16 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.662 HG21 ' CE ' ' A' ' 70' ' ' LYS . 24.1 m -80.59 145.75 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.041 179.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 16.5 m -126.31 110.12 13.03 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 122.217 1.008 . . . . 0.0 110.972 179.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . 0.448 ' HE2' HG21 ' A' ' 19' ' ' VAL . 2.2 mpp? -109.64 151.0 27.42 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 125.278 1.431 . . . . 0.0 110.095 -178.51 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 37.5 mtm180 -136.17 110.29 8.32 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.69 1.196 . . . . 0.0 109.677 -176.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -76.44 109.01 9.81 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 177.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -69.73 -13.78 62.46 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.498 1.119 . . . . 0.0 113.818 176.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -60.44 -39.49 87.7 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 125.559 1.543 . . . . 0.0 112.75 178.108 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -128.59 -18.82 3.86 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 125.793 1.637 . . . . 0.0 113.915 178.404 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.2 15.42 48.0 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 125.438 1.494 . . . . 0.0 114.766 -177.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -78.41 163.98 25.17 Favored 'General case' 0 CA--C 1.54 0.574 0 CA-C-N 118.416 1.108 . . . . 0.0 112.376 175.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 25.9 m -128.98 142.0 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.146 1.379 . . . . 0.0 110.665 175.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 21.9 m -131.87 133.71 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 125.114 1.366 . . . . 0.0 108.719 177.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -129.72 127.11 39.79 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 124.257 1.023 . . . . 0.0 109.051 177.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.415 ' O ' HG22 ' A' ' 45' ' ' VAL . 27.5 m -133.73 156.66 79.25 Favored Pre-proline 0 N--CA 1.471 0.596 0 C-N-CA 124.3 1.04 . . . . 0.0 111.635 178.119 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.606 ' CB ' HD11 ' A' ' 42' ' ' LEU . 45.5 Cg_endo -76.1 116.71 4.45 Favored 'Trans proline' 0 CA--C 1.535 0.565 0 C-N-CA 123.567 2.845 . . . . 0.0 114.571 176.391 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -63.65 -34.89 78.84 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 120.537 -1.352 . . . . 0.0 114.024 177.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.1 6.86 78.91 Favored Glycine 0 N--CA 1.473 1.139 0 C-N-CA 124.201 0.905 . . . . 0.0 114.693 176.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.404 ' HE3' ' HG2' ' A' ' 40' ' ' GLN . 0.9 OUTLIER -136.74 3.98 2.77 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.225 1.41 . . . . 0.0 113.698 -178.779 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.486 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.2 m -49.86 -28.54 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.556 1.543 . . . . 0.0 113.421 175.442 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 12.0 mt -56.54 -29.77 62.3 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 125.805 1.642 . . . . 0.0 112.3 176.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.51 -49.89 15.35 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.811 1.644 . . . . 0.0 112.493 176.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.6 mp -65.7 -32.9 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 124.488 1.115 . . . . 0.0 111.741 177.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 85.21 4.41 86.48 Favored Glycine 0 CA--C 1.536 1.379 0 C-N-CA 125.397 1.475 . . . . 0.0 114.093 -175.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 13.9 p -80.83 132.9 30.53 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 124.905 1.282 . . . . 0.0 110.988 175.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.6 mmt180 -109.87 109.32 19.92 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 174.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.662 ' CE ' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.465 0.277 0 C-N-CA 123.879 0.872 . . . . 0.0 109.337 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.7 mm? . . . . . 0 N--CA 1.467 0.391 0 CA-C-O 120.957 0.408 . . . . 0.0 110.841 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.22 174.51 10.47 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.503 1.521 . . . . 0.0 111.39 176.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.5 t -60.89 126.2 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 123.718 0.807 . . . . 0.0 110.772 177.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.55 -8.74 74.45 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 125.131 1.348 . . . . 0.0 115.186 -176.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.1 t0 -71.51 167.6 19.33 Favored 'General case' 0 CA--C 1.548 0.9 0 CA-C-N 119.195 1.497 . . . . 0.0 111.4 174.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 12.4 tpp180 -92.98 151.39 19.94 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.036 0.934 . . . . 0.0 111.877 -179.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.669 HG11 ' HG2' ' A' ' 47' ' ' MET . 2.0 p -151.99 130.01 2.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 C-N-CA 124.895 1.278 . . . . 0.0 110.622 178.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.6 p -137.09 155.82 33.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 C-N-CA 125.837 1.655 . . . . 0.0 108.484 174.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.466 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.5 OUTLIER -101.46 158.69 31.3 Favored Pre-proline 0 CA--C 1.537 0.467 0 C-N-CA 125.047 1.339 . . . . 0.0 111.373 175.091 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.446 ' CD ' HG12 ' A' ' 68' ' ' VAL . 66.7 Cg_endo -68.21 -21.48 41.89 Favored 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 123.103 2.536 . . . . 0.0 112.458 -176.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -159.8 51.31 0.33 Allowed 'General case' 0 CA--C 1.557 1.221 0 C-N-CA 124.875 1.27 . . . . 0.0 112.896 176.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -140.36 -61.6 0.51 Allowed 'General case' 0 N--CA 1.483 1.216 0 O-C-N 120.835 -1.166 . . . . 0.0 113.116 -177.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 162.42 174.98 32.97 Favored Glycine 0 CA--C 1.534 1.245 0 C-N-CA 124.927 1.251 . . . . 0.0 113.65 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.9 t -91.19 140.42 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 125.461 1.504 . . . . 0.0 110.233 176.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 38.1 m -130.34 -177.85 4.5 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 126.258 1.823 . . . . 0.0 110.198 178.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 -141.96 124.21 15.56 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.074 0.95 . . . . 0.0 110.661 176.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.7 t -58.24 121.32 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 123.849 0.859 . . . . 0.0 110.815 -178.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.5 t -116.28 -35.2 4.4 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.458 1.503 . . . . 0.0 112.179 -175.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -148.14 157.95 43.8 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 125.179 1.392 . . . . 0.0 110.914 175.049 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 65.6 mt -143.15 132.59 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 O-C-N 120.816 -1.177 . . . . 0.0 108.242 175.238 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -138.51 172.25 13.16 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 125.247 1.419 . . . . 0.0 111.422 175.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.474 HG22 ' HA ' ' A' ' 43' ' ' THR . 21.9 t -129.88 136.9 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.619 1.168 . . . . 0.0 109.3 179.682 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.0 ptmt -144.46 161.98 37.69 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.694 1.198 . . . . 0.0 111.817 177.535 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -90.14 116.05 27.85 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 124.458 1.103 . . . . 0.0 109.631 175.111 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 p -112.72 128.14 69.58 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 125.348 1.459 . . . . 0.0 109.346 174.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.94 29.07 3.17 Favored 'General case' 0 CA--C 1.557 1.214 0 N-CA-C 114.815 1.413 . . . . 0.0 114.815 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.86 23.57 55.31 Favored Glycine 0 CA--C 1.541 1.715 0 C-N-CA 124.647 1.117 . . . . 0.0 115.323 -175.287 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -138.25 118.7 13.8 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 126.277 1.831 . . . . 0.0 111.194 178.513 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.461 ' HG2' HG12 ' A' ' 34' ' ' VAL . 1.8 tttt -85.68 135.85 33.6 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 123.904 0.882 . . . . 0.0 111.439 175.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.594 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.5 OUTLIER -154.93 159.16 40.23 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 122.823 0.449 . . . . 0.0 111.832 177.633 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.474 ' HA ' HG22 ' A' ' 34' ' ' VAL . 6.6 m -68.99 116.69 9.74 Favored 'General case' 0 N--CA 1.478 0.956 0 C-N-CA 124.056 0.942 . . . . 0.0 111.835 178.047 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -104.72 113.15 26.55 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 119.667 1.121 . . . . 0.0 110.776 174.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.7 m -84.73 136.86 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 123.796 0.838 . . . . 0.0 110.71 178.01 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 13.6 m -126.49 132.24 51.45 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 122.924 1.345 . . . . 0.0 111.876 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . 0.669 ' HG2' HG11 ' A' ' 19' ' ' VAL . 0.7 OUTLIER -130.13 161.93 29.98 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 125.151 1.381 . . . . 0.0 110.661 -174.217 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 14.3 mtp85 -131.09 103.12 6.33 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.911 1.284 . . . . 0.0 110.425 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.75 109.06 13.81 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.612 0.765 . . . . 0.0 110.766 177.345 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -63.56 -20.41 65.61 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.901 1.28 . . . . 0.0 112.72 178.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -58.63 -38.45 78.09 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.207 1.803 . . . . 0.0 113.344 -178.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -128.56 4.18 5.58 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 125.797 1.639 . . . . 0.0 112.702 174.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 62.91 29.86 75.49 Favored Glycine 0 CA--C 1.533 1.196 0 C-N-CA 125.526 1.536 . . . . 0.0 113.711 -174.336 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.62 172.26 7.6 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 118.343 1.072 . . . . 0.0 111.399 -174.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 30.3 m -114.55 144.25 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 C-N-CA 123.566 0.746 . . . . 0.0 111.098 174.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.9 t -124.33 112.11 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.253 1.421 . . . . 0.0 107.987 176.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.2 ttt -120.73 118.82 31.06 Favored 'General case' 0 C--O 1.235 0.317 0 C-N-CA 124.516 1.126 . . . . 0.0 109.734 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.433 HG21 ' NZ ' ' A' ' 70' ' ' LYS . 17.1 m -137.03 158.32 72.98 Favored Pre-proline 0 N--CA 1.471 0.607 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -178.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.594 ' CB ' HD11 ' A' ' 42' ' ' LEU . 64.7 Cg_endo -78.69 111.87 3.05 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.192 2.595 . . . . 0.0 114.56 176.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -60.95 -35.28 76.32 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 120.398 -1.439 . . . . 0.0 113.567 178.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.12 5.74 78.58 Favored Glycine 0 N--CA 1.474 1.222 0 C-N-CA 124.543 1.068 . . . . 0.0 114.961 176.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -135.51 1.47 2.86 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 125.207 1.403 . . . . 0.0 113.353 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.559 HG13 ' O ' ' A' ' 59' ' ' PRO . 3.0 m -49.86 -28.1 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.917 1.687 . . . . 0.0 114.149 176.524 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.1 mt -56.22 -34.53 66.4 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.064 1.746 . . . . 0.0 112.071 175.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.78 -48.61 45.45 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.779 1.632 . . . . 0.0 112.586 177.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.404 HG22 HG13 ' A' ' 68' ' ' VAL . 3.5 mp -68.28 -27.92 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 123.972 0.909 . . . . 0.0 111.49 176.432 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.78 19.49 63.38 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.433 1.492 . . . . 0.0 113.853 -178.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.466 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 15.6 m -95.27 123.16 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 126.254 1.821 . . . . 0.0 111.059 -175.583 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 11.0 mmt180 -107.7 109.24 20.79 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 121.272 -0.892 . . . . 0.0 109.076 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.509 ' HB3' HG23 ' A' ' 19' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.473 0.689 0 O-C-N 121.525 -0.734 . . . . 0.0 110.558 -179.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.444 HD11 HG21 ' A' ' 29' ' ' VAL . 0.4 OUTLIER . . . . . 0 CA--C 1.537 0.461 0 CA-C-O 120.737 0.303 . . . . 0.0 110.602 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -128.37 169.65 14.01 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.9 1.68 . . . . 0.0 112.052 178.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.4 t -63.75 130.47 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 O-C-N 121.226 -0.921 . . . . 0.0 110.693 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.73 -8.81 76.45 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.216 1.389 . . . . 0.0 114.663 -177.3 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -67.65 154.91 40.42 Favored 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 118.958 1.379 . . . . 0.0 110.818 174.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -74.96 157.41 35.01 Favored 'General case' 0 N--CA 1.472 0.664 0 O-C-N 121.312 -0.867 . . . . 0.0 110.046 174.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 14.9 m -149.25 138.2 15.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 C-N-CA 124.676 1.19 . . . . 0.0 110.449 179.279 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.6 p -137.09 157.79 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 125.355 1.462 . . . . 0.0 109.56 177.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -102.9 160.36 26.45 Favored Pre-proline 0 CA--C 1.542 0.667 0 C-N-CA 124.919 1.288 . . . . 0.0 111.732 175.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_endo -68.95 -28.02 29.71 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 123.806 3.004 . . . . 0.0 112.102 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.8 t30 -158.51 55.5 0.44 Allowed 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 124.472 1.109 . . . . 0.0 112.848 177.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.82 -60.79 0.29 Allowed 'General case' 0 N--CA 1.482 1.139 0 O-C-N 121.009 -1.057 . . . . 0.0 113.351 -174.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 162.43 -173.34 38.7 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 124.818 1.199 . . . . 0.0 113.59 -177.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.7 p -100.49 144.95 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 126.362 1.865 . . . . 0.0 110.945 176.211 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.417 ' SG ' HG21 ' A' ' 56' ' ' VAL . 38.7 m -131.75 -175.85 3.85 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 125.49 1.516 . . . . 0.0 110.306 175.434 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -137.53 124.8 21.78 Favored 'General case' 0 N--CA 1.48 1.028 0 O-C-N 121.091 -1.006 . . . . 0.0 111.634 177.021 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.444 HG21 HD11 ' A' ' 13' ' ' LEU . 60.4 t -64.61 136.04 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 C-N-CA 124.425 1.09 . . . . 0.0 110.657 -179.493 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.5 p -115.44 -44.95 2.94 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 124.635 1.174 . . . . 0.0 113.026 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.3 163.56 37.25 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 126.319 1.847 . . . . 0.0 110.796 176.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 75.0 mt -141.83 132.82 26.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 124.543 1.137 . . . . 0.0 108.979 178.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -147.37 167.23 24.86 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.615 0.766 . . . . 0.0 112.581 175.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.485 HG12 ' HA ' ' A' ' 43' ' ' THR . 20.9 m -103.3 141.93 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 O-C-N 121.117 -0.989 . . . . 0.0 110.699 175.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 3.9 ptmt -154.83 170.18 22.24 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 124.25 1.02 . . . . 0.0 112.234 175.47 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -102.46 116.34 32.42 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 125.999 1.72 . . . . 0.0 109.579 175.013 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.6 p -126.5 137.87 56.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.901 0.88 . . . . 0.0 110.025 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.5 28.97 1.89 Allowed 'General case' 0 CA--C 1.558 1.251 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 -177.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.28 22.69 53.81 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 125.172 1.367 . . . . 0.0 115.516 -176.565 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 35.8 tt0 -136.51 113.7 10.65 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 119.062 1.431 . . . . 0.0 111.666 -173.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 13.0 tttt -94.47 116.04 28.32 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.054 1.342 . . . . 0.0 111.747 -178.135 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.614 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -157.16 173.26 17.25 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.394 0.678 . . . . 0.0 111.887 177.777 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.485 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.2 m -73.96 116.41 14.55 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 124.934 1.293 . . . . 0.0 111.351 175.016 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -109.44 113.22 25.85 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.614 1.166 . . . . 0.0 109.939 177.195 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.613 HG21 ' HE2' ' A' ' 70' ' ' LYS . 27.3 m -73.61 150.71 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 O-C-N 121.817 -0.552 . . . . 0.0 110.894 177.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.2 m -126.5 121.18 31.62 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.801 0.84 . . . . 0.0 110.407 176.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -124.43 158.98 31.49 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 125.759 1.624 . . . . 0.0 110.51 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 13.4 ptm180 -136.18 111.5 9.11 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 126.061 1.744 . . . . 0.0 110.306 -178.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.9 109.07 19.08 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 123.258 0.623 . . . . 0.0 109.95 176.596 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 22.5 pt-20 -65.16 -18.43 65.3 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 113.337 0.866 . . . . 0.0 113.337 177.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -59.78 -36.72 77.26 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.027 1.731 . . . . 0.0 113.379 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -128.62 3.24 5.53 Favored 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.98 1.312 . . . . 0.0 112.665 174.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 64.61 24.18 69.37 Favored Glycine 0 CA--C 1.535 1.341 0 C-N-CA 125.447 1.498 . . . . 0.0 114.089 -172.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -90.74 173.53 7.97 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 118.671 1.236 . . . . 0.0 111.429 -176.361 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 27.0 m -117.9 143.77 27.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 124.168 0.987 . . . . 0.0 110.483 174.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.417 HG21 ' SG ' ' A' ' 27' ' ' CYS . 45.0 t -125.86 112.31 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 C-N-CA 125.375 1.47 . . . . 0.0 107.499 177.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.1 tmm? -125.34 119.34 28.1 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.145 0.978 . . . . 0.0 109.972 176.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.8 m -132.14 156.76 79.71 Favored Pre-proline 0 N--CA 1.469 0.519 0 C-N-CA 124.746 1.219 . . . . 0.0 111.834 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.614 ' CB ' HD11 ' A' ' 42' ' ' LEU . 58.3 Cg_endo -78.01 113.61 3.46 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 124.053 3.169 . . . . 0.0 115.38 179.576 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -60.78 -34.42 74.46 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 120.134 -1.604 . . . . 0.0 114.315 178.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.17 5.57 78.37 Favored Glycine 0 N--CA 1.474 1.218 0 C-N-CA 124.202 0.905 . . . . 0.0 114.847 176.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 17.4 tttt -137.56 3.05 2.51 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 125.413 1.485 . . . . 0.0 113.212 -176.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 59' ' ' PRO . 3.0 m -50.21 -29.13 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 C-N-CA 125.581 1.552 . . . . 0.0 113.513 175.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.8 mt -58.41 -28.77 65.52 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 126.098 1.759 . . . . 0.0 112.201 177.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.9 -51.64 13.32 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.035 1.734 . . . . 0.0 112.479 175.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.538 HG22 HG13 ' A' ' 68' ' ' VAL . 2.3 mp -68.61 -31.11 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 124.192 0.997 . . . . 0.0 111.367 178.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.83 10.48 72.4 Favored Glycine 0 CA--C 1.538 1.504 0 C-N-CA 126.047 1.784 . . . . 0.0 114.468 -177.555 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.538 HG13 HG22 ' A' ' 66' ' ' ILE . 31.2 m -97.35 123.47 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 C-N-CA 125.705 1.602 . . . . 0.0 110.75 -173.263 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 21.3 mmt85 -107.2 109.32 21.1 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.613 ' HE2' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.47 0.543 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -177.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.521 HD21 ' CG1' ' A' ' 19' ' ' VAL . 0.7 OUTLIER . . . . . 0 CA--C 1.546 0.807 0 CA-C-O 120.831 0.348 . . . . 0.0 110.876 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.428 ' N ' HD13 ' A' ' 13' ' ' LEU . . . -146.81 176.42 9.89 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.469 1.908 . . . . 0.0 112.137 177.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.3 t -59.14 129.2 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 O-C-N 120.965 -1.084 . . . . 0.0 111.786 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.53 -4.93 85.0 Favored Glycine 0 CA--C 1.534 1.243 0 C-N-CA 125.197 1.38 . . . . 0.0 114.1 -178.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -67.32 161.44 25.04 Favored 'General case' 0 CA--C 1.547 0.858 0 CA-C-N 118.454 1.127 . . . . 0.0 112.561 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -96.55 124.14 40.44 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.951 1.701 . . . . 0.0 111.968 -173.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.521 ' CG1' HD21 ' A' ' 13' ' ' LEU . 19.4 m -139.75 139.72 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 C-N-CA 123.34 0.656 . . . . 0.0 110.968 -175.102 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.9 p -137.03 145.1 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 124.002 0.921 . . . . 0.0 110.384 177.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.528 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.9 OUTLIER -74.71 160.51 80.77 Favored Pre-proline 0 CA--C 1.547 0.83 0 O-C-N 121.83 -0.544 . . . . 0.0 110.59 174.997 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.599 ' CD ' HG12 ' A' ' 68' ' ' VAL . 60.8 Cg_endo -67.97 -25.73 38.17 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.04 2.493 . . . . 0.0 112.253 -179.048 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.3 t30 -159.07 48.87 0.33 Allowed 'General case' 0 CA--C 1.554 1.12 0 C-N-CA 124.494 1.117 . . . . 0.0 113.633 178.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -139.41 -64.12 0.5 Allowed 'General case' 0 N--CA 1.482 1.157 0 O-C-N 120.85 -1.156 . . . . 0.0 113.132 -174.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 166.39 172.49 33.76 Favored Glycine 0 CA--C 1.533 1.162 0 C-N-CA 125.015 1.293 . . . . 0.0 113.192 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.29 142.58 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 124.893 1.277 . . . . 0.0 110.804 -178.249 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 6.2 m -131.48 173.0 11.54 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.917 1.687 . . . . 0.0 111.148 176.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.8 tmt_? -133.76 118.96 18.67 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 125.863 1.665 . . . . 0.0 110.325 -178.022 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.634 HG22 ' SD ' ' A' ' 47' ' ' MET . 39.3 t -60.84 131.1 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 O-C-N 121.762 -0.586 . . . . 0.0 111.01 -175.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 83.0 p -112.06 -42.64 3.71 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -178.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.8 162.68 34.83 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.527 1.531 . . . . 0.0 110.817 178.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 71.1 mt -143.69 136.04 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.5 1.12 . . . . 0.0 108.965 -178.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -149.04 163.49 37.37 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 124.352 1.061 . . . . 0.0 111.913 175.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.8 p -106.85 141.91 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 124.593 1.157 . . . . 0.0 109.775 175.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.28 168.04 26.68 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 125.259 1.423 . . . . 0.0 110.854 176.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -101.38 118.71 37.51 Favored 'General case' 0 N--CA 1.467 0.395 0 C-N-CA 125.307 1.443 . . . . 0.0 109.488 175.41 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.0 p -121.08 132.54 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 124.272 1.029 . . . . 0.0 109.774 174.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.05 29.08 2.29 Favored 'General case' 0 CA--C 1.557 1.218 0 N-CA-C 114.775 1.398 . . . . 0.0 114.775 -178.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.29 26.23 48.58 Favored Glycine 0 CA--C 1.542 1.781 0 C-N-CA 124.692 1.139 . . . . 0.0 115.296 -175.111 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 5.9 mt-30 -135.42 113.53 11.27 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 126.401 1.881 . . . . 0.0 111.081 -178.043 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 8.9 tttt -94.01 121.43 35.48 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.968 1.307 . . . . 0.0 111.423 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.613 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -157.1 161.47 39.43 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 122.848 0.459 . . . . 0.0 111.41 178.859 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.4 m -67.77 116.39 8.4 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 121.313 -0.867 . . . . 0.0 110.516 177.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -104.65 113.56 27.22 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 120.869 -1.144 . . . . 0.0 110.041 175.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.9 m -83.22 141.16 15.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 C-N-CA 123.525 0.73 . . . . 0.0 110.184 177.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 24.8 m -122.32 112.7 18.44 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.668 1.187 . . . . 0.0 109.896 -178.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . 0.634 ' SD ' HG22 ' A' ' 29' ' ' VAL . 1.0 OUTLIER -112.15 154.9 24.79 Favored 'General case' 0 C--O 1.233 0.224 0 C-N-CA 124.011 0.924 . . . . 0.0 109.405 -178.9 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 41.7 mtm180 -133.72 154.73 50.74 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 124.495 1.118 . . . . 0.0 109.791 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . 0.593 ' HE ' ' HB3' ' A' ' 54' ' ' ALA . 0.2 OUTLIER -120.94 109.08 14.66 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.85 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -67.57 -19.87 65.32 Favored 'General case' 0 CA--C 1.544 0.714 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 177.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -51.1 -46.81 61.97 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 127.046 2.139 . . . . 0.0 112.75 175.423 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -123.61 -19.19 5.89 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.517 1.527 . . . . 0.0 113.424 -179.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.25 37.61 8.93 Favored Glycine 0 CA--C 1.538 1.488 0 C-N-CA 125.429 1.49 . . . . 0.0 114.372 -177.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.593 ' HB3' ' HE ' ' A' ' 49' ' ' ARG . . . -110.06 166.64 10.79 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.4 1.48 . . . . 0.0 112.085 177.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.4 m -129.7 146.91 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 125.047 1.339 . . . . 0.0 111.52 178.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.0 m -136.94 112.2 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 C-N-CA 126.409 1.883 . . . . 0.0 109.151 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 9.4 ptt? -107.9 124.45 50.14 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 124.424 1.09 . . . . 0.0 110.364 176.037 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.615 HG21 ' HE2' ' A' ' 70' ' ' LYS . 30.1 m -131.97 157.21 78.83 Favored Pre-proline 0 N--CA 1.469 0.488 0 C-N-CA 123.949 0.9 . . . . 0.0 111.119 -178.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.613 ' CB ' HD11 ' A' ' 42' ' ' LEU . 56.1 Cg_endo -77.73 114.94 3.75 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.382 2.721 . . . . 0.0 114.596 176.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -62.54 -35.77 80.51 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 120.37 -1.456 . . . . 0.0 113.909 178.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.99 6.35 79.1 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.245 0.926 . . . . 0.0 114.794 176.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 3.0 tttm -136.0 4.5 3.0 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.685 1.594 . . . . 0.0 112.861 -178.705 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -50.05 -30.0 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 126.12 1.768 . . . . 0.0 113.072 175.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.7 mt -55.05 -29.91 58.46 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.315 1.846 . . . . 0.0 112.585 176.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.78 -50.47 13.45 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.647 1.579 . . . . 0.0 112.529 177.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.509 HG22 HG13 ' A' ' 68' ' ' VAL . 3.6 mp -66.42 -32.98 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 C-N-CA 124.664 1.186 . . . . 0.0 111.237 177.574 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.4 4.61 76.8 Favored Glycine 0 CA--C 1.534 1.278 0 C-N-CA 125.647 1.594 . . . . 0.0 114.137 -176.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.599 HG12 ' CD ' ' A' ' 22' ' ' PRO . 30.2 m -82.31 137.55 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 124.404 1.082 . . . . 0.0 111.105 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -117.79 109.62 16.8 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.012 0.925 . . . . 0.0 110.535 175.771 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.615 ' HE2' HG21 ' A' ' 58' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.468 0.435 0 C-N-CA 126.51 1.924 . . . . 0.0 109.345 178.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.542 0.656 0 CA-C-O 120.852 0.358 . . . . 0.0 111.109 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -121.45 169.08 10.99 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 125.926 1.69 . . . . 0.0 111.972 175.005 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.4 t -61.37 129.84 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 O-C-N 121.413 -0.805 . . . . 0.0 110.634 176.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.12 -6.54 78.78 Favored Glycine 0 CA--C 1.534 1.23 0 C-N-CA 124.876 1.227 . . . . 0.0 114.651 -177.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -69.61 176.41 3.54 Favored 'General case' 0 CA--C 1.546 0.814 0 CA-C-N 119.079 1.439 . . . . 0.0 110.593 174.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.42 169.91 10.67 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.998 1.38 . . . . 0.0 112.998 -179.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.54 HG13 ' HB2' ' A' ' 27' ' ' CYS . 2.5 p -161.02 149.78 5.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 C-N-CA 125.539 1.536 . . . . 0.0 110.643 175.366 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.8 p -127.42 160.43 36.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 126.991 2.116 . . . . 0.0 107.685 174.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -125.84 154.55 73.46 Favored Pre-proline 0 CA--C 1.539 0.547 0 C-N-CA 125.063 1.345 . . . . 0.0 110.974 176.696 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.83 -9.83 26.5 Favored 'Trans proline' 0 CA--C 1.545 1.06 0 C-N-CA 123.17 2.58 . . . . 0.0 113.761 178.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 26.7 m-20 -133.46 -60.17 0.85 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.352 1.861 . . . . 0.0 112.922 176.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 65.5 mm-40 -52.48 -54.35 33.56 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 125.133 1.373 . . . . 0.0 112.952 -175.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 114.53 -147.36 18.82 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 125.479 1.514 . . . . 0.0 111.68 -174.059 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.2 m -70.17 144.66 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 124.004 0.922 . . . . 0.0 112.984 -177.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.54 ' HB2' HG13 ' A' ' 19' ' ' VAL . 30.9 m -141.81 177.53 8.11 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 126.383 1.873 . . . . 0.0 110.653 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -132.38 129.47 39.43 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 124.759 1.224 . . . . 0.0 111.881 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.6 t -72.56 142.48 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 O-C-N 121.758 -0.588 . . . . 0.0 110.946 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.9 t -116.94 -44.78 2.79 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.419 1.488 . . . . 0.0 112.593 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.95 159.27 37.92 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 124.437 1.095 . . . . 0.0 110.553 177.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -142.59 133.59 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 120.911 -1.118 . . . . 0.0 108.823 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -149.47 169.4 20.97 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.298 0.639 . . . . 0.0 111.953 175.566 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.504 HG12 ' HA ' ' A' ' 43' ' ' THR . 18.6 m -103.57 142.59 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 O-C-N 120.942 -1.099 . . . . 0.0 110.576 175.584 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.9 pttt -154.65 172.58 17.65 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.664 0.786 . . . . 0.0 112.011 176.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -104.64 116.6 32.33 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 125.727 1.611 . . . . 0.0 110.177 175.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.9 p -125.98 137.73 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 C-N-CA 124.262 1.025 . . . . 0.0 109.965 174.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.81 28.86 2.05 Favored 'General case' 0 CA--C 1.556 1.193 0 C-N-CA 125.182 1.393 . . . . 0.0 114.69 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.94 27.94 48.01 Favored Glycine 0 CA--C 1.541 1.701 0 C-N-CA 124.936 1.255 . . . . 0.0 115.144 -174.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.96 115.53 11.28 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 125.577 1.551 . . . . 0.0 111.856 -176.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -98.45 111.02 23.51 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 126.104 1.762 . . . . 0.0 111.356 -176.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.601 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -155.36 172.82 17.56 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.401 0.68 . . . . 0.0 111.655 -179.425 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.504 ' HA ' HG12 ' A' ' 34' ' ' VAL . 6.0 m -73.64 116.29 14.06 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.248 1.019 . . . . 0.0 111.116 175.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -108.94 113.21 25.91 Favored 'General case' 0 N--CA 1.467 0.394 0 O-C-N 121.221 -0.924 . . . . 0.0 109.612 176.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.57 HG21 ' HE3' ' A' ' 70' ' ' LYS . 19.3 m -73.2 146.56 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 123.3 0.64 . . . . 0.0 110.452 176.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 3.7 m -126.58 109.93 12.67 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 122.623 1.201 . . . . 0.0 110.243 176.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . 0.461 ' HG2' HG11 ' A' ' 19' ' ' VAL . 1.6 mpp? -112.91 165.43 12.34 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.274 1.43 . . . . 0.0 110.483 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 26.8 ptt180 -142.75 117.29 9.72 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 124.835 1.254 . . . . 0.0 110.079 179.295 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 8.7 ttp180 -74.46 109.07 7.64 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.333 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -70.23 -14.32 62.56 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 178.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -57.58 -39.91 77.84 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 126.204 1.802 . . . . 0.0 112.791 176.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.63 -20.94 3.51 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 126.346 1.858 . . . . 0.0 114.75 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.12 14.49 51.46 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 125.104 1.335 . . . . 0.0 115.199 -174.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -76.85 163.34 26.86 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-N 118.85 1.325 . . . . 0.0 112.597 175.327 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 33.6 m -108.57 147.66 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.586 1.154 . . . . 0.0 110.344 174.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.2 t -138.53 112.72 8.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 C-N-CA 125.403 1.481 . . . . 0.0 107.699 -178.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.24 132.02 53.03 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 123.689 0.795 . . . . 0.0 111.89 178.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.449 ' O ' HG22 ' A' ' 45' ' ' VAL . 33.4 m -139.9 157.38 69.66 Favored Pre-proline 0 N--CA 1.473 0.681 0 C-N-CA 124.164 0.985 . . . . 0.0 112.088 -178.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.601 ' CB ' HD11 ' A' ' 42' ' ' LEU . 55.5 Cg_endo -77.95 116.28 3.94 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 123.705 2.937 . . . . 0.0 114.576 175.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -64.35 -33.74 76.55 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 120.327 -1.483 . . . . 0.0 114.284 178.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.64 6.7 80.08 Favored Glycine 0 N--CA 1.475 1.275 0 O-C-N 121.264 -0.897 . . . . 0.0 114.64 176.06 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 30.5 tttt -137.57 3.11 2.51 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 125.34 1.456 . . . . 0.0 113.194 -177.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.411 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.2 m -49.55 -29.22 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.631 1.572 . . . . 0.0 113.282 176.122 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 12.4 mt -56.08 -29.55 60.71 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.172 1.789 . . . . 0.0 112.574 176.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.6 -50.88 12.73 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.891 1.676 . . . . 0.0 112.98 175.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.8 mp -65.41 -33.2 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 C-N-CA 124.117 0.967 . . . . 0.0 111.537 178.147 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 87.4 0.2 84.84 Favored Glycine 0 CA--C 1.536 1.364 0 C-N-CA 125.623 1.582 . . . . 0.0 113.97 -175.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.402 HG13 HG12 ' A' ' 63' ' ' VAL . 7.7 p -73.53 123.15 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 124.588 1.155 . . . . 0.0 110.338 174.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -106.07 109.29 21.18 Favored 'General case' 0 N--CA 1.473 0.709 0 O-C-N 121.071 -1.018 . . . . 0.0 108.789 175.174 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.57 ' HE3' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.469 0.478 0 C-N-CA 123.642 0.777 . . . . 0.0 110.177 178.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.469 HD22 ' HB3' ' A' ' 17' ' ' ASP . 9.7 mt . . . . . 0 CA--C 1.537 0.446 0 CA-C-O 121.588 0.708 . . . . 0.0 112.53 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -125.62 166.5 16.61 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.981 1.712 . . . . 0.0 111.122 176.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 75.2 t -67.93 131.87 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 123.628 0.771 . . . . 0.0 110.135 175.147 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.03 -3.45 70.18 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 125.84 1.686 . . . . 0.0 114.737 -178.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.469 ' HB3' HD22 ' A' ' 13' ' ' LEU . 0.5 OUTLIER -76.63 152.15 35.94 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 119.085 1.443 . . . . 0.0 112.719 -179.29 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -86.89 135.0 33.47 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 125.453 1.501 . . . . 0.0 111.68 -177.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.477 HG23 ' HB2' ' A' ' 27' ' ' CYS . 28.3 m -143.54 135.71 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.796 1.239 . . . . 0.0 111.167 -177.579 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.7 p -102.92 165.63 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 O-C-N 121.152 -0.967 . . . . 0.0 111.33 175.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -125.99 158.44 65.94 Favored Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 125.277 1.431 . . . . 0.0 111.886 175.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.429 ' CD ' HG12 ' A' ' 68' ' ' VAL . 58.6 Cg_endo -71.36 -40.78 2.85 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 123.328 2.685 . . . . 0.0 112.615 -178.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -148.75 32.37 0.78 Allowed 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.707 1.203 . . . . 0.0 112.87 -177.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -130.03 -23.11 2.79 Favored 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 125.817 1.647 . . . . 0.0 114.245 -173.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 104.17 168.15 24.94 Favored Glycine 0 CA--C 1.539 1.592 0 C-N-CA 126.406 1.955 . . . . 0.0 114.436 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 42.9 t -66.52 133.47 31.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 O-C-N 121.1 -1.235 . . . . 0.0 110.338 176.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.477 ' HB2' HG23 ' A' ' 19' ' ' VAL . 63.4 m -122.53 -179.85 4.35 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 126.302 1.841 . . . . 0.0 111.226 178.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.0 ttt180 -144.43 120.64 10.84 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 125.066 1.347 . . . . 0.0 110.562 176.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.402 HG21 HD13 ' A' ' 13' ' ' LEU . 39.7 t -57.96 126.76 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 C-N-CA 123.643 0.777 . . . . 0.0 111.089 -177.192 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.3 m -112.99 -36.46 5.1 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 124.748 1.219 . . . . 0.0 113.463 -176.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.88 159.54 41.82 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.96 1.704 . . . . 0.0 110.582 175.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 41.0 mt -143.81 118.19 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 124.851 1.26 . . . . 0.0 108.631 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -144.72 171.71 14.02 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 123.653 0.781 . . . . 0.0 112.003 177.33 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.41 HG12 ' HA ' ' A' ' 43' ' ' THR . 14.5 m -111.8 142.18 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 O-C-N 121.331 -0.855 . . . . 0.0 111.455 175.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.46 170.82 21.06 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 124.314 1.045 . . . . 0.0 112.122 175.407 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -102.52 118.29 36.55 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.935 1.694 . . . . 0.0 109.536 174.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.8 p -129.68 137.65 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.695 0.798 . . . . 0.0 109.691 174.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.41 29.2 1.91 Allowed 'General case' 0 CA--C 1.556 1.184 0 C-N-CA 125.17 1.388 . . . . 0.0 114.696 -176.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.2 22.2 55.16 Favored Glycine 0 CA--C 1.538 1.528 0 C-N-CA 125.131 1.348 . . . . 0.0 115.454 -177.23 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -135.97 113.5 10.85 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 119.149 1.475 . . . . 0.0 111.062 -173.38 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -96.0 114.06 25.74 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 125.541 1.536 . . . . 0.0 111.843 -176.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.597 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -158.21 173.69 16.32 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 123.437 0.695 . . . . 0.0 111.924 179.283 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.41 ' HA ' HG12 ' A' ' 34' ' ' VAL . 5.3 m -73.36 116.28 13.73 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.456 1.103 . . . . 0.0 111.165 174.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -108.75 113.13 25.84 Favored 'General case' 0 C--O 1.235 0.311 0 O-C-N 120.969 -1.082 . . . . 0.0 109.43 175.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.604 HG21 ' HE3' ' A' ' 70' ' ' LYS . 16.2 m -70.49 150.95 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 CA-C-N 116.242 -0.436 . . . . 0.0 109.993 175.28 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 25.4 m -126.47 128.58 47.16 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 125.252 1.421 . . . . 0.0 109.533 175.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.94 166.98 23.73 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 125.674 1.589 . . . . 0.0 110.599 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.23 141.31 27.27 Favored 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 124.347 1.059 . . . . 0.0 111.165 175.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 59.9 mtm180 -78.71 124.62 28.38 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.106 1.362 . . . . 0.0 111.059 178.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -63.18 -40.64 98.1 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.441 1.096 . . . . 0.0 113.237 177.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -87.09 -46.65 9.6 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.977 0.911 . . . . 0.0 112.666 178.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -71.78 -21.61 61.7 Favored 'General case' 0 N--CA 1.475 0.809 0 O-C-N 121.517 -0.739 . . . . 0.0 112.815 -177.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 66.26 12.47 58.23 Favored Glycine 0 CA--C 1.536 1.38 0 C-N-CA 126.062 1.791 . . . . 0.0 114.81 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -109.32 145.59 35.74 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.672 1.589 . . . . 0.0 112.56 -168.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 16.3 m -70.21 150.87 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.871 1.268 . . . . 0.0 111.837 177.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.2 t -145.21 123.67 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 125.602 1.561 . . . . 0.0 108.91 178.127 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 43.8 mtt -141.26 121.74 14.12 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 123.813 0.845 . . . . 0.0 109.845 178.009 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 26.8 m -132.67 157.48 78.21 Favored Pre-proline 0 N--CA 1.475 0.796 0 C-N-CA 124.0 0.92 . . . . 0.0 112.335 177.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.597 ' CB ' HD11 ' A' ' 42' ' ' LEU . 57.6 Cg_endo -77.91 114.33 3.6 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 123.546 2.831 . . . . 0.0 114.915 178.082 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -60.69 -36.51 78.95 Favored 'General case' 0 N--CA 1.476 0.828 0 O-C-N 120.346 -1.471 . . . . 0.0 114.297 178.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.11 5.77 78.61 Favored Glycine 0 N--CA 1.475 1.246 0 C-N-CA 124.338 0.97 . . . . 0.0 114.863 176.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 15.0 tttp -135.88 3.2 2.93 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.286 1.435 . . . . 0.0 113.106 -177.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.441 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.8 m -49.75 -29.87 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 125.635 1.574 . . . . 0.0 113.11 175.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.0 mt -57.56 -28.65 63.75 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 126.164 1.786 . . . . 0.0 112.595 176.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.03 -50.04 15.89 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 125.863 1.665 . . . . 0.0 112.605 176.078 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.437 HG22 HG13 ' A' ' 68' ' ' VAL . 4.0 mp -69.56 -33.68 58.05 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 124.15 0.98 . . . . 0.0 111.465 178.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.97 3.25 73.67 Favored Glycine 0 CA--C 1.537 1.466 0 C-N-CA 125.799 1.666 . . . . 0.0 114.208 -174.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.437 HG13 HG22 ' A' ' 66' ' ' ILE . 31.3 m -71.5 125.96 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 124.774 1.229 . . . . 0.0 110.834 177.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.3 mmm180 -109.72 109.34 20.01 Favored 'General case' 0 N--CA 1.474 0.769 0 O-C-N 121.076 -1.015 . . . . 0.0 108.931 175.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.604 ' HE3' HG21 ' A' ' 45' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.465 0.3 0 C-N-CA 125.901 1.681 . . . . 0.0 109.117 179.803 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.605 HD11 HG21 ' A' ' 29' ' ' VAL . 0.6 OUTLIER . . . . . 0 CA--C 1.544 0.746 0 CA-C-O 120.521 0.201 . . . . 0.0 111.492 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.449 ' N ' HD13 ' A' ' 13' ' ' LEU . . . -140.57 172.74 12.29 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.86 1.664 . . . . 0.0 112.382 175.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 85.2 t -59.72 131.93 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 O-C-N 120.977 -1.077 . . . . 0.0 111.095 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.52 -6.24 83.73 Favored Glycine 0 CA--C 1.535 1.332 0 C-N-CA 125.045 1.307 . . . . 0.0 114.958 -177.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -69.65 176.85 3.28 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-N 118.805 1.303 . . . . 0.0 112.815 175.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 15.8 mmt85 -119.91 134.15 55.34 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.449 1.5 . . . . 0.0 111.884 -174.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.508 ' CG1' HD21 ' A' ' 13' ' ' LEU . 17.2 m -139.35 136.92 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 125.091 1.356 . . . . 0.0 109.506 -173.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.6 p -137.03 139.05 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 C-N-CA 123.989 0.916 . . . . 0.0 110.118 176.503 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -69.61 160.4 79.74 Favored Pre-proline 0 CA--C 1.542 0.646 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 174.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.546 ' CD ' HG22 ' A' ' 68' ' ' VAL . 58.3 Cg_endo -68.8 -27.29 31.52 Favored 'Trans proline' 0 CA--C 1.54 0.802 0 C-N-CA 122.781 2.32 . . . . 0.0 112.326 -177.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 56.9 t30 -157.77 47.66 0.38 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 124.401 1.081 . . . . 0.0 113.553 177.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -137.86 -64.19 0.55 Allowed 'General case' 0 N--CA 1.481 1.099 0 O-C-N 121.155 -0.965 . . . . 0.0 112.994 -174.117 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.55 168.44 30.63 Favored Glycine 0 CA--C 1.534 1.246 0 C-N-CA 125.081 1.324 . . . . 0.0 113.398 178.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.3 p -77.73 146.83 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 124.891 1.277 . . . . 0.0 111.411 175.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.484 ' SG ' HG11 ' A' ' 56' ' ' VAL . 3.7 m -130.36 173.83 10.43 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.568 1.547 . . . . 0.0 111.271 175.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.11 117.78 17.92 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.552 1.541 . . . . 0.0 110.909 -176.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.605 HG21 HD11 ' A' ' 13' ' ' LEU . 25.4 t -65.95 116.09 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.078 1.351 . . . . 0.0 111.124 -177.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.3 m -107.62 -47.85 3.54 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.852 1.261 . . . . 0.0 112.34 -176.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -148.8 169.71 19.87 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.334 1.854 . . . . 0.0 110.403 178.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 48.8 mt -147.28 140.36 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.054 1.342 . . . . 0.0 108.266 175.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.34 173.65 11.3 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.106 0.962 . . . . 0.0 112.313 175.706 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.468 HG12 ' HA ' ' A' ' 43' ' ' THR . 28.9 m -123.26 140.77 45.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 124.711 1.204 . . . . 0.0 110.728 177.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -155.53 167.42 30.44 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 123.935 0.894 . . . . 0.0 112.385 177.209 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -100.56 119.79 39.06 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.349 1.459 . . . . 0.0 108.745 174.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.0 p -127.33 136.8 59.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.851 1.261 . . . . 0.0 109.058 175.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.85 28.95 1.48 Allowed 'General case' 0 CA--C 1.557 1.233 0 N-CA-C 114.882 1.438 . . . . 0.0 114.882 -178.003 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.06 26.51 48.54 Favored Glycine 0 CA--C 1.542 1.72 0 C-N-CA 124.822 1.201 . . . . 0.0 115.363 -176.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -137.57 116.98 12.79 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 126.229 1.811 . . . . 0.0 110.835 -175.459 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -96.3 118.94 33.87 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 125.338 1.455 . . . . 0.0 111.105 179.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.503 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.9 OUTLIER -155.16 172.63 17.84 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 123.432 0.693 . . . . 0.0 111.892 -179.623 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.468 ' HA ' HG12 ' A' ' 34' ' ' VAL . 48.2 m -82.25 116.41 21.77 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.078 1.351 . . . . 0.0 111.943 176.61 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -102.2 113.17 26.22 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.483 1.113 . . . . 0.0 109.529 174.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.0 m -63.04 148.1 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 O-C-N 121.895 -0.503 . . . . 0.0 110.812 174.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 1.5 m -126.61 109.85 12.56 Favored 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 122.09 0.948 . . . . 0.0 110.605 176.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . 0.455 ' HB2' HG13 ' A' ' 56' ' ' VAL . 2.4 mpp? -123.58 160.17 27.64 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 124.055 0.942 . . . . 0.0 110.239 -178.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.469 ' HG3' HG12 ' A' ' 55' ' ' VAL . 1.1 mpt_? -130.91 125.06 32.51 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 123.843 0.857 . . . . 0.0 110.831 174.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 79.4 mtm180 -83.38 109.02 16.96 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 125.355 1.462 . . . . 0.0 108.462 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -65.62 -18.09 65.07 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.865 0.866 . . . . 0.0 112.494 177.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 31.0 tt0 -57.54 -39.22 76.16 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.622 1.969 . . . . 0.0 113.225 177.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -128.62 1.73 5.52 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 125.011 1.324 . . . . 0.0 113.645 177.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.79 11.77 60.98 Favored Glycine 0 CA--C 1.538 1.476 0 C-N-CA 125.427 1.489 . . . . 0.0 114.306 -171.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -81.04 159.01 24.91 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.489 1.516 . . . . 0.0 112.566 -176.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.469 HG12 ' HG3' ' A' ' 48' ' ' ARG . 20.4 m -97.95 162.05 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 123.481 0.712 . . . . 0.0 110.601 175.033 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.484 HG11 ' SG ' ' A' ' 27' ' ' CYS . 3.9 p -151.95 122.05 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 125.347 1.459 . . . . 0.0 109.111 174.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 19.3 ptm -125.93 135.26 51.68 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 125.076 1.35 . . . . 0.0 110.608 175.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.2 m -137.58 154.24 74.88 Favored Pre-proline 0 N--CA 1.468 0.454 0 C-N-CA 123.819 0.847 . . . . 0.0 111.253 175.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.503 ' CB ' HD11 ' A' ' 42' ' ' LEU . 44.2 Cg_endo -75.51 117.24 4.73 Favored 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 123.271 2.648 . . . . 0.0 114.439 178.084 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -59.65 -40.53 87.97 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.61 7.31 79.86 Favored Glycine 0 N--CA 1.474 1.173 0 C-N-CA 124.418 1.009 . . . . 0.0 114.588 178.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.2 tttm -133.7 3.4 3.53 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.203 1.401 . . . . 0.0 113.509 -178.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.5 m -48.75 -28.87 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.933 1.293 . . . . 0.0 113.598 175.007 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.3 mt -57.31 -29.09 63.63 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.989 1.715 . . . . 0.0 112.61 177.276 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.05 -50.61 15.9 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 125.64 1.576 . . . . 0.0 112.673 175.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.463 HG22 HG23 ' A' ' 68' ' ' VAL . 3.9 mp -68.75 -33.55 60.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 124.244 1.018 . . . . 0.0 111.435 178.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.7 2.19 79.23 Favored Glycine 0 CA--C 1.537 1.415 0 C-N-CA 125.844 1.688 . . . . 0.0 114.349 -175.198 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.546 HG22 ' CD ' ' A' ' 22' ' ' PRO . 71.6 t -80.69 123.16 37.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 CA-C-N 118.96 1.38 . . . . 0.0 110.472 178.273 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 3.3 mmt180 -99.58 109.24 21.76 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 174.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.472 0.651 0 C-N-CA 125.527 1.531 . . . . 0.0 109.352 176.521 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.541 0.63 0 CA-C-O 121.074 0.464 . . . . 0.0 111.836 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -140.06 172.91 12.08 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.017 1.327 . . . . 0.0 112.559 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.3 t -60.22 126.37 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.123 0.969 . . . . 0.0 110.475 177.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.23 -8.36 72.48 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.051 1.31 . . . . 0.0 114.856 -177.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -72.2 169.53 15.94 Favored 'General case' 0 CA--C 1.55 0.973 0 CA-C-N 119.215 1.507 . . . . 0.0 111.056 174.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -88.3 159.26 18.16 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.614 1.566 . . . . 0.0 112.018 175.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.44 HG13 ' HB2' ' A' ' 27' ' ' CYS . 1.5 p -150.86 130.14 3.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 C-N-CA 124.739 1.216 . . . . 0.0 110.134 175.216 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.2 p -137.19 142.59 36.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 C-N-CA 125.995 1.718 . . . . 0.0 107.903 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.419 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.4 OUTLIER -88.46 161.97 40.94 Favored Pre-proline 0 CA--C 1.545 0.765 0 C-N-CA 124.685 1.194 . . . . 0.0 110.965 175.784 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.67 -26.66 27.77 Favored 'Trans proline' 0 CA--C 1.536 0.59 0 C-N-CA 123.439 2.759 . . . . 0.0 112.37 -175.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -158.15 62.77 0.45 Allowed 'General case' 0 CA--C 1.551 1.013 0 C-N-CA 125.863 1.665 . . . . 0.0 111.57 176.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -146.43 -61.88 0.31 Allowed 'General case' 0 N--CA 1.481 1.084 0 O-C-N 121.085 -1.009 . . . . 0.0 112.463 179.147 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 158.67 -179.42 34.35 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 124.661 1.124 . . . . 0.0 113.422 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.3 m -81.87 147.8 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.542 1.537 . . . . 0.0 112.037 175.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.44 ' HB2' HG13 ' A' ' 19' ' ' VAL . 97.7 m -138.18 179.62 6.34 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.856 2.062 . . . . 0.0 109.851 179.027 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.01 135.6 39.61 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 125.102 1.361 . . . . 0.0 110.462 175.245 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -66.54 129.99 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 C-N-CA 123.95 0.9 . . . . 0.0 110.401 175.074 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -115.06 -51.69 2.71 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.622 1.169 . . . . 0.0 111.759 -178.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.73 164.54 37.57 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.849 1.66 . . . . 0.0 110.875 175.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 64.2 mt -144.9 134.45 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 O-C-N 120.752 -1.217 . . . . 0.0 108.756 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -143.53 174.09 11.07 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.355 1.062 . . . . 0.0 112.162 176.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.4 p -124.75 137.89 55.94 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 125.168 1.387 . . . . 0.0 110.842 177.378 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 13.2 ptmt -150.74 153.4 35.44 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 124.961 1.304 . . . . 0.0 112.088 178.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -81.05 115.18 20.38 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 123.787 0.835 . . . . 0.0 108.924 174.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.6 p -118.6 133.36 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 124.311 1.044 . . . . 0.0 109.653 174.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.54 29.01 2.74 Favored 'General case' 0 CA--C 1.557 1.227 0 N-CA-C 114.772 1.397 . . . . 0.0 114.772 -178.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.43 20.42 56.74 Favored Glycine 0 CA--C 1.538 1.529 0 C-N-CA 124.854 1.216 . . . . 0.0 115.422 -175.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -142.87 114.11 7.81 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.491 1.516 . . . . 0.0 111.814 -176.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 5.1 ptmt -91.77 133.96 35.16 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.721 1.208 . . . . 0.0 111.656 175.007 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.645 HD11 ' CB ' ' A' ' 59' ' ' PRO . 1.3 pp -160.05 163.58 33.84 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.266 1.026 . . . . 0.0 110.483 176.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.0 m -66.39 116.49 7.46 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 121.279 -0.888 . . . . 0.0 110.986 178.012 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -104.91 113.3 26.82 Favored 'General case' 0 N--CA 1.467 0.407 0 O-C-N 120.748 -1.22 . . . . 0.0 109.409 175.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.2 m -75.73 143.68 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-O 119.035 -0.507 . . . . 0.0 110.19 177.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -125.82 112.86 16.51 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 122.41 1.1 . . . . 0.0 110.918 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -122.73 165.74 16.07 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.897 1.279 . . . . 0.0 109.647 -176.033 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.5 mtt180 -134.98 160.79 37.2 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 124.425 1.09 . . . . 0.0 110.589 175.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -122.28 109.1 14.03 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 125.733 1.613 . . . . 0.0 109.463 174.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -64.86 -17.66 64.48 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 113.331 0.863 . . . . 0.0 113.331 176.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -54.63 -44.37 73.1 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 127.199 2.2 . . . . 0.0 112.451 178.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -126.19 -1.29 7.05 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.47 1.908 . . . . 0.0 112.494 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.62 34.31 88.61 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 125.157 1.361 . . . . 0.0 113.552 -174.066 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.59 165.61 10.95 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 124.252 1.021 . . . . 0.0 112.145 -176.233 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.5 m -110.28 155.78 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.013 1.325 . . . . 0.0 111.265 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 3.7 p -151.05 125.83 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 124.713 1.205 . . . . 0.0 109.405 175.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 22.8 ptt? -130.21 137.81 50.26 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 123.9 0.88 . . . . 0.0 110.803 175.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.461 ' CG2' ' HE2' ' A' ' 70' ' ' LYS . 14.0 m -140.24 157.34 69.01 Favored Pre-proline 0 N--CA 1.474 0.731 0 C-N-CA 123.584 0.754 . . . . 0.0 111.414 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.645 ' CB ' HD11 ' A' ' 42' ' ' LEU . 53.7 Cg_endo -75.59 116.03 4.37 Favored 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 123.726 2.95 . . . . 0.0 114.861 176.482 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -63.97 -33.42 75.69 Favored 'General case' 0 N--CA 1.482 1.132 0 O-C-N 120.394 -1.441 . . . . 0.0 113.573 178.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.92 4.57 78.57 Favored Glycine 0 N--CA 1.476 1.328 0 C-N-CA 124.769 1.176 . . . . 0.0 114.686 175.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.0 tttm -136.74 3.84 2.76 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.437 1.495 . . . . 0.0 112.992 -177.207 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.2 m -50.26 -28.31 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 C-N-CA 125.731 1.613 . . . . 0.0 113.012 175.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.0 mt -56.02 -30.16 61.45 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 125.945 1.698 . . . . 0.0 112.385 176.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.53 -50.34 15.95 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 125.86 1.664 . . . . 0.0 112.828 175.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.486 HG22 HG13 ' A' ' 68' ' ' VAL . 4.0 mp -68.16 -33.38 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 124.054 0.941 . . . . 0.0 111.465 178.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.49 3.56 77.91 Favored Glycine 0 CA--C 1.537 1.445 0 C-N-CA 126.166 1.841 . . . . 0.0 114.605 -177.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.486 HG13 HG22 ' A' ' 66' ' ' ILE . 31.4 m -82.21 125.56 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 C-N-CA 126.451 1.9 . . . . 0.0 111.216 -178.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.69 109.25 17.92 Favored 'General case' 0 N--CA 1.475 0.782 0 O-C-N 121.252 -0.905 . . . . 0.0 110.105 177.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.461 ' HE2' ' CG2' ' A' ' 58' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.47 0.536 0 C-N-CA 123.226 0.61 . . . . 0.0 110.477 178.127 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.541 0.605 0 CA-C-O 120.438 0.161 . . . . 0.0 110.803 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -124.79 169.85 11.61 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.141 1.377 . . . . 0.0 112.316 177.193 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.42 129.11 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 O-C-N 121.414 -0.803 . . . . 0.0 110.567 176.305 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.26 -6.15 75.29 Favored Glycine 0 CA--C 1.534 1.231 0 C-N-CA 125.075 1.322 . . . . 0.0 114.901 -179.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -68.77 176.74 2.86 Favored 'General case' 0 CA--C 1.549 0.917 0 CA-C-N 119.068 1.434 . . . . 0.0 111.883 174.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.9 mmt180 -113.08 139.57 48.59 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.564 1.545 . . . . 0.0 111.35 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.419 HG21 ' CE ' ' A' ' 47' ' ' MET . 15.1 m -139.71 137.09 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 C-N-CA 124.204 1.002 . . . . 0.0 109.477 -178.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.5 p -137.04 137.99 46.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 124.151 0.981 . . . . 0.0 110.085 177.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.465 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 1.3 m-85 -71.67 161.95 75.77 Favored Pre-proline 0 CA--C 1.546 0.826 0 N-CA-C 112.113 0.412 . . . . 0.0 112.113 175.39 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.498 ' CD ' HG12 ' A' ' 68' ' ' VAL . 59.9 Cg_endo -70.11 -28.54 23.46 Favored 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.43 2.753 . . . . 0.0 112.265 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 32.3 m-20 -157.95 64.4 0.46 Allowed 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 127.026 2.13 . . . . 0.0 111.357 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 5.4 mm-40 -151.9 -71.07 0.16 Allowed 'General case' 0 N--CA 1.479 1.021 0 O-C-N 120.794 -1.191 . . . . 0.0 111.776 174.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 173.55 174.09 40.28 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.403 1.478 . . . . 0.0 112.406 -174.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.5 p -84.39 149.3 4.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 124.949 1.299 . . . . 0.0 110.704 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.553 ' SG ' HG11 ' A' ' 56' ' ' VAL . 4.7 m -128.82 174.59 9.34 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.774 1.63 . . . . 0.0 110.52 175.069 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -131.82 118.82 20.4 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 124.004 0.922 . . . . 0.0 110.9 -178.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.2 t -57.82 126.88 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 C-N-CA 124.111 0.964 . . . . 0.0 110.593 -179.399 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.9 t -111.01 -51.88 2.83 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 125.135 1.374 . . . . 0.0 110.984 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.81 169.87 21.72 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 124.861 1.265 . . . . 0.0 111.064 177.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 62.0 mt -145.2 138.68 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 124.722 1.209 . . . . 0.0 108.457 175.042 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -150.26 167.0 28.24 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 124.853 1.261 . . . . 0.0 112.158 175.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 13.8 m -106.77 143.09 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.109 0.964 . . . . 0.0 110.908 176.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -155.25 170.82 20.97 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 124.623 1.169 . . . . 0.0 111.795 175.423 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -106.28 116.22 31.57 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.949 1.699 . . . . 0.0 109.697 175.001 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.8 p -125.62 138.03 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 C-N-CA 124.462 1.105 . . . . 0.0 110.725 174.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.53 29.09 1.95 Allowed 'General case' 0 CA--C 1.556 1.208 0 C-N-CA 124.856 1.262 . . . . 0.0 114.26 -179.019 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.35 27.04 53.36 Favored Glycine 0 CA--C 1.54 1.604 0 C-N-CA 125.2 1.381 . . . . 0.0 115.613 -174.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.8 tp60 -135.14 113.54 11.48 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.761 1.624 . . . . 0.0 110.436 -175.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 18.6 tttt -96.28 114.86 26.58 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 124.899 1.28 . . . . 0.0 111.25 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.5 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -157.59 173.07 17.42 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 123.155 0.582 . . . . 0.0 111.765 179.532 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 17.2 m -79.73 116.58 19.99 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.367 1.067 . . . . 0.0 111.595 175.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -102.38 114.5 28.73 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.03 0.932 . . . . 0.0 109.763 175.028 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.513 HG13 ' CG ' ' A' ' 60' ' ' GLU . 5.7 m -66.87 145.27 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 O-C-N 121.863 -0.523 . . . . 0.0 110.783 174.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -126.65 109.8 12.49 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.532 1.133 . . . . 0.0 111.109 -179.445 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . 0.439 ' HB2' HG13 ' A' ' 56' ' ' VAL . 1.8 mpp? -123.22 160.72 25.99 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 124.229 1.011 . . . . 0.0 110.546 -177.144 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.605 ' HG3' HG12 ' A' ' 55' ' ' VAL . 0.1 OUTLIER -134.64 134.03 40.74 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.875 0.87 . . . . 0.0 110.905 174.859 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 60.9 mtm180 -94.27 108.76 20.62 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 124.824 1.25 . . . . 0.0 108.209 176.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -69.53 -17.78 63.61 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.343 1.057 . . . . 0.0 113.562 175.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -55.49 -42.12 73.98 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 126.032 1.733 . . . . 0.0 112.538 178.338 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -121.97 -20.25 6.39 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 125.474 1.509 . . . . 0.0 113.387 177.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.47 49.15 4.5 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 125.305 1.431 . . . . 0.0 113.122 -177.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -125.37 159.98 30.47 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.097 1.359 . . . . 0.0 112.163 178.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.605 HG12 ' HG3' ' A' ' 48' ' ' ARG . 27.1 m -98.41 158.62 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.431 1.092 . . . . 0.0 111.117 176.288 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.553 HG11 ' SG ' ' A' ' 27' ' ' CYS . 3.4 p -150.17 122.86 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 125.271 1.428 . . . . 0.0 109.324 175.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.0 ptm -126.9 139.44 53.07 Favored 'General case' 0 C--O 1.233 0.211 0 C-N-CA 124.098 0.959 . . . . 0.0 111.018 175.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 27.0 m -142.82 154.73 62.75 Favored Pre-proline 0 N--CA 1.468 0.473 0 C-N-CA 123.986 0.914 . . . . 0.0 111.469 177.385 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.5 ' CB ' HD11 ' A' ' 42' ' ' LEU . 43.6 Cg_endo -74.8 119.92 5.9 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.156 2.571 . . . . 0.0 114.381 177.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.513 ' CG ' HG13 ' A' ' 45' ' ' VAL . 14.1 mt-10 -62.09 -39.93 94.11 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 178.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.27 7.71 78.01 Favored Glycine 0 N--CA 1.475 1.273 0 C-N-CA 124.677 1.132 . . . . 0.0 114.762 178.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 7.9 tttt -135.53 5.56 3.19 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.775 1.63 . . . . 0.0 112.451 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.462 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -49.65 -29.36 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 C-N-CA 125.329 1.452 . . . . 0.0 113.476 174.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 11.4 mt -58.01 -28.68 64.67 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.003 1.721 . . . . 0.0 112.286 177.178 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.42 -51.01 14.07 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.834 1.653 . . . . 0.0 112.218 177.202 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.485 HG22 HG13 ' A' ' 68' ' ' VAL . 4.5 mp -67.53 -29.47 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 124.375 1.07 . . . . 0.0 111.216 176.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 84.61 8.39 83.06 Favored Glycine 0 CA--C 1.536 1.358 0 C-N-CA 125.815 1.674 . . . . 0.0 114.069 -176.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.498 HG12 ' CD ' ' A' ' 22' ' ' PRO . 17.0 m -90.84 123.32 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 125.373 1.469 . . . . 0.0 111.345 -175.302 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.35 109.6 21.51 Favored 'General case' 0 N--CA 1.469 0.507 0 O-C-N 120.881 -1.137 . . . . 0.0 109.434 178.224 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.468 0.427 0 C-N-CA 123.989 0.916 . . . . 0.0 109.06 177.271 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.557 HD11 HG21 ' A' ' 29' ' ' VAL . 0.3 OUTLIER . . . . . 0 CA--C 1.54 0.566 0 CA-C-O 120.567 0.222 . . . . 0.0 111.1 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.0 177.28 8.16 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.711 1.604 . . . . 0.0 112.184 176.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.8 t -59.69 129.3 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.175 0.99 . . . . 0.0 110.777 175.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.66 -4.68 85.76 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 124.835 1.207 . . . . 0.0 115.151 -177.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -70.83 165.75 22.5 Favored 'General case' 0 CA--C 1.549 0.916 0 CA-C-N 119.211 1.506 . . . . 0.0 111.613 174.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -89.56 148.73 23.21 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.902 0.881 . . . . 0.0 111.883 177.232 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.8 m -147.48 138.88 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 125.976 1.71 . . . . 0.0 109.184 176.266 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.0 p -137.11 146.33 28.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 C-N-CA 124.741 1.216 . . . . 0.0 110.483 176.273 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.5 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.8 OUTLIER -84.19 158.77 60.69 Favored Pre-proline 0 CA--C 1.548 0.867 0 C-N-CA 123.409 0.684 . . . . 0.0 111.959 175.168 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.433 ' CD ' HG12 ' A' ' 68' ' ' VAL . 71.6 Cg_endo -68.69 -25.91 33.59 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 123.809 3.006 . . . . 0.0 112.993 -178.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -160.2 62.62 0.34 Allowed 'General case' 0 CA--C 1.554 1.118 0 C-N-CA 124.764 1.226 . . . . 0.0 112.316 177.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.86 -68.53 0.17 Allowed 'General case' 0 N--CA 1.48 1.053 0 O-C-N 120.988 -1.07 . . . . 0.0 112.222 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.42 179.82 43.5 Favored Glycine 0 CA--C 1.534 1.221 0 C-N-CA 125.04 1.305 . . . . 0.0 113.215 -174.36 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.7 m -94.94 149.96 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.466 1.506 . . . . 0.0 111.38 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.4 m -133.85 -177.85 4.75 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 124.622 1.169 . . . . 0.0 111.544 174.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -137.85 124.59 21.08 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.365 1.466 . . . . 0.0 111.749 177.236 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.557 HG21 HD11 ' A' ' 13' ' ' LEU . 61.1 t -63.47 126.74 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.036 0 C-N-CA 124.735 1.214 . . . . 0.0 111.173 -177.307 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 21.6 t -109.37 -53.92 2.6 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.049 1.34 . . . . 0.0 111.869 -177.092 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -151.68 162.02 41.7 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.142 1.377 . . . . 0.0 111.042 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -141.44 136.53 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 124.649 1.18 . . . . 0.0 108.55 -179.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -144.42 172.1 13.42 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 123.942 0.897 . . . . 0.0 111.773 177.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.3 p -120.54 138.29 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 O-C-N 120.691 -1.256 . . . . 0.0 110.758 175.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.89 164.29 36.66 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.175 1.39 . . . . 0.0 111.543 178.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -97.48 118.88 34.96 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 125.204 1.401 . . . . 0.0 109.77 174.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.3 p -123.54 135.47 63.22 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 124.303 1.041 . . . . 0.0 109.783 174.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.09 29.13 2.35 Favored 'General case' 0 CA--C 1.557 1.245 0 N-CA-C 114.625 1.343 . . . . 0.0 114.625 -177.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.01 25.28 52.9 Favored Glycine 0 CA--C 1.54 1.646 0 C-N-CA 124.787 1.184 . . . . 0.0 115.188 -176.184 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -139.44 116.78 11.24 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.35 1.46 . . . . 0.0 111.175 -174.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 3.5 tttt -95.21 124.81 39.45 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 124.83 1.252 . . . . 0.0 111.656 -178.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.613 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -158.17 162.97 37.97 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 123.033 0.533 . . . . 0.0 111.697 179.428 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.3 m -69.37 116.43 9.79 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 124.192 0.997 . . . . 0.0 111.147 177.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -105.2 113.14 26.56 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 124.875 1.27 . . . . 0.0 110.068 175.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.532 HG21 ' CD ' ' A' ' 70' ' ' LYS . 30.1 m -81.42 144.06 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.838 177.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 26.2 m -126.55 117.12 22.17 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.277 1.031 . . . . 0.0 110.735 178.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 1.5 mpp? -119.15 156.17 30.28 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 124.818 1.247 . . . . 0.0 110.116 -176.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -132.09 136.35 47.11 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.184 1.394 . . . . 0.0 110.259 -178.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 13.0 mtm180 -98.36 109.12 21.93 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 177.076 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -70.28 -15.46 62.9 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 123.239 0.616 . . . . 0.0 112.557 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -57.57 -42.18 82.56 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 126.779 2.031 . . . . 0.0 112.961 176.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -128.66 -15.41 4.45 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 124.874 1.27 . . . . 0.0 114.111 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.23 4.99 64.11 Favored Glycine 0 CA--C 1.538 1.5 0 C-N-CA 126.105 1.812 . . . . 0.0 114.952 -177.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -74.07 163.47 27.84 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 118.644 1.222 . . . . 0.0 112.819 177.449 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 15.9 m -126.32 156.12 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 125.592 1.557 . . . . 0.0 110.727 174.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 23.3 m -140.13 150.94 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 125.951 1.701 . . . . 0.0 109.898 176.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 62.9 ttp -145.03 122.08 11.4 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.791 0.836 . . . . 0.0 110.139 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.6 m -130.4 155.14 81.45 Favored Pre-proline 0 N--CA 1.476 0.84 0 C-N-CA 124.034 0.934 . . . . 0.0 112.17 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.613 ' CB ' HD11 ' A' ' 42' ' ' LEU . 52.3 Cg_endo -76.05 115.82 4.24 Favored 'Trans proline' 0 CA--C 1.538 0.698 0 C-N-CA 123.486 2.791 . . . . 0.0 114.438 176.742 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -64.63 -34.02 77.29 Favored 'General case' 0 N--CA 1.479 0.992 0 O-C-N 120.335 -1.478 . . . . 0.0 114.013 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.23 5.06 78.03 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 124.403 1.001 . . . . 0.0 114.876 176.32 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.6 tttm -135.57 3.34 3.03 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.493 1.517 . . . . 0.0 112.922 -177.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.43 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.6 m -49.7 -29.53 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 C-N-CA 125.685 1.594 . . . . 0.0 113.308 175.612 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.6 mt -57.62 -28.9 64.08 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.093 1.757 . . . . 0.0 112.302 177.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.81 -49.92 16.65 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.974 1.709 . . . . 0.0 112.854 175.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.432 HG22 HG13 ' A' ' 68' ' ' VAL . 3.8 mp -67.85 -33.21 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 124.013 0.925 . . . . 0.0 111.37 177.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 91.68 3.68 68.43 Favored Glycine 0 CA--C 1.537 1.434 0 C-N-CA 125.776 1.655 . . . . 0.0 114.239 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.5 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 29.1 m -87.47 123.18 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.045 1.338 . . . . 0.0 110.616 -176.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -104.46 109.28 21.1 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 120.625 -1.297 . . . . 0.0 108.652 176.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.532 ' CD ' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.468 0.475 0 C-N-CA 123.1 0.56 . . . . 0.0 109.532 177.397 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.641 HD13 ' HE2' ' A' ' 70' ' ' LYS . 1.4 tt . . . . . 0 CA--C 1.548 0.891 0 CA-C-O 120.827 0.346 . . . . 0.0 111.671 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -143.77 177.36 8.57 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 125.544 1.538 . . . . 0.0 112.214 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 97.5 t -60.02 130.96 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 O-C-N 121.082 -1.012 . . . . 0.0 110.796 178.049 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.32 -2.57 88.06 Favored Glycine 0 CA--C 1.537 1.455 0 C-N-CA 124.809 1.195 . . . . 0.0 115.02 -179.228 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -71.09 -179.84 2.5 Favored 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.22 1.408 . . . . 0.0 112.539 176.095 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 26.7 mmt180 -112.44 154.08 26.37 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 124.953 1.301 . . . . 0.0 112.966 -178.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.4 p -152.63 126.83 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 125.77 1.628 . . . . 0.0 110.493 -179.073 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.0 p -135.6 120.08 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 C-N-CA 126.79 2.036 . . . . 0.0 110.486 174.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 -58.65 156.61 22.9 Favored Pre-proline 0 CA--C 1.544 0.74 0 O-C-N 121.055 -1.028 . . . . 0.0 112.281 175.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.423 ' CD ' HG22 ' A' ' 68' ' ' VAL . 60.0 Cg_endo -67.16 -24.59 44.25 Favored 'Trans proline' 0 CA--C 1.539 0.77 0 C-N-CA 122.716 2.277 . . . . 0.0 112.52 -176.312 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -157.78 62.48 0.47 Allowed 'General case' 0 CA--C 1.555 1.149 0 C-N-CA 124.809 1.244 . . . . 0.0 112.444 175.528 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.9 mm-40 -150.24 -66.37 0.2 Allowed 'General case' 0 N--CA 1.483 1.189 0 O-C-N 120.841 -1.162 . . . . 0.0 112.451 179.362 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 166.01 175.17 36.19 Favored Glycine 0 CA--C 1.533 1.198 0 C-N-CA 124.929 1.252 . . . . 0.0 113.451 -178.074 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 38.4 t -93.42 145.64 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 125.929 1.692 . . . . 0.0 110.818 -177.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.3 m -130.34 178.41 6.61 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 126.503 1.921 . . . . 0.0 111.116 174.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.3 130.48 44.55 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.128 1.771 . . . . 0.0 110.658 -179.304 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.402 HG21 HD21 ' A' ' 13' ' ' LEU . 35.7 t -68.05 125.47 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 124.61 1.164 . . . . 0.0 110.903 178.355 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.9 p -109.3 -41.16 4.72 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.728 0.811 . . . . 0.0 112.776 178.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -160.5 173.3 15.77 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 126.746 2.018 . . . . 0.0 110.659 175.754 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.432 HD11 HD23 ' A' ' 13' ' ' LEU . 64.2 mt -146.88 139.87 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.311 1.444 . . . . 0.0 108.728 174.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -146.62 172.72 13.17 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.803 1.241 . . . . 0.0 112.116 174.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.43 HG12 ' HA ' ' A' ' 43' ' ' THR . 20.6 m -115.81 142.63 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.344 1.058 . . . . 0.0 110.523 176.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -157.89 171.95 19.35 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.895 0.878 . . . . 0.0 112.18 176.663 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.61 115.17 29.93 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.906 1.682 . . . . 0.0 110.464 174.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 m -121.97 138.72 51.28 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 124.811 1.244 . . . . 0.0 109.092 174.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 46.06 28.99 0.7 Allowed 'General case' 0 CA--C 1.559 1.317 0 N-CA-C 115.391 1.626 . . . . 0.0 115.391 179.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.11 24.22 52.77 Favored Glycine 0 CA--C 1.544 1.895 0 C-N-CA 124.892 1.234 . . . . 0.0 115.88 -175.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 7.4 tp60 -135.39 113.52 11.29 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.593 1.957 . . . . 0.0 110.268 -174.305 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -95.37 113.38 25.04 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 125.121 1.369 . . . . 0.0 111.218 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.557 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -156.19 173.65 16.53 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.375 0.67 . . . . 0.0 112.049 179.537 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.43 ' HA ' HG12 ' A' ' 34' ' ' VAL . 10.0 m -76.88 116.37 17.49 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 124.338 1.055 . . . . 0.0 111.895 175.309 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -106.54 115.33 30.01 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.971 1.308 . . . . 0.0 109.222 175.248 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.694 HG11 ' HE3' ' A' ' 70' ' ' LYS . 13.6 m -63.94 153.5 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 O-C-N 121.877 -0.514 . . . . 0.0 111.609 176.001 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 10.9 m -126.48 109.82 12.61 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 122.137 0.97 . . . . 0.0 111.043 175.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . 0.534 ' HB2' HG13 ' A' ' 56' ' ' VAL . 0.2 OUTLIER -128.89 155.77 44.74 Favored 'General case' 0 C--O 1.236 0.38 0 C-N-CA 124.703 1.201 . . . . 0.0 109.865 -178.704 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -131.08 125.54 33.44 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.893 1.277 . . . . 0.0 110.183 176.349 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.0 ttm-85 -85.08 109.06 17.96 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.524 1.13 . . . . 0.0 109.123 175.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.68 -15.38 63.16 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 176.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -62.23 -35.46 78.97 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.18 1.792 . . . . 0.0 112.779 -177.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 29.8 p30 -128.63 -16.68 4.23 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 126.637 1.975 . . . . 0.0 114.129 175.053 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.65 4.66 63.64 Favored Glycine 0 CA--C 1.538 1.49 0 C-N-CA 126.137 1.827 . . . . 0.0 115.086 -177.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -77.1 168.9 19.29 Favored 'General case' 0 CA--C 1.546 0.798 0 CA-C-N 119.387 1.594 . . . . 0.0 113.149 178.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 m -111.48 157.59 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 125.092 1.357 . . . . 0.0 111.138 175.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.534 HG13 ' HB2' ' A' ' 47' ' ' MET . 4.4 p -147.48 118.86 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 124.517 1.127 . . . . 0.0 110.017 179.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -132.93 97.01 3.91 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 124.822 1.249 . . . . 0.0 110.076 -178.02 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 36.0 m -99.86 157.24 34.25 Favored Pre-proline 0 N--CA 1.472 0.638 0 C-N-CA 123.369 0.668 . . . . 0.0 111.684 176.708 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.557 ' CB ' HD11 ' A' ' 42' ' ' LEU . 45.9 Cg_endo -77.22 118.75 4.77 Favored 'Trans proline' 0 CA--C 1.536 0.608 0 C-N-CA 123.488 2.792 . . . . 0.0 114.558 175.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.406 ' CG ' HG13 ' A' ' 45' ' ' VAL . 14.9 mt-10 -61.6 -38.98 89.59 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 120.479 -1.388 . . . . 0.0 114.22 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.14 5.97 78.57 Favored Glycine 0 N--CA 1.476 1.338 0 C-N-CA 124.723 1.154 . . . . 0.0 115.027 178.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 17.9 tttp -133.21 3.37 3.66 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 125.751 1.62 . . . . 0.0 112.597 -178.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.3 m -48.33 -29.63 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 125.428 1.491 . . . . 0.0 113.726 175.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 17.2 mt -54.71 -30.64 56.51 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.024 1.73 . . . . 0.0 112.492 176.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.07 -48.69 22.66 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.734 1.613 . . . . 0.0 112.872 176.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.445 HG22 HG23 ' A' ' 68' ' ' VAL . 4.0 mp -66.74 -32.52 58.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.431 1.093 . . . . 0.0 111.285 176.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 87.05 3.99 82.22 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 125.545 1.545 . . . . 0.0 114.014 -176.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.445 HG23 HG22 ' A' ' 66' ' ' ILE . 93.2 t -81.51 147.95 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.598 1.159 . . . . 0.0 109.888 175.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.73 124.54 49.89 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 104.745 -2.317 . . . . 0.0 104.745 175.008 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.694 ' HE3' HG11 ' A' ' 45' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.467 0.389 0 C-N-CA 124.497 1.119 . . . . 0.0 108.269 177.301 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.1 mm? . . . . . 0 CA--C 1.533 0.323 0 CA-C-O 121.24 0.543 . . . . 0.0 110.578 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.74 175.5 9.66 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 125.871 1.668 . . . . 0.0 111.254 179.006 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 59.7 t -58.05 129.8 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 123.811 0.844 . . . . 0.0 110.772 176.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.52 -5.25 85.07 Favored Glycine 0 CA--C 1.536 1.359 0 C-N-CA 125.136 1.351 . . . . 0.0 115.2 -175.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -69.72 163.28 26.03 Favored 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 119.836 1.818 . . . . 0.0 112.099 175.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -101.04 130.87 47.11 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.71 1.204 . . . . 0.0 111.06 -175.494 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.6 m -142.34 143.3 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.797 0.839 . . . . 0.0 110.326 -178.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.4 p -137.08 148.22 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 C-N-CA 124.526 1.13 . . . . 0.0 110.685 178.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.436 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 1.0 OUTLIER -79.15 161.13 69.23 Favored Pre-proline 0 CA--C 1.549 0.919 0 O-C-N 121.853 -0.529 . . . . 0.0 111.655 175.091 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -71.57 -22.33 24.57 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 123.312 2.675 . . . . 0.0 112.837 -177.24 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 16.2 t-20 -162.68 68.29 0.23 Allowed 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 126.273 1.829 . . . . 0.0 111.296 175.007 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -156.28 -71.83 0.11 Allowed 'General case' 0 N--CA 1.482 1.141 0 O-C-N 121.15 -0.968 . . . . 0.0 112.319 177.224 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 176.43 172.93 41.6 Favored Glycine 0 CA--C 1.534 1.222 0 C-N-CA 124.548 1.07 . . . . 0.0 113.734 -176.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.1 m -85.86 148.47 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 125.187 1.395 . . . . 0.0 111.231 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.404 ' SG ' HG11 ' A' ' 56' ' ' VAL . 15.6 m -137.18 171.87 13.85 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.996 1.718 . . . . 0.0 110.921 179.535 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -137.71 120.01 15.78 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 124.414 1.086 . . . . 0.0 110.596 -175.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -63.73 124.78 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 123.615 0.766 . . . . 0.0 111.518 -174.106 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 86.1 p -107.43 -40.95 5.21 Favored 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 -177.769 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.43 162.78 35.75 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.489 1.516 . . . . 0.0 110.839 176.127 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 67.8 mt -141.83 134.87 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.781 0 O-C-N 121.029 -1.044 . . . . 0.0 109.076 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -142.72 177.64 8.18 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 124.269 1.028 . . . . 0.0 111.854 178.017 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 p -127.31 137.09 58.8 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 C-N-CA 124.963 1.305 . . . . 0.0 110.425 176.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.43 165.81 32.01 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 124.698 1.199 . . . . 0.0 111.963 178.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -97.89 118.93 35.56 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 125.088 1.355 . . . . 0.0 109.763 174.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.9 p -124.43 134.9 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 C-N-CA 124.251 1.02 . . . . 0.0 109.562 175.112 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.75 29.0 2.05 Favored 'General case' 0 CA--C 1.556 1.2 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 -177.208 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.99 25.66 51.67 Favored Glycine 0 CA--C 1.541 1.708 0 C-N-CA 124.616 1.103 . . . . 0.0 115.174 -176.266 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -137.43 119.73 15.74 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 126.02 1.728 . . . . 0.0 111.053 -178.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 13.7 ttpt -96.12 124.34 40.08 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.636 1.175 . . . . 0.0 111.582 178.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.603 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -157.69 163.53 38.09 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.008 0.523 . . . . 0.0 111.805 178.771 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.8 m -68.64 116.58 9.33 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.997 0.919 . . . . 0.0 110.971 177.365 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -105.51 113.26 26.72 Favored 'General case' 0 N--CA 1.467 0.377 0 O-C-N 121.076 -1.015 . . . . 0.0 109.591 174.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.0 m -78.16 141.9 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 C-N-CA 123.486 0.714 . . . . 0.0 110.502 176.338 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 8.1 m -120.31 120.32 35.7 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.602 1.161 . . . . 0.0 109.281 176.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . 0.446 ' HB2' HG13 ' A' ' 56' ' ' VAL . 2.1 mpp? -123.18 157.49 32.88 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 124.703 1.201 . . . . 0.0 109.736 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 31.2 mtt85 -136.58 132.56 35.3 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 124.39 1.076 . . . . 0.0 109.875 -179.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -93.89 109.16 20.88 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 177.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -70.32 -14.37 62.55 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 175.151 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -60.21 -36.97 78.88 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.459 1.504 . . . . 0.0 113.066 177.652 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -127.99 -23.31 3.36 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.459 1.503 . . . . 0.0 113.356 178.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 96.3 25.98 11.73 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 125.565 1.555 . . . . 0.0 114.42 -177.05 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.62 169.53 10.26 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.957 1.303 . . . . 0.0 112.752 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.7 m -124.4 154.38 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 125.255 1.422 . . . . 0.0 111.65 177.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.446 HG13 ' HB2' ' A' ' 47' ' ' MET . 2.8 p -151.1 123.47 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 C-N-CA 125.581 1.553 . . . . 0.0 109.689 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.9 ttt -125.83 121.21 32.61 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.625 1.17 . . . . 0.0 109.914 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 28.6 m -129.21 156.33 78.48 Favored Pre-proline 0 N--CA 1.478 0.932 0 C-N-CA 124.087 0.955 . . . . 0.0 112.112 -179.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.603 ' CB ' HD11 ' A' ' 42' ' ' LEU . 55.2 Cg_endo -77.84 114.58 3.66 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 123.628 2.885 . . . . 0.0 114.586 176.631 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -63.83 -33.72 76.32 Favored 'General case' 0 N--CA 1.481 1.096 0 O-C-N 120.271 -1.518 . . . . 0.0 113.957 179.422 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.19 4.43 77.53 Favored Glycine 0 N--CA 1.475 1.272 0 C-N-CA 124.459 1.028 . . . . 0.0 115.074 175.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.1 tttm -135.58 3.42 3.03 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 125.489 1.515 . . . . 0.0 112.978 -177.569 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.428 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.6 m -49.98 -30.77 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 125.598 1.559 . . . . 0.0 113.079 175.402 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.1 mt -56.51 -28.9 61.1 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.123 1.769 . . . . 0.0 112.494 177.227 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.95 -48.66 17.48 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.736 1.614 . . . . 0.0 112.66 177.223 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.442 HG22 HG13 ' A' ' 68' ' ' VAL . 2.9 mp -68.59 -30.55 47.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 124.085 0.954 . . . . 0.0 111.357 176.264 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.58 3.23 78.08 Favored Glycine 0 CA--C 1.537 1.416 0 C-N-CA 126.092 1.806 . . . . 0.0 114.309 -176.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.442 HG13 HG22 ' A' ' 66' ' ' ILE . 18.7 m -80.17 123.2 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.8 0 C-N-CA 125.596 1.558 . . . . 0.0 110.858 -178.541 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.66 109.39 20.97 Favored 'General case' 0 N--CA 1.472 0.653 0 O-C-N 120.847 -1.158 . . . . 0.0 108.881 175.103 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.471 0.576 0 O-C-N 121.749 -0.595 . . . . 0.0 109.76 176.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.585 HD11 HG21 ' A' ' 29' ' ' VAL . 0.8 OUTLIER . . . . . 0 CA--C 1.543 0.676 0 CA-C-O 120.644 0.259 . . . . 0.0 111.188 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -133.82 166.34 22.89 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 125.516 1.526 . . . . 0.0 112.297 179.538 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.8 t -56.65 135.76 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.399 1.08 . . . . 0.0 111.035 175.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.15 -13.01 60.72 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 125.635 1.588 . . . . 0.0 115.216 -176.515 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -72.88 170.0 15.66 Favored 'General case' 0 CA--C 1.549 0.921 0 CA-C-N 119.06 1.43 . . . . 0.0 111.376 175.075 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.9 mmt180 -108.56 142.81 38.45 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 126.194 1.797 . . . . 0.0 111.141 -171.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.468 HG21 ' CE ' ' A' ' 47' ' ' MET . 32.9 m -143.92 128.04 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 124.278 1.031 . . . . 0.0 111.769 -171.099 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 8.2 p -95.2 164.45 2.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 125.416 1.487 . . . . 0.0 111.052 176.092 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -137.01 156.6 75.66 Favored Pre-proline 0 CA--C 1.535 0.381 0 C-N-CA 124.571 1.148 . . . . 0.0 112.991 178.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.7 -28.84 30.36 Favored 'Trans proline' 0 CA--C 1.538 0.721 0 C-N-CA 123.038 2.492 . . . . 0.0 112.762 -178.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -151.88 54.28 0.83 Allowed 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 125.337 1.455 . . . . 0.0 111.919 178.435 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -145.01 -60.58 0.36 Allowed 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 124.332 1.053 . . . . 0.0 110.653 175.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 124.2 -169.4 16.28 Favored Glycine 0 CA--C 1.535 1.284 0 C-N-CA 126.413 1.958 . . . . 0.0 112.25 -173.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -72.42 136.51 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.642 1.177 . . . . 0.0 110.932 177.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 25.6 m -128.7 175.13 8.83 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 126.105 1.762 . . . . 0.0 111.777 175.229 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -130.57 119.02 21.89 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 126.242 1.817 . . . . 0.0 110.833 -179.258 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.585 HG21 HD11 ' A' ' 13' ' ' LEU . 47.5 t -64.61 127.87 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 123.691 0.796 . . . . 0.0 111.025 -178.608 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.7 p -112.5 -40.55 4.07 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.219 1.008 . . . . 0.0 112.699 -176.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -155.1 167.11 31.46 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.716 2.006 . . . . 0.0 110.656 175.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 60.7 mt -146.06 137.16 19.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.895 1.278 . . . . 0.0 108.504 176.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -146.02 171.92 14.15 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.01 0.924 . . . . 0.0 112.059 176.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.2 m -113.9 144.57 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.147 -0.971 . . . . 0.0 111.543 175.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 9.7 ptmt -156.25 171.99 19.23 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 124.854 1.262 . . . . 0.0 111.874 177.197 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -108.03 117.73 34.91 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.168 1.787 . . . . 0.0 109.79 174.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.3 p -127.67 138.21 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 124.843 1.257 . . . . 0.0 109.322 174.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.74 29.35 1.52 Allowed 'General case' 0 CA--C 1.557 1.23 0 N-CA-C 114.707 1.373 . . . . 0.0 114.707 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.0 24.39 57.84 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.281 1.42 . . . . 0.0 115.543 -176.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -132.55 113.54 13.19 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 126.106 1.762 . . . . 0.0 110.817 -175.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 67.3 tttt -95.96 114.35 26.05 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.085 1.354 . . . . 0.0 111.321 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.565 HD11 ' CB ' ' A' ' 59' ' ' PRO . 1.0 OUTLIER -157.89 173.61 16.53 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 123.066 0.547 . . . . 0.0 111.791 -179.376 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 20.1 m -79.01 116.43 19.31 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.362 1.065 . . . . 0.0 112.122 175.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -105.04 115.83 30.94 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.512 1.125 . . . . 0.0 109.77 175.094 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.446 HG13 ' CG ' ' A' ' 60' ' ' GLU . 15.8 m -66.24 147.53 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.382 0.673 . . . . 0.0 111.245 176.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 19.7 m -123.27 110.06 14.72 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.723 0.809 . . . . 0.0 109.634 177.123 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . 0.468 ' CE ' HG21 ' A' ' 19' ' ' VAL . 0.0 OUTLIER -126.92 162.44 25.94 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 121.724 0.773 . . . . 0.0 110.929 178.409 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 3.0 ptt180 -144.88 116.81 8.28 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 124.801 1.24 . . . . 0.0 109.987 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 6.4 mtp85 -62.69 115.01 3.93 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 124.818 1.247 . . . . 0.0 110.602 179.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.2 pp20? -60.54 -36.03 77.44 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.658 0.783 . . . . 0.0 112.877 179.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -91.45 -46.73 7.83 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 123.889 0.875 . . . . 0.0 113.033 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -73.1 -19.41 61.16 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 113.543 0.942 . . . . 0.0 113.543 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.44 8.77 56.64 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 126.27 1.89 . . . . 0.0 115.151 -178.53 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.0 138.32 40.71 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.6 1.56 . . . . 0.0 112.246 -173.257 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 26.7 m -80.02 152.26 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 123.319 0.648 . . . . 0.0 110.023 174.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 13.6 p -145.23 138.7 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 124.514 1.125 . . . . 0.0 109.887 177.139 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 11.4 ttp -145.03 115.9 7.79 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 124.579 1.152 . . . . 0.0 110.004 -179.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.6 m -121.66 156.93 58.14 Favored Pre-proline 0 N--CA 1.472 0.673 0 C-N-CA 124.83 1.252 . . . . 0.0 111.27 177.021 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.565 ' CB ' HD11 ' A' ' 42' ' ' LEU . 55.8 Cg_endo -79.8 114.45 3.19 Favored 'Trans proline' 0 CA--C 1.537 0.637 0 C-N-CA 123.488 2.792 . . . . 0.0 114.954 178.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.446 ' CG ' HG13 ' A' ' 45' ' ' VAL . 18.9 mt-10 -58.39 -39.23 79.11 Favored 'General case' 0 N--CA 1.48 1.041 0 O-C-N 120.424 -1.422 . . . . 0.0 114.286 -178.496 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.06 7.32 78.78 Favored Glycine 0 N--CA 1.474 1.19 0 C-N-CA 124.751 1.167 . . . . 0.0 114.753 179.008 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.0 tttt -134.62 1.72 3.12 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.596 1.559 . . . . 0.0 112.888 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 59' ' ' PRO . 7.0 m -48.34 -30.74 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.593 1.557 . . . . 0.0 113.546 175.762 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.6 mt -57.66 -29.86 64.96 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 126.47 1.908 . . . . 0.0 112.735 176.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.99 -49.97 16.18 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.781 1.632 . . . . 0.0 112.635 176.025 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.3 mp -67.93 -32.22 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 123.66 0.784 . . . . 0.0 111.31 177.757 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.52 9.41 66.76 Favored Glycine 0 CA--C 1.534 1.256 0 C-N-CA 125.532 1.539 . . . . 0.0 113.889 -174.446 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 12.2 m -75.8 155.89 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 118.317 1.058 . . . . 0.0 110.804 177.79 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -139.91 109.69 6.36 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.881 1.272 . . . . 0.0 110.221 175.264 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.445 ' HE3' ' O ' ' A' ' 70' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.47 0.567 0 C-N-CA 125.454 1.502 . . . . 0.0 110.65 177.528 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 14.3 tp . . . . . 0 CA--C 1.542 0.65 0 CA-C-O 120.62 0.248 . . . . 0.0 110.887 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -148.19 177.63 9.23 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.508 1.523 . . . . 0.0 111.427 175.02 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.9 t -59.33 133.7 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 O-C-N 121.395 -0.815 . . . . 0.0 111.296 176.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.31 -4.48 85.54 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 124.817 1.198 . . . . 0.0 115.211 -178.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -71.56 178.35 3.56 Favored 'General case' 0 CA--C 1.553 1.066 0 CA-C-N 118.835 1.318 . . . . 0.0 110.906 174.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 19.2 mmt180 -98.49 151.44 20.61 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.499 1.52 . . . . 0.0 111.378 178.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.6 HG23 ' HB3' ' A' ' 70' ' ' LYS . 2.8 p -140.02 125.67 21.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 C-N-CA 124.225 1.01 . . . . 0.0 110.94 176.47 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.7 p -132.14 145.68 34.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 C-N-CA 125.59 1.556 . . . . 0.0 108.532 175.186 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -91.72 161.06 34.98 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 125.005 1.322 . . . . 0.0 111.948 175.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.34 -28.84 26.8 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.848 2.365 . . . . 0.0 111.954 -175.208 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -159.08 54.16 0.41 Allowed 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 124.311 1.044 . . . . 0.0 113.032 176.348 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -142.86 -62.25 0.42 Allowed 'General case' 0 N--CA 1.478 0.974 0 O-C-N 121.14 -0.975 . . . . 0.0 113.567 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.1 -172.52 44.44 Favored Glycine 0 CA--C 1.533 1.168 0 C-N-CA 124.291 0.948 . . . . 0.0 113.514 -176.193 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.6 p -115.68 144.5 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 126.728 2.011 . . . . 0.0 110.567 179.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 77.2 m -132.84 -175.02 3.64 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 126.614 1.966 . . . . 0.0 110.572 175.565 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -129.46 123.94 32.82 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 125.037 1.335 . . . . 0.0 111.198 -177.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.6 t -63.42 128.38 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 O-C-N 121.778 -0.576 . . . . 0.0 111.189 -177.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.4 t -109.92 -53.52 2.66 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.981 1.712 . . . . 0.0 111.515 -176.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.64 165.95 34.8 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 125.204 1.402 . . . . 0.0 111.032 174.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.4 mt -142.05 130.92 22.49 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 124.62 1.168 . . . . 0.0 108.76 178.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -147.73 173.93 12.29 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 123.543 0.737 . . . . 0.0 112.338 175.292 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.486 HG12 ' HA ' ' A' ' 43' ' ' THR . 25.5 m -106.72 142.21 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.984 0 O-C-N 121.022 -1.049 . . . . 0.0 110.852 176.106 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -156.14 171.63 19.82 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.986 0.914 . . . . 0.0 112.336 176.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -104.55 115.77 30.92 Favored 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 125.94 1.696 . . . . 0.0 109.704 175.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.1 p -127.89 138.12 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.792 0.837 . . . . 0.0 109.626 175.122 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.77 28.98 1.43 Allowed 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 114.905 1.446 . . . . 0.0 114.905 -177.22 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.49 23.98 55.02 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.235 1.398 . . . . 0.0 115.441 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -131.97 113.48 13.46 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 126.193 1.797 . . . . 0.0 109.771 -174.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 16.5 tttt -96.43 112.43 24.17 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.48 1.112 . . . . 0.0 111.635 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.609 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -157.43 173.78 16.4 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 123.407 0.683 . . . . 0.0 112.217 179.262 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.486 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.2 m -73.34 116.49 13.95 Favored 'General case' 0 N--CA 1.475 0.82 0 C-N-CA 124.724 1.209 . . . . 0.0 111.101 175.113 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -111.38 113.78 26.48 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 124.671 1.189 . . . . 0.0 110.036 177.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 27.4 m -75.2 145.45 10.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 123.326 0.65 . . . . 0.0 110.537 177.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 21.7 m -126.52 116.05 20.48 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 124.367 1.067 . . . . 0.0 110.948 -179.603 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . 0.428 ' CE ' HG21 ' A' ' 19' ' ' VAL . 2.1 mpp? -126.32 141.94 51.72 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.097 0.959 . . . . 0.0 109.619 -175.236 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.7 mtt85 -127.58 109.65 11.92 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 125.233 1.413 . . . . 0.0 109.2 -172.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -77.32 109.11 10.94 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 56.5 mt-10 -67.05 -23.0 65.84 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.886 0.875 . . . . 0.0 112.56 178.292 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -55.81 -39.56 71.51 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.462 1.905 . . . . 0.0 113.14 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -128.55 2.94 5.56 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.598 1.559 . . . . 0.0 113.377 -179.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.56 17.3 64.35 Favored Glycine 0 CA--C 1.538 1.472 0 C-N-CA 126.1 1.81 . . . . 0.0 114.669 -171.415 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -75.84 165.55 24.85 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 124.903 1.281 . . . . 0.0 112.484 -178.489 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.5 m -131.61 150.83 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 124.918 1.287 . . . . 0.0 111.02 177.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.8 p -146.73 144.18 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 C-N-CA 125.22 1.408 . . . . 0.0 109.49 176.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 8.8 ttm -138.28 127.25 24.01 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.62 1.168 . . . . 0.0 108.997 174.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.8 m -129.44 156.26 78.82 Favored Pre-proline 0 N--CA 1.473 0.718 0 C-N-CA 123.576 0.751 . . . . 0.0 111.615 175.066 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.609 ' CB ' HD11 ' A' ' 42' ' ' LEU . 57.5 Cg_endo -79.45 115.7 3.46 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.511 2.807 . . . . 0.0 114.9 177.191 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -62.31 -35.28 78.55 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 119.988 -1.695 . . . . 0.0 114.689 176.307 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.4 6.34 80.68 Favored Glycine 0 N--CA 1.473 1.131 0 O-C-N 121.547 -0.721 . . . . 0.0 114.639 176.691 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.5 tttt -137.06 0.59 2.38 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.902 1.281 . . . . 0.0 113.687 -177.182 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.468 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.5 m -49.93 -29.02 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 C-N-CA 125.166 1.386 . . . . 0.0 113.795 175.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.2 mt -58.32 -27.44 64.12 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.594 1.557 . . . . 0.0 112.127 177.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.13 -50.96 11.84 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.945 1.698 . . . . 0.0 112.386 175.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.5 mp -69.51 -33.55 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 123.863 0.865 . . . . 0.0 111.824 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 90.35 12.72 61.02 Favored Glycine 0 CA--C 1.538 1.521 0 C-N-CA 126.03 1.776 . . . . 0.0 114.914 -178.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 97.6 t -89.56 135.38 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 C-N-CA 125.375 1.47 . . . . 0.0 110.657 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.37 109.2 11.54 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 123.721 0.808 . . . . 0.0 110.315 175.039 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.6 ' HB3' HG23 ' A' ' 19' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.471 0.596 0 CA-C-O 121.631 0.729 . . . . 0.0 110.192 179.42 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.544 HD22 HG21 ' A' ' 29' ' ' VAL . 11.8 mt . . . . . 0 CA--C 1.543 0.692 0 CA-C-O 121.459 0.647 . . . . 0.0 110.281 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -146.78 157.1 43.59 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 125.196 1.398 . . . . 0.0 110.849 175.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.4 t -57.31 125.72 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.834 0.854 . . . . 0.0 111.056 178.016 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.44 -5.06 84.61 Favored Glycine 0 CA--C 1.533 1.165 0 C-N-CA 124.973 1.273 . . . . 0.0 115.005 -176.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -68.69 152.8 44.86 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 118.97 1.385 . . . . 0.0 109.79 174.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 9.4 mpt_? -85.0 167.74 15.57 Favored 'General case' 0 N--CA 1.471 0.616 0 O-C-N 121.246 -0.909 . . . . 0.0 110.74 176.363 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 70' ' ' LYS . 26.1 m -151.16 158.54 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 127.054 2.141 . . . . 0.0 111.068 175.067 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.4 p -136.55 160.11 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 125.8 1.64 . . . . 0.0 109.515 174.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -114.16 160.43 32.57 Favored Pre-proline 0 CA--C 1.542 0.664 0 C-N-CA 125.354 1.461 . . . . 0.0 111.539 175.016 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.57 ' HD3' HG22 ' A' ' 68' ' ' VAL . 59.0 Cg_endo -67.48 -27.66 39.39 Favored 'Trans proline' 0 CA--C 1.539 0.734 0 C-N-CA 123.002 2.468 . . . . 0.0 112.822 178.357 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -158.77 53.81 0.42 Allowed 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 124.081 0.952 . . . . 0.0 113.278 178.502 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.11 -57.73 0.38 Allowed 'General case' 0 N--CA 1.479 0.997 0 O-C-N 121.107 -0.996 . . . . 0.0 113.58 -176.83 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 156.09 -160.26 29.96 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.526 1.06 . . . . 0.0 112.513 -174.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.4 m -118.98 147.97 22.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 125.844 1.658 . . . . 0.0 111.524 177.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 6.3 m -139.02 178.87 6.85 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.303 1.441 . . . . 0.0 110.886 177.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 49.4 ttt-85 -133.74 131.87 39.9 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.16 1.384 . . . . 0.0 111.673 179.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.544 HG21 HD22 ' A' ' 13' ' ' LEU . 40.0 t -59.09 132.64 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.674 1.189 . . . . 0.0 111.293 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.9 t -112.07 -53.05 2.74 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 126.505 1.922 . . . . 0.0 111.15 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -145.98 159.14 43.67 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.562 1.145 . . . . 0.0 111.023 -178.17 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.4 mt -143.74 127.26 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.514 1.125 . . . . 0.0 109.108 178.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -149.8 157.14 42.91 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.218 1.007 . . . . 0.0 112.351 175.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.54 HG12 ' HA ' ' A' ' 43' ' ' THR . 21.5 m -97.02 141.56 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 O-C-N 121.279 -0.888 . . . . 0.0 110.342 175.474 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -154.51 171.44 19.41 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.878 0.871 . . . . 0.0 111.728 175.171 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -103.61 116.62 32.69 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.543 1.537 . . . . 0.0 109.372 175.373 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 p -124.33 137.86 55.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.025 0 C-N-CA 124.419 1.088 . . . . 0.0 108.941 175.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.22 29.74 1.97 Allowed 'General case' 0 CA--C 1.557 1.233 0 N-CA-C 114.809 1.411 . . . . 0.0 114.809 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.39 23.36 56.79 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 125.046 1.308 . . . . 0.0 115.49 -176.458 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -136.91 113.48 10.17 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 125.365 1.466 . . . . 0.0 111.822 -173.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -94.81 114.41 26.28 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.862 1.665 . . . . 0.0 111.132 -177.207 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.611 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -155.07 171.59 19.51 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.2 0.6 . . . . 0.0 111.669 178.698 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.54 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.7 m -73.8 116.56 14.54 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 124.035 0.934 . . . . 0.0 110.945 175.287 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -107.08 113.13 26.39 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 122.239 1.018 . . . . 0.0 109.68 176.03 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.556 HG23 ' HE1' ' A' ' 47' ' ' MET . 18.0 m -83.11 146.16 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 C-N-CA 123.438 0.695 . . . . 0.0 110.148 176.708 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 3.9 m -124.39 113.46 18.21 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 125.142 1.377 . . . . 0.0 109.865 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . 0.556 ' HE1' HG23 ' A' ' 45' ' ' VAL . 2.8 mtm -107.28 165.21 11.55 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 124.685 1.194 . . . . 0.0 110.221 175.025 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 35.2 ptt180 -140.48 162.03 36.31 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 125.873 1.669 . . . . 0.0 111.219 175.12 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.0 mpt_? -109.25 131.26 55.23 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.745 0.818 . . . . 0.0 110.035 175.015 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 70.2 mt-10 -68.3 -35.64 78.14 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.988 0.915 . . . . 0.0 111.827 176.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -91.96 -46.58 7.75 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 124.523 1.129 . . . . 0.0 112.831 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.05 -24.04 62.26 Favored 'General case' 0 N--CA 1.476 0.864 0 O-C-N 121.559 -0.713 . . . . 0.0 111.937 -178.133 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.81 9.77 47.46 Favored Glycine 0 CA--C 1.536 1.371 0 C-N-CA 125.719 1.628 . . . . 0.0 114.651 -179.176 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -101.1 159.88 14.86 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.289 1.836 . . . . 0.0 111.235 -177.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 31.3 m -111.63 151.57 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 124.881 1.272 . . . . 0.0 110.479 175.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.4 p -135.04 124.91 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.66 1.584 . . . . 0.0 108.42 176.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.41 125.3 54.06 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 124.734 1.214 . . . . 0.0 109.033 176.092 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.763 HG21 ' HE3' ' A' ' 70' ' ' LYS . 15.4 m -137.74 156.24 74.63 Favored Pre-proline 0 N--CA 1.472 0.652 0 C-N-CA 123.108 0.563 . . . . 0.0 111.524 176.164 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.611 ' CB ' HD11 ' A' ' 42' ' ' LEU . 57.2 Cg_endo -77.14 115.66 4.03 Favored 'Trans proline' 0 CA--C 1.536 0.59 0 C-N-CA 123.516 2.811 . . . . 0.0 114.232 177.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -59.08 -45.62 90.35 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 120.557 -1.339 . . . . 0.0 112.497 175.639 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -83.33 6.37 72.65 Favored Glycine 0 N--CA 1.475 1.25 0 O-C-N 120.999 -1.063 . . . . 0.0 115.282 178.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 15.6 tttt -137.5 4.6 2.63 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 125.434 1.493 . . . . 0.0 113.027 -178.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.519 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.8 m -51.88 -29.15 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 125.297 1.439 . . . . 0.0 113.35 176.097 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.1 mt -58.06 -29.14 65.17 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 125.926 1.691 . . . . 0.0 112.426 176.348 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.09 -49.48 23.78 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 125.672 1.589 . . . . 0.0 112.61 175.22 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.441 HG22 HG23 ' A' ' 68' ' ' VAL . 2.5 mp -67.0 -32.68 59.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 C-N-CA 123.476 0.71 . . . . 0.0 111.339 177.764 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.79 20.38 43.89 Favored Glycine 0 CA--C 1.534 1.243 0 C-N-CA 124.834 1.207 . . . . 0.0 113.811 -177.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.57 HG22 ' HD3' ' A' ' 22' ' ' PRO . 40.9 t -102.58 123.75 56.11 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 124.328 1.051 . . . . 0.0 110.096 -178.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -98.67 110.14 22.79 Favored 'General case' 0 N--CA 1.475 0.821 0 O-C-N 121.178 -0.951 . . . . 0.0 110.523 175.041 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.763 ' HE3' HG21 ' A' ' 58' ' ' VAL . 1.7 ptpm? . . . . . 0 N--CA 1.47 0.55 0 C-N-CA 127.423 2.289 . . . . 0.0 109.699 179.138 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.542 0.666 0 CA-C-O 120.71 0.29 . . . . 0.0 110.514 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -147.45 177.34 9.32 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.198 1.399 . . . . 0.0 112.013 177.021 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -58.71 129.84 21.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 123.756 0.822 . . . . 0.0 111.276 175.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 88.5 -4.3 85.19 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 125.191 1.377 . . . . 0.0 115.126 -178.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -72.0 176.37 5.11 Favored 'General case' 0 CA--C 1.551 0.986 0 CA-C-N 118.946 1.373 . . . . 0.0 112.075 175.027 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 2.4 tpt180 -119.49 142.01 48.67 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 125.278 1.431 . . . . 0.0 111.578 -177.186 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 15.6 m -136.76 142.39 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 123.996 0.918 . . . . 0.0 110.541 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 p -136.99 141.0 41.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 124.08 0.952 . . . . 0.0 110.724 177.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.479 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 1.3 m-85 -80.51 158.66 71.03 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 124.271 1.028 . . . . 0.0 112.126 176.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.441 ' CD ' HG12 ' A' ' 68' ' ' VAL . 70.8 Cg_endo -68.55 -23.41 37.07 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 123.699 2.933 . . . . 0.0 112.98 -177.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -159.91 51.73 0.33 Allowed 'General case' 0 CA--C 1.555 1.164 0 C-N-CA 124.752 1.221 . . . . 0.0 112.656 177.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.41 -58.11 0.37 Allowed 'General case' 0 N--CA 1.483 1.184 0 O-C-N 120.743 -1.223 . . . . 0.0 112.982 -176.407 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 155.97 179.25 30.89 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.099 1.333 . . . . 0.0 113.314 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.2 p -85.27 152.28 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.959 1.304 . . . . 0.0 111.268 175.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.52 ' SG ' HG11 ' A' ' 56' ' ' VAL . 4.0 m -132.77 170.18 15.64 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.195 1.798 . . . . 0.0 110.725 174.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -128.68 121.05 27.69 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.369 1.068 . . . . 0.0 111.36 -174.313 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.403 HG22 ' CE ' ' A' ' 47' ' ' MET . 50.0 t -63.61 121.5 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 124.436 1.094 . . . . 0.0 110.617 -178.139 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.8 m -112.42 -41.51 3.86 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.573 1.149 . . . . 0.0 112.1 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.98 165.21 36.81 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.287 1.835 . . . . 0.0 110.612 174.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 41.7 mt -147.65 138.15 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.971 1.308 . . . . 0.0 108.76 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -147.48 170.58 17.1 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.449 1.1 . . . . 0.0 112.785 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.6 m -108.51 139.25 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 124.909 1.284 . . . . 0.0 110.599 175.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 7.5 ptmt -155.92 168.13 28.21 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.291 1.036 . . . . 0.0 112.543 175.311 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.12 116.05 31.24 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 125.648 1.579 . . . . 0.0 109.516 175.006 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.7 p -126.09 137.25 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.15 0.98 . . . . 0.0 109.648 174.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.94 28.98 2.17 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 114.829 1.418 . . . . 0.0 114.829 -179.02 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.45 25.18 48.28 Favored Glycine 0 CA--C 1.54 1.597 0 C-N-CA 124.839 1.209 . . . . 0.0 115.322 -176.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -139.08 113.52 8.95 Favored 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 125.413 1.485 . . . . 0.0 111.462 -174.133 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -95.85 116.7 29.3 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.144 1.377 . . . . 0.0 111.917 -179.29 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.55 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -159.75 175.08 13.57 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 123.813 0.845 . . . . 0.0 112.02 179.224 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 15.3 m -77.35 116.33 17.86 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.314 1.046 . . . . 0.0 111.934 175.001 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -106.01 113.45 27.01 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 124.849 1.26 . . . . 0.0 109.351 175.194 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.2 m -63.73 150.7 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 O-C-N 122.052 -0.405 . . . . 0.0 111.331 175.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -126.55 109.89 12.64 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 122.037 0.922 . . . . 0.0 110.638 174.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . 0.471 ' HB2' HG13 ' A' ' 56' ' ' VAL . 0.7 OUTLIER -128.43 162.57 26.86 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 125.095 1.358 . . . . 0.0 110.181 179.597 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.3 mtt180 -138.67 113.85 9.44 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 125.491 1.516 . . . . 0.0 109.298 177.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 44.5 mtp85 -69.91 109.09 4.29 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 174.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -70.17 -13.86 62.38 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.188 0.995 . . . . 0.0 113.286 176.072 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -59.36 -42.82 92.49 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 125.96 1.704 . . . . 0.0 112.66 177.253 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -128.52 -15.45 4.51 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.843 1.424 . . . . 0.0 114.843 177.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 84.07 59.03 2.12 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 125.578 1.561 . . . . 0.0 113.446 -179.242 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -135.66 128.72 31.59 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.657 1.183 . . . . 0.0 112.532 179.021 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.0 p -67.05 141.87 17.36 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 C-N-CA 124.286 1.034 . . . . 0.0 110.127 175.367 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.52 HG11 ' SG ' ' A' ' 27' ' ' CYS . 5.6 p -137.31 114.41 12.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 C-N-CA 126.244 1.818 . . . . 0.0 108.969 178.344 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.3 ptt? -126.79 125.63 42.04 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 125.794 1.638 . . . . 0.0 109.832 179.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 33.8 m -131.89 152.98 81.23 Favored Pre-proline 0 N--CA 1.468 0.457 0 C-N-CA 123.7 0.8 . . . . 0.0 111.359 178.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.55 ' CB ' HD11 ' A' ' 42' ' ' LEU . 51.5 Cg_endo -77.01 116.5 4.22 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.912 2.408 . . . . 0.0 114.557 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -60.65 -38.22 84.13 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 114.572 1.323 . . . . 0.0 114.572 -179.623 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.91 5.81 79.21 Favored Glycine 0 N--CA 1.476 1.34 0 C-N-CA 124.545 1.069 . . . . 0.0 114.697 178.408 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.9 tttt -133.85 3.03 3.46 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.474 1.51 . . . . 0.0 112.889 -177.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.54 -29.72 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 125.533 1.533 . . . . 0.0 113.745 175.306 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.5 mt -56.3 -29.4 61.17 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 126.093 1.757 . . . . 0.0 112.542 177.164 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.42 -50.4 15.94 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 125.849 1.66 . . . . 0.0 112.873 175.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.429 HG22 HG13 ' A' ' 68' ' ' VAL . 3.9 mp -67.33 -33.31 61.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 124.134 0.973 . . . . 0.0 111.355 178.034 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.53 8.29 68.16 Favored Glycine 0 CA--C 1.535 1.335 0 C-N-CA 125.617 1.58 . . . . 0.0 114.356 -176.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.479 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 24.9 m -93.26 123.27 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 125.407 1.483 . . . . 0.0 110.763 -176.689 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.62 109.31 21.37 Favored 'General case' 0 N--CA 1.471 0.607 0 O-C-N 120.827 -1.17 . . . . 0.0 109.58 178.089 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.47 0.566 0 C-N-CA 123.764 0.826 . . . . 0.0 109.91 176.255 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.641 HD11 HG21 ' A' ' 29' ' ' VAL . 0.7 OUTLIER . . . . . 0 CA--C 1.544 0.725 0 CA-C-O 120.505 0.193 . . . . 0.0 110.981 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -135.25 175.16 9.83 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.572 1.549 . . . . 0.0 112.336 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.6 t -59.61 132.8 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 O-C-N 121.184 -0.948 . . . . 0.0 111.127 177.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.62 -5.52 83.33 Favored Glycine 0 CA--C 1.537 1.427 0 C-N-CA 124.854 1.216 . . . . 0.0 115.005 -179.272 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -68.51 173.32 5.12 Favored 'General case' 0 CA--C 1.553 1.058 0 CA-C-N 118.761 1.281 . . . . 0.0 110.246 175.041 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -84.33 158.31 21.2 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 125.102 1.361 . . . . 0.0 112.007 174.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.745 HG11 ' HG2' ' A' ' 47' ' ' MET . 2.4 p -160.32 124.37 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 124.688 1.195 . . . . 0.0 109.997 175.019 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 2.9 m -131.56 159.74 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.618 0.723 . . . . 0.0 109.35 174.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.494 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.8 OUTLIER -95.27 162.02 26.08 Favored Pre-proline 0 CA--C 1.544 0.72 0 C-N-CA 123.515 0.726 . . . . 0.0 110.796 177.043 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.437 ' CD ' HG12 ' A' ' 68' ' ' VAL . 68.0 Cg_endo -69.35 -24.84 31.1 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 123.191 2.594 . . . . 0.0 112.429 -179.2 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -159.48 55.65 0.39 Allowed 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 124.725 1.21 . . . . 0.0 112.572 178.608 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 9.8 tm0? -142.7 -58.81 0.44 Allowed 'General case' 0 N--CA 1.482 1.165 0 O-C-N 120.832 -1.167 . . . . 0.0 113.024 -178.506 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 158.58 -168.66 34.87 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 124.849 1.214 . . . . 0.0 112.995 -174.266 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.5 m -109.52 146.8 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 125.176 1.39 . . . . 0.0 112.656 -176.547 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.551 ' HB2' HG13 ' A' ' 19' ' ' VAL . 61.3 m -137.25 179.55 6.33 Favored 'General case' 0 CA--C 1.551 1.01 0 C-N-CA 126.168 1.787 . . . . 0.0 110.944 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.89 132.35 43.54 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 126.892 2.077 . . . . 0.0 111.362 175.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.641 HG21 HD11 ' A' ' 13' ' ' LEU . 21.9 t -67.6 129.94 32.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.149 0.98 . . . . 0.0 111.233 179.523 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.76 -48.57 3.12 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.9 1.28 . . . . 0.0 112.781 -175.56 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.99 163.06 36.79 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.372 1.469 . . . . 0.0 110.961 174.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -140.94 133.42 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 124.263 1.025 . . . . 0.0 109.252 178.166 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -148.46 168.04 23.73 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.713 1.205 . . . . 0.0 112.19 176.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.539 HG12 ' HA ' ' A' ' 43' ' ' THR . 18.8 m -106.69 141.3 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 O-C-N 121.257 -0.902 . . . . 0.0 110.373 175.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.1 ptmt -153.45 168.59 25.59 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 123.809 0.843 . . . . 0.0 112.211 176.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -100.67 117.62 35.15 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 125.485 1.514 . . . . 0.0 109.991 175.014 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.0 p -127.26 138.14 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 124.106 0.962 . . . . 0.0 109.656 175.021 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.98 29.06 1.59 Allowed 'General case' 0 CA--C 1.557 1.223 0 N-CA-C 114.776 1.398 . . . . 0.0 114.776 -177.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.08 27.52 49.19 Favored Glycine 0 CA--C 1.542 1.748 0 C-N-CA 124.88 1.229 . . . . 0.0 115.361 -176.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 10.5 tp60 -137.41 114.95 11.16 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.223 1.809 . . . . 0.0 110.656 -175.7 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.02 115.07 26.96 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.69 1.196 . . . . 0.0 111.492 178.621 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.602 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -153.11 172.56 16.71 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 123.448 0.699 . . . . 0.0 111.649 177.388 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.539 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.3 m -74.16 116.35 14.7 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 125.011 1.324 . . . . 0.0 111.105 175.793 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -109.83 113.07 25.52 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 124.451 1.1 . . . . 0.0 110.105 177.071 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.535 HG21 ' HE3' ' A' ' 70' ' ' LYS . 22.0 m -77.45 145.0 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 123.156 0.582 . . . . 0.0 110.903 178.323 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.1 m -126.31 112.36 15.61 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 122.116 0.96 . . . . 0.0 110.689 -179.053 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . 0.745 ' HG2' HG11 ' A' ' 19' ' ' VAL . 2.0 mpp? -122.42 162.7 21.16 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 124.816 1.246 . . . . 0.0 109.638 -176.423 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.438 ' CG ' HG12 ' A' ' 55' ' ' VAL . 1.3 mtt180 -134.84 151.87 51.28 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 125.38 1.472 . . . . 0.0 110.314 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.5 ptt180 -118.58 109.12 15.79 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.379 1.072 . . . . 0.0 109.793 175.028 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -64.96 -17.37 64.34 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.745 1.218 . . . . 0.0 112.408 174.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -55.4 -42.92 74.73 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 126.249 1.82 . . . . 0.0 112.693 175.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -128.68 3.4 5.5 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 125.126 1.37 . . . . 0.0 113.845 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 64.56 33.89 88.45 Favored Glycine 0 CA--C 1.535 1.292 0 C-N-CA 125.659 1.6 . . . . 0.0 113.979 -174.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -103.82 167.43 9.78 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.15 0.98 . . . . 0.0 111.988 -176.493 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.438 HG12 ' CG ' ' A' ' 48' ' ' ARG . 17.3 m -116.85 151.0 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.092 1.357 . . . . 0.0 110.258 178.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.3 p -143.82 126.36 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 C-N-CA 124.821 1.249 . . . . 0.0 109.202 176.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.6 tmm? -127.86 128.17 44.73 Favored 'General case' 0 C--O 1.234 0.267 0 C-N-CA 124.408 1.083 . . . . 0.0 109.839 177.759 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.7 m -132.95 155.45 81.14 Favored Pre-proline 0 N--CA 1.469 0.485 0 C-N-CA 124.396 1.078 . . . . 0.0 111.599 178.448 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.602 ' CB ' HD11 ' A' ' 42' ' ' LEU . 52.6 Cg_endo -76.14 116.14 4.3 Favored 'Trans proline' 0 CA--C 1.537 0.634 0 C-N-CA 123.749 2.966 . . . . 0.0 114.466 176.361 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -63.43 -34.64 78.2 Favored 'General case' 0 N--CA 1.479 1.005 0 O-C-N 120.341 -1.474 . . . . 0.0 114.172 177.484 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.17 5.9 78.47 Favored Glycine 0 N--CA 1.472 1.055 0 C-N-CA 124.175 0.893 . . . . 0.0 114.653 176.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.4 ttmm -136.76 4.11 2.78 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.269 1.428 . . . . 0.0 113.364 -178.588 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.429 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.4 m -49.38 -30.13 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.468 1.507 . . . . 0.0 113.042 175.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.3 mt -56.58 -29.14 61.73 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 126.288 1.835 . . . . 0.0 112.684 176.634 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.31 -50.2 13.34 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 126.05 1.74 . . . . 0.0 112.645 177.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.455 HG22 HG13 ' A' ' 68' ' ' VAL . 3.7 mp -66.8 -32.38 57.74 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 124.211 1.004 . . . . 0.0 111.291 176.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.39 2.71 79.39 Favored Glycine 0 CA--C 1.535 1.303 0 C-N-CA 125.789 1.662 . . . . 0.0 113.866 -174.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.494 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 18.6 m -83.57 123.23 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 118.338 1.069 . . . . 0.0 111.031 -178.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.1 mmt-85 -100.4 127.21 46.78 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 174.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.535 ' HE3' HG21 ' A' ' 45' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.464 0.225 0 C-N-CA 123.331 0.652 . . . . 0.0 110.481 176.794 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.597 HD23 HG21 ' A' ' 29' ' ' VAL . 0.3 OUTLIER . . . . . 0 CA--C 1.54 0.573 0 CA-C-O 120.773 0.32 . . . . 0.0 110.893 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -144.91 169.28 18.36 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.378 1.071 . . . . 0.0 111.772 177.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.3 t -61.21 130.34 25.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 123.586 0.754 . . . . 0.0 110.572 176.23 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.27 -8.81 79.0 Favored Glycine 0 CA--C 1.537 1.414 0 C-N-CA 124.997 1.284 . . . . 0.0 114.886 -176.036 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -72.67 165.16 25.3 Favored 'General case' 0 CA--C 1.551 0.998 0 CA-C-N 119.302 1.551 . . . . 0.0 111.496 175.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -85.82 154.93 21.22 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.669 0.747 . . . . 0.0 112.288 178.234 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 24.2 m -144.09 147.69 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 C-N-CA 125.204 1.402 . . . . 0.0 109.623 174.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.94 155.75 41.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 C-N-CA 126.461 1.905 . . . . 0.0 108.984 176.054 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -126.35 161.99 49.03 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 125.4 1.48 . . . . 0.0 111.433 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -74.02 -17.66 22.05 Favored 'Trans proline' 0 CA--C 1.541 0.841 0 C-N-CA 123.132 2.555 . . . . 0.0 113.023 -177.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -151.97 -40.08 0.11 Allowed 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 125.611 1.564 . . . . 0.0 112.543 176.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -53.91 -26.49 25.42 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.71 1.604 . . . . 0.0 114.777 179.428 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.46 -176.18 32.38 Favored Glycine 0 CA--C 1.535 1.336 0 C-N-CA 125.014 1.292 . . . . 0.0 114.383 179.306 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.0 m -74.74 144.14 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 O-C-N 121.234 -1.157 . . . . 0.0 111.788 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.495 ' SG ' HG11 ' A' ' 56' ' ' VAL . 33.5 m -136.26 -177.11 4.56 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 125.154 1.381 . . . . 0.0 110.809 177.793 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -138.16 115.91 11.45 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.913 1.285 . . . . 0.0 111.563 -173.187 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.597 HG21 HD23 ' A' ' 13' ' ' LEU . 42.4 t -63.45 128.18 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 C-N-CA 123.907 0.883 . . . . 0.0 111.541 -172.411 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 44.0 t -111.02 -49.39 3.03 Favored 'General case' 0 N--CA 1.469 0.505 0 C-N-CA 125.653 1.581 . . . . 0.0 112.039 -174.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -154.73 161.85 41.36 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.919 1.288 . . . . 0.0 111.208 175.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -142.81 127.93 16.21 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 124.713 1.205 . . . . 0.0 108.785 177.373 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -148.92 169.54 20.33 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 123.647 0.779 . . . . 0.0 112.361 175.447 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.466 HG12 ' HA ' ' A' ' 43' ' ' THR . 19.9 m -104.93 142.43 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 O-C-N 121.229 -0.919 . . . . 0.0 110.946 174.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.9 ptmt -155.51 171.0 20.67 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.745 0.818 . . . . 0.0 112.683 175.206 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -103.59 117.47 34.5 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.136 1.374 . . . . 0.0 109.821 176.403 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.7 p -129.69 135.96 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 178.243 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.38 28.73 1.75 Allowed 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 125.582 1.553 . . . . 0.0 114.656 -177.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.14 23.77 50.59 Favored Glycine 0 CA--C 1.538 1.519 0 C-N-CA 125.45 1.5 . . . . 0.0 115.286 -176.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -134.26 113.76 12.32 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 126.16 1.784 . . . . 0.0 111.128 -174.591 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 54.6 tttt -96.33 112.48 24.2 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 124.942 1.297 . . . . 0.0 111.585 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.63 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.8 OUTLIER -156.09 172.41 18.47 Favored 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 123.405 0.682 . . . . 0.0 112.161 179.035 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.466 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.8 m -72.95 119.17 16.82 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.644 1.178 . . . . 0.0 110.591 175.431 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -110.19 116.65 31.88 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 174.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.7 m -81.3 143.57 12.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 123.935 0.894 . . . . 0.0 109.027 175.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.9 m -126.38 117.34 22.77 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.527 1.531 . . . . 0.0 110.054 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -120.71 160.23 23.74 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 125.257 1.423 . . . . 0.0 110.202 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 55.0 mtm180 -140.51 121.29 14.41 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 124.926 1.29 . . . . 0.0 110.338 -179.131 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.68 108.85 17.61 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 124.647 1.179 . . . . 0.0 111.045 176.238 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -69.96 -15.39 63.04 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 124.026 0.93 . . . . 0.0 112.264 175.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -59.67 -37.65 79.33 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 124.949 1.3 . . . . 0.0 113.439 177.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -128.39 -12.83 5.0 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 124.892 1.277 . . . . 0.0 113.677 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.57 50.94 5.42 Favored Glycine 0 CA--C 1.531 1.077 0 C-N-CA 125.56 1.552 . . . . 0.0 113.177 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -124.53 162.6 23.67 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.741 1.216 . . . . 0.0 112.264 178.529 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.1 m -109.13 152.84 11.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 125.07 1.348 . . . . 0.0 110.736 178.07 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.495 HG11 ' SG ' ' A' ' 27' ' ' CYS . 3.9 p -151.57 122.25 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 125.21 1.404 . . . . 0.0 109.252 178.756 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 22.6 ptt? -127.01 139.38 53.06 Favored 'General case' 0 C--O 1.236 0.374 0 C-N-CA 123.644 0.778 . . . . 0.0 110.884 177.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.1 m -141.19 158.2 64.85 Favored Pre-proline 0 N--CA 1.473 0.707 0 C-N-CA 123.858 0.863 . . . . 0.0 112.069 178.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.63 ' CB ' HD11 ' A' ' 42' ' ' LEU . 56.6 Cg_endo -76.67 115.02 3.97 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 123.497 2.798 . . . . 0.0 114.509 176.175 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.5 -34.43 77.76 Favored 'General case' 0 N--CA 1.477 0.912 0 O-C-N 120.315 -1.49 . . . . 0.0 114.173 178.604 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.0 5.98 78.96 Favored Glycine 0 N--CA 1.473 1.158 0 C-N-CA 124.017 0.818 . . . . 0.0 114.509 176.483 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 19.5 tttp -136.24 2.23 2.75 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.293 1.437 . . . . 0.0 113.359 -178.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -48.93 -30.12 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 125.612 1.565 . . . . 0.0 113.116 175.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.9 mt -57.34 -28.82 63.46 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 126.435 1.894 . . . . 0.0 112.556 177.133 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.74 -50.47 15.22 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.986 1.714 . . . . 0.0 112.668 175.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.436 ' H ' HD12 ' A' ' 66' ' ' ILE . 3.6 mp -68.53 -31.1 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 124.145 0.978 . . . . 0.0 111.227 178.309 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.35 8.85 70.62 Favored Glycine 0 CA--C 1.535 1.285 0 C-N-CA 125.82 1.676 . . . . 0.0 114.187 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 15.2 m -87.66 137.43 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.669 1.588 . . . . 0.0 110.356 -177.473 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.9 108.88 13.47 Favored 'General case' 0 N--CA 1.469 0.511 0 O-C-N 120.881 -1.137 . . . . 0.0 110.737 176.04 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.452 ' HE2' HD22 ' A' ' 13' ' ' LEU . 0.1 OUTLIER . . . . . 0 N--CA 1.464 0.274 0 C-N-CA 124.25 1.02 . . . . 0.0 109.3 175.594 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.542 0.646 0 N-CA-C 110.224 -0.287 . . . . 0.0 110.224 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.56 163.7 19.5 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.363 1.465 . . . . 0.0 112.433 177.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 98.1 t -60.35 129.57 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 123.975 0.91 . . . . 0.0 110.225 178.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.11 -11.86 65.59 Favored Glycine 0 CA--C 1.534 1.267 0 C-N-CA 125.012 1.291 . . . . 0.0 114.761 -176.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -74.99 168.52 19.8 Favored 'General case' 0 CA--C 1.544 0.729 0 CA-C-N 119.445 1.622 . . . . 0.0 110.971 175.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.84 163.86 20.91 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 123.964 0.906 . . . . 0.0 111.426 175.133 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 17.9 m -149.84 150.49 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 125.488 1.515 . . . . 0.0 109.691 175.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 6.6 p -137.03 156.3 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 C-N-CA 126.239 1.815 . . . . 0.0 110.035 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -130.43 157.62 76.88 Favored Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 125.471 1.508 . . . . 0.0 111.638 -177.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.11 -40.47 6.3 Favored 'Trans proline' 0 CA--C 1.536 0.582 0 C-N-CA 123.913 3.075 . . . . 0.0 112.313 -177.15 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -148.96 43.82 0.98 Allowed 'General case' 0 CA--C 1.552 1.034 0 C-N-CA 126.057 1.743 . . . . 0.0 112.153 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -128.35 -51.3 1.29 Allowed 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 124.38 1.072 . . . . 0.0 111.945 177.252 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 128.88 -179.02 16.91 Favored Glycine 0 CA--C 1.535 1.305 0 C-N-CA 126.41 1.957 . . . . 0.0 113.035 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.1 m -77.49 143.76 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 O-C-N 121.766 -0.843 . . . . 0.0 111.281 174.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 85.3 m -136.04 -176.96 4.49 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 125.116 1.366 . . . . 0.0 110.786 176.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.5 ttt180 -140.7 124.54 17.18 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 125.01 1.324 . . . . 0.0 110.921 -178.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.8 t -62.06 119.22 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 123.464 0.706 . . . . 0.0 111.827 -175.575 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.9 p -100.58 -46.21 5.27 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.031 0.932 . . . . 0.0 111.902 -178.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.76 172.06 17.92 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 126.366 1.866 . . . . 0.0 111.133 176.166 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 79.8 mt -146.02 137.15 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 C-N-CA 124.759 1.224 . . . . 0.0 108.358 174.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -141.97 168.97 18.49 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 124.146 0.978 . . . . 0.0 111.781 176.227 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.463 HG12 ' HA ' ' A' ' 43' ' ' THR . 15.9 m -116.19 145.25 22.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 O-C-N 120.986 -1.072 . . . . 0.0 110.924 175.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.6 174.74 14.07 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.199 0.999 . . . . 0.0 111.952 174.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -107.75 121.68 45.21 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 125.906 1.682 . . . . 0.0 108.9 175.008 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.6 p -125.2 129.15 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 125.058 1.343 . . . . 0.0 109.159 174.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.97 28.99 2.19 Favored 'General case' 0 CA--C 1.556 1.203 0 N-CA-C 114.735 1.383 . . . . 0.0 114.735 -178.509 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.78 21.08 54.57 Favored Glycine 0 CA--C 1.539 1.571 0 C-N-CA 124.814 1.197 . . . . 0.0 115.301 -176.504 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -126.16 113.5 17.12 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 125.924 1.69 . . . . 0.0 110.275 -176.275 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 11.2 tttt -96.77 117.75 31.73 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 124.734 1.213 . . . . 0.0 111.068 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.566 HD11 ' CB ' ' A' ' 59' ' ' PRO . 1.1 pp -158.56 172.46 18.26 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 122.984 0.514 . . . . 0.0 111.75 178.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.463 ' HA ' HG12 ' A' ' 34' ' ' VAL . 22.6 m -80.04 116.47 20.18 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 124.946 1.298 . . . . 0.0 112.521 176.219 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -102.89 113.24 26.52 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 124.487 1.115 . . . . 0.0 109.104 174.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.1 m -63.79 149.05 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 O-C-N 121.843 -0.536 . . . . 0.0 111.223 175.133 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 24.6 m -126.49 109.95 12.74 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.447 1.099 . . . . 0.0 110.942 178.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -128.8 165.43 20.97 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 121.512 -0.742 . . . . 0.0 111.002 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -140.0 120.07 13.68 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.417 1.087 . . . . 0.0 111.403 178.016 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 15.0 ptm180 -74.08 110.06 8.07 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 125.089 1.356 . . . . 0.0 110.865 175.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -64.51 -17.25 63.72 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 177.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -59.43 -37.71 78.78 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.453 1.501 . . . . 0.0 113.895 177.821 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.63 -0.39 5.5 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 124.834 1.253 . . . . 0.0 112.908 178.079 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.65 20.9 68.57 Favored Glycine 0 CA--C 1.537 1.419 0 C-N-CA 125.254 1.407 . . . . 0.0 113.851 -170.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -87.87 163.55 16.34 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 118.516 1.158 . . . . 0.0 111.541 -176.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 27.5 m -108.8 143.74 18.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.064 1.346 . . . . 0.0 110.874 -179.67 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.7 m -135.33 130.44 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 124.813 1.245 . . . . 0.0 109.483 178.068 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 38.8 mtm -141.84 123.82 15.37 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.336 1.054 . . . . 0.0 110.261 -178.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.5 m -135.05 157.21 77.45 Favored Pre-proline 0 N--CA 1.474 0.744 0 C-N-CA 123.952 0.901 . . . . 0.0 112.116 179.173 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.566 ' CB ' HD11 ' A' ' 42' ' ' LEU . 42.9 Cg_endo -76.79 117.49 4.52 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 123.374 2.716 . . . . 0.0 114.949 179.721 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -60.54 -38.92 86.04 Favored 'General case' 0 N--CA 1.478 0.928 0 O-C-N 120.463 -1.398 . . . . 0.0 114.253 179.617 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.18 5.71 78.37 Favored Glycine 0 N--CA 1.475 1.244 0 C-N-CA 124.549 1.071 . . . . 0.0 114.9 179.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 5.2 tttm -133.92 2.8 3.42 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.658 1.583 . . . . 0.0 112.639 -178.415 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.406 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -48.64 -30.19 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 C-N-CA 125.405 1.482 . . . . 0.0 113.233 175.028 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.5 mt -57.04 -28.74 62.8 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 125.938 1.695 . . . . 0.0 112.641 177.558 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.61 -50.91 14.11 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.593 1.557 . . . . 0.0 112.713 175.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.556 HG22 HG13 ' A' ' 68' ' ' VAL . 4.0 mp -69.04 -33.6 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 124.001 0.92 . . . . 0.0 111.264 179.201 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.66 4.36 76.23 Favored Glycine 0 CA--C 1.536 1.406 0 C-N-CA 125.881 1.705 . . . . 0.0 114.352 -177.033 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.556 HG13 HG22 ' A' ' 66' ' ' ILE . 27.3 m -83.57 133.29 29.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.952 1.701 . . . . 0.0 109.837 179.812 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.9 mtp180 -122.55 109.17 13.99 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 119.957 1.253 . . . . 0.0 110.194 175.385 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.467 0.402 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.114 178.181 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.435 ' HG ' ' HE2' ' A' ' 70' ' ' LYS . 0.5 OUTLIER . . . . . 0 CA--C 1.544 0.732 0 CA-C-O 120.567 0.222 . . . . 0.0 111.394 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -143.2 179.01 7.32 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.937 1.695 . . . . 0.0 112.199 176.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.4 t -59.51 129.34 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 O-C-N 121.054 -1.029 . . . . 0.0 110.821 175.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.28 -2.63 86.73 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 125.109 1.338 . . . . 0.0 115.372 -178.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -70.98 170.17 13.34 Favored 'General case' 0 CA--C 1.55 0.972 0 CA-C-N 119.319 1.56 . . . . 0.0 112.284 174.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.71 142.86 28.99 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.796 1.238 . . . . 0.0 111.602 178.263 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.9 m -139.02 146.48 25.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 124.061 0.944 . . . . 0.0 110.286 175.078 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 13.7 p -137.09 149.5 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 C-N-CA 124.554 1.142 . . . . 0.0 110.584 174.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.1 m-85 -86.33 162.67 45.1 Favored Pre-proline 0 CA--C 1.545 0.764 0 C-N-CA 124.034 0.934 . . . . 0.0 111.704 175.027 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.475 ' CD ' HG22 ' A' ' 68' ' ' VAL . 62.1 Cg_endo -71.15 -24.97 22.88 Favored 'Trans proline' 0 CA--C 1.539 0.772 0 C-N-CA 122.883 2.389 . . . . 0.0 112.434 -176.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -165.91 55.02 0.1 Allowed 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 126.755 2.022 . . . . 0.0 111.844 -176.435 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 7.3 tp-100 -148.06 -63.52 0.26 Allowed 'General case' 0 N--CA 1.478 0.942 0 O-C-N 120.964 -1.085 . . . . 0.0 112.935 179.076 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.06 178.3 41.49 Favored Glycine 0 CA--C 1.534 1.245 0 C-N-CA 124.574 1.083 . . . . 0.0 113.754 -179.165 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.5 m -88.28 153.12 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 125.167 1.387 . . . . 0.0 110.783 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.2 m -140.02 172.45 12.74 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 125.256 1.423 . . . . 0.0 110.635 176.2 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 47.8 ttt-85 -133.81 123.95 25.69 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.108 0.963 . . . . 0.0 112.746 -179.283 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.3 t -69.39 122.76 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 125.751 1.62 . . . . 0.0 111.086 -179.28 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.6 t -108.87 -34.63 6.6 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 124.55 1.14 . . . . 0.0 112.485 178.352 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.14 167.28 29.54 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 126.224 1.81 . . . . 0.0 110.483 175.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 50.1 mt -144.89 140.61 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 125.19 1.396 . . . . 0.0 108.993 175.407 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -148.04 169.01 20.86 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.732 0.813 . . . . 0.0 112.568 175.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 10.9 m -104.69 143.21 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 124.819 1.248 . . . . 0.0 111.796 175.561 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.66 172.77 18.01 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 124.457 1.103 . . . . 0.0 112.311 174.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.64 121.83 45.47 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 126.137 1.775 . . . . 0.0 109.291 175.171 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.7 p -132.77 136.83 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 124.443 1.097 . . . . 0.0 109.259 174.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.91 29.05 1.54 Allowed 'General case' 0 CA--C 1.556 1.206 0 N-CA-C 114.939 1.459 . . . . 0.0 114.939 -177.063 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.9 26.21 50.21 Favored Glycine 0 CA--C 1.541 1.666 0 C-N-CA 124.76 1.172 . . . . 0.0 115.349 -177.2 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -134.44 113.46 11.88 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.054 1.742 . . . . 0.0 109.7 -175.54 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 20.9 tttt -96.85 116.4 29.1 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 124.696 1.199 . . . . 0.0 111.677 -179.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.525 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.9 OUTLIER -159.73 174.55 14.36 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 123.634 0.774 . . . . 0.0 112.203 -179.682 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 17.6 m -79.06 116.39 19.32 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.588 1.555 . . . . 0.0 112.107 176.03 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -104.77 113.28 26.78 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 124.416 1.086 . . . . 0.0 109.88 175.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 25.4 m -63.68 151.92 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 O-C-N 121.707 -0.621 . . . . 0.0 111.5 175.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -126.51 109.82 12.58 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-O 121.723 0.773 . . . . 0.0 110.499 176.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 5.2 mpp? -113.42 157.52 21.82 Favored 'General case' 0 C--O 1.232 0.144 0 C-N-CA 124.804 1.242 . . . . 0.0 111.616 176.78 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 43.1 mtp85 -133.88 105.58 6.84 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 126.191 1.797 . . . . 0.0 109.926 179.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 46.8 mtp85 -74.91 109.05 8.06 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.664 0.786 . . . . 0.0 109.435 175.034 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -69.73 -14.55 62.84 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 176.558 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -57.96 -43.2 86.3 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 126.072 1.749 . . . . 0.0 112.97 175.115 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -128.57 -12.93 4.88 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 125.024 1.33 . . . . 0.0 114.123 -177.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.92 4.88 78.19 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 125.935 1.731 . . . . 0.0 114.802 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -75.04 161.44 29.45 Favored 'General case' 0 CA--C 1.543 0.692 0 CA-C-N 118.532 1.166 . . . . 0.0 113.166 179.469 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.3 m -105.85 139.24 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 125.397 1.479 . . . . 0.0 109.865 174.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.3 t -123.31 114.96 44.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.82 1.248 . . . . 0.0 108.427 177.146 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.1 tmm? -127.97 123.91 35.97 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 124.94 1.296 . . . . 0.0 109.547 178.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.4 m -131.56 155.02 82.0 Favored Pre-proline 0 N--CA 1.469 0.52 0 C-N-CA 124.592 1.157 . . . . 0.0 111.388 176.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.525 ' CB ' HD11 ' A' ' 42' ' ' LEU . 46.4 Cg_endo -76.68 118.52 4.86 Favored 'Trans proline' 0 CA--C 1.536 0.577 0 C-N-CA 123.488 2.792 . . . . 0.0 114.763 177.597 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -59.87 -41.03 90.65 Favored 'General case' 0 N--CA 1.475 0.775 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.89 6.31 79.35 Favored Glycine 0 N--CA 1.475 1.299 0 C-N-CA 124.344 0.974 . . . . 0.0 114.69 178.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.9 tttp -132.98 3.63 3.74 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.667 1.587 . . . . 0.0 112.773 -178.533 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.61 -30.07 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 C-N-CA 125.128 1.371 . . . . 0.0 113.453 175.149 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.8 mt -55.93 -29.33 59.94 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 126.208 1.803 . . . . 0.0 112.652 177.591 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.83 -49.16 21.59 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 125.702 1.601 . . . . 0.0 112.837 175.76 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.405 HG22 HG23 ' A' ' 68' ' ' VAL . 4.0 mp -69.12 -33.61 59.35 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 124.202 1.001 . . . . 0.0 111.387 178.327 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.38 3.06 78.93 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 125.717 1.627 . . . . 0.0 114.365 -175.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.475 HG22 ' CD ' ' A' ' 22' ' ' PRO . 71.6 t -75.79 148.58 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 CA-C-N 118.47 1.135 . . . . 0.0 110.281 175.002 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.38 109.3 10.97 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-O 122.033 0.921 . . . . 0.0 108.679 175.018 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.435 ' HE2' ' HG ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER . . . . . 0 N--CA 1.466 0.37 0 C-N-CA 125.5 1.52 . . . . 0.0 108.896 179.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.184 0 CA-C-O 120.67 0.271 . . . . 0.0 111.344 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 75.15 154.89 4.55 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 125.384 1.469 . . . . 0.0 112.996 -173.218 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 19.1 m80 -78.97 144.18 35.02 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 121.771 -0.841 . . . . 0.0 110.466 174.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 5.8 mtm -74.12 163.05 71.1 Favored Pre-proline 0 CA--C 1.544 0.744 0 C-N-CA 123.355 0.662 . . . . 0.0 112.542 175.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -70.61 79.49 1.2 Allowed 'Trans proline' 0 CA--C 1.543 0.94 0 C-N-CA 124.722 3.615 . . . . 0.0 112.287 175.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -71.56 174.81 6.19 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 124.097 0.959 . . . . 0.0 112.058 174.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -130.92 124.1 4.06 Favored Glycine 0 C--N 1.342 0.895 0 C-N-CA 124.378 0.989 . . . . 0.0 114.841 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -152.76 18.76 0.6 Allowed 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 125.355 1.462 . . . . 0.0 113.779 -178.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -122.85 -170.04 2.03 Favored 'General case' 0 CA--C 1.549 0.923 0 C-N-CA 126.227 1.811 . . . . 0.0 112.267 -176.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -61.84 177.03 0.47 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 126.318 1.847 . . . . 0.0 112.856 175.042 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 10.5 mp -66.49 -73.63 0.13 Allowed 'General case' 0 N--CA 1.473 0.687 0 O-C-N 121.166 -0.959 . . . . 0.0 111.764 178.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 -55.24 140.53 38.66 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 123.937 0.895 . . . . 0.0 112.133 177.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.607 HD21 HG21 ' A' ' 29' ' ' VAL . 1.2 tt -63.14 148.42 48.0 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 123.699 0.799 . . . . 0.0 111.234 175.533 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -129.73 178.85 6.2 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 125.615 1.566 . . . . 0.0 112.045 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.87 133.0 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 O-C-N 121.003 -1.061 . . . . 0.0 110.574 174.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.03 -0.15 87.48 Favored Glycine 0 CA--C 1.532 1.144 0 C-N-CA 124.711 1.148 . . . . 0.0 114.868 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -66.08 171.41 4.62 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 124.39 1.076 . . . . 0.0 112.397 175.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -107.07 144.2 34.08 Favored 'General case' 0 N--CA 1.463 0.203 0 C-N-CA 125.392 1.477 . . . . 0.0 111.347 -176.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.448 HG21 ' HE2' ' A' ' 47' ' ' MET . 4.9 m -138.84 144.64 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 123.482 0.713 . . . . 0.0 109.76 -176.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.0 p -137.09 140.64 42.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 124.527 1.131 . . . . 0.0 109.4 175.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -92.37 161.55 32.35 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 124.488 1.115 . . . . 0.0 111.169 176.425 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -67.9 -14.01 40.08 Favored 'Trans proline' 0 CA--C 1.546 1.106 0 C-N-CA 122.816 2.344 . . . . 0.0 113.632 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.4 m-80 -148.76 -41.19 0.15 Allowed 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 126.064 1.746 . . . . 0.0 114.36 177.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 3.2 tm0? -52.34 -44.41 65.15 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 126.672 1.989 . . . . 0.0 114.107 -172.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 132.26 -150.28 19.6 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 125.937 1.732 . . . . 0.0 111.738 -178.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.9 m -112.27 146.57 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 C-N-CA 125.505 1.522 . . . . 0.0 110.917 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 78.1 m -137.06 179.71 6.22 Favored 'General case' 0 CA--C 1.551 1.016 0 C-N-CA 125.922 1.689 . . . . 0.0 110.589 175.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -136.1 129.49 31.92 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 125.185 1.394 . . . . 0.0 110.901 -179.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.607 HG21 HD21 ' A' ' 13' ' ' LEU . 26.5 t -68.73 139.21 20.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.362 0.665 . . . . 0.0 110.565 -175.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 46.7 t -117.89 -45.44 2.67 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 124.462 1.105 . . . . 0.0 112.647 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -151.93 160.7 43.43 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 124.483 1.113 . . . . 0.0 111.046 175.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -141.93 135.72 29.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 C-N-CA 124.663 1.185 . . . . 0.0 108.653 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -148.4 169.72 19.57 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.453 0.701 . . . . 0.0 111.646 175.298 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.603 HG12 ' HA ' ' A' ' 43' ' ' THR . 21.9 m -109.58 140.42 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 O-C-N 120.782 -1.199 . . . . 0.0 110.203 176.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -152.6 169.42 22.71 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.589 0.755 . . . . 0.0 111.974 176.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.73 116.22 32.24 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.205 1.402 . . . . 0.0 109.742 174.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.4 p -124.61 139.39 51.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 C-N-CA 124.227 1.011 . . . . 0.0 109.574 175.014 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.52 29.1 1.95 Allowed 'General case' 0 CA--C 1.558 1.253 0 N-CA-C 114.702 1.371 . . . . 0.0 114.702 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.08 25.19 52.97 Favored Glycine 0 CA--C 1.54 1.594 0 C-N-CA 125.044 1.307 . . . . 0.0 115.414 -175.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . 0.404 ' HG2' ' HE3' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -138.59 115.06 10.49 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 125.85 1.66 . . . . 0.0 111.387 -172.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 10.5 tttt -95.01 118.28 31.56 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.639 1.176 . . . . 0.0 111.79 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.606 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -155.51 171.6 19.65 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.344 0.658 . . . . 0.0 111.662 177.797 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.603 ' HA ' HG12 ' A' ' 34' ' ' VAL . 6.8 m -74.55 116.48 15.28 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.179 0.992 . . . . 0.0 111.296 175.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -109.83 113.35 26.03 Favored 'General case' 0 C--O 1.234 0.252 0 C-N-CA 124.627 1.171 . . . . 0.0 110.16 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.662 HG21 ' CE ' ' A' ' 70' ' ' LYS . 24.1 m -80.59 145.75 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.041 179.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 16.5 m -126.31 110.12 13.03 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 122.217 1.008 . . . . 0.0 110.972 179.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . 0.448 ' HE2' HG21 ' A' ' 19' ' ' VAL . 2.2 mpp? -109.64 151.0 27.42 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 125.278 1.431 . . . . 0.0 110.095 -178.51 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 37.5 mtm180 -136.17 110.29 8.32 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.69 1.196 . . . . 0.0 109.677 -176.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -76.44 109.01 9.81 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 177.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -69.73 -13.78 62.46 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.498 1.119 . . . . 0.0 113.818 176.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -60.44 -39.49 87.7 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 125.559 1.543 . . . . 0.0 112.75 178.108 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -128.59 -18.82 3.86 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 125.793 1.637 . . . . 0.0 113.915 178.404 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.2 15.42 48.0 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 125.438 1.494 . . . . 0.0 114.766 -177.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -78.41 163.98 25.17 Favored 'General case' 0 CA--C 1.54 0.574 0 CA-C-N 118.416 1.108 . . . . 0.0 112.376 175.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 25.9 m -128.98 142.0 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.146 1.379 . . . . 0.0 110.665 175.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 21.9 m -131.87 133.71 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 125.114 1.366 . . . . 0.0 108.719 177.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -129.72 127.11 39.79 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 124.257 1.023 . . . . 0.0 109.051 177.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.415 ' O ' HG22 ' A' ' 45' ' ' VAL . 27.5 m -133.73 156.66 79.25 Favored Pre-proline 0 N--CA 1.471 0.596 0 C-N-CA 124.3 1.04 . . . . 0.0 111.635 178.119 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.606 ' CB ' HD11 ' A' ' 42' ' ' LEU . 45.5 Cg_endo -76.1 116.71 4.45 Favored 'Trans proline' 0 CA--C 1.535 0.565 0 C-N-CA 123.567 2.845 . . . . 0.0 114.571 176.391 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -63.65 -34.89 78.84 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 120.537 -1.352 . . . . 0.0 114.024 177.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.1 6.86 78.91 Favored Glycine 0 N--CA 1.473 1.139 0 C-N-CA 124.201 0.905 . . . . 0.0 114.693 176.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.404 ' HE3' ' HG2' ' A' ' 40' ' ' GLN . 0.9 OUTLIER -136.74 3.98 2.77 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.225 1.41 . . . . 0.0 113.698 -178.779 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.486 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.2 m -49.86 -28.54 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 125.556 1.543 . . . . 0.0 113.421 175.442 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 12.0 mt -56.54 -29.77 62.3 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 125.805 1.642 . . . . 0.0 112.3 176.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.51 -49.89 15.35 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.811 1.644 . . . . 0.0 112.493 176.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.6 mp -65.7 -32.9 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 124.488 1.115 . . . . 0.0 111.741 177.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 85.21 4.41 86.48 Favored Glycine 0 CA--C 1.536 1.379 0 C-N-CA 125.397 1.475 . . . . 0.0 114.093 -175.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 13.9 p -80.83 132.9 30.53 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 124.905 1.282 . . . . 0.0 110.988 175.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.6 mmt180 -109.87 109.32 19.92 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 174.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.662 ' CE ' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER -122.32 106.54 11.18 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 123.879 0.872 . . . . 0.0 109.337 177.071 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.401 ' HB ' ' HB3' ' A' ' 74' ' ' ALA . 4.4 t -155.45 165.42 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 124.791 1.236 . . . . 0.0 109.276 -178.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -51.89 -28.07 14.99 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 113.661 0.986 . . . . 0.0 113.661 174.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.6 t -120.97 -41.59 2.54 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.43 1.092 . . . . 0.0 113.285 176.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.401 ' HB3' ' HB ' ' A' ' 71' ' ' VAL . . . -64.66 131.66 47.54 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.011 0.924 . . . . 0.0 113.315 -179.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 . . . . . 0 C--O 1.254 1.325 0 C-N-CA 128.531 2.732 . . . . 0.0 111.581 175.026 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.24 0 CA-C-O 119.395 -0.336 . . . . 0.0 111.373 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.61 113.49 0.57 Allowed Glycine 0 N--CA 1.472 1.063 0 C-N-CA 124.381 0.991 . . . . 0.0 112.669 -179.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.0 m80 -92.77 105.97 18.02 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.056 0.943 . . . . 0.0 110.805 174.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -86.69 162.02 46.06 Favored Pre-proline 0 CA--C 1.543 0.697 0 C-N-CA 124.669 1.188 . . . . 0.0 110.619 174.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.574 ' HG3' HG11 ' A' ' 20' ' ' VAL . 71.7 Cg_endo -68.94 136.05 34.12 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 122.716 2.277 . . . . 0.0 109.811 175.006 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -142.22 169.15 18.12 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 126.688 1.995 . . . . 0.0 110.647 176.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.41 -147.51 8.58 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 125.169 1.366 . . . . 0.0 111.303 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.5 t -131.15 -74.33 0.53 Allowed 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 123.835 0.854 . . . . 0.0 111.845 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -165.97 118.66 1.1 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 126.238 1.815 . . . . 0.0 110.307 177.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.67 158.17 43.85 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.589 1.155 . . . . 0.0 111.229 178.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 50.8 mt -115.66 -71.67 0.73 Allowed 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 124.627 1.171 . . . . 0.0 111.11 -179.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.65 148.4 35.05 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 124.886 1.274 . . . . 0.0 111.671 175.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -82.34 128.97 34.74 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.62 1.168 . . . . 0.0 110.841 175.012 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.22 174.51 10.47 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.503 1.521 . . . . 0.0 111.39 176.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.5 t -60.89 126.2 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 123.718 0.807 . . . . 0.0 110.772 177.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.55 -8.74 74.45 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 125.131 1.348 . . . . 0.0 115.186 -176.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.1 t0 -71.51 167.6 19.33 Favored 'General case' 0 CA--C 1.548 0.9 0 CA-C-N 119.195 1.497 . . . . 0.0 111.4 174.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 12.4 tpp180 -92.98 151.39 19.94 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.036 0.934 . . . . 0.0 111.877 -179.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.669 HG11 ' HG2' ' A' ' 47' ' ' MET . 2.0 p -151.99 130.01 2.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 C-N-CA 124.895 1.278 . . . . 0.0 110.622 178.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.574 HG11 ' HG3' ' A' ' 5' ' ' PRO . 3.6 p -137.09 155.82 33.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 C-N-CA 125.837 1.655 . . . . 0.0 108.484 174.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.466 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.5 OUTLIER -101.46 158.69 31.3 Favored Pre-proline 0 CA--C 1.537 0.467 0 C-N-CA 125.047 1.339 . . . . 0.0 111.373 175.091 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.446 ' CD ' HG12 ' A' ' 68' ' ' VAL . 66.7 Cg_endo -68.21 -21.48 41.89 Favored 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 123.103 2.536 . . . . 0.0 112.458 -176.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -159.8 51.31 0.33 Allowed 'General case' 0 CA--C 1.557 1.221 0 C-N-CA 124.875 1.27 . . . . 0.0 112.896 176.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -140.36 -61.6 0.51 Allowed 'General case' 0 N--CA 1.483 1.216 0 O-C-N 120.835 -1.166 . . . . 0.0 113.116 -177.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 162.42 174.98 32.97 Favored Glycine 0 CA--C 1.534 1.245 0 C-N-CA 124.927 1.251 . . . . 0.0 113.65 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.9 t -91.19 140.42 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 125.461 1.504 . . . . 0.0 110.233 176.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 38.1 m -130.34 -177.85 4.5 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 126.258 1.823 . . . . 0.0 110.198 178.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 -141.96 124.21 15.56 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.074 0.95 . . . . 0.0 110.661 176.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.7 t -58.24 121.32 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 123.849 0.859 . . . . 0.0 110.815 -178.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.5 t -116.28 -35.2 4.4 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.458 1.503 . . . . 0.0 112.179 -175.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -148.14 157.95 43.8 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 125.179 1.392 . . . . 0.0 110.914 175.049 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 65.6 mt -143.15 132.59 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 O-C-N 120.816 -1.177 . . . . 0.0 108.242 175.238 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -138.51 172.25 13.16 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 125.247 1.419 . . . . 0.0 111.422 175.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.474 HG22 ' HA ' ' A' ' 43' ' ' THR . 21.9 t -129.88 136.9 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.619 1.168 . . . . 0.0 109.3 179.682 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.0 ptmt -144.46 161.98 37.69 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.694 1.198 . . . . 0.0 111.817 177.535 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -90.14 116.05 27.85 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 124.458 1.103 . . . . 0.0 109.631 175.111 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 p -112.72 128.14 69.58 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 125.348 1.459 . . . . 0.0 109.346 174.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.94 29.07 3.17 Favored 'General case' 0 CA--C 1.557 1.214 0 N-CA-C 114.815 1.413 . . . . 0.0 114.815 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.86 23.57 55.31 Favored Glycine 0 CA--C 1.541 1.715 0 C-N-CA 124.647 1.117 . . . . 0.0 115.323 -175.287 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -138.25 118.7 13.8 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 126.277 1.831 . . . . 0.0 111.194 178.513 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.461 ' HG2' HG12 ' A' ' 34' ' ' VAL . 1.8 tttt -85.68 135.85 33.6 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 123.904 0.882 . . . . 0.0 111.439 175.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.594 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.5 OUTLIER -154.93 159.16 40.23 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 122.823 0.449 . . . . 0.0 111.832 177.633 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.474 ' HA ' HG22 ' A' ' 34' ' ' VAL . 6.6 m -68.99 116.69 9.74 Favored 'General case' 0 N--CA 1.478 0.956 0 C-N-CA 124.056 0.942 . . . . 0.0 111.835 178.047 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -104.72 113.15 26.55 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 119.667 1.121 . . . . 0.0 110.776 174.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.7 m -84.73 136.86 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 123.796 0.838 . . . . 0.0 110.71 178.01 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 13.6 m -126.49 132.24 51.45 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 122.924 1.345 . . . . 0.0 111.876 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . 0.669 ' HG2' HG11 ' A' ' 19' ' ' VAL . 0.7 OUTLIER -130.13 161.93 29.98 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 125.151 1.381 . . . . 0.0 110.661 -174.217 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 14.3 mtp85 -131.09 103.12 6.33 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.911 1.284 . . . . 0.0 110.425 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.75 109.06 13.81 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.612 0.765 . . . . 0.0 110.766 177.345 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -63.56 -20.41 65.61 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.901 1.28 . . . . 0.0 112.72 178.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -58.63 -38.45 78.09 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 126.207 1.803 . . . . 0.0 113.344 -178.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -128.56 4.18 5.58 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 125.797 1.639 . . . . 0.0 112.702 174.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 62.91 29.86 75.49 Favored Glycine 0 CA--C 1.533 1.196 0 C-N-CA 125.526 1.536 . . . . 0.0 113.711 -174.336 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.62 172.26 7.6 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 118.343 1.072 . . . . 0.0 111.399 -174.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 30.3 m -114.55 144.25 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 C-N-CA 123.566 0.746 . . . . 0.0 111.098 174.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.9 t -124.33 112.11 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 125.253 1.421 . . . . 0.0 107.987 176.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.2 ttt -120.73 118.82 31.06 Favored 'General case' 0 C--O 1.235 0.317 0 C-N-CA 124.516 1.126 . . . . 0.0 109.734 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.433 HG21 ' NZ ' ' A' ' 70' ' ' LYS . 17.1 m -137.03 158.32 72.98 Favored Pre-proline 0 N--CA 1.471 0.607 0 N-CA-C 112.796 0.665 . . . . 0.0 112.796 -178.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.594 ' CB ' HD11 ' A' ' 42' ' ' LEU . 64.7 Cg_endo -78.69 111.87 3.05 Favored 'Trans proline' 0 CA--C 1.538 0.703 0 C-N-CA 123.192 2.595 . . . . 0.0 114.56 176.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -60.95 -35.28 76.32 Favored 'General case' 0 N--CA 1.476 0.861 0 O-C-N 120.398 -1.439 . . . . 0.0 113.567 178.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.12 5.74 78.58 Favored Glycine 0 N--CA 1.474 1.222 0 C-N-CA 124.543 1.068 . . . . 0.0 114.961 176.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -135.51 1.47 2.86 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 125.207 1.403 . . . . 0.0 113.353 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.559 HG13 ' O ' ' A' ' 59' ' ' PRO . 3.0 m -49.86 -28.1 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.917 1.687 . . . . 0.0 114.149 176.524 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.1 mt -56.22 -34.53 66.4 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.064 1.746 . . . . 0.0 112.071 175.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.78 -48.61 45.45 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.779 1.632 . . . . 0.0 112.586 177.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.404 HG22 HG13 ' A' ' 68' ' ' VAL . 3.5 mp -68.28 -27.92 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 123.972 0.909 . . . . 0.0 111.49 176.432 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.78 19.49 63.38 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.433 1.492 . . . . 0.0 113.853 -178.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.466 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 15.6 m -95.27 123.16 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 126.254 1.821 . . . . 0.0 111.059 -175.583 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 11.0 mmt180 -107.7 109.24 20.79 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 121.272 -0.892 . . . . 0.0 109.076 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.509 ' HB3' HG23 ' A' ' 19' ' ' VAL . 0.0 OUTLIER -100.97 106.59 17.92 Favored 'General case' 0 N--CA 1.473 0.689 0 O-C-N 121.525 -0.734 . . . . 0.0 110.558 -179.338 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.548 HG12 ' H ' ' A' ' 72' ' ' ALA . 1.6 t -153.98 176.68 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 123.412 0.685 . . . . 0.0 110.168 -175.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . 0.548 ' H ' HG12 ' A' ' 71' ' ' VAL . . . -61.98 -19.44 62.81 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 125.018 1.327 . . . . 0.0 114.269 175.013 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 3.5 m -138.31 -51.3 0.58 Allowed 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 125.472 1.509 . . . . 0.0 113.311 178.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.439 ' HB3' ' CG2' ' A' ' 71' ' ' VAL . . . -56.11 147.21 20.81 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 124.121 0.969 . . . . 0.0 112.497 176.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 24.8 pt-20 . . . . . 0 C--O 1.255 1.372 0 C-N-CA 128.062 2.545 . . . . 0.0 113.11 -178.081 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.275 0 N-CA-C 110.568 -0.16 . . . . 0.0 110.568 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 157.26 -168.93 34.21 Favored Glycine 0 CA--C 1.535 1.317 0 C-N-CA 125.011 1.291 . . . . 0.0 112.858 -178.442 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 -56.98 133.91 55.28 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 123.943 0.897 . . . . 0.0 111.979 174.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -88.36 163.63 35.8 Favored Pre-proline 0 CA--C 1.544 0.747 0 C-N-CA 125.388 1.475 . . . . 0.0 112.425 175.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.46 ' HG3' HG11 ' A' ' 20' ' ' VAL . 75.1 Cg_endo -72.35 124.69 10.12 Favored 'Trans proline' 0 CA--C 1.539 0.749 0 C-N-CA 124.048 3.165 . . . . 0.0 110.931 174.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -134.87 116.64 14.99 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.98 1.312 . . . . 0.0 110.455 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.72 -172.38 30.11 Favored Glycine 0 CA--C 1.534 1.256 0 C-N-CA 125.331 1.443 . . . . 0.0 112.919 -178.33 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.2 m -59.11 95.51 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 126.544 1.937 . . . . 0.0 112.912 -177.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -61.84 126.38 27.14 Favored 'General case' 0 CA--C 1.545 0.762 0 O-C-N 121.26 -0.9 . . . . 0.0 112.413 -176.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.9 t -154.51 169.92 22.66 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 124.852 1.261 . . . . 0.0 112.333 178.279 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 6.0 mp -79.6 -61.62 1.94 Allowed 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.837 1.255 . . . . 0.0 111.151 176.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -77.81 177.36 8.25 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.505 1.522 . . . . 0.0 111.66 177.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.444 HD11 HG21 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -118.2 124.51 48.09 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.712 1.205 . . . . 0.0 110.602 -179.981 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -128.37 169.65 14.01 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 125.9 1.68 . . . . 0.0 112.052 178.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.4 t -63.75 130.47 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 O-C-N 121.226 -0.921 . . . . 0.0 110.693 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.73 -8.81 76.45 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.216 1.389 . . . . 0.0 114.663 -177.3 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -67.65 154.91 40.42 Favored 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 118.958 1.379 . . . . 0.0 110.818 174.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -74.96 157.41 35.01 Favored 'General case' 0 N--CA 1.472 0.664 0 O-C-N 121.312 -0.867 . . . . 0.0 110.046 174.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 14.9 m -149.25 138.2 15.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 C-N-CA 124.676 1.19 . . . . 0.0 110.449 179.279 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.46 HG11 ' HG3' ' A' ' 5' ' ' PRO . 7.6 p -137.09 157.79 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 125.355 1.462 . . . . 0.0 109.56 177.549 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -102.9 160.36 26.45 Favored Pre-proline 0 CA--C 1.542 0.667 0 C-N-CA 124.919 1.288 . . . . 0.0 111.732 175.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_endo -68.95 -28.02 29.71 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 123.806 3.004 . . . . 0.0 112.102 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.8 t30 -158.51 55.5 0.44 Allowed 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 124.472 1.109 . . . . 0.0 112.848 177.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.82 -60.79 0.29 Allowed 'General case' 0 N--CA 1.482 1.139 0 O-C-N 121.009 -1.057 . . . . 0.0 113.351 -174.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 162.43 -173.34 38.7 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 124.818 1.199 . . . . 0.0 113.59 -177.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.7 p -100.49 144.95 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 126.362 1.865 . . . . 0.0 110.945 176.211 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.417 ' SG ' HG21 ' A' ' 56' ' ' VAL . 38.7 m -131.75 -175.85 3.85 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 125.49 1.516 . . . . 0.0 110.306 175.434 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -137.53 124.8 21.78 Favored 'General case' 0 N--CA 1.48 1.028 0 O-C-N 121.091 -1.006 . . . . 0.0 111.634 177.021 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.444 HG21 HD11 ' A' ' 13' ' ' LEU . 60.4 t -64.61 136.04 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 C-N-CA 124.425 1.09 . . . . 0.0 110.657 -179.493 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.5 p -115.44 -44.95 2.94 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 124.635 1.174 . . . . 0.0 113.026 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.3 163.56 37.25 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 126.319 1.847 . . . . 0.0 110.796 176.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 75.0 mt -141.83 132.82 26.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 124.543 1.137 . . . . 0.0 108.979 178.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -147.37 167.23 24.86 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.615 0.766 . . . . 0.0 112.581 175.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.485 HG12 ' HA ' ' A' ' 43' ' ' THR . 20.9 m -103.3 141.93 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 O-C-N 121.117 -0.989 . . . . 0.0 110.699 175.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 3.9 ptmt -154.83 170.18 22.24 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 124.25 1.02 . . . . 0.0 112.234 175.47 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -102.46 116.34 32.42 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 125.999 1.72 . . . . 0.0 109.579 175.013 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.6 p -126.5 137.87 56.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.901 0.88 . . . . 0.0 110.025 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.5 28.97 1.89 Allowed 'General case' 0 CA--C 1.558 1.251 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 -177.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.28 22.69 53.81 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 125.172 1.367 . . . . 0.0 115.516 -176.565 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 35.8 tt0 -136.51 113.7 10.65 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 119.062 1.431 . . . . 0.0 111.666 -173.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 13.0 tttt -94.47 116.04 28.32 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.054 1.342 . . . . 0.0 111.747 -178.135 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.614 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -157.16 173.26 17.25 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.394 0.678 . . . . 0.0 111.887 177.777 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.485 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.2 m -73.96 116.41 14.55 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 124.934 1.293 . . . . 0.0 111.351 175.016 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -109.44 113.22 25.85 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.614 1.166 . . . . 0.0 109.939 177.195 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.613 HG21 ' HE2' ' A' ' 70' ' ' LYS . 27.3 m -73.61 150.71 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 O-C-N 121.817 -0.552 . . . . 0.0 110.894 177.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.2 m -126.5 121.18 31.62 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.801 0.84 . . . . 0.0 110.407 176.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -124.43 158.98 31.49 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 125.759 1.624 . . . . 0.0 110.51 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 13.4 ptm180 -136.18 111.5 9.11 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 126.061 1.744 . . . . 0.0 110.306 -178.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.9 109.07 19.08 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 123.258 0.623 . . . . 0.0 109.95 176.596 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 22.5 pt-20 -65.16 -18.43 65.3 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 113.337 0.866 . . . . 0.0 113.337 177.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -59.78 -36.72 77.26 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 126.027 1.731 . . . . 0.0 113.379 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -128.62 3.24 5.53 Favored 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.98 1.312 . . . . 0.0 112.665 174.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 64.61 24.18 69.37 Favored Glycine 0 CA--C 1.535 1.341 0 C-N-CA 125.447 1.498 . . . . 0.0 114.089 -172.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -90.74 173.53 7.97 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 118.671 1.236 . . . . 0.0 111.429 -176.361 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 27.0 m -117.9 143.77 27.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 124.168 0.987 . . . . 0.0 110.483 174.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.417 HG21 ' SG ' ' A' ' 27' ' ' CYS . 45.0 t -125.86 112.31 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 C-N-CA 125.375 1.47 . . . . 0.0 107.499 177.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.1 tmm? -125.34 119.34 28.1 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.145 0.978 . . . . 0.0 109.972 176.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.8 m -132.14 156.76 79.71 Favored Pre-proline 0 N--CA 1.469 0.519 0 C-N-CA 124.746 1.219 . . . . 0.0 111.834 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.614 ' CB ' HD11 ' A' ' 42' ' ' LEU . 58.3 Cg_endo -78.01 113.61 3.46 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 124.053 3.169 . . . . 0.0 115.38 179.576 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -60.78 -34.42 74.46 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 120.134 -1.604 . . . . 0.0 114.315 178.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.17 5.57 78.37 Favored Glycine 0 N--CA 1.474 1.218 0 C-N-CA 124.202 0.905 . . . . 0.0 114.847 176.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 17.4 tttt -137.56 3.05 2.51 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 125.413 1.485 . . . . 0.0 113.212 -176.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 59' ' ' PRO . 3.0 m -50.21 -29.13 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 C-N-CA 125.581 1.552 . . . . 0.0 113.513 175.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.8 mt -58.41 -28.77 65.52 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 126.098 1.759 . . . . 0.0 112.201 177.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.9 -51.64 13.32 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.035 1.734 . . . . 0.0 112.479 175.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.538 HG22 HG13 ' A' ' 68' ' ' VAL . 2.3 mp -68.61 -31.11 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 124.192 0.997 . . . . 0.0 111.367 178.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.83 10.48 72.4 Favored Glycine 0 CA--C 1.538 1.504 0 C-N-CA 126.047 1.784 . . . . 0.0 114.468 -177.555 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.538 HG13 HG22 ' A' ' 66' ' ' ILE . 31.2 m -97.35 123.47 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 C-N-CA 125.705 1.602 . . . . 0.0 110.75 -173.263 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 21.3 mmt85 -107.2 109.32 21.1 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.613 ' HE2' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER -97.71 106.53 18.85 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -177.472 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.489 ' CG2' ' HB3' ' A' ' 74' ' ' ALA . 0.2 OUTLIER -158.73 171.78 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 C-N-CA 126.257 1.823 . . . . 0.0 110.784 -175.08 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -61.0 -16.46 43.48 Favored 'General case' 0 CA--C 1.547 0.838 0 N-CA-C 115.415 1.635 . . . . 0.0 115.415 178.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.6 t -146.88 -55.71 0.25 Allowed 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 126.758 2.023 . . . . 0.0 111.727 -173.47 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.489 ' HB3' ' CG2' ' A' ' 71' ' ' VAL . . . -55.27 144.5 24.57 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 124.093 0.957 . . . . 0.0 112.515 175.458 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.115 0 C-N-CA 128.333 2.653 . . . . 0.0 113.757 -173.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.137 0 CA-C-O 121.22 0.533 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -143.06 77.73 0.28 Allowed Glycine 0 N--CA 1.469 0.842 0 C-N-CA 125.424 1.488 . . . . 0.0 111.666 -177.287 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 28.1 m-70 -63.59 152.94 37.4 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 123.773 0.829 . . . . 0.0 111.507 175.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.12 157.67 38.15 Favored Pre-proline 0 CA--C 1.54 0.592 0 C-N-CA 125.449 1.5 . . . . 0.0 111.894 -179.311 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -70.03 120.45 7.19 Favored 'Trans proline' 0 CA--C 1.535 0.556 0 C-N-CA 122.97 2.447 . . . . 0.0 110.199 176.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -138.63 164.96 28.16 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.638 1.175 . . . . 0.0 111.554 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -75.78 170.9 54.57 Favored Glycine 0 CA--C 1.536 1.388 0 C-N-CA 123.344 0.497 . . . . 0.0 113.437 177.091 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 44.7 m -132.78 -78.96 0.49 Allowed 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 124.687 1.195 . . . . 0.0 111.252 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -158.31 48.01 0.36 Allowed 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 125.447 1.499 . . . . 0.0 112.331 -178.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 24.0 m -130.1 163.96 25.45 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 125.619 1.568 . . . . 0.0 112.474 -179.156 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.1 mp -117.0 -34.81 4.28 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.298 1.439 . . . . 0.0 113.014 -177.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 33.5 mt-30 -131.14 166.86 20.17 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 126.35 1.86 . . . . 0.0 110.754 179.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.521 HD21 ' CG1' ' A' ' 19' ' ' VAL . 0.7 OUTLIER -64.8 123.06 18.38 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 123.956 0.903 . . . . 0.0 110.876 176.469 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.428 ' N ' HD13 ' A' ' 13' ' ' LEU . . . -146.81 176.42 9.89 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.469 1.908 . . . . 0.0 112.137 177.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 48.3 t -59.14 129.2 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 O-C-N 120.965 -1.084 . . . . 0.0 111.786 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.53 -4.93 85.0 Favored Glycine 0 CA--C 1.534 1.243 0 C-N-CA 125.197 1.38 . . . . 0.0 114.1 -178.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -67.32 161.44 25.04 Favored 'General case' 0 CA--C 1.547 0.858 0 CA-C-N 118.454 1.127 . . . . 0.0 112.561 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -96.55 124.14 40.44 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 125.951 1.701 . . . . 0.0 111.968 -173.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.521 ' CG1' HD21 ' A' ' 13' ' ' LEU . 19.4 m -139.75 139.72 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 C-N-CA 123.34 0.656 . . . . 0.0 110.968 -175.102 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.444 HG12 ' HA ' ' A' ' 75' ' ' GLU . 11.9 p -137.03 145.1 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 124.002 0.921 . . . . 0.0 110.384 177.212 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.528 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.9 OUTLIER -74.71 160.51 80.77 Favored Pre-proline 0 CA--C 1.547 0.83 0 O-C-N 121.83 -0.544 . . . . 0.0 110.59 174.997 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.599 ' CD ' HG12 ' A' ' 68' ' ' VAL . 60.8 Cg_endo -67.97 -25.73 38.17 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.04 2.493 . . . . 0.0 112.253 -179.048 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.3 t30 -159.07 48.87 0.33 Allowed 'General case' 0 CA--C 1.554 1.12 0 C-N-CA 124.494 1.117 . . . . 0.0 113.633 178.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -139.41 -64.12 0.5 Allowed 'General case' 0 N--CA 1.482 1.157 0 O-C-N 120.85 -1.156 . . . . 0.0 113.132 -174.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 166.39 172.49 33.76 Favored Glycine 0 CA--C 1.533 1.162 0 C-N-CA 125.015 1.293 . . . . 0.0 113.192 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.29 142.58 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 124.893 1.277 . . . . 0.0 110.804 -178.249 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 6.2 m -131.48 173.0 11.54 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.917 1.687 . . . . 0.0 111.148 176.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.8 tmt_? -133.76 118.96 18.67 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 125.863 1.665 . . . . 0.0 110.325 -178.022 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.634 HG22 ' SD ' ' A' ' 47' ' ' MET . 39.3 t -60.84 131.1 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 O-C-N 121.762 -0.586 . . . . 0.0 111.01 -175.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 83.0 p -112.06 -42.64 3.71 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -178.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.8 162.68 34.83 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.527 1.531 . . . . 0.0 110.817 178.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 71.1 mt -143.69 136.04 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.5 1.12 . . . . 0.0 108.965 -178.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -149.04 163.49 37.37 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 124.352 1.061 . . . . 0.0 111.913 175.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.8 p -106.85 141.91 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 124.593 1.157 . . . . 0.0 109.775 175.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.28 168.04 26.68 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 125.259 1.423 . . . . 0.0 110.854 176.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -101.38 118.71 37.51 Favored 'General case' 0 N--CA 1.467 0.395 0 C-N-CA 125.307 1.443 . . . . 0.0 109.488 175.41 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.0 p -121.08 132.54 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 124.272 1.029 . . . . 0.0 109.774 174.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.05 29.08 2.29 Favored 'General case' 0 CA--C 1.557 1.218 0 N-CA-C 114.775 1.398 . . . . 0.0 114.775 -178.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.29 26.23 48.58 Favored Glycine 0 CA--C 1.542 1.781 0 C-N-CA 124.692 1.139 . . . . 0.0 115.296 -175.111 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 5.9 mt-30 -135.42 113.53 11.27 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 126.401 1.881 . . . . 0.0 111.081 -178.043 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 8.9 tttt -94.01 121.43 35.48 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.968 1.307 . . . . 0.0 111.423 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.613 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -157.1 161.47 39.43 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 122.848 0.459 . . . . 0.0 111.41 178.859 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.4 m -67.77 116.39 8.4 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 121.313 -0.867 . . . . 0.0 110.516 177.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -104.65 113.56 27.22 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 120.869 -1.144 . . . . 0.0 110.041 175.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.9 m -83.22 141.16 15.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 C-N-CA 123.525 0.73 . . . . 0.0 110.184 177.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 24.8 m -122.32 112.7 18.44 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.668 1.187 . . . . 0.0 109.896 -178.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . 0.634 ' SD ' HG22 ' A' ' 29' ' ' VAL . 1.0 OUTLIER -112.15 154.9 24.79 Favored 'General case' 0 C--O 1.233 0.224 0 C-N-CA 124.011 0.924 . . . . 0.0 109.405 -178.9 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 41.7 mtm180 -133.72 154.73 50.74 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 124.495 1.118 . . . . 0.0 109.791 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.593 ' HE ' ' HB3' ' A' ' 54' ' ' ALA . 0.2 OUTLIER -120.94 109.08 14.66 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.85 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -67.57 -19.87 65.32 Favored 'General case' 0 CA--C 1.544 0.714 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 177.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -51.1 -46.81 61.97 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 127.046 2.139 . . . . 0.0 112.75 175.423 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -123.61 -19.19 5.89 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.517 1.527 . . . . 0.0 113.424 -179.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.25 37.61 8.93 Favored Glycine 0 CA--C 1.538 1.488 0 C-N-CA 125.429 1.49 . . . . 0.0 114.372 -177.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.593 ' HB3' ' HE ' ' A' ' 49' ' ' ARG . . . -110.06 166.64 10.79 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 125.4 1.48 . . . . 0.0 112.085 177.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.4 m -129.7 146.91 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 125.047 1.339 . . . . 0.0 111.52 178.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.0 m -136.94 112.2 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 C-N-CA 126.409 1.883 . . . . 0.0 109.151 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 9.4 ptt? -107.9 124.45 50.14 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 124.424 1.09 . . . . 0.0 110.364 176.037 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.615 HG21 ' HE2' ' A' ' 70' ' ' LYS . 30.1 m -131.97 157.21 78.83 Favored Pre-proline 0 N--CA 1.469 0.488 0 C-N-CA 123.949 0.9 . . . . 0.0 111.119 -178.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.613 ' CB ' HD11 ' A' ' 42' ' ' LEU . 56.1 Cg_endo -77.73 114.94 3.75 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.382 2.721 . . . . 0.0 114.596 176.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -62.54 -35.77 80.51 Favored 'General case' 0 N--CA 1.479 0.998 0 O-C-N 120.37 -1.456 . . . . 0.0 113.909 178.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.99 6.35 79.1 Favored Glycine 0 N--CA 1.473 1.164 0 C-N-CA 124.245 0.926 . . . . 0.0 114.794 176.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 3.0 tttm -136.0 4.5 3.0 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.685 1.594 . . . . 0.0 112.861 -178.705 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -50.05 -30.0 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 126.12 1.768 . . . . 0.0 113.072 175.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.7 mt -55.05 -29.91 58.46 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.315 1.846 . . . . 0.0 112.585 176.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.78 -50.47 13.45 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.647 1.579 . . . . 0.0 112.529 177.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.509 HG22 HG13 ' A' ' 68' ' ' VAL . 3.6 mp -66.42 -32.98 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 C-N-CA 124.664 1.186 . . . . 0.0 111.237 177.574 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.4 4.61 76.8 Favored Glycine 0 CA--C 1.534 1.278 0 C-N-CA 125.647 1.594 . . . . 0.0 114.137 -176.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.599 HG12 ' CD ' ' A' ' 22' ' ' PRO . 30.2 m -82.31 137.55 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 C-N-CA 124.404 1.082 . . . . 0.0 111.105 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.421 ' HB3' ' HB1' ' A' ' 74' ' ' ALA . 0.6 OUTLIER -117.79 109.62 16.8 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.012 0.925 . . . . 0.0 110.535 175.771 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.615 ' HE2' HG21 ' A' ' 58' ' ' VAL . 0.0 OUTLIER -124.05 106.6 10.5 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 126.51 1.924 . . . . 0.0 109.345 178.403 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 2.7 t -154.05 167.47 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 C-N-CA 124.599 1.159 . . . . 0.0 109.184 177.675 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -52.68 -19.33 2.31 Favored 'General case' 0 CA--C 1.546 0.804 0 N-CA-C 115.536 1.68 . . . . 0.0 115.536 175.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -124.52 -25.33 4.05 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.597 1.559 . . . . 0.0 113.404 175.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.421 ' HB1' ' HB3' ' A' ' 69' ' ' ARG . . . -73.98 98.63 3.09 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.585 1.154 . . . . 0.0 111.18 179.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.444 ' HA ' HG12 ' A' ' 20' ' ' VAL . 3.3 mt-10 . . . . . 0 C--O 1.253 1.269 0 C-N-CA 126.235 1.814 . . . . 0.0 110.946 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.182 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -91.91 -104.63 1.46 Allowed Glycine 0 N--CA 1.476 1.33 0 C-N-CA 124.641 1.115 . . . . 0.0 111.609 177.471 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.409 ' O ' HG11 ' A' ' 26' ' ' VAL . 32.5 m80 -91.83 144.66 25.26 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.551 1.14 . . . . 0.0 109.94 175.174 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -55.43 155.19 10.37 Favored Pre-proline 0 CA--C 1.546 0.798 0 C-N-CA 125.631 1.572 . . . . 0.0 112.789 175.04 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.419 ' HD3' HG12 ' A' ' 26' ' ' VAL . 82.5 Cg_endo -69.71 118.68 5.83 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 123.231 2.621 . . . . 0.0 110.614 -177.047 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -55.75 121.84 10.1 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.613 1.165 . . . . 0.0 112.371 179.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 163.96 155.58 8.35 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 124.176 0.893 . . . . 0.0 112.522 176.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.6 t -147.23 -33.49 0.28 Allowed 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.43 1.092 . . . . 0.0 113.292 -176.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -69.37 165.17 21.32 Favored 'General case' 0 CA--C 1.552 1.028 0 C-N-CA 124.52 1.128 . . . . 0.0 112.052 175.018 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 m -130.36 89.4 2.78 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.786 1.634 . . . . 0.0 111.338 -178.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.4 mp -138.21 179.2 6.59 Favored 'General case' 0 CA--C 1.546 0.79 0 C-N-CA 125.848 1.659 . . . . 0.0 111.553 177.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -58.39 152.96 16.6 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 124.784 1.234 . . . . 0.0 111.836 175.148 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -77.88 123.01 26.23 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.728 0.811 . . . . 0.0 111.109 179.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -121.45 169.08 10.99 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 125.926 1.69 . . . . 0.0 111.972 175.005 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.4 t -61.37 129.84 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 O-C-N 121.413 -0.805 . . . . 0.0 110.634 176.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.12 -6.54 78.78 Favored Glycine 0 CA--C 1.534 1.23 0 C-N-CA 124.876 1.227 . . . . 0.0 114.651 -177.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -69.61 176.41 3.54 Favored 'General case' 0 CA--C 1.546 0.814 0 CA-C-N 119.079 1.439 . . . . 0.0 110.593 174.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.42 169.91 10.67 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.998 1.38 . . . . 0.0 112.998 -179.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.54 HG13 ' HB2' ' A' ' 27' ' ' CYS . 2.5 p -161.02 149.78 5.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 C-N-CA 125.539 1.536 . . . . 0.0 110.643 175.366 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 11.8 p -127.42 160.43 36.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 126.991 2.116 . . . . 0.0 107.685 174.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -125.84 154.55 73.46 Favored Pre-proline 0 CA--C 1.539 0.547 0 C-N-CA 125.063 1.345 . . . . 0.0 110.974 176.696 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.83 -9.83 26.5 Favored 'Trans proline' 0 CA--C 1.545 1.06 0 C-N-CA 123.17 2.58 . . . . 0.0 113.761 178.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 26.7 m-20 -133.46 -60.17 0.85 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 126.352 1.861 . . . . 0.0 112.922 176.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 65.5 mm-40 -52.48 -54.35 33.56 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 125.133 1.373 . . . . 0.0 112.952 -175.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 114.53 -147.36 18.82 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 125.479 1.514 . . . . 0.0 111.68 -174.059 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.419 HG12 ' HD3' ' A' ' 5' ' ' PRO . 10.2 m -70.17 144.66 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 124.004 0.922 . . . . 0.0 112.984 -177.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.54 ' HB2' HG13 ' A' ' 19' ' ' VAL . 30.9 m -141.81 177.53 8.11 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 126.383 1.873 . . . . 0.0 110.653 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -132.38 129.47 39.43 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 124.759 1.224 . . . . 0.0 111.881 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.6 t -72.56 142.48 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 O-C-N 121.758 -0.588 . . . . 0.0 110.946 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.9 t -116.94 -44.78 2.79 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.419 1.488 . . . . 0.0 112.593 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.95 159.27 37.92 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 124.437 1.095 . . . . 0.0 110.553 177.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -142.59 133.59 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 120.911 -1.118 . . . . 0.0 108.823 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -149.47 169.4 20.97 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.298 0.639 . . . . 0.0 111.953 175.566 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.504 HG12 ' HA ' ' A' ' 43' ' ' THR . 18.6 m -103.57 142.59 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 O-C-N 120.942 -1.099 . . . . 0.0 110.576 175.584 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.9 pttt -154.65 172.58 17.65 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.664 0.786 . . . . 0.0 112.011 176.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -104.64 116.6 32.33 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 125.727 1.611 . . . . 0.0 110.177 175.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.9 p -125.98 137.73 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 C-N-CA 124.262 1.025 . . . . 0.0 109.965 174.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.81 28.86 2.05 Favored 'General case' 0 CA--C 1.556 1.193 0 C-N-CA 125.182 1.393 . . . . 0.0 114.69 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.94 27.94 48.01 Favored Glycine 0 CA--C 1.541 1.701 0 C-N-CA 124.936 1.255 . . . . 0.0 115.144 -174.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.96 115.53 11.28 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 125.577 1.551 . . . . 0.0 111.856 -176.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -98.45 111.02 23.51 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 126.104 1.762 . . . . 0.0 111.356 -176.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.601 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -155.36 172.82 17.56 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.401 0.68 . . . . 0.0 111.655 -179.425 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.504 ' HA ' HG12 ' A' ' 34' ' ' VAL . 6.0 m -73.64 116.29 14.06 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.248 1.019 . . . . 0.0 111.116 175.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -108.94 113.21 25.91 Favored 'General case' 0 N--CA 1.467 0.394 0 O-C-N 121.221 -0.924 . . . . 0.0 109.612 176.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.57 HG21 ' HE3' ' A' ' 70' ' ' LYS . 19.3 m -73.2 146.56 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 123.3 0.64 . . . . 0.0 110.452 176.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 3.7 m -126.58 109.93 12.67 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 122.623 1.201 . . . . 0.0 110.243 176.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . 0.461 ' HG2' HG11 ' A' ' 19' ' ' VAL . 1.6 mpp? -112.91 165.43 12.34 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 125.274 1.43 . . . . 0.0 110.483 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 26.8 ptt180 -142.75 117.29 9.72 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 124.835 1.254 . . . . 0.0 110.079 179.295 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 8.7 ttp180 -74.46 109.07 7.64 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.333 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -70.23 -14.32 62.56 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 178.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -57.58 -39.91 77.84 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 126.204 1.802 . . . . 0.0 112.791 176.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.63 -20.94 3.51 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 126.346 1.858 . . . . 0.0 114.75 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.12 14.49 51.46 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 125.104 1.335 . . . . 0.0 115.199 -174.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -76.85 163.34 26.86 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-N 118.85 1.325 . . . . 0.0 112.597 175.327 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 33.6 m -108.57 147.66 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 124.586 1.154 . . . . 0.0 110.344 174.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.2 t -138.53 112.72 8.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 C-N-CA 125.403 1.481 . . . . 0.0 107.699 -178.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.24 132.02 53.03 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 123.689 0.795 . . . . 0.0 111.89 178.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.449 ' O ' HG22 ' A' ' 45' ' ' VAL . 33.4 m -139.9 157.38 69.66 Favored Pre-proline 0 N--CA 1.473 0.681 0 C-N-CA 124.164 0.985 . . . . 0.0 112.088 -178.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.601 ' CB ' HD11 ' A' ' 42' ' ' LEU . 55.5 Cg_endo -77.95 116.28 3.94 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 123.705 2.937 . . . . 0.0 114.576 175.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -64.35 -33.74 76.55 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 120.327 -1.483 . . . . 0.0 114.284 178.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.64 6.7 80.08 Favored Glycine 0 N--CA 1.475 1.275 0 O-C-N 121.264 -0.897 . . . . 0.0 114.64 176.06 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 30.5 tttt -137.57 3.11 2.51 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 125.34 1.456 . . . . 0.0 113.194 -177.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.411 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.2 m -49.55 -29.22 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 125.631 1.572 . . . . 0.0 113.282 176.122 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 12.4 mt -56.08 -29.55 60.71 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 126.172 1.789 . . . . 0.0 112.574 176.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.6 -50.88 12.73 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.891 1.676 . . . . 0.0 112.98 175.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.8 mp -65.41 -33.2 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 C-N-CA 124.117 0.967 . . . . 0.0 111.537 178.147 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 87.4 0.2 84.84 Favored Glycine 0 CA--C 1.536 1.364 0 C-N-CA 125.623 1.582 . . . . 0.0 113.97 -175.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.402 HG13 HG12 ' A' ' 63' ' ' VAL . 7.7 p -73.53 123.15 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 124.588 1.155 . . . . 0.0 110.338 174.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.418 ' HB3' ' HB1' ' A' ' 74' ' ' ALA . 0.5 OUTLIER -106.07 109.29 21.18 Favored 'General case' 0 N--CA 1.473 0.709 0 O-C-N 121.071 -1.018 . . . . 0.0 108.789 175.174 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.57 ' HE3' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER -117.15 106.63 13.55 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 123.642 0.777 . . . . 0.0 110.177 178.993 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.2 t -154.07 166.39 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 C-N-CA 123.921 0.888 . . . . 0.0 109.478 177.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -55.96 -31.05 62.63 Favored 'General case' 0 CA--C 1.555 1.16 0 C-N-CA 124.414 1.086 . . . . 0.0 112.521 175.009 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 46.5 m -104.29 -41.33 5.81 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 124.764 1.226 . . . . 0.0 112.97 174.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.418 ' HB1' ' HB3' ' A' ' 69' ' ' ARG . . . -62.21 106.83 0.79 Allowed 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.905 1.282 . . . . 0.0 111.461 -177.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 . . . . . 0 C--O 1.251 1.18 0 C-N-CA 126.503 1.921 . . . . 0.0 113.684 -170.768 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.277 0 N-CA-C 111.435 0.161 . . . . 0.0 111.435 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.68 58.89 0.22 Allowed Glycine 0 CA--C 1.529 0.949 0 C-N-CA 124.378 0.99 . . . . 0.0 112.689 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -57.97 114.75 2.48 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 124.281 1.033 . . . . 0.0 110.848 175.434 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -57.42 156.37 16.23 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 123.828 0.851 . . . . 0.0 112.621 178.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -64.03 127.25 18.94 Favored 'Trans proline' 0 CA--C 1.542 0.879 0 C-N-CA 123.341 2.694 . . . . 0.0 111.457 177.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -142.98 157.29 44.7 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 125.909 1.683 . . . . 0.0 111.923 177.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 178.56 -178.83 48.76 Favored Glycine 0 CA--C 1.538 1.514 0 C-N-CA 125.929 1.728 . . . . 0.0 113.226 177.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 49.7 m -71.9 -171.77 0.75 Allowed 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 125.908 1.683 . . . . 0.0 112.366 175.078 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -124.85 115.37 20.54 Favored 'General case' 0 CA--C 1.546 0.803 0 O-C-N 120.38 -1.45 . . . . 0.0 111.852 177.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.0 m -143.76 170.46 15.83 Favored 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 126.17 1.788 . . . . 0.0 111.615 -179.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -69.52 -75.41 0.11 Allowed 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.886 1.275 . . . . 0.0 111.233 176.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -78.94 162.08 26.24 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 124.718 1.207 . . . . 0.0 111.513 175.38 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.469 HD22 ' HB3' ' A' ' 17' ' ' ASP . 9.7 mt -97.33 168.23 10.53 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 124.549 1.14 . . . . 0.0 112.53 175.015 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -125.62 166.5 16.61 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.981 1.712 . . . . 0.0 111.122 176.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 75.2 t -67.93 131.87 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 123.628 0.771 . . . . 0.0 110.135 175.147 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.03 -3.45 70.18 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 125.84 1.686 . . . . 0.0 114.737 -178.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.469 ' HB3' HD22 ' A' ' 13' ' ' LEU . 0.5 OUTLIER -76.63 152.15 35.94 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 119.085 1.443 . . . . 0.0 112.719 -179.29 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -86.89 135.0 33.47 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 125.453 1.501 . . . . 0.0 111.68 -177.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.477 HG23 ' HB2' ' A' ' 27' ' ' CYS . 28.3 m -143.54 135.71 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.796 1.239 . . . . 0.0 111.167 -177.579 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.7 p -102.92 165.63 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 O-C-N 121.152 -0.967 . . . . 0.0 111.33 175.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -125.99 158.44 65.94 Favored Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 125.277 1.431 . . . . 0.0 111.886 175.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.429 ' CD ' HG12 ' A' ' 68' ' ' VAL . 58.6 Cg_endo -71.36 -40.78 2.85 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 123.328 2.685 . . . . 0.0 112.615 -178.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -148.75 32.37 0.78 Allowed 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.707 1.203 . . . . 0.0 112.87 -177.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -130.03 -23.11 2.79 Favored 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 125.817 1.647 . . . . 0.0 114.245 -173.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 104.17 168.15 24.94 Favored Glycine 0 CA--C 1.539 1.592 0 C-N-CA 126.406 1.955 . . . . 0.0 114.436 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 42.9 t -66.52 133.47 31.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 O-C-N 121.1 -1.235 . . . . 0.0 110.338 176.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.477 ' HB2' HG23 ' A' ' 19' ' ' VAL . 63.4 m -122.53 -179.85 4.35 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 126.302 1.841 . . . . 0.0 111.226 178.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.0 ttt180 -144.43 120.64 10.84 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 125.066 1.347 . . . . 0.0 110.562 176.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.402 HG21 HD13 ' A' ' 13' ' ' LEU . 39.7 t -57.96 126.76 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 C-N-CA 123.643 0.777 . . . . 0.0 111.089 -177.192 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.3 m -112.99 -36.46 5.1 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 124.748 1.219 . . . . 0.0 113.463 -176.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.88 159.54 41.82 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.96 1.704 . . . . 0.0 110.582 175.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 41.0 mt -143.81 118.19 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 124.851 1.26 . . . . 0.0 108.631 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -144.72 171.71 14.02 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 123.653 0.781 . . . . 0.0 112.003 177.33 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.41 HG12 ' HA ' ' A' ' 43' ' ' THR . 14.5 m -111.8 142.18 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 O-C-N 121.331 -0.855 . . . . 0.0 111.455 175.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.46 170.82 21.06 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 124.314 1.045 . . . . 0.0 112.122 175.407 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -102.52 118.29 36.55 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.935 1.694 . . . . 0.0 109.536 174.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.8 p -129.68 137.65 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.695 0.798 . . . . 0.0 109.691 174.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.41 29.2 1.91 Allowed 'General case' 0 CA--C 1.556 1.184 0 C-N-CA 125.17 1.388 . . . . 0.0 114.696 -176.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.2 22.2 55.16 Favored Glycine 0 CA--C 1.538 1.528 0 C-N-CA 125.131 1.348 . . . . 0.0 115.454 -177.23 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -135.97 113.5 10.85 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 119.149 1.475 . . . . 0.0 111.062 -173.38 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -96.0 114.06 25.74 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 125.541 1.536 . . . . 0.0 111.843 -176.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.597 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -158.21 173.69 16.32 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 123.437 0.695 . . . . 0.0 111.924 179.283 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.41 ' HA ' HG12 ' A' ' 34' ' ' VAL . 5.3 m -73.36 116.28 13.73 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.456 1.103 . . . . 0.0 111.165 174.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -108.75 113.13 25.84 Favored 'General case' 0 C--O 1.235 0.311 0 O-C-N 120.969 -1.082 . . . . 0.0 109.43 175.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.604 HG21 ' HE3' ' A' ' 70' ' ' LYS . 16.2 m -70.49 150.95 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 CA-C-N 116.242 -0.436 . . . . 0.0 109.993 175.28 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 25.4 m -126.47 128.58 47.16 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 125.252 1.421 . . . . 0.0 109.533 175.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.94 166.98 23.73 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 125.674 1.589 . . . . 0.0 110.599 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.23 141.31 27.27 Favored 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 124.347 1.059 . . . . 0.0 111.165 175.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 59.9 mtm180 -78.71 124.62 28.38 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.106 1.362 . . . . 0.0 111.059 178.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -63.18 -40.64 98.1 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 124.441 1.096 . . . . 0.0 113.237 177.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -87.09 -46.65 9.6 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.977 0.911 . . . . 0.0 112.666 178.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -71.78 -21.61 61.7 Favored 'General case' 0 N--CA 1.475 0.809 0 O-C-N 121.517 -0.739 . . . . 0.0 112.815 -177.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 66.26 12.47 58.23 Favored Glycine 0 CA--C 1.536 1.38 0 C-N-CA 126.062 1.791 . . . . 0.0 114.81 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -109.32 145.59 35.74 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.672 1.589 . . . . 0.0 112.56 -168.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 16.3 m -70.21 150.87 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.871 1.268 . . . . 0.0 111.837 177.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.2 t -145.21 123.67 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 125.602 1.561 . . . . 0.0 108.91 178.127 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 43.8 mtt -141.26 121.74 14.12 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 123.813 0.845 . . . . 0.0 109.845 178.009 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 26.8 m -132.67 157.48 78.21 Favored Pre-proline 0 N--CA 1.475 0.796 0 C-N-CA 124.0 0.92 . . . . 0.0 112.335 177.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.597 ' CB ' HD11 ' A' ' 42' ' ' LEU . 57.6 Cg_endo -77.91 114.33 3.6 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 123.546 2.831 . . . . 0.0 114.915 178.082 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -60.69 -36.51 78.95 Favored 'General case' 0 N--CA 1.476 0.828 0 O-C-N 120.346 -1.471 . . . . 0.0 114.297 178.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.11 5.77 78.61 Favored Glycine 0 N--CA 1.475 1.246 0 C-N-CA 124.338 0.97 . . . . 0.0 114.863 176.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 15.0 tttp -135.88 3.2 2.93 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.286 1.435 . . . . 0.0 113.106 -177.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.441 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.8 m -49.75 -29.87 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 125.635 1.574 . . . . 0.0 113.11 175.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.0 mt -57.56 -28.65 63.75 Favored 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 126.164 1.786 . . . . 0.0 112.595 176.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.03 -50.04 15.89 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 125.863 1.665 . . . . 0.0 112.605 176.078 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.437 HG22 HG13 ' A' ' 68' ' ' VAL . 4.0 mp -69.56 -33.68 58.05 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 124.15 0.98 . . . . 0.0 111.465 178.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.97 3.25 73.67 Favored Glycine 0 CA--C 1.537 1.466 0 C-N-CA 125.799 1.666 . . . . 0.0 114.208 -174.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.437 HG13 HG22 ' A' ' 66' ' ' ILE . 31.3 m -71.5 125.96 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 124.774 1.229 . . . . 0.0 110.834 177.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.3 mmm180 -109.72 109.34 20.01 Favored 'General case' 0 N--CA 1.474 0.769 0 O-C-N 121.076 -1.015 . . . . 0.0 108.931 175.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.604 ' HE3' HG21 ' A' ' 45' ' ' VAL . 0.5 OUTLIER -131.78 106.62 8.23 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 125.901 1.681 . . . . 0.0 109.117 179.803 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.403 HG12 ' H ' ' A' ' 72' ' ' ALA . 3.4 t -153.76 168.28 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 C-N-CA 124.76 1.224 . . . . 0.0 107.708 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . 0.403 ' H ' HG12 ' A' ' 71' ' ' VAL . . . -53.06 -33.66 52.99 Favored 'General case' 0 CA--C 1.549 0.938 0 CA-C-N 119.097 0.862 . . . . 0.0 112.726 177.275 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 2.0 t -104.52 -16.7 14.98 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.991 1.716 . . . . 0.0 114.46 176.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -87.39 89.28 7.94 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.545 1.138 . . . . 0.0 110.394 -179.287 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 . . . . . 0 C--O 1.255 1.361 0 C-N-CA 127.677 2.391 . . . . 0.0 113.556 -169.577 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.299 0 N-CA-C 110.932 -0.025 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 92.05 42.11 4.76 Favored Glycine 0 CA--C 1.534 1.224 0 C-N-CA 124.296 0.95 . . . . 0.0 114.021 -178.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 49.5 m80 -62.35 105.91 0.68 Allowed 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 124.898 1.279 . . . . 0.0 111.155 175.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -76.45 164.16 61.49 Favored Pre-proline 0 CA--C 1.549 0.905 0 C-N-CA 124.166 0.986 . . . . 0.0 113.295 178.513 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -70.6 98.25 0.76 Allowed 'Trans proline' 0 CA--C 1.54 0.806 0 C-N-CA 124.232 3.288 . . . . 0.0 112.383 175.055 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -142.83 161.51 37.91 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 126.116 1.766 . . . . 0.0 111.541 178.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 164.85 82.87 0.05 OUTLIER Glycine 0 CA--C 1.534 1.268 0 N-CA-C 114.953 0.741 . . . . 0.0 114.953 -175.077 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 14.8 p -79.73 98.97 7.21 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 125.661 1.584 . . . . 0.0 113.615 177.288 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -152.99 -82.15 0.09 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 124.858 1.263 . . . . 0.0 111.757 174.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 31.9 p -79.15 173.16 12.86 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 126.588 1.955 . . . . 0.0 112.941 177.033 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 45.4 mt -95.64 -66.92 0.88 Allowed 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.693 1.197 . . . . 0.0 111.113 178.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.11 171.14 13.47 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 125.319 1.447 . . . . 0.0 112.114 176.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.605 HD11 HG21 ' A' ' 29' ' ' VAL . 0.6 OUTLIER -73.91 133.38 43.09 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 123.893 0.877 . . . . 0.0 111.492 176.74 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.449 ' N ' HD13 ' A' ' 13' ' ' LEU . . . -140.57 172.74 12.29 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.86 1.664 . . . . 0.0 112.382 175.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 85.2 t -59.72 131.93 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 O-C-N 120.977 -1.077 . . . . 0.0 111.095 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.52 -6.24 83.73 Favored Glycine 0 CA--C 1.535 1.332 0 C-N-CA 125.045 1.307 . . . . 0.0 114.958 -177.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -69.65 176.85 3.28 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-N 118.805 1.303 . . . . 0.0 112.815 175.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 15.8 mmt85 -119.91 134.15 55.34 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.449 1.5 . . . . 0.0 111.884 -174.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.508 ' CG1' HD21 ' A' ' 13' ' ' LEU . 17.2 m -139.35 136.92 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 125.091 1.356 . . . . 0.0 109.506 -173.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.6 p -137.03 139.05 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 C-N-CA 123.989 0.916 . . . . 0.0 110.118 176.503 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -69.61 160.4 79.74 Favored Pre-proline 0 CA--C 1.542 0.646 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 174.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.546 ' CD ' HG22 ' A' ' 68' ' ' VAL . 58.3 Cg_endo -68.8 -27.29 31.52 Favored 'Trans proline' 0 CA--C 1.54 0.802 0 C-N-CA 122.781 2.32 . . . . 0.0 112.326 -177.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 56.9 t30 -157.77 47.66 0.38 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 124.401 1.081 . . . . 0.0 113.553 177.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -137.86 -64.19 0.55 Allowed 'General case' 0 N--CA 1.481 1.099 0 O-C-N 121.155 -0.965 . . . . 0.0 112.994 -174.117 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.55 168.44 30.63 Favored Glycine 0 CA--C 1.534 1.246 0 C-N-CA 125.081 1.324 . . . . 0.0 113.398 178.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.3 p -77.73 146.83 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 124.891 1.277 . . . . 0.0 111.411 175.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.484 ' SG ' HG11 ' A' ' 56' ' ' VAL . 3.7 m -130.36 173.83 10.43 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.568 1.547 . . . . 0.0 111.271 175.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.11 117.78 17.92 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.552 1.541 . . . . 0.0 110.909 -176.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.605 HG21 HD11 ' A' ' 13' ' ' LEU . 25.4 t -65.95 116.09 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.078 1.351 . . . . 0.0 111.124 -177.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.3 m -107.62 -47.85 3.54 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.852 1.261 . . . . 0.0 112.34 -176.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -148.8 169.71 19.87 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.334 1.854 . . . . 0.0 110.403 178.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 48.8 mt -147.28 140.36 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.054 1.342 . . . . 0.0 108.266 175.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.34 173.65 11.3 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 124.106 0.962 . . . . 0.0 112.313 175.706 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.468 HG12 ' HA ' ' A' ' 43' ' ' THR . 28.9 m -123.26 140.77 45.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 124.711 1.204 . . . . 0.0 110.728 177.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -155.53 167.42 30.44 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 123.935 0.894 . . . . 0.0 112.385 177.209 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -100.56 119.79 39.06 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.349 1.459 . . . . 0.0 108.745 174.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.0 p -127.33 136.8 59.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.851 1.261 . . . . 0.0 109.058 175.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.85 28.95 1.48 Allowed 'General case' 0 CA--C 1.557 1.233 0 N-CA-C 114.882 1.438 . . . . 0.0 114.882 -178.003 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.06 26.51 48.54 Favored Glycine 0 CA--C 1.542 1.72 0 C-N-CA 124.822 1.201 . . . . 0.0 115.363 -176.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -137.57 116.98 12.79 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 126.229 1.811 . . . . 0.0 110.835 -175.459 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -96.3 118.94 33.87 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 125.338 1.455 . . . . 0.0 111.105 179.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.503 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.9 OUTLIER -155.16 172.63 17.84 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 123.432 0.693 . . . . 0.0 111.892 -179.623 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.468 ' HA ' HG12 ' A' ' 34' ' ' VAL . 48.2 m -82.25 116.41 21.77 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.078 1.351 . . . . 0.0 111.943 176.61 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -102.2 113.17 26.22 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.483 1.113 . . . . 0.0 109.529 174.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.0 m -63.04 148.1 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 O-C-N 121.895 -0.503 . . . . 0.0 110.812 174.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 1.5 m -126.61 109.85 12.56 Favored 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 122.09 0.948 . . . . 0.0 110.605 176.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . 0.455 ' HB2' HG13 ' A' ' 56' ' ' VAL . 2.4 mpp? -123.58 160.17 27.64 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 124.055 0.942 . . . . 0.0 110.239 -178.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.469 ' HG3' HG12 ' A' ' 55' ' ' VAL . 1.1 mpt_? -130.91 125.06 32.51 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 123.843 0.857 . . . . 0.0 110.831 174.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 79.4 mtm180 -83.38 109.02 16.96 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 125.355 1.462 . . . . 0.0 108.462 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -65.62 -18.09 65.07 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.865 0.866 . . . . 0.0 112.494 177.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 31.0 tt0 -57.54 -39.22 76.16 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.622 1.969 . . . . 0.0 113.225 177.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -128.62 1.73 5.52 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 125.011 1.324 . . . . 0.0 113.645 177.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.79 11.77 60.98 Favored Glycine 0 CA--C 1.538 1.476 0 C-N-CA 125.427 1.489 . . . . 0.0 114.306 -171.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -81.04 159.01 24.91 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.489 1.516 . . . . 0.0 112.566 -176.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.469 HG12 ' HG3' ' A' ' 48' ' ' ARG . 20.4 m -97.95 162.05 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 123.481 0.712 . . . . 0.0 110.601 175.033 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.484 HG11 ' SG ' ' A' ' 27' ' ' CYS . 3.9 p -151.95 122.05 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 125.347 1.459 . . . . 0.0 109.111 174.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 19.3 ptm -125.93 135.26 51.68 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 125.076 1.35 . . . . 0.0 110.608 175.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.2 m -137.58 154.24 74.88 Favored Pre-proline 0 N--CA 1.468 0.454 0 C-N-CA 123.819 0.847 . . . . 0.0 111.253 175.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.503 ' CB ' HD11 ' A' ' 42' ' ' LEU . 44.2 Cg_endo -75.51 117.24 4.73 Favored 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 123.271 2.648 . . . . 0.0 114.439 178.084 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -59.65 -40.53 87.97 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.61 7.31 79.86 Favored Glycine 0 N--CA 1.474 1.173 0 C-N-CA 124.418 1.009 . . . . 0.0 114.588 178.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.2 tttm -133.7 3.4 3.53 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.203 1.401 . . . . 0.0 113.509 -178.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.5 m -48.75 -28.87 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.933 1.293 . . . . 0.0 113.598 175.007 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.3 mt -57.31 -29.09 63.63 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.989 1.715 . . . . 0.0 112.61 177.276 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.05 -50.61 15.9 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 125.64 1.576 . . . . 0.0 112.673 175.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.463 HG22 HG23 ' A' ' 68' ' ' VAL . 3.9 mp -68.75 -33.55 60.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 124.244 1.018 . . . . 0.0 111.435 178.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.7 2.19 79.23 Favored Glycine 0 CA--C 1.537 1.415 0 C-N-CA 125.844 1.688 . . . . 0.0 114.349 -175.198 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.546 HG22 ' CD ' ' A' ' 22' ' ' PRO . 71.6 t -80.69 123.16 37.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 CA-C-N 118.96 1.38 . . . . 0.0 110.472 178.273 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 3.3 mmt180 -99.58 109.24 21.76 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 174.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.7 106.48 13.93 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.527 1.531 . . . . 0.0 109.352 176.521 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 3.2 t -161.37 157.52 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.275 0 C-N-CA 126.281 1.833 . . . . 0.0 109.172 -178.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -54.02 -25.29 20.49 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.893 1.677 . . . . 0.0 115.156 176.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 3.5 t -126.7 11.86 7.31 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 126.104 1.762 . . . . 0.0 113.326 -178.308 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -80.95 -66.83 0.84 Allowed 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.483 1.113 . . . . 0.0 112.406 177.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 7.1 tm-20 . . . . . 0 C--O 1.253 1.238 0 C-N-CA 126.062 1.745 . . . . 0.0 112.674 -165.785 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.32 0 CA-C-O 120.636 0.255 . . . . 0.0 111.462 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 168.88 54.47 0.03 OUTLIER Glycine 0 CA--C 1.535 1.301 0 C-N-CA 124.257 0.932 . . . . 0.0 114.073 178.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 19.0 m80 -70.95 135.8 48.11 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.508 1.123 . . . . 0.0 111.98 -179.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 5.2 mtt -79.58 163.94 56.25 Favored Pre-proline 0 CA--C 1.545 0.781 0 N-CA-C 113.467 0.914 . . . . 0.0 113.467 176.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -72.59 103.93 1.63 Allowed 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 123.694 2.929 . . . . 0.0 109.316 175.01 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -138.0 161.7 36.03 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.458 1.503 . . . . 0.0 111.69 178.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.49 ' HA3' ' HB1' ' A' ' 72' ' ' ALA . . . -170.2 -178.38 41.06 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 124.968 1.271 . . . . 0.0 113.149 -177.765 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 24.2 m -85.46 -46.96 10.4 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.21 1.004 . . . . 0.0 113.27 -175.045 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -148.79 167.24 26.14 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.866 1.667 . . . . 0.0 112.473 -179.176 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 39.3 t -86.97 100.59 12.72 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 125.902 1.681 . . . . 0.0 111.294 177.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -110.88 168.34 9.55 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 125.881 1.673 . . . . 0.0 111.817 176.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.76 143.04 57.77 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 124.88 1.272 . . . . 0.0 111.741 179.063 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -68.47 120.64 14.87 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 124.288 1.035 . . . . 0.0 111.836 -174.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -140.06 172.91 12.08 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 125.017 1.327 . . . . 0.0 112.559 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.3 t -60.22 126.37 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.123 0.969 . . . . 0.0 110.475 177.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.23 -8.36 72.48 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.051 1.31 . . . . 0.0 114.856 -177.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -72.2 169.53 15.94 Favored 'General case' 0 CA--C 1.55 0.973 0 CA-C-N 119.215 1.507 . . . . 0.0 111.056 174.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -88.3 159.26 18.16 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.614 1.566 . . . . 0.0 112.018 175.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.44 HG13 ' HB2' ' A' ' 27' ' ' CYS . 1.5 p -150.86 130.14 3.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 C-N-CA 124.739 1.216 . . . . 0.0 110.134 175.216 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.2 p -137.19 142.59 36.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 C-N-CA 125.995 1.718 . . . . 0.0 107.903 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.419 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.4 OUTLIER -88.46 161.97 40.94 Favored Pre-proline 0 CA--C 1.545 0.765 0 C-N-CA 124.685 1.194 . . . . 0.0 110.965 175.784 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.67 -26.66 27.77 Favored 'Trans proline' 0 CA--C 1.536 0.59 0 C-N-CA 123.439 2.759 . . . . 0.0 112.37 -175.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -158.15 62.77 0.45 Allowed 'General case' 0 CA--C 1.551 1.013 0 C-N-CA 125.863 1.665 . . . . 0.0 111.57 176.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -146.43 -61.88 0.31 Allowed 'General case' 0 N--CA 1.481 1.084 0 O-C-N 121.085 -1.009 . . . . 0.0 112.463 179.147 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 158.67 -179.42 34.35 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 124.661 1.124 . . . . 0.0 113.422 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.3 m -81.87 147.8 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 125.542 1.537 . . . . 0.0 112.037 175.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.44 ' HB2' HG13 ' A' ' 19' ' ' VAL . 97.7 m -138.18 179.62 6.34 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 126.856 2.062 . . . . 0.0 109.851 179.027 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.01 135.6 39.61 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 125.102 1.361 . . . . 0.0 110.462 175.245 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -66.54 129.99 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 C-N-CA 123.95 0.9 . . . . 0.0 110.401 175.074 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -115.06 -51.69 2.71 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.622 1.169 . . . . 0.0 111.759 -178.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.73 164.54 37.57 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.849 1.66 . . . . 0.0 110.875 175.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 64.2 mt -144.9 134.45 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 O-C-N 120.752 -1.217 . . . . 0.0 108.756 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -143.53 174.09 11.07 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.355 1.062 . . . . 0.0 112.162 176.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.4 p -124.75 137.89 55.94 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 C-N-CA 125.168 1.387 . . . . 0.0 110.842 177.378 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 13.2 ptmt -150.74 153.4 35.44 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 124.961 1.304 . . . . 0.0 112.088 178.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -81.05 115.18 20.38 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 123.787 0.835 . . . . 0.0 108.924 174.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.6 p -118.6 133.36 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 124.311 1.044 . . . . 0.0 109.653 174.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.54 29.01 2.74 Favored 'General case' 0 CA--C 1.557 1.227 0 N-CA-C 114.772 1.397 . . . . 0.0 114.772 -178.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.43 20.42 56.74 Favored Glycine 0 CA--C 1.538 1.529 0 C-N-CA 124.854 1.216 . . . . 0.0 115.422 -175.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -142.87 114.11 7.81 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.491 1.516 . . . . 0.0 111.814 -176.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 5.1 ptmt -91.77 133.96 35.16 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.721 1.208 . . . . 0.0 111.656 175.007 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.645 HD11 ' CB ' ' A' ' 59' ' ' PRO . 1.3 pp -160.05 163.58 33.84 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.266 1.026 . . . . 0.0 110.483 176.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.0 m -66.39 116.49 7.46 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 121.279 -0.888 . . . . 0.0 110.986 178.012 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -104.91 113.3 26.82 Favored 'General case' 0 N--CA 1.467 0.407 0 O-C-N 120.748 -1.22 . . . . 0.0 109.409 175.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.2 m -75.73 143.68 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-O 119.035 -0.507 . . . . 0.0 110.19 177.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -125.82 112.86 16.51 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 122.41 1.1 . . . . 0.0 110.918 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -122.73 165.74 16.07 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 124.897 1.279 . . . . 0.0 109.647 -176.033 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.5 mtt180 -134.98 160.79 37.2 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 124.425 1.09 . . . . 0.0 110.589 175.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -122.28 109.1 14.03 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 125.733 1.613 . . . . 0.0 109.463 174.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -64.86 -17.66 64.48 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 113.331 0.863 . . . . 0.0 113.331 176.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -54.63 -44.37 73.1 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 127.199 2.2 . . . . 0.0 112.451 178.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -126.19 -1.29 7.05 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.47 1.908 . . . . 0.0 112.494 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.62 34.31 88.61 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 125.157 1.361 . . . . 0.0 113.552 -174.066 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.59 165.61 10.95 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 124.252 1.021 . . . . 0.0 112.145 -176.233 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.5 m -110.28 155.78 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.013 1.325 . . . . 0.0 111.265 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 3.7 p -151.05 125.83 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 124.713 1.205 . . . . 0.0 109.405 175.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 22.8 ptt? -130.21 137.81 50.26 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 123.9 0.88 . . . . 0.0 110.803 175.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.461 ' CG2' ' HE2' ' A' ' 70' ' ' LYS . 14.0 m -140.24 157.34 69.01 Favored Pre-proline 0 N--CA 1.474 0.731 0 C-N-CA 123.584 0.754 . . . . 0.0 111.414 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.645 ' CB ' HD11 ' A' ' 42' ' ' LEU . 53.7 Cg_endo -75.59 116.03 4.37 Favored 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 123.726 2.95 . . . . 0.0 114.861 176.482 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -63.97 -33.42 75.69 Favored 'General case' 0 N--CA 1.482 1.132 0 O-C-N 120.394 -1.441 . . . . 0.0 113.573 178.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.92 4.57 78.57 Favored Glycine 0 N--CA 1.476 1.328 0 C-N-CA 124.769 1.176 . . . . 0.0 114.686 175.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.0 tttm -136.74 3.84 2.76 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.437 1.495 . . . . 0.0 112.992 -177.207 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.2 m -50.26 -28.31 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 C-N-CA 125.731 1.613 . . . . 0.0 113.012 175.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.0 mt -56.02 -30.16 61.45 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 125.945 1.698 . . . . 0.0 112.385 176.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.53 -50.34 15.95 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 125.86 1.664 . . . . 0.0 112.828 175.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.486 HG22 HG13 ' A' ' 68' ' ' VAL . 4.0 mp -68.16 -33.38 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 124.054 0.941 . . . . 0.0 111.465 178.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.49 3.56 77.91 Favored Glycine 0 CA--C 1.537 1.445 0 C-N-CA 126.166 1.841 . . . . 0.0 114.605 -177.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.486 HG13 HG22 ' A' ' 66' ' ' ILE . 31.4 m -82.21 125.56 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 C-N-CA 126.451 1.9 . . . . 0.0 111.216 -178.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.69 109.25 17.92 Favored 'General case' 0 N--CA 1.475 0.782 0 O-C-N 121.252 -0.905 . . . . 0.0 110.105 177.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.461 ' HE2' ' CG2' ' A' ' 58' ' ' VAL . 0.0 OUTLIER -98.37 106.59 18.89 Favored 'General case' 0 N--CA 1.47 0.536 0 C-N-CA 123.226 0.61 . . . . 0.0 110.477 178.127 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.6 t -153.35 170.37 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 125.231 1.412 . . . . 0.0 108.567 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . 0.49 ' HB1' ' HA3' ' A' ' 7' ' ' GLY . . . -61.5 -20.89 63.7 Favored 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 124.547 1.139 . . . . 0.0 113.632 175.053 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 9.0 m -129.27 -40.43 1.46 Allowed 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 125.519 1.528 . . . . 0.0 114.621 178.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.91 159.27 20.15 Favored 'General case' 0 CA--C 1.545 0.768 0 CA-C-N 119.002 0.819 . . . . 0.0 112.484 176.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.254 1.328 0 C-N-CA 126.447 1.899 . . . . 0.0 111.945 175.566 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.161 0 CA-C-O 120.605 0.24 . . . . 0.0 110.414 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.59 -165.66 36.28 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 123.806 0.717 . . . . 0.0 113.402 -175.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 82.5 m-70 -98.89 146.26 26.16 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 124.463 1.105 . . . . 0.0 111.135 174.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 7.7 ptp -111.93 157.22 40.25 Favored Pre-proline 0 CA--C 1.547 0.831 0 C-N-CA 125.772 1.629 . . . . 0.0 111.523 178.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -71.52 132.67 20.94 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 123.99 3.127 . . . . 0.0 111.095 175.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -168.17 174.37 7.24 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 126.201 1.8 . . . . 0.0 111.077 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 145.94 179.63 22.3 Favored Glycine 0 CA--C 1.534 1.235 0 C-N-CA 125.627 1.584 . . . . 0.0 112.85 178.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 15.9 p -151.95 116.33 5.03 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.376 1.47 . . . . 0.0 111.369 -178.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -164.99 -172.99 2.76 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 125.624 1.57 . . . . 0.0 111.564 179.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 22.2 m -64.15 172.07 2.63 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 125.509 1.524 . . . . 0.0 112.116 174.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 39.6 mt -84.06 55.64 3.39 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 124.589 1.156 . . . . 0.0 112.402 -177.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.32 117.27 7.73 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 124.049 0.94 . . . . 0.0 111.72 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.94 126.56 30.24 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.096 0.958 . . . . 0.0 110.803 176.26 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -124.79 169.85 11.61 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.141 1.377 . . . . 0.0 112.316 177.193 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.42 129.11 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 O-C-N 121.414 -0.803 . . . . 0.0 110.567 176.305 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.26 -6.15 75.29 Favored Glycine 0 CA--C 1.534 1.231 0 C-N-CA 125.075 1.322 . . . . 0.0 114.901 -179.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -68.77 176.74 2.86 Favored 'General case' 0 CA--C 1.549 0.917 0 CA-C-N 119.068 1.434 . . . . 0.0 111.883 174.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.9 mmt180 -113.08 139.57 48.59 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.564 1.545 . . . . 0.0 111.35 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.419 HG21 ' CE ' ' A' ' 47' ' ' MET . 15.1 m -139.71 137.09 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 C-N-CA 124.204 1.002 . . . . 0.0 109.477 -178.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.5 p -137.04 137.99 46.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 124.151 0.981 . . . . 0.0 110.085 177.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.465 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 1.3 m-85 -71.67 161.95 75.77 Favored Pre-proline 0 CA--C 1.546 0.826 0 N-CA-C 112.113 0.412 . . . . 0.0 112.113 175.39 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.498 ' CD ' HG12 ' A' ' 68' ' ' VAL . 59.9 Cg_endo -70.11 -28.54 23.46 Favored 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.43 2.753 . . . . 0.0 112.265 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 32.3 m-20 -157.95 64.4 0.46 Allowed 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 127.026 2.13 . . . . 0.0 111.357 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 5.4 mm-40 -151.9 -71.07 0.16 Allowed 'General case' 0 N--CA 1.479 1.021 0 O-C-N 120.794 -1.191 . . . . 0.0 111.776 174.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 173.55 174.09 40.28 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.403 1.478 . . . . 0.0 112.406 -174.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.5 p -84.39 149.3 4.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 124.949 1.299 . . . . 0.0 110.704 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.553 ' SG ' HG11 ' A' ' 56' ' ' VAL . 4.7 m -128.82 174.59 9.34 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 125.774 1.63 . . . . 0.0 110.52 175.069 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -131.82 118.82 20.4 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 124.004 0.922 . . . . 0.0 110.9 -178.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.2 t -57.82 126.88 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 C-N-CA 124.111 0.964 . . . . 0.0 110.593 -179.399 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.9 t -111.01 -51.88 2.83 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 125.135 1.374 . . . . 0.0 110.984 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.81 169.87 21.72 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 124.861 1.265 . . . . 0.0 111.064 177.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 62.0 mt -145.2 138.68 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 124.722 1.209 . . . . 0.0 108.457 175.042 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -150.26 167.0 28.24 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 124.853 1.261 . . . . 0.0 112.158 175.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 13.8 m -106.77 143.09 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.109 0.964 . . . . 0.0 110.908 176.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -155.25 170.82 20.97 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 124.623 1.169 . . . . 0.0 111.795 175.423 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -106.28 116.22 31.57 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.949 1.699 . . . . 0.0 109.697 175.001 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.8 p -125.62 138.03 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 C-N-CA 124.462 1.105 . . . . 0.0 110.725 174.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.53 29.09 1.95 Allowed 'General case' 0 CA--C 1.556 1.208 0 C-N-CA 124.856 1.262 . . . . 0.0 114.26 -179.019 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.35 27.04 53.36 Favored Glycine 0 CA--C 1.54 1.604 0 C-N-CA 125.2 1.381 . . . . 0.0 115.613 -174.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.8 tp60 -135.14 113.54 11.48 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.761 1.624 . . . . 0.0 110.436 -175.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 18.6 tttt -96.28 114.86 26.58 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 124.899 1.28 . . . . 0.0 111.25 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.5 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -157.59 173.07 17.42 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 123.155 0.582 . . . . 0.0 111.765 179.532 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 17.2 m -79.73 116.58 19.99 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.367 1.067 . . . . 0.0 111.595 175.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -102.38 114.5 28.73 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.03 0.932 . . . . 0.0 109.763 175.028 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.513 HG13 ' CG ' ' A' ' 60' ' ' GLU . 5.7 m -66.87 145.27 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 O-C-N 121.863 -0.523 . . . . 0.0 110.783 174.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -126.65 109.8 12.49 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.532 1.133 . . . . 0.0 111.109 -179.445 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . 0.439 ' HB2' HG13 ' A' ' 56' ' ' VAL . 1.8 mpp? -123.22 160.72 25.99 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 124.229 1.011 . . . . 0.0 110.546 -177.144 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.605 ' HG3' HG12 ' A' ' 55' ' ' VAL . 0.1 OUTLIER -134.64 134.03 40.74 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.875 0.87 . . . . 0.0 110.905 174.859 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 60.9 mtm180 -94.27 108.76 20.62 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 124.824 1.25 . . . . 0.0 108.209 176.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -69.53 -17.78 63.61 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.343 1.057 . . . . 0.0 113.562 175.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -55.49 -42.12 73.98 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 126.032 1.733 . . . . 0.0 112.538 178.338 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -121.97 -20.25 6.39 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 125.474 1.509 . . . . 0.0 113.387 177.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.47 49.15 4.5 Favored Glycine 0 CA--C 1.532 1.14 0 C-N-CA 125.305 1.431 . . . . 0.0 113.122 -177.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -125.37 159.98 30.47 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.097 1.359 . . . . 0.0 112.163 178.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.605 HG12 ' HG3' ' A' ' 48' ' ' ARG . 27.1 m -98.41 158.62 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.431 1.092 . . . . 0.0 111.117 176.288 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.553 HG11 ' SG ' ' A' ' 27' ' ' CYS . 3.4 p -150.17 122.86 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 125.271 1.428 . . . . 0.0 109.324 175.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 26.0 ptm -126.9 139.44 53.07 Favored 'General case' 0 C--O 1.233 0.211 0 C-N-CA 124.098 0.959 . . . . 0.0 111.018 175.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 27.0 m -142.82 154.73 62.75 Favored Pre-proline 0 N--CA 1.468 0.473 0 C-N-CA 123.986 0.914 . . . . 0.0 111.469 177.385 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.5 ' CB ' HD11 ' A' ' 42' ' ' LEU . 43.6 Cg_endo -74.8 119.92 5.9 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.156 2.571 . . . . 0.0 114.381 177.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.513 ' CG ' HG13 ' A' ' 45' ' ' VAL . 14.1 mt-10 -62.09 -39.93 94.11 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 178.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.27 7.71 78.01 Favored Glycine 0 N--CA 1.475 1.273 0 C-N-CA 124.677 1.132 . . . . 0.0 114.762 178.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 7.9 tttt -135.53 5.56 3.19 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.775 1.63 . . . . 0.0 112.451 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.462 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -49.65 -29.36 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 C-N-CA 125.329 1.452 . . . . 0.0 113.476 174.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 11.4 mt -58.01 -28.68 64.67 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.003 1.721 . . . . 0.0 112.286 177.178 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.42 -51.01 14.07 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 125.834 1.653 . . . . 0.0 112.218 177.202 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.485 HG22 HG13 ' A' ' 68' ' ' VAL . 4.5 mp -67.53 -29.47 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 124.375 1.07 . . . . 0.0 111.216 176.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 84.61 8.39 83.06 Favored Glycine 0 CA--C 1.536 1.358 0 C-N-CA 125.815 1.674 . . . . 0.0 114.069 -176.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.498 HG12 ' CD ' ' A' ' 22' ' ' PRO . 17.0 m -90.84 123.32 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 125.373 1.469 . . . . 0.0 111.345 -175.302 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.35 109.6 21.51 Favored 'General case' 0 N--CA 1.469 0.507 0 O-C-N 120.881 -1.137 . . . . 0.0 109.434 178.224 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.61 106.63 17.72 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.989 0.916 . . . . 0.0 109.06 177.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 85.8 t -150.41 -75.81 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 124.68 1.192 . . . . 0.0 111.246 179.437 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -177.57 -45.44 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 127.666 2.386 . . . . 0.0 111.186 -179.094 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -127.33 -1.69 6.3 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 126.49 1.916 . . . . 0.0 113.957 -178.393 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -73.71 -53.6 10.0 Favored 'General case' 0 CA--C 1.548 0.889 0 C-N-CA 125.332 1.453 . . . . 0.0 113.069 -176.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . 0.315 13.3 pt-20 . . . . . 0 N--CA 1.486 1.349 0 C-N-CA 131.571 3.948 . . . . 0.0 118.524 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.183 0 CA-C-O 120.666 0.269 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.86 39.82 0.39 Allowed Glycine 0 N--CA 1.475 1.285 0 C-N-CA 124.043 0.83 . . . . 0.0 114.441 -175.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 37.6 m170 -80.81 105.94 12.43 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 124.406 1.082 . . . . 0.0 111.781 177.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.3 mtm -67.64 161.09 68.94 Favored Pre-proline 0 CA--C 1.551 1.002 0 C-N-CA 124.63 1.172 . . . . 0.0 112.157 174.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -72.42 89.55 0.82 Allowed 'Trans proline' 0 CA--C 1.547 1.131 0 C-N-CA 124.491 3.461 . . . . 0.0 112.942 -179.337 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 10.2 mt-10 -75.39 -63.87 1.19 Allowed 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 124.35 1.06 . . . . 0.0 113.585 174.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 82.83 -110.79 3.29 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 124.706 1.146 . . . . 0.0 113.335 -178.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.7 t -144.01 173.28 11.86 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 125.078 1.351 . . . . 0.0 112.436 -178.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -82.41 63.39 6.56 Favored 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 125.979 1.712 . . . . 0.0 112.263 -179.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.5 m -142.06 169.25 17.94 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 125.701 1.601 . . . . 0.0 111.73 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -109.03 -45.37 3.79 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 124.988 1.315 . . . . 0.0 111.429 174.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 40.3 mt-30 -68.12 170.08 9.1 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 124.681 1.192 . . . . 0.0 111.834 176.233 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.642 HD23 ' HA ' ' A' ' 71' ' ' VAL . 0.3 OUTLIER -107.24 126.84 52.94 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 125.013 1.325 . . . . 0.0 111.1 -179.48 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.0 177.28 8.16 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 125.711 1.604 . . . . 0.0 112.184 176.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.8 t -59.69 129.3 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.175 0.99 . . . . 0.0 110.777 175.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.66 -4.68 85.76 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 124.835 1.207 . . . . 0.0 115.151 -177.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -70.83 165.75 22.5 Favored 'General case' 0 CA--C 1.549 0.916 0 CA-C-N 119.211 1.506 . . . . 0.0 111.613 174.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.5 mmt180 -89.56 148.73 23.21 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.902 0.881 . . . . 0.0 111.883 177.232 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.8 m -147.48 138.88 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 125.976 1.71 . . . . 0.0 109.184 176.266 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.0 p -137.11 146.33 28.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 C-N-CA 124.741 1.216 . . . . 0.0 110.483 176.273 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.5 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.8 OUTLIER -84.19 158.77 60.69 Favored Pre-proline 0 CA--C 1.548 0.867 0 C-N-CA 123.409 0.684 . . . . 0.0 111.959 175.168 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.433 ' CD ' HG12 ' A' ' 68' ' ' VAL . 71.6 Cg_endo -68.69 -25.91 33.59 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 123.809 3.006 . . . . 0.0 112.993 -178.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -160.2 62.62 0.34 Allowed 'General case' 0 CA--C 1.554 1.118 0 C-N-CA 124.764 1.226 . . . . 0.0 112.316 177.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.86 -68.53 0.17 Allowed 'General case' 0 N--CA 1.48 1.053 0 O-C-N 120.988 -1.07 . . . . 0.0 112.222 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.42 179.82 43.5 Favored Glycine 0 CA--C 1.534 1.221 0 C-N-CA 125.04 1.305 . . . . 0.0 113.215 -174.36 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.7 m -94.94 149.96 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.466 1.506 . . . . 0.0 111.38 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.4 m -133.85 -177.85 4.75 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 124.622 1.169 . . . . 0.0 111.544 174.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -137.85 124.59 21.08 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.365 1.466 . . . . 0.0 111.749 177.236 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.557 HG21 HD11 ' A' ' 13' ' ' LEU . 61.1 t -63.47 126.74 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.036 0 C-N-CA 124.735 1.214 . . . . 0.0 111.173 -177.307 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 21.6 t -109.37 -53.92 2.6 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.049 1.34 . . . . 0.0 111.869 -177.092 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -151.68 162.02 41.7 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 125.142 1.377 . . . . 0.0 111.042 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -141.44 136.53 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 124.649 1.18 . . . . 0.0 108.55 -179.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -144.42 172.1 13.42 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 123.942 0.897 . . . . 0.0 111.773 177.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.3 p -120.54 138.29 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 O-C-N 120.691 -1.256 . . . . 0.0 110.758 175.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.89 164.29 36.66 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.175 1.39 . . . . 0.0 111.543 178.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -97.48 118.88 34.96 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 125.204 1.401 . . . . 0.0 109.77 174.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.3 p -123.54 135.47 63.22 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 124.303 1.041 . . . . 0.0 109.783 174.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 49.09 29.13 2.35 Favored 'General case' 0 CA--C 1.557 1.245 0 N-CA-C 114.625 1.343 . . . . 0.0 114.625 -177.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.01 25.28 52.9 Favored Glycine 0 CA--C 1.54 1.646 0 C-N-CA 124.787 1.184 . . . . 0.0 115.188 -176.184 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -139.44 116.78 11.24 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.35 1.46 . . . . 0.0 111.175 -174.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 3.5 tttt -95.21 124.81 39.45 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 124.83 1.252 . . . . 0.0 111.656 -178.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.613 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -158.17 162.97 37.97 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 123.033 0.533 . . . . 0.0 111.697 179.428 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.3 m -69.37 116.43 9.79 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 124.192 0.997 . . . . 0.0 111.147 177.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -105.2 113.14 26.56 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 124.875 1.27 . . . . 0.0 110.068 175.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.532 HG21 ' CD ' ' A' ' 70' ' ' LYS . 30.1 m -81.42 144.06 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.838 177.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 26.2 m -126.55 117.12 22.17 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.277 1.031 . . . . 0.0 110.735 178.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 1.5 mpp? -119.15 156.17 30.28 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 124.818 1.247 . . . . 0.0 110.116 -176.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -132.09 136.35 47.11 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.184 1.394 . . . . 0.0 110.259 -178.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 13.0 mtm180 -98.36 109.12 21.93 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 177.076 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -70.28 -15.46 62.9 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 123.239 0.616 . . . . 0.0 112.557 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -57.57 -42.18 82.56 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 126.779 2.031 . . . . 0.0 112.961 176.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -128.66 -15.41 4.45 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 124.874 1.27 . . . . 0.0 114.111 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.23 4.99 64.11 Favored Glycine 0 CA--C 1.538 1.5 0 C-N-CA 126.105 1.812 . . . . 0.0 114.952 -177.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -74.07 163.47 27.84 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 118.644 1.222 . . . . 0.0 112.819 177.449 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 15.9 m -126.32 156.12 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 125.592 1.557 . . . . 0.0 110.727 174.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 23.3 m -140.13 150.94 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 125.951 1.701 . . . . 0.0 109.898 176.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 62.9 ttp -145.03 122.08 11.4 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.791 0.836 . . . . 0.0 110.139 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.6 m -130.4 155.14 81.45 Favored Pre-proline 0 N--CA 1.476 0.84 0 C-N-CA 124.034 0.934 . . . . 0.0 112.17 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.613 ' CB ' HD11 ' A' ' 42' ' ' LEU . 52.3 Cg_endo -76.05 115.82 4.24 Favored 'Trans proline' 0 CA--C 1.538 0.698 0 C-N-CA 123.486 2.791 . . . . 0.0 114.438 176.742 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -64.63 -34.02 77.29 Favored 'General case' 0 N--CA 1.479 0.992 0 O-C-N 120.335 -1.478 . . . . 0.0 114.013 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.23 5.06 78.03 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 124.403 1.001 . . . . 0.0 114.876 176.32 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 2.6 tttm -135.57 3.34 3.03 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.493 1.517 . . . . 0.0 112.922 -177.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.43 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.6 m -49.7 -29.53 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 C-N-CA 125.685 1.594 . . . . 0.0 113.308 175.612 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 13.6 mt -57.62 -28.9 64.08 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 126.093 1.757 . . . . 0.0 112.302 177.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.81 -49.92 16.65 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.974 1.709 . . . . 0.0 112.854 175.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.432 HG22 HG13 ' A' ' 68' ' ' VAL . 3.8 mp -67.85 -33.21 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 124.013 0.925 . . . . 0.0 111.37 177.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 91.68 3.68 68.43 Favored Glycine 0 CA--C 1.537 1.434 0 C-N-CA 125.776 1.655 . . . . 0.0 114.239 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.5 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 29.1 m -87.47 123.18 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 125.045 1.338 . . . . 0.0 110.616 -176.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -104.46 109.28 21.1 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 120.625 -1.297 . . . . 0.0 108.652 176.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.532 ' CD ' HG21 ' A' ' 45' ' ' VAL . 0.0 OUTLIER -106.85 106.52 17.09 Favored 'General case' 0 N--CA 1.468 0.475 0 C-N-CA 123.1 0.56 . . . . 0.0 109.532 177.397 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.642 ' HA ' HD23 ' A' ' 13' ' ' LEU . 0.6 OUTLIER -157.74 169.07 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 C-N-CA 124.987 1.315 . . . . 0.0 110.212 -175.019 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -56.29 -19.62 15.08 Favored 'General case' 0 CA--C 1.551 0.992 0 N-CA-C 115.152 1.538 . . . . 0.0 115.152 177.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 47.2 m -137.5 -48.66 0.58 Allowed 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 125.483 1.513 . . . . 0.0 113.516 174.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.429 ' HB3' ' CG2' ' A' ' 71' ' ' VAL . . . -58.77 147.25 33.98 Favored 'General case' 0 CA--C 1.552 1.024 0 C-N-CA 124.479 1.112 . . . . 0.0 113.453 -179.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 . . . . . 0 C--O 1.256 1.428 0 C-N-CA 129.13 2.972 . . . . 0.0 112.397 -172.468 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.242 0 CA-C-O 120.858 0.361 . . . . 0.0 110.89 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 139.25 61.95 0.04 OUTLIER Glycine 0 N--CA 1.476 1.315 0 C-N-CA 124.441 1.019 . . . . 0.0 113.705 -179.213 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 23.5 t60 -75.05 157.85 34.15 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 117.653 0.726 . . . . 0.0 111.65 175.372 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.8 mtt -71.83 161.01 81.01 Favored Pre-proline 0 CA--C 1.545 0.768 0 O-C-N 121.863 -0.523 . . . . 0.0 111.587 175.038 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -65.1 152.59 81.78 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 122.611 2.207 . . . . 0.0 109.404 175.007 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -138.07 -54.59 0.65 Allowed 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 123.875 0.87 . . . . 0.0 113.243 177.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 79.93 164.63 29.92 Favored Glycine 0 CA--C 1.539 1.566 0 C-N-CA 124.119 0.866 . . . . 0.0 114.527 -177.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 78.9 p -156.48 97.57 1.75 Allowed 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.18 1.392 . . . . 0.0 112.31 178.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.706 ' HB3' ' HB2' ' A' ' 72' ' ' ALA . . . -156.43 173.53 16.76 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 126.035 1.734 . . . . 0.0 110.988 174.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 55.6 m -66.54 -74.24 0.12 Allowed 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 124.642 1.177 . . . . 0.0 111.952 176.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 53.0 mt -123.6 -80.02 0.62 Allowed 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 125.915 1.686 . . . . 0.0 110.183 -178.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 21.4 mt-30 -64.24 163.59 12.54 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 126.432 1.893 . . . . 0.0 113.182 174.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.641 HD13 ' HE2' ' A' ' 70' ' ' LYS . 1.4 tt -65.44 150.45 48.32 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 124.148 0.979 . . . . 0.0 111.671 175.487 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -143.77 177.36 8.57 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 125.544 1.538 . . . . 0.0 112.214 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 97.5 t -60.02 130.96 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 O-C-N 121.082 -1.012 . . . . 0.0 110.796 178.049 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.32 -2.57 88.06 Favored Glycine 0 CA--C 1.537 1.455 0 C-N-CA 124.809 1.195 . . . . 0.0 115.02 -179.228 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -71.09 -179.84 2.5 Favored 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 125.22 1.408 . . . . 0.0 112.539 176.095 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 26.7 mmt180 -112.44 154.08 26.37 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 124.953 1.301 . . . . 0.0 112.966 -178.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 2.4 p -152.63 126.83 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 125.77 1.628 . . . . 0.0 110.493 -179.073 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.0 p -135.6 120.08 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 C-N-CA 126.79 2.036 . . . . 0.0 110.486 174.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 -58.65 156.61 22.9 Favored Pre-proline 0 CA--C 1.544 0.74 0 O-C-N 121.055 -1.028 . . . . 0.0 112.281 175.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.423 ' CD ' HG22 ' A' ' 68' ' ' VAL . 60.0 Cg_endo -67.16 -24.59 44.25 Favored 'Trans proline' 0 CA--C 1.539 0.77 0 C-N-CA 122.716 2.277 . . . . 0.0 112.52 -176.312 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -157.78 62.48 0.47 Allowed 'General case' 0 CA--C 1.555 1.149 0 C-N-CA 124.809 1.244 . . . . 0.0 112.444 175.528 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 1.9 mm-40 -150.24 -66.37 0.2 Allowed 'General case' 0 N--CA 1.483 1.189 0 O-C-N 120.841 -1.162 . . . . 0.0 112.451 179.362 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 166.01 175.17 36.19 Favored Glycine 0 CA--C 1.533 1.198 0 C-N-CA 124.929 1.252 . . . . 0.0 113.451 -178.074 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 38.4 t -93.42 145.64 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 125.929 1.692 . . . . 0.0 110.818 -177.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.3 m -130.34 178.41 6.61 Favored 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 126.503 1.921 . . . . 0.0 111.116 174.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.3 130.48 44.55 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 126.128 1.771 . . . . 0.0 110.658 -179.304 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.402 HG21 HD21 ' A' ' 13' ' ' LEU . 35.7 t -68.05 125.47 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 124.61 1.164 . . . . 0.0 110.903 178.355 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.9 p -109.3 -41.16 4.72 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.728 0.811 . . . . 0.0 112.776 178.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -160.5 173.3 15.77 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 126.746 2.018 . . . . 0.0 110.659 175.754 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.432 HD11 HD23 ' A' ' 13' ' ' LEU . 64.2 mt -146.88 139.87 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.311 1.444 . . . . 0.0 108.728 174.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -146.62 172.72 13.17 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.803 1.241 . . . . 0.0 112.116 174.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.43 HG12 ' HA ' ' A' ' 43' ' ' THR . 20.6 m -115.81 142.63 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.344 1.058 . . . . 0.0 110.523 176.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -157.89 171.95 19.35 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.895 0.878 . . . . 0.0 112.18 176.663 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.61 115.17 29.93 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.906 1.682 . . . . 0.0 110.464 174.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 m -121.97 138.72 51.28 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 124.811 1.244 . . . . 0.0 109.092 174.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 46.06 28.99 0.7 Allowed 'General case' 0 CA--C 1.559 1.317 0 N-CA-C 115.391 1.626 . . . . 0.0 115.391 179.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.11 24.22 52.77 Favored Glycine 0 CA--C 1.544 1.895 0 C-N-CA 124.892 1.234 . . . . 0.0 115.88 -175.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 7.4 tp60 -135.39 113.52 11.29 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.593 1.957 . . . . 0.0 110.268 -174.305 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -95.37 113.38 25.04 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 125.121 1.369 . . . . 0.0 111.218 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.557 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -156.19 173.65 16.53 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.375 0.67 . . . . 0.0 112.049 179.537 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.43 ' HA ' HG12 ' A' ' 34' ' ' VAL . 10.0 m -76.88 116.37 17.49 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 124.338 1.055 . . . . 0.0 111.895 175.309 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -106.54 115.33 30.01 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.971 1.308 . . . . 0.0 109.222 175.248 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.694 HG11 ' HE3' ' A' ' 70' ' ' LYS . 13.6 m -63.94 153.5 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 O-C-N 121.877 -0.514 . . . . 0.0 111.609 176.001 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 10.9 m -126.48 109.82 12.61 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 122.137 0.97 . . . . 0.0 111.043 175.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . 0.534 ' HB2' HG13 ' A' ' 56' ' ' VAL . 0.2 OUTLIER -128.89 155.77 44.74 Favored 'General case' 0 C--O 1.236 0.38 0 C-N-CA 124.703 1.201 . . . . 0.0 109.865 -178.704 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -131.08 125.54 33.44 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.893 1.277 . . . . 0.0 110.183 176.349 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.0 ttm-85 -85.08 109.06 17.96 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.524 1.13 . . . . 0.0 109.123 175.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.68 -15.38 63.16 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 176.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -62.23 -35.46 78.97 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.18 1.792 . . . . 0.0 112.779 -177.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 29.8 p30 -128.63 -16.68 4.23 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 126.637 1.975 . . . . 0.0 114.129 175.053 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.65 4.66 63.64 Favored Glycine 0 CA--C 1.538 1.49 0 C-N-CA 126.137 1.827 . . . . 0.0 115.086 -177.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -77.1 168.9 19.29 Favored 'General case' 0 CA--C 1.546 0.798 0 CA-C-N 119.387 1.594 . . . . 0.0 113.149 178.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 m -111.48 157.59 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 125.092 1.357 . . . . 0.0 111.138 175.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.534 HG13 ' HB2' ' A' ' 47' ' ' MET . 4.4 p -147.48 118.86 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 124.517 1.127 . . . . 0.0 110.017 179.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -132.93 97.01 3.91 Favored 'General case' 0 C--O 1.234 0.241 0 C-N-CA 124.822 1.249 . . . . 0.0 110.076 -178.02 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 36.0 m -99.86 157.24 34.25 Favored Pre-proline 0 N--CA 1.472 0.638 0 C-N-CA 123.369 0.668 . . . . 0.0 111.684 176.708 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.557 ' CB ' HD11 ' A' ' 42' ' ' LEU . 45.9 Cg_endo -77.22 118.75 4.77 Favored 'Trans proline' 0 CA--C 1.536 0.608 0 C-N-CA 123.488 2.792 . . . . 0.0 114.558 175.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.406 ' CG ' HG13 ' A' ' 45' ' ' VAL . 14.9 mt-10 -61.6 -38.98 89.59 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 120.479 -1.388 . . . . 0.0 114.22 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.14 5.97 78.57 Favored Glycine 0 N--CA 1.476 1.338 0 C-N-CA 124.723 1.154 . . . . 0.0 115.027 178.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 17.9 tttp -133.21 3.37 3.66 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 125.751 1.62 . . . . 0.0 112.597 -178.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.3 m -48.33 -29.63 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 125.428 1.491 . . . . 0.0 113.726 175.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 17.2 mt -54.71 -30.64 56.51 Favored 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 126.024 1.73 . . . . 0.0 112.492 176.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.07 -48.69 22.66 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 125.734 1.613 . . . . 0.0 112.872 176.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.445 HG22 HG23 ' A' ' 68' ' ' VAL . 4.0 mp -66.74 -32.52 58.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.431 1.093 . . . . 0.0 111.285 176.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 87.05 3.99 82.22 Favored Glycine 0 CA--C 1.536 1.381 0 C-N-CA 125.545 1.545 . . . . 0.0 114.014 -176.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.445 HG23 HG22 ' A' ' 66' ' ' ILE . 93.2 t -81.51 147.95 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 C-N-CA 124.598 1.159 . . . . 0.0 109.888 175.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.73 124.54 49.89 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 104.745 -2.317 . . . . 0.0 104.745 175.008 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.694 ' HE3' HG11 ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.3 106.56 5.25 Favored 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 124.497 1.119 . . . . 0.0 108.269 177.301 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.522 HG12 ' H ' ' A' ' 72' ' ' ALA . 1.1 t -159.49 173.43 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 C-N-CA 124.901 1.28 . . . . 0.0 110.347 -174.521 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . 0.706 ' HB2' ' HB3' ' A' ' 9' ' ' ALA . . . -59.94 -15.32 20.91 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.348 1.859 . . . . 0.0 115.551 -179.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -137.19 -47.02 0.57 Allowed 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 126.271 1.828 . . . . 0.0 110.904 175.688 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -78.2 62.5 2.92 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 125.379 1.472 . . . . 0.0 110.018 174.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.259 1.566 0 C-N-CA 125.339 1.456 . . . . 0.0 114.857 176.267 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.276 0 CA-C-O 120.339 0.114 . . . . 0.0 111.147 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.65 88.52 0.08 OUTLIER Glycine 0 N--CA 1.474 1.171 0 C-N-CA 123.922 0.772 . . . . 0.0 113.185 179.347 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 34.1 m80 -82.68 161.81 22.03 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 124.119 0.968 . . . . 0.0 111.677 174.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 15.4 ptm -60.33 156.87 38.03 Favored Pre-proline 0 CA--C 1.55 0.968 0 C-N-CA 124.708 1.203 . . . . 0.0 112.904 175.31 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -72.4 88.25 0.88 Allowed 'Trans proline' 0 CA--C 1.542 0.896 0 C-N-CA 124.228 3.285 . . . . 0.0 111.843 179.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -121.57 146.75 46.65 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 126.354 1.862 . . . . 0.0 110.97 178.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 178.35 87.6 0.07 OUTLIER Glycine 0 CA--C 1.533 1.203 0 C-N-CA 123.905 0.764 . . . . 0.0 113.635 -178.478 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 36.7 p -81.83 83.91 7.04 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.024 1.329 . . . . 0.0 112.512 178.323 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -140.98 -48.49 0.41 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.164 1.386 . . . . 0.0 113.347 179.634 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.0 m -148.43 156.35 42.37 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 125.812 1.645 . . . . 0.0 111.8 175.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -94.71 -33.15 13.04 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.842 1.257 . . . . 0.0 112.428 176.01 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -66.68 156.3 35.64 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 124.45 1.1 . . . . 0.0 112.604 175.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.459 HD21 ' HA ' ' A' ' 71' ' ' VAL . 4.1 mm? -95.01 113.98 25.74 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 125.392 1.477 . . . . 0.0 110.578 -179.581 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.74 175.5 9.66 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 125.871 1.668 . . . . 0.0 111.254 179.006 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 59.7 t -58.05 129.8 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 123.811 0.844 . . . . 0.0 110.772 176.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 86.52 -5.25 85.07 Favored Glycine 0 CA--C 1.536 1.359 0 C-N-CA 125.136 1.351 . . . . 0.0 115.2 -175.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -69.72 163.28 26.03 Favored 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 119.836 1.818 . . . . 0.0 112.099 175.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -101.04 130.87 47.11 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.71 1.204 . . . . 0.0 111.06 -175.494 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.6 m -142.34 143.3 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.797 0.839 . . . . 0.0 110.326 -178.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.4 p -137.08 148.22 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 C-N-CA 124.526 1.13 . . . . 0.0 110.685 178.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.436 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 1.0 OUTLIER -79.15 161.13 69.23 Favored Pre-proline 0 CA--C 1.549 0.919 0 O-C-N 121.853 -0.529 . . . . 0.0 111.655 175.091 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -71.57 -22.33 24.57 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 123.312 2.675 . . . . 0.0 112.837 -177.24 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 16.2 t-20 -162.68 68.29 0.23 Allowed 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 126.273 1.829 . . . . 0.0 111.296 175.007 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -156.28 -71.83 0.11 Allowed 'General case' 0 N--CA 1.482 1.141 0 O-C-N 121.15 -0.968 . . . . 0.0 112.319 177.224 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 176.43 172.93 41.6 Favored Glycine 0 CA--C 1.534 1.222 0 C-N-CA 124.548 1.07 . . . . 0.0 113.734 -176.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.1 m -85.86 148.47 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 125.187 1.395 . . . . 0.0 111.231 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.404 ' SG ' HG11 ' A' ' 56' ' ' VAL . 15.6 m -137.18 171.87 13.85 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.996 1.718 . . . . 0.0 110.921 179.535 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -137.71 120.01 15.78 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 124.414 1.086 . . . . 0.0 110.596 -175.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -63.73 124.78 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 123.615 0.766 . . . . 0.0 111.518 -174.106 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 86.1 p -107.43 -40.95 5.21 Favored 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 -177.769 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.43 162.78 35.75 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.489 1.516 . . . . 0.0 110.839 176.127 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 67.8 mt -141.83 134.87 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.781 0 O-C-N 121.029 -1.044 . . . . 0.0 109.076 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -142.72 177.64 8.18 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 124.269 1.028 . . . . 0.0 111.854 178.017 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 p -127.31 137.09 58.8 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 C-N-CA 124.963 1.305 . . . . 0.0 110.425 176.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.43 165.81 32.01 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 124.698 1.199 . . . . 0.0 111.963 178.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -97.89 118.93 35.56 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 125.088 1.355 . . . . 0.0 109.763 174.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.9 p -124.43 134.9 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 C-N-CA 124.251 1.02 . . . . 0.0 109.562 175.112 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.75 29.0 2.05 Favored 'General case' 0 CA--C 1.556 1.2 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 -177.208 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.99 25.66 51.67 Favored Glycine 0 CA--C 1.541 1.708 0 C-N-CA 124.616 1.103 . . . . 0.0 115.174 -176.266 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -137.43 119.73 15.74 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 126.02 1.728 . . . . 0.0 111.053 -178.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 13.7 ttpt -96.12 124.34 40.08 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.636 1.175 . . . . 0.0 111.582 178.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.603 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -157.69 163.53 38.09 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.008 0.523 . . . . 0.0 111.805 178.771 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.8 m -68.64 116.58 9.33 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.997 0.919 . . . . 0.0 110.971 177.365 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -105.51 113.26 26.72 Favored 'General case' 0 N--CA 1.467 0.377 0 O-C-N 121.076 -1.015 . . . . 0.0 109.591 174.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.0 m -78.16 141.9 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 C-N-CA 123.486 0.714 . . . . 0.0 110.502 176.338 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 8.1 m -120.31 120.32 35.7 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.602 1.161 . . . . 0.0 109.281 176.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . 0.446 ' HB2' HG13 ' A' ' 56' ' ' VAL . 2.1 mpp? -123.18 157.49 32.88 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 124.703 1.201 . . . . 0.0 109.736 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 31.2 mtt85 -136.58 132.56 35.3 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 124.39 1.076 . . . . 0.0 109.875 -179.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -93.89 109.16 20.88 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 177.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -70.32 -14.37 62.55 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 113.815 1.043 . . . . 0.0 113.815 175.151 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -60.21 -36.97 78.88 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.459 1.504 . . . . 0.0 113.066 177.652 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -127.99 -23.31 3.36 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.459 1.503 . . . . 0.0 113.356 178.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 96.3 25.98 11.73 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 125.565 1.555 . . . . 0.0 114.42 -177.05 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.62 169.53 10.26 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.957 1.303 . . . . 0.0 112.752 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.7 m -124.4 154.38 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 125.255 1.422 . . . . 0.0 111.65 177.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.446 HG13 ' HB2' ' A' ' 47' ' ' MET . 2.8 p -151.1 123.47 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 C-N-CA 125.581 1.553 . . . . 0.0 109.689 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.9 ttt -125.83 121.21 32.61 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.625 1.17 . . . . 0.0 109.914 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 28.6 m -129.21 156.33 78.48 Favored Pre-proline 0 N--CA 1.478 0.932 0 C-N-CA 124.087 0.955 . . . . 0.0 112.112 -179.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.603 ' CB ' HD11 ' A' ' 42' ' ' LEU . 55.2 Cg_endo -77.84 114.58 3.66 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 123.628 2.885 . . . . 0.0 114.586 176.631 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -63.83 -33.72 76.32 Favored 'General case' 0 N--CA 1.481 1.096 0 O-C-N 120.271 -1.518 . . . . 0.0 113.957 179.422 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.19 4.43 77.53 Favored Glycine 0 N--CA 1.475 1.272 0 C-N-CA 124.459 1.028 . . . . 0.0 115.074 175.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.1 tttm -135.58 3.42 3.03 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 125.489 1.515 . . . . 0.0 112.978 -177.569 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.428 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.6 m -49.98 -30.77 6.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 125.598 1.559 . . . . 0.0 113.079 175.402 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.1 mt -56.51 -28.9 61.1 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 126.123 1.769 . . . . 0.0 112.494 177.227 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.95 -48.66 17.48 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.736 1.614 . . . . 0.0 112.66 177.223 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.442 HG22 HG13 ' A' ' 68' ' ' VAL . 2.9 mp -68.59 -30.55 47.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 124.085 0.954 . . . . 0.0 111.357 176.264 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.58 3.23 78.08 Favored Glycine 0 CA--C 1.537 1.416 0 C-N-CA 126.092 1.806 . . . . 0.0 114.309 -176.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.442 HG13 HG22 ' A' ' 66' ' ' ILE . 18.7 m -80.17 123.2 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.8 0 C-N-CA 125.596 1.558 . . . . 0.0 110.858 -178.541 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.66 109.39 20.97 Favored 'General case' 0 N--CA 1.472 0.653 0 O-C-N 120.847 -1.158 . . . . 0.0 108.881 175.103 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.13 106.6 17.15 Favored 'General case' 0 N--CA 1.471 0.576 0 O-C-N 121.749 -0.595 . . . . 0.0 109.76 176.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.459 ' HA ' HD21 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -157.48 166.58 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 125.668 1.587 . . . . 0.0 110.706 -176.383 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -52.64 -16.25 0.9 Allowed 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 126.875 2.07 . . . . 0.0 115.8 175.415 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 36.1 p -142.42 -52.52 0.4 Allowed 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 125.651 1.58 . . . . 0.0 113.34 175.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.422 ' HB3' ' CG2' ' A' ' 71' ' ' VAL . . . -54.45 145.61 17.97 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 125.585 1.554 . . . . 0.0 113.512 178.625 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 . . . . . 0 C--O 1.251 1.172 0 C-N-CA 127.81 2.444 . . . . 0.0 113.273 -177.937 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.185 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -164.36 46.22 0.3 Allowed Glycine 0 N--CA 1.473 1.153 0 C-N-CA 123.585 0.612 . . . . 0.0 113.836 -176.218 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -75.23 157.81 33.92 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.531 0.732 . . . . 0.0 111.859 175.469 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.78 162.23 22.72 Favored Pre-proline 0 CA--C 1.541 0.627 0 C-N-CA 125.45 1.5 . . . . 0.0 111.061 175.254 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -70.11 148.52 62.95 Favored 'Trans proline' 0 CA--C 1.54 0.819 0 C-N-CA 123.278 2.652 . . . . 0.0 110.857 175.079 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 179.18 -55.7 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 125.892 1.677 . . . . 0.0 112.182 176.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 91.88 -126.0 8.3 Favored Glycine 0 CA--C 1.535 1.322 0 C-N-CA 124.731 1.158 . . . . 0.0 112.298 -172.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.7 t -154.74 -45.9 0.09 Allowed 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 124.559 1.143 . . . . 0.0 112.995 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -121.41 163.52 18.58 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 125.891 1.676 . . . . 0.0 112.499 -178.329 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 27.8 t -95.99 90.08 5.44 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 125.241 1.416 . . . . 0.0 111.636 -178.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 5.6 mp -140.93 179.53 6.66 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 126.391 1.877 . . . . 0.0 111.322 179.681 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.9 mm-40 -62.6 161.04 12.79 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.516 1.126 . . . . 0.0 111.18 174.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.585 HD11 HG21 ' A' ' 29' ' ' VAL . 0.8 OUTLIER -66.53 129.75 40.88 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 123.864 0.866 . . . . 0.0 111.188 179.19 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -133.82 166.34 22.89 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 125.516 1.526 . . . . 0.0 112.297 179.538 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.8 t -56.65 135.76 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.399 1.08 . . . . 0.0 111.035 175.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.15 -13.01 60.72 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 125.635 1.588 . . . . 0.0 115.216 -176.515 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -72.88 170.0 15.66 Favored 'General case' 0 CA--C 1.549 0.921 0 CA-C-N 119.06 1.43 . . . . 0.0 111.376 175.075 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.9 mmt180 -108.56 142.81 38.45 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 126.194 1.797 . . . . 0.0 111.141 -171.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.468 HG21 ' CE ' ' A' ' 47' ' ' MET . 32.9 m -143.92 128.04 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 124.278 1.031 . . . . 0.0 111.769 -171.099 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 8.2 p -95.2 164.45 2.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 125.416 1.487 . . . . 0.0 111.052 176.092 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -137.01 156.6 75.66 Favored Pre-proline 0 CA--C 1.535 0.381 0 C-N-CA 124.571 1.148 . . . . 0.0 112.991 178.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.7 -28.84 30.36 Favored 'Trans proline' 0 CA--C 1.538 0.721 0 C-N-CA 123.038 2.492 . . . . 0.0 112.762 -178.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -151.88 54.28 0.83 Allowed 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 125.337 1.455 . . . . 0.0 111.919 178.435 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -145.01 -60.58 0.36 Allowed 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 124.332 1.053 . . . . 0.0 110.653 175.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 124.2 -169.4 16.28 Favored Glycine 0 CA--C 1.535 1.284 0 C-N-CA 126.413 1.958 . . . . 0.0 112.25 -173.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -72.42 136.51 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.642 1.177 . . . . 0.0 110.932 177.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 25.6 m -128.7 175.13 8.83 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 126.105 1.762 . . . . 0.0 111.777 175.229 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -130.57 119.02 21.89 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 126.242 1.817 . . . . 0.0 110.833 -179.258 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.585 HG21 HD11 ' A' ' 13' ' ' LEU . 47.5 t -64.61 127.87 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 123.691 0.796 . . . . 0.0 111.025 -178.608 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.7 p -112.5 -40.55 4.07 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.219 1.008 . . . . 0.0 112.699 -176.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -155.1 167.11 31.46 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 126.716 2.006 . . . . 0.0 110.656 175.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 60.7 mt -146.06 137.16 19.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.895 1.278 . . . . 0.0 108.504 176.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -146.02 171.92 14.15 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.01 0.924 . . . . 0.0 112.059 176.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.2 m -113.9 144.57 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 O-C-N 121.147 -0.971 . . . . 0.0 111.543 175.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 9.7 ptmt -156.25 171.99 19.23 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 124.854 1.262 . . . . 0.0 111.874 177.197 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -108.03 117.73 34.91 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.168 1.787 . . . . 0.0 109.79 174.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.3 p -127.67 138.21 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 124.843 1.257 . . . . 0.0 109.322 174.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.74 29.35 1.52 Allowed 'General case' 0 CA--C 1.557 1.23 0 N-CA-C 114.707 1.373 . . . . 0.0 114.707 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.0 24.39 57.84 Favored Glycine 0 CA--C 1.539 1.588 0 C-N-CA 125.281 1.42 . . . . 0.0 115.543 -176.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 8.8 mt-30 -132.55 113.54 13.19 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 126.106 1.762 . . . . 0.0 110.817 -175.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 67.3 tttt -95.96 114.35 26.05 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 125.085 1.354 . . . . 0.0 111.321 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.565 HD11 ' CB ' ' A' ' 59' ' ' PRO . 1.0 OUTLIER -157.89 173.61 16.53 Favored 'General case' 0 CA--C 1.546 0.801 0 C-N-CA 123.066 0.547 . . . . 0.0 111.791 -179.376 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 20.1 m -79.01 116.43 19.31 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.362 1.065 . . . . 0.0 112.122 175.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -105.04 115.83 30.94 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.512 1.125 . . . . 0.0 109.77 175.094 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.446 HG13 ' CG ' ' A' ' 60' ' ' GLU . 15.8 m -66.24 147.53 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.382 0.673 . . . . 0.0 111.245 176.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 19.7 m -123.27 110.06 14.72 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.723 0.809 . . . . 0.0 109.634 177.123 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . 0.468 ' CE ' HG21 ' A' ' 19' ' ' VAL . 0.0 OUTLIER -126.92 162.44 25.94 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 121.724 0.773 . . . . 0.0 110.929 178.409 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 3.0 ptt180 -144.88 116.81 8.28 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 124.801 1.24 . . . . 0.0 109.987 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 6.4 mtp85 -62.69 115.01 3.93 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 124.818 1.247 . . . . 0.0 110.602 179.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.2 pp20? -60.54 -36.03 77.44 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.658 0.783 . . . . 0.0 112.877 179.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -91.45 -46.73 7.83 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 123.889 0.875 . . . . 0.0 113.033 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -73.1 -19.41 61.16 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 113.543 0.942 . . . . 0.0 113.543 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.44 8.77 56.64 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 126.27 1.89 . . . . 0.0 115.151 -178.53 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.0 138.32 40.71 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.6 1.56 . . . . 0.0 112.246 -173.257 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 26.7 m -80.02 152.26 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 123.319 0.648 . . . . 0.0 110.023 174.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 13.6 p -145.23 138.7 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 124.514 1.125 . . . . 0.0 109.887 177.139 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 11.4 ttp -145.03 115.9 7.79 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 124.579 1.152 . . . . 0.0 110.004 -179.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.6 m -121.66 156.93 58.14 Favored Pre-proline 0 N--CA 1.472 0.673 0 C-N-CA 124.83 1.252 . . . . 0.0 111.27 177.021 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.565 ' CB ' HD11 ' A' ' 42' ' ' LEU . 55.8 Cg_endo -79.8 114.45 3.19 Favored 'Trans proline' 0 CA--C 1.537 0.637 0 C-N-CA 123.488 2.792 . . . . 0.0 114.954 178.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.446 ' CG ' HG13 ' A' ' 45' ' ' VAL . 18.9 mt-10 -58.39 -39.23 79.11 Favored 'General case' 0 N--CA 1.48 1.041 0 O-C-N 120.424 -1.422 . . . . 0.0 114.286 -178.496 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.06 7.32 78.78 Favored Glycine 0 N--CA 1.474 1.19 0 C-N-CA 124.751 1.167 . . . . 0.0 114.753 179.008 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.0 tttt -134.62 1.72 3.12 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.596 1.559 . . . . 0.0 112.888 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 59' ' ' PRO . 7.0 m -48.34 -30.74 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.593 1.557 . . . . 0.0 113.546 175.762 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.6 mt -57.66 -29.86 64.96 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 126.47 1.908 . . . . 0.0 112.735 176.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.99 -49.97 16.18 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.781 1.632 . . . . 0.0 112.635 176.025 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.3 mp -67.93 -32.22 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 C-N-CA 123.66 0.784 . . . . 0.0 111.31 177.757 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.52 9.41 66.76 Favored Glycine 0 CA--C 1.534 1.256 0 C-N-CA 125.532 1.539 . . . . 0.0 113.889 -174.446 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 12.2 m -75.8 155.89 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 118.317 1.058 . . . . 0.0 110.804 177.79 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -139.91 109.69 6.36 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.881 1.272 . . . . 0.0 110.221 175.264 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.445 ' HE3' ' O ' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -126.28 106.56 9.61 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 125.454 1.502 . . . . 0.0 110.65 177.528 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.493 ' HA ' HD23 ' A' ' 13' ' ' LEU . 3.5 t -160.09 157.91 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 127.173 2.189 . . . . 0.0 107.755 -177.131 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -55.26 -31.62 61.7 Favored 'General case' 0 CA--C 1.55 0.972 0 N-CA-C 113.415 0.895 . . . . 0.0 113.415 177.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -93.93 -26.91 16.66 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 124.83 1.252 . . . . 0.0 114.295 175.64 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.98 -18.58 65.45 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 124.059 0.943 . . . . 0.0 111.491 175.084 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 . . . . . 0 C--O 1.249 1.049 0 C-N-CA 127.465 2.306 . . . . 0.0 113.466 -169.674 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.263 0 CA-C-O 119.517 -0.278 . . . . 0.0 111.648 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -169.32 96.93 0.12 Allowed Glycine 0 CA--C 1.533 1.163 0 C-N-CA 124.277 0.942 . . . . 0.0 112.773 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -97.02 115.83 28.15 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 125.053 1.341 . . . . 0.0 111.713 177.521 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.28 161.86 44.84 Favored Pre-proline 0 CA--C 1.545 0.78 0 C-N-CA 124.109 0.964 . . . . 0.0 111.239 174.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.536 ' HG3' HG11 ' A' ' 20' ' ' VAL . 68.1 Cg_endo -68.33 115.52 3.9 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 123.916 3.078 . . . . 0.0 109.359 174.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -143.3 157.43 44.48 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.797 1.239 . . . . 0.0 111.708 177.632 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 135.8 175.16 13.68 Favored Glycine 0 CA--C 1.535 1.32 0 C-N-CA 125.4 1.476 . . . . 0.0 113.399 -178.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -153.55 18.28 0.54 Allowed 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 114.09 1.144 . . . . 0.0 114.09 179.291 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -53.96 -57.11 12.22 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 126.13 1.772 . . . . 0.0 114.155 -172.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.9 m -135.09 166.77 22.29 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 125.932 1.693 . . . . 0.0 111.416 178.609 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 11.0 mp -96.1 -61.18 1.48 Allowed 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 124.791 1.237 . . . . 0.0 111.458 -177.18 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -63.67 152.75 38.19 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 124.515 1.126 . . . . 0.0 112.214 176.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 14.3 tp -81.52 137.57 35.56 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.428 1.091 . . . . 0.0 110.887 174.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -148.19 177.63 9.23 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 125.508 1.523 . . . . 0.0 111.427 175.02 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.9 t -59.33 133.7 24.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 O-C-N 121.395 -0.815 . . . . 0.0 111.296 176.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.31 -4.48 85.54 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 124.817 1.198 . . . . 0.0 115.211 -178.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -71.56 178.35 3.56 Favored 'General case' 0 CA--C 1.553 1.066 0 CA-C-N 118.835 1.318 . . . . 0.0 110.906 174.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 19.2 mmt180 -98.49 151.44 20.61 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 125.499 1.52 . . . . 0.0 111.378 178.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.6 HG23 ' HB3' ' A' ' 70' ' ' LYS . 2.8 p -140.02 125.67 21.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 C-N-CA 124.225 1.01 . . . . 0.0 110.94 176.47 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.536 HG11 ' HG3' ' A' ' 5' ' ' PRO . 3.7 p -132.14 145.68 34.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 C-N-CA 125.59 1.556 . . . . 0.0 108.532 175.186 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -91.72 161.06 34.98 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 125.005 1.322 . . . . 0.0 111.948 175.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.34 -28.84 26.8 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 122.848 2.365 . . . . 0.0 111.954 -175.208 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -159.08 54.16 0.41 Allowed 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 124.311 1.044 . . . . 0.0 113.032 176.348 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -142.86 -62.25 0.42 Allowed 'General case' 0 N--CA 1.478 0.974 0 O-C-N 121.14 -0.975 . . . . 0.0 113.567 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.1 -172.52 44.44 Favored Glycine 0 CA--C 1.533 1.168 0 C-N-CA 124.291 0.948 . . . . 0.0 113.514 -176.193 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.6 p -115.68 144.5 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 126.728 2.011 . . . . 0.0 110.567 179.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 77.2 m -132.84 -175.02 3.64 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 126.614 1.966 . . . . 0.0 110.572 175.565 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -129.46 123.94 32.82 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 125.037 1.335 . . . . 0.0 111.198 -177.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.6 t -63.42 128.38 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 O-C-N 121.778 -0.576 . . . . 0.0 111.189 -177.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.4 t -109.92 -53.52 2.66 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.981 1.712 . . . . 0.0 111.515 -176.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.64 165.95 34.8 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 125.204 1.402 . . . . 0.0 111.032 174.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 74.4 mt -142.05 130.92 22.49 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 124.62 1.168 . . . . 0.0 108.76 178.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -147.73 173.93 12.29 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 123.543 0.737 . . . . 0.0 112.338 175.292 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.486 HG12 ' HA ' ' A' ' 43' ' ' THR . 25.5 m -106.72 142.21 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.984 0 O-C-N 121.022 -1.049 . . . . 0.0 110.852 176.106 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -156.14 171.63 19.82 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.986 0.914 . . . . 0.0 112.336 176.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -104.55 115.77 30.92 Favored 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 125.94 1.696 . . . . 0.0 109.704 175.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.1 p -127.89 138.12 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.792 0.837 . . . . 0.0 109.626 175.122 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.77 28.98 1.43 Allowed 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 114.905 1.446 . . . . 0.0 114.905 -177.22 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.49 23.98 55.02 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.235 1.398 . . . . 0.0 115.441 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -131.97 113.48 13.46 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 126.193 1.797 . . . . 0.0 109.771 -174.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 16.5 tttt -96.43 112.43 24.17 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.48 1.112 . . . . 0.0 111.635 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.609 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -157.43 173.78 16.4 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 123.407 0.683 . . . . 0.0 112.217 179.262 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.486 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.2 m -73.34 116.49 13.95 Favored 'General case' 0 N--CA 1.475 0.82 0 C-N-CA 124.724 1.209 . . . . 0.0 111.101 175.113 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -111.38 113.78 26.48 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 124.671 1.189 . . . . 0.0 110.036 177.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 27.4 m -75.2 145.45 10.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 123.326 0.65 . . . . 0.0 110.537 177.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 21.7 m -126.52 116.05 20.48 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 124.367 1.067 . . . . 0.0 110.948 -179.603 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . 0.428 ' CE ' HG21 ' A' ' 19' ' ' VAL . 2.1 mpp? -126.32 141.94 51.72 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.097 0.959 . . . . 0.0 109.619 -175.236 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.7 mtt85 -127.58 109.65 11.92 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 125.233 1.413 . . . . 0.0 109.2 -172.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -77.32 109.11 10.94 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 56.5 mt-10 -67.05 -23.0 65.84 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.886 0.875 . . . . 0.0 112.56 178.292 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -55.81 -39.56 71.51 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 126.462 1.905 . . . . 0.0 113.14 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -128.55 2.94 5.56 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.598 1.559 . . . . 0.0 113.377 -179.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.56 17.3 64.35 Favored Glycine 0 CA--C 1.538 1.472 0 C-N-CA 126.1 1.81 . . . . 0.0 114.669 -171.415 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -75.84 165.55 24.85 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 124.903 1.281 . . . . 0.0 112.484 -178.489 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.5 m -131.61 150.83 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 124.918 1.287 . . . . 0.0 111.02 177.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.8 p -146.73 144.18 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 C-N-CA 125.22 1.408 . . . . 0.0 109.49 176.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 8.8 ttm -138.28 127.25 24.01 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.62 1.168 . . . . 0.0 108.997 174.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.8 m -129.44 156.26 78.82 Favored Pre-proline 0 N--CA 1.473 0.718 0 C-N-CA 123.576 0.751 . . . . 0.0 111.615 175.066 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.609 ' CB ' HD11 ' A' ' 42' ' ' LEU . 57.5 Cg_endo -79.45 115.7 3.46 Favored 'Trans proline' 0 CA--C 1.539 0.767 0 C-N-CA 123.511 2.807 . . . . 0.0 114.9 177.191 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -62.31 -35.28 78.55 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 119.988 -1.695 . . . . 0.0 114.689 176.307 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.4 6.34 80.68 Favored Glycine 0 N--CA 1.473 1.131 0 O-C-N 121.547 -0.721 . . . . 0.0 114.639 176.691 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.5 tttt -137.06 0.59 2.38 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.902 1.281 . . . . 0.0 113.687 -177.182 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.468 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.5 m -49.93 -29.02 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 C-N-CA 125.166 1.386 . . . . 0.0 113.795 175.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.2 mt -58.32 -27.44 64.12 Favored 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.594 1.557 . . . . 0.0 112.127 177.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.13 -50.96 11.84 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.945 1.698 . . . . 0.0 112.386 175.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.5 mp -69.51 -33.55 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 C-N-CA 123.863 0.865 . . . . 0.0 111.824 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 90.35 12.72 61.02 Favored Glycine 0 CA--C 1.538 1.521 0 C-N-CA 126.03 1.776 . . . . 0.0 114.914 -178.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 97.6 t -89.56 135.38 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 C-N-CA 125.375 1.47 . . . . 0.0 110.657 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.37 109.2 11.54 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 123.721 0.808 . . . . 0.0 110.315 175.039 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.6 ' HB3' HG23 ' A' ' 19' ' ' VAL . 0.0 OUTLIER -97.11 106.62 18.98 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 121.631 0.729 . . . . 0.0 110.192 179.42 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 6.8 t -154.01 169.27 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 125.454 1.502 . . . . 0.0 108.28 -177.257 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . -62.6 -20.51 64.81 Favored 'General case' 0 CA--C 1.55 0.975 0 N-CA-C 113.8 1.037 . . . . 0.0 113.8 175.057 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 69.5 m -127.26 -40.6 1.81 Allowed 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 114.606 1.336 . . . . 0.0 114.606 176.235 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.55 161.43 20.25 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.693 0.797 . . . . 0.0 112.571 177.051 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 . . . . . 0 C--O 1.254 1.334 0 C-N-CA 127.283 2.233 . . . . 0.0 112.075 178.864 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.196 0 CA-C-O 120.567 0.222 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 134.56 -97.26 0.29 Allowed Glycine 0 N--CA 1.473 1.104 0 C-N-CA 125.071 1.319 . . . . 0.0 112.656 178.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -70.69 131.13 43.43 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 124.061 0.944 . . . . 0.0 111.689 176.368 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.38 161.17 80.33 Favored Pre-proline 0 CA--C 1.548 0.878 0 C-N-CA 123.735 0.814 . . . . 0.0 113.037 175.215 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -68.5 110.31 2.26 Favored 'Trans proline' 0 CA--C 1.541 0.868 0 C-N-CA 124.345 3.363 . . . . 0.0 112.33 174.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -162.03 -175.66 4.75 Favored 'General case' 0 CA--C 1.55 0.961 0 C-N-CA 125.575 1.55 . . . . 0.0 111.967 177.353 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 168.22 -175.96 42.82 Favored Glycine 0 CA--C 1.538 1.5 0 C-N-CA 126.607 2.051 . . . . 0.0 112.478 -175.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.4 t -142.19 16.13 2.07 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 124.625 1.17 . . . . 0.0 114.02 -179.101 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.44 ' HB3' ' HB2' ' A' ' 72' ' ' ALA . . . -70.55 -174.72 0.92 Allowed 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 124.893 1.277 . . . . 0.0 113.084 176.744 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.2 m -66.14 -179.66 0.8 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 125.332 1.453 . . . . 0.0 113.184 176.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 38.1 mt -74.29 46.13 0.25 Allowed 'General case' 0 CA--C 1.551 0.986 0 C-N-CA 126.194 1.797 . . . . 0.0 113.976 -178.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -160.12 163.44 33.79 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 125.43 1.492 . . . . 0.0 111.609 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.544 HD22 HG21 ' A' ' 29' ' ' VAL . 11.8 mt -71.13 159.55 34.48 Favored 'General case' 0 CA--C 1.543 0.692 0 CA-C-O 121.459 0.647 . . . . 0.0 110.281 174.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -146.78 157.1 43.59 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 125.196 1.398 . . . . 0.0 110.849 175.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.4 t -57.31 125.72 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.834 0.854 . . . . 0.0 111.056 178.016 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.44 -5.06 84.61 Favored Glycine 0 CA--C 1.533 1.165 0 C-N-CA 124.973 1.273 . . . . 0.0 115.005 -176.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -68.69 152.8 44.86 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 118.97 1.385 . . . . 0.0 109.79 174.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 9.4 mpt_? -85.0 167.74 15.57 Favored 'General case' 0 N--CA 1.471 0.616 0 O-C-N 121.246 -0.909 . . . . 0.0 110.74 176.363 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 70' ' ' LYS . 26.1 m -151.16 158.54 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 127.054 2.141 . . . . 0.0 111.068 175.067 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.4 p -136.55 160.11 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 125.8 1.64 . . . . 0.0 109.515 174.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -114.16 160.43 32.57 Favored Pre-proline 0 CA--C 1.542 0.664 0 C-N-CA 125.354 1.461 . . . . 0.0 111.539 175.016 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.57 ' HD3' HG22 ' A' ' 68' ' ' VAL . 59.0 Cg_endo -67.48 -27.66 39.39 Favored 'Trans proline' 0 CA--C 1.539 0.734 0 C-N-CA 123.002 2.468 . . . . 0.0 112.822 178.357 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -158.77 53.81 0.42 Allowed 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 124.081 0.952 . . . . 0.0 113.278 178.502 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.11 -57.73 0.38 Allowed 'General case' 0 N--CA 1.479 0.997 0 O-C-N 121.107 -0.996 . . . . 0.0 113.58 -176.83 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 156.09 -160.26 29.96 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.526 1.06 . . . . 0.0 112.513 -174.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.4 m -118.98 147.97 22.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 125.844 1.658 . . . . 0.0 111.524 177.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 6.3 m -139.02 178.87 6.85 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.303 1.441 . . . . 0.0 110.886 177.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 49.4 ttt-85 -133.74 131.87 39.9 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.16 1.384 . . . . 0.0 111.673 179.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.544 HG21 HD22 ' A' ' 13' ' ' LEU . 40.0 t -59.09 132.64 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.674 1.189 . . . . 0.0 111.293 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.9 t -112.07 -53.05 2.74 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 126.505 1.922 . . . . 0.0 111.15 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -145.98 159.14 43.67 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.562 1.145 . . . . 0.0 111.023 -178.17 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.4 mt -143.74 127.26 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.514 1.125 . . . . 0.0 109.108 178.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -149.8 157.14 42.91 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 124.218 1.007 . . . . 0.0 112.351 175.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.54 HG12 ' HA ' ' A' ' 43' ' ' THR . 21.5 m -97.02 141.56 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 O-C-N 121.279 -0.888 . . . . 0.0 110.342 175.474 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -154.51 171.44 19.41 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.878 0.871 . . . . 0.0 111.728 175.171 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -103.61 116.62 32.69 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 125.543 1.537 . . . . 0.0 109.372 175.373 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.0 p -124.33 137.86 55.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.025 0 C-N-CA 124.419 1.088 . . . . 0.0 108.941 175.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.22 29.74 1.97 Allowed 'General case' 0 CA--C 1.557 1.233 0 N-CA-C 114.809 1.411 . . . . 0.0 114.809 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.39 23.36 56.79 Favored Glycine 0 CA--C 1.539 1.543 0 C-N-CA 125.046 1.308 . . . . 0.0 115.49 -176.458 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -136.91 113.48 10.17 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 125.365 1.466 . . . . 0.0 111.822 -173.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -94.81 114.41 26.28 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 125.862 1.665 . . . . 0.0 111.132 -177.207 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.611 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.6 OUTLIER -155.07 171.59 19.51 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.2 0.6 . . . . 0.0 111.669 178.698 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.54 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.7 m -73.8 116.56 14.54 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 124.035 0.934 . . . . 0.0 110.945 175.287 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -107.08 113.13 26.39 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 122.239 1.018 . . . . 0.0 109.68 176.03 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.556 HG23 ' HE1' ' A' ' 47' ' ' MET . 18.0 m -83.11 146.16 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 C-N-CA 123.438 0.695 . . . . 0.0 110.148 176.708 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 3.9 m -124.39 113.46 18.21 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 125.142 1.377 . . . . 0.0 109.865 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . 0.556 ' HE1' HG23 ' A' ' 45' ' ' VAL . 2.8 mtm -107.28 165.21 11.55 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 124.685 1.194 . . . . 0.0 110.221 175.025 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 35.2 ptt180 -140.48 162.03 36.31 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 125.873 1.669 . . . . 0.0 111.219 175.12 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.0 mpt_? -109.25 131.26 55.23 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.745 0.818 . . . . 0.0 110.035 175.015 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 70.2 mt-10 -68.3 -35.64 78.14 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.988 0.915 . . . . 0.0 111.827 176.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -91.96 -46.58 7.75 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 124.523 1.129 . . . . 0.0 112.831 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.05 -24.04 62.26 Favored 'General case' 0 N--CA 1.476 0.864 0 O-C-N 121.559 -0.713 . . . . 0.0 111.937 -178.133 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.81 9.77 47.46 Favored Glycine 0 CA--C 1.536 1.371 0 C-N-CA 125.719 1.628 . . . . 0.0 114.651 -179.176 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -101.1 159.88 14.86 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.289 1.836 . . . . 0.0 111.235 -177.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 31.3 m -111.63 151.57 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 124.881 1.272 . . . . 0.0 110.479 175.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.4 p -135.04 124.91 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.66 1.584 . . . . 0.0 108.42 176.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -112.41 125.3 54.06 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 124.734 1.214 . . . . 0.0 109.033 176.092 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.763 HG21 ' HE3' ' A' ' 70' ' ' LYS . 15.4 m -137.74 156.24 74.63 Favored Pre-proline 0 N--CA 1.472 0.652 0 C-N-CA 123.108 0.563 . . . . 0.0 111.524 176.164 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.611 ' CB ' HD11 ' A' ' 42' ' ' LEU . 57.2 Cg_endo -77.14 115.66 4.03 Favored 'Trans proline' 0 CA--C 1.536 0.59 0 C-N-CA 123.516 2.811 . . . . 0.0 114.232 177.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -59.08 -45.62 90.35 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 120.557 -1.339 . . . . 0.0 112.497 175.639 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -83.33 6.37 72.65 Favored Glycine 0 N--CA 1.475 1.25 0 O-C-N 120.999 -1.063 . . . . 0.0 115.282 178.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 15.6 tttt -137.5 4.6 2.63 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 125.434 1.493 . . . . 0.0 113.027 -178.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.519 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.8 m -51.88 -29.15 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 125.297 1.439 . . . . 0.0 113.35 176.097 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.1 mt -58.06 -29.14 65.17 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 125.926 1.691 . . . . 0.0 112.426 176.348 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.09 -49.48 23.78 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 125.672 1.589 . . . . 0.0 112.61 175.22 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.441 HG22 HG23 ' A' ' 68' ' ' VAL . 2.5 mp -67.0 -32.68 59.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 C-N-CA 123.476 0.71 . . . . 0.0 111.339 177.764 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.79 20.38 43.89 Favored Glycine 0 CA--C 1.534 1.243 0 C-N-CA 124.834 1.207 . . . . 0.0 113.811 -177.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.57 HG22 ' HD3' ' A' ' 22' ' ' PRO . 40.9 t -102.58 123.75 56.11 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 124.328 1.051 . . . . 0.0 110.096 -178.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -98.67 110.14 22.79 Favored 'General case' 0 N--CA 1.475 0.821 0 O-C-N 121.178 -0.951 . . . . 0.0 110.523 175.041 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.763 ' HE3' HG21 ' A' ' 58' ' ' VAL . 1.7 ptpm? -127.83 106.55 9.19 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 127.423 2.289 . . . . 0.0 109.699 179.138 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 3.8 t -161.19 159.68 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 125.648 1.579 . . . . 0.0 107.607 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . 0.44 ' HB2' ' HB3' ' A' ' 9' ' ' ALA . . . -48.11 -41.08 25.48 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.492 1.117 . . . . 0.0 113.322 176.227 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 36.6 p -87.3 -41.88 13.33 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 125.238 1.415 . . . . 0.0 114.51 175.172 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -54.47 -62.76 1.44 Allowed 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.334 1.454 . . . . 0.0 111.442 -176.156 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.251 1.158 0 C-N-CA 131.438 3.895 . . . . 0.0 107.742 -179.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.164 0 N-CA-C 110.524 -0.176 . . . . 0.0 110.524 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 132.06 -70.45 0.52 Allowed Glycine 0 N--CA 1.475 1.256 0 C-N-CA 125.204 1.383 . . . . 0.0 112.63 178.714 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -81.69 114.51 20.41 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.175 1.39 . . . . 0.0 111.288 177.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 37.8 mtm -108.5 159.77 29.59 Favored Pre-proline 0 CA--C 1.545 0.765 0 C-N-CA 124.805 1.242 . . . . 0.0 112.782 177.088 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -68.46 120.71 7.64 Favored 'Trans proline' 0 CA--C 1.538 0.706 0 C-N-CA 124.075 3.184 . . . . 0.0 111.486 177.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -154.47 156.49 36.83 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 125.645 1.578 . . . . 0.0 111.477 175.023 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 142.4 147.82 4.87 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 125.288 1.423 . . . . 0.0 113.552 175.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 50.5 m -145.02 97.96 3.1 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 125.574 1.55 . . . . 0.0 110.761 -176.22 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -135.86 -71.27 0.47 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.496 1.118 . . . . 0.0 112.498 -178.313 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 95.5 p -119.48 175.9 5.61 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 125.936 1.694 . . . . 0.0 112.022 178.229 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 42.1 mt -101.77 14.87 30.69 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 125.325 1.45 . . . . 0.0 113.026 -178.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.9 mt-30 -119.8 171.52 8.35 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 126.512 1.925 . . . . 0.0 112.208 177.384 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -118.34 153.9 33.25 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.81 1.644 . . . . 0.0 110.514 174.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -147.45 177.34 9.32 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 125.198 1.399 . . . . 0.0 112.013 177.021 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.8 t -58.71 129.84 21.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 123.756 0.822 . . . . 0.0 111.276 175.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 88.5 -4.3 85.19 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 125.191 1.377 . . . . 0.0 115.126 -178.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -72.0 176.37 5.11 Favored 'General case' 0 CA--C 1.551 0.986 0 CA-C-N 118.946 1.373 . . . . 0.0 112.075 175.027 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 2.4 tpt180 -119.49 142.01 48.67 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 125.278 1.431 . . . . 0.0 111.578 -177.186 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 15.6 m -136.76 142.39 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 123.996 0.918 . . . . 0.0 110.541 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 p -136.99 141.0 41.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 124.08 0.952 . . . . 0.0 110.724 177.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.479 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 1.3 m-85 -80.51 158.66 71.03 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 124.271 1.028 . . . . 0.0 112.126 176.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.441 ' CD ' HG12 ' A' ' 68' ' ' VAL . 70.8 Cg_endo -68.55 -23.41 37.07 Favored 'Trans proline' 0 CA--C 1.538 0.701 0 C-N-CA 123.699 2.933 . . . . 0.0 112.98 -177.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -159.91 51.73 0.33 Allowed 'General case' 0 CA--C 1.555 1.164 0 C-N-CA 124.752 1.221 . . . . 0.0 112.656 177.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.41 -58.11 0.37 Allowed 'General case' 0 N--CA 1.483 1.184 0 O-C-N 120.743 -1.223 . . . . 0.0 112.982 -176.407 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 155.97 179.25 30.89 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.099 1.333 . . . . 0.0 113.314 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.2 p -85.27 152.28 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.959 1.304 . . . . 0.0 111.268 175.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.52 ' SG ' HG11 ' A' ' 56' ' ' VAL . 4.0 m -132.77 170.18 15.64 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 126.195 1.798 . . . . 0.0 110.725 174.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -128.68 121.05 27.69 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.369 1.068 . . . . 0.0 111.36 -174.313 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.403 HG22 ' CE ' ' A' ' 47' ' ' MET . 50.0 t -63.61 121.5 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 124.436 1.094 . . . . 0.0 110.617 -178.139 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.8 m -112.42 -41.51 3.86 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.573 1.149 . . . . 0.0 112.1 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -156.98 165.21 36.81 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.287 1.835 . . . . 0.0 110.612 174.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 41.7 mt -147.65 138.15 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.971 1.308 . . . . 0.0 108.76 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -147.48 170.58 17.1 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.449 1.1 . . . . 0.0 112.785 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.6 m -108.51 139.25 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 124.909 1.284 . . . . 0.0 110.599 175.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 7.5 ptmt -155.92 168.13 28.21 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.291 1.036 . . . . 0.0 112.543 175.311 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.12 116.05 31.24 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 125.648 1.579 . . . . 0.0 109.516 175.006 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.7 p -126.09 137.25 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.15 0.98 . . . . 0.0 109.648 174.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.94 28.98 2.17 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 114.829 1.418 . . . . 0.0 114.829 -179.02 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.45 25.18 48.28 Favored Glycine 0 CA--C 1.54 1.597 0 C-N-CA 124.839 1.209 . . . . 0.0 115.322 -176.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -139.08 113.52 8.95 Favored 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 125.413 1.485 . . . . 0.0 111.462 -174.133 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -95.85 116.7 29.3 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.144 1.377 . . . . 0.0 111.917 -179.29 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.55 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -159.75 175.08 13.57 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 123.813 0.845 . . . . 0.0 112.02 179.224 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 15.3 m -77.35 116.33 17.86 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.314 1.046 . . . . 0.0 111.934 175.001 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -106.01 113.45 27.01 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 124.849 1.26 . . . . 0.0 109.351 175.194 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.2 m -63.73 150.7 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 O-C-N 122.052 -0.405 . . . . 0.0 111.331 175.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -126.55 109.89 12.64 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 122.037 0.922 . . . . 0.0 110.638 174.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . 0.471 ' HB2' HG13 ' A' ' 56' ' ' VAL . 0.7 OUTLIER -128.43 162.57 26.86 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 125.095 1.358 . . . . 0.0 110.181 179.597 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.3 mtt180 -138.67 113.85 9.44 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 125.491 1.516 . . . . 0.0 109.298 177.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 44.5 mtp85 -69.91 109.09 4.29 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 174.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -70.17 -13.86 62.38 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.188 0.995 . . . . 0.0 113.286 176.072 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -59.36 -42.82 92.49 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 125.96 1.704 . . . . 0.0 112.66 177.253 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -128.52 -15.45 4.51 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.843 1.424 . . . . 0.0 114.843 177.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 84.07 59.03 2.12 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 125.578 1.561 . . . . 0.0 113.446 -179.242 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -135.66 128.72 31.59 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.657 1.183 . . . . 0.0 112.532 179.021 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 9.0 p -67.05 141.87 17.36 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 C-N-CA 124.286 1.034 . . . . 0.0 110.127 175.367 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.52 HG11 ' SG ' ' A' ' 27' ' ' CYS . 5.6 p -137.31 114.41 12.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 C-N-CA 126.244 1.818 . . . . 0.0 108.969 178.344 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.3 ptt? -126.79 125.63 42.04 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 125.794 1.638 . . . . 0.0 109.832 179.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 33.8 m -131.89 152.98 81.23 Favored Pre-proline 0 N--CA 1.468 0.457 0 C-N-CA 123.7 0.8 . . . . 0.0 111.359 178.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.55 ' CB ' HD11 ' A' ' 42' ' ' LEU . 51.5 Cg_endo -77.01 116.5 4.22 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.912 2.408 . . . . 0.0 114.557 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -60.65 -38.22 84.13 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 114.572 1.323 . . . . 0.0 114.572 -179.623 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.91 5.81 79.21 Favored Glycine 0 N--CA 1.476 1.34 0 C-N-CA 124.545 1.069 . . . . 0.0 114.697 178.408 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.9 tttt -133.85 3.03 3.46 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.474 1.51 . . . . 0.0 112.889 -177.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.54 -29.72 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 125.533 1.533 . . . . 0.0 113.745 175.306 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.5 mt -56.3 -29.4 61.17 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 126.093 1.757 . . . . 0.0 112.542 177.164 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.42 -50.4 15.94 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 125.849 1.66 . . . . 0.0 112.873 175.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.429 HG22 HG13 ' A' ' 68' ' ' VAL . 3.9 mp -67.33 -33.31 61.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 124.134 0.973 . . . . 0.0 111.355 178.034 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 89.53 8.29 68.16 Favored Glycine 0 CA--C 1.535 1.335 0 C-N-CA 125.617 1.58 . . . . 0.0 114.356 -176.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.479 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 24.9 m -93.26 123.27 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 125.407 1.483 . . . . 0.0 110.763 -176.689 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.62 109.31 21.37 Favored 'General case' 0 N--CA 1.471 0.607 0 O-C-N 120.827 -1.17 . . . . 0.0 109.58 178.089 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.5 106.58 17.7 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 123.764 0.826 . . . . 0.0 109.91 176.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 97.3 t -147.49 -71.19 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 C-N-CA 124.654 1.182 . . . . 0.0 111.798 176.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . 175.32 -46.18 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 128.052 2.541 . . . . 0.0 110.924 -175.629 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 71.3 p -123.52 -4.61 8.25 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 126.007 1.723 . . . . 0.0 114.652 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -73.23 -59.01 2.91 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 125.283 1.433 . . . . 0.0 113.341 -173.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 68.4 tt0 . . . . . 0 C--O 1.254 1.301 0 C-N-CA 129.704 3.201 . . . . 0.0 117.116 175.207 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.207 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 142.14 106.33 0.59 Allowed Glycine 0 N--CA 1.474 1.199 0 C-N-CA 124.269 0.937 . . . . 0.0 113.221 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.2 m170 -69.11 155.18 40.81 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 123.871 0.868 . . . . 0.0 111.662 174.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 3.9 mpp? -83.32 164.97 43.19 Favored Pre-proline 0 CA--C 1.545 0.785 0 C-N-CA 124.444 1.098 . . . . 0.0 112.686 175.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -71.09 113.38 3.57 Favored 'Trans proline' 0 CA--C 1.54 0.796 0 C-N-CA 123.743 2.962 . . . . 0.0 112.039 175.054 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -126.69 94.39 4.04 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 125.478 1.511 . . . . 0.0 110.364 178.511 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -167.25 65.9 0.19 Allowed Glycine 0 CA--C 1.531 1.06 0 N-CA-C 115.026 0.77 . . . . 0.0 115.026 -178.263 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.441 ' HA ' ' HB1' ' A' ' 72' ' ' ALA . 57.8 m -67.46 110.03 3.45 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 124.867 1.267 . . . . 0.0 113.525 177.014 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -61.87 -71.11 0.16 Allowed 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 124.104 0.962 . . . . 0.0 112.507 174.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.2 p -158.88 -79.24 0.06 Allowed 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 125.277 1.431 . . . . 0.0 111.813 -177.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -117.6 -61.8 1.65 Allowed 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 126.541 1.937 . . . . 0.0 111.308 -177.034 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 -110.41 175.45 5.42 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.899 1.68 . . . . 0.0 110.703 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.699 HD23 ' HA ' ' A' ' 71' ' ' VAL . 0.7 OUTLIER -66.02 128.91 37.92 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.285 1.034 . . . . 0.0 110.981 175.127 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -135.25 175.16 9.83 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.572 1.549 . . . . 0.0 112.336 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 57.6 t -59.61 132.8 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 O-C-N 121.184 -0.948 . . . . 0.0 111.127 177.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 85.62 -5.52 83.33 Favored Glycine 0 CA--C 1.537 1.427 0 C-N-CA 124.854 1.216 . . . . 0.0 115.005 -179.272 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -68.51 173.32 5.12 Favored 'General case' 0 CA--C 1.553 1.058 0 CA-C-N 118.761 1.281 . . . . 0.0 110.246 175.041 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -84.33 158.31 21.2 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 125.102 1.361 . . . . 0.0 112.007 174.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.745 HG11 ' HG2' ' A' ' 47' ' ' MET . 2.4 p -160.32 124.37 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 124.688 1.195 . . . . 0.0 109.997 175.019 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 2.9 m -131.56 159.74 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.618 0.723 . . . . 0.0 109.35 174.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.494 ' CZ ' HG11 ' A' ' 68' ' ' VAL . 0.8 OUTLIER -95.27 162.02 26.08 Favored Pre-proline 0 CA--C 1.544 0.72 0 C-N-CA 123.515 0.726 . . . . 0.0 110.796 177.043 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.437 ' CD ' HG12 ' A' ' 68' ' ' VAL . 68.0 Cg_endo -69.35 -24.84 31.1 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 123.191 2.594 . . . . 0.0 112.429 -179.2 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -159.48 55.65 0.39 Allowed 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 124.725 1.21 . . . . 0.0 112.572 178.608 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 9.8 tm0? -142.7 -58.81 0.44 Allowed 'General case' 0 N--CA 1.482 1.165 0 O-C-N 120.832 -1.167 . . . . 0.0 113.024 -178.506 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 158.58 -168.66 34.87 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 124.849 1.214 . . . . 0.0 112.995 -174.266 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.5 m -109.52 146.8 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 125.176 1.39 . . . . 0.0 112.656 -176.547 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.551 ' HB2' HG13 ' A' ' 19' ' ' VAL . 61.3 m -137.25 179.55 6.33 Favored 'General case' 0 CA--C 1.551 1.01 0 C-N-CA 126.168 1.787 . . . . 0.0 110.944 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.89 132.35 43.54 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 126.892 2.077 . . . . 0.0 111.362 175.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.641 HG21 HD11 ' A' ' 13' ' ' LEU . 21.9 t -67.6 129.94 32.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.149 0.98 . . . . 0.0 111.233 179.523 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.76 -48.57 3.12 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.9 1.28 . . . . 0.0 112.781 -175.56 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.99 163.06 36.79 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.372 1.469 . . . . 0.0 110.961 174.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 73.4 mt -140.94 133.42 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 124.263 1.025 . . . . 0.0 109.252 178.166 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -148.46 168.04 23.73 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.713 1.205 . . . . 0.0 112.19 176.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.539 HG12 ' HA ' ' A' ' 43' ' ' THR . 18.8 m -106.69 141.3 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 O-C-N 121.257 -0.902 . . . . 0.0 110.373 175.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.1 ptmt -153.45 168.59 25.59 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 123.809 0.843 . . . . 0.0 112.211 176.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -100.67 117.62 35.15 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 125.485 1.514 . . . . 0.0 109.991 175.014 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.0 p -127.26 138.14 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 124.106 0.962 . . . . 0.0 109.656 175.021 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.98 29.06 1.59 Allowed 'General case' 0 CA--C 1.557 1.223 0 N-CA-C 114.776 1.398 . . . . 0.0 114.776 -177.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.08 27.52 49.19 Favored Glycine 0 CA--C 1.542 1.748 0 C-N-CA 124.88 1.229 . . . . 0.0 115.361 -176.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 10.5 tp60 -137.41 114.95 11.16 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.223 1.809 . . . . 0.0 110.656 -175.7 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.02 115.07 26.96 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.69 1.196 . . . . 0.0 111.492 178.621 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.602 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.7 OUTLIER -153.11 172.56 16.71 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 123.448 0.699 . . . . 0.0 111.649 177.388 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.539 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.3 m -74.16 116.35 14.7 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 125.011 1.324 . . . . 0.0 111.105 175.793 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -109.83 113.07 25.52 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 124.451 1.1 . . . . 0.0 110.105 177.071 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.535 HG21 ' HE3' ' A' ' 70' ' ' LYS . 22.0 m -77.45 145.0 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 123.156 0.582 . . . . 0.0 110.903 178.323 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.1 m -126.31 112.36 15.61 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 122.116 0.96 . . . . 0.0 110.689 -179.053 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . 0.745 ' HG2' HG11 ' A' ' 19' ' ' VAL . 2.0 mpp? -122.42 162.7 21.16 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 124.816 1.246 . . . . 0.0 109.638 -176.423 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.438 ' CG ' HG12 ' A' ' 55' ' ' VAL . 1.3 mtt180 -134.84 151.87 51.28 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 125.38 1.472 . . . . 0.0 110.314 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.5 ptt180 -118.58 109.12 15.79 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.379 1.072 . . . . 0.0 109.793 175.028 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -64.96 -17.37 64.34 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.745 1.218 . . . . 0.0 112.408 174.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -55.4 -42.92 74.73 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 126.249 1.82 . . . . 0.0 112.693 175.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -128.68 3.4 5.5 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 125.126 1.37 . . . . 0.0 113.845 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 64.56 33.89 88.45 Favored Glycine 0 CA--C 1.535 1.292 0 C-N-CA 125.659 1.6 . . . . 0.0 113.979 -174.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -103.82 167.43 9.78 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.15 0.98 . . . . 0.0 111.988 -176.493 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.438 HG12 ' CG ' ' A' ' 48' ' ' ARG . 17.3 m -116.85 151.0 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.092 1.357 . . . . 0.0 110.258 178.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 7.3 p -143.82 126.36 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 C-N-CA 124.821 1.249 . . . . 0.0 109.202 176.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.6 tmm? -127.86 128.17 44.73 Favored 'General case' 0 C--O 1.234 0.267 0 C-N-CA 124.408 1.083 . . . . 0.0 109.839 177.759 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.7 m -132.95 155.45 81.14 Favored Pre-proline 0 N--CA 1.469 0.485 0 C-N-CA 124.396 1.078 . . . . 0.0 111.599 178.448 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.602 ' CB ' HD11 ' A' ' 42' ' ' LEU . 52.6 Cg_endo -76.14 116.14 4.3 Favored 'Trans proline' 0 CA--C 1.537 0.634 0 C-N-CA 123.749 2.966 . . . . 0.0 114.466 176.361 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -63.43 -34.64 78.2 Favored 'General case' 0 N--CA 1.479 1.005 0 O-C-N 120.341 -1.474 . . . . 0.0 114.172 177.484 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.17 5.9 78.47 Favored Glycine 0 N--CA 1.472 1.055 0 C-N-CA 124.175 0.893 . . . . 0.0 114.653 176.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.4 ttmm -136.76 4.11 2.78 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.269 1.428 . . . . 0.0 113.364 -178.588 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.429 HG13 ' O ' ' A' ' 59' ' ' PRO . 1.4 m -49.38 -30.13 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 125.468 1.507 . . . . 0.0 113.042 175.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.3 mt -56.58 -29.14 61.73 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 126.288 1.835 . . . . 0.0 112.684 176.634 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.31 -50.2 13.34 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 126.05 1.74 . . . . 0.0 112.645 177.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.455 HG22 HG13 ' A' ' 68' ' ' VAL . 3.7 mp -66.8 -32.38 57.74 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 124.211 1.004 . . . . 0.0 111.291 176.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.39 2.71 79.39 Favored Glycine 0 CA--C 1.535 1.303 0 C-N-CA 125.789 1.662 . . . . 0.0 113.866 -174.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.494 HG11 ' CZ ' ' A' ' 21' ' ' TYR . 18.6 m -83.57 123.23 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 118.338 1.069 . . . . 0.0 111.031 -178.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.1 mmt-85 -100.4 127.21 46.78 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 174.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.535 ' HE3' HG21 ' A' ' 45' ' ' VAL . 0.5 OUTLIER -138.29 106.55 5.78 Favored 'General case' 0 N--CA 1.464 0.225 0 C-N-CA 123.331 0.652 . . . . 0.0 110.481 176.794 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.699 ' HA ' HD23 ' A' ' 13' ' ' LEU . 3.2 t -159.52 163.02 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 125.511 1.524 . . . . 0.0 108.628 -173.561 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . 0.441 ' HB1' ' HA ' ' A' ' 8' ' ' SER . . . -48.83 -32.9 9.53 Favored 'General case' 0 CA--C 1.551 0.999 0 C-N-CA 125.717 1.607 . . . . 0.0 114.681 175.099 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.1 m -115.35 -50.95 2.72 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.859 1.663 . . . . 0.0 113.064 175.262 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -72.53 83.9 1.12 Allowed 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 124.239 1.016 . . . . 0.0 111.48 174.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . 0.266 54.7 mt-10 . . . . . 0 C--O 1.251 1.166 0 C-N-CA 128.576 2.75 . . . . 0.0 115.698 177.57 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.279 0 CA-C-O 119.492 -0.29 . . . . 0.0 110.946 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -125.56 -179.07 15.57 Favored Glycine 0 CA--C 1.534 1.236 0 C-N-CA 125.533 1.54 . . . . 0.0 112.901 175.06 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -129.64 149.26 51.47 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 125.662 1.585 . . . . 0.0 110.432 175.024 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.9 ptt? -114.89 158.53 40.4 Favored Pre-proline 0 CA--C 1.544 0.743 0 C-N-CA 125.575 1.55 . . . . 0.0 111.504 177.212 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -72.37 86.55 0.98 Allowed 'Trans proline' 0 CA--C 1.539 0.748 0 C-N-CA 123.795 2.996 . . . . 0.0 111.744 177.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -99.61 177.74 5.06 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 125.753 1.621 . . . . 0.0 112.425 177.188 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.47 -124.54 1.09 Allowed Glycine 0 CA--C 1.53 0.995 0 C-N-CA 124.445 1.021 . . . . 0.0 111.638 177.416 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 19.6 p -162.46 -75.69 0.05 OUTLIER 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 125.075 1.35 . . . . 0.0 110.944 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -157.95 105.22 1.96 Allowed 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 126.167 1.787 . . . . 0.0 111.099 178.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 74.1 m -140.98 154.4 46.03 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 125.295 1.438 . . . . 0.0 111.615 176.114 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -111.75 -75.54 0.61 Allowed 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 125.785 1.634 . . . . 0.0 110.384 178.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -65.48 152.35 44.18 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 123.875 0.87 . . . . 0.0 110.973 175.028 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.597 HD23 HG21 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -109.69 162.8 14.09 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.946 1.298 . . . . 0.0 110.893 179.59 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -144.91 169.28 18.36 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.378 1.071 . . . . 0.0 111.772 177.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.3 t -61.21 130.34 25.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 123.586 0.754 . . . . 0.0 110.572 176.23 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.27 -8.81 79.0 Favored Glycine 0 CA--C 1.537 1.414 0 C-N-CA 124.997 1.284 . . . . 0.0 114.886 -176.036 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -72.67 165.16 25.3 Favored 'General case' 0 CA--C 1.551 0.998 0 CA-C-N 119.302 1.551 . . . . 0.0 111.496 175.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -85.82 154.93 21.22 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.669 0.747 . . . . 0.0 112.288 178.234 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 24.2 m -144.09 147.69 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 C-N-CA 125.204 1.402 . . . . 0.0 109.623 174.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.94 155.75 41.89 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 C-N-CA 126.461 1.905 . . . . 0.0 108.984 176.054 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -126.35 161.99 49.03 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 125.4 1.48 . . . . 0.0 111.433 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -74.02 -17.66 22.05 Favored 'Trans proline' 0 CA--C 1.541 0.841 0 C-N-CA 123.132 2.555 . . . . 0.0 113.023 -177.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -151.97 -40.08 0.11 Allowed 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 125.611 1.564 . . . . 0.0 112.543 176.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -53.91 -26.49 25.42 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 125.71 1.604 . . . . 0.0 114.777 179.428 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 96.46 -176.18 32.38 Favored Glycine 0 CA--C 1.535 1.336 0 C-N-CA 125.014 1.292 . . . . 0.0 114.383 179.306 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.0 m -74.74 144.14 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 O-C-N 121.234 -1.157 . . . . 0.0 111.788 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.495 ' SG ' HG11 ' A' ' 56' ' ' VAL . 33.5 m -136.26 -177.11 4.56 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 125.154 1.381 . . . . 0.0 110.809 177.793 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -138.16 115.91 11.45 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.913 1.285 . . . . 0.0 111.563 -173.187 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.597 HG21 HD23 ' A' ' 13' ' ' LEU . 42.4 t -63.45 128.18 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 C-N-CA 123.907 0.883 . . . . 0.0 111.541 -172.411 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 44.0 t -111.02 -49.39 3.03 Favored 'General case' 0 N--CA 1.469 0.505 0 C-N-CA 125.653 1.581 . . . . 0.0 112.039 -174.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -154.73 161.85 41.36 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.919 1.288 . . . . 0.0 111.208 175.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -142.81 127.93 16.21 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 124.713 1.205 . . . . 0.0 108.785 177.373 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -148.92 169.54 20.33 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 123.647 0.779 . . . . 0.0 112.361 175.447 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.466 HG12 ' HA ' ' A' ' 43' ' ' THR . 19.9 m -104.93 142.43 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 O-C-N 121.229 -0.919 . . . . 0.0 110.946 174.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.9 ptmt -155.51 171.0 20.67 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.745 0.818 . . . . 0.0 112.683 175.206 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -103.59 117.47 34.5 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.136 1.374 . . . . 0.0 109.821 176.403 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.7 p -129.69 135.96 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 178.243 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.38 28.73 1.75 Allowed 'General case' 0 CA--C 1.555 1.147 0 C-N-CA 125.582 1.553 . . . . 0.0 114.656 -177.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.14 23.77 50.59 Favored Glycine 0 CA--C 1.538 1.519 0 C-N-CA 125.45 1.5 . . . . 0.0 115.286 -176.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -134.26 113.76 12.32 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 126.16 1.784 . . . . 0.0 111.128 -174.591 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 54.6 tttt -96.33 112.48 24.2 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 124.942 1.297 . . . . 0.0 111.585 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.63 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.8 OUTLIER -156.09 172.41 18.47 Favored 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 123.405 0.682 . . . . 0.0 112.161 179.035 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.466 ' HA ' HG12 ' A' ' 34' ' ' VAL . 4.8 m -72.95 119.17 16.82 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.644 1.178 . . . . 0.0 110.591 175.431 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -110.19 116.65 31.88 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 174.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.7 m -81.3 143.57 12.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 123.935 0.894 . . . . 0.0 109.027 175.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.9 m -126.38 117.34 22.77 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.527 1.531 . . . . 0.0 110.054 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -120.71 160.23 23.74 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 125.257 1.423 . . . . 0.0 110.202 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 55.0 mtm180 -140.51 121.29 14.41 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 124.926 1.29 . . . . 0.0 110.338 -179.131 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.68 108.85 17.61 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 124.647 1.179 . . . . 0.0 111.045 176.238 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -69.96 -15.39 63.04 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 124.026 0.93 . . . . 0.0 112.264 175.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -59.67 -37.65 79.33 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 124.949 1.3 . . . . 0.0 113.439 177.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -128.39 -12.83 5.0 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 124.892 1.277 . . . . 0.0 113.677 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.57 50.94 5.42 Favored Glycine 0 CA--C 1.531 1.077 0 C-N-CA 125.56 1.552 . . . . 0.0 113.177 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -124.53 162.6 23.67 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.741 1.216 . . . . 0.0 112.264 178.529 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.1 m -109.13 152.84 11.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 125.07 1.348 . . . . 0.0 110.736 178.07 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.495 HG11 ' SG ' ' A' ' 27' ' ' CYS . 3.9 p -151.57 122.25 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 125.21 1.404 . . . . 0.0 109.252 178.756 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 22.6 ptt? -127.01 139.38 53.06 Favored 'General case' 0 C--O 1.236 0.374 0 C-N-CA 123.644 0.778 . . . . 0.0 110.884 177.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.1 m -141.19 158.2 64.85 Favored Pre-proline 0 N--CA 1.473 0.707 0 C-N-CA 123.858 0.863 . . . . 0.0 112.069 178.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.63 ' CB ' HD11 ' A' ' 42' ' ' LEU . 56.6 Cg_endo -76.67 115.02 3.97 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 123.497 2.798 . . . . 0.0 114.509 176.175 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.5 -34.43 77.76 Favored 'General case' 0 N--CA 1.477 0.912 0 O-C-N 120.315 -1.49 . . . . 0.0 114.173 178.604 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.0 5.98 78.96 Favored Glycine 0 N--CA 1.473 1.158 0 C-N-CA 124.017 0.818 . . . . 0.0 114.509 176.483 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 19.5 tttp -136.24 2.23 2.75 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.293 1.437 . . . . 0.0 113.359 -178.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -48.93 -30.12 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 125.612 1.565 . . . . 0.0 113.116 175.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 16.9 mt -57.34 -28.82 63.46 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 126.435 1.894 . . . . 0.0 112.556 177.133 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.74 -50.47 15.22 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 125.986 1.714 . . . . 0.0 112.668 175.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.436 ' H ' HD12 ' A' ' 66' ' ' ILE . 3.6 mp -68.53 -31.1 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 124.145 0.978 . . . . 0.0 111.227 178.309 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.35 8.85 70.62 Favored Glycine 0 CA--C 1.535 1.285 0 C-N-CA 125.82 1.676 . . . . 0.0 114.187 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 15.2 m -87.66 137.43 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.669 1.588 . . . . 0.0 110.356 -177.473 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.9 108.88 13.47 Favored 'General case' 0 N--CA 1.469 0.511 0 O-C-N 120.881 -1.137 . . . . 0.0 110.737 176.04 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.452 ' HE2' HD22 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -90.21 106.72 18.68 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 124.25 1.02 . . . . 0.0 109.3 175.594 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 57.6 t -151.45 -69.97 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 C-N-CA 124.939 1.296 . . . . 0.0 111.398 176.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . 175.32 -56.51 0.01 OUTLIER 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 128.565 2.746 . . . . 0.0 110.002 -176.548 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 3.3 m -121.76 1.02 9.92 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 125.556 1.542 . . . . 0.0 114.439 -179.111 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -71.28 -50.6 31.0 Favored 'General case' 0 CA--C 1.548 0.88 0 C-N-CA 124.694 1.198 . . . . 0.0 113.348 -179.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . 0.302 10.0 pt-20 . . . . . 0 N--CA 1.485 1.302 1 C-N-CA 131.868 4.067 . . . . 0.0 119.615 -177.997 . . . . . . . . 2 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.202 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -91.45 5.91 80.53 Favored Glycine 0 CA--C 1.538 1.475 0 C-N-CA 124.627 1.108 . . . . 0.0 115.079 178.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 30.2 m170 -60.83 127.94 34.05 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 125.25 1.42 . . . . 0.0 112.153 -179.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 22.8 mtt -65.16 160.22 59.15 Favored Pre-proline 0 CA--C 1.547 0.832 0 C-N-CA 123.938 0.895 . . . . 0.0 112.42 175.06 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -69.6 131.67 21.96 Favored 'Trans proline' 0 CA--C 1.537 0.637 0 C-N-CA 123.5 2.8 . . . . 0.0 110.354 175.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -162.06 175.92 11.27 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 125.19 1.396 . . . . 0.0 111.409 177.527 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 97.62 66.41 0.9 Allowed Glycine 0 CA--C 1.531 1.083 0 C-N-CA 124.882 1.229 . . . . 0.0 113.298 175.381 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.2 t -111.71 161.75 15.94 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 124.867 1.267 . . . . 0.0 112.447 177.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -161.96 -62.75 0.05 OUTLIER 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 125.372 1.469 . . . . 0.0 111.628 176.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 43.5 m -66.86 155.9 37.12 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.234 1.014 . . . . 0.0 112.586 177.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.5 mp -86.51 21.13 2.22 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 125.775 1.63 . . . . 0.0 113.378 179.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -147.89 145.32 28.61 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 125.122 1.369 . . . . 0.0 111.173 178.211 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.486 HD23 ' HA ' ' A' ' 71' ' ' VAL . 0.3 OUTLIER -83.37 132.41 35.0 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.152 0.981 . . . . 0.0 110.224 175.138 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.56 163.7 19.5 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.363 1.465 . . . . 0.0 112.433 177.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 98.1 t -60.35 129.57 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 123.975 0.91 . . . . 0.0 110.225 178.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.11 -11.86 65.59 Favored Glycine 0 CA--C 1.534 1.267 0 C-N-CA 125.012 1.291 . . . . 0.0 114.761 -176.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -74.99 168.52 19.8 Favored 'General case' 0 CA--C 1.544 0.729 0 CA-C-N 119.445 1.622 . . . . 0.0 110.971 175.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.84 163.86 20.91 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 123.964 0.906 . . . . 0.0 111.426 175.133 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 17.9 m -149.84 150.49 13.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 125.488 1.515 . . . . 0.0 109.691 175.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 6.6 p -137.03 156.3 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 C-N-CA 126.239 1.815 . . . . 0.0 110.035 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -130.43 157.62 76.88 Favored Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 125.471 1.508 . . . . 0.0 111.638 -177.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.11 -40.47 6.3 Favored 'Trans proline' 0 CA--C 1.536 0.582 0 C-N-CA 123.913 3.075 . . . . 0.0 112.313 -177.15 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -148.96 43.82 0.98 Allowed 'General case' 0 CA--C 1.552 1.034 0 C-N-CA 126.057 1.743 . . . . 0.0 112.153 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -128.35 -51.3 1.29 Allowed 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 124.38 1.072 . . . . 0.0 111.945 177.252 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 128.88 -179.02 16.91 Favored Glycine 0 CA--C 1.535 1.305 0 C-N-CA 126.41 1.957 . . . . 0.0 113.035 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.1 m -77.49 143.76 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 O-C-N 121.766 -0.843 . . . . 0.0 111.281 174.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 85.3 m -136.04 -176.96 4.49 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 125.116 1.366 . . . . 0.0 110.786 176.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.5 ttt180 -140.7 124.54 17.18 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 125.01 1.324 . . . . 0.0 110.921 -178.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.8 t -62.06 119.22 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 123.464 0.706 . . . . 0.0 111.827 -175.575 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.9 p -100.58 -46.21 5.27 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.031 0.932 . . . . 0.0 111.902 -178.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.76 172.06 17.92 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 126.366 1.866 . . . . 0.0 111.133 176.166 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 79.8 mt -146.02 137.15 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 C-N-CA 124.759 1.224 . . . . 0.0 108.358 174.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -141.97 168.97 18.49 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 124.146 0.978 . . . . 0.0 111.781 176.227 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.463 HG12 ' HA ' ' A' ' 43' ' ' THR . 15.9 m -116.19 145.25 22.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 O-C-N 120.986 -1.072 . . . . 0.0 110.924 175.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.6 174.74 14.07 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.199 0.999 . . . . 0.0 111.952 174.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -107.75 121.68 45.21 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 125.906 1.682 . . . . 0.0 108.9 175.008 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.6 p -125.2 129.15 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 125.058 1.343 . . . . 0.0 109.159 174.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 48.97 28.99 2.19 Favored 'General case' 0 CA--C 1.556 1.203 0 N-CA-C 114.735 1.383 . . . . 0.0 114.735 -178.509 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.78 21.08 54.57 Favored Glycine 0 CA--C 1.539 1.571 0 C-N-CA 124.814 1.197 . . . . 0.0 115.301 -176.504 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -126.16 113.5 17.12 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 125.924 1.69 . . . . 0.0 110.275 -176.275 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 11.2 tttt -96.77 117.75 31.73 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 124.734 1.213 . . . . 0.0 111.068 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.566 HD11 ' CB ' ' A' ' 59' ' ' PRO . 1.1 pp -158.56 172.46 18.26 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 122.984 0.514 . . . . 0.0 111.75 178.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.463 ' HA ' HG12 ' A' ' 34' ' ' VAL . 22.6 m -80.04 116.47 20.18 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 124.946 1.298 . . . . 0.0 112.521 176.219 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -102.89 113.24 26.52 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 124.487 1.115 . . . . 0.0 109.104 174.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.1 m -63.79 149.05 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 O-C-N 121.843 -0.536 . . . . 0.0 111.223 175.133 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 24.6 m -126.49 109.95 12.74 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.447 1.099 . . . . 0.0 110.942 178.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -128.8 165.43 20.97 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 121.512 -0.742 . . . . 0.0 111.002 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -140.0 120.07 13.68 Favored 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 124.417 1.087 . . . . 0.0 111.403 178.016 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 15.0 ptm180 -74.08 110.06 8.07 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 125.089 1.356 . . . . 0.0 110.865 175.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -64.51 -17.25 63.72 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 177.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -59.43 -37.71 78.78 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.453 1.501 . . . . 0.0 113.895 177.821 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -128.63 -0.39 5.5 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 124.834 1.253 . . . . 0.0 112.908 178.079 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.65 20.9 68.57 Favored Glycine 0 CA--C 1.537 1.419 0 C-N-CA 125.254 1.407 . . . . 0.0 113.851 -170.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -87.87 163.55 16.34 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-N 118.516 1.158 . . . . 0.0 111.541 -176.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 27.5 m -108.8 143.74 18.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 C-N-CA 125.064 1.346 . . . . 0.0 110.874 -179.67 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.7 m -135.33 130.44 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 124.813 1.245 . . . . 0.0 109.483 178.068 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 38.8 mtm -141.84 123.82 15.37 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.336 1.054 . . . . 0.0 110.261 -178.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.5 m -135.05 157.21 77.45 Favored Pre-proline 0 N--CA 1.474 0.744 0 C-N-CA 123.952 0.901 . . . . 0.0 112.116 179.173 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.566 ' CB ' HD11 ' A' ' 42' ' ' LEU . 42.9 Cg_endo -76.79 117.49 4.52 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 123.374 2.716 . . . . 0.0 114.949 179.721 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -60.54 -38.92 86.04 Favored 'General case' 0 N--CA 1.478 0.928 0 O-C-N 120.463 -1.398 . . . . 0.0 114.253 179.617 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.18 5.71 78.37 Favored Glycine 0 N--CA 1.475 1.244 0 C-N-CA 124.549 1.071 . . . . 0.0 114.9 179.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 5.2 tttm -133.92 2.8 3.42 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.658 1.583 . . . . 0.0 112.639 -178.415 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.406 HG13 ' O ' ' A' ' 59' ' ' PRO . 2.4 m -48.64 -30.19 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 C-N-CA 125.405 1.482 . . . . 0.0 113.233 175.028 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 15.5 mt -57.04 -28.74 62.8 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 125.938 1.695 . . . . 0.0 112.641 177.558 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.61 -50.91 14.11 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 125.593 1.557 . . . . 0.0 112.713 175.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.556 HG22 HG13 ' A' ' 68' ' ' VAL . 4.0 mp -69.04 -33.6 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 124.001 0.92 . . . . 0.0 111.264 179.201 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.66 4.36 76.23 Favored Glycine 0 CA--C 1.536 1.406 0 C-N-CA 125.881 1.705 . . . . 0.0 114.352 -177.033 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.556 HG13 HG22 ' A' ' 66' ' ' ILE . 27.3 m -83.57 133.29 29.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 125.952 1.701 . . . . 0.0 109.837 179.812 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 5.9 mtp180 -122.55 109.17 13.99 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 119.957 1.253 . . . . 0.0 110.194 175.385 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.77 106.63 18.57 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.114 178.181 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.486 ' HA ' HD23 ' A' ' 13' ' ' LEU . 69.4 t -149.25 -65.94 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.2 0 C-N-CA 124.0 0.92 . . . . 0.0 112.587 178.012 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . 169.99 -59.25 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 128.7 2.8 . . . . 0.0 109.247 -173.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 m -117.33 -2.76 11.52 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 125.651 1.581 . . . . 0.0 114.561 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.97 -59.91 3.09 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.311 1.044 . . . . 0.0 112.746 -179.45 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.484 1.227 0 C-N-CA 129.19 2.996 . . . . 0.0 116.579 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.301 0 CA-C-O 121.007 0.432 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 159.46 95.1 0.1 Allowed Glycine 0 N--CA 1.472 1.09 0 O-C-N 121.013 -1.054 . . . . 0.0 112.558 -175.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 18.5 t60 -87.22 105.84 17.49 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.814 0.807 . . . . 0.0 110.953 179.116 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.1 mpt? -78.29 161.43 70.28 Favored Pre-proline 0 CA--C 1.548 0.873 0 C-N-CA 124.799 1.24 . . . . 0.0 112.098 178.511 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -68.27 -21.35 41.74 Favored 'Trans proline' 0 CA--C 1.539 0.758 0 C-N-CA 123.664 2.909 . . . . 0.0 113.828 177.04 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -51.65 -34.58 38.55 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 126.449 1.9 . . . . 0.0 114.879 -177.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 40.51 -132.74 2.75 Favored Glycine 0 CA--C 1.538 1.483 0 C-N-CA 126.274 1.892 . . . . 0.0 113.825 -176.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.0 p -165.22 74.39 0.22 Allowed 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 125.695 1.598 . . . . 0.0 111.484 175.024 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -156.86 177.73 11.16 Favored 'General case' 0 CA--C 1.55 0.969 0 C-N-CA 125.471 1.508 . . . . 0.0 112.926 176.424 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.6 p -147.55 75.04 1.34 Allowed 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 125.659 1.584 . . . . 0.0 112.336 175.28 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -121.09 165.4 15.38 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 126.16 1.784 . . . . 0.0 111.936 -179.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.1 152.07 42.61 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 124.166 0.986 . . . . 0.0 112.046 174.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.435 ' HG ' ' HE2' ' A' ' 70' ' ' LYS . 0.5 OUTLIER -67.91 129.54 40.23 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 124.373 1.069 . . . . 0.0 111.394 176.105 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -143.2 179.01 7.32 Favored 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.937 1.695 . . . . 0.0 112.199 176.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.4 t -59.51 129.34 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 O-C-N 121.054 -1.029 . . . . 0.0 110.821 175.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 87.28 -2.63 86.73 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 125.109 1.338 . . . . 0.0 115.372 -178.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -70.98 170.17 13.34 Favored 'General case' 0 CA--C 1.55 0.972 0 CA-C-N 119.319 1.56 . . . . 0.0 112.284 174.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.71 142.86 28.99 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.796 1.238 . . . . 0.0 111.602 178.263 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.9 m -139.02 146.48 25.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 124.061 0.944 . . . . 0.0 110.286 175.078 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 13.7 p -137.09 149.5 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 C-N-CA 124.554 1.142 . . . . 0.0 110.584 174.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 1.1 m-85 -86.33 162.67 45.1 Favored Pre-proline 0 CA--C 1.545 0.764 0 C-N-CA 124.034 0.934 . . . . 0.0 111.704 175.027 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.475 ' CD ' HG22 ' A' ' 68' ' ' VAL . 62.1 Cg_endo -71.15 -24.97 22.88 Favored 'Trans proline' 0 CA--C 1.539 0.772 0 C-N-CA 122.883 2.389 . . . . 0.0 112.434 -176.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -165.91 55.02 0.1 Allowed 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 126.755 2.022 . . . . 0.0 111.844 -176.435 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 7.3 tp-100 -148.06 -63.52 0.26 Allowed 'General case' 0 N--CA 1.478 0.942 0 O-C-N 120.964 -1.085 . . . . 0.0 112.935 179.076 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.06 178.3 41.49 Favored Glycine 0 CA--C 1.534 1.245 0 C-N-CA 124.574 1.083 . . . . 0.0 113.754 -179.165 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.5 m -88.28 153.12 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 125.167 1.387 . . . . 0.0 110.783 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 4.2 m -140.02 172.45 12.74 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 125.256 1.423 . . . . 0.0 110.635 176.2 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 47.8 ttt-85 -133.81 123.95 25.69 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.108 0.963 . . . . 0.0 112.746 -179.283 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.3 t -69.39 122.76 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 125.751 1.62 . . . . 0.0 111.086 -179.28 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.6 t -108.87 -34.63 6.6 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 124.55 1.14 . . . . 0.0 112.485 178.352 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -159.14 167.28 29.54 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 126.224 1.81 . . . . 0.0 110.483 175.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 50.1 mt -144.89 140.61 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 125.19 1.396 . . . . 0.0 108.993 175.407 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -148.04 169.01 20.86 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.732 0.813 . . . . 0.0 112.568 175.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 10.9 m -104.69 143.21 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 124.819 1.248 . . . . 0.0 111.796 175.561 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.66 172.77 18.01 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 124.457 1.103 . . . . 0.0 112.311 174.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.64 121.83 45.47 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 126.137 1.775 . . . . 0.0 109.291 175.171 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.7 p -132.77 136.83 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 124.443 1.097 . . . . 0.0 109.259 174.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 47.91 29.05 1.54 Allowed 'General case' 0 CA--C 1.556 1.206 0 N-CA-C 114.939 1.459 . . . . 0.0 114.939 -177.063 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.9 26.21 50.21 Favored Glycine 0 CA--C 1.541 1.666 0 C-N-CA 124.76 1.172 . . . . 0.0 115.349 -177.2 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -134.44 113.46 11.88 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 126.054 1.742 . . . . 0.0 109.7 -175.54 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 20.9 tttt -96.85 116.4 29.1 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 124.696 1.199 . . . . 0.0 111.677 -179.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.525 HD11 ' CB ' ' A' ' 59' ' ' PRO . 0.9 OUTLIER -159.73 174.55 14.36 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 123.634 0.774 . . . . 0.0 112.203 -179.682 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 17.6 m -79.06 116.39 19.32 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.588 1.555 . . . . 0.0 112.107 176.03 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -104.77 113.28 26.78 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 124.416 1.086 . . . . 0.0 109.88 175.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 25.4 m -63.68 151.92 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 O-C-N 121.707 -0.621 . . . . 0.0 111.5 175.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -126.51 109.82 12.58 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-O 121.723 0.773 . . . . 0.0 110.499 176.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 5.2 mpp? -113.42 157.52 21.82 Favored 'General case' 0 C--O 1.232 0.144 0 C-N-CA 124.804 1.242 . . . . 0.0 111.616 176.78 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 43.1 mtp85 -133.88 105.58 6.84 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 126.191 1.797 . . . . 0.0 109.926 179.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 46.8 mtp85 -74.91 109.05 8.06 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.664 0.786 . . . . 0.0 109.435 175.034 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -69.73 -14.55 62.84 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 176.558 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -57.96 -43.2 86.3 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 126.072 1.749 . . . . 0.0 112.97 175.115 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -128.57 -12.93 4.88 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 125.024 1.33 . . . . 0.0 114.123 -177.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.92 4.88 78.19 Favored Glycine 0 CA--C 1.537 1.443 0 C-N-CA 125.935 1.731 . . . . 0.0 114.802 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -75.04 161.44 29.45 Favored 'General case' 0 CA--C 1.543 0.692 0 CA-C-N 118.532 1.166 . . . . 0.0 113.166 179.469 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.3 m -105.85 139.24 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 125.397 1.479 . . . . 0.0 109.865 174.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.3 t -123.31 114.96 44.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.82 1.248 . . . . 0.0 108.427 177.146 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.1 tmm? -127.97 123.91 35.97 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 124.94 1.296 . . . . 0.0 109.547 178.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.4 m -131.56 155.02 82.0 Favored Pre-proline 0 N--CA 1.469 0.52 0 C-N-CA 124.592 1.157 . . . . 0.0 111.388 176.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.525 ' CB ' HD11 ' A' ' 42' ' ' LEU . 46.4 Cg_endo -76.68 118.52 4.86 Favored 'Trans proline' 0 CA--C 1.536 0.577 0 C-N-CA 123.488 2.792 . . . . 0.0 114.763 177.597 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -59.87 -41.03 90.65 Favored 'General case' 0 N--CA 1.475 0.775 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -91.89 6.31 79.35 Favored Glycine 0 N--CA 1.475 1.299 0 C-N-CA 124.344 0.974 . . . . 0.0 114.69 178.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.9 tttp -132.98 3.63 3.74 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.667 1.587 . . . . 0.0 112.773 -178.533 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.4 m -48.61 -30.07 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 C-N-CA 125.128 1.371 . . . . 0.0 113.453 175.149 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 14.8 mt -55.93 -29.33 59.94 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 126.208 1.803 . . . . 0.0 112.652 177.591 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.83 -49.16 21.59 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 125.702 1.601 . . . . 0.0 112.837 175.76 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.405 HG22 HG23 ' A' ' 68' ' ' VAL . 4.0 mp -69.12 -33.61 59.35 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 124.202 1.001 . . . . 0.0 111.387 178.327 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 88.38 3.06 78.93 Favored Glycine 0 CA--C 1.537 1.433 0 C-N-CA 125.717 1.627 . . . . 0.0 114.365 -175.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.475 HG22 ' CD ' ' A' ' 22' ' ' PRO . 71.6 t -75.79 148.58 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 CA-C-N 118.47 1.135 . . . . 0.0 110.281 175.002 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.38 109.3 10.97 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-O 122.033 0.921 . . . . 0.0 108.679 175.018 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.435 ' HE2' ' HG ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER -112.5 106.59 15.09 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 125.5 1.52 . . . . 0.0 108.896 179.42 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 87.0 t -148.87 -72.29 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 C-N-CA 125.091 1.356 . . . . 0.0 111.07 177.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ALA . . . . . . . . . . . . . . . 179.1 -57.61 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 128.777 2.831 . . . . 0.0 109.215 -176.513 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 86.2 p -114.08 3.71 15.37 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 126.769 2.028 . . . . 0.0 114.392 -176.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -77.04 -65.38 0.96 Allowed 'General case' 0 CA--C 1.547 0.835 0 C-N-CA 125.196 1.398 . . . . 0.0 111.968 -179.511 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.483 1.202 0 C-N-CA 130.162 3.385 . . . . 0.0 116.583 178.595 . . . . . . . . 1 1 . 1 stop_ save_